Human genes and gene expression products II

ABSTRACT

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is the National Phase under 35 U.S.C. § 371 of International Application No. PCT/US99/01619, filed Jan. 28, 1999, which International Application was published by the International Bureau in English on Aug. 5, 1999, which International Application claims the benefit of U.S. provisional patent application Ser. No. 60/072,910, filed Jan. 28, 1998; U.S. provisional patent application Ser. No. 60/075,954, filed Feb. 24, 1998; U.S. provisional patent application Ser. No. 60/080,114, filed Mar. 31, 1998; U.S. provisional patent application Ser. No. 60/080,515, filed Apr. 3, 1998; U.S. provisional patent application Ser. No. 60/080,666, filed Apr. 3, 1998; U.S. provisional patent application Ser. No. 60/105,234, filed Oct. 21, 1998; and of U.S. provisional patent application Ser. No. 60/105,877, filed Oct. 27, 1998, each of which applications are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to novel polynucleotides, particularly to novel polynucleotides of human origin that are expressed in a selected cell type, are differentially expressed in one cell type relative to another cell type (e.g., in cancerous cells, or in cells of a specific tissue origin) and/or share homology to polynucleotides encoding a gene product having an identified functional domain and/or activity.

BACKGROUND OF THE INVENTION

Identification of novel polynucleotides, particularly those that encode an expressed gene product is important in the advancement of drug discovery, diagnostic technologies, and the understanding of the progression and nature of complex diseases such as cancer. Identification of genes expressed in different cell types isolated from sources that differ in disease state or stage, developmental stage, exposure to various environmental factors, the tissue of origin, the species from which the tissue was isolated, and the like is key to identifying the genetic factors that are responsible for the phenotypes associated with these various differences

This invention provides novel human polynucleotides, the polypeptides encoded by these polynucleotides, and the genes and proteins corresponding to these novel polynucleotides.

SUMMARY OF THE INVENTION

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies. The polynucleotides of the invention correspond to a polynucleotide comprising the sequence information of at least one of SEQ ID NOS: 1-3544, 3546-4510, 4512-4725, 4727-4748, and 4750-5252, which for convenience sake is referred to herein as “SEQ ID NOS:1-5252.”

Accordingly, in one embodiment, the present invention features a library of polynucleotides, the library comprising the sequence information of at least one of “SEQ ID NOS:1-5252”. In related aspects, the invention features a library provided on a nucleic acid array, or in a computer-readable format.

In one embodiment, the library is comprises a differentially expressed polynucleotide comprising a sequence selected from one of the differentially expressed polynucleotides disclosed herein. In specific related embodiments, the library comprises: 1) a polynucleotide that is differentially expressed in a human breast cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS:15, 36, 44, 45, 89, 146, 154, 159, 165, 172, 174, 183, 203, 261, 364, 366, 387, 419, 420, 496, 503, 510, 512, 529, 552, 560, 564, 570, 590, 606, 644, 646, 693, 707, 711, 726, 746, 754, 756, 875, 902, 921, 942, 990, 1095, 1104, 1122, 1131, 1142, 1170, 1184, 1205, 1286, 1289, 1354, 1387, 1435, 1535, 1751, 1764, 1777, 1795, 1860, 1869, 1882, 1890, 1915, 1933, 1934, 1979, 1980, 2007, 2023, 2040, 2059, 2223, 2245, 2300, 2325, 2409, 2462, 2488, 2486, and 2492; 2) a polynucleotide differentially expressed in a human colon cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 33, 65, 228, 250, 252, 253, 280, 282, 355, 370, 387, 443, 460, 491, 545, 560, 581, 603, 680, 693, 703, 704, 716, 726, 746, 752, 753, 1095, 1104, 1205, 1241, 1264, 1354, 1387, 1401, 1442, 1514, 1734, 1742, 1780, 1851, 1899, 1915, 1954, 2024, 2066, 2262, and 2325; 3) a polynucleotide differentially expressed in a human lung cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS:10, 54, 65, 171, 174, 203, 252, 253, 254, 285, 419, 420, 466, 491, 525, 526, 552, 571, 574, 590, 693, 700, 726, 742, 746, 861, 922, 990, 1088, 1288, 1355, 1417, 1422, 1444, 1454, 1570, 1597, 1979, 2007, 2024, 2034, 2038, 2126, and 2245; 4) a polynucleotide differentially expressed in growth factor-treated human microvascular endothelial cells (HMEC) relative to untreated HMEC, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS:648, 1899, and 648; or 5) polynucleotides that are differentially expressed across multiple libraries, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 65, 174, 203, 252, 253, 387, 419, 420, 491, 552, 560, 581, 590, 648, 693, 726, 746, 990, 1095, 1124, 1205, 1354, 1387, 1780, 1899, 1915, 1979, 2007, 2024, 2245, and 2325.

In another aspect, the invention features an isolated polynucleotide comprising a nucleotide sequence having at least 90% sequence identity to an identifying sequence of “SEQ ID NOS:1-5252” or a degenerate variant thereof. In related aspects, the invention features recombinant host cells and vectors comprising the polynucleotides of the invention, as well as isolated polypeptides encoded by the polynucleotides of the invention and antibodies that specifically bind such polypeptides.

In one embodiment, the invention features an isolated polynucleotide comprising a sequence encoding a polypeptide of a protein family or having a functional domain selected from the group consisting of: 4 transmembrane segments integral membrane proteins, 7 transmembrane receptors (rhodopsin family or secretin family), eukaryotic aspartyl proteases, ATPases associated with various cellular activities (AAA), Bcl-2, cyclins, DEAD box protein family, DEAD/H helicase protein family, MAP kinase protein family, novel 3′5′-cyclic nucleotide phosphodiesterases, protein kinases, ras protein family, G-protein alpha subunit, phorbol esters/diacylglycerol binding proteins, protein kinase, trypsin, protein tyrosine phosphatase, wnt family of developmental signaling proteins, WW/rsp5/WWP domain containing proteins, Ank repeat, basic region plus leucine zipper domain, bromodomain, eukaryotic thiol (cysteine) protease active site, EF-hand, ETS domain, type II fibronectin collagen binding domain, thioredoxin, homeobox domain, TNFR/NGFR family cysteine-rich region, WD domain/G-beta repeats, zinc finger (C2H2 type), zinc finger (CCHC class), and zinc finger (C3HC4 type). In a specific related embodiment, the invention features a polynucleotide comprising a sequence of one of the SEQ ID NOS: listed in Table 3 or Table 20.

In another aspect, the invention features a method of detecting differentially expressed genes correlated with a cancerous state of a mammalian cell, where the method comprises the step of detecting at least one differentially expressed gene product in a test sample derived from a cell suspected of being cancerous, where the gene product is encoded by a gene corresponding to a sequence of at least one of the differentially expressed polynucleotides disclosed herein. Detection of the differentially expressed gene product is correlated with a cancerous state of the cell from which the test sample was derived. In one embodiment, the detecting is by hybridization of the test sample to a reference array, wherein the reference array comprises an identifying sequence of at least one of the differentially expressed polynucleotides disclosed herein.

In one embodiment of the method of the invention, the cell is a breast tissue derived cell, and the differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS:15, 36, 44, 45, 89, 146, 154, 159, 165, 172, 174, 183, 203, 261, 364, 366, 387, 419, 420, 496, 503, 510, 512, 529, 552, 560, 564, 570, 590, 606, 644, 646, 693, 707, 711, 726, 746, 754, 756, 875, 902, 921, 942, 990, 1095, 1104, 1122, 1131, 1142, 1170, 1184, 1205, 1286, 1289, 1354, 1387, 1435, 1535, 1751, 1764, 1777, 1795, 1860, 1869, 1882, 1890, 1915, 1933, 1934, 1979, 1980, 2007, 2023, 2040, 2059, 2223, 2245, 2300, 2325, 2409, 2462, 2486 2488, and 2492.

In another embodiment of the method of the invention, the cell is a colon tissue derived cell, and differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS: 65, 228, 252, 253, 280, 355, 491, 581, 603, 680, 693, 716, 726, 746, 752, 753, 1241, 1264, 1401, 1442, 1514, 1851, 1915, 2024, 2066, 33, 250, 282, 370, 387, 443, 460, 545, 560, 703, 704, 1095, 1104, 1205, 1354, 1387, 1734, 1742, 1780, 1899, 1954, 2262, and 2325.

In yet another embodiment of the method of the invention, the cell is a lung tissue derived cell, and differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS:10, 54, 65, 171, 174, 203, 252, 253, 254, 285, 419, 420, 466, 491, 525, 526, 552, 571, 574, 590, 693, 700, 726, 742, 746, 861, 922, 990, 1088, 1288, 1355, 1417, 1422, 1444, 1454, 1570, 1597, 1979, 2007, 2024, 2034, 2038, 2126, and 2245.

In another embodiment, the cell is any of a lung, breast, or colon cell and the differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS:648 and 1899.

In still another embodiment, the cell is any of a breast, colon, or lung cell and the differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS: 65, 174, 203, 252, 253, 387, 419, 420, 491, 552, 560, 581, 590, 648, 693, 726, 746, 990, 1095, 1124, 1205, 1354, 1387, 1780, 1899, 1915, 1979, 2007, 2024, 2245, and 2325.

Other aspects and embodiments of the invention will be readily apparent to the ordinarily skilled artisan upon reading the description provided herein.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to polynucleotides comprising the disclosed nucleotide sequences, to full length cDNA, mRNA and genes corresponding to these sequences, and to polypeptides and proteins encoded by these polynucleotides and genes.

Also included are polynucleotides that encode polypeptides and proteins encoded by the polynucleotides of the Sequence Listing. The various polynucleotides that can encode these polypeptides and proteins differ because of the degeneracy of the genetic code, in that most amino acids are encoded by more than one triplet codon. The identity of such codons is well-known in this art, and this information can be used for the construction of the polynucleotides within the scope of the invention.

Polynucleotides encoding polypeptides and proteins that are variants of the polypeptides and proteins encoded by the polynucleotides and related cDNA and genes are also within the scope of the invention. The variants differ from wild type protein in having one or more amino acid substitutions that either enhance, add, or diminish a biological activity of the wild type protein. Once the amino acid change is selected, a polynucleotide encoding that variant is constructed according to the invention.

The following detailed description describes the polynucleotide compositions encompassed by the invention, methods for obtaining cDNA or genomic DNA encoding a full-length gene product, expression of these polynucleotides and genes, identification of structural motifs of the polynucleotides and genes, identification of the function of a gene product encoded by a gene corresponding to a polynucleotide of the invention, use of the provided polynucleotides as probes and in mapping and in tissue profiling, use of the corresponding polypeptides and other gene products to raise antibodies, and use of the polynucleotides and their encoded gene products for therapeutic and diagnostic purposes.

I. Polynucleotide Compositions

The scope of the invention with respect to polynucleotide compositions includes, but is not necessarily limited to, polynucleotides having a sequence set forth in any one of “SEQ ID NOS:1-5252”; polynucleotides obtained from the biological materials described herein or other biological sources (particularly human sources) by hybridization under stringent conditions (particularly conditions of high stringency); genes corresponding to the provided polynucleotides; variants of the provided polynucleotides and their corresponding genes, particularly those variants that retain a biological activity of the encoded gene product (e.g., a biological activity ascribed to a gene product corresponding to the provided polynucleotides as a result of the assignment of the gene product to a protein family(ies) and/or identification of a functional domain present in the gene product). Other nucleic acid compositions contemplated by and within the scope of the present invention will be readily apparent to one of ordinary skill in the art when provided with the disclosure here.

The invention features polynucleotides that are expressed in cells of human tissue, specifically human colon, breast, and/or lung tissue. Novel nucleic acid compositions of the invention of particular interest comprise a sequence set forth in any one of “SEQ ID NOS:1-5252” or an identifying sequence thereof. An “identifying sequence” is a contiguous sequence of residues at least about 10 nt to about 20 nt in length, usually at least about 50 nt to about 100 nt in length, that uniquely identifies a polynucleotide sequence, e.g., exhibits less than 90%, usually less than about 80% to about 85% sequence identity to any contiguous nucleotide sequence of more than about 20 nt. Thus, the subject novel nucleic acid compositions include full length cDNAs or mRNAs that encompass an identifying sequence of contiguous nucleotides from any one of “SEQ ID NOS:1-5252.”

The polynucleotides of the invention also include polynucleotides having sequence similarity or sequence identity. Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50° C. and 10×SSC (0.9 M saline/0.09 M sodium citrate) arid remain bound when subjected to washing at 55° C. in 1×SSC. Sequence identity can be determined by hybridization under stringent conditions, for example, at 50° C. or higher and 0.1×SSC (9 mM saline/0.9 mM sodium citrate). Hybridization methods and conditions are well known in the art, see, e.g., U.S. Pat. No. 5,707,829. Nucleic acids that are substantially identical to the provided polynucleotide sequences, e.g. allelic variants, genetically altered versions of the gene, etc., bind to the provided polynucleotide sequences (“SEQ ID NOS:1-5252”) under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes can be any species, e.g. primate species, particularly human; rodents, such as rats and mice; canines, felines, bovines, ovines, equines, yeast, nematodes, etc.

Preferably, hybridization is performed using at least 15 contiguous nucleotides of at least one of “SEQ ID NOS:1-5252.” That is, when at least 15 contiguous nucleotides of one of the disclosed SEQ ID NOs. is used as a probe, the probe will preferentially hybridize with a gene or mRNA (of the biological material) comprising the complementary sequence, allowing the identification and retrieval of the nucleic acids of the biological material that uniquely hybridize to the selected probe. Probes from more than one SEQ ID NO. will hybridize with the same gene or mRNA if the cDNA from which they were derived corresponds to one mRNA. Probes of more than 15 nucleotides can be used, but 15 nucleotides represents enough sequence for unique identification.

The polynucleotides of the invention also include naturally occurring variants of the nucleotide sequences (e.g., degenerate variants, allelic variants, etc.). Variants of the polynucleotides of the invention are identified by hybridization of putative variants with nucleotide sequences disclosed herein, preferably by hybridization under stringent conditions. For example, by using appropriate wash conditions, variants of the polynucleotides of the invention can be identified where the allelic variant exhibits at most about 25-30% base pair mismatches relative to the selected polynucleotide probe. In general, allelic variants contain 15-25% base pair mismatches, and can contain as little as even 5-15%, or 2-5%, or 1-2% base pair mismatches, as well as a single base-pair mismatch.

The invention also encompasses homologs corresponding to the polynucleotides of “SEQ ID NOS:1-5252”, where the source of homologous genes can be any mammalian species, e.g., primate species, particularly human; rodents, such as rats; canines, felines, bovines, ovines, equines, yeast, nematodes, etc. Between mammalian species, e.g., human and mouse, homologs have substantial sequence similarity, e.g., at least 75% sequence identity, usually at least 90%, more usually at least 95% between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 contiguous nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul et al., J. Mol. Biol. (1990) 215:403-10.

In general, variants of the invention have a sequence identity greater than at least about 65%, preferably at least about 75%, more preferably at least about 85%, and can be greater than at least about 90% or more as determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular). For the purposes of this invention, a preferred method of calculating percent identity is the Smith-Waterman algorithm, using the following. Global DNA sequence identity must be greater than 65% as determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular) using an affine gap search with the following search parameters: gap open penalty, 12; and gap extension penalty, 1.

The subject nucleic acids can be cDNAs or genomic DNAs, as well as fragments thereof, particularly fragments that encode a biologically active gene product and/or are useful in the methods disclosed herein (e.g., in diagnosis, as a unique identifier of a differentially expressed gene of interest, etc.). The term “cDNA” as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3′ and 5′ non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding a polypeptide of the invention.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It can further include the 3′ and 5′ untranslated regions found in the mature mRNA. It can further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about 1 kb, but possibly more, of flanking genomic DNA at either the 5′ and 3′ end of the transcribed region. The genomic DNA can be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3′ and 5′, or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue, stage-specific, or disease-state specific expression.

The nucleic acid compositions of the subject invention can encode all or a part of the subject polypeptides. Double or single stranded fragments can be obtained from the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc. Isolated polynucleotides and polynucleotide fragments of the invention comprise at least about 10, about 15, about 20, about 35, about 50, about 100, about 150 to about 200, about 250 to about 300, or about 350 contiguous nucleotides selected from the polynucleotide sequences as shown in “SEQ ID NOS:1-5252.” For the most part, fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and up to at least about 50 contiguous nt in length or more. In a preferred embodiment, the polynucleotide molecules comprise a contiguous sequence of at least twelve nucleotides selected from the group consisting of the polynucleotides shown in “SEQ ID NOS:1-5252.”

Probes specific to the polynucleotides of the invention can be generated using the polynucleotide sequences disclosed in “SEQ ID NOS:1-5252.” The probes are preferably at least about 12, 15, 16, 18, 20, 22, 24, or 25 nucleotide fragment of a corresponding contiguous sequence of “SEQ ID NOS:1-5252”, and can be less than 2, 1, 0.5, 0.1, or 0.05 kb in length. The probes can be synthesized chemically or can be generated from longer polynucleotides using restriction enzymes. The probes can be labeled, for example, with a radioactive, biotinylated, or fluorescent tag. Preferably, probes are designed based upon an identifying sequence of a polynucleotide of one of “SEQ ID NOS:1-5252.” More preferably, probes are designed based on a contiguous sequence of one of the subject polynucleotides that remain unmasked following application of a masking program for masking low complexity (e.g., XBLAST) to the sequence., i.e., one would select an unmasked region, as indicated by the polynucleotides outside the poly-n stretches of the masked sequence produced by the masking program.

The polynucleotides of the subject invention are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the polynucleotides, either as DNA or RNA, will be obtained substantially free of other naturally-occurring nucleic acid sequences, generally being at least about 50%, usually at least about 90% pure and are typically “recombinant”, e.g., flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The polynucleotides of the invention can be provided as a linear molecule or within a circular molecule. They can be provided within autonomously replicating molecules (vectors) or within molecules without replication sequences. They can be regulated by their own or by other regulatory sequences, as is known in the art. The polynucleotides of the invention can be introduced into suitable host cells using a variety of techniques which are available in the art, such as transferrin polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated DNA transfer, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, gene gun, calcium phosphate-mediated transfection, and the like.

The subject nucleic acid compositions can be used to, for example, produce polypeptides, as probes for the detection of mRNA of the invention in biological samples (e.g., extracts of human cells) to generate additional copies of the polynucleotides, to generate ribozymes or antisense oligonucleotides, and as single stranded DNA probes or as triple-strand forming oligonucleotides. The probes described herein can be used to, for example, determine the presence or absence of the polynucleotide sequences as shown in “SEQ ID NOS:1-5252” or variants thereof in a sample. These and other uses are described in more detail below.

Use of Polynucleotides to Obtain Full-length cDNA and Full-Length Human Gene and Promoter Region

Full-length cDNA molecules comprising the disclosed polynucleotides are obtained as follows. A polynucleotide having a sequence of one of “SEQ ID NOS:1-5252”, or a portion thereof comprising at least 12, 15, 18, or 20 nucleotides, is used as a hybridization probe to detect hybridizing members of a cDNA library using probe design methods, cloning methods, and clone selection techniques such as those described in U.S. Pat. No. 5,654,173. Libraries of cDNA are made from selected tissues, such as normal or tumor tissue, or from tissues of a mammal treated with, for example, a pharmaceutical agent. Preferably, the tissue is the same as the tissue from which the polynucleotides of the invention were isolated, as both the polynucleotides described herein and the cDNA represent expressed genes. Most preferably, the cDNA library is made from the biological material described herein in the Examples. Alternatively, many cDNA libraries are available commercially. (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, N.Y.). The choice of cell type for library construction can be made after the identity of the protein encoded by the gene corresponding to the polynucleotide of the invention is known. This will indicate which tissue and cell types are likely to express the related gene, and thus represent a suitable source for the mRNA for generating the cDNA. Where the provided polynucleotides are isolated from cDNA libraries, the libraries are prepared from mRNA of human colon cells, more preferably, human colon cancer cells, even more preferably, from a highly metastatic colon cell, Km12L4-A.

Techniques for producing and probing nucleic acid sequence libraries are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, N.Y. The cDNA can be prepared by using primers based on sequence from “SEQ ID NOS:1-5252.” In one embodiment, the cDNA library can be made from only poly-adenylated mRNA. Thus, poly-T primers can be used to prepare cDNA from the mRNA.

Members of the library that are larger than the provided polynucleotides, and preferably that encompass the complete coding sequence of the native message, are obtained. In order to confirm that the entire cDNA has been obtained, RNA protection experiments are performed as follows. Hybridization of a full-length cDNA to an mRNA will protect the RNA from RNase degradation. If the cDNA is not full length, then the portions of the mRNA that are not hybridized will be subject to RNase degradation. This is assayed, as is known in the art, by changes in electrophoretic mobility on polyacrylamide gels, or by detection of released monoribonucleotides. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, N.Y. In order to obtain additional sequences 5′ to the end of a partial cDNA, 5′ RACE (PCR Protocols: A Guide to Methods and Applications, (1990) Academic Press, Inc.) is performed.

Genomic DNA is isolated using the provided polynucleotides in a manner similar to the isolation of full-length cDNAs. Briefly, the provided polynucleotides, or portions thereof, are used as probes to libraries of genomic DNA. Preferably, the library is obtained from the cell type that was used to generate the polynucleotides of the invention, but this is not essential. Most preferably, the genomic DNA is obtained from the biological material described herein in the Examples. Such libraries can be in vectors suitable for carrying large segments of a genome, such as P1 or YAC, as described in detail in Sambrook et al., 9.4-9.30. In addition, genomic sequences can be isolated from human BAC libraries, which are commercially available from Research Genetics, Inc., Huntville, Ala., USA, for example. In order to obtain additional 5′ or 3′ sequences, chromosome walking is performed, as described in Sambrook et al., such that adjacent and overlapping fragments of genomic DNA are isolated. These are mapped and pieced together, as is known in the art, using restriction digestion enzymes and DNA ligase.

Using the polynucleotide sequences of the invention, corresponding full-length genes can be isolated using both classical and PCR methods to construct and probe cDNA libraries. Using either method, Northern blots, preferably, are performed on a number of cell types to determine which cell lines express the gene of interest at the highest level. Classical methods of constructing cDNA libraries are taught in Sambrook et al., supra. With these methods, cDNA can be produced from mRNA and inserted into viral or expression vectors. Typically, libraries of mRNA comprising poly(A) tails can be produced with poly(T) primers. Similarly, cDNA libraries can be produced using the instant sequences as primers;

PCR methods are used to amplify the members of a cDNA library that comprise the desired insert. In this case, the desired insert will contain sequence from the full length cDNA that corresponds to the instant polynucleotides. Such PCR methods include gene trapping and RACE methods. Gene trapping entails inserting a member of a cDNA library into a vector. The vector then is denatured to produce single stranded molecules. Next, a substrate-bound probe, such a biotinylated oligo, is used to trap cDNA inserts of interest. Biotinylated probes can be linked to an avidin-bound solid substrate. PCR methods can be used to amplify the trapped cDNA. To trap sequences corresponding to the full length genes, the labeled probe sequence is based on the polynucleotide sequences of the invention. Random primers or primers specific to the library vector can be used to amplify the trapped cDNA. Such gene trapping techniques are described in Gruber et al., WO 95/04745 and Gruber et al., U.S. Pat. No. 5,500,356. Kits are commercially available to perform gene trapping experiments from, for example, Life Technologies, Gaithersburg, Md., USA.

“Rapid amplification of cDNA ends,” or RACE, is a PCR method of amplifying cDNAs from a number of different RNAs. The cDNAs are ligated to an oligonucleotide linker, and amplified by PCR using two primers. One primer is based on sequence from the instant polynucleotides, for which full length sequence is desired, and a second primer comprises sequence that hybridizes to the oligonucleotide linker to amplify the cDNA. A description of this methods is reported in WO 97/19110. In preferred embodiments of RACE, a common primer is designed to anneal to an arbitrary adaptor sequence ligated to cDNA ends (Apte and Siebert, Biotechniques (1993) 15:890-893; Edwards et al., Nuc. Acids Res. (1991) 19:5227-5232). When a single gene-specific RACE primer is paired with the common primer, preferential amplification of sequences between the single gene specific primer and the common primer occurs. Commercial cDNA pools modified for use in RACE are available.

Another PCR-based method generates full-length cDNA library with anchored ends without needing specific knowledge of the cDNA sequence. This method is described in WO 96/40998.

The promoter region of a gene generally is located 5′ to the initiation site for RNA polymerase II. Hundreds of promoter regions contain the “TATA” box, a sequence such as TATTA or TATAA, which is sensitive to mutations. The promoter region can be obtained by performing 5′ RACE using a primer from the coding region of the gene. Alternatively, the cDNA can be used as a probe for the genomic sequence, and the region 5′ to the coding region is identified by “walking up.” If the gene is highly expressed or differentially expressed, the promoter from the gene can be of use in a regulatory construct for a heterologous gene.

Once the full-length cDNA or gene is obtained, DNA encoding variants can be prepared by site-directed mutagenesis, described in detail in Sambrook et al., 15.3-15.63. The choice of codon or nucleotide to be replaced can be based on disclosure herein on optional changes in amino acids to achieve altered protein structure and/or function.

As an alternative method to obtaining DNA or RNA from a biological material, nucleic acid comprising nucleotides having the sequence of one or more polynucleotides of the invention can be synthesized. Thus, the invention encompasses nucleic acid molecules ranging in length from 15 nucleotides (corresponding to at least 15 contiguous nucleotides of one of “SEQ ID NOS:1-5252”) up to a maximum length suitable for one or more biological manipulations, including replication and expression, of the nucleic acid molecule. The invention includes but is not limited to (a) nucleic acid having the size of a full gene, and comprising at least one of “SEQ ID NOS:1-5252;”; (b) the nucleic acid of (a) also comprising at least one additional gene, operably linked to permit expression of a fusion protein; (c) an expression vector comprising (a) or (b); (d) a plasmid comprising (a) or (b); and (e) a recombinant viral particle comprising (a) or (b). Once provided with the polynucleotides disclosed herein, construction or preparation of (a)-(e) are well within the skill in the art.

The sequence of a nucleic acid comprising at least 15 contiguous nucleotides of at least any one of “SEQ ID NOS:1-5252,”, preferably the entire sequence of at least any one of “SEQ ID NOS:1-5252,” is not limited and can be any sequence of A, T, G, and/or C (for DNA) and A, U, G, and/or C (for RNA) or modified bases thereof, including inosine and pseudouridine. The choice of sequence will depend on the desired function and can be dictated by coding regions desired, the intron-like regions desired, and the regulatory regions desired. Where the entire sequence of any one of “SEQ ID NOS:1-5252” is within the nucleic acid, the nucleic acid obtained is referred to herein as a polynucleotide comprising the sequence of any one of “SEQ ID NOS:1-5252.”

II. Expression of Polypeptide Encoded by Full-length cDNA or Full-length Gene

The provided polynucleotide (e.g., a polynucleotide having a sequence of one of “SEQ ID NOS:1-5252”), the corresponding cDNA, or the full-length gene is used to express a partial or complete gene product. Constructs of polynucleotides having sequences of “SEQ ID NOS:1-5252” can be generated synthetically. Alternatively, single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides is described by, e.g., Stemmer et al., Gene (Amsterdam) (1995) 164(1):49-53. In this method, assembly PCR (the synthesis of long DNA sequences from large numbers of oligodeoxyribonucleotides (oligos)) is described. The method is derived from DNA shuffling (Stemmer, Nature (1994) 370:389-391), and does not rely on DNA ligase, but instead relies on DNA polymerase to build increasingly longer DNA fragments during the assembly process.

Appropriate polynucleotide constructs are purified using standard recombinant DNA techniques as described in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, N.Y., and under current regulations described in United States Dept. of HHS, National Institute of Health (NIH) Guidelines for Recombinant DNA Research. The gene product encoded by a polynucleotide of the invention is expressed in any expression system, including, for example, bacterial, yeast, insect, amphibian and mammalian systems. Suitable vectors and host cells are described in U.S. Pat. No. 5,654,173.

Bacteria. Expression systems in bacteria include those described in Chang et al., Nature (1978) 275:615; Goeddel et al., Nature (1979) 281:544; Goeddel et al., Nucleic Acids Res. (1980) 8:4057; EP 0 036,776; U.S. Pat. No. 4,551,433; DeBoer et al., Proc. Nat. Acad. Sci. (USA) (1983) 80:21-25; and Siebenlist et al., Cell (1980) 20:269.

Yeast. Expression systems in yeast include those described in Hinnen et al., Proc. Natl. Acad. Sci. (USA) (1978) 75:1929; Ito et al., J. Bacteriol. (1983) 153:163; Kurtz et al., Mol Cell. Biol. (1986) 6:142; Kunze et al., J. Basic Microbiol. (1985) 25:141; Gleeson et al., J. Gen. Microbiol. (1986) 132:3459; Roggenkamp et al., Mol Gen. Genet. (1986) 202:302; Das et al., J. Bacteriol. (1984) 158:1165; De Louveacourt et al., J. Bacteriol. (1983) 154:737; Van den Berg et al., Bio/Technology (1990) 8:135; Kunze et al., J. Basic Microbiol. (1985) 25:141; Cregg et al., Mol. Cell. Biol. (1985) 5:3376; U.S. Pat. Nos. 4,837,148 and 4,929,555; Beach and Nurse, Nature (1981) 300:706; Davidow et al., Curr. Genet. (1985) 10:380; Gaillardin et al., Curr. Genet. (1985) 10:49; Ballance et al., Biochem. Biophys. Res. Commun. (1983) 112:284-289; Tilburn et al., Gene (1983) 26:205-221; Yelton et al., Proc. Natl. Acad. Sci. (USA) (1984) 81:1470-1474; Kelly and Hynes, EMBO J. (1985) 4:475479; EP 0 244,234; and WO 91/00357.

Insect Cells. Expression of heterologous genes in insects is accomplished as described in U.S. Pat. No. 4,745,051; Friesen et al., “The Regulation of Baculovirus Gene Expression”, in: The Molecular Biology Of Baculoviruses (1986) (W. Doerfler, ed.); EP 0 127,839; EP 0 155,476; and Vlak et al., J. Gen. Virol. (1988) 69:765-776; Miller et al., Ann. Rev. Microbiol. (1988) 42:177; Carbonell et al., Gene (1988) 73:409; Maeda et al., Nature (1985) 315:592-594; Lebacq-Verheyden et al., Mol. Cell. Biol. (1988) 8:3129; Smith et al., Proc. Natl. Acad. Sci. (USA) (1985) 82:8844; Miyajima et al., Gene (1987) 58:273; and Martin et al., DNA (1988) 7:99. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts are described in Luckow et al., Bio/Technology (1988) 6:47-55, Miller et al., Generic Engineering (1986) 8:277-279, and Maeda et al., Nature (1985) 315:592-594.

Mammalian Cells. Mammalian expression is accomplished as described in Dijkema et al., EMBO J. (1985) 4:761, Gorman et al., Proc. Nat. Acad. Sci. (USA) (1982) 79:6777, Boshart et al., Cell (1985) 41:521 and U.S. Pat. No. 4,399,216. Other features of mammalian expression are facilitated as described in Ham and Wallace, Meth. Enz. (1979) 58:44, Barnes and Sato, Anal. Biochem. (1980) 102:255, U.S. Pat. Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, WO 90/103430, WO 87/00195, and U.S. Pat. No. RE 30,985.

Polynucleotide molecules comprising a polynucleotide sequence provided herein propagated by placing the molecule in a vector. Viral and non-viral vectors are used, including plasmids. The choice of plasmid will depend on the type of cell in which propagation is desired and the purpose of propagation. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence. Other vectors are suitable for expression in cells in culture. Still other vectors are suitable for transfer and expression in cells in a whole animal or person. The choice of appropriate vector is well within the skill of the art. Many such vectors are available commercially. The partial or full-length polynucleotide is inserted into a vector typically by means of DNA ligase attachment to a cleaved restriction enzyme site in the vector. Alternatively, the desired nucleotide sequence can be inserted by homologous recombination in vivo. Typically this is accomplished by attaching regions of homology to the vector on the flanks of the desired nucleotide sequence. Regions of homology are added by ligation of oligonucleotides, or by polymerase chain reaction using primers comprising both the region of homology and a portion of the desired nucleotide sequence, for example.

The polynucleotides set forth in “SEQ ID NOS:1-5252” or their corresponding full-length polynucleotides are linked to regulatory sequences as appropriate to obtain the desired expression properties. These can include promoters (attached either at the 5′ end of the sense strand or at the 3′ end of the antisense strand), enhancers, terminators, operators, repressors, and inducers. The promoters can be regulated or constitutive. In some situations it may be desirable to use conditionally active promoters, such as tissue-specific or developmental stage-specific promoters. These are linked to the desired nucleotide sequence using the techniques described above for linkage to vectors. Any techniques known in the art can be used.

When any of the above host cells, or other appropriate host cells or organisms, are used to replicate and/or express the polynucleotides or nucleic acids of the invention, the resulting replicated nucleic acid, RNA, expressed protein or polypeptide, is within the scope of the invention as a product of the host cell or organism. The product is recovered by any appropriate means known in the art.

Once the gene corresponding to a selected polynucleotide is identified, its expression can be regulated in the cell to which the gene is native. For example, an endogenous gene of a cell can be regulated by an exogenous regulatory sequence as disclosed in U.S. Pat. No. 5,641,670.

III. Identification of Functional and Structural Motifs of Novel Genes

A. Screening Polynucleotide Sequences and Amino Acid Sequences Against Publicly Available Databases

Translations of the nucleotide sequence of the provided polynucleotides, cDNAs or full genes can be aligned with individual known sequences. Similarity with individual sequences can be used to determine the activity of the polypeptides encoded by the polynucleotides of the invention. For example, sequences that show similarity with a chemokine sequence can exhibit chemokine activities. Also, sequences exhibiting similarity with more than one individual sequence can exhibit activities that are characteristic of either or both individual sequences.

The full length sequences and fragments of the polynucleotide sequences of the nearest neighbors can be used as probes and primers to identify and isolate the full length sequence corresponding to provided polynucleotides. The nearest neighbors can indicate a tissue or cell type to be used to construct a library for the full-length sequences corresponding to the provided polynucleotides.

Typically, a selected polynucleotide is translated in all six frames to determine the best alignment with the individual sequences. The sequences disclosed herein in the Sequence Listing are in a 5′ to 3′ orientation and translation in three frames can be sufficient (with a few specific exceptions as described in the Examples). These amino acid sequences are referred to, generally, as query sequences, which will be aligned with the individual sequences. Databases with individual sequences are described in “Computer Methods for Macromolecular Sequence Analysis” Methods in Enzymology (1996) 266, Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, Calif., USA. Databases include Genbank, EMBL, and DNA Database of Japan (DDBJ).

Query and individual sequences can be aligned using the methods and computer programs described above, and include BLAST, available over the world wide web at http://ww.ncbi.nlm.nih.gov/BLAST/. Another alignment algorithm is Fasta, available in the Genetics Computing Group (GCG) package, Madison, Wis., USA, a wholly owned subsidiary of Oxford Molecular Group, Inc. Other techniques for alignment are described in Doolittle, supra. Preferably, an alignment program that permits gaps in the sequence is utilized to align the sequences. The Smith-Waterman is one type of algorithm that permits gaps in sequence alignments. See Meth Mol. Biol. (1997) 70: 173-187. Also, the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. An alternative search strategy uses MPSRCH software, which runs on a MASPAR computer. MPSRCH uses a Smith-Waterman algorithm to score sequences on a massively parallel computer. This approach improves ability to identify sequences that are distantly related matches, and is especially tolerant of small gaps and nucleotide sequence errors. Amino acid sequences encoded by the provided polynucleotides can be used to search both protein and DNA databases.

Results of individual and query sequence alignments can be divided into three categories, high similarity, weak similarity, and no similarity. Individual alignment results ranging from high similarity to weak similarity provide a basis for determining polypeptide activity and/or structure. Parameters for categorizing individual results include: percentage of the alignment region length where the strongest alignment is found, percent sequence identity, and p value.

The percentage of the alignment region length is calculated by counting the number of residues of the individual sequence found in the region of strongest alignment, e.g., contiguous region of the individual sequence that contains the greatest number of residues that are identical to the residues of the corresponding region of the aligned query sequence. This number is divided by the total residue length of the query sequence to calculate a percentage. For example, a query sequence of 20 amino acid residues might be aligned with a 20 amino acid region of an individual sequence. The individual sequence might be identical to amino acid residues 5, 9-15, and 17-19 of the query sequence. The region of strongest alignment is thus the region stretching from residue 9-19, an 11 amino acid, stretch. The percentage of the alignment region length is: 11 (length of the region of strongest alignment) divided by (query sequence length) 20 or 55%.

Percent sequence identity is calculated by counting the number of amino acid matches between the query and individual sequence and dividing total number of matches by the number of residues of the individual sequences found in the region of strongest alignment. Thus, the percent identity in the example above would be 10 matches divided by 11 amino acids, or approximately, 90.9%.

P value is the probability that the alignment was produced by chance. For a single alignment, the p value can be calculated according to Karlin et al., Proc. Natl. Acad Sci. (1990) 87:2264 and Karlin et al., Proc. Natl. Acad Sci. (1993) 90. The p value of multiple alignments using the same query sequence can be calculated using an heuristic approach described in Altschul et al., Nat. Genet. (1994) 6:119. Alignment programs such as BLAST program can calculate the p value.

Another factor to consider for determining identity or similarity is the location of the similarity or identity. Strong local alignment can indicate similarity even if the length of alignment is short. Sequence identity scattered throughout the length of the query sequence also can indicate a similarity between the query and profile sequences. The boundaries of the region where the sequences align can be determined according to Doolittle. supra; BLAST or FAST programs; or by determining the area where sequence identity is highest.

High Similarity. In general, in alignment results considered to be of high similarity, the percent of the alignment region length is typically at least about 55% of total length query sequence; more typically, at least, about 58%; even more typically; at least about 60% of the total residue length of the query sequence. Usually, percent length of the alignment region can be as much as about 62%; more usually, as much as about 64%; even more usually, as much as about 66%. Further, for high similarity, the region of alignment, typically, exhibits at least about 75% of sequence identity; more typically, at least about 78%; even more typically; at least about 80% sequence identity. Usually, percent sequence identity can be as much as about 82%; more usually, as much as about 84%; even more usually, as much as about 86%.

The p value is used in conjunction with these methods. If high similarity is found, the query sequence is considered to have high similarity with a profile sequence when the p value is less than or equal to about 10⁻²; more usually; less than or equal to about 10⁻³; even more usually; less than or equal to about 10⁻⁴. More typically, the p value is no more than about 10⁻⁵; more typically; no more than or equal to about 10⁻¹⁰; even more typically; no more than or equal to about 10⁻¹⁵ for the query sequence to be considered high similarity.

Weak Similarity. In general, where alignment results considered to be of weak similarity, there is no minimum percent length of the alignment region nor minimum length of alignment. A better showing of weak similarity is considered when the region of alignment is, typically, at least about 15 amino acid residues in length; more typically, at least about 20; even more typically; at least about 25 amino acid residues in length. Usually, length of the alignment region can be as much as about 30 amino acid residues; more usually, as much as about 40; even more usually, as much as about 60 amino acid residues. Further, for weak similarity, the region of alignment, typically, exhibits at least about 35% of sequence identity; more typically, at least about 40%; even more typically; at least about 45% sequence identity. Usually, percent sequence identity can be as much as about 50%; more usually, as much as about 55%; even more usually, as much as about 60%.

If low similarity is found, the query sequence is considered to have weak similarity with a profile sequence when the p value is usually less than or equal to about 10⁻²; more usually; less than or equal to about 10⁻³; even more usually; less than or equal to about 10⁻⁴. More typically, the p value is no more than about 10⁻⁵; more usually; no more than or equal to about 10⁻¹⁰; even more usually; no more than or equal to about 10⁻¹⁵ for the query sequence to be considered weak similarity.

Similarity Determined by Sequence Identity Alone. Sequence identity alone can be used to determine similarity of a query sequence to an individual sequence and can indicate the activity of the sequence. Such an alignment, preferably, permits gaps to align sequences. Typically, the query sequence is related to the profile sequence if the sequence identity over the entire query sequence is at least about 15%; more typically, at least about 20%; even more typically, at least about 25%; even more typically, at least about 50%. Sequence identity alone as a measure of similarity is most useful when the query sequence is usually, at least 80 residues in length; more usually, 90 residues; even more usually, at least 95 amino acid residues in length. More typically, similarity can be concluded based on sequence identity alone when the query sequence is preferably 100 residues in length; more preferably, 120 residues in length; even more preferably, 150 amino acid residues in length.

Determining Activity from Alignments with Profile and Multiple Aligned Sequences. Translations of the provided polynucleotides can be aligned with amino acid profiles that define either protein families or common motifs. Also, translations of the provided polynucleotides can be aligned to multiple sequence alignments (MSA) comprising the polypeptide sequences of members of protein families or motifs. Similarity or identity with profile sequences or MSAs can be used to determine the activity of the gene products (e.g., polypeptides) encoded by the provided polynucleotides or corresponding cDNA or genes. For example, sequences that show an identity or similarity with a chemokine profile or MSA can exhibit chemokine activities.

Profiles can designed manually by (1) creating an MSA, which is an alignment of the amino acid sequence of members that belong to the family and (2) constructing a statistical representation of the alignment. Such methods are described, for example, in Birney et al., Nucl. Acid Res. (1996) 24(14): 2730-2739. MSAs of some protein families and motifs are publicly available. For example, http://genome.wustl.edu/Pfam/ includes MSAs of 547 different families and motifs. These MSAs are described also in Sonnhammer et al., Proteins (1997) 28: 405-420. Other sources over the world wide web include the site at http://www.embl-heidelberg.de/argos/ali/ali.html; alternatively, a message can be sent to ALI@EMBL-HEIDELBERG.DE for the information. A brief description of these MSAs is reported in Pascarella et al., Prot. Eng. (1996) 9(3):249-251. Techniques for building profiles from MSAs are described in Sonnhammer et al., supra; Birney et al., supra; and “Computer Methods for Macromolecular Sequence Analysis,” Methods in Enzymology (1996) 266, Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, Calif., USA.

Similarity between a query sequence and a protein family or motif can be determined by (a) comparing the query sequence against the profile and/or (b) aligning the query sequence with the members of the family or motif. Typically, a program such as Search wise is used to compare the query sequence to the statistical representation of the multiple alignment, also known as a profile. The program is described in Birney et al., supra. Other techniques to compare the sequence and profile are described in Sonnhammer et al., supra and Doolittle, supra.

Next, methods described by Feng et al., J. Mol. Evol. (1987) 25:351 and Higgins et al., CABIOS (1989) 5:151 can be used align the query sequence with the members of a family or motif, also known as a MSA. Computer programs, such as PILEUP, can be used. See Feng et al., infra. In general, the following factors are used to determine if a similarity between a query sequence and a profile or MSA exists: (1) number of conserved residues found in the query sequence, (2) percentage of conserved residues found in the query sequence, (3) number of frameshifts, and (4) spacing between conserved residues.

Some alignment programs that both translate and align sequences can make any number of frameshifts when translating the nucleotide sequence to produce the best alignment. The fewer frameshifts needed to produce an alignment, the stronger the similarity or identity between the query and profile or MSAs. For example, a weak similarity resulting from no frameshifts can be a better indication of activity or structure of a query sequence, than a strong similarity resulting from two frameshifts. Preferably, three or fewer frameshifts are found in an alignment; more preferably two or fewer frameshifts; even more preferably, one or fewer frameshifts; even more preferably, no frameshifts are found in an alignment of query and profile or MSAs.

Conserved residues are those amino acids found at a particular position in all or some of the family or motif members. For example, most chemokines contain four conserved cysteines. Alternatively, a position is considered conserved if only a certain class of amino acids is found in a particular position in all or some of the family members. For example, the N-terminal position can contain a positively charged amino acid, such as lysine, arginine, or histidine.

Typically, a residue of a polypeptide is conserved when a class of amino acids or a single amino acid is found at a particular position in at least about 40% of all class members; more typically, at least about 50%; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%; even more usually, at least about 90%; even more usually, at least about 95%.

A residue is considered conserved when three unrelated amino acids are found at a particular position in the some or all of the members; more usually, two unrelated amino acids. These residues are conserved when the unrelated amino acids are found at particular positions in at least about 40% of all class member; more typically, at least about 50%; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%; even more usually, at least about 90%; even more usually, at least about 95%.

A query sequence has similarity to a profile or MSA when the query sequence comprises at least about 25% of the conserved residues of the profile or MSA; more usually, at least about 30%; even more usually; at least about 40%. Typically, the query sequence has a stronger similarity to a profile sequence or MSA when the query sequence comprises at least about 45% of the conserved residues of the profile or MSA; more typically, at least about 50%; even more typically; at least about 55%.

B. Screening Polynucleotide and Amino Acid Sequences Against Protein Profiles

The identify and function of the gene that correlates to a polynucleotide described herein can be determined by screening the polynucleotides or their corresponding amino acid sequences against profiles of protein families. Such profiles focus on common structural motifs among proteins of each family. Publicly available profiles are described above in Section IVA. Additional or alternative profiles are described below.

In comparing a novel polynucleotide with known sequences, several alignment tools are available. Examples include PileUp, which creates a multiple sequence alignment, and is described in Feng et al., J. Mol. Evol. (1987) 25:351. Another method, GAP, uses the alignment method of Needleman et al., J. Mol. Biol. (1970) 48:443. GAP is best suited for global alignment of sequences. A third method, BestFit, functions by inserting gaps to maximize the number of matches using the local homology algorithm of Smith et al., Adv. Appl. Math. (1981) 2:482.

C. Identification of Secreted & Membrane-bound Polypeptides

Both secreted and membrane-bound polypeptides of the present invention are of particular interest. For example, levels of secreted polypeptides can be assayed in body fluids that are convenient, such as blood, urine, prostatic fluid and semen. Membrane-bound polypeptides are useful for constructing vaccine antigens or inducing an immune response. Such antigens would comprise all or part of the extracellular region of the membrane-bound polypeptides. Because both secreted and membrane-bound polypeptides comprise a fragment of contiguous hydrophobic amino acids, hydrophobicity predicting algorithms can be used to identify such polypeptides.

A signal sequence is usually encoded by both secreted and membrane-bound polypeptide genes to direct a polypeptide to the surface of the cell. The signal sequence usually comprises a stretch of hydrophobic residues. Such signal sequences can fold into helical structures. Membrane-bound polypeptides typically comprise at least one transmembrane region that possesses a stretch of hydrophobic amino acids that can transverse the membrane. Some transmembrane regions also exhibit a helical structure. Hydrophobic fragments within a polypeptide can be identified by using computer algorithms. Such algorithms include Hopp & Woods, Proc. Natl. Acad Sci. USA (1981) 78:3824-3828; Kyte & Doolittle, J. Mol. Biol. (1982) 157: 105-132; and RAOAR algorithm, Degli Esposti et al., Eur. J. Biochem. (1990) 190: 207-219.

Another method of identifying secreted and membrane-bound polypeptides is to translate the polynucleotides of the invention in all six frames and determine if at least 8 contiguous hydrophobic amino acids are present. Those translated polypeptides with at least 8; more typically, 10; even more typically, 12 contiguous hydrophobic amino acids are considered to be either a putative secreted or membrane bound polypeptide. Hydrophobic amino acids include alanine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, and valine.

IV. Identification of the Function of an Expression Product of a Full-length Gene Corresponding to a Polynucleotide

Ribozymes, antisense constructs, and dominant negative mutants can be used to determine function of the expression product of a gene corresponding to a polynucleotide provided herein. These methods and compositions are particularly useful where the provided novel polynucleotide exhibits no significant or substantial homology to a sequence encoding a gene of known function. Antisense molecules and ribozymes can be constructed from synthetic polynucleotides. Typically, the phosphoramidite method of oligonucleotide synthesis is used. See Beaucage et al., Tet. Lett. (1981) 22:1859 and U.S. Pat. No. 4,668,777. Automated devices for synthesis are available to create oligonucleotides using this chemistry. Examples of such devices include Biosearch 8600, Models 392 and 394 by Applied Biosystems, a division of Perkin-Elmer Corp., Foster City, Calif., USA; and Expedite by Perceptive Biosystems, Framingham, Mass., USA. Synthetic RNA, phosphate analog oligonucleotides, and chemically derivatized oligonucleotides can also be produced, and can be covalently attached to other molecules. RNA oligonucleotides can be synthesized, for example, using RNA phosphoramidites. This method can be performed on an automated synthesizer, such as Applied Biosystems, Models 392 and 394, Foster City, Calif., USA. See Applied Biosystems User Bulletin 53 and Ogilvie et al., Pure & Applied Chem. (1987) 59:325.

Phosphorothioate oligonucleotides can also be synthesized for antisense construction. A sulfurizing reagent, such as tetraethylthiruam disulfide (TETD) in acetonitrile can be used to convert the internucleotide cyanoethyl phosphite to the phosphorothioate triester within 15 minutes at room temperature. TETD replaces the iodine reagent, while all other reagents used for standard phosphoramidite chemistry remain the same. Such a synthesis method can be automated using Models 392 and 394 by Applied Biosystems, for example.

Oligonucleotides of up to 200 nucleotides can be synthesized, more typically, 100 nucleotides, more typically 50 nucleotides; even more typically 30 to 40 nucleotides. These synthetic fragments can be annealed and ligated together to construct larger fragments. See, for example, Sambrook et al., supra.

A. Ribozymes

Trans-cleaving catalytic RNAs (ribozymes) are RNA molecules possessing endoribonuclease activity. Ribozymes are specifically designed for a particular target, and the target message must contain a specific nucleotide sequence. They are engineered to cleave any RNA species site-specifically in the background of cellular RNA. The cleavage event renders the mRNA unstable and prevents protein expression. Importantly, ribozymes can be used to inhibit expression of a gene of unknown function for the purpose of determining its function in an in vitro or in vivo context, by detecting the phenotypic effect.

One commonly used ribozyme motif is the hammerhead, for which the substrate sequence requirements are minimal. Design of the hammerhead ribozyme is disclosed in Usman et al., Current Opin. Struct. Biol. (1996) 6:527. Ribozymes can also be prepared and used as described in Long et al., FASEB J. (1993) 7:25; Symons, Ann. Rev. Biochem. (1992) 61:641; Perrotta et al., Biochem. (1992) 31:16; Ojwang et al., Proc. Natl. Acad. Sci. (USA) (1992) 89:10802; and U.S. Pat. No. 5,254,678. Ribozyme cleavage of HIV-I RNA is described in U.S. Pat. No. 5,144,019; methods of cleaving RNA using ribozymes is described in U.S. Pat. No. 5,116,742; and methods for increasing the specificity of ribozymes are described in U.S. Pat. No. 5,225,337 and Koizumi et al., Nucleic Acid Res. (1989) 17:7059. Preparation and use of ribozyme fragments in a hammerhead structure are also described by Koizumi et al., Nucleic Acids Res. (1989) 17:7059. Preparation and use of ribozyme fragments in a hairpin structure are described by Chowrira and Burke, Nucleic Acids Res. (1992) 20:2835. Ribozymes can also be made by rolling transcription as described in Daubendiek and Kool, Nat. Biotechnol. (1997) 15(3):273.

The hybridizing region of the ribozyme can be modified or can be prepared as a branched structure as described in Hom and Urdea, Nucleic Acids Res. (1989) 17:6959. The basic structure of the ribozymes can also be chemically altered in ways familiar to those skilled in the art, and chemically synthesized ribozymes can be administered as synthetic oligonucleotide derivatives modified by monomeric units. In a therapeutic context, liposome mediated delivery of ribozymes improves cellular uptake, as described in Birikh et al., Eur. J. Biochem. (1997) 245:1.

Using the polynucleotide sequences of the invention and methods known in the art, ribozymes are designed to specifically bind and cut the corresponding mRNA species. Ribozymes thus provide a means to inhibit the expression of any of the proteins encoded by the disclosed polynucleotides or their full-length genes. The full-length gene need not be known in order to design and use specific inhibitory ribozymes. In the case of a polynucleotide or full-length cDNA of unknown function, ribozymes corresponding to that nucleotide sequence can be tested in vitro for efficacy in cleaving the target transcript. Those ribozymes that effect cleavage in vitro are further tested in vivo. The ribozyme can also be used to generate an animal model for a disease, as described in Birikh et al., supra. An effective ribozyme is used to determine the function of the gene of interest by blocking its transcription and detecting a change in the cell. Where the gene is found to be a mediator in a disease, an effective ribozyme is designed and delivered in a gene therapy for blocking transcription and expression of the gene.

Therapeutic and functional genomic applications of ribozymes proceed beginning with knowledge of a portion of the coding sequence of the gene to be inhibited. Thus, for many genes, a partial polynucleotide sequence provides adequate sequence for constructing an effective ribozyme. A target cleavage site is selected in the target sequence, and a ribozyme is constructed based on the 5′ and 3′ nucleotide sequences that flank the cleavage site. Retroviral vectors are engineered to express monomeric and multimeric hammerhead ribozymes targeting the mRNA of the target coding sequence. These monomeric and multimeric ribozymes are tested in vitro for an ability to cleave the target mRNA. A cell line is stably transduced with the retroviral vectors expressing the ribozymes, and the transduction is confirmed by Northern blot analysis and reverse-transcription polymerase chain reaction (RT-PCR). The cells are screened for inactivation of the target mRNA by such indicators as reduction of expression of disease markers or reduction of the gene product of the target mRNA.

B. Antisense

Antisense nucleic acids are designed to specifically bind to RNA, resulting in the formation of RNA-DNA or RNA-RNA hybrids, with an arrest of DNA replication, reverse transcription or messenger RNA translation. Antisense polynucleotides based on a selected polynucleotide sequence can interfere with expression of the corresponding gene. Antisense polynucleotides are typically generated within the cell by expression from antisense constructs that contain the antisense strand as the transcribed strand. Antisense polynucleotides based on the disclosed polynucleotides will bind and/or interfere with the translation of mRNA comprising a sequence complementary to the antisense polynucleotide. The expression products of control cells and cells treated with the antisense construct are compared to detect the protein product of the gene corresponding to the polynucleotide upon which the antisense construct is based. The protein is isolated and identified using routine biochemical methods.

Given the extensive background literature and clinical experience in antisense therapy, one skilled in the art can use selected polynucleotides of the invention as additional potential therapeutics. The choice of polynucleotide can be narrowed by first testing them for binding to “hot spot” regions of the genome of cancerous cells. If a polynucleotide is identified as binding to a “hot spot”, testing the polynucleotide as an antisense compound in the corresponding cancer cells clearly is warranted.

C. Dominant Negative Mutations

As an alternative method for identifying function of the gene corresponding to a polynucleotide disclosed herein, dominant negative mutations are readily generated for corresponding proteins that are active as homomultimers. A mutant polypeptide will interact with wild-type polypeptides (made from the other allele) and form a non-functional multimer. Thus, a mutation is in a substrate-binding domain, a catalytic domain, or a cellular localization domain. Preferably, the mutant polypeptide will be overproduced. Point mutations are made that have such an effect. In addition, fusion of different polypeptides of various lengths to the terminus of a protein can yield dominant negative mutants. General strategies are available for making dominant negative mutants (see, e.g., Herskowitz, Nature (1987) 329:219). Such techniques can be used to create loss of function mutations, which are useful for determining protein function.

V. Construction of Polypeptides of the Invention and Variants Thereof

The polypeptides of the invention include those encoded by the disclosed polynucleotides. These polypeptides can also be encoded by nucleic acids that, by virtue of the degeneracy of the genetic code, are not identical in sequence to the disclosed polynucleotides. Thus, the invention includes within its scope a polypeptide encoded by a polynucleotide having the sequence of any one of “SEQ ID NOS:1-5252” or a variant thereof.

In general, the term “polypeptide” as used herein refers to both the full length polypeptide encoded by the recited polynucleotide, the polypeptide encoded by the gene represented by the recited polynucleotide, as well as portions or fragments thereof. “Polypeptides” also includes variants of the naturally occurring proteins, where such variants are homologous or substantially similar to the naturally occurring protein, and can be of an origin of the same or different species as the naturally occurring protein (e.g., human, murine, or some other species that naturally expresses the recited polypeptide, usually a mammalian species). In general, variant polypeptides have a sequence that has at least about 80%, usually at least about 90%, and more usually at least about 98% sequence identity with a differentially expressed polypeptide of the invention, as measured by BLAST using the parameters described above. The variant polypeptides can be naturally or non-naturally glycosylated, i.e., the polypeptide has a glycosylation pattern that differs from the glycosylation pattern found in the corresponding naturally occurring protein.

The invention also encompasses homologs of the disclosed polypeptides (or fragments thereof) where the homologs are isolated from other species, i.e. other animal or plant species, where such homologs, usually mammalian species, e.g. rodents, such as mice, rats; domestic animals, e.g., horse, cow, dog, cat; and humans. By homolog is meant a polypeptide having at least about 35%, usually at least about 40% and more usually at least about 60% amino acid sequence identity a particular differentially expressed protein as identified above, where sequence identity is determined using the BLAST algorithm, with the parameters described supra.

In general, the polypeptides of the subject invention are provided in a non-naturally occurring environment, e.g. are separated from their naturally occurring environment. In certain embodiments, the subject protein is present in a composition that is enriched for the protein as compared to a control. As such, purified polypeptide is provided, where by purified is meant that the protein is present in a composition that is substantially free of non-differentially expressed polypeptides, where by substantially free is meant that less than 90%, usually less than 60% and more usually less than 50% of the composition is made up of non-differentially expressed polypeptides.

Also within the scope of the invention are variants; variants of polypeptides include mutants, fragments, and fusions. Mutants can include amino acid substitutions, additions or deletions. The amino acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acids, such as to alter a glycosylation site, a phosphorylation site or an acetylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function. Conservative amino acid substitutions are those that preserve the general charge, hydrophobicity/hydrophilicity, and/or steric bulk of the amino acid substituted. For example, substitutions between the following groups are conservative: Gly/Ala, Val/Ile/Leu, Asp/Glu, Lys/Arg, Asn/Gln, Ser/Cys, Thr, and Phe/Trp/Tyr.

Variants can be designed so as to retain biological activity of a particular region of the protein (e.g., a functional domain and/or, where the polypeptide is a member of a protein family, a region associated with a consensus sequence). In a non-limiting example, Osawa et al., Biochem Mol. Int. (1994) 34:1003, discusses the actin binding region of a protein from several different species. The actin binding regions of the these species are considered homologous based on the fact that they have amino acids that fall within “homologous residue groups.” Homologous residues are judged according to the following groups (using single letter amino acid designations): STAG; ILVMF; HRK; DEQN; and FYW. For example, and S, a T, an A or a G can be in a position and the function (in this case actin binding) is retained.

Additional guidance on amino acid substitution is available from studies of protein evolution. Go et al., Int. J. Peptide Protein Res. (1980) 15:211, classified amino acid residue sites as interior or exterior depending on their accessibility. More frequent substitution on exterior sites was confirmed to be general in eight sets of homologous protein families regardless of their biological functions and the presence or absence of a prosthetic group. Virtually all types of amino acid residues had higher mutabilities on the exterior than in the interior. No correlation between mutability and polarity was observed of amino acid residues in the interior and exterior, respectively. Amino acid residues were classified into one of three groups depending on their polarity: polar (Arg, Lys, His, Gln, Asn, Asp, and Glu); weak polar (Ala, Pro, Gly, Thr, and Ser), and nonpolar (Cys, Val, Met, Ile, Leu, Phe, Tyr, and Trp). Amino acid replacements during protein evolution were very conservative: 88% and 76% of them in the interior or exterior, respectively, were within the same group of the three. Inter-group replacements are such that weak polar residues are replaced more often by nonpolar residues in the interior and more often by polar residues on the exterior.

Additional guidance for production of polypeptide variants is provided in Querol et al., Prot. Eng. (1996) 9:265, which provides general rules for amino acid substitutions to enhance protein thermostability. New glycosylation sites can be introduced as discussed in Olsen and Thomsen, J. Gen. Microbiol. (1991) 137:579. An additional disulfide bridge can be introduced, as discussed by Perry and Wetzel, Science (1984) 226:555; Pantoliano et al., Biochemistry (1987) 26:2077; Matsumura et al., Nature (1989) 342:291; Nishikawa et al., Protein Eng. (1990) 3:443; Takagi et al., J. Biol. Chem. (1990) 265:6874; Clarke et al., Biochemistry (1993) 32:4322; and Wakarchuk et al., Protein Eng. (1994) 7:1379. Metal binding sites can be introduced, according to Toma et al., Biochemistry (1991) 30:97, and Haezerbrouck et al., Protein Eng. (1993) 6:643. Substitutions with prolines in loops can be made according to Masul et al., Appl. Env. Microbiol. (1994) 60:3579; and Hardy et al., FEBS Lett. 317:89.

Cysteine-depleted muteins are considered variants within the scope of the invention. These variants can be constructed according to methods disclosed in U.S. Pat. No. 4,959,314, which discloses substitution of cysteines with other amino acids, and methods for assaying biological activity and effect of the substitution. Such methods are suitable for proteins according to this invention that have cysteine residues suitable for such substitutions, for example to eliminate disulfide bond formation.

Variants also include fragments of the polypeptides disclosed herein, particularly biologically active fragments and/or fragments corresponding to functional domains. Fragments of interest will typically be at least about 10 aa to at least about 15 aa in length, usually at least about 50 aa in length, and can be as long as 300 aa in length or longer, but will usually not exceed about 1000 aa in length, where the fragment will have a stretch of amino acids that is identical to a polypeptide encoded by a polynucleotide having a sequence of any “SEQ ID NOS:1-5252”, or a homolog thereof.

The protein variants described herein are encoded by polynucleotides that are within the scope of the invention. The genetic code can be used to select the appropriate codons to construct the corresponding variants.

VI. Computer-related Embodiments

In general, a library of polynucleotides is a collection of sequence information, which information is provided in either biochemical form (e.g., as a collection of polynucleotide molecules), or in electronic form (e.g., as a collection of polynucleotide sequences stored in a computer-readable form, as in a computer system and/or as part of a computer program). The sequence information of the polynucleotides can be used in a variety of ways, e.g., as a resource for gene discovery, as a representation of sequences expressed in a selected cell type (e.g., cell type markers), and/or as markers of a given disease or disease state. In general, a disease marker is a representation of a gene product that is present in all cells affected by disease either at an increased or decreased level relative to a normal cell (e.g., a cell of the same or similar type that is not substantially affected by disease). For example, a polynucleotide sequence in a library can be a polynucleotide that represents an mRNA,polypeptide, or other gene product encoded by the polynucleotide, that is either overexpressed or underexpressed in a breast ductal cell affected by cancer relative to a normal (i.e., substantially disease-free) breast cell.

The nucleotide sequence information of the library can be embodied in any suitable form, e.g., electronic or biochemical forms. For example, a library of sequence information embodied in electronic form includes an accessible computer data file (or, in biochemical form, a collection of nucleic acid molecules) that contains the representative nucleotide sequences of genes that are differentially expressed (e.g., overexpressed or underexpressed) as between, for example, i) a cancerous cell and a normal cell; ii) a cancerous cell and a dysplastic cell; iii) a cancerous cell and a cell affected by a disease or condition other than cancer; iv) a metastatic cancerous cell and a normal cell and/or non-metastatic cancerous cell; v) a malignant cancerous cell and a non-malignant cancerous cell (or a normal cell) and/or vi) a dysplastic cell relative to a normal cell. Other combinations and comparisons of cells affected by various diseases or stages of disease will be readily apparent to the ordinarily skilled artisan. Biochemical embodiments of the library include a collection of nucleic acids that have the sequences of the genes in the library, where the nucleic acids can correspond to the entire gene in the library or to a fragment thereof, as described in greater detail below.

The polynucleotide libraries of the subject invention include sequence information of a plurality of polynucleotide sequences, where at least one of the polynucleotides has a sequence of any of “SEQ ID NOS:1-5252.” By plurality is meant at least 2, usually at least and can include up to all of “SEQ ID NOS:1-5252.” The length and number of polynucleotides in the library will vary with the nature of the library, e.g., if the library is an oligonucleotide array, a cDNA array, a computer database of the sequence information, etc.

Where the library is an electronic library, the nucleic acid sequence information can be present in a variety of media. “Media” refers to a manufacture, other than an isolated nucleic acid molecule, that contains the sequence information of the present invention. Such a manufacture provides the genome sequence or a subset thereof in a form that can be examined by means not directly applicable to the sequence as it exists in a nucleic acid. For example, the nucleotide sequence of the present invention, e.g. the nucleic acid sequences of any of the polynucleotides of “SEQ ID NOS:1-5252,” can be recorded on computer readable media, e.g. any medium that can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as a floppy disc, a hard disc storage medium, and a magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. One of skill in the art can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising a recording of the present sequence information. “Recorded” refers to a process for storing information on computer readable medium, using any such methods as known in the art. Any convenient data storage structure can be chosen, based on the means used to access the stored information. A variety of data processor programs and formats can be used for storage, e.g. word processing text file, database format, etc. In addition to the sequence information, electronic versions of the libraries of the invention can be provided in conjunction or connection with other computer-readable information and/or other types of computer-readable files (e.g., searchable files, executable files, etc, including, but not limited to, for example, search program software, etc.).

By providing the nucleotide sequence in computer readable form, the information can be accessed for a variety of purposes. Computer software to access sequence information is publicly available. For example, the BLAST (Altschul et al., supra.) and BLAZE (Brutlag et al. Comp. Chem. (1993) 17:203) search algorithms on a Sybase system can be used to identify open reading frames (ORFs) within the genome that contain homology to ORFs from other organisms.

As used herein, “a computer-based system” refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based system are suitable for use in the present invention. The data storage means can comprise any manufacture comprising a recording of the present sequence information as described above, or a memory access means that can access such a manufacture.

“Search means” refers to one or more programs implemented on the computer-based system, to compare a target sequence or target structural motif with the stored sequence information. Search means are used to identify fragments or regions of the genome that match a particular target sequence or target motif. A variety of known algorithms are publicly known and commercially available, e.g. MacPattern (EMBL), BLASTN and BLASTX (NCBI). A “target sequence” can be any DNA or amino acid sequence of six or more nucleotides or two or more amino acids, preferably from about 10 to 100 amino acids or from about 30 to 300 nucleotide residues.

A “target structural motif,” or “target motif,” refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration that is formed upon the folding of the target motif, or on consensus sequences of regulatory or active sites. There are a variety of target motifs known in the art. Protein target motifs include, but arc not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, hairpin structures, promoter sequences and other expression elements such as binding sites for transcription factors.

A variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems of the present invention. One format for an output means ranks fragments of the genome possessing varying degrees of homology to a target sequence or target motif. Such presentation provides a skilled artisan with a ranking of sequences and identifies the degree of sequence similarity contained in the identified fragment.

A variety of comparing means can be used to compare a target sequence or target motif with the data storage means to identify sequence fragments of the genome. A skilled artisan can readily recognize that any one of the publicly available homology search programs can be used as the search means for the computer based systems of the present invention.

As discussed above, the “library” of the invention also encompasses biochemical libraries of the polynucleotides of “SEQ ID NOS:1-5252,” e.g., collections of nucleic acids representing the provided polynucleotides. The biochemical libraries can take a variety of forms, e.g., a solution of cDNAs, a pattern of probe nucleic acids stably associated with a surface of a solid support (i.e., an array) and the like. Of particular interest are nucleic acid arrays in which one or more of “SEQ ID NOS:1-5252” is represented on the array. By array is meant a an article of manufacture that has at least a substrate with at least two distinct nucleic acid targets on one of its surfaces, where the number of distinct nucleic acids can be considerably higher, typically being at least 10 nt, usually at least 20 nt and often at least 25 nt. A variety of different array formats have been developed and are known to those of skill in the art, including those described in U.S. Pat. No. 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,445,934; 5,472,672; 5,527,681; 5,529,756; 5,545,531; 5,554,501; 5,556,752; 5,561,071; 5,599,895; 5,624,711; 5,639,603; 5,658,734; WO 93/17126; WO 95/11995; WO 95/35505; EP 742287; and EP 799897. The arrays of the subject invention find use in a variety of applications, including gene expression analysis, drug screening, mutation analysis and the like, as disclosed in the above-listed exemplary patent documents.

In addition to the above nucleic acid libraries, analogous libraries of polypeptides are also provided, where the where the polypeptides of the library will represent at least a portion of the polypeptides encoded by “SEQ ID NOS:1-5252.”

VII. Utilities

A. Use of Polynucleotide Probes in Mapping, and in Tissue Profiling

Polynucleotide probes, generally comprising at least 12 contiguous nucleotides of a polynucleotide as shown in the Sequence Listing, are used for a variety of purposes, such as chromosome mapping of the polynucleotide and detection of transcription levels. Additional disclosure about preferred regions of the disclosed polynucleotide sequences is found in the Examples. A probe that hybridizes specifically to a polynucleotide disclosed herein should provide a detection signal at least 5-, 10-, or 20-fold higher than the background hybridization provided with other unrelated sequences.

Probes in Detection of Expression Levels. Nucleotide probes are used to detect expression of a gene corresponding to the provided polynucleotide. In Northern blots, mRNA is separated electrophoretically and contacted with a probe. A probe is detected as hybridizing to an mRNA species of a particular size. The amount of hybridization is quantitated to determine relative amounts of expression, for example under a particular condition. Probes are used for in situ hybridization to cells to detect expression. Probes can also be used in vivo for diagnostic detection of hybridizing sequences. Probes are typically labeled with a radioactive isotope. Other types of detectable labels can be used such as chromophores, fluors, and enzymes. Other examples of nucleotide hybridization assays are described in WO92/02526 and U.S. Pat. No. 5,124,246.

The Polymerase Chain Reaction (PCR) is another means for detecting small amounts of target nucleic acids (see, e.g., Mullis et al., Meth. Enzymol. (1987) 155:335; U.S. Pat. No. 4,683,195; and U.S. Pat. No. 4,683,202). Two primer polynucleotides nucleotides hybridize with the target nucleic acids and are used to prime the reaction. The primers can be composed of sequence within or 3′ and 5′ to the polynucleotides of the Sequence Listing. Alternatively, if the primers are 3′ and 5′ to these polynucleotides, they need not hybridize to them or the complements. A thermostable polymerase creates copies of target nucleic acids from the primers using the original target nucleic acids as a template. After a large amount of target nucleic acids is generated by the polymerase, it is detected by methods such as Southern blots. When using the Southern blot method, the labeled probe will hybridize to a polynucleotide of the Sequence Listing or complement.

Furthermore, mRNA or cDNA can be detected by traditional blotting techniques described in Sambrook et al., “Molecular Cloning: A Laboratory Manual” (New York, Cold Spring Harbor Laboratory, 1989). mRNA or cDNA generated from mRNA using a polymerase enzyme can be purified and separated using gel electrophoresis. The nucleic acids on the gel are then blotted onto a solid support, such as nitrocellulose. The solid support is exposed to a labeled probe and then washed to remove any unhybridized probe. Next, the duplexes containing the labeled probe are detected. Typically, the probe is labeled with radioactivity.

Mapping. Polynucleotides of the present invention are used to identify a chromosome on which the corresponding gene resides. Such mapping can be useful in identifying the function of the polynucleotide-related gene by its proximity to other genes with known function. Function can also be assigned to the polynucleotide-related gene when particular syndromes or diseases map to the same chromosome. For example, use of polynucleotide probes in identification and quantification of nucleic acid sequence aberrations is described in U.S. Pat. No. 5,783,387.

For example, fluorescence in situ hybridization (FISH) on normal metaphase spreads facilitates comparative genomic hybridization to allow total genome assessment of changes in relative copy number of DNA sequences. See Schwartz and Samad, Curr. Opin. Biotechnol. (1994) 8:70; Kallioniemi et al., Sem. Cancer Biol. (1993) 4:41; Valdes et al., Methods in Molecular Biology (1997) 68:1, Boultwood, ed., Human Press, Totowa, N.J.

Polynucleotides are mapped to particular chromosomes using, for example, radiation hybrids or chromosome-specific hybrid panels. See Leach et al., Advances in Genetics, (1995) 33:63-99; Walter et al., Nature Genetics (1994) 7:22; Walter and Goodfellow, Trends in Genetics (1992) 9:352. Panels for radiation hybrid mapping are available from Research Genetics, Inc., Huntsville, Ala., USA. Databases for markers using various panels are available via the world wide web at http:/F/shgc-www.stanford.edu; and http://www-penome.wi.mit.edu/cpi-bin/contig/rhmapper.pl. The statistical program RHMAP can be used to construct a map based on the data from radiation hybridization with a measure of the relative likelihood of one order versus another. RHMAP is available via the world wide web at http://www.sph.umich.edu/group/statgen/software.

In addition, commercial programs are available for identifying regions of chromosomes commonly associated with disease, such as cancer. Polynucleotides based on the polynucleotides of the invention can be used to probe these regions. For example, if through profile searching a provided polynucleotide is identified as corresponding to a gene encoding a kinase, its ability to bind to a cancer-related chromosomal region will suggest its role as a kinase in one or more stages of tumor cell development/growth. Although some experimentation would be required to elucidate the role, the polynucleotide constitutes a new material for isolating a specific protein that has potential for developing a cancer diagnostic or therapeutic.

Tissue Typing or Profiling. Expression of specific mRNA corresponding to the provided polynucleotides can vary in different cell types and can be tissue-specific. This variation of mRNA levels in different cell types can be exploited with nucleic acid probe assays to determine tissue types. For example, PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes substantially identical or complementary to polynucleotides listed in the Sequence Listing can determine the presence or absence of the corresponding cDNA or mRNA.

For example, a metastatic lesion is identified by its developmental organ or tissue source by identifying the expression of a particular marker of that organ or tissue. If a polynucleotide is expressed only in a specific tissue type, and a metastatic lesion is found to express that polynucleotide, then the developmental source of the lesion has been identified. Expression of a particular polynucleotide is assayed by detection of either the corresponding mRNA or the protein product. Immunological methods, such as antibody staining, are used to detect a particular protein product. Hybridization methods can be used to detect particular mRNA species, including but not limited to in situ hybridization and Northern blotting.

Use of Polymorphisms. A polynucleotide of the invention will be useful in forensics, genetic analysis, mapping, and diagnostic applications if the corresponding region of a gene is polymorphic in the human population. Particular polymorphic forms of the provided polynucleotides can be used to either identify a sample as deriving from a suspect or rule out the possibility that the sample derives from the suspect. Any means for detecting a polymorphism in a gene are used, including but not limited to electrophoresis of protein polymorphic variants, differential sensitivity to restriction enzyme cleavage, and hybridization to allele-specific probes.

B. Antibody Production

Expression products of a polynucleotide of the invention, the corresponding mRNA or cDNA, or the corresponding complete gene are prepared and used for raising antibodies for experimental, diagnostic, and therapeutic purposes. For polynucleotides to which a corresponding gene has not been assigned, this provides an additional method of identifying the corresponding gene. The polynucleotide or related cDNA is expressed as described above, and antibodies are prepared. These antibodies are specific to an epitope on the polypeptide encoded by the polynucleotide, and can precipitate or bind to the corresponding native protein in a cell or tissue preparation or in a cell-free extract of an in vitro expression system.

Immunogens for raising antibodies are prepared by mixing the polypeptides encoded by the polynucleotides of the present invention with adjuvants. Alternatively, polypeptides are made as fusion proteins to larger immunogenic proteins. Polypeptides are also covalently linked to other larger immunogenic proteins, such as keyhole limpet hemocyanin. Immunogens are typically administered intradermally, subcutaneously or intramuscularly. Immunogens are administered to experimental animals such as rabbits, sheep, and mice, to generate antibodies. Optionally, the animal spleen cells are isolated and fused with myeloma cells to form hybridomas which secrete monoclonal antibodies. Such methods are well known in the art. According to another method known in the art, the selected polynucleotide is administered directly, such as by intramuscular injection, and expressed in vivo. The expressed protein generates a variety of protein-specific immune responses, including production of antibodies, comparable to administration of the protein.

Preparations of polyclonal and monoclonal antibodies specific for polypeptides encoded by a selected polynucleotide are made using standard methods known in the art. The antibodies specifically bind to epitopes present in the polypeptides encoded by polynucleotides disclosed in the Sequence Listing. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, for example at least 15, 25, or 50 amino acids. A short sequence of a polynucleotide may then be unsuitable for use as an epitope to raise antibodies for identifying the corresponding novel protein, because of the potential for cross-reactivity with a known protein. However, the antibodies can be useful for other purposes, particularly if they identify common structural features of a known protein and a novel polypeptide encoded by a polynucleotide of the invention.

Antibodies that specifically bind to human polypeptides encoded by the provided polypeptides should provide a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in Western blots or other immunochemical assays. Preferably, antibodies that specifically polypeptides of the invention do not bind to other proteins in immunochemical assays at detectable levels and can immunoprecipitate the specific polypeptide from solution.

To test for the presence of serum antibodies to the polypeptide of the invention in a human population, human antibodies are purified by methods well known in the art. Preferably, the antibodies are affinity purified by passing antiserum over a column to which the corresponding selected polypeptide or fusion protein is bound. The bound antibodies can then be eluted from the column, for example using a buffer with a high salt concentration.

In addition to the antibodies discussed above, genetically engineered antibody derivatives are made, such as single chain antibodies, according to methods well known in the art.

C. Use of Polynucleotides to Construct Arrays for Diagnostics

Polynucleotide arrays provide a high throughput technique that can assay a large number of polynucleotide sequences in a sample. This technology can be used as a diagnostic and as a tool to test for differential expression to determine function of an encoded protein. Arrays can be created by spotting polynucleotide probes onto a substrate (e.g., glass, nitrocellulose, etc.) in a two-dimensional matrix or array having bound probes. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. Samples of polynucleotides can be detectably labeled (e.g., using radioactive or fluorescent labels) and then hybridized to the probes. Double stranded polynucleotides, comprising the labeled sample polynucleotides bound to probe polynucleotides, can be detected once the unbound portion of the sample is washed away. Techniques for constructing arrays and methods of using these arrays are described in EP No. 0 799 897; PCT No. WO 97/29212; PCT No. WO 97/27317; EP No. 0 785 280; PCT No. WO 97/02357; U.S. Pat. No. 5,593,839; U.S. Pat. No. 5,578,832; EP No. 0 728 520; U.S. Pat. No. 5,599,695; EP No. 0 721 016; U.S. Pat. No. 5,556,752; PCT No. WO 95/22058; and U.S. Pat. No. 5,631,734.

As discussed in some detail above, arrays can be used to examine differential expression of genes and can be used to determine gene function. For example, arrays of the instant polynucleotide sequences can be used to determine if any of the provided polynucleotides are differentially expressed between a test cell and control cell (e.g., cancer cells and normal cells). For example, high expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, can indicate a cancer specific protein. Exemplary uses of arrays are further described in, for example, Pappalarado et al., Sem. Radiation Oncol. (1998) 8:217; and Rarmsay Nature Biotechnol. (1998) 16:40.

D. Differential Expression

The polynucleotides of the invention can also be used to detect differences in expression levels between two cells, e.g., as a method to identify abnormal or diseased tissue in a human. For polynucleotides corresponding to profiles of protein families, the choice of tissue can be selected according to the putative biological function. In general, the expression of a gene corresponding to a specific polynucleotide is compared between a first tissue that is suspected of being diseased and a second, normal tissue of the human. The tissue suspected of being abnormal or diseased can be derived from a different tissue type of the human, but preferably it is derived from the same tissue type; for example an intestinal polyp or other abnormal growth should be compared with normal intestinal tissue. The normal tissue can be the same tissue as that of the test sample, or any normal tissue of the patient, especially those that express the polynucleotide-related gene of interest (e.g., brain, thymus, testis, heart, prostate, placenta, spleen, small intestine, skeletal muscle, pancreas, and the mucosal lining of the colon). A difference between the polynucleotide-related gene, mRNA, or protein in the two tissues which are compared, for example in molecular weight, amino acid or nucleotide sequence, or relative abundance, indicates a change in the gene, or a gene which regulates it, in the tissue of the human that was suspected of being diseased. Examples of detection of differential expression and its use in diagnosis of cancer are described in U.S. Pat. Nos. 5,688,641 and 5,677,125.

The polynucleotide-related genes in the two tissues are compared by any means known in the art. For example, the two genes can be sequenced, and the sequence of the gene in the tissue suspected of being diseased compared with the gene sequence in the normal tissue. The genes corresponding to a provided polynucleotide, or portions thereof, in the two tissues are amplified, for example using nucleotide primers based on the nucleotide sequence shown in the Sequence Listing, using the polymerase chain reaction. The amplified genes or portions of genes are hybridized to detectably labeled nucleotide probes selected from a nucleotide sequence shown in the Sequence Listing. A difference in the nucleotide sequence of the isolated gene in the tissue suspected of being diseased compared with the normal nucleotide sequence suggests a role of the gene product encoded by the subject polynucleotide in the disease, and provides guidance for preparing a therapeutic agent.

Alternatively, mRNA corresponding to a provided polynucleotide in the two tissues is compared. PolyA⁺ RNA is isolated from the two tissues as is known in the art. For example, one of skill in the art can readily determine differences in the size or amount of mRNA transcripts between the two tissues using Northern blots and detectably labeled nucleotide probes selected from the nucleotide sequence shown in the Sequence Listing. Increased or decreased expression of a given mRNA in a tissue sample suspected of being diseased, compared with the expression of the same mRNA in a normal tissue, suggests that the expressed protein has a role in the disease, and also provides a lead for preparing a therapeutic agent.

The comparison can also be accomplished by analyzing polypeptides between the matched samples. The sizes of the proteins in the two tissues are compared, for example, using antibodies of the present invention to detect polypeptides in Western blots of protein extracts from the two tissues. Other changes, such as expression levels and subcellular localization, can also be detected immunologically, using antibodies to the corresponding protein. A higher or lower level of expression of a given polypeptide in a tissue suspected of being diseased, compared with the same protein expression level in a normal tissue, is indicative that the expressed protein has a role in the disease, and provides guidance for preparing a therapeutic agent.

Similarly, comparison of polynucleotide sequences or of gene expression products, e.g., mRNA and protein, between a human tissue that is suspected of being diseased and a normal tissue of a human, are used to follow disease progression or remission in the human. Such comparisons are made as described above. For example, increased or decreased expression of a gene corresponding to an inventive polynucleotide in the tissue suspected of being neoplastic can indicate the presence of neoplastic cells in the tissue. The degree of increased expression of a given gene in the neoplastic tissue relative to expression of the same gene in normal tissue, or differences in the amount of increased expression of a given gene in the neoplastic tissue over time, is used to assess the progression of the neoplasia in that tissue or to monitor the response of the neoplastic tissue to a therapeutic protocol over time.

The expression pattern of any two cell types can be compared, such as low and high metastatic tumor cell lines, malignant or non-malignant cells, or cells from tissue which have and have not been exposed to a therapeutic agent. A genetic predisposition to disease in a human is detected by comparing expression levels of an mRNA or protein corresponding to a polynucleotide of the invention in a fetal tissue with levels associated in normal fetal tissue. Fetal tissues that are used for this purpose include, but are not limited to, amniotic fluid, chorionic villi, blood, and the blastomere of an in vitro-fertilized embryo. The comparable normal polynucleotide-related gene is obtained from any tissue. The mRNA or protein is obtained from a normal tissue of a human in which the polynucleotide-related gene is expressed. Differences such as alterations in the nucleotide sequence or size of the same product of the fetal polynucleotide-related gene or mRNA, or alterations in the molecular weight, amino acid sequence, or relative abundance of fetal protein, can indicate a germline mutation in the polynucleotide-related gene of the fetus, which indicates a genetic predisposition to disease. Particular diagnostic and prognostic uses of the disclosed polynucleotides are described in more detail below.

E. Diagnostic, Prognostic, and Other Uses Based on Differential Expression

In general, diagnostic methods of the invention for involve detection of a level or amount of a gene product, particularly a differentially expressed gene product, in a test sample obtained from a patient suspected of having or being susceptible to a disease (e.g., breast cancer, lung cancer, colon cancer and/or metastatic forms thereof), and comparing the detected levels to those levels found in normal cells (e.g., cells substantially unaffected by cancer) and/or other control cells (e.g., to differentiate a cancerous cell from a cell affected by dysplasia). Furthermore, the severity of the disease can be assessed by comparing the detected levels of a differentially expressed gene product with those levels detected in samples representing the levels of differentially gene product associated with varying degrees of severity of disease.

The term “differentially expressed gene” is intended to encompass a polynucleotide that can, for example; include an open reading frame encoding a gene product (e.g., a polypeptide), and/or introns of such genes and adjacent 5′ and 3′ non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene can be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome. In general, a difference in expression level associated with a decrease in expression level of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% or more is indicative of a differentially expressed gene of interest, i.e., a gene that is underexpressed or down-regulated in the test sample relative to a control sample. Furthermore, a difference in expression level associated with an increase in expression of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% and can be at least about 1½-fold, usually at least about 2-fold to about 10-fold, and can be about 100-fold to about 1,000-fold increase relative to a control sample is indicative of a differentially expressed gene of interest, i.e., an overexpressed or up-regulated gene.

“Differentially expressed polynucleotide” as used herein means a nucleic acid molecule (RNA or DNA) having a sequence that represents a differentially expressed gene, e.g., the differentially expressed polynucleotide comprises a sequence (e.g., an open reading frame encoding a gene product) that uniquely identifies a differentially expressed gene so that detection of the differentially expressed polynucleotide in a sample is correlated with the presence of a differentially expressed gene in a sample. “Differentially expressed polynucleotides” is also meant to encompass fragments of the disclosed polynucleotides, e.g., fragments retaining biological activity, as well as nucleic acids homologous, substantially similar, or substantially identical (e.g., having about 90% sequence identity) to the disclosed polynucleotides.

Methods of the subject invention useful in diagnosis or prognosis typically involve comparison of the abundance of a selected differentially expressed gene product in a sample of interest with that of a control to determine any relative differences in the expression of the gene product, where the difference can be measured qualitatively and/or quantitatively. Quantitation can be accomplished, for example, by comparing the level of expression product detected in the sample with the amounts of product present in a standard curve. A comparison can be made visually; by using a technique such as densitometry, with or without computerized assistance; by preparing a representative library of cDNA clones of mRNA isolated from a test sample, sequencing the clones in the library to determine that number of cDNA clones corresponding to the same gene product, and analyzing the number of clones corresponding to that same gene product relative to the number of clones of the same gene product in a control sample; or by using an array to detect relative levels of hybridization to a selected sequence or set of sequences, and comparing the hybridization pattern to that of a control. The differences in expression are then correlated with the presence or absence of an abnormal expression pattern. A variety of different methods for determining the nucleic acid abundance in a sample are known to those of skill in the art, where particular methods of interest include those described in: Pietu et al., Genome Res. (1996) 6:492; Zhao et al., Gene (1995) 156:207; Soares, Curr. Opin. Biotechnol. (1977) 8: 542; Raval, J. Pharmacol Toxicol Methods (1994) 32:125; Chalifour et at., Anal. Biochem (1994) 216:299; Stolz et al., Mol. Biolechnol. (1996) 6:225; Hong et al., Biosci. Reports (1982) 2:907; and McGraw, Anal. Biochem. (1984) 143:298. Also of interest are the methods disclosed in WO 97/27317, the disclosure of which is herein incorporated by reference.

In general, diagnostic assays of the invention involve detection of a gene product of a the polynucleotide sequence (e.g., mRNA or polypeptide) that corresponds to a sequence of “SEQ ID NOS:1-5252.” The patient from whom the sample is obtained can be apparently healthy, susceptible to disease (e.g., as determined by family history or exposure to certain environmental factors), or can already be identified as having a condition in which altered expression of a gene product of the invention is implicated.

In the assays of the invention, the diagnosis can be determined based on detected gene product expression levels of a gene product encoded by at least one, preferably at least two or more, at least 3 or more, or at least 4 or more of the polynucleotides having a sequence set forth in “SEQ ID NOS:1-5252,” and can involve detection of expression of genes corresponding to all of “SEQ ID NOS:1-5252” and/or additional sequences that can serve as additional diagnostic markers and/or reference sequences. Where the diagnostic method is designed to detect the presence or susceptibility of a patient to cancer, the assay preferably involves detection of a gene product encoded by a gene corresponding to a polynucleotide that is differentially expressed in cancer. For example, a higher level of expression of a polynucleotide corresponding to SEQ ID NO:2024 relative to a level associated with a normal sample can indicate the presence of cancer in the patient from whom the sample is derived. In another example, detection of a lower level of a polynucleotide corresponding to SEQ ID NO:590 relative to a normal level is indicative of the presence of cancer in the patient. Further examples of such differentially expressed polynucleotides are described in the Examples below. Given the provided polynucleotides and information regarding their relative expression levels provided herein, assays using such polynucleotides and detection of their expression levels in diagnosis and prognosis will be readily apparent to the ordinarily skilled artisan.

Any of a variety of detectable labels can be used in connection with the various embodiments of the diagnostic methods of the invention. Suitable detectable labels include fluorochromes,(e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2′,7′-dimethoxy-4′,5′-dichloro-6-carboxyfluorescein, 6-carboxy-X-rhodamine (ROX), 6-carboxy-2′,4′,7′,4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N′,N′-tetramethyl-6-carboxyrhodamine (TAMRA)), radioactive labels, (e.g. ³²P, ³⁵S, ³H, etc.), and the like. The detectable label can involve a two stage systems (e.g., biotin-avidin, hapten-anti-hapten antibody, etc.)

Reagents specific for the polynucleotides and polypeptides of the invention, such as antibodies and nucleotide probes, can be supplied in a kit for detecting the presence of an expression product in a biological sample. The kit can also contain buffers or labeling components, as well as instructions for using the reagents to detect and quantify expression products in the biological sample. Exemplary embodiments of the diagnostic methods of the invention are described below in more detail.

Polypeptide detection in diagnosis. In one embodiment, the test sample is assayed for the level of a differentially expressed polypeptide. Diagnosis can be accomplished using any of a number of methods to determine the absence or presence or altered amounts of the differentially expressed polypeptide in the test sample. For example, detection can utilize staining of cells or histological sections with labeled antibodies, performed in accordance with conventional methods. Cells can be permeabilized to stain cytoplasmic molecules. In general, antibodies that specifically bind a differentially expressed polypeptide of the invention are added to a sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody can be detectably labeled for direct detection (e.g., using radioisotopes, enzymes, fluorescers, chemiluminescers, and the like), or can be used in conjunction with a second stage antibody or reagent to detect binding (e.g., biotin with horseradish peroxidase-conjugated avidin, a secondary antibody conjugated to a fluorescent compound, e.g. fluorescein, rhodamine, Texas red, etc.). The absence or presence of antibody binding can be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc. Any suitable alternative methods can of qualitative or quantitative detection of levels or amounts of differentially expressed polypeptide can be used, for example ELISA, western blot, immunoprecipitation, radioimmunoassay, etc.

In general, the detected level of differentially expressed polypeptide in the test sample is compared to a level of the differentially expressed gene product in a reference or control sample, e.g., in a normal cell (negative control) or in a cell having a known disease state (positive control).

mRNA detection. The diagnostic methods of the invention can also or alternatively involve detection of mRNA encoded by a gene corresponding to a differentially expressed polynucleotides of the invention. Any suitable qualitative or quantitative methods known in the art for detecting specific mRNAs can be used. mRNA can be detected by, for example, in situ hybridization in tissue sections, by reverse transcriptase-PCR, or in Northern blots containing poly A+ mRNA. One of skill in the art can readily use these methods to determine differences in the size or amount of mRNA transcripts between two samples. For example, the level of mRNA of the invention in a tissue sample suspected of being cancerous or dysplastic is compared with the expression of the mRNA in a reference sample, e.g., a positive or negative control sample (e.g., normal tissue, cancerous tissue, etc.).

Any suitable method for detecting and comparing mRNA expression levels in a sample can be used in connection with the diagnostic methods of the invention (see, e.g., U.S. Pat. No. 5,804,382). For example, mRNA expression levels in a sample can be determined by generation of a library of expressed sequence tags (ESTs) from the sample, where the EST library is representative of sequences present in the sample (Adams, et al., (1991) Science 252:1651). Enumeration of the relative representation of ESTs within the library can be used to approximate the relative representation of the gene transcript within the starting sample. The results of EST analysis of a test sample can then be compared to EST analysis of a reference sample to determine the relative expression levels of a selected polynucleotide, particularly a polynucleotide corresponding to one or more of the differentially expressed genes described herein.

Alternatively, gene expression in a test sample can be performed using serial analysis of gene expression (SAGE) methodology (Velculescu et al., Science (1995) 70:484). In short, SAGE involves the isolation of short unique sequence tags from a specific location within each transcript. The sequence tags are concatenated, cloned, and sequenced. The frequency of particular transcripts within the starting sample is reflected by the number of times the associated sequence tag is encountered with the sequence population.

Gene expression in a test sample can also be analyzed using differential display (DD) methodology. In DD, fragments defined by specific sequence delimiters (e.g., restriction enzyme sites) are used as unique identifiers of genes, coupled with information about fragment length or fragment location within the expressed gene. The relative representation of an expressed gene with a sample can then be estimated based on the relative representation of the fragment associated with that gene within the pool of all possible fragments. Methods and compositions for carrying out DD are well known in the art, see, e.g., U.S. Pat. No. 5,776,683; and U.S. Pat. No. 5,807,680.

Alternatively, gene expression in a sample using hybridization analysis, which is based on the specificity of nucleotide interactions. Oligonucleotides or cDNA can be used to selectively identify or capture DNA or RNA of specific sequence composition, and the amount of RNA or cDNA hybridized to a known capture sequence determined qualitatively or quantitatively, to provide information about the relative representation of a particular message within the pool of cellular messages in a sample. Hybridization analysis can be designed to allow for concurrent screening of the relative expression of hundreds to thousands of genes by using, for example, array-based technologies having high density formats, including filters, microscope slides, or microchips, or solution-based technologies that use spectroscopic analysis (e.g., mass spectrometry). One exemplary use of arrays in the diagnostic methods of the invention is described below in more detail.

Use of a single gene in diagnostic applications. The diagnostic methods of the invention can focus on the expression of a single differentially expressed gene. For example, the diagnostic method can involve detecting a differentially expressed gene, or a polymorphism of such a gene (e.g., a polymorphism in an coding region or control region), that is associated with disease. Disease-associated polymorphisms can include deletion or truncation of the gene, mutations that alter expression level and/or affect activity of the encoded protein, etc.

Changes in the promoter or enhancer sequence that affect expression levels of an differentially gene can be compared to expression levels of the normal allele by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β-galactosidase, luciferase, chloramphenicol acetyltransferase, etc. that provides for convenient quantitation; and the like.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence, e.g. a disease associated polymorphism. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express a differentially expressed gene can be used as a source of mRNA, which can be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid can be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis, and a detectable label can be included in the amplification reaction (e.g., using a detectably labeled primer or detectably labeled oligonucleotides) to facilitate detection. The use of the polymerase chain reaction is described in Saiki, et al., Science (1985) 239:487, and a review of techniques can be found in Sambrook, et al., Molecular Cloning: A Laboratory Manual, (1989) pp. 14.2. Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, for examples see Riley et al., Nucl. Acids Res. (1990) 18:2887; and Delahunty et al., Am. J. Hum. Genet. (1996) 58:1239.

The sample nucleic acid, e.g. amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid can be sequenced by dideoxy or other methods, and the sequence of bases compared to a selected sequence, e.g., to a wild-type sequence. Hybridization with the polymorphic or variant sequence can also be used to determine its presence in a sample (e.g., by Southern blot, dot blot, etc.). The hybridization pattern of a polymorphic or variant sequence and a control sequence to an array of oligonucleotide probes immobilized on a solid support, as described in U.S. Pat. No. 5,445,934, or in WO 95/35505, can also be used as a means of identifying polymorphic or variant sequences associated with disease. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease, the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

Screening for mutations in an differentially expressed gene can be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting deletions that can affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in proteins can be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded protein can be determined by comparison with the wild-type protein.

Pattern matching in diagnosis using arrays. In another embodiment, the diagnostic and/or prognostic methods of the invention involve detection of expression of a selected set of genes in a test sample to produce a test expression pattern (TEP). The TEP is compared to a reference expression pattern (REP), which is generated by detection of expression of the selected set of genes in a reference sample (e.g., a positive or negative control sample). The selected set of genes includes at least one of the genes of the invention, which genes correspond to the polynucleotide sequences of “SEQ ID NOS:1-5252.” Of particular interest is a selected set of genes that includes gene differentially expressed in the disease for which the test sample is to be screened.

“Reference sequences” or “reference polynucleotides” as used herein in the context of differential gene expression analysis and diagnosis/prognosis refers to a selected set of polynucleotides, which selected set includes at least one or more of the differentially expressed polynucleotides described herein. A plurality of reference sequences, preferably comprising positive and negative control sequences, can be included as reference sequences. Additional suitable reference sequences are found in Genbank, Unigene, and other nucleotide sequence databases (including, e.g., expressed sequence tag (EST), partial, and full-length sequences).

“Reference array” means an array having reference sequences for use in hybridization with a sample, where the reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Usually such an array will include at least 3 different reference sequences, and can include any one or all of the provided differentially expressed sequences. Arrays of interest can further comprise sequences, including polymorphisms, of other genetic sequences, particularly other sequences of interest for screening for a disease or disorder (e.g., cancer, dysplasia, or other related or unrelated diseases, disorders, or conditions). The oligonucleotide sequence on the array will usually be at least about 12 nt in length, and can be of about the length of the provided sequences, or can extend into the flanking regions to generate fragments of 100 nt to 200 nt in length or more.

A “reference expression pattern” or “REP” as used herein refers to the relative levels of expression of a selected set of genes, particularly of differentially expressed genes, that is associated with a selected cell type, e.g., a normal cell, a cancerous cell, a cell exposed to an environmental stimulus, and the like. A “test expression pattern” or “TEP” refers to relative levels of expression of a selected set of genes, particularly of differentially expressed genes, in a test sample (e.g., a cell of unknown or suspected disease state, from which mRNA is isolated).

“Diagnosis” as used herein generally includes determination of a subject's susceptibility to a disease or disorder, determination as to whether a subject is presently affected by a disease or disorder, as well as to the prognosis of a subject affected by a disease or disorder (e.g., identification of pre-metastatic or metastatic cancerous states, stages of cancer, or responsiveness of cancer to therapy). The present invention particularly encompasses diagnosis of subjects in the context of breast cancer (e.g., carcinoma in situ (e.g., ductal carcinoma in situ), estrogen receptor (ER)-positive breast cancer, ER-negative breast cancer, or other forms and/or stages of breast cancer), lung cancer (e.g., small cell carcinoma, non-small cell carcinoma, mesothelioma, and other forms and/or stages of lung cancer), and colon cancer (e.g., adenomatous polyp, colorectal carcinoma, and other forms and/or stages of colon cancer).

“Sample” or “biological sample” as used throughout here are generally meant to refer to samples of biological fluids or tissues, particularly samples obtained from tissues, especially from cells of the type associated with the disease for which the diagnostic application is designed (e.g., ductal adenocarcinoma), and the like. “Samples” is also meant to encompass derivatives and fractions of such samples (e.g., cell lysates). Where the sample is solid tissue, the cells of the tissue can be dissociated or tissue sections can be analyzed.

REPs can be generated in a variety of ways according to methods well known in the art. For example, REPs can be generated by hybridizing a control sample to an array having a selected set of polynucleotides (particularly a selected set of differentially expressed polynucleotides), acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of the REP with a TEP. Alternatively, all expressed sequences in a control sample can be isolated and sequenced, e.g., by isolating mRNA from a control sample, converting the mRNA into cDNA, and sequencing the cDNA. The resulting sequence information roughly or precisely reflects the identity and relative number of expressed sequences in the sample. The sequence information can then be stored in a format (e.g., a computer-readable format) that allows for ready comparison of the REP with a TEP. The REP can be normalized prior to or after data storage, and/or can be processed to selectively remove sequences of expressed genes that are of less interest or that might complicate analysis (e.g., some or all of the sequences associated with housekeeping genes can be eliminated from REP data).

TEPs can be generated in a manner similar to REPs, e.g., by hybridizing a test sample to an array having a selected set of polynucleotides, particularly a selected set of differentially expressed polynucleotides, acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of the TEP with a REP. The REP and TEP to be used in a comparison can be generated simultaneously, or the TEP can be compared to previously generated and stored REPs.

In one embodiment of the invention, comparison of a TEP with a REP involves hybridizing a test sample with a reference array, where the reference array has one or more reference sequences for use in hybridization with a sample. The reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Hybridization data for the test sample is acquired, the data normalized, and the produced TEP compared with a REP generated using an array having the same or similar selected set of differentially expressed polynucleotides. Probes that correspond to sequences differentially expressed between the two samples will show decreased or increased hybridization efficiency for one of the samples relative to the other.

Reference arrays can be produced according to any suitable methods known in the art. For example, methods of producing large arrays of oligonucleotides are described in U.S. Pat. No. 5,134,854, and U.S. Pat. No. 5,445,934 using light-directed synthesis techniques. Using a computer controlled system, a heterogeneous array of monomers is converted, through simultaneous coupling at a number of reaction sites, into a heterogeneous array of polymers. Alternatively, microarrays are generated by deposition of pre-synthesized oligonucleotides onto a solid substrate, for example as described in PCT published application no. WO 95/35505.

Methods for collection of data from hybridization of samples with a reference arrays are also well known in the art. For example, the polynucleotides of the reference and test samples can be generated using a detectable fluorescent label, and hybridization of the polynucleotides in the samples detected by scanning the microarrays for the presence of the detectable label. Methods and devices for detecting fluorescently marked targets on devices are known in the art. Generally, such detection devices include a microscope and light source for directing light at a substrate. A photon counter detects fluorescence from the substrate, while an x-y translation stage varies the location of the substrate. A confocal detection device that can be used in the subject methods is described in U.S. Pat. No. 5,631,734. A scanning laser microscope is described in Shalon et al., Genome Res. (1996) 6:639. A scan, using the appropriate excitation line, is performed for each fluorophore used. The digital images generated from the scan are then combined for subsequent analysis. For any particular array element, the ratio of the fluorescent signal from one sample (e.g., a test sample) is compared to the fluorescent signal from another sample (e.g., a reference sample), and the relative signal intensity determined.

Methods for analyzing the data collected from hybridization to arrays are well known in the art. For example, where detection of hybridization involves a fluorescent label, data analysis can include the steps of determining fluorescent intensity as a function of substrate position from the data collected, removing outliers, i.e. data deviating from a predetermined statistical distribution, and calculating the relative binding affinity of the targets from the remaining data. The resulting data can be displayed as an image with the intensity in each region varying according to the binding affinity between targets and probes.

In general, the test sample is classified as having a gene expression profile corresponding to that associated with a disease or non-disease state by comparing the TEP generated from the test sample to one or more REPs generated from reference samples (e.g., from samples associated with cancer or specific stages of cancer, dysplasia, samples affected by a disease other than cancer, normal samples, etc.). The criteria for a match or a substantial match between a TEP and a REP include expression of the same or substantially the same set of reference genes, as well as expression of these reference genes at substantially the same levels (e.g., no significant difference between the samples for a signal associated with a selected reference sequence after normalization of the samples, or at least no greater than about 25% to about 40% difference in signal strength for a given reference sequence. In general, a pattern match between a TEP and a REP includes a match in expression, preferably a match in qualitative or quantitative expression level, of at least one of, all or any subset of the differentially expressed genes of the invention.

Pattern matching can be performed manually, or can be performed using a computer program. Methods for preparation of substrate matrices (e.g., arrays), design of oligonucleotides for use with such matrices, labeling of probes, hybridization conditions, scanning of hybridized matrices, and analysis of patterns generated, including comparison analysis, are described in, for example, U.S. Pat. No. 5,800,992.

F. Use of the Polynucleotides of the Invention in Cancer

Oncogenesis involves the unbridled growth, dedifferentiation and abnormal migration of cells. Cancerous cells can have the ability to compress, invade, and destroy normal tissue. Cancerous cells may also metastasize to other parts of the body via the bloodstream or the lymph system and colonize in these other areas. Different cancers are classified by the cell from which the cancerous cell is derived and from its cellular morphology and/or state of differentiation.

Somatic genetic abnormalities cause cancer initiation and progression. Cancer generally is clonally formed, i.e. gain of function of oncogenes and loss of function of tumor suppressor genes within a single cell transform the cell to be cancerous, and that single cell grows and divides to form a cancerous lesion. The genes known to be involved in cancer initiation and progression are involved in numerous cellular functions, including developmental differentiation, cell cycle regulation, cell signaling, immunological response, DNA replication, and DNA repair.

The identification and characterization of genetic or biochemical markers in blood or tissues that will detect the earliest changes along the carcinogenesis pathway and monitor the efficacy of various therapies and preventive interventions is a major goal of cancer research. Scientists have identified genetic changes in stool specimens that indicate the stages of colon cancer, and other biomarkers such as gene mutations, hormone receptors, proteins that inhibit metastasis, and enzymes that metabolize drugs are all being used to determine the severity and predict the course of breast, prostate, lung, and other cancers.

Recent advances in the pathogenesis of certain cancers has been helpful in determining patient treatment. The level of expression of certain polynucteotides can indicative of a poorer prognosis, and therefore warrant more aggressive chemo- or radio-therapy for a patient. The correlation of novel surrogate tumor specific features with response to treatment and outcome in patients has defined certain prognostic indicators that allow the design of tailored therapy based on the molecular profile of the tumor. These therapies include antibody targeting and gene therapy. Moreover, a promising level of one or more marker polynucleotides can provide impetus for not aggressively treating a particular patient, thus sparing the patient the deleterious side effects of aggressive therapy. Determining expression of certain polynucleotides and comparison of a patients profile with known expression in normal tissue and variants of the disease allows a determination of the best possible treatment for a patient, both in terms of specificity of treatment and in terms of comfort level of the patient.

Surrogate tumor markers, such as polynucleotide expression, can also be used to better classify, and thus diagnose and treat, different forms and disease states of cancer. Two classifications widely used in oncology that can benefit from identification of the expression levels of the polynucleotides of the invention are staging of the cancerous disorder, and grading the nature of the cancerous tissue.

Staging. Staging is a process used by physicians to describe how advanced the cancerous state is in a patient. Staging assists the physician in determining a prognosis, planning treatment and evaluating the results of such treatment. Different staging systems are used for different types of cancer, but each generally involves the following determinations: the type of tumor, indicated by T; whether the cancer has metastasized to nearby lymph nodes, indicated by N; and whether the cancer has metastasized to more distant parts of the body, indicated by M. This system of staging is called the TNM system. Generally, if a cancer is only detectable in the area of the primary lesion without having spread to any lymph nodes it is called Stage I. If it has spread only to the closest lymph nodes, it is called Stage II. In Stage III, the cancer has generally spread to the lymph nodes in near proximity to the site of the primary lesion. Cancers that have spread to a distant part of the body, such as the liver, bone, brain or another site, are called Stage IV, the most advanced stage.

Currently, the determination of staging is done using pathological techniques and is based more on the presence or absence of malignant tissue rather than the characteristics of the tumor type. Presence or absence of malignant tissue is based primarily on the gross morphology of the cells in the areas biopsied. The polynucleotides of the invention can facilitate fine-tuning of the staging process by identifying markers for the aggresivity of a cancer, e.g. the metastatic potential, as well as the presence in different areas of the body. Thus, a Stage II cancer with a polynucleotide signifying a high metastatic potential cancer can be used to change a borderline Stage II tumor to a Stage III tumor, justifying more aggressive therapy. Conversely, the presence of a polynucleotide signifying a lower metastatic potential allows more conservative staging of a tumor.

Grading of cancers. Grade is a term used to describe how closely a tumor resembles normal tissue of its same type. Based on the microscopic appearance of a tumor, pathologists will identify the grade of a tumor based on parameters such as cell morphology, cellular organization, and other markers of differentiation. As a general rule, the grade of a tumor corresponds to its rate of growth or aggressiveness. That is, undifferentiated or high-grade tumors grow more quickly than well differentiated or low-grade tumors. Information about tumor grade is useful in planning treatment and predicting prognosis.

The American Joint Commission on Cancer has recommended the following guidelines for grading tumors: 1) GX Grade cannot be assessed; 2) G1 Well differentiated; G2 Moderately well differentiated; 3) G3 Poorly differentiated; 4) G4 Undifferentiated. Although grading is used by pathologists to describe most cancers, it plays a more important role in treatment planning for certain types than for others. An example is the Gleason system that is specific for prostate cancer, which uses grade numbers to describe the degree of differentiation. Lower Gleason scores indicate well-differentiated cells. Intermediate scores denote tumors with moderately differentiated cells. Higher scores describe poorly differentiated cells. Grade is also important in some types of brain tumors and soft tissue sarcomas.

The polynucleotides of the invention can be especially valuable in determining the grade of the tumor, as they not only can aid in determining the differentiation status of the cells of a tumor, they can also identify factors other than differentiation that are valuable in determining the aggressivity of a tumor, such as metastatic potential.

Familial Cancer Genes. A number of cancer syndromes are linked to Mendelian inheritance of a predisposition to develop particular cancers. The following table contains a list of cancer types that can be inherited, and for which the gene or genes responsible have been identified. Most of the cancer types listed can occur as part of several different genetic conditions, each caused by alterations in a different gene.

Cancer Type Genetic Condition Gene Brain Li-Fraumeni syndrome TP53 Brain Neurofibromatosis 1 NF1 Neurofibromatosis 2 NF2 von Hippel-Lindau syndrome VHL Tuberous sclerosis 2 TSC2 Breast Hereditary breast/ovarian cancer 1 BRCA1 Hereditary breast/ovarian cancer 2 BRCA2 Li-Fraumeni syndrome TP53 Ataxia telangiectasia ATM Colon Familial adenomatous polyposis (FAP) APC Hereditary non-polyposis colon cancer (HNPCC) 1 HMSH2 Hereditary non-polyposis colon cancer (HNPCC) 2 hMLH1 Hereditary non-polyposis colon cancer (HNPCC) 3 hPMS1 Hereditary non-polyposis colon cancer (HNPCC) 4 hPMS2 Endocrine Multiple endocrine neoplasia 1 (MEN1) MEN1 (parathyroid, pituitary, GI endocrine) Endocrine Multiple endocrine neoplasia 2 (MEN2) RET (pheochromacytoma, medullary thyroid) Endometrial Hereditary non-polyposis colon cancer (HNPCC) 1 hMSH2 Hereditary non-polyposis colon cancer (HNPCC) 2 hMLH1 Hereditary non-polyposis colon cancer (HNPCC) 3 hPMS1 Hereditary non-polyposis colon cancer (HNPCC) 4 hPMS2 Eye Hereditary retinoblastoma RB1 Hematologic Li-Fraumeni syndrome TP53 (lymphomas and leukemia) Ataxia telangiectasia ATM Kidney Hereditary Wilms' tumor WT1 von Hippel-Lindau syndrome VHL Tuberous sclerosis 2 TSC2 Ovary Hereditary breast/ovarian cancer 1 BRCA1 Hereditary breast/ovarian cancer 2 BRCA2 Sarcoma Hereditary retinoblastoma RB1 Li-Fraumeni syndrome TP53 Neurofibromatosis 1 NF1 Skin Hereditary melanoma 1 CDKN2 Hereditary melanoma 2 CDK4 Basal cell naevus (Gorlin) syndrome PTCH Stomach Hereditary non-polyposis colon cancer (HNPCC) 1 hMSH2 Hereditary non-polyposis colon cancer (HNPCC) 2 hMLH1 Hereditary non-polyposis colon cancer (HNPCC) 3 hPMS1 Hereditary non-polyposis colon cancer (HNPCC) 4 hPMS2 The polynucleotides of the invention can be especially useful to monitor patients having any of the above syndromes to detect potentially malignant events at a molecular level before they are detectable at a gross morphological level. As can be seen from the table, a number of genes are involved in multiple forms of cancer. Thus, a polynucleotide of the invention identified as important for metastatic colon cancer can also have clinical implications for a patient diagnosed with stomach cancer or endometrial cancer.

Lung Cancer. Lung cancer is one of the most common cancers in the United States, accounting for about 15 percent of all cancer cases, or 170,000 new cases each year. At this time, over half of the lung cancer cases in the United States are in men, but the number found in women is increasing and will soon equal that in men. Today more women die of lung cancer than of breast cancer. Lung cancer is especially difficult to diagnose and treat because of the large size of the lungs, which allows cancer to develop for years undetected. In fact, lung cancer can spread outside the lungs without causing any symptoms. Adding to the confusion, the most common symptom of lung cancer, a persistent cough, can often be mistaken for a cold or bronchitis.

Although there are more than a dozen different kinds of lung cancer, the two main types of lung cancer are small cell and nonsmall cell, which encompass about 90% of all lung cancer cases. Small cell carcinoma (also called oat cell carcinoma), which usually starts in one of the larger bronchial tubes, grows fairly rapidly, and is likely to be large by the time of diagnosis. Nonsmall cell lung cancer (NSCLC) is made up of three general subtypes of lung cancer. Epidermoid carcinoma (also called squamous cell carcinoma) usually starts in one of the larger bronchial tubes and grows relatively slowly. The size of these tumors can range from very small to quite large. Adenocarcinoma starts growing near the outside surface of the lung and can vary in both size and growth rate. Some slowly growing adenocarcinomas are described as alveolar cell cancer. Large cell carcinoma starts near the surface of the lung, grows rapidly, and the growth is usually fairly large when diagnosed. Other less common forms of lung cancer are carcinoid, cylindroma, mucoepiderrnoid, and malignant mesothelioma.

Currently, CT scans, MRIs, X-rays, sputum cytology, and biopsies are used to diagnose nonsmall cell lung cancer. The form and cellular origin of the lung cancer is diagnosed primarily through biopsy from either a surgical biopsy or a needle aspiration of lung tissue, and usually the biopsy is prompted from an abnormality identified on an X-ray. In some cases, sputum cytology can reveal lung cancers in patients with normal X-rays or can determine the type of lung cancer, but because it cannot pinpoint the tumor's location, a positive sputum cytology test is usually followed by further tests. Since these tests are based in large part on gross morphology of the tissue, the diagnosis of a particular kind of tumor is largely subjective, and the diagnosis can vary significantly between clinicians.

The polynucleotides of the invention can be used to distinguish types of lung cancer well as identifying traits specific to a certain patient's cancer. For example, if the patient's biopsy expresses a polynucleotide that is associated with a low metastatic potential, it may justify leaving a larger portion of the patient's lung in surgery to remove the lesion. Alternatively, a smaller lesion with expression of a polynucleotide that is associated with high metastatic potential may justify a more radical removal of lung tissue and/or the surrounding lymph nodes, even if no metastasis can be identified through pathological examination.

Similarly, the expression of polynucleotides of the invention can be used in the diagnosis, prognosis and management of colorectal cancer. The differential expression of a polynucleotide in hyperplasia can be used as a diagnostic marker for metastatic lung cancer. The polynucleotides of the invention that would be especially useful for this purpose are those that exhibit differential expression between high metastatic versus low metastatic lung cancer, i.e. SEQ ID NOS: 174, 254, 466, 571, 574, 590, 922, 1355, 1422, 2007, 2038, 2245, 10, 54, 65, 171, 203, 252, 253, 285, 419, 420, 491, 525, 526, 552, 693, 700, 726, 742, 746, 861, 990, 1088, 1288, 1417, 1444, 1454, 1570, 1597, 1979, 2024, 2034, and 2126. Detection of malignant lung cancer with a higher metastatic potential can be determined using expression levels of any of these sequences alone or in combination with the levels of expression of other known genes.

Breast Cancer. The National Cancer Institute (NCI) estimates that about 1 in 8 women in the United States will develop breast cancer during her lifetime. Clinical breast examination and mammography are recommended as combined modalities for breast cancer screening, and the nature of the cancer will often depend upon the location of the tumor and the cell type from which the tumor is derived. The majority of breast cancers are adenocarcinomas subtypes, which can be summarized as follows:

Ductal carcinoma in situ (DCIS): Ductal carcinoma in situ is the most common type of noninvasive breast cancer. In DCIS, the malignant cells have not metastasized through the walls of the ducts into the fatty tissue of the breast. Comedocarcinoma is a type of DCIS that is more likely than other types of DCIS to come back in the same area after lumpectomy. It is more closely linked to eventual development of invasive ductal carcinoma than other forms of DCIS.

Infiltrating (or invasive) ductal carcinoma (IDC): this type of cancer has metastasized through the wall of the duct and invaded the fatty tissue of the breast. At this point, it has the potential to use the lymphatic system and bloodstream for metastasis to more distant parts of the body. Infiltrating ductal carcinoma accounts for about 80% of breast cancers.

Lobular carcinoma in situ (LCIS): While not a true cancer, LCIS (also called lobular neoplasia) is sometimes classified as a type of noninvasive breast cancer. It does not penetrate through the wall of the lobules. Although it does not itself usually become an invasive cancer, women with this condition have a higher risk of developing an invasive breast cancer in the same breast, or in the opposite breast.

Infiltrating (or invasive) lobular carcinoma (ILC): ILC is similar to IDC, in that it has the potential metastasize elsewhere in the body. About 10% to 15% of invasive breast cancers are invasive lobular carcinomas. ILC can be more difficult to detect by mammogram than IDC.

Inflammatory breast cancer: This rare type of invasive breast cancer accounts for about 1% of all breast cancers and is extremely aggressive. Multiple skin symptoms associated with this cancer are caused by cancer cells blocking lymph vessels or channels in the skin over the breast.

Medullary carcinoma: This special type of infiltrating breast cancer has a relatively well defined, distinct boundary between tumor tissue and normal tissue. It accounts for about 5% of breast cancers. The prognosis for this kind of breast cancer is better than for other types of invasive breast cancer.

Mucinous carcinoma: This rare type of invasive breast cancer originates from mucus-producing cells. The prognosis for mucinous carcinoma is better than for the more common types of invasive breast cancer.

Paget's disease of the nipple: This type of breast cancer starts in the ducts and spreads to the skin of the nipple and the areola. It is a rare type of breast cancer, occurring in only 1% of all cases. Paget's disease can be associated with in situ carcinoma, or with infiltrating breast carcinoma. If no lump can be felt in the breast tissue, and the biopsy shows DCIS but no invasive cancer, the prognosis is excellent.

Phyllodes tumor: This very rare type of breast tumor forms from the stroma of the breast, in contrast to carcinomas which develop in the ducts or lobules. Phyllodes (also spelled phylloides) tumors are usually benign, but are malignant on rare occasions. Nevertheless, malignant phyllodes tumors are very rare and less than 10 women per year in the US die of this disease. Benign phyllodes tumors are successfully treated by removing the mass and a narrow margin of normal breast tissue.

Tubular carcinoma: Accounting for about 2% of all breast cancers, tubular carcinomas are a special type of infiltrating breast carcinoma. They have a better prognosis than usual infiltrating ductal or lobular carcinomas.

High-quality mammography combined with clinical breast exam remains the only screening method clearly tied to reduction in breast cancer mortality. Lower dose x-rays, digitized computer rather than film images, and the use of computer programs to assist diagnosis, are almost ready for widespread dissemination. Other technologies also are being developed, including magnetic resonance imaging and ultrasound. In addition, a very low radiation exposure technique, positron emission tomography has the potential for detecting early breast cancer.

It is also possible to differentiate between non-cancerous breast tissue and malignant breast tissue by analyzing differential gene expression between tissues. In addition, there may be several possible alterations that lead to the various possible types of breast cancer. The different types of breast tumors (e.g., invasive vs. non-invasive, ductal vs. axillary lymph node) can be differentiable from one another by the identification of the differences in genes expressed by different types-of breast tumor tissues (Porter-Jordan et al., Hematol Oncol Clin North Am (1994) 8:73). Breast cancer can thus be generally diagnosed by detection of expression of a gene or genes associated with breast tumors. Where enough information is available about the differential gene expression between various types of breast tumor tissues, the specific type of breast tumor can also be diagnosed.

For example, increased estrogen receptor (ER) expression in normal breast epithileum, while not itself indicative of malignant tissue, is a known risk marker for development of breast cancer. Khan S A et al., Cancer Res (1994) 54:993. Malignant breast cancer is often divided into two groups, ER-positive and ER-negative, based on the estrogen receptor status of the tissue. The ER status represents different survival length and response to hormone therapy, and is thought to represent either: 1) an indicator of different stages of the disease, or 2) an indicator that allows differentiation between two similar but distinct diseases. K. Zhu et al., Med. Hypoth (1997) 49:69. A number of other genes are known to vary expression between either different stages of cancer or different types of similar breast cancer.

Similarly, the expression of polynucleotides of the invention can be used in the diagnosis and management of breast cancer. The differential expression of a polynucleotide in human breast tumor tissue can be used as a diagnostic marker for human breast cancer. The polynucleotides of the invention that would be especially useful for this purpose are those that exhibit differential expression between breast cancer tissue with a high metastatic potential and a low metastatic potential, i.e. SEQ ID NOS:15, 36, 44, 89, 172, 203, 261, 419, 420, 503, 552, 564, 570, 590, 693, 707, 711, 726, 746, 756, 990, 1122, 1142, 1286, 1289, 1435, 1860, 1933, 1934, 1979, 1980, 2007, 2023, 2409, 2486, 45, 146, 154, 159, 165, 174, 183, 364, 366, 387, 496, 510, 512, 529, 560, 606, 644, 646, 754, 875, 902, 921, 942, 1095, 1104, 1131, 1170, 1184, 1205, 1354, 1387, 1535, 1751, 1764, 1777, 1795, 1869, 1882, 1890, 1915, 2040, 2059, 2223, 2245, 2300, 2325, 2462, 2488, 2492; Detection of breast cancer can be determined using expression levels of any of these sequences alone or in combination. Determination of the aggressive nature and/or the metastatic potential of a breast cancer can also be determined by comparing levels of one or more polynucleotides of the invention and comparing levels of another sequence known to vary in cancerous tissue, e.g. ER expression. In addition, development of breast cancer can be detected by examining the ratio of SEQ ID NO: to the levels of steroid hormones (e.g., testosterone or estrogen) or to other hormones (e.g., growth hormone, insulin). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous breast tissue, to discriminate between breast cancers with different cells of origin, to discriminate between breast cancers with different potential metastatic rates, etc.

Diagnosis of breast cancer can also involve comparing the expression of a polynucleotide of the invention with the expression of other sequences in non-malignant breast tissue samples in comparison to one or more forms of the diseased tissue. A comparison of expression of one or more polynucleotides of the invention between the samples provides information on relative levels of these polynucleotides as well as the ratio of these polynucleotides to the expression of other sequences in the tissue of interest compared to normal.

This risk of breast cancer is elevated significantly by the presence of an inherited risk for breast cancer, such as a mutation in BRCA-1 or BRCA-2. New diagnostic tools are being developed to address the needs of higher risk patients to complement mammography and physical examinations for early detection of breast cancer, particularly among younger women. The presence of antigen or expression markers in nipple aspirate fluid (NAF) samples collected from one or both breasts can be useful for useful for risk assessment or early cancer detection. Breast cytology and biomarkers obtained by random fine needle aspiration have been used to identify hyperplasia with atypia and overexpression of p53 and EGFR. The polynucleotides of the invention can be used in multivariate analysis with expression studies with genes such as p53 and EGFR as risk predictors and as surrogate endpoint biomarkers for breast cancer.

As well as being used for diagnosis and risk assessment, the expression of certain genes can also correlated to prognosis of a disease state. The expression of particular gene have been used as prognostic indicators for breast cancer including increased expression of c-erbB-2, pS2, ER, progesterone receptor, epidermal growth factor receptor (EGFR), neu, myc, bcl-2, int2, cytosolic tyrosine kinase, cyclin E, prad-1, hst, uPA, PAI-1, PAI-2, cathepsin D, as well as the presence of a number of cancer-specific antigens, e.g. CEA, CA M26, CA M29 and CA 15.3. Davis, Br. J. Biomed Sci. (1996) 53:157. Poor prognosis has also been linked to a decrease in expression of certain genes, such as p53, Rb, nm23. The expression of the polynucleotides of the invention can be of prognostic value for determining the metastatic potential of a malignant breast cancer, as this molecules are differentially expressed between high and low metastatic potential tissues tumors. The levels of these polynucleotides in patients with malignant breast cancer can compared to normal tissue, malignant tissue with a known high potential metastatic level, and malignant tissue with a known lower level of metastatic potential to provide a prognosis for a particular patient. Such a prognosis is predictive of the extent and nature of the cancer. The determined prognosis is useful in determining the prognosis of a patient with breast cancer, both for initial treatment of the disease and for longer-term monitoring of the same patient. If samples are taken from the same individual over a period of time, differences in polynucleotide expression that are specific to that patient can be identified and closely watched.

Colon Cancer. Colorectal cancer is one of the most common neoplasms in humans and perhaps the most frequent form of hereditary neoplasia. Prevention and early detection are key factors in controlling and curing colorectal cancer. Indeed, colorectal cancer is the second most preventable cancer, after lung cancer. Colorectal cancer begins as polyps, which are small, benign growths of cells that form on the inner lining of the colon. Over a period of several years, some of these polyps accumulate additional mutations and become cancerous. About 20 percent of all cases of colon cancer are thought to be related to heredity. Currently, multiple familial colorectal cancer disorders have been identified, which are summarized as follows:

Familial adenomatous polyposis (FAP): This condition results in a person having hundreds or even thousands of polyps in the colon and rectum that usually first appear during the teenage years. Cancer nearly always develops in one or more of these polyps between the ages of 30 and 50.

Gardner's syndrome: Like FAP, Gardner's syndrome results in polyps and colorectal cancers that develop at a young age. It can also cause benign tumors of the skin, soft connective tissue and bones.

Hereditary nonpolyposis colon cancer (HNPCC): People with this condition tend to develop colorectal cancer at a young age, without first having many polyps. HNPCC has an autosomal dominant pattern of inheritance with variable but high penetrance estimated to be about 90%. HNPCC underlies 0.5%-10% of all cases of colorectal cancer. An understanding of the mechanisms behind the development of HNPCC is emerging, and genetic presymptomatic testing, now being conducted in research settings, soon will be available on a widespread basis for individuals identified at risk for this disease.

Familial colorectal cancer in Ashkenazi Jews: Recent research has found an inherited tendency to developing colorectal cancer among some Jews of Eastern European descent. Like people with FAP, Gardner's syndrome, and HNPCC, their increased risk is due to an inherited mutation present in about 6% of American Jews.

Several tests are currently used to screen for colorectal cancer, including digital rectal examination, fecal occult blood test, sigmoidoscopy, colonoscopy, virtual colonoscopy and MRI. Each of these tests identifies potential colorectal cancer lesions, or a risk of development of these lesions, at a fairly gross morphological level.

The sequential alteration of a number of genes is associated with malignant adenocarcinoma, including the genes DCC, p53, ras, and FAP. For a review, see e.g. Fearon E R, et al., Cell (1990) 61(S):759; Hamilton S R et al., Cancer (1993) 72:957; Bodmer W, et al., Nat Genet. (1994) 4(3):217; Fearon E R, Ann NY Acad Sci. (1995) 768:101. Molecular genetic alterations are thus promising as potential diagnostic and prognostic indicators in colorectal carcinoma and molecular genetics of colorectal carcinoma since it is possible to differentiate between different types of colorectal neoplasias using molecular markers. Colorectal cancer can thus be generally diagnosed by detection of expression of a gene or genes associated with colorectal tumors.

Similarly, the expression of polynucleotides of the invention can be used in the diagnosis, prognosis and management of colorectal cancer. The differential expression of a polynucleotide in hyperplasia can be used as a diagnostic marker for colon cancer. The polynucleotides of the invention that would be especially useful for this purpose are those that exhibit differential expression between malignant metastatic colon cancer and normal patient tissue, i.e. SEQ ID NOS:228, 280, 355, 491, 603, 680, 752, 753, 1241, 1264, 1401, 1442, 1514, 1851, 1915, 2024, 2066, 33, 250, 282, 370, 387, 443, 460, 545, 560, 703, 704, 1095, 1104, 1205, 1354, 1387, 1734, 1742, 1954, 2262, 2325, 1899, 252, 253, 491, 581, 693, 726, 746, 1780, 1899, 65, 252, 253, 581, 693, 716, 726, 746, 1780, 1899, and 1780. Detection of malignant colon cancer can be determined using expression levels of any of these sequences alone or in combination with the levels of expression.

Determination of the aggressive nature and/or the metastatic potential of a colon cancer can also be determined by comparing levels of one or more polynucleotides of the invention and comparing total levels of another sequence known to vary in cancerous tissue, e.g. p53 expression. In addition, development of colon cancer can be detected by examining the ratio of any of the polynucleotides of the invention to the levels of oncogenes (e.g. ras) or tumor suppressor genes (e.g. FAP or p53). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous breast tissue, to discriminate between breast cancers with different cells of origin, to discriminate between breast cancers with different potential metastatic rates, etc.

G. Use of Polynucleotides to Screen for Peptide Analogs and Antagonists

Polypeptides encoded by the instant polynucleotides and corresponding full length genes can be used to screen peptide libraries to identify binding partners, such as receptors, from among the encoded polypeptides.

A library of peptides can be synthesized following the methods disclosed in U.S. Pat. No. 5,010,175 ('175), and in WO 91/17823. As described below in brief, one prepares a mixture of peptides, which is then screened to identify the peptides exhibiting the desired signal transduction and receptor binding activity. In the '175 method, a suitable peptide synthesis support (e.g., a resin) is coupled to a mixture of appropriately protected, activated amino acids. The concentration of each amino acid in the reaction mixture is balanced or adjusted in inverse proportion to its coupling reaction rate so that the product is an equimolar mixture of amino acids coupled to the starting resin. The bound amino acids are then deprotected, and reacted with another balanced amino acid mixture to form an equimolar mixture of all possible dipeptides. This process is repeated until a mixture of peptides of the desired length (e.g., hexamers) is formed. Note that one need not include all amino acids in each step: one can include only one or two amino acids in some steps (e.g., where it is known that a particular amino acid is essential in a given position), thus reducing the complexity of the mixture. After the synthesis of the peptide library is completed, the mixture of peptides is screened for binding to the selected polypeptide. The peptides are then tested for their ability to inhibit or enhance activity. Peptides exhibiting the desired activity are then isolated and sequenced.

The method described in WO 91/17823 is similar. However, instead of reacting the synthesis resin with a mixture of activated amino acids, the resin is divided into twenty equal portions (or into a number of portions corresponding to the number of different amino acids to be added in that step), and each amino acid is coupled individually to its portion of resin. The resin portions are then combined, mixed, and again divided into a number of equal portions for reaction with the second amino acid. In this manner, each reaction can be easily driven to completion. Additionally, one can maintain separate “subpools” by treating portions in parallel, rather than combining all resins at each step. This simplifies the process of determining which peptides are responsible for any observed receptor binding or signal transduction activity.

In such cases, the subpools containing, e.g., 1-2,000 candidates each are exposed to one or more polypeptides of the invention. Each subpool that produces a positive result is then resynthesized as a group of smaller subpools (sub-subpools) containing, e.g., 20-100 candidates, and reassayed. Positive sub-subpools can be resynthesized as individual compounds, and assayed finally to determine the peptides that exhibit a high binding constant. These peptides can be tested for their ability to inhibit or enhance the native activity. The methods described in WO 91/823 and U.S. Pat. No. 5,194,392 (herein incorporated by reference) enable the preparation of such pools and subpools by automated techniques in parallel, such that all synthesis and resynthesis can be performed in a matter of days.

Peptide agonists or antagonists are screened using any available method, such as signal transduction, antibody binding, receptor binding, mitogenic assays, chemotaxis assays, etc. The methods described herein are presently preferred. The assay conditions ideally should resemble the conditions under which the native activity is exhibited in vivo, that is, under physiologic pH, temperature, and ionic strength. Suitable agonists or antagonists will exhibit strong inhibition or enhancement of the native activity at concentrations that do not cause toxic side effects in the subject. Agonists or antagonists that compete for binding to the native polypeptide can require concentrations equal to or greater than the native concentration, while inhibitors capable of binding irreversibly to the polypeptide can be added in concentrations on the order of the native concentration.

The end results of such screening and experimentation will be at least one novel polypeptide binding partner, such as a receptor, encoded by a gene or a cDNA corresponding to a polynucleotide of the invention, and at least one peptide agonist or antagonist of the novel binding partner. Such agonists and antagonists can be used to modulate, enhance, or inhibit receptor function in cells to which the receptor is native, or in cells that possess the receptor as a result of genetic engineering. Further, if the novel receptor shares biologically important characteristics with a known receptor, information about agonist/antagonist binding can facilitate development of improved agonists/antagonists of the known receptor.

H. Pharmaceutical Compositions and Therapeutic Uses

Pharmaceutical compositions can comprise polypeptides, antibodies, or polynucleotides of the claimed invention. The pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides, antibodies, or polynucleotides of the claimed invention.

The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation is determined by routine experimentation and is within the judgment of the clinician. For purposes of the present invention, an effective dose will generally be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which can be administered without undue toxicity. Suitable carriers can be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions can include liquids such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, can also be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

Delivery Methods. Once formulated, the compositions of the invention can be (1) administered directly to the subject (e.g., as polynucleotide or polypeptides); (2) delivered ex vivo, to cells derived from the subject (e.g., as in ex vivo gene therapy); or (3) delivered in vitro for expression of recombinant proteins (e.g., polynucleotides). Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a tumor or lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal applications, needles, and gene guns or hyposprays. Dosage treatment can be a single dose schedule or a multiple dose schedule.

Methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and described in e.g., International Publication No. WO 93/14778. Examples of cells useful in ex vivo applications include, for example, stem cells, particularly hematopoetic, lymph cells, macrophages, dendritic cells, or tumor cells. Generally, delivery of nucleic acids for both ex vivo and in vitro applications can be accomplished by, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.

Once a gene corresponding to a polynucleotide of the invention has been found to correlate with a proliferative disorder, such as neoplasia, dysplasia, and hyperplasia, the disorder can be amenable to treatment by administration of a therapeutic agent based on the provided polynucleotide or corresponding polypeptide.

Preparation of antisense polynucleotides is discussed above. Neoplasias that are treated with the antisense composition include, but are not limited to, cervical cancers, melanomas, colorectal adenocarcinomas, Wilms' tumor, retinoblastoma, sarcomas, myosarcomas, lung carcinomas, leukemias, such as chronic myelogenous leukemia, promyelocytic leukemia, monocytic leukemia, and myeloid leukemia, and lymphomas, such as histiocytic lymphoma. Proliferative disorders that are treated with the therapeutic composition include disorders such as anhydric hereditary ectodermal dysplasia, congenital alveolar dysplasia, epithelial dysplasia of the cervix, fibrous dysplasia of bone, and mammary dysplasia. Hyperplasias, for example, endometrial, adrenal, breast, prostate, or thyroid hyperplasias or pseudoepitheliomatous hyperplasia of the skin, are treated with antisense therapeutic compositions based upon a polynucleotide of the invention. Even in disorders in which mutations in the corresponding gene are not implicated, downregulation or inhibition of expression of a gene corresponding to a polynucleotide of the invention can have therapeutic application. For example, decreasing gene expression can help to suppress tumors in which enhanced expression of the gene is implicated.

Both the dose of the antisense composition and the means of administration are determined based on the specific qualities of the therapeutic composition, the condition, age, and weight of the patient, the progression of the disease, and other relevant factors. Administration of the therapeutic antisense agents of the invention includes local or systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration. Preferably, the therapeutic antisense composition contains an expression construct comprising a promoter and a polynucleotide segment of at least 12, 22, 25, 30, or 35 contiguous nucleotides of the antisense strand of a polynucleotide disclosed herein. Within the expression construct, the polynucleotide segment is located downstream from the promoter, and transcription of the polynucleotide segment initiates at the promoter.

Various methods are used to administer the therapeutic composition directly to a specific site in the body. For example, a small metastatic lesion is located and the therapeutic composition injected several times in several different locations within the body of tumor. Alternatively, arteries which serve a tumor are identified, and the therapeutic composition injected into such an artery, in order to deliver the composition directly into the tumor. A tumor that has a necrotic center is aspirated and the composition injected directly into the now empty center of the tumor. The antisense composition is directly administered to the surface of the tumor, for example, by topical application of the composition. X-ray imaging is used to assist in certain of the above delivery methods.

Receptor-mediated targeted delivery of therapeutic compositions containing an antisense polynucleotide, subgenomic polynucleotides, or antibodies to specific tissues is also used. Receptor-mediated DNA delivery techniques are described in, for example, Findeis et al., Trends Biotechnol (1993) 11:202; Chiou et al., Gene Therapeutics: Methods And Applicalions Of Direct Gene Transfer (J. A. Wolff, ed.) (1994); Wu et al., J. Biol. Chem. (1988) 263:621; Wu et al., J. Biol. Chem. (1994) 269:542; Zenke et al., Proc. Natl. Acad. Sci. (USA) (1990) 87:3655; Wu et al., J. Biol. Chem. (1991) 266:338. Preferably, receptor-mediated targeted delivery of therapeutic compositions containing antibodies of the invention is used to deliver the antibodies to specific tissue.

Therapeutic compositions containing antisense subgenomic polynucleotides are administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. Concentration ranges of about 500 ng to about 50 mg, about 1 pg to about 2 mg, about 5 μg to about 500 μg, and about 20 μg to about 100 μg of DNA can also be used during a gene therapy protocol. Factors such as method of action and efficacy of transformation and expression are considerations which will affect the dosage required for ultimate efficacy of the antisense subgenomic polynucleotides. Where greater expression is desired over a larger area of tissue, larger amounts of antisense subgenomic polynucleotides or the same amounts readministered in a successive protocol of administrations, or several administrations to different adjacent or close tissue portions of, for example, a tumor site, may be required to effect a positive therapeutic outcome. In all cases, routine experimentation in clinical trials will determine specific ranges for optimal therapeutic effect. A more complete description of gene therapy vectors, especially retroviral vectors, is contained in U.S. Ser. No. 08/869,309, which is expressly incorporated herein, and in section G below.

For polynucleotide-related genes encoding polypeptides or proteins with anti-inflammatory activity, suitable use, doses, and administration are described in U.S. Pat. No. 5,654,173. Therapeutic agents also include antibodies to proteins and polypeptides encoded by the polynucleotides of the invention and related genes, as described in U.S. Pat. No. 5,654,173.

I. Gene Therapy

The therapeutic polynucleotides and polypeptides of the present invention can be utilized in gene delivery vehicles. The gene delivery vehicle can be of viral or non-viral origin (see generally, Jolly, Cancer Gene Therapy (1994) 1:51; Kimura, Human Gene Therapy (1994) 5:845; Connelly, Human Gene Therapy (1995) 1:185; and Kaplitt, Nature Genetics (1994) 6:148). Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches. Expression of such coding sequences can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence can be either constitutive or regulated.

The present invention can employ recombinant retroviruses which are constructed to carry or express a selected nucleic acid molecule of interest. Retrovirus vectors that can be employed include those described in EP 0 415 731; WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; U.S. Pat. No. 5,219,740; WO 93/11230; WO 93/10218; Vile and Hart, Cancer Res. (1993) 53:3860; Vile et al., Cancer Res. (1993) 53:962; Ram et al., Cancer Res. (1993) 53:83; Takamiya et al., J. Neurosci Res. (1992) 33:493; Baba et al., J. Neurosurg. (1993) 79:729; U.S. Pat. No. 4,777,127; GB Patent No. 2,200,651; and EP 0 345 242. Preferred recombinant retroviruses include those described in WO 91/02805.

Packaging cell lines suitable for use with the above-described retroviral vector constructs can be readily prepared (see, e.g., WO 95/30763 and WO 92/05266), and used to create producer cell lines (also termed vector cell lines) for the production of recombinant vector particles. Within particularly preferred embodiments of the invention, packaging cell lines are made from human (such as HT1080 cells) or mink parent cell lines, thereby allowing production of recombinant retroviruses that can survive inactivation in human serum.

The present invention also employs alphavirus-based vectors that can function as gene delivery vehicles. Such vectors can be constructed from a wide variety of alphaviruses, including, for example, Sindbis virus vectors, Semliki forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR 1249; ATCC VR-532). Representative examples of such vector systems include those described in U.S. Pat. Nos. 5,091,309; 5,217,879; and 5,185,440; WO 92/10578; WO 94/21792; WO 95/27069; WO 95/27044; and WO 95/07994. Gene delivery vehicles of the present invention can also employ parvovirus such as adeno-associated virus (AAV) vectors. Representative examples include the AAV vectors disclosed by Srivastava in WO 93/09239, Samulski et al., J. Virol. (1989) 63:3822; Mendelson et al., Virol. (1988) 166:154; and Flone et al., PNAS (1993) 90:10613.

Representative examples of adenoviral vectors include those described by Berkner, Biotechniques (1988) 6:616; Rosenfeld et al., Science (1991) 252:431; WO 93/19191; Kolls et al., PNAS (1994) 91:215; Kass-Eisler et al., PNAS (1993) 90:11498; Guzman et al., Circulation (1993) 88:2838; Guzman et al., Cir. Res. (1993) 73:1202; Zabner et al., Cell (1993) 75:207; Li et al., Hum. Gene Ther. (1993) 4:403; Cailaud et al., Eur. J. Neurosci. (1993) 5:1287; Vincent et al., Nat. Genet. (1993) 5:130; Jaffe et al., Nat. Genet. (1992) 1:372; and Levrero et al., Gene (1991) 101:195. Exemplary adenoviral gene therapy vectors employable in this invention also include those described in WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655.

Administration of DNA linked to killed adenovirus as described in Curiel, Hum. Gene Ther. (1992) 3:147 can be employed.

Other gene delivery vehicles and methods can be employed, including polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example Curiel, Hum. Gene Ther. (1992) 3:147; ligand linked DNA, for example see Wu, J. Biol. Chem. (1989) 264:16985; eukaryotic cell delivery vehicles cells, for example see U.S. Pat. No. 5,814,482; WO 95/07994; WO 96/17072; WO 95/30763; and WO 97/42338; deposition of photopolymerized hydrogel materials; hand-held gene transfer particle gun, as described in U.S. Pat. No. 5,149,655; ionizing radiation as described in U.S. Pat. No. 5,206,152 and in WO92/11033; nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip, Mol. Cell Biol. (1994) 14:2411, and in Woffendin, Proc. Natl. Acad. Sci. (1994) 91:1581.

Naked DNA can also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and U.S. Pat. No. 5,580,859. Liposomes that can act as gene delivery vehicles are described in U.S. Pat. No. 5,422,120; WO 95/13796; WO 94/23697; WO 91/14445; and EP 0524968.

Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin et al., Proc. Natl. Acad. Sci. USA (1994) 91(24):11581. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials. Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in U.S. Pat. No. 5,149,655; use of ionizing radiation for activating transferred gene, as described in U.S. Pat. No. 5,206,152 and WO 92/11033.

The present invention will now be illustrated by reference to the following examples which set forth particularly advantageous embodiments. However, it should be noted that these embodiments are illustrative and are not to be construed as restricting the invention in any way.

EXAMPLES Example 1 Source of Biological Materials and Overview of Novel Polynucleotides Expressed by the Biological Materials

Human colon cancer cell line Km12L4-A (Morika, W. A. K. et al., Cancer Research (1988) 48:6863) was used to construct a cDNA library from mRNA isolated from the cells. As described in the above overview, a total of 4,693 sequences expressed by the Km12L4-A cell line were isolated and analyzed; most sequences were about 275-300 nucleotides in length. The KM12L4-A cell line is derived from the KM12C cell line. The KM12C cell line, which is poorly metastatic (low metastatic) was established in culture from a Dukes' stage B₂ surgical specimen (Morikawa et al. Cancer Res. (1988) 48:6863). The KML4-A is a highly metastatic subline derived from KM12C (Yeatman et al. Nucl. Acids. Res. (1995) 23:4007; Bao-Ling et al. Proc. Annu. Meet. Am. Assoc. Cancer. Res. (1995) 21:3269). The KM12C and KM12C-derived cell lines (e.g., KM12L4, KM12L4-A, etc.) are well-recognized in the art as a model cell line for the study of colon cancer (see, e.g., Moriakawa et al., supra; Radinsky et al. Clin. Cancer Res. (1995) 1:19; Yeatman et al., (1995) supra; Yeatman et al. Clin. Exp. Metastasis (1996) 14:246).

The sequences were first masked to eliminate low complexity sequences using the XBLAST masking program (Claverie “Effective Large-Scale Sequence Similarity Searches,” In: Computer Methods for Macromolecular Sequence Analysis, Doolittle, ed., Meth. Enzymol. 266:212-227 Academic Press, NY, N.Y. (1996); see particularly Claverie, in “Automated DNA Sequencing and Analysis Techniques” Adams et al., eds., Chap. 36, p. 267 Academic Press, San Diego, 1994 and Claverie et al. Comput. Chem. (1993) 17:191). Generally, masking does not influence the final search results, except to eliminate sequences of relative little interest due to their low complexity, and to eliminate multiple “hits” based on similarity to repetitive regions common to multiple sequences, e.g., Alu repeats. Masking resulted in the elimination of 43 sequences. The remaining sequences were then used in a BLASTN vs. Genbank search with search parameters of greater than 70% overlap, 99% identity, and a p value of less than 1×10⁻⁴⁰, which search resulted in the discarding of 1,432 sequences. Sequences from this search also were discarded if the inclusive parameters were met, but the sequence was ribosomal or vector-derived.

The resulting sequences from the previous search were classified into three groups (1, 2 and 3 below) and searched in a BLASIX vs. NRP (non-redundant proteins) database search: (1) unknown (no hits in the Genbank search), (2) weak similarity (greater than 45% identity and p value of less than 1×10⁻⁵), and (3) high similarity (greater than 60% overlap, greater than 80% identity, and p value less than 1×10⁻⁵). This search resulted in discard of 98 sequences as having greater than 70% overlap, greater than 99% identity, and p value of less than 1×10⁻⁴⁰.

The remaining sequences were classified as unknown (no hits), weak similarity, and high similarity (parameters as above). Two searches were performed on these sequences. First, a BLAST vs. EST database search resulted in discard of 1771 sequences (sequences with greater than 99% overlap, greater than 99% similarity and a p value of less than 1×10⁻⁴⁰; sequences with a p value of less than 1×10⁻⁶⁵ when compared to a database sequence of human origin were also excluded). Second, a BLASTN vs. Patent GeneSeq database resulted in discard of 15 sequences (greater than 99% identity; p value less than 1×10⁻⁴⁰; greater than 99% overlap).

The remaining sequences were subjected to screening using other rules and redundancies in the dataset. Sequences with a p value of less than 1×10⁻¹¹¹ in relation to a database sequence of human origin were specifically excluded. The final result provided the 2502 sequences listed in the accompanying Sequence Listing. The Sequence Listing is arranged beginning with sequences with no similarity to any sequence in a database searched, and ending with sequences with the greatest similarity. Each identified polynucleotide represents sequence from at least a partial mRNA transcript. Polynucleotides that were determined to be novel were assigned a sequence identification number.

The novel polynucleotides were assigned sequence identification numbers SEQ ID NOS:1-2502. The DNA sequences corresponding to the novel polynucleotides are provided in the Sequence Listing. The majority of the sequences are presented in the Sequence Listing in the 5′ to 3′ direction. A small number of sequences are listed in the Sequence Listing in the 5′ to 3′ direction but the sequence as written is actually 3′ to 5′. These sequences are readily identified with the designation “AR” in the Sequence Name in Table 1 (inserted before the claims). The sequences correctly listed in the 5′ to 3′ direction in the Sequence Listing are designated “AF.” Table 1 provides: 1) the SEQ ID NO assigned to each sequence for use in the present specification; 2) the filing date of the U.S. priority application in which the sequence was first filed; 3) the SEQ ID NO assigned to the sequence in the priority application; 4) the sequence name used as an internal identifier of the sequence; 5) the name assigned to the clone from which the sequence was isolated; and 6) the number of the cluster to which the sequence is assigned (Cluster ID; where the cluster ID is 0, the sequence was not assigned to any cluster.

Because the provided polynucleotides represent partial mRNA transcripts, two or more polynucleotides of the invention may represent different regions of the same mRNA transcript and the same gene. Thus, if two or more SEQ ID NOS: are identified as belonging to the same clone, then either sequence can be used to obtain the full-length mRNA or gene. In addition, some sequences are identified with multiple SEQ ID NOS, since these sequences were present in more than one filing. For example, SEQ ID NO:87 and SEQ ID NO:1000 represent the same sequence.

In order to confirm the sequences of SEQ ID NOS:1-2502, inserts of the clones corresponding to these polynucleotides were re-sequenced. These “validation” sequences are provided in SEQ ID NOS:2503-5106. Of these validation sequences, SEQ ID NOS:3040, 3545, 3863, 4511, 4726, and 4749 are not true validation sequences. Instead, SEQ ID NOS:3545, 4511, 4726, and 4749 represent “placeholder” sequences, i.e., sequences that were inserted into the Sequence Listing only to prevent renumbering of the subsequent sequences during generation of the Sequence Listing. Thus, reference to “SEQ ID NOS:1-5252,” “SEQ ID NOS:1-5106,” or other ranges of SEQ ID NOS that include these placeholder sequences should be read to exclude SEQ ID NOS:3545, 4511, 4726, and 4749.

The validation sequences were often longer than the original polynucleotide sequences they validate, and thus often provide additional sequence information. Validation sequences can be correlated with the original sequences they validate by referring to Table 1. For example, validation sequences of SEQ ID NOS:2503-3039, 3041-3544, 3546-3862 3864-4510, and 4512-4725 share the clone name of the sequence of SEQ ID NOS:1-2502 that they validate.

Example 2 Results of Public Database Search to Identify Function of Gene Products

SEQ ID NOS:1-2502, as well as the validation sequences SEQ ID NOS:2503-3039, 3041-3544, 3546-3862 3864-4510, and 4512-4725 xx:clf were translated in all three reading frames to determine the best alignment with the individual sequences. These amino acid sequences and nucleotide sequences are referred, generally, as query sequences, which are aligned with the individual sequences. Query and individual sequences were aligned using the BLAST programs, available over the world wide web at http://ww.ncbi.nlm.nih.gov/BLAST/. Again the sequences were masked to various extents to prevent searching of repetitive sequences or poly-A sequences, using the XBLAST program for masking low complexity as described above in Example 1.

Table 2 (inserted before the claims) shows the results of the alignments. Table 2 refers to each sequence by its SEQ ID NO:, the accession numbers and descriptions of nearest neighbors from the Genbank and Non-Redundant Protein searches, and the p values of the search results.

For each of “SEQ ID NOS:1-5106,” the best alignment to a protein or DNA sequence is included in Table 2. The activity of the polypeptide encoded by “SEQ ID NOS:1-5106” is the same or similar to the nearest neighbor reported in Table 2. The accession number of the nearest neighbor is reported, providing a reference to the activities exhibited by the nearest neighbor. The search program and database used for the alignment also are indicated as well as a calculation of the p value.

Full length sequences or fragments of the polynucleotide sequences of the nearest neighbors can be used as probes and primers to identify and isolate the full length sequence of “SEQ ID NOS:1-5106.” The nearest neighbors can indicate a tissue or cell type to be used to construct a library for the full-length sequences of “SEQ ID NOS:1-5106.”

“SEQ ID NOS:1-5106” and the translations thereof may be human homologs of known genes of other species or novel allelic variants of known human genes. In such cases, these new human sequences are suitable as diagnostics or therapeutics. As diagnostics, the human sequences “SEQ ID NOS:1-5106” exhibit greater specificity in detecting and differentiating human cell lines and types than homologs of other species. The human polypeptides encoded by “SEQ ID NOS1-5106” are likely to be less immunogenic when administered to humans than homologs from other species. Further, on administration to humans, the polypeptides encoded by “SEQ ID NOS:1-5106” can show greater specificity or can be better regulated by other human proteins than are homologs from other species.

Example 3 Members of Protein Families

The validation sequences (“SEQ ID NOS:2503-5106”) were used to conduct a profile search as described in the specification above. Several of the polynucleotides of the invention were found to encode polypeptides having characteristics of a polypeptide belonging to a known protein families (and thus represent new members of these protein families) and/or comprising a known functional domain (Table 3, inserted prior to claims). Thus the invention encompasses fragments, fusions, and variants of such polynucleotides that retain biological activity associated with the protein family and/or functional domain identified herein.

Start and stop indicate the position within the individual sequences that align with the query sequence having the indicated SEQ ID NO. The direction (Dir) indicates the orientation of the query sequence with respect to the individual sequence, where forward (for) indicates that the alignment is in the same direction (left to right) as the sequence provided in the Sequence Listing and reverse (rev) indicates that the alignment is with a sequence complementary to the sequence provided in the Sequence Listing.

Some polynucleotides exhibited multiple profile hits because, for example, the particular sequence contains overlapping profile regions, and/or the sequence contains two different functional domains. These profile hits are described in more detail below. The acronyms used in Table 3 are provided in parentheses following the full name of the protein family or functional domain to which they refer.

a) Seven Transmembrane Integral Membrane Proteins—Rhodopsin Family (7tm 1). Several of the validation sequences, and thus their corresponding sequence within SEQ ID NOS:1-2502, correspond to a sequence encoding a polypeptide that is a member of the seven transmembrane receptor rhodopsin family. G-protein coupled receptors of the seven transmembrane rhodopsin family (also called R7G) are an extensive group of hormones, neurotransmitters, and light receptors which transduce extracellular signals by interaction with guanine nucleotide-binding (G) proteins (Strosberg A. D. Eur. J. Biochem. (1991) 196:1, Kerlavage A. R. Curr. Opin. Struct. Biol. (1991) 1:394, Probst, et al., DNA Cell Biol. (1992) 11:1, Savarese, et al., Biochem. J. (1992) 283:1, http://www.gcrdb.uthscsa.edu/, http://swift.embl-heidelberg.de/7tm/. The receptors that are currently known to belong to this family are: 1) 5-hydroxytryptamine (serotonin) 1A to 1F, 2A to 2C, 4, 5A, 5B, 6 and 7 (Branchek T., Curr. Biol. (1993) 3:315), 2) acetylcholine, muscarinic-type, M1 to M5; 3) adenosine A1, A2A, A2B and A3 (Stiles G. L. J. Biol. Chem. (1992) 267:6451; 4) adrenergic alpha-1A to -1C; alpha-2A to -2D; beta-1 to -3 (Friell T. et al., Trends Neurosci. (1988) 11:321); 5) angiotensin II types I and II; 6) bombesin subtypes 3 and 4; 7) bradykinin B1 and B2; 8) c3a and C5a anaphylatoxin; 9) cannabinoid CB1 and CB2; 10) chemokines C-C CC-CKR-1 to CC-CKR-8; 11) Chemokines C-X-C CXC-CKR-1 to CXC-CKR4; 12) Cholecystokinin-A and cholecystokinin-B/gastrin Dopamine D1 to D5 (Stevens C. F., Curr. Biol. (1991) 1:20); 13) Endothelin ET-a and ET-b (Sakurai T. et al., Trends Pharmacol. Sci. (1992) 13:103-107); 14) fMet-Leu-Phe (fMLP) (Nfornyl peptide); 15) Follicle stimulating hormone (FSH-R); 16) Galanin; 17) Gastrin-releasing peptide (GRP-R); 18) Gonadotropin-releasing hormone (GNRH-R); 19) Histamine H1 and H2 (gastric receptor 1); 20) Lutropin-choriogonadotropic hormone (LSH-R) (Salesse R., et al., Biochimie (1991) 73:109); 21) Melanocortin MC1R to MC5R; 22) Melatonin; 23) Neuromedin B (NMB-R); 24) Neuromedin K (NK-3R); 25) Neuropeptide Y types 1 to 6; 26) Neurotensin (NT-R); 27) Octopamine (tyramine), from insects; 28) Odorants (Lancet D., et al., Curr. Biol. (1993) 3:668; 29) Opioids delta-, kappa- and mu-types (Uhl G. R., et al., Trends Neurosci. (1994) 17:89; 30) Oxytocin (OT-R); 31) Platelet activating factor (PAF-R); 32) Prostacyclin; 33) Prostaglandin D2; 34) Prostaglandin E2, EP1 to EP4 subtypes; 35) Prostaglandin F2; 36) Purinoreceptors (ATP) (Barnard E. A., et al., Trends Pharmacol. Sci. (1994) 15:67; 37); Somatostatin types 1 to 5; 38) Substance-K (NK-2R); Substance-P (NK-1R); 39) Thrombin; 40) Thromboxane A2; 41) Thyrotropin (TSH-R) (Salesse R., et al., Biochimie (1991) 73:109); 42) Thyrotropin releasing factor (TRH-R); 42) Vasopressin V1a, V1b and V2; 43) Visual pigments (opsins and rhodopsin) (Applebury M. L., et al., Vision Res. (1986) 26:1881; 44) Proto-oncogene mas; 45) A number of orphan receptors (whose ligand is not known) from mammals and birds; 46) Caenorhabditis elegans putative receptors C06G4.5, C38C10.1, C43C3.2; 47) T27D1.3 and ZC84.4; 48) Three putative receptors encoded in the genome of cytomegalovirus: US27, US28, and UL33; and 49) ECRF3, a putative receptor encoded in the genome of herpesvirus saimin.

The structure of these receptors is thought to be identical. They have seven hydrophobic regions, each of which most probably spans the membrane. The N-terminus is located on the extracellular side of the membrane and is often glycosylated, while the C-terminus is cytoplasmic and generally phosphorylated. Three extracellular loops alternate with three intracellular loops to link the seven transmembrane regions. Most, but not all of these receptors, lack a signal peptide. The most conserved parts of these proteins are the transmembrane regions and the first two cytoplasmic loops. A conserved acidic-Arg-aromatic triplet is present in the N-terminal extremity of the second cytoplasmic loop (Attwood T. K., Eliopoulos E. E., Findlay J. B. C. Gene (1991) 98:153-159) and could be implicated in the interaction with G proteins.

A consensus pattern that contains the conserved triplet and that also spans the major part of the third transmembrane helix is used to detect this widespread family of proteins: [GSTALIVMFYWC]-[GSTANCPDE]-[EDPKRH]-x(2)-[LIVMNQGA]-x(2)-[LIVMFT]-[GSTANC]-[LIVMFYWSTAC]-[DENH]-R-[FYWCSH]-x(2)-[LIVM].

b) Seven Transmembrane Integral Membrane Proteins—Secretin Family (7tm 2). Several of the validation sequences, and thus their corresponding sequence within SEQ ID NOS:1-2502, correspond to a sequence encoding a polypeptide that is a member of the seven transmembrane receptor secretin family. A number of peptide hormones bind to G-protein coupled receptors that, while structurally similar to the majority of G-protein coupled receptors (R7G) (see profile for 7 transmembrane receptors (rhodopsin family), do not show any similarity at the level of their sequence, thus new family whose current known members (Jueppner et al. Science (1991) 254:1024; Hamann et al. Genomics (1996) 32:144) are: 1) calcitonin receptor, 2) calcitonin gene-related peptide receptor; 3) corticotropin releasing factor receptor types 1 and 2; 4) gastric inhibitory polypeptide receptor; 5) glucagon receptor; 6) glucagon-like peptide 1 receptor; 7) growth hormone-releasing hormone receptor; 7) parathyroid hormone/parathyroid hormone-related peptide types 1 and 2; 8) pituitary adenylate cyclase activating polypeptide receptor, 9) secretin receptor, 10) vasoactive intestinal peptide receptor types 1 and 2; 10) insects diuretic hormone receptor; 11) Caenorhabditis elegans putative receptor C13B9.4; 12) Caenorhabditis elegans putative receptor ZK643.3; 13) human leucocyte CD97 (which contains 3 EGF-like domains in its N-terminal section); 14) human cell surface glycoprotein EMR1 (which contains 6 EGF-like domains in it N-terminal section); and 15) mouse cell surface glycoprotein F4/80 (which contains 7 EGF-like domains in its N-terminal section). All of 1) through 10) are coupled to G-proteins which activate both adenylyl cyclase and the phosphatidylinositol-calcium pathway.

Like classical R7G the secretin family of 7 transmembrane proteins contain seven transmembrane regions. Their N-terminus is located on the extracellular side of the membrane and potentially glycosylated, while their C-terminus is cytoplasmic. But apart from these topological similarities they do not share any region of sequence similarity and are therefore probably not evolutionary related.

Every receptor in the 7 transmember secretin family is encoded on multiple exons, and several of these functionally distinct products. The N-terminal extracellular domain of these receptors contains five conserved cysteines residues that may be involved in disulfide bonds, with a consensus pattern in the region that spans the first three cysteines. One of the most highly conserved regions spans the C-terminal part of the last transmembrane region and the beginning of the adjacent intracellular region. This second region is used as a second signature pattern. The two consensus patterns are:

-   1) C-x(3)-[FYWLIV]-D-x(3,4)-C-[F-W]-x(2)-[STAGV]-x(8,9)-C-[PF] -   2)     Q-G-[LMFCA]-[LIVMFT]-[LIV]-x-[LIVFST]-[LIF]-[VFYH]-C-[LFY]-x-N-x(2)-V

c) Ank Repeats (ANK). SEQ IS NO:2656, and thus its corresponding sequence within SEQ ID NOS:1-2502, represents a polynucleotide encoding an Ank repeat-containing protein. The ankyrin motif is a 33 amino acid sequence named after the protein ankyrin which has 24 tandem 33-amino-acid motifs. Ank repeats were originally identified in the cell-cycle-control protein cdc10 (Breeden et al., Nature (1987) 329:651). Proteins containing ankyrin repeats include ankyrin, myotropin, I-kappaB proteins, cell cycle protein cdc10, the Notch receptor (Matsuno et al., Development (1997) 124(21):4265); G9a (or BAT8) of the class III region of the major histocompatibility complex (Biochem J. 290:811-818, 1993), FABP, GABP, 53BP2, Lin12, glp1, SW14, and SW16. The functions of the ankyrin repeats are compatible with a role in protein-protein interactions (Bork, Proteins (1993) 17(4):363; Lambert and Bennet, Eur. J. Biochem. (1993) 211:1; Kerr et al., Current Op. Cell Biol. (1992) 4:496; Bennet et al., J. Biol. Chem. (1980) 255:6424).

The 90 kD N-terminal domain of ankyrin contains a series of 24 33-amino-acid ank repeats. (Lux et al., Nature (1990) 344:36-42, Lambert et al., PNAS USA (1990) 87:1730.) The 24 ank repeats form four folded subdomains of 6 repeats each. These four repeat subdomains mediate interactions with at least 7 different families of membrane proteins. Ankyrin contains two separate binding sites for anion exchanger dimers. One site utilizes repeat subdomain two (repeats 7-12) and the other requires both repeat subdomains 3 and 4 (repeats 13-24). Since the anion exchangers exist in dimers, ankyrin binds 4 anion exchangers at the same time (Michaely and Bennett, J. Biol. Chem. (1995) 270(37):22050). The repeat motifs are involved in ankyrin interaction with tubulin, spectrin, and other membrane proteins. (Lux et al., Nature (1990) 344:36.)

The Rel/NF-kappaB/Dorsal family of transcription factors have activity that is controlled by sequestration in the cytoplasm in association with inhibitory proteins referred to as I-kappaB. (Gilmore, Cell (1990) 62:841; Nolan and Baltimore, Curr Opin Genet Dev. (1992) 2:211; Baeuerle, Biochim Biophys Acta (1991) 1072:63; Schmitz et al., Trends Cell Biol. (1991) 1:130.) I-kappaB proteins contain 5 to 8 copies of 33 amino acid ankyrin repeats and certain NF-kappaB/rel proteins are also regulated by cis-acting ankyrin repeat containing domains including p105NF-kappaB which contains a series of ankyrin repeats (Diehl and Hannink, J. Virol. (1993) 67(12):7161). The I-kappaBs and Cactus (also containing ankyrin repeats) inhibit activators through differential interactions with the Rel-homology domain. The gene family includes proto-oncogenes, thus broadly implicating I-kappaB in the control of both normal gene expression and the aberrant gene expression that makes cells cancerous. (Nolan and Baltimore, Curr Opin Genet Dev. (1992) 2(2):211-220). In the case of rel/NF-kappaB and pp40/I-kappaB(, both the ankyrin repeats and the carboxy-terminal domain are required for inhibiting DNA-binding activity and direct association of pp40/I-kappaB(with rel/NF-kappaB protein. The ankyrin repeats and the carboxy-terminal of pp40/I-kappaB(form a structure that associates with the rel homology domain to inhibit DNA binding activity (Inoue et al., PNAS USA (1992) 89:4333).

The 4 ankyrin repeats in the amino terminus of the transcription factor subunit GABP are required for its interaction with the GABP subunit to form a functional high affinity DNA-binding protein. These repeats can be crosslinked to DNA when GABP is bound to its target sequence. (Thompson et al., Science μ(1991) 253:762; LaMarco et al., Science (1991) 253:789). Myotrophin, a 12.5 kDa protein having a key role in the initiation of cardiac hypertrophy, comprises ankyrin repeats. The ankyrin repeats are characteristic of a hairpin-like protruding tip followed by a helix-turn-helix motif. The V-shaped helix-turn-helix of the repeats stack sequentially in bundles and are stabilized by compact hydrophobic cores, whereas the protruding tips are less ordered.

d) Eukaryotic Aspartyl Proteases (asp). Several of the validation sequences, and thus their corresponding sequence within SEQ ID NOS:1-2502, correspond to a sequence encoding a novel eukaryotic aspartyl protease. Aspartyl proteases, known as acid proteases, (EC 3.4.23.-) are a widely distributed family of proteolytic enzymes (Foltmann B., Essays Biochem. (1981) 17:52; Davies D. R., Annu. Rev. Biophys. Chem. (1990) 19:189; Rao J. K. M., et al., Biochemistry (1991) 30:4663) known to exist in vertebrates, fungi, plants, retroviruses and some plant viruses. Aspartate proteases of eukaryotes are monomeric enzymes which consist of two domains. Each domain contains an active site centered on a catalytic aspartyl residue. The two domains most probably evolved from the duplication of an ancestral gene encoding a primordial domain. Currently known eukaryotic aspartyl proteases include: 1) Vertebrate gastric pepsins A and C (also known as gastricsin); 2) Vertebrate chymosin (rennin), involved in digestion and used for making cheese; 3) Vertebrate lysosomal cathepsins D (EC 3.4.23.5) and E (EC 3.4.23.34); 4) Mammalian renin (EC 3.4.23.15) whose function is to generate angiotensin I from angiotensinogen in the plasma; 5) Fungal proteases such as aspergillopepsin A (EC 3.4.23.18), candidapepsin (EC 3.4.23.24), mucoropepsin (EC 3.4.23.23) (mucor rennin), endothiapepsin (EC 3.4.23.22), polyporopepsin (EC 3.4.23.29), and rhizopuspepsin (EC 3.4.23.21); and 6) Yeast saccharopepsin (EC 3.4.23.25) (proteinase A) (gene PEP4). PEP4 is implicated in posttranslational regulation of vacuolar hydrolases; 7) Yeast barrierpepsin (EC 3.4.23.35) (gene BAR1); a protease that cleaves alpha-factor and thus acts as an antagonist of the mating pheromone; and 8) Fission yeast sxal which is involved in degrading or processing the mating pheromones.

Most retroviruses and some plant viruses, such as badnaviruses, encode for an aspartyl protease which is an homodimer of a chain of about 95 to 125 amino acids. In most retroviruses, the protease is encoded as a segment of a polyprotein which is cleaved during the maturation process of the virus. It is generally part of the pol polyprotein and, more rarely, of the gag polyprotein. Because the sequence around the two aspartates of eukaryotic aspartyl proteases and around the single active site of the viral proteases is conserved, a single signature pattern can be used to identify members of both groups of proteases. The consensus pattern is: [LIVMFGAC]-[LIVMTADN]-[LIVFSA]-D-[ST]-G-[STAV]-[STAPDENQ]-x-[LIVMFSTNC]-x-[LIVMFGTA), where D is the active site residue.

e) ATPases Associated with Various Cellular Activities (ATPases). Several of the validation sequences, and thus their corresponding sequence within SEQ ID NOS:1-2502, correspond to a sequence that encodes a novel member of the “ATPases Associated with diverse cellular Activities” (AAA) protein family. The AAA protein family is composed of a large number of ATPases that share a conserved region of about 220 amino acids that contains an ATP-binding site (Froehlich et al., J. Cell Biol. (1991) 114:443; Erdmann et al. Cell (1991) 64:499; Peters et al., EMBO J. (1990) 9:1757; Kunau et al., Biochimie (1993) 75:209-224; Confalonieri et al., BioEssays (1995) 17:639; http://yeamnob.pci.chemie.uni-tuebingen.de/AAA/Description.html). The proteins that belong to this family either contain one or two AAA domains.

Proteins containing two AAA domains include: 1) Mammalian and drosophila NSF (N-ethylmaleimide-sensitive fusion protein) and the fungal homolog, SEC18, which are involved in intracellular transport between the endoplasmic reticulum and Golgi, as well as between different Golgi cistemae; 2) Mammalian transitional endoplasmic reticulum ATPase (previously known as p97 or VCP), which is involved in the transfer of membranes from the endoplasmic reticulum to the golgi apparatus. This ATPase forms a ring-shaped homooligomer composed of six subunits. The yeast homolog, CDC48, plays a role in spindle pole proliferation; 3) Yeast protein PAS1 essential for peroxisome assembly and the related protein PAS1 from Pichia pastoris; 4) Yeast protein AFG2; 5) Sulfolobus acidocaldarius protein SAV and Halobacterium salinarium cdcH, which may be part of a transduction pathway connecting light to cell division.

Proteins containing a single AAA domain include: 1) Escherichia coli and other bacteria ftsH (or hflb) protein. FtsH is an ATP-dependent zinc metallopeptidase that degrades the heat-shock sigma-32 factor, and is an integral membrane protein with a large cytoplasmic C-terminal domain that contain both the AAA and the protease domains; 2) Yeast protein YME1, a protein important for maintaining the integrity of the mitochondrial compartment. YME1 is also a zinc-dependent protease; 3) Yeast protein AFG3 (or YTA10). This protein also contains an AAA domain followed by a zinc-dependent protease domain; 4) Subunits from regulatory complex of the 26S proteasome (Hilt et al., Trends Biochem. Sci. (1996) 21:96), which is involved in the ATP-dependent degradation of ubiquitinated proteins, which subunits include: a) Mammalian 4 and homologs in other higher eukaryotes, in yeast (gene YTA5) and fission yeast (gene mts2); b) Mammalian 6 (TBP7) and homologs in other higher eukaryotes and in yeast (gene YTA2); c) Mammalian subunit 7 (MSS1) and homologs in other higher eukaryotes and in yeast (gene CIM5 or YTA3); d) Mammalian subunit 8 (P45) and homologs in other higher eukaryotes and in yeast (SUG1 or CIM3 or TBY1) and fission yeast (gene let1); e) Other probable subunits include human TBP1, which influences HIV gene expression by interacting with the virus tat transactivator protein, and yeast YTA1 and YTA6; 5) Yeast protein BCS1, a mitochondrial protein essential for the expression of the Rieske iron-sulfur protein; 6) Yeast protein MSP1, a protein involved in intramitochondrial sorting of proteins; 7) Yeast protein PAS8, and the corresponding proteins PAS5 from Pichia pastoris and PAY4 from Yarrowia lipolytica; 8) Mouse protein SKD1 and its fission yeast homolog (SpAC2G11.06); 9) Caenorhabditis elegans meiotic spindle formation protein mei-1; 10) Yeast protein SAP1; 11) Yeast protein YTA7; and 12) Mycobacterium leprae hypothetical protein A2126A.

In general, the AAA domains in these proteins act as ATP-dependent protein clamps (Confalonieri et al. (1995) BioEssays 17:639). In addition to the ATP-binding ‘A’ and ‘B’ motifs, which are located in the N-terminal half of this domain, there is a highly conserved region located in the central part of the domain which was used in the development of the signature pattern. The consensus pattern is: [LIVMT]-x-[LIVMT]-[LIVMF]-x-[GATMC]-[ST]-[NS]-x(4)-[LIVM]-D-x-A-[LIFA]-x-R.

f) Bcl-2 family (Bcl-2). SEQ ID NO:3404, and thus the corresponding sequence it validates, represents a polynucleotide encoding an apoptosis regulator protein of the Bcl-2 family. Active cell suicide (apoptosis) is induced by events such as growth factor withdrawal and toxins. It is controlled by regulators, which have either an inhibitory effect on programmed cell death (anti-apoptotic) or block the protective effect of inhibitors (pro-apoptotic) (Vaux, 1993, Curr. Biol. 3:877-878, and White, 1996, Genes Dev. 10:2859-2869). Many viruses have found a way of countering defensive apoptosis by encoding their own anti-apoptosis genes, preventing their target cells from dying prematurely.

All proteins belonging to the Bcl-2 family (Reed et al., 1996, Adv. Exp. Med. Biol. 406:99-112) contain either a BH1, BH2, BH3, or BH4 domain. All anti-apoptotic proteins contain BH1 and BH2 domains; some of them contain an additional N-terminal BH4 domain (Bcl-2, Bcl-x(L), Bcl-w), which is never seen in pro-apoptotic proteins, except for Bcl-x(S). On the other hand, all pro-apoptotic proteins contain a BH3 domain (except for Bad) necessary for dimerization with other proteins of Bcl-2 family and crucial for their killing activity; some of them also contain BH1 and BH2 domains (Bax, Bak). The BH3 domain is also present in some anti-apoptotic protein, such as Bcl-2 or Bcl-x(L). Proteins that are known to contain these domains are listed below.

-   1. Vertebrate protein Bcl-2. Bcl-2 blocks apoptosis; it prolongs the     survival of hematopoietic cells in the absence of required growth     factors and also in the presence of various stimuli inducing     cellular death. Two isoforms of bcl-2 (alpha and beta) are generated     by alternative splicing. Bcl-2 is expressed in a wide range of     tissues at various times during development. It forms heterodimers     with the Bax proteins. -   2. Vertebrate protein Bcl-x. Two isoforms of Bcl-x (Bcl-x(L) and     Bcl-x(S)) are generated by alternative splicing. While the longer     product (Bcl-x(L)) can protect a growth-factor-dependent cell line     from apoptosis, the shorter form blocks the protective effect of     Bcl-2 and Bcl-x(L) and acts as an anti-anti-apoptosis protein. -   3. Mammalian protein Bax. Bax blocks the anti-apoptosis ability of     Bcl-2 with which it forms heterodimers. There is no evidence that     Bax has any activity in the absence of Bcl-2. Three isoforms of bax     (alpha, beta and gamma) are generated by alternative splicing. -   4. Mammalian protein Bak, which promotes cell death and counteracts     the protection from apoptosis provided by Bcl-2. -   5. Mammalian protein Bcl-w, which promotes cell survival. -   6. Mammalian protein bad, which promotes cell death, and counteracts     the protection from apoptosis provided by Bcl-x(L), but not that of     Bcl-2. -   7. Human protein Bik, which promotes cell death, but cannot     counteract the protection from apoptosis provided by Bcl-2. -   8. Mouse protein Bid, which induces caspases and apoptosis, and     counteracts the protection from apoptosis provided by Bcl-2. -   9. Human induced myeloid leukemia cell differentiation protein MCL1.     MCL1 is probably involved in programming of differentiation and     concomitant maintenance of viability but not proliferation. Its     expression increases early during phorbol ester induced     differentiation in myeloid leukemia cell line ML-1. -   10. Mouse hemopoietic-specific early response protein A1. -   11. Mammalian activator of apoptosis Harakiri (Inohara et al., 1997,     EMBO J. 16:1686-1694) (also known as neuronal death protein Dp5).     This is a small protein of 92 residues that activates apoptosis. It     contains a BH3 domain, but no BH1, BH2 or BH4 domains.

The following consensus patterns have been developed for the four BH domains:

-   1)     [LVME]-[FT]-x-[GSD]-x-[GL]-x(1,2)-[NS]-[YW]-G-R-[LIV]-[LIVC]-[GAT]-[LIVMF](2)-x-F-[GSAE]-[GSARY] -   2) W-[LIM]-x(3)-[GR]-G-[WQ]-[DENSAV]-x-[FLGA]-[LIVFTC] -   3)     [LIVAT]-x(3)-L-[KARQ]-x-[IVAL]-G-D-[DESG]-[LIMFV]-[DENSHQ]-[LVSHRQ]-[NSR] -   4)     [DS]-[NT]-R-[AE]-[LI]-V-x-[KD]-[FY]-[LIV]-[GHS]-Y-K-L-[SR]-Q-[RK]-G-[HY]-x-[CW].

g) Bromodomain (bromodomain). SEQ ID NOS:4036 and 4489, and thus the corresponding sequences they validate, represent polynucleotides encoding a polypeptide having a bromodomain region (Haynes et al., 1992, Nucleic Acids Res. 20:2693-2603, Tamkun et al., 1992, Cell 68-561-572, and Tamkun, 1995, Curr. Opin. Genet. Dev. 5:473-477), which is a conserved region of about 70 amino acids found in the following proteins: 1) Higher eukaryotes transcription initiation factor TFIID 250 Kd subunit (TBP-associated factor p250) (gene CCG1); P250 is associated with the TFIID TATA-box binding protein and seems essential for progression of the G1 phase of the cell cycle. 2) Human RING3, a protein of unknown function encoded in the MHC class II locus; 3) Mammalian CREB-binding protein (CBP), which mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein; 4) Mammalian homologs of brahma, including three brahma-like human: SNF2a(hBRM), SNF2b, and BRG1; 5) Human BS69, a protein that binds to adenovirus E1A and inhibits E1A transactivation; 6) Human peregrin (or Br140).

The bromodomain is thought to be involved in protein-protein interactions and may be important for the assembly or activity of multicomponent complexes involved in transcriptional activation. The consensus pattern, which spans a major part of the bromodomain, is: [STANVF]-x(2)-F-x(4)-[DNS]-x(5,7)-[DENQTF]-Y-[HFY]-x(2)-[LIVMFY]-x(3)-[LIVM]-x(4)-[LIVM]-x(6,8)-Y-x(12,13)-[LIVM]-x(2)-N-[SACF]-x(2)-[FY].

h) Basic Region Plus Leucine Zipper Transcription Factors (BZIP). SEQ ID NO:3408, 2951, and 4850, and thus the corresponding sequences these sequences validate, represent polynucleotides encoding a novel member of the family of basic region plus leucine zipper transcription factors. The bZIP superfamily (Hurst, Protein Prof. (1995) 2:105; and Ellenberger, Curr. Opin. Struct. Biol. (1994) 4:12) of eukaryotic DNA-binding transcription factors encompasses proteins that contain a basic region mediating sequence-specific DNA-binding followed by a leucine zipper required for dimerization. Members of the family include transcription factor AP-1, which binds selectively to enhancer elements in the cis control regions of SV40 and metallothionein IIA. AP-1, also known as c-jun, is the cellular homolog of the avian sarcoma virus 17 (ASV 17) oncogene v-jun. Other members of this protein family include jun-B and jun-D, probable transcription factors that are highly similar to jun/AP-1; the fos protein, a proto-oncogene that forms a non-covalent dimer with c-jun; the fos-related proteins fra-1, and fos B; and mammalian cAMP response element (CRE) binding proteins CREB, CREM, ATF-1, ATF-3, ATF-4, ATF-5, ATF-6 and LRF-1. The consensus pattern for this protein family is: [KR]-x(1,3)-[RKSAQ]-N-x(2)-[SAQ](2)-x-[RKTAENQ]-x-R-x-[RK].

i) Cyclins (cyclin). SEQ ID NOS:3618, 3895, and 4536, and thus the corresponding sequences these sequences validate, represent polynucleotides encoding cyclins, and SEQ ID NO:55 and 56, respectively, show the corresponding full-length polynucleotides. SEQ ID NO:57 and 58 show, respectively, the translations of SEQ ID NO:55 and 56. Cyclins (Nurse, 1990, Nature 344:503-508; Norbury et al., 1991, Curr. Biol. 1:23-24; and Lew et al., 1992, Trends Cell Biol. 2:77-81) are eukaryotic proteins that play an active role in controlling nuclear cell division cycles. There are two main groups of cyclins. G2/M cyclins are essential for the control of the cell cycle at the G2/M (mitosis) transition. G2/M cyclins accumulate steadily during G2 and are abruptly destroyed as cells exit from mitosis (at the end of the M-phase). G1/S cyclins are essential for the control of the cell cycle at the G1/S (start) transition.

The best conserved region is in the central part of the cyclins' sequences, known as the “cyclin-box,” from which a 32 residue consensus pattern was derived: R-x(2)-[LIVMSA]-x(2)-[FYWS]-[LIVM]-x(8)-[LIVMFC]-x(4)-[LIVMFYA]-x(2)-[STAGC]-[LIVMFYQ]-x-[LIVMFYC]-[LIVMFY]-D-[RKH]-[LIVMFYW].

j) Eukaryotic thiol (cysteine) proteases active sites (Cys-protease). SEQ ID NOS:3344, 3684, 3688, and 4801, and thus also the sequences they validate, repreasent polynucleotides encoding proteins having a eukaryotic thiol (cysteine) protease active site. Eukaryotic thiol proteases (Dufour E., Biochimie (1988) 70:1335); are a family of proteolytic enzymes which contain an active site cysteine. Catalysis proceeds through a thioester intermediate and is facilitated by a nearby histidine side chain; an asparagine completes the essential catalytic triad. The proteases that belong to this family are: 1) vertebrate lysosomal cathepsins B (Kirschke H., et al., Protein Prof. (1995) 2:1587-1643); 2) vertebrate lysosomal dipeptidyl peptidase 1 (also known as cathepsin C) (Kirschke H., et al., supra); 3) vertebrate calpains (Calpains are intracellular calcium-activated thiol protease that contain both an N-terminal catalytic domain and a C-terminal calcium-binding domain); 4) mammalian cathepsin K, which seems involved in osteoclastic bone resorption (Shi G.-P., et al., FEBS Lett. (1995) 357:129); 5) human cathepsin O ([4] Velasco G., Ferrando A. A., Puente X. S., Sanchez L. M., Lopez-Otin C. J. Biol. Chem. (1994) 269:27136); 6) bleomycin hydrolase (which catalyzes the inactivation of the antitumor drug BLM (a glycopeptide)); 7) Plant enzymes such as: barley aleurain, EP-B1/B4; kidney bean EP-C1, rice bean SH-EP; kiwi fruit actinidin; papaya latex papin, chyrnopapain, caricain, and proteinase IV; pea turgor-responsive protein 15A; pineapple stem bromelain; rape COT44; rice oryzain alpha, beta, and gamma; tomato low-temperature induced, Arabidopsis thaliana A494, RD19A and RD21A; 8)—House-dust mites allergens DerP1 and EurM1; 9) cathepsin B-like proteinases from the worms Caenorhabditis elegans (genes gcp-1, cpr-3, cpr-4, cpr-5 and cpr-6), Schistosoma mansoni (antigen SM31) and Japonica (antigen SJ31), Haemonchus contortus (genes AC-1 and AC-2), and Ostertagia ostertagi (CP-1 and CP-3); 10) slime mold cysteine proteinases CP1 and CP2; 11) cruzipain from Trypanosoma cruzi and brucei; 12) throphozoite cysteine proteinase (TCP) from various Plasmodium species; 13) proteases from Leishmania mexicana, Theileria annulata and Theileria parva; 14) Baculoviruses cathepsin-like enzyme (v-cath); 15) Drosophila small optic lobes protein (gene sol), a neuronal protein that contains a calpain-like domain; 16) yeast thiol protease BLH1/YCP1/LAP3; 17) Caenorhabditis elegans hypothetical protein C06G4.2, a calpain-like protein.

In addition, two bacterial peptidases are also part of this family: 1) aminopeptidase C- from Lactococcus lactis (gene pepC) (Chapot-Chartier M. P., et al., Appl. Environ. Microbiol. (1993) 59:330); and 2) thiol protease tpr from Porphyromonas gingivalis. Three other proteins are structurally related to this family, but may have lost their proteolytic activity. These include: 1) soybean oil body protein P34 (which has its active site cysteine replaced by a glycine); 2) rat testin (which is a sertoli cell secretory protein highly similar to cathepsin L but with the active site cysteine is replaced by a serine); and 3) Plasmodium falciparum serine-repeat protein (SERA) (which is the major blood stage antigen and possesses a C-terminal thiol-protease-like domain (Higgins D. G., et al., Nature (1989) 340:604), with the active site cysteine is replaced by a serine).

The sequences around the three active site residues are well conserved and can be used as signature patterns:

Consensus pattern #1: Q-x(3)-[GE]-x-C-[YW]-x(2)-[STAGC]-[STAGCV] (where C is the active site residue)

Consensus pattern #2: [LIVMGSTAN]-x-H-[GSACE]-[LIVM]-x-[LIVMAT](2)-G-x-[GSADNH] (where H is the active site residue);

Consensus pattern #3: [FYCH]-[WI]-[LIVT]-x-[KRQAG]-N-[ST]-W-x(3)-[FYW]-G-x(2)-G-[LFYW]-[LIVMFYG]-x-[LIVMF] (where N is the active site residue).

k) Phorbol Esters/Diacylplycerol Binding (DAG_PE_bind). SEQ ID NO:4659, and thus the sequence it validates, represents a polynucleotide encoding a protein belonging to the family including phorbol esters/diacylglycerol binding proteins. Diacylglycerol (DAG) is an important second messenger. Phorbol esters (PE) are analogues of DAG and potent tumor promoters that cause a variety of physiological changes when administered to both cells and tissues. DAG activates a family of serine/threonine protein kinases, collectively known as protein kinase C (PKC) (Azzi et al, Eur. J. Biochem. (1992) 208:547). Phorbol esters can directly stimulate PKC. The N-terminal region of PKC, known as C1, has been shown (Ono et al., Proc. Natl. Acad. Sci. USA (1989) 86:4868) to bind PE and DAG in a phospholipid and zinc-dependent fashion. The C1 region contains one or two copies (depending on the isozyme of PKC) of a cysteine-rich domain about 50 amino-acid residues long and essential for DAG/PE-binding. Such a domain has also been found in, for example, the following proteins.

(1) Diacylglycerol kinase (EC 2.7.1.107) (DGK) (Sakane et al., Nature (1990) 344:345), the enzyme that converts DAG into phosphatidate. It contains two copies of the DAG/PE-binding domain in its N-terminal section. At least five different forms of DGK are known in mammals; and

(2) N-chimaerin, a brain specific protein which shows sequence similarities with the BCR protein at its C-terminal part and contains a single copy of the DAG/PE-binding domain at its N-terminal part. It has been shown (Ahmed et al., Biochem. J. (1990) 272:767, and Ahmed et al., Biochem. J. (1991) 280:233) to be able to bind phorbol esters.

The DAG/PE-binding domain binds two zinc ions; the ligands of these metal ions are probably the six cysteines and two histidines that are conserved in this domain. The signature pattern completely spans the DAGIPE domain. The consensus pattern is: H-x-[LIVMFYW]-x(8,11)-C-x(2)-C-x(3)-[LIVMFC]-x(5,10)-C-x(2)-C-x(4)-[HD]-x(2)-C-x(5,9)-C. All the C and H are probably involved in binding zinc.

l) DEAD and DEAH box families ATP-dependent helicases signatures (Dead_box_helic). SEQ ID NOS:4821 and 5083, and thus the sequences they validate, represent polynucleotides encoding a novel member of the DEAD box family. A number of eukaryotic and prokaryotic proteins have been characterized (Schmid S. R., et al., Mol. Microbiol. (1992) 6:283; Linder P., et al., Nature (1989) 337:121; Wassarman D. A., et al., Nature (1991) 349:463) on the basis of their structural similarity. All are involved in ATP-dependent, nucleic-acid unwinding. Proteins currently known to belong to this family are:

1) Initiation factor eIF-4A. Found in eukaryotes, this protein is a subunit of a high molecular weight complex involved in 5 ′cap recognition and the binding of mRNA to ribosomes. It is an ATP-dependent RNA-helicase.

2) PRP5 and PRP28. These yeast proteins are involved in various ATP-requiring steps of the pre-mRNA splicing process.

3) P110, a mouse protein expressed specifically during spermatogenesis.

4) An3, a Xenopus putative RNA helicase, closely related to P110.

5) SPP81/DED1 and DBP1, two yeast proteins involved in pre-mRNA splicing and related to P110.

6) Caenorhabditis elegans helicase glh-1.

7) MSS116, a yeast protein required for mitochondrial splicing.

8) SPB4, a yeast protein involved in the maturation of 25S ribosomal RNA.

9) p68, a human nuclear antigen. p68 has ATPase and DNA-helicase activities in vitro. It is involved in cell growth and division.

10) Rm62 (p62), a Drosophila putative RNA helicase related to p68.

11) DBP2, a yeast protein related to p68.

12) DHH1, a yeast protein.

13) DRS1, a yeast protein involved in ribosome assembly.

14) MAK5, a yeast protein involved in maintenance of dsRNA killer plasmid.

15) ROK1, a yeast protein.

16) ste13, a fission yeast protein.

17) Vasa, a Drosophila protein important for oocyte formation and specification of embryonic posterior structures.

18) Me3 B, a Drosophila alternally expressed protein of unknown function.

19) dbpA, an Escherichia coli putative RNA helicase.

20) deaD, an Escherichia coli putative RNA helicase which can suppress a mutation in the rpsB gene for ribosomal protein S2.

21) rhlB, an Escherichia coli putative RNA helicase.

22) rhlE, an Escherichia coli putative RNA helicase.

23) rmB, an Escherichia coli protein that shows RNA-dependent ATPase activity, which interacts with 23S ribosomal RNA.

24) Caenorhabditis elegans hypothetical proteins T26G10.1, ZK512.2 and ZK686.2.

25) Yeast hypothetical protein YHR065c.

26) Yeast hypothetical protein YHR169w.

27) Fission yeast hypothetical protein SpAC31A2.07c.

28) Bacillus subtilis hypothetical protein yxiN.

All of the above proteins share a number of conserved sequence motifs. Some of them are specific to this family while others are shared by other ATP-binding proteins or by proteins belonging to the helicases ‘superfamily’ (Hodgman T. C., Nature (1988) 333:22 and Nature (1988) 333:578 (Errata); http://www.expasy.ch/www/linder/HELICASES_TEXT.html). One of these motifs, called the ‘D-E-A-D-box’, represents a special version of the B motif of ATP-binding proteins. Some other proteins belong to a subfamily which have His instead of the second Asp and are thus said to be ‘D-E-A-H-box’ proteins (Wassarman D. A., et al., Nature (1991) 349:463; Harosh I., et al., Nucleic Acids Res. (1991) 19:6331; Koonin E. V., et al., J. Gen. Virol. (1992) 73:989; http://www.expasy.ch/www/linder/HELICASES_TEXT.html). Proteins currently known to belong to this DEAH subfamily are:

1) PRP2, PRP16, PRP22 and PRP43. These yeast proteins are all involved in various ATP-requiring steps of the pre-mRNA splicing process. 2) Fission yeast prh1, which my be involved in pre-mRNA splicing. 3) Male-less (mle), a Drosophila protein required in males, for dosage compensation of X chromosome linked genes. 4) RAD3 from yeast. RAD3 is a DNA helicase involved in excision repair of DNA damaged by UV light, bulky adducts or cross-linking agents. Fission yeast rad15 (rhp3) and mammalian DNA excision repair protein XPD (ERCC-2) are the homologs of RAD3. 5) Yeast CHL1 (or CTF1), which is important for chromosome transmission and normal cell cycle progression in G(2)/M. 6) Yeast TPS1. 7) Yeast hypothetical protein YKL078w. 8) Caenorhabditis elegans hypothetical proteins C06E1.10 and KO3H1.2. 9) Poxviruses' early transcription factor 70 Kd subunit which acts with RNA polymerase to initiate transcription from early gene promoters. 10) I8, a putative vaccinia virus helicase. 11) hrpA, an Escherichia coli putative RNA helicase.

The following signature patterns are used to identify member for both subfamilies:

Consensus pattern: [LVMF](2)-D-E-A-D-[RKEN]-x-[LIVMFYGSTN]

Consensus pattern: [GSAH]-x-[LIVMF](3)-D-E-[ALIV]-H-[NECR].

m) EF Hand (EFhand). Several of the validation sequences, and thus the sequences they validate, correspond to polynucleotides encoding a novel protein in the family of EF-hand proteins. Many calcium-binding proteins belong to the same evolutionary family and share a type of calcium-binding domain known as the EF-hand (Kawasaki et al., Protein. Prof. (1995) 2:305-490). This type of domain consists of a twelve residue loop flanked on both sides by a twelve residue alpha-helical domain. In an EF-hand loop the calcium ion is coordinated in a pentagonal bipyramidal configuration. The six residues involved in the binding are in positions 1, 3, 5, 7, 9 and 12; these residues are denoted by X, Y, Z, -Y, -X and -Z. The invariant Glu or Asp at position 12 provides two oxygens for liganding Ca (bidentate ligand).

Proteins known to contain EF-hand regions include: Calmodulin (Ca=4, except in yeast where Ca=3) (“Ca=” indicates approximate number of EF-hand regions); diacylglycerol kinase (EC 2.7.1.107) (DGK) (Ca=2); 2) FAD-dependent glycerol-3-phosphate dehydrogenase (EC 1.1.99.5) from mammals (Ca=1); guanylate cyclase activating protein (GCAP) (Ca=3); MIF related proteins 8 (MRP-8 or CFAG) and 14 (MRP-14) (Ca=2); myosin regulatory light chains (Ca=1); oncomodulin (Ca=2); osteonectin (basement membrane protein BM40) (SPARC); and proteins that contain an “osteonectin[ domain (QR1, matrix glycoprotein SC1).

The consensus pattern includes the complete EF-hand loop as well as the first residue which follows the loop and which seem to always be hydrophobic: D-x-[DNS]-{ILVFYW}-[DENSTG]-[DNQGHRK]-{GP}-LIVMC]-[DENQSTAGC]-x(2)-[DE]-[LIVMFYW].

n) Ets Domain (Ets_Nterm). SEQ ID NO:2849, and thus the sequence it validates, represents a polynucleotide encoding a polypeptide with N-terminal homology in ETS domain. Proteins of this family contain a conserved domain, the “ETS-domain,” that is involved in DNA binding. The domain appears to recognize purine-rich sequences; it is about 85 to 90 amino acids in length, and is rich in aromatic and positively charged residues (Wasylyk, et al., Eur. J. Biochem. (1993) 211:718).

The ets gene family encodes a novel class of DNA-binding proteins, each of which binds a specific DNA sequence. These proteins comprise an ets domain that specifically interacts with sequences containing the common core tri-nucleotide sequence GGA. In addition to an ets domain, native ets proteins comprise other sequences which can modulate the biological specificity of the protein. Ets genes and proteins are involved in a variety of essential biological processes including cell growth, differentiation and development, and three members are implicated in oncogenic process.

o) Type II fibronectin collagen-binding domain (FntypeII). A few of the validation sequences, and thus the sequences they validate, represent polynucleotides encoding a polypeptide having a type II fibronectin collagen binding domain. Fibronectin is a plasma protein that binds cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. The major part of the sequence of fibronectin consists of the repetition of three types of domains, which are called type I, II, and III (Skorstengaard K., et al., Er. J. Biochem. (1986) 161:441). Type II domain is approximately forty residues long, contains four conserved cysteines involved in disulfide bonds and is part of the collagen-binding region of fibronectin. In fibronectin the type II domain is duplicated. Type II domains have also been found in the following proteins: 1) blood coagulation factor XII (Hageman factor) (1 copy); 2) bovine seminal plasma proteins PDC-109 (BSP-A1/A2) and BSP-A3 (Seidah N. G., et al., Biochem. J. (1987) 243:195. (twice); 3) cation-independent mannose-6-phosphate receptor (which is also the insulin-like growth factor II receptor) Kornfeld S., Annu. Rev. Biochem. (1992) 61:307) (1 copy); 4) Mannose receptor of macrophages (Taylor M. E., et al., J. Biol. Chem. (1990) 265:12156) (1 copy); 5) 180 Kd secretory phospholipase A2 receptor (1 copy) Lanbeau G., et al., J. Biol. Chem. (1994) 269:1575; 6) DEC-205 receptor (1 copy); 6) Jiang W., et al., Nature (1995) 375:151); 7) 72 Kd type IV collagenase (EC 3.4.24.24) (MMP-2) (Collier I. E., et al., J. Biol. Chem. (1988) 263:6579) (3 copies); 7) 92 Kd type IV collagenase (EC 3.4.24.24) (MMP-9) (3 copies); 8) Hepatocyte growth factor activator (Miyazawa K., et al., J. Biol. Chem. (1993) 268:10024) (1 copy).

A schematic representation of the position of the invariant residues and the topology of the disulfide bonds in fibronectin type II domain is shown below:

-   xxCxxPFx#xxxxxxxCxxxxxxxxWCxxxxx#xxx#x#Cxx     where ‘C’ represents the conserved cysteine involved in a disulfide     bond and ‘#’ represents a large hydrophobic residue. The consensus     pattern for identifying members of this family, which pattern spans     this entire domain, is:     C-x(2)-P-F-x-[FYWI]-x(7)-C-x(8,10)-W-C-x(4)-[DNSR]-[FYW]-x(3,5)-[FYW]-x-[FYWI]-C     (where the four C's are involved in disulfide bonds).

p) G-Protein Alpha Subunit (G-alpha). Several of the validation sequences, and thus the sequences they validate, correspond to a gene encoding a novel polypeptide of the G-protein alpha subunit family. Guanine nucleotide binding proteins (G-proteins) are a family of membrane-associated proteins that couple extracellularly-activated integral-membrane receptors to intracellular effectors, such as ion channels and enzymes that vary the concentration of second messenger molecules. G-proteins are composed of 3 subunits (alpha, beta and gamma) which, in the resting state, associate as a trimer at the inner face of the plasma membrane. The alpha subunit has a molecule of guanosine diphosphate (GDP) bound to it. Stimulation of the G-protein by an activated receptor leads to its exchange for GTP (guanosine triphosphate). This results in the separation of the alpha from the beta and gamma subunits, which always remain tightly associated as a dimer. Both the alpha and beta-gamma subunits are then able to interact with effectors, either individually or in a cooperative manner. The intrinsic GTPase activity of the alpha subunit hydrolyses the bound GTP to GDP. This returns the alpha subunit to its inactive conformation and allows it to reassociate with the beta-gamma subunit, thus restoring the system to its resting state.

G-protein alpha subunits are 350-400 amino acids in length and have molecular weights in the range 40-45 kDa. Seventeen distinct types of alpha subunit have been identified in mammals. These fall into 4 main groups on the basis of both sequence similarity and function: alpha-s, alpha-q, alpha-i and alpha-12 (Simon et al., Science (1993) 252:802). Many alpha subunits are substrates for ADP-ribosylation by cholera or pertussis toxins. They are often N-terminally acylated, usually with myristate and/or palmitoylate, and these fatty acid modifications are probably important for membrane association and high-affinity interactions with other proteins. The atomic structure of the alpha subunit of the G-protein involved in mammalian vision, transducin, has been elucidated in both GTP- and GDB-bound forms, and shows considerable similarity in both primary and tertiary structure in the nucleotide-binding regions to other guanine nucleotide binding proteins, such as p21-ras and EF-Tu.

q) Helicases conserved C-terminal domain (helicase_C). SEQ ID NOS:2503, 4469, and 5020, and thus the sequences they validate, represent polynucleotides encoding novel members of the DEAD/H helicase family. The DEAD and DEAH families are described above.

r) Homeobox domain (homeobox). SEQ ID NO:4241, and thus the sequence it validates, represents a polynucleotide encoding a protein having a homeobox domain. The ‘homeobox’ is a protein domain of 60 amino acids (Gehring In: Guidebook to the Homebox Genes. Duboule D., Ed., pp 1-10, Oxford University Press, Oxford, (1994); Buerglin In: Guidebook to the Homebox Genes, pp 25-72, Oxford University Press, Oxford, (1994); Gehring Trends Biochem. Sci. (1992) 17:277-280; Gehring et al Annu. Rev. Genet. (1986) 20:147-173; Schofield Trends Neurosci. (1987) 10:3-6; http://copan.bioz.unibas.ch/homeo.html) first identified in number of Drosophila homeotic and segmentation proteins. It is extremely well conserved in many other animals, including vertebrates. This domain binds DNA through a helix-turn-helix type of structure. Several proteins that contain a homeobox domain play an important role in development. Most of these proteins are sequence-specific DNA-binding transcription factors. The homeobox domain is also very similar to a region of the yeast mating type proteins. These are sequence-specific DNA-binding proteins that act as master switches in yeast differentiation by controlling gene expression in a cell type-specific fashion.

A schematic representation of the homeobox domain is shown below. The helix-turn-helix region is shown by the symbols ‘H’ (for helix), and ‘t’ (for turn).

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxHHHHHHHHtttHHHHHHHHHxxxxxxxxxx 1                                                         60 The pattern detects homeobox sequences 24 residues long and spans positions 34 to 57 of the homeobox domain. The consensus pattern is as follows: [LIVMFYG]-[ASLVR]-x(2)-[LIVMSTACN]-x-[LIVM]-x(4)-[LIV]-[RKNQESTAIY]-[LIVFSTNKH]-W-[FYVC]-x-[NDQTAH]-x(5)-[RKNAIMW].

x) MAP kinase kinase (mkk). Several validation sequences, and thus the sequences they validate, represent novel members of the MAP kinase kinase family. MAP kinases (MAPK) are involved in signal transduction, and are important in cell cycle and cell growth controls. The MAP kinase kinases (MAPKK) are dual-specificity protein kinases which phosphorylate and activate MAP kinases. MAPKK homologues have been found in yeast, invertebrates, amphibians, and mammals. Moreover, the MAPKK/MAPK phosphorylation switch constitutes a basic module activated in distinct pathways in yeast and in vertebrates. MAPKK regulation studies have led to the discovery of at least four MAPKK convergent pathways in higher organisms. One of these is similar to the yeast pheromone response pathway which includes the ste11 protein kinase. Two other pathways require the activation of either one or both of the serine/threonine kinase-encoded oncogenes c-Raf-1 and c-Mos. Additionally, several studies suggest a possible effect of the cell cycle control regulator cyclin-dependent kinase 1 (cdc2) on MAPKK activity. Finally, MAPKKs are apparently essential trasducers through which signals must pass before reaching the nucleus. For review, see, e.g., Biologique Biol Cell (1993) 79:193-207; Nishida et al., Trends Biochem Sci (1993) 18:128-31; Ruderman Curr Opin Cell Biol (1993) 5:207-13; Dhanasekam et al., Oncogene (1998) 17:1447-55; Kiefer et al., Biochem Soc Trans (1997) 25:491-8; and Hill, Cell Signal (1996) 8:533-44.

y) 3′5′-cyclic nucleotide phosphodiesterases signature (PDEase). SEQ ID NO:4482, and thus the sequence it validates, represents a polynucleotide encoding a novel 3′5′-cyclic nucleotide phosphodiesterases (PDEases). PDEases catalyze the hydrolysis of cAMP or cGMP to the corresponding nucleoside 5′ monophosphates (Charbonneau H., et al., Proc. Natl. Acad. Sci. U.S.A. (1986) 83:9308). There are at least seven different subfamilies of PDEases (Beavo J. A., et al., Trends Pharmacol. Sci. (1990) 11:150; http://weber.u.washington.edu/˜pde/: 1) Type 1, calmodulin/calcium-dependent PDEases; 2) Type 2, cGMP-stimulated PDEases; 3) Type 3, cGMP-inhibited PDEases; 4) Type 4, cAMP-specific PDEases.; 5) Type 5, cGMP-specific PDEases; 6) Type 6, rhodopsin-sensitive cGMP-specific PDEases; and 7) Type 7, High affinity cAMP-specific PDEases.

All PDEase forms share a conserved domain of about 270 residues. The signature pattern is determined from a stretch of 12 residues that contains two conserved histidines: H-D-[LIVMFY]-x-H-x-[AG]-x(2)-[Q]-x-[LIVMFY].

z) Protein Kinase (protkinase). Several validation sequences, and thus the sequences they validate, represent polynucleotides encoding protein kinases. Protein kinases catalyze phosphorylation of proteins in a variety of pathways, and are implicated in cancer. Eukaryotic protein kinases (Hanks S. K., et al., FASEB J. (1995) 9:576; Hunter T., Meth. Enzymol. (1991) 200:3; Hanks S. K., et al., Meth. Enzymol (1991) 200:38; Hanks S. K., Curr. Opin. Struct. Biol. (1991) 1:369; Hanks S. K., et al., Science (1988) 241:42) are enzymes that belong to a very extensive family of proteins which share a conserved catalytic core common to both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. Two of the conserved regions are the basis for the signature pattern in the protein kinase profile. The first region, which is located in the N-terminal extremity of the catalytic domain, is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. The second region, which is located in the central part of the catalytic domain, contains a conserved aspartic acid residue which is important for the catalytic activity of the enzyme (Knighton D. R., et al., Science (1991) 253:407). The protein kinase profile includes two signature patterns for this second region: one specific for serine/threonine kinases and the other for tyrosine kinases. A third profile is based on the alignment in (Hanks S. K., et al., FASEB J. (1995) 9:576) and covers the entire catalytic domain. The consensus patterns are as follows:

1) Consensus pattern: [LIV]-G-{P}-G-{P}-[FYWMGSTNH]-[SGA]-{PW}-[LIVCAT]-{PD}-x-[GSTACLIVMFY]-x(5,18)-[LIVMFYWCSTAR]-[AIVP]-[LIVMFAGCKR]-K, where K binds ATP. The majority of known protein kinases are detected by this pattern. Proteins kinases that are not detected by this consensus include viral kinases, which are quite divergent in this region and are completely missed by this pattern.

2) Consensus pattern: [LIVMFYC]-x-[HY]-x-D-[LIVMFY]-K-x(2)-N-[LIVMFYCT](3), where D is an active site residue. This consensus sequence identifies most serine/threonine-specific protein kinases with only 10 exceptions. Half of the exceptions are viral kinases, while the other exceptions include Epstein-Barr virus BGLF4 and Drosophila ninaC, which have Ser and Arg, respectively, instead of the conserved Lys. These latter two protein kinases are detected by the tyrosine kinase specific pattern described below.

3) Consensus pattern: [LIVMFYC]-x-[HY]-x-D-[LIVMFY]-[RSTAC]-x(2)-N-[LIVMFYC], where D is an active site residue. All tyrosine-specific protein kinases are detected by this consensus pattern, with the exception of human ERBB3 and mouse blk. This pattern also detects most bacterial aminoglycoside phosphotransferases (Benner S., Nature (1987) 329:21; Kirby R., J. Mol. Evol. (1992) 30:489) and herpesviruses ganciclovir kinases (Littler E., et al., Nature (1992) 358:160), which are structurally and evolutionary related to protein kinases.

The protein kinase profile also detects receptor guanylate cyclases and 2-5A-dependent ribonucleases. Sequence similarities between these two families and the eukaryotic protein kinase family have been noticed previously. The profile also detects Arabidopsis thaliana kinase-like protein TMKL1 which seems to have lost its catalytic activity.

If a protein analyzed includes the two of the above protein kinase signatures, the probability of it being a protein kinase is close to 100%. Eukaryotic-type protein kinases have also been found in prokaryotes such as Myxococcus xanthus (Munoz-Dorado J., et al., Cell (1991) 67:995) and Yersinia pseudotuberculosis. The patterns shown above has been updated since their publication in (Bairoch A., et al., Nature (1988) 331:22).

aa) Ras family proteins (ras). SEQ ID NO:3671, and thus the sequence it validates, represent polynucleotides encoding the ras family of small GTP/GDP-binding proteins (Valencia et al., 1991, Biochemistry 30:4637-4648). Ras family members generally require a specific guanine nucleotide exchange factor (GEF) and a specific GTPase activating protein (GAP) as stimulators of overall GTPase activity. Among ras-related proteins, the highest degree of sequence conservation is found in four regions that are directly involved in guanine nucleotide binding. The first two constitute most of the phosphate and Mg2+ binding site (PM site) and are located in the first half of the G-domain. The other two regions are involved in guanosine binding and are located in the C-terminal half of the molecule. Motifs and conserved structural features of the ras-related proteins are described in Valencia et al., 1991, Biochemistry 30:4637-4648.

A major consensus pattern of ras proteins is: D-T-A-G-Q-E-K-[LF]-G-G-L-R-[DE]-G-Y-Y.

bb) Thioredoxin family active site (Thioredox). SEQ ID NO:3936, and thus the sequence it validates, represent a polynucleotide encoding a protein having a thioredoxin family active site. Thioredoxins (Holmgren A., Annu. Rev. Biochem. (1985) 54:237; Gleason F. K., et al., FEMS Microbiol. Rev. (1988) 54:271; Holmgren A. J. Biol. Chem. (1989) 264:13963; Eklund H., et al. Proteins (1991) 11:13) are small proteins of approximately one hundred amino-acid residues which participate in various redox reactions via the reversible oxidation of an active center disulfide bond. They exist in either a reduced form or an oxidized form where the two cysteine residues are linked in an intramolecular disulfide bond. Thioredoxin is present in prokaryotes and eukaryotes and the sequence around the redox-active disulfide bond is well conserved.

A number of eukaryotic proteins contain domains evolutionary related to thioredoxin, and all of them are protein disulphide isomerases (PDI). PDI (Freedman R. B., et al., Biochem. Soc. Trans. (1988) 16:96; Kivirikko K. I., et al., FASEB J. (1989) 3:1609; Freedman R. B., et al. Trends Biochem. Sci. (1994) 19:331) is an endoplasmic reticulum enzyme that catalyzes the rearrangement of disulfide bonds in various proteins. The various forms of PDI which are currently known are: 1) PDI major isozyme; a multifunctional protein that also function as the beta subunit of prolyl 4-hydroxylase (EC 1.14.11.2), as a component of oligosaccharyl transferase (EC 2.4.1.119), as thyroxine deiodinase, as glutathione-insulin transhydrogenase, and as a thyroid hormone-binding protein; 2) ERp60 (ER-60; 58 Kd microsomal protein), which is a protease; 3) ERp72; and 4) P5.

All PDI contains two or three (ERp72) copies of the thioredoxin domain. The consensus pattern is: [LIVMF]-[LIVMSTA]-x-[LIVMFYC]-[FYWSTHE]-x(2)-[FYWGTN]-C-[GATPLVE]-[PHYWSTA]-C-x(6)-[LIVMFYWT] (where the two C's form the redox-active bond.

cc) TNFR/NGFR family cysteine-rich region (TNFR_c6). SEQ ID NO:3927, and thus the sequence it validates, represent a polynucleotide encoding a protein having a TNFR/NGFR family cysteine-rich region. A number of proteins, some of which are known to be receptors for growth factors, have been found to contain a cysteine-rich domain of about 110 to 160 amino acids in their N-terminal part, that can be subdivided into four (or in some cases, three) modules of about 40 residues containing 6 conserved cysteines. Proteins known to belong to this family (Mallet S., et al., Immunol. Today (1991) 12:220; Sprang S. R., Trends Biochem. Sci. (1990) 15:366; Krammer P. H., et al., Curr. Biol. (1992) 2:383; Bazan J. F., Curr. Biol. (1993) 3:603) are: 1) Tumor Necrosis Factor type I and type II receptors (TNFR) (Both receptors bind TNF-alpha and TNF-beta, but are only similar in the cysteine-rich region.); 2) Shope fibroma virus soluble TNF receptor (protein T2); 3) Lymphotoxin alphalbeta receptor; 4) Low-affinity nerve growth factor receptor (LA-NGFR); 5) CD40 (Bp50), the receptor for the CD40L (or TRAP) cytokine; 6) CD27, the receptor for the CD27L cytokine; 8) CD30, the receptor for the CD30L cytokine; 9) T-cell protein 4-1BB, the receptor for the 4-1BBL putative cytokine; 10) FAS antigen (or APO-1), the receptor for FASL, a protein involved in apoptosis (programmed cell death); 11) T-cell antigen OX40, the receptor for the OX40L cytokine; 12) Wsl-1, a receptor (for a yet undefined ligand) that mediates apoptosis; 13) Vaccinia virus protein A53 (SalF 19R).

The six cysteines all involved in intrachain disulfide bonds (Banner D. W., et al, Cell (1993) 73:431). A schematic representation of the structure of the 40 residue module of these receptors is shown below:

-   xCxxxxxxxxxxxxxCxCxxCxxxxxxxxxCxxxxCxx     where ‘C’ represents the conserved cysteine involved in a disulfide     bond. The signature pattern for the cysteine-rich region is based     mainly on the position of the six conserved cysteines in each of the     repeats: Consensus pattern:     C-x(4,6)-[FYH]-x(5,10)-C-x(0,2)-C-x(2,3)-C-x(7,11)-C-x(4,6)-[DNEQSKP]-x(2)-C     (where the six C's are involved in disulfide bonds).

dd) Four Transmembrane Integral Membrane Proteins (transmembrane4). Several of the validation sequences, and thus the sequences they validate, correspond to a sequence encoding a polypeptide that is a member of the 4 transmembrane segments integral membrane protein family (transmembrane 4 family). The transmembrane 4 family of proteins includes a number of evolutionarily-related eukaryotic cell surface antigens (Levy et al., J. Biol. Chem., (1991) 266:14597; Tomlinson et al., Eur. J. Immunol. (1993) 23:136; Barclay et al. The leucocyte antigen factbooks. (1993) Academic Press, London/San Diego). The proteins belonging to this family include: 1) Mammalian antigen CD9 (MIC3), which is involved in platelet activation and aggregation; 2) Mammalian leukocyte antigen CD37, expressed on B lymphocytes; 3) Mammalian leukocyte antigen CD53 (OX-44), which is implicated in growth regulation in hematopoietic cells; 4) Mammalian lysosomal membrane protein CD63 (melanoma-associated antigen ME491; antigen AD1); 5) Mammalian antigen CD81 (cell surface protein TAPA-1), which is implicated in regulation of lymphoma cell growth; 6) Mammalian antigen CD82 (protein R2; antigen C33; Kangai 1 (KAI1)), which associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway; 7) Mammalian antigen CD151 (SFA-1; platelet-endothelial tetrspan antigen 3 (PETA-3)); 8) Mammalian cell surface glycoprotein A15 (TALLA-1; MXS1); 9) Mammalian novel antigen 2 (NAG-2); 10) Human tumor-associated antigen CO-029; 11) Schistosoma mansoni and japonicum 23 Kd surface antigen (SM23/SJ23).

The members of the 4 transmembrane family share several characteristics. First, they all are apparently type III membrane proteins, which are integral membrane proteins containing an N-terminal membrane-anchoring domain which is not cleaved during biosynthesis and which functions both as a translocation signal and as a membrane anchor. The family members also contain three additional transmembrane regions, at least seven conserved cysteines residues, and are of approximately the same size (218 to 284 residues). These proteins are collectively know as the “transmembrane 4 superfamily” (TM4) because they span plasma membrane four times.

A schematic diagram of the domain structure of these proteins is as follows:

where Cyt is the cytoplasmic domain, TMa is the transmembrane anchor; TM2 to TM4 represents transmembrane regions 2 to 4, ‘C’ are conserved cysteines, and ‘*’ indicates the position of the consensus pattern. The consensus pattern spans a conserved region including two cysteines located in a short cytoplasmic loop between two transmembrane domains: Consensus pattern: G-x(3)-[LIVMF]-x(2)-[GSA]-[LIVMF](2)-G-C-x-[GA]-[STA]-x(2)-[EG]-x(2)-[CWN]-[LIVM](2).

ee) Trypsin (trypsin). SEQ ID NOS:3381, 4684, and 4688, and thus the sequences they validate, correspond to novel serine proteases of the trypsin family. The catalytic activity of the serine proteases from the trypsin family is provided by a charge relay system involving an aspartic acid residue hydrogen-bonded to a histidine, which itself is hydrogen-bonded to a serine. The sequences in the vicinity of the active site serine and histidine residues are well conserved in this family of proteases (Brenner S., Nature (1988) 334:528). Proteases known to belong to the trypsin family include: 1) Acrosin; 2) Blood coagulation factors VII, IX, X, XI and XII, thrombin, plasminogen, and protein C; 3) Cathepsin G; 4) Chymotrypsins; 5) Complement components C1r, C1s, C2, and complement factors B, D and I; 6) Complement-activating component of RA-reactive factor; 7) Cytotoxic cell proteases (granzymes A to H); 8) Duodenase I; 9) Elastases 1, 2, 3A, 3B (protease E), leukocyte (medullasin).; 10) Enterokinase (EC 3.4.21.9) (enteropeptidase); 11) Hepatocyte growth factor activator; 12) Hepsin; 13) Glandular (tissue) kallikreins (including EGF-binding protein types A, B, and C, NGF-gamma chain, gamma-renin, prostate specific antigen (PSA) and tonin); 14) Plasma kallikrein; 15) Mast cell proteases (MCP) 1 (chymase) to 8; 16) Myeloblastin (proteinase 3) (Wegener's autoantigen); 17) Plasminogen activators (urokinase-type, and tissue-type); 18) Trypsins I, II, III, and IV; 19) Tryptases; 20) Snake venom proteases such as ancrod, batroxobin, cerastobin, flavoxobin, and protein C activator; 21) Collagenase from common cattle grub and collagenolytic protease from Atlantic sand fiddler crab; 22) Apolipoprotein(a); 23) Blood fluke cercarial protease; 24) Drosophila trypsin like proteases: alpha, easter, snake-locus; 25) Drosophila protease stubble (gene sb); and 26) Major mite fecal allergen Der p III. All the above proteins belong to family SI in the classification of peptidases (Rawlings N. D., et al., Meth. Enzymol. (1994) 244:19; http://www.expasv.ch/cgi-bin/lists?peptidas.txt) and originate from eukaryotic species. It should be noted that bacterial proteases that belong to family S2A are similar enough in the regions of the active site residues that they can be picked up by the same patterns.

The consensus patterns for this trypsin protein family are: 1) [LIVM]-[ST]-A-[STAG]-H-C, where H is the active site residue. All sequences known to belong to this class detected by the pattern, except for complement components C1r and C1s, pig plasminogen, bovine protein C, rodent urokinase, ancrod, gyroxin and two insect trypsins; 2) [DNSTAGC]-[GSTAPIMVQH]-x(2)-G-[DE]-S-G-[GS]-[SAPHV]-[LIVMFYWH]-[LIVMFYSTANQH], where S is the active site residue. All sequences known to belong to this family are detected by the above consensus sequences, except for 18 different proteases which have lost the first conserved glycine. If a protein includes both the serine and the histidine active site signatures, the probability of it being a trypsin family serine protease is 100%.

ff) WD Domain, G-Beta Repeats (WD_domain). A few of the validation sequences, and the sequences they validate, represent novel members of the WD domain/G-beta repeat family. Beta-transducin (G-beta) is one of the three subunits (alpha, beta, and gamma) of the guanine nucleotide-binding proteins (G proteins) which act as intermediaries in the transduction of signals generated by transmembrane receptors (Gilman, Annu. Rev. Biochem. (1987) 56:615). The alpha subunit binds to and hydrolyzes GTP; the functions of the beta and gamma subunits are less clear but they seem to be required for the replacement of GDP by GTP as well as for membrane anchoring and receptor recognition.

In higher eukaryotes, G-beta exists as a small multigene family of highly conserved proteins of about 340 amino acid residues. Structurally, G-beta consists of eight tandem repeats of about 40 residues, each containing a central Trp-Asp motif (this type of repeat is sometimes called a WD-40 repeat). Such a repetitive segment has been shown to exist in a number of other proteins including: human LIS1, a neuronal protein involved in type-1 lissencephaly; and mammalian coatomer beta′ subunit (beta′-COP), a component of a cytosolic protein complex that reversibly associates with Golgi membranes to form vesicles that mediate biosynthetic protein transport.

The consensus pattern for the WD domain/G-Beta repeat family is: [LIVMSTAC]-[IVMFYWSTAGC]-[LIMSTAG]-[LIVMSTAGC]-x(2)-[DN]-x(2)-[LIVMWSTAC]-x-[LIVMFSTAG]-W-[DEN]-[LIVMFSTAGCN].

gg) wnt Family of Developmental Signaling Proteins (Wnt_dev_sign). Several of the validation sequences, and thus the sequences they validate, correspond to novel members of the wnt family of developmental signaling proteins. Wnt-1 (previously known as int-1), the seminal member of this family, (Nusse R., Trends Genet. (1988) 4:291) is a proto-oncogene induced by the integration of the mouse mammary tumor virus. It is thought to play a role in intercellular communication and seems to be a signalling molecule important in the development of the central nervous system (CNS). The sequence of wnt-1 is highly conserved in mammals, fish, and amphibians. Wnt-1 was found to be a member of a large family of related proteins (Nusse R., et al., Cell (1992) 69:1073; McMahon A. P., Trends Genet. (1992) 8:1; Moon R. T., BioEssays (1993) 15:91) that are all thought to be developmental regulators. These proteins are known as wnt-2 (also known as irp), wnt-3, -3A, 4, -5A, -5B, -6, -7A, -7B, -8, -8B, -9 and -10. At least four members of this family are present in Drosophila; one of them, wingless (wg), is implicated in segmentation polarity.

All these proteins share the following features characteristics of secretory proteins: a signal peptide, several potential N-glycosylation sites and 22 conserved cysteines that are probably involved in disulfide bonds. The Wnt proteins seem to adhere to the plasma membrane of the secreting cells and are therefore likely to signal over only few cell diameters. The consensus pattern, which is based upon a highly conserved region including three cysteines, is as follows: C-K-C-H-G-[LIVMT]-S-G-x-C. All sequences known to belong to this family are detected by the provided consensus pattern.

hh) Protein Tyrosine Phosphatase (Y_phosphatase). Several of the validation sequences, and thus the sequences they validate, represent a polynucleotide encoding a protein tyrosine kinase. Tyrosine specific protein phosphatases (EC 3.1.3.48) (PTPase) (Fischer et al., Science (1991) 253:401; Charbonneau et al., Annu. Rev. Cell Biol. (1992) 8:463; Trowbridge, J. Biol. Chem. (1991) 266:23517; Tonks et al., Trends Biochem. Sci. (1989) 14:497; and Hunter, Cell (1989) 58:1013) catalyze the removal of a phosphate group attached to a tyrosine residue. These enzymes are very important in the control of cell growth, proliferation, differentiation and transformation. Multiple forms of PTPase have been characterized and can be classified into two categories: soluble PTPases and transmembrane receptor proteins that contain PTPase domain(s).

Soluble PTPases include PTPN3 (H1) and PTPN4 (MEG), enzymes that contain an N-terminal band 4.1-like domain and could act at junctions between the membrane and cytoskeleton; PTPN6 (PTP-1C; HCP; SHP) and PTPN11 (PTP-2C; SH-PTP3; Syp), enzymes that contain two copies of the SH2 domain at its N-terminal extremity.

Dual specificity PTPases include DUSP1 (PTPN10; MAP kinase phosphatase-1; MKP-1) which dephosphorylates MAP kinase on both Thr-183 and Tyr-185; and DUSP2 (PAC-1), a nuclear enzyme that dephosphorylates MAP kinases ERK1 and ERK2 on both Thr and Tyr residues.

Structurally, all known receptor PTPases are made up of a variable length extracellular domain, followed by a transmembrane region and a C-terminal catalytic cytoplasmic domain. Some of the receptor PTPases contain fibronectin type III (FN-III) repeats, immunoglobulin-like domains, MAM domains or carbonic anhydrase-like domains in their extracellular region. The cytoplasmic region generally contains two copies of the PTPAse domain. The first seems to have enzymatic activity, while the second is inactive but seems to affect substrate specificity of the first. In these domains, the catalytic cysteine is generally conserved but some other, presumably important, residues are not.

PTPase domains consist of about 300 amino acids. There are two conserved cysteines and the second one has been shown to be absolutely required for activity. Furthermore, a number of conserved residues in its immediate vicinity have also been shown to be important. The consensus pattern for PTPases is: [LIVMF]-H-C-x(2)-G-x(3)-[STC]-[STAGP]-x-[LIVMFY]; C is the active site residue.

ii) Zinc Finger, C2H2 Type (Zincfing_C2H2). Several of the validation sequences, and thus the sequences they validate, correspond to polynucleotides encoding novel members of the of the C2H2 type zinc finger protein family. Zinc finger domains (Klug et al, Trends Biochem. Sci. (1987) 12:464; Evans et al., Cell (1988) 52:1; Payre et al., FEBS Lett. (1988) 234:245; Miller et al., EMBO J. (1985) 4:1609; and Berg, Proc. Natl. Acad. Sci. USA (1988) 85:99) are nucleic acid-binding protein structures first identified in the Xenopus transcription factor TFIIIA. These domains have since been found in numerous nucleic acid-binding proteins. A zinc finger domain is composed of 25 to 30 amino acid residues. Two cysteine or histidine residues are positioned at both extremities of the domain, which are involved in the tetrahedral coordination of a zinc atom. It has been proposed that such a domain interacts with about five nucleotides.

Many classes of zinc fingers are characterized according to the number and positions of the histidine and cysteine residues involved in the zinc atom coordination. In the first class to be characterized, called C2H2, the first pair of zinc coordinating residues are cysteines, while the second pair are histidines. A number of experimental reports have demonstrated the zinc-dependent DNA or RNA binding property of some members of this class.

Mammalian proteins having a C2H2 zipper include (number in parenthesis indicates number of zinc finger regions in the protein): basonuclin (6), BCL-6/LAZ-3 (6), erythroid krueppel-like transcription factor (3), transcription factors Sp1 (3), Sp2 (3), Sp3 (3) and Sp(4) 3, transcriptional repressor YY1 (4), Wilms' tumor protein (4), EGR1/Krox24 (3), EGR2/Krox20 (3), EGR3/Pilot (3), EGR4/AT133 (4), Evi-1 (10), GL11 (5), GL12 (4+), GL13 (3+), HIV-EP1/ZNF40 (4), HIV-EP2 (2), KR1 (9+), KR2 (9), KR3 (15+), KR4 (14+), KR5 (11+), HF.12 (6+), REX-1 (4), ZfX (13), ZfY (13), Zfp-35 (18), ZNF7 (15), ZNF8 (7), ZNF35 (10), ZNF42/MZF-1 (13), ZNF43 (22), ZNF46/Kup (2), ZNF76 (7), ZNF91 (36), ZNF133 (3).

In addition to the conserved zinc ligand residues, it has been shown that a number of other positions are also important for the structural integrity of the C2H2 zinc fingers. (Rosenfeld et al., J. Biomol. Struct. Dyn. (1993) 11:557) The best conserved position is found four residues after the second cysteine; it is generally an aromatic or aliphatic residue. The consensus pattern for C2H2 zinc fingers is: C-x(2,4)-C-x(3)-[LIVMFYWC]-x(8)-H-x(3,5)-H. The two C's and two H's are zinc ligands.

jj) Zinc finger, C3HC4 type (RING finger), signature (Zincfing_C3H4). SEQ ID NOS:3774 and 4477, and thus the sequences they validate, represent polynucleotides encoding a polypeptide having a C3HC4 type zinc finger signature. A number of eukaryotic and viral proteins contain this signature, which is primarily a conserved cysteine-rich domain of 40 to 60 residues (Borden K. L. B., et al., Curr. Opin. Struct. Biol. (1996) 6:395) that binds two atoms of zinc, and is probably involved in mediating protein-protein interactions. The 3D structure of the zinc ligation system is unique to the RING domain and is referred to as the “cross-brace” motif. The spacing of the cysteines in such a domain is C-x(2)-C-x(9 to 39)C-x(1 to 3)-H-x(2 to 3)-C-x(2)-C-x(4 to 48)-C-x(2)-C. Proteins that include the C3HC4 domain include:

1) Mammalian V(D)J recombination activating protein (RAG1). RAG1 activates the rearrangement of immunoglobulin and T-cell receptor genes.

2) Mouse rpt-1. Rpt-1 is a trans-acting factor that regulates gene expression directed by the promoter region of the interleukin-2 receptor alpha chain or the LTR promoter region of HIV-1.

3) Human rfp. Rfp is a developmentally regulated protein that may function in male germ cell development. Recombination of the N-terminal section of rfp with a protein tyrosine kinase produces the ret transforming protein.

4) Human 52 Kd Ro/SS-A protein. A protein of unknown function from the Ro/SS-A ribonucleoprotein complex. Sera from patients with systemic lupus erythematosus or primary Sjogren's syndrome often contain antibodies that react with the Ro proteins.

5) Human histocompatibility locus protein RING1.

6) Human PML, a probable transcription factor. Chromosomal translocation of PML with retinoic receptor alpha creates a fusion protein which is the cause of acute promyelocytic leukemia (APL).

7) Mammalian breast cancer type 1 susceptibility protein (BRCA1) ([E1] http://bioinformatics.weizmann.ac.il/hotmolecbase/entries/brcal.htm).

8) Mammalian cbl proto-oncogene.

9) Mammalian bmi-1 proto-oncogene.

10) Vertebrate CDK-activating kinase (CAK) assembly factor MAT1, a protein that stabilizes the complex between the CDK7 kinase and cyclin H (MAT1 stands for ‘Menage A Trois’).

11) Mammalian mel-18 protein. Mel-18 which is expressed in a variety of tumor cells is a transcriptional repressor that recognizes and bind a specific DNA sequence.

12) Mammalian peroxisome assembly factor-1 (PAF-1) (PMP35), which is somewhat involved in the biogenesis of peroxisomes. In humans, defects in PAF-1 are responsible for a form of Zellweger syndrome, an autosomal recessive disorder associated with peroxisomal deficiencies.

13) Human MAT1 protein, which interacts with the CDK7-cyclin H complex.

14) Human RING1 protein.

15) Xenopus XNF7 protein, a probable transcription factor.

16) Trypanosoma protein ESAG-8 (T-LR), which may be involved in the postranscriptional regulation of genes in VSG expression sites or may interact with adenylate cyclase to regulate its activity.

17) Drosophila proteins Posterior Sex Combs (Psc) and Suppressor two of zeste (Su(z) 2). The two proteins belong to the Polycomb group of genes needed to maintain the segment-specific repression of homeotic selector genes.

18) Drosophila protein male-specific msl-2, a DNA-binding protein which is involved in X chromosome dosage compensation (the elevation of transcription of the male single X chromosome).

19) Arabidopsis thaliana protein COP1 which is involved in the regulation of photomorphogenesis.

20) Fungal DNA repair proteins RAD5, RAD16, RAD18 and rad8.

21) Herpesviruses trans-acting transcriptional protein ICP0/IE110. This protein which has been characterized in many different herpesviruses is a trans-activator and/or -repressor of the expression of many viral and cellular promoters.

22) Baculoviruses protein CG30.

23) Baculoviruses major immediate early protein (PE-38).

24) Baculoviruses immediate-early regulatory protein IE-N/IE-2.

25) Caenorhabditis elegans hypothetical proteins F54G8.4, R05D3.4 and T02C1.1.

26) Yeast hypothetical proteins YER116c and YKR017c.

The signature pattern for the C3HC4 finger is based on the central region of the domain:

Consensus pattern: C-x-H-x-[LIVMFY]-C-x(2)-C-[LIVMYA].

Example 4 Differential Expression of Polynucleotides of the Invention: Description of Libraries and Detection of Differential Expression

The relative expression levels of the polynucleotides of the invention was assessed in several libraries prepared from various sources, including cell lines and patient tissue samples. Table 4 provides a summary of these libraries, including the shortened library name (used hereafter), the mRNA source used to prepared the cDNA library, the “nickname” of the library that is used in the tables below (in quotes), and the approximate number of clones in the library.

TABLE 4 Description of cDNA Libraries Number of Library Clones in this (lib #) Description Clustering 1 Km12L4 307133 Human Colon Cell Line, High Metastatic Potential (derived from Km12C) “High Colon” 2 Km12C 284755 Human Colon Cell Line, Low Metastatic Potential “Low Colon” 3 MDA-MB-231 326937 Human Breast Cancer Cell Line, High Metastatic Potential; micro- metastases in lung “High Breast” 4 MCF7 318979 Human Breast Cancer Cell, Non Metastatic “Low Breast” 8 MV-522 223620 Human Lung Cancer Cell Line, High Metastatic Potential “High Lung” 9 UCP-3 312503 Human Lung Cancer Cell Line, Low Metastatic Potential “Low Lung” 12 Human microvascular endothelial cells (HMEC) - Untreated 41938 PCR (OligodT) cDNA-library 13 Human microvascular endothelial cells (HMEC) - Basic fibroblast 42100 growth factor (bFGF) treated PCR (OligodT) cDNA library 14 Human microvascular endothelial cells (HMEC) - Vascular endothelial 42825 growth factor (VEGF) treated PCR (OligodT) cDNA library 15 Normal Colon - UC#2 Patient 34285 PCR (OligodT) cDNA library “Normal Colon Tumor Tissue” 16 Colon Tumor - UC#2 Patient 35625 PCR (OligodT) cDNA library “Normal Colon Tumor Tissue” 17 Liver Metastasis from Colon Tumor of UC#2 Patient 36984 PCR (OligodT) cDNA library “High Colon Metastasis Tissue” 18 Normal Colon - UC#3 Patient 36216 PCR (OligodT) cDNA library “Normal Colon Tumor Tissue” 19 Colon Tumor - UC#3 Patient 41388 PCR (OligodT) cDNA library “High Colon Tumor Tissue” 20 Liver Metastasis from Colon Tumor of UC#3 Patient 30956 PCR (OligodT) cDNA library “High Colon Metastasis Tissue”

The KM12L4 and KM12C cell lines are described in Example 1 above. The MDA-231 cell line was originally isolated from pleural effusions (Cailleau, J. Natl. Cancer. Inst. (1974) 53:661), is of high metastatic potential, and forms poorly differentiated adenocarcinoma-grade II in nude mice consistent with breast carcinoma. The MCF7 cell line was derived from a pleural effusion of a breast adenocarcinoma and is non-metastatic. The MV-522 cell line is derived from a human lung carcinoma and is of high metastatic potential. The UCP-3 cell line is a low metastatic human lung carcinoma cell line; the MV-522 is a high metastatic variant of UCP-3. These cell lines are well-recognized in the art as models for the study of human breast and lung cancer (see, e.g., Chandrasekaran et al., Cancer Res. (1979) 39:870 (MDA-MB-231 and MCF-7); Gastpar et al., J Med Chem (1998) 41:4965 (MDA-MB-231 and MCF-7); Ranson et al., Br J Cancer (1998) 77:1586 (MDA-MB-231 and MCF-7); Kuang et al., Nucleic Acids Res (1998) 26:1116 (MDA-MB-231 and MCF-7); Varki et al., Int J Cancer (1987) 40:46 (UCP-3); Varki et al., Tumour Biol. (1990) 11:327; (MV-522 and UCP-3); Varki et al., Anticancer Res. (1990) 10:637; (MV-522); Kelner et al., Anticancer Res (1995) 15:867 (MV-522); and Zhang et al., Anticancer Drugs (1997) 8:696 (MV522)). The samples of libraries 15-20 are derived from two different patients (UC#2, and UC#3). The bFGF-treated HMEC were prepared by incubation with bFGF at 10 ng/ml for 2 hrs; the VEGF-treated HMEC were prepared by incubation with 20 ng/ml BEGF for 2 hrs. Following incubation with the respective growth factor, the cells were washed and lysis buffer added for RNA preparation.

Each of the libraries is composed of a collection of cDNA clones that in turn are representative of the mRNAs expressed in the indicated mRNA source. In order to facilitate the analysis of the millions of sequences in each library, the sequences were assigned to clusters. The concept of “cluster of clones” is derived from a sorting/grouping of cDNA clones based on their hybridization pattern to a panel of roughly 300 7bp oligonucleotide probes (see Drmanac et al., Genomics (1996) 37(1):29). Random cDNA clones from a tissue library are hybridized at moderate stringency to 300 7bp oligonucleotides. Each oligonucleotide has some measure of specific hybridization to that specific clone. The combination of 300 of these measures of hybridization for 300 probes equals the “hybridization signature” for a specific clone. Clones with similar sequence will have similar hybridization signatures. By developing a sorting/grouping algorithm to analyze these signatures, groups of clones in a library can be identified and brought together computationally. These groups of clones are termed “clusters”. Depending on the stringency of the selection in the algorithm (similar to the stringency of hybridization in a classic library cDNA screening protocol), the purity” of each cluster can be controlled. For example, artifacts of clustering may occur in computational clustering just as artifacts can occur in “wet-lab” screening of a cDNA library with 400 bp cDNA fragments, at even the highest stringency. The stringency used in the implementation of cluster herein provides groups of clones that are in general from the same cDNA or closely related cDNAs. Closely related clones can be a result of different length clones of the same cDNA, closely related clones from highly related gene families, or splice variants of the same cDNA.

Differential expression for a selected cluster was assessed by first determining the number of cDNA clones corresponding to the selected cluster in the first library (Clones in 1^(st)), and the determining the number of cDNA clones corresponding to the selected cluster in the second library (Clones in 2^(nd)). Differential expression of the selected cluster in the first library relative to the second library is expressed as a “ratio” of percent expression between the two libraries. In general, the “ratio” is calculated by: 1) calculating the percent expression of the selected cluster in the first library by dividing the number of clones corresponding to a selected cluster in the first library by the total number of clones analyzed from the first library; 2) calculating the percent expression of the selected cluster in the second library by dividing the number of clones corresponding to a selected cluster in a second library by the total number of clones analyzed from the second library; 3) dividing the calculated percent expression from the first library by the calculated percent expression from the second library. If the “number of clones” corresponding to a selected cluster in a library is zero, the value is set at 1 to aid in calculation. The formula used in calculating the ratio takes into account the “depth” of each of the libraries being compared, i.e., the total number of clones analyzed in each library.

In general, a polynucleotide is said to be significantly differentially expressed between two samples when the ratio value is greater than at least about 2, preferably greater than at least about 3, more preferably greater than at least about 5, where the ratio value is calculated using the method described above. The significance of differential expression is determined using a z score test (Zar, Biostatistical Analysis, Prentice Hall, Inc., USA, “Differences between Proportions,” pp 296-298 (1974).

Example 5 Polynucleotides Differentially Expressed in High Metastatic Potential Breast Cancer Cells Versus Low Metastatic Breast Cancer Cells

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high metastatic potential breast cancer tissue and low metastatic breast cancer cells. Expression of these sequences in breast cancer can be valuable in determining diagnostic, prognostic and/or treatment information. For example, sequences that are highly expressed in the high metastatic potential cells can be indicative of increased expression of genes or regulatory sequences involved in the metastatic process. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant more aggressive treatment. In another example, sequences that display higher expression in the low metastatic potential cells can be associated with genes or regulatory sequences that inhibit metastasis, and thus the expression of these polynucleotides in a sample may warrant a more positive prognosis than the gross pathology would suggest.

The differential expression of these polynucleotides can be used as a diagnostic marker, a prognostic marker, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The following tables summarize polynucleotides that are differentially expressed between high metastatic potential breast cancer cells and low metastatic potential breast cancer cells.

TABLE 5 Differentially expressed polynucleotides: Higher expression in high metastatic potential breast cancer (lib3) relative to low metastatic breast cancer cells (lib4) SEQ ID Lib3 Lib4 NOS: Sequence Name Cluster ID clones clones lib3/lib4 Zscore 45 RTA00000197AR.f.12.1 3513 17 5 3.317240 2.287632 146 RTA00000185AF.a.19.2 5749 9 0 8.780930 2.629923 154 RTA00000196F.e.7.1 1039 10 2 4.878294 1.978215 159 RTA00000182AF.l.12.1 1027 41 17 2.353059 2.926571 165 RTA00000192AF.g.23.1 6455 6 0 5.853953 2.011224 174 RTA00000181AF.e.22.3 3442 17 4 4.146550 2.562391 183 RTA00000198AF.c.17.1 6923 6 0 5.853953 2.011224 364 RTA00000187AF.g.13.1 2991 10 1 9.756589 2.371428 366 RTA00000192AF.o.19.1 3549 10 1 9.756589 2.371428 387 RTA00000191AF.j.14.1 1002 42 20 2.048883 2.570309 496 RTA00000190AF.p.3.1 2378 34 0 33.17240 5.588184 510 RTA00000178AF.n.23.1 3298 12 1 11.70790 2.729313 512 RTA00000191AF.c.3.1 3549 10 1 9.756589 2.371428 529 RTA00000178AF.b.13.1 3114 9 1 8.780930 2.174815 560 RTA00000184AF.i.23.3 1577 25 3 8.130490 3.903813 606 RTA00000179AR.e.01.4 2493 33 9 3.577416 3.469507 644 RTA00000197F.i.12.1 3605 14 1 13.65922 3.050936 646 RTA00000186AF.d.24.1 3114 9 1 8.780930 2.174815 754 RTA00000187AF.l.11.1 4482 14 3 4.553074 2.374769 875 RTA00000401F.m.02.1 1573 34 7 4.738914 3.982056 902 RTA00000422F.c.02.1 2902 18 5 3.512372 2.443314 921 RTA00000418F.m.19.1 8890 6 0 5.853953 2.011224 942 RTA00000351R.g.11.1 3077 17 4 4.146550 2.562391 1095 RTA00000408F.l.13.1 4423 12 1 11.70790 2.729313 1104 RTA00000404F.m.10.2 779 60 22 2.660887 3.974953 1131 RTA00000400F.k.22.1 2512 7 0 6.829612 2.235371 1170 RTA00000340R.f.05.1 3202 18 3 5.853953 2.998867 1184 RTA00000422F.c.17.1 1360 26 11 2.306102 2.226876 1205 RTA00000118A.a.23.1 3500 12 3 3.902635 2.018050 1354 RTA00000401F.k.14.1 211 121 43 2.745458 5.856098 2124 RTA00000191AF.j.14.1 1002 42 20 2.048883 2.570309 1535 RTA00000405F.l.11.1 2055 29 8 3.536763 3.213373 1751 RTA00000423F.j.03.1 5391 6 0 5.853953 2.011224 1764 RTA00000399F.o.24.1 2272 17 1 16.58620 3.483575 1777 RTA00000401F.j.15.1 3061 14 0 13.65922 3.428594 1795 RTA00000348R.o.12.1 2263 6 0 5.853953 2.011224 1869 RTA00000340F.f.22.1 1720 57 8 6.951569 5.855075 1882 RTA00000401F.g.22.1 1147 28 12 2.276537 2.294031 1890 RTA00000346F.o.16.1 176 170 44 3.769591 8.366611 1915 RTA00000400F.g.02.1 1508 21 5 4.097767 2.879196 2040 RTA00000527F.j.02.2 4896 11 0 10.73224 2.974502 2059 RTA00000528F.i.22.1 2478 17 5 3.317240 2.287632 2223 RTA00000528F.j.11.1 1070 26 6 4.227855 3.289393 2245 RTA00000527F.k.09.1 213 17 4 4.146550 2.562391 2300 RTA00000528F.b.03.1 2078 11 2 5.366124 2.174565 2325 RTA00000525F.d.13.1 349 77 1 75.12573 8.384408 2462 RTA00000528F.g.22.2 920 76 32 2.317189 4.010278 2488 RTA00000528F.h.02.2 1701 18 4 4.390465 2.714073 2492 RTA00000528F.c.11.1 1701 18 4 4.390465 2.714073

TABLE 6 Differentially expressed polynucleotides: Higher expression in low metastatic breast cancer cells (lib4) relative to high metastatic potential breast cancer (lib3) SEQ ID Lib4 Lib3 NOS: Sequence Name Cluster ID Clones Clones lib4/lib3 Zscore 15 RTA00000177AR.n.8.1 4188 4 13 3.33108 1.99126 36 RTA00000181AF.p.4.3 40392 1 8 8.19958 2.03713 44 RTA00000199F.f.08.2 12445 0 11 11.2744 3.05623 89 RTA00000177AF.n.8.3 4188 4 13 3.33108 1.99126 172 RTA00000186AF.p.09.2 6879 3 43 14.6909 5.83444 203 RTA00000201F.d.09.1 1827 37 157 4.34910 8.71727 261 RTA00000192AF.a.24.1 13183 0 7 7.17463 2.30057 419 RTA00000182AF.j.20.1 4769 2 20 10.2494 3.68254 420 RTA00000181AF.c.11.1 4769 2 20 10.2494 3.68254 503 RTA00000197AF.k.9.1 3138 1 10 10.2494 2.45316 552 RTA00000193AF.b.24.1 35 386 1967 5.22298 33.2328 564 RTA00000200AF.g.18.1 1600 0 23 23.5738 4.64683 570 RTA00000183AF.a.19.2 3788 0 6 6.14969 2.07158 590 RTA00000190AF.d.2.1 2444 26 55 2.16815 3.22244 693 RTA00000198F.m.12.1 4 987 2807 2.91492 30.3819 707 RTA00000179AF.p.15.1 5622 2 13 6.66216 2.62993 711 RTA00000198F.i.2.1 8076 0 9 9.22453 2.70385 726 RTA00000200R.f.10.1 4 987 2807 2.91492 30.3819 746 RTA00000178AF.i.01.2 4 987 2807 2.91492 30.3819 756 RTA00000404F.a.02.1 9738 1 13 13.3243 2.98623 990 RTA00000126A.o.23.1 6268 3 18 6.14969 3.11179 1122 RTA00000401F.o.06.1 2679 4 23 5.89345 3.52846 1142 RTA00000411F.a.15.1 73812 0 12 12.2993 3.21838 1286 RTA00000345F.n.12.1 7337 3 16 5.46639 2.80694 1289 RTA00000126A.g.7.1 1902 13 48 3.78442 4.45002 1435 RTA00000345F.e.11.1 4392 1 8 8.19958 2.03713 1860 RTA00000340F.p.18.1 287 6 173 29.5526 12.5749 1933 RTA00000400F.f.11.1 4088 0 82 84.0457 9.05778 1934 RTA00000341F.o.12.1 2883 9 21 2.39154 2.07600 1979 RTA00000122A.h.24.1 48 412 1020 2.53749 16.5262 1980 RTA00000346F.j.13.1 5337 5 17 3.48482 2.40321 2007 RTA00000400F.g.08.1 1275 15 32 2.18655 2.41857 2023 RTA00000523F.d.19.1 26489 1 8 8.19958 2.03713 2409 RTA00000526F.d.17.1 2757 4 16 4.09979 2.51500 1220 RTA00000528F.d.04.1 2395 12 37 3.16025 3.51521

Example 6 Polynucleotides Differentially Expressed in High Metastatic Potential Lung Cancer Cells Versus Low Metastatic Lung Cancer Cells

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high metastatic potential lung cancer tissue and low metastatic lung cancer cells. Expression of these sequences in lung cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information. For example, sequences that are highly expressed in the high metastatic potential cells are associated can be indicative of increased expression of genes or regulatory sequences involved in the metastatic process. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant more aggressive treatment. In another example, sequences that display higher expression in the low metastatic potential cells can be associated with genes or regulatory sequences that inhibit metastasis, and thus the expression of these polynucleotides in a sample may warrant a more positive prognosis than the gross pathology would suggest.

he differential expression of these polynucleotides can be used as a diagnostic marker, a prognostic marker, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The following tables summarize polynucleotides that are differentially expressed between high metastatic potential lung cancer cells and low metastatic potential lung cancer cells:

TABLE 7 Differentially expressed polynucleotides: Higher expression in high metastatic potential lung cancer cells (lib8) relative to low metastatic lung cancer cells (lib9) SEQ ID Lib8 Lib9 NO: Sequence Name Cluster ID clones clones lib8/lib9 Zscore 10 RTA00000198AF.n.16.1 3721 9 0 12.5772 3.20845 54 RTA00000200F.o.22.1 983 8 1 11.1797 2.53243 65 RTA00000198AF.m.16.1 51 348 66 7.36849 17.4315 171 RTA00000198R.c.07.1 19181 6 0 8.38484 2.48169 203 RTA00000201F.d.09.1 1827 45 15 4.19242 5.09891 252 RTA00000181AF.e.18.3 8 1355 122 15.5211 39.0214 253 RTA00000181AF.e.17.3 8 1355 122 15.5211 39.0214 285 RTA00000181AR.j.14.3 5399 12 0 16.7696 3.80239 419 RTA00000182AF.j.20.1 4769 10 3 4.65824 2.29362 420 RTA00000181AF.c.11.1 4769 10 3 4.65824 2.29362 491 RTA00000196F.k.11.1 3 986 392 3.51507 22.4683 525 RTA00000198AF.c.7.1 19181 6 0 8.38484 2.48169 526 RTA00000185AF.e.20.1 5865 12 0 16.7696 3.80239 552 RTA00000193AF.b.24.1 35 868 11 110.273 34.2897 693 RTA00000198F.m.12.1 4 506 209 3.38335 15.7309 700 RTA00000183AF.i.18.2 40129 7 0 9.78231 2.74441 726 RTA00000200R.f.10.1 4 506 209 3.38335 15.7309 742 RTA00000177AF.m.1.1 14929 23 16 2.00886 2.02420 746 RTA00000178AF.i.01.2 4 506 209 3.38335 15.7309 861 RTA00000339F.f.11.1 5832 5 0 6.98736 2.18988 990 RTA00000126A.o.23.1 6268 5 0 6.98736 2.18988 1088 RTA00000399F.f.11.1 40167 8 0 11.1797 2.98512 1288 RTA00000423F.e.11.1 2566 11 2 7.68610 2.85611 1417 RTA00000339F.o.07.1 2566 11 2 7.68610 2.85611 1444 RTA00000419F.p.03.1 1937 10 3 4.65824 2.29362 1454 RTA00000340F.l.05.1 38935 7 0 9.78231 2.74441 1570 RTA00000403F.a.17.1 13686 8 0 11.1797 2.98512 1597 RTA00000401F.n.23.1 1552 8 1 11.1797 2.53243 1979 RTA00000122A.h.24.1 48 342 155 3.08345 12.2138 2024 RTA00000528F.b.23.1 1605 22 4 7.68610 4.23808 2034 RTA00000528F.m.16.1 4468 6 1 8.38484 1.97787 2126 RTA00000526F.d.01.1 4468 6 1 8.38484 1.97787

TABLE 8 Differentially expressed polynucleotides: Higher expression in low metastatic lung cancer cells (lib9) relative to high metastatic potential lung cancer cells SEQ ID Cluster Lib8 Lib9 NO: Sequence Name ID clones clones lib9/lib8 Zscore 174 RTA00000181AF.e.22.3 3442 5 23 3.291654 2.368262 254 RTA00000178AF.n.2.1 17083 0 8 5.724617 2.034117 466 RTA00000177AF.p.20.1 4141 4 27 4.830145 3.070829 571 RTA00000198AF.b.14.1 801 16 46 2.057284 2.411087 574 RTA00000192AF.f.3.1 5257 5 25 3.577885 2.596857 590 RTA00000190AF.d.2.1 2444 12 37 2.206362 2.299984 922 RTA00000399F.l.14.1 3354 5 20 2.862308 1.998763 1355 RTA00000406F.m.04.1 14959 11 41 2.667151 2.865855 1422 RTA00000405F.h.07.2 4984 3 16 3.816411 2.058861 2007 RTA00000400F.g.08.1 1275 10 42 3.005423 3.147111 2038 RTA00000527F.p.06.1 1292 8 33 2.951755 2.724411 2245 RTA00000527F.k.09.1 213 137 403 2.104945 7.661033

Example 7 Polynucleotides Differentially Expressed in High Metastatic Potential Colon Cancer Cells Versus Low Metastatic Colon Cancer Cells

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high metastatic potential colon cancer tissue and low metastatic colon cancer cells. Expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information. For example, sequences that are highly expressed in the high metastatic potential cells can be indicative of increased expression of genes or regulatory sequences involved in the metastatic process. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant more aggressive treatment. In another example, sequences that display higher expression in the low metastatic potential cells can be associated with genes or regulatory sequences that inhibit metastasis, and thus the expression of these polynucleotides in a sample may warrant a more positive prognosis than the gross pathology would suggest.

The differential expression of these polynucleotides can be used as a diagnostic marker, a prognostic marker, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The following table summarizes identified polynucleotides with differential expression between high metastatic potential colon cancer cells and low metastatic potential colon cancer cells:

TABLE 9 Differentially expressed polynucleotides: Higher expression in high metastatic potential colon cancer (lib1) relative to low metastatic colon cancer cells (lib2) SEQ ID Lib1 Lib2 NO: Sequence Name Cluster ID clones clones lib1/lib2 Zscore 228 RTA00000187AR.h.15.2 6660 7 0 6.489973399 2.169320547 280 RTA00000193AF.b.18.1 7542 8 0 7.417112456 2.36964728 355 RTA00000184AR.b.24.1 5777 9 1 8.344251513 2.09555146 491 RTA00000196F.k.11.1 3 5268 2164 2.257009497 32.96556438 603 RTA00000183AR.d.11.3 6420 8 0 7.417112456 2.36964728 680 RTA00000177AF.f.10.1 6420 8 0 7.417112456 2.36964728 752 RTA00000192AF.o.7.1 5275 11 2 5.099264814 2.083995588 753 RTA00000192AF.o.17.1 5275 11 2 5.099264814 2.083995588 1241 RTA00000346F.l.13.1 7542 8 0 7.417112456 2.36964728 1264 RTA00000349R.g.10.1 5777 9 1 8.344251513 2.09555146 1401 RTA00000421F.m.14.1 3524 21 6 3.2449867 2.499690198 1442 RTA00000350R.g.10.1 9026 7 0 6.489973399 2.169320547 1514 RTA00000399F.o.06.1 13574 7 0 6.489973399 2.169320547 1851 RTA00000421F.a.06.1 2385 27 4 6.258188635 3.743586088 1915 RTA00000400F.g.02.1 1508 46 17 2.508729213 3.230059264 2024 RTA00000528F.b.23.1 1605 36 11 3.034273278 3.244010467 2066 RTA00000528F.m.12.1 5768 12 0 3.046665462

TABLE 10 Differentially expressed polynucleotides: Higher expression in low metastatic colon cancer cells (lib2)relative to high metastatic potential colon cancer (lib1) SEQ ID Cluster Lib1 Lib2 NOS: Sequence Name ID clones clones lib2/lib1 Zscore 33 RTA00000178AR.a.20.1 945 9 21 2.51670 2.21703 250 RTA00000192AF.j.21.1 2289 3 23 8.26916 3.92187 282 RTA00000193AF.c.15.1 3726 3 14 5.03340 2.58312 370 RTA00000179AF.c.15.3 2995 4 13 3.50540 2.09770 387 RTA00000191AF.j.14.1 1002 12 65 5.84234 6.26259 443 RTA00000197AR.i.17.1 3516 5 17 3.66719 2.52439 460 RTA00000179AF.c.15.1 2995 4 13 3.50540 2.09770 545 RTA00000196F.a.2.1 3575 5 14 3.02004 2.00158 560 RTA00000184AF.i.23.3 1577 12 40 3.59528 4.01991 703 RTA00000198F.l.09.1 3611 2 13 7.01081 2.73040 704 RTA00000190AF.o.12.1 3438 5 14 3.02004 2.00158 1095 RTA00000408F.l.13.1 4423 1 8 8.62869 2.11495 1104 RTA00000404F.m.10.2 779 27 54 2.15717 3.23169 1205 RTA00000118A.a.23.1 3500 3 13 4.67387 2.40298 1354 RTA00000401F.k.14.1 211 109 206 2.03843 6.08597 1387 RTA00000191AF.j.14.1 1002 12 65 5.84234 6.26259 1734 RTA00000345F.b.17.1 945 9 21 2.51670 2.21703 1742 RTA00000422F.b.22.1 2368 14 34 2.61942 3.00662 1954 RTA00000401F.j.23.1 570 59 148 2.70560 6.66631 2262 RTA00000527F.o.12.1 688 29 60 2.23155 3.53946 2325 RTA00000525F.d.13.1 349 69 138 2.15717 5.27497

Example 8 Polynucleotides Differentially Expressed in High Metastatic Potential Colon Cancer Patient Tissue Versus Normal Patient Tissue

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high metastatic potential colon cancer tissue and normal tissue. Expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information. For example, sequences that are highly expressed in the high metastatic potential cells are associated can be indicative of increased expression of genes or regulatory sequences involved in the advanced disease state which involves processes such as angiogenesis, dedifferentiation, cell replication, and metastasis. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant more aggressive treatment.

The differential expression of these polynucleotides can be used as a diagnostic marker, a prognostic marker, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The following tables summarize polynucleotides that are differentially expressed between high metastatic potential colon cancer cells and normal colon cells:

TABLE 11 Differentially expressed polynucleotides isolated from samples from two patients (UC#2 and UC#3): Higher expression in high metastatic potential colon tissue (UC#2:lib17; UC#3:lib20) vs. normal colon tissue (UC#2:lib15; UC#3:lib18) SEQ ID Cluster NO: Sequence Name ID Zscore lib15 lib17 clones clones lib17/lib15 65 RTA00000198AF.m.16.1 51 1 10 9.27022 2.28830 1780 RTA00000118A.j.24.1 18 4 23 5.33037 3.27028 1899 RTA00000345F.j.09.1 13 14 80 5.29727 6.34580 lib18 lib20 clones clones lib20/lib18 1899 RTA00000345F.j.09.1 13 12 23 2.24234 2.16077

TABLE 12 Differentially expressed polynucleotides isolated from samples from two patients (UC#2 and UC#3): Higher expression in normal colon tissue (UC#2:lib15; UC#3:lib18)vs. high metastatic potential colon tissue (UC#2:lib17; UC#3:lib20). SEQ ID Cluster NO: Sequence Name ID Z Score: Lib5 Lib7 >2.5899%; Clones Clones lib15/lib17 >1.96 491 RTA00000196F.k.11.1 3 242 26 10.04 13.78900072 Lib18 Lib20 clones clones lib18/lib20 Zscore 491 RTA00000196F.k.11.1 3 409 46 7.59993 15.3998

Example 9 Polynucleotides Differentially Expressed in High Colon Tumor Potential Patient Tissue Versus Metastasized Colon Cancer Patient Tissue

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high tumor potential colon cancer tissue and cells derived from high metastatic potential colon cancer cells. Expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information associated with the transformation of precancerous tissue to malignant tissue. This information can be useful in the prevention of achieving the advanced malignant state in these tissues, and can be important in risk assessment for a patient.

The following table summarizes identified polynucleotides with differential expression between high tumor potential colon cancer tissue and cells derived from high metastatic potential colon cancer cells:

TABLE 13 Differentially expressed polynucleotides: High tumor potential colon tissue vs. metastatic colon tissue SEQ ID L19 L20 NO: Sequence Name Cluster ID clones clones lib19/lib20 Zscore 252 RTA00000181AF.e.18.3 8 14 1 10.4712 2.56699 253 RTA00000181AF.e.17.3 8 14 1 10.4712 2.56699 491 RTA00000196F.k.11.1 3 328 46 5.33318 11.8962 581 RTA00000191AF.p.3.2 17 24 2 8.97535 3.41950 693 RTA00000198F.m.12.1 4 26 8 2.43082 2.09705 726 RTA00000200R.f.10.1 4 26 8 2.43082 2.09705 746 RTA00000178AF.i.01.2 4 26 8 2.43082 2.09705 1780 RTA00000118A.j.24.1 18 80 13 4.60274 5.51440 1899 RTA00000345F.j.09.1 13 148 23 4.81287 7.68618

Example 10 Polynucleotides Differentially Expressed in High Tumor Potential Colon Cancer Patient Tissue Versus Normal Patient Tissue

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high tumor potential colon cancer tissue and normal tissue. Expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information associated with the prevention of achieving the malignant state in these tissues, and can be important in risk assessment for a patient. For example, sequences that are highly expressed in the potential colon cancer cells are associated with or can be indicative of increased expression of genes or regulatory sequences involved in early tumor progression. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant closer attention or more frequent screening procedures to catch the malignant state as early as possible.

The following tables summarize polynucleotides that are differentially expressed between high metastatic potential colon cancer cells and normal colon cells:

TABLE 14 Differentially expressed polynucleotides detected in samples from two patients (UC#2 and UC#3): Higher expression in tumor potential colon tissue (UC#2:lib16; UC#3:lib19)vs. normal colon tissue (UC#2:lib15; UC#3:lib18) SEQ ID Cluster NO: Sequence Name ID Zscore Lib15 Lib16 clones clones lib16/lib15 1899 RTA00000345Fj.09.1 13 14 50 3.43709 4.22436 Lib18 Lib19 clones clones lib19/lib18 65 RTA00000198AF.m.16.1 51 0 14 12.2505 3.23250 252 RTA00000181AF.e.18.3 8 1 14 12.2505 2.84687 253 RTA00000181AF.e.17.3 8 1 14 12.2505 2.84687 581 RTA00000191AF.p.3.2 17 4 24 5.25021 3.24580 693 RTA00000198F.m.12.1 4 6 26 3.79182 2.98901 716 RTA00000200F.p.05.1 3984 0 7 6.12525 2.09621 726 RTA00000200R.f.10.1 4 6 26 3.79182 2.98901 746 RTA00000178AF.i.01.2 4 6 26 3.79182 2.98901 1780 RTA00000118A.j.24.1 18 10 80 7.00028 6.65963 1899 RTA00000345F.j.09.1 13 12 148 10.7921 9.86174

TABLE 15 Differentially expressed polynucleotides: Higher expression in normal colon tissue (UC#2:lib15) vs. tumor potential colon tissue (UC#2:lib16) SEQ ID Cluster Lib15 Lib16 NO: Sequence Name ID clones clones lib15/lib16 Zscore 491 RTA00000196F.k.11.1 3 242 39 6.44765 12.3988

Example 11 Polynucleotides Differentially Expressed in Growth Factor-stimulated Human Microvascular Endothelial Cells (HMEC) Relative to Untreated HMEC

A number of polynucleotide sequences have been identified that are differentially expressed between human microvascular endothelial cells (HMEC) that have been treated with growth factors relative to untreated HMEC.

Sequences that are differentially expressed between growth factor-treated HMEC and untreated HMEC can represent sequences encoding gene products involved in angiogenesis, metastasis (cell migration), and other development and oncogenic processes. For example, sequences that are more highly expressed in HMEC treated with growth factors (such as bFGF or VEGF) relative to untreated HMEC can serve as markers of cancer cells of higher metastatic potential. Detection of expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information associated with the prevention of achieving the malignant state in these tissues, and can be important in risk assessment for a patient. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant closer attention or more frequent screening procedures to catch the malignant state as early as possible.

The following table summarizes identified polynucleotides with differential expression between growth factor-treated and untreated HMEC.

TABLE 16 Differentially expressed polynucleotides: Higher expression in bFGF treated HMEC (lib13) vs. untreated HMEC (lib12) SEQ ID Cluster Lib12 Lib13 NO: Sequence Name ID clones clones lib13/lib12 Zscore 648 RTA00000199F.i.9.1 7 25 52 2.07199 2.94741

TABLE 17 Differentially expressed polynucleotides: Higher expression in VEGF treated HMEC (lib14) vs. untreated HMEC (lib12) SEQ ID Cluster Lib12 Lib14 NO: Sequence Name ID clones clones lib14/lib12 Zscore 648 RTA00000199F.i.9.1 7 25 67 2.62449 4.17666 1899 RTA00000345F.j.09.1 13 22 49 2.18114 2.99887

Example 12 Polynucleotides Differentially Expressed Across Multiple Libraries

A number of polynucleotide sequences have been identified that are differentially expressed between cancerous cells and normal cells across all three tissue types tested (i.e., breast, colon, and lung). Expression of these sequences in a tissue or any origin can be valuable in determining diagnostic, prognostic and/or treatment information associated with the prevention of achieving the malignant state in these tissues, and can be important in risk assessment for a patient. These polynucleotides can also serve as non-tissue specific markers of, for example, risk of metastasis of a tumor. The following table summarizes identified polynucleotides that were differentially expressed but without tissue type-specificity in the breast, colon, and lung libraries tested.

TABLE 18 Polynucleotides Differentially Expressed Across Multiple Library Comparisons Cell or Tissue Sample and Cancer SEQ ID Clones in 1st Clones in 2nd State Compared NO. Cluster Lib Lib Ratio (Z Score) 2024 1605 lib1 lib2 lib1/lib2 colon: high met > low met 36 11 3.0342732 (3.2440104) lib8 lib9 lib8/lib9 lung: high met > low met 22 4 7.6861036 (4.2380835) 65 51 lib8 lib9 lib8/lib9 lung: high met > low met 348 66 7.3684960 (17.431560) lib18 lib19 lib19/lib18 pt #3 colon: tumor > normal 0 14 12.250507 (3.2325073) lib15 lib17 lib17/lib15 pt #2 colon: met > normal 1 10 9.2702249 (2.2883061) 174 3442 lib8 lib9 lib9/lib8 lung: low met > high met 5 23 3.2916548 (2.3682625) lib3 lib4 lib3/lib4 breast: high met > low met 17 4 4.1465504 (2.5623912) 203 1827 lib8 lib9 lib8/lib9 lung: high met > low met 45 15 4.1924201 (5.0989192) lib3 lib4 lib4/lib3 breast: low met > high met 37 157 4.3491051 (8.7172773) 2245 213 lib8 lib9 lib9/lib8 lung: low met > high met 137 403 2.1049458 (7.6610331) lib3 lib4 lib3/lib4 breast: high met > low met 17 4 4.1465504 (2.5623912) 990 6268 lib8 lib9 lib8/lib9 lung: high met > low met 5 0 6.9873669 (2.1898837) lib3 lib4 lib4/lib3 breast: low met > high met 3 18 6.1496901 (3.1117967) 252 8 lib8 lib9 lib8/lib9 lung: high met > low met 1355 122 15.521118 (39.021411) lib19 lib20 lib19/lib20 pt. #3 colon: tumor > met 14 1 10.471247 (2.5669948) lib18 lib19 lib19/lib18 pt #3 colon: tumor > normal 1 14 12.250507 (2.8468716) 253 8 lib8 lib9 lib8/lib9 lung: high met > low met 1355 122 15.521118 (39.021411) lib19 lib20 lib19/lib20 pt. #3 colon: tumor > met 14 1 10.471247 (2.5669948) lib18 lib19 lib19/lib18 pt #3 colon: tumor > normal 1 14 12.250507 (2.8468716) 2325 349 lib3 lib4 lib3/lib4 breast: high met > low met 77 1 75.125736 (°.3°440°7) lib1 lib2 lib2/lib1 colon: low met > high met 69 138 2.1571737 (5.2749799) 1095 4423 lib3 lib4 lib3/lib4 breast: high met > low met 12 1 11.707907 (2.7293134) lib1 lib2 lib2/lib1 colon: low met > high met 1 8 8.6286948 (2.1149516) 1124 779 lib3 lib4 lib3/lib4 breast: high met > low met 60 22 2.6608879 (3.9749537) lib1 lib2 lib2/lib1 colon: low met > high met 27 54 2.1571737 (3.2316908) 387 1002 lib3 lib4 lib3/lib4 breast: high met > low met 42 20 2.0488837 (2.5703094) lib1 lib2 lib2/lib1 colon: low met > high met 12 65 5.8423454 (6.2625969) 419 4769 lib8 lib9 lib8/lib9 lung: high met > low met 10 3 4.6582446 (2.2936274) lib3 lib4 lib4/lib3 breast: low met > high met 2 20 10.249483 (3.6825426) 420 4769 lib8 lib9 lib8/lib9 lung: high met > low met 10 3 4.6582446 (2.2936274) lib3 lib4 lib4/lib3 breast: low met > high met 2 20 10.249483 (3.6825426) 1205 3500 lib3 lib4 lib3/lib4 breast: high met > low met 12 3 3.9026356 (2.0180506) lib1 lib2 lib2/lib1 colon: low met > high met 3 13 4.6738763 (2.4029818) 491 3 lib1 lib2 lib1/lib2 colon: high met > low met 5268 2164 2.2570094 (32.965564) lib8 lib9 lib8/lib9 lung: high met > low met 986 392 3.5150733 (22.468331) lib19 lib20 lib19/lib20 pt #3 colon: tumor > met 328 46 5.3331820 (11.896271) lib18 lib20 lib18/lib20 pt #3 colon: normal > met 409 46 7.5999342 (15.399861) lib15 lib17 lib15/lib17 pt #2 colon: normal > met 242 26 10.04 (13.789000) lib15 lib16 lib15/lib16 pt #2 colon: normal > tumor 242 39 6.44765 12.39883 552 35 lib8 lib9 lib8/lib9 lung: high met > low met 868 11 110.27335 (34.289704) lib3 lib4 lib4/lib3 breast: low met > high met 386 1967 5.2229880 (33.232871) 560 1577 lib3 lib4 lib3/lib4 breast: high met > low met 25 3 8.1304909 (3.9038139) lib1 lib2 lib2/lib1 colon: low met > high met 12 40 3.5952895 (4.0199130) 581 17 lib19 lib20 lib19/lib20 pt #3 colon: tumor > met 24 2 8.9753551 (3.4195074) lib18 lib19 lib19/lib18 pt #3 colon: tumor > normal 4 24 5.2502174 (3.2458055) 590 2444 lib3 lib4 lib4/lib3 breast: low met > high met 26 55 2.1681599 (3.2224421) lib8 lib9 lib9/lib8 lung: low met > high met 12 37 2.2063628 (2.2999846) 1354 211 lib3 lib4 lib3/lib4 breast: high met > low met 121 43 2.7454588 (5.8560985) lib1 lib2 lib2/lib1 colon: low met > high met 109 206 2.0384302 (6.0859794) 1387 1002 lib3 lib4 lib3/lib4 breast: high met > low met 42 20 2.0488837 (2.5703094) lib1 lib2 lib2/lib1 colon: low met > high met 12 65 5.8423454 (6.2625969) 648 7 lib12 lib14 lib14/lib12 HMEC: VEGF > untreated 25 67 2.6244913 (4.1766696) lib12 lib13 lib13/lib12 HMEC: bFGF > untreated 25 52 2.0719962 (2.9474155) 693 4 lib8 lib9 lib8/lib9 lung: high met > low met 506 209 3.3833566 (15.730912) lib3 lib4 lib4/lib3 breast: low met > high met 987 2807 2.9149240 (30.381945) lib19 lib20 lib19/lib20 pt #3 colon: tumor > met 26 8 2.4308253 (2.0970580) lib18 lib19 lib19/lib18 pt #3 colon: tumor > normal 6 26 3.7918237 (2.9890107) 726 4 lib8 lib9 lib8/lib9 lung: high met > low met 506 209 3.3833566 (15.730912) lib3 lib4 lib4/lib3 breast: low met > high met 987 2807 2.9149240 (30.381945) lib19 lib20 lib19/lib20 pt #3 colon: tumor > met 26 8 2.4308253 (2.0970580) lib18 lib19 lib19/lib18 pt #3 colon: tumor > normal 6 26 3.7918237 (2.9890107) 746 4 lib8 lib9 lib8/lib9 lung: high met > low met 506 209 3.3833566 (15.730912) lib3 lib4 lib4/lib3 breast: low met > high met 987 2807 2.9149240 (30.381945) lib19 lib20 lib19/lib20 pt #3 colon: tumor > met 26 8 2.4308253 (2.0970580) lib18 lib19 lib19/lib18 pt #3 colon: tumor > normal 6 26 3.7918237 (2.9890107) 1780 18 lib19 lib20 lib19/lib20 pt #3 colon: tumor > met 80 13 4.6027462 (5.5144093) lib18 lib19 lib19/lib18 pt #3 colon: tumor > normal 10 80 7.0002899 (6.6596394) lib15 lib17 lib17/lib15 pt #3 colon: met > normal 4 23 5.3303793 (3.2702852) 1899 13 lib19 lib20 lib19/lib20 pt #3 colon: tumor > met 148 23 4.8128716 (7.6861840) lib18 lib20 lib20/lib18 pt #3 colon: met > normal 12 23 2.2423439 (2.1607719) lib18 lib19 lib19/lib18 pt #3 colon: tumor > normal 12 148 10.792113 (9.8617485) lib15 lib17 lib17/lib15 pt #2 colon: met > normal 14 80 5.2972714 (6.3458044) lib15 lib16 lib16/lib15 pt #2 colon: tumor > normal 14 50 3.4370927 (4.2243697) lib12 lib14 lib14/lib12 HMEC: VEGF > untreated 22 49 2.1811410 (2.9988774) 1915 1508 lib1 lib2 lib1/lib2 colon: high met > low met 46 17 2.5087292 (3.2300592) lib3 lib4 lib3/lib4 breast: high met > low met 21 5 4.0977674 (2.8791960) 1979 48 lib8 lib9 lib8/lib9 lung: high met > low met 342 155 3.0834574 (12.213852) lib3 lib4 lib4/lib3 breast: low met > high met 412 1020 2.5374934 (16.526285) 2007 1275 lib3 lib4 lib4/lib3 breast: low met > high met 15 32 2.1865564 (2.4185764) lib8 lib9 lib9/lib8 lung: low met > high met 10 42 3.0054239 3.1471113 high met = high metastatic potential; low met = low metastatic potential; met = metastasized; tumor = non-metastasized tumor; pt = patient; #2 = UC#2; #3 = UC#3; HMEC = human microvascular endothelial cell; bFGF = bFGF treated; VEGF = VEGF treated

Example 12 Polynucleotides Exhibiting Colon-specific Expression

The cDNA libraries described herein were also analyzed to identify those polynucleotides that were specifically expressed in colon cells or tissue, i.e., the polynucleotides were identified in libraries prepared from colon cell lines or tissue, but not in libraries of breast or lung origin. The polynucleotides that were expressed in a colon cell line and/or in colon tissue, but were present in the breast or lung cDNA libraries described herein, are shown in Table 19 (inserted before claims).

No clones corresponding to the colon-specific polynucleotides in the table above were present in any of Libraries 3, 4, 8, 9, 12, 13, 14, or 15. The polynucleotide provided above can be used as markers of cells of colon origin, and find particular use in reference arrays, as described above.

Example 13 Identification of Continuous Sequences Having a Polynucleotide of the Invention

The novel polynucleotides were used to screen publicly available and proprietary databases to determine if any of the polynucleotides of SEQ ID NOS:1-2502 would facilitate identification of a contiguous sequence, e.g., the polynucleotides would provide sequence that would result in 5′ extension of another DNA sequence, resulting in production of a longer contiguous sequence composed of the provided polynucleotide and the other DNA sequence(s). Contiging was performed using the Gelmerge application (default settings) of GCG from the Univ. of Wisconsin.

Using these parameters, 146 contiged sequences were generated. These contiged sequences are provided as SEQ ID NOS:5107-5252 (see Table 1). The contiged sequences can be correlated with the sequences of SEQ ID NOS:1-2502 upon which the contiged sequences are based by, for example, identifying those sequences of SEQ ID NOS:1-2502 and the contiged sequences of SEQ ID NOS:5107-5252 that share the same clone name in Table 1.

The contiged sequences (SEQ ID NO:5107-5252) thus represent longer sequences that encompass a polynucleotide sequence of the invention. The contiged sequences were then translated in all three reading frames to determine the best alignment with individual sequences using the BLAST programs as described above for SEQ ID NOS:1-2502 and the validation sequences “SEQ ID NOS:2503-5106.” Again the sequences were masked using the XBLAST program for masking low complexity as described above in Example 1 (Table 2). Several of the contiged sequences were found to encode polypeptides having characteristics of a polypeptide belonging to a known protein families (and thus represent new members of these protein families) and/or comprising a known functional domain (Table 20). Thus the invention encompasses fragments, fusions, and variants of such polynucleotides that retain biological activity associated with the protein family and/or functional domain identified herein.

TABLE 20 Profile hits using contiged sequences Bio- logi- cal Act- SEQ ivity Di- ID (Pro- rec- NO file) Start Stop Score tion Sequence Name 5111 7tm_2 71 915 8090 for RTA00000399F.o.01.1 5120 7tm_2 101 919 8475 rev RTA00000341F.m.21.1 5174 7tm_2 3 963 9431 for RTA00000192AF.h.19.1 5197 7tm_2 214 1073 8528 rev RTA00000192AF.f.3.1 5208 ANK 546 629 4920 for RTA00000190AF.f.5.1 5120 asp 126 1067 6620 rev RTA00000341F.m.21.1. 5241 asp 112 1094 6553 for RTA00000418F.i.06.1 5243 asp 347 1028 5981 for RTA00000339F.b.02.1 5197 AT- 113 781 5690 for RTA00000192AF.f.3.1 Pases 5239 AT- 1 348 15955 for RTA00000401F.m.07.1 Pases 5241 AT- 110 823 6782 for RTA00000418F.i.06.1 Pases 5243 AT- 338 874 5832 for RTA00000339F.b.02.1 Pases 5125 prot- 59 685 5791 for RTA00000182AF.c.5.1 kinase 5217 prot- 75 1035 5405 for RTA00000181AF.p.12.3 kinase 5237 prot- 25 546 5107 rev RTA00000118A.n.5.1 kinase 5248 prot- 14 422 5103 rev RTA00000419F.k.05.1 kinase 5252 prot- 89 755 5499 for RTA00000404F.m.17.2 kinase 5120 Wnt_ 3 948 11036 for RTA00000341F.m.21.1 dev_ sign All stop/start sequences are provided in the forward direction.

Descriptions of the profiles for the indicated protein families and functional domains are provided in Example 3 above.

Those skilled in the art will recognize, or be able to ascertain, using not more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such specific embodiments and equivalents are intended to be encompassed by the following claims.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

DEPOSIT INFORMATION:

The following materials were deposited with the American Type Culture Collection: CMCC=(Chiron Master Culture Collection)

Cell Lines Deposited with ATCC ATCC CMCC Cell Line Deposit Date Accession No. Accession No. KM12L4-A Mar. 9, 1998 CRL-12496 11606 Km12C May 15, 1998 CRL-12533 11611 MDA-MB-231 May 15, 1998 CRL-12532 10583 MCF-7 Oct. 9, 1998 CRL-12584 10377 cDNA Libraries Deposited with ATCC cDNA Library No. cDNA Library ES10 Deposit Date Jan. 13, 1999 ATCC Accession No. ATCC No. 207032 Clone Names M00001358C:C06 M00001388D:G05 M00001394A:F01 M00001429A:H04 M00001447A:G03 M00001448D:C09 M00001454D:G03 cDNA Library No. cDNA Library ES21 cDNA Library ES22 cDNA Library ES23 Deposit Date Jan. 22, 1999 Jan. 22, 1999 Jan. 22, 1999 ATCC Accession No. ATCC No. ATCC No. ATCC No. Clone Names M00001575D:G05 M00001364A:E11 M00001489B:A06 M00001460A:A03 M00001694C:H10 M00001585A:D06 M00001655C:E04 M00003841D:E03 M00001637B:E07 M00001676C:C11 M00004176D:B12 M00001529D:H02 M00001679D:D05 M00001387B:E02 M00001500C:C08 M00001546B:C05 M00004282B:A04 M00001483B:D03 M00001453B:E10 M00001376B:F03 M00001623C:H07 M00001445D:A06 M00003975B:F03 M00001399C:H12 M00004208D:H08 cDNA Library No. cDNA Library ES24 cDNA Library ES25 cDNA Library ES26 Deposit Date Jan. 22, 1999 Jan. 22, 1999 Jan. 22, 1999 ATCC Accession No. ATCC No. ATCC No. ATCC No. Clone Names M00003987D:D06 M00001675D:B08 M00001479C:F10 M00004073A:H12 M00001589B:E12 M00003842D:F08 M00004104B:F11 M00001607D:A11 M00003901A:C09 M00004237D:D08 M00001636A:E07 M00003982A:B06 M00004111D:B07 M00001530A:B12 M00003824A:A06 M00004138B:B11 M00001495B:B08 M00003845D:C03 M00001391C:C04 M00001487C:F01 M00003856A:B07 M00001448D:E12 M00001644B:D06 M00004104B:A02 M00001450A:B03 M00003751C:A04 M00004110C:E03 M00001451B:F01

In addition, libraries of selected clones were deposited. The details of these deposits are provided in Tables 21-24.

This deposit is provided merely as convenience to those of skill in the art, and is not an admission that a deposit is required under 35 U.S.C. §112. The sequence of the polynucleotides contained within the deposited material, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with the written description of sequences herein. A license may be required to make, use, or sell the deposited material, and no such license is granted hereby.

Retrieval of Individual Clones from Deposit of Pooled Clones

Where the ATCC deposit is composed of a pool of cDNA clones, the deposit was prepared by first transfecting each of the clones into separate bacterial cells. the clones were then deposited as a pool of equal mixtures in the composite deposit. Particular clones can be obtained from the composite deposit using methods well known in the art. For example, a bacterial cell containing a particular clone can be identified by isolating single colonies, and identifying colonies containing the specific clone through standard colony hybridization techniques, using an oligonucleotide probe or probes designed to specifically hybridize to a sequence of the clone insert (e.g., a probe based upon unmasked sequence of the encoded polynucleotide having the indicated SEQ ID NO). The probe should be designed to have a T_(m) of approximately 80° C. (assuming 2° C. for each A or T and 4° C. for each G or C). Positive colonies can then be picked, grown in culture, and the recombinant clone isolated. Alternatively, probes designed in this manner can be used to PCR to isolate a nucleic acid molecule from the pooled clones according to methods well known in the art, e.g., by purifying the cDNA from the deposited culture pool, and using the probes in PCR reactions to produce an amplified product having the corresponding desired polynucleotide sequence.

TABLE 1 Filing SEQ ID Date of NO: in SEQ ID Priority Priority Cluster NO: Appln Appln Sequence Name Clone Name ID 1 Jan. 28, 1998 1 RTA00000197AF.i.16.1 M00001490A:D11 16402 2 Jan. 28, 1998 2 RTA00000188AF.n.15.1 M00003804A:H04 0 3 Jan. 28, 1998 3 RTA00000197AF.e.24.1 M00001456B:F10 39250 4 Jan. 28, 1998 4 RTA00000198R.f.04.1 M00001607D:F07 5023 5 Jan. 28, 1998 5 RTA00000195R.c.11.1 M00003811A:E03 66087 6 Jan. 28, 1998 6 RTA00000195AF.c.16.1 M00003829C:A11 23508 7 Jan. 28, 1998 7 RTA00000197AR.e.12.1 M00001454B:G07 22095 8 Jan. 28, 1998 8 RTA00000200AF.h.11.2 M00004146A:C08 8399 9 Jan. 28, 1998 9 RTA00000177AF.g.22.1 M00001347C:G08 7031 10 Jan. 28, 1998 10 RTA00000198AF.n.16.1 M00001694C:H10 3721 11 Jan. 28, 1998 11 RTA00000199AF.i.17.1 M00003880C:F10 9615 12 Jan. 28, 1998 12 RTA00000183AF.i.15.2 M00001529B:C04 2642 13 Jan. 28, 1998 13 RTA00000190AF.i.5.1 M00003919A:A10 0 14 Jan. 28, 1998 14 RTA00000196R.c.11.2 M00001352A:E12 13658 15 Jan. 28, 1998 15 RTA00000177AR.n.8.1 M00001356D:F06 4188 16 Jan. 28, 1998 16 RTA00000196AF.e.16.1 M00001363C:H02 39252 17 Jan. 28, 1998 17 RTA00000183AR.e.14.2 M00001506B:D09 17437 18 Jan. 28, 1998 18 RTA00000196AF.c.17.1 M00001352C:F06 39602 19 Jan. 28, 1998 19 RTA00000185AF.a.8.1 M00001570D:A03 4868 20 Jan. 28, 1998 20 RTA00000181AF.l.14.2 M00001454D:D06 2364 21 Jan. 28, 1998 21 RTA00000131A.g.19.2 M00001449A:G10 36535 22 Jan. 28, 1998 22 RTA00000187AR.o.10.2 M00001718D:F07 8984 23 Jan. 28, 1998 23 RTA00000198R.b.08.1 M00001567C:H12 22636 24 Jan. 28, 1998 24 RTA00000200AF.f.11.1 M00004111D:D11 0 25 Jan. 28, 1998 25 RTA00000196AF.c.1.1 M00001349C:C05 8171 26 Jan. 28, 1998 26 RTA00000200R.g.09.1 M00004131B:H09 22785 27 Jan. 28, 1998 27 RTA00000192AF.i.12.1 M00004169C:C12 5319 28 Jan. 28, 1998 28 RTA00000178AR.o.01.5 M00001387B:H07 0 29 Jan. 28, 1998 29 RTA00000200AF.b.19.1 M00004042D:H02 22847 30 Jan. 28, 1998 30 RTA00000184AR.n.07.2 M00001561C:F06 0 31 Jan. 28, 1998 31 RTA00000200F.m.15.1 M00004236C:D10 22601 32 Jan. 28, 1998 32 RTA00000198R.m.19.1 M00001680D:D02 40041 33 Jan. 28, 1998 33 RTA00000178AR.a.20.1 M00001362C:H11 945 34 Jan. 28, 1998 34 RTA00000197AF.n.8.1 M00001536D:A12 4101 35 Jan. 28, 1998 35 RTA00000191AF.n.17.1 M00004091B:D11 7848 36 Jan. 28, 1998 36 RTA00000181AF.p.4.3 M00001460A:A03 40392 37 Jan. 28, 1998 37 RTA00000181AF.n.15.2 M00001457A:B07 86128 38 Jan. 28, 1998 38 RTA00000196R.k.07.1 M00001399C:D09 22443 39 Jan. 28, 1998 39 RTA00000189AR.b.19.1 M00003832B:E01 5294 40 Jan. 28, 1998 40 RTA00000200AR.e.02.1 M00004090A:F09 36059 41 Jan. 28, 1998 41 RTA00000184F.k.12.1 M00001557D:D09 8761 42 Jan. 28, 1998 42 RTA00000184F.j.21.1 M00001557A:D02 7065 43 Jan. 28, 1998 43 RTA00000179AF.c.14.3 M00001392D:H04 0 44 Jan. 28, 1998 44 RTA00000199F.f.08.2 M00003841D:E03 12445 45 Jan. 28, 1998 45 RTA00000197AR.f.12.1 M00001458C:E01 3513 46 Jan. 28, 1998 46 RTA00000182AF.f.13.1 M00001470C:B10 8010 47 Jan. 28, 1998 47 RTA00000192AF.m.12.1 M00004191D:B11 0 48 Jan. 28, 1998 48 RTA00000177AR.a.23.5 M00001339D:G02 6995 49 Jan. 28, 1998 49 RTA00000198R.o.05.1 M00003750A:D01 26702 50 Jan. 28, 1998 50 RTA00000201R.a.02.1 M00004295B:D02 35362 51 Jan. 28, 1998 51 RTA00000199R.k.07.1 M00003901C:A03 12973 52 Jan. 28, 1998 52 RTA00000201R.b.02.1 M00004319D:G09 22660 53 Jan. 28, 1998 53 RTA00000199AF.p.9.1 M00003988A:E10 10430 54 Jan. 28, 1998 54 RTA00000200F.o.22.1 M00004282B:A04 983 55 Jan. 28, 1998 55 RTA00000186AF.i.21.1 M00001636C:H09 6033 56 Jan. 28, 1998 56 RTA00000177AF.e.9.1 M00001343D:C04 37442 57 Jan. 28, 1998 57 RTA00000198AF.k.20.1 M00001660C:B12 22553 58 Jan. 28, 1998 58 RTA00000199F.b.01.2 M00003778A:D08 19118 59 Jan. 28, 1998 59 RTA00000195AF.b.13.1 M00001560D:A03 12605 59 Feb. 24, 1998 78 RTA00000195AF.b.13.1 M00001560D:A03 12605 60 Jan. 28, 1998 60 RTA00000196AR.i.12.3 M00001389D:G11 38800 61 Jan. 28, 1998 61 RTA00000197AF.h.11.1 M00001476D:G03 22264 62 Jan. 28, 1998 62 RTA00000190AF.a.18.2 M00003900D:B10 0 63 Jan. 28, 1998 63 RTA00000184AF.k.19.1 M00001558B:D08 8022 64 Jan. 28, 1998 64 RTA00000198AF.p.12.1 M00003763D:E10 8878 65 Jan. 28, 1998 65 RTA00000198AF.m.16.1 M00001679D:D05 51 66 Jan. 28, 1998 66 RTA00000199F.c.09.2 M00003800A:C09 16824 67 Jan. 28, 1998 67 RTA00000200AF.g.07.1 M00004128B:G01 0 68 Jan. 28, 1998 68 RTA00000184F.k.19.1 M00001558B:D08 8022 69 Jan. 28, 1998 69 RTA00000186AF.h.8.1 M00001632C:C09 35547 70 Jan. 28, 1998 70 RTA00000192AF.e.3.1 M00004138B:H02 13272 71 Jan. 28, 1998 71 RTA00000193AR.o.16.3 M00004409B:A11 52972 72 Jan. 28, 1998 72 RTA00000200F.a.6.1 M00004029B:F11 36952 73 Jan. 28, 1998 73 RTA00000177AF.e.21.3 M00001344A:H07 4306 74 Jan. 28, 1998 74 RTA00000196AF.h.20.1 M00001385B:F10 0 75 Jan. 28, 1998 75 RTA00000180AR.h.19.2 M00001428A:H10 84182 76 Jan. 28, 1998 76 RTA00000200AF.h.05.2 M00004142D:E10 10950 77 Jan. 28, 1998 77 RTA00000197AF.n.2.1 M00001535A:D02 6229 78 Jan. 28, 1998 78 RTA00000199R.f.09.1 M00003842B:D09 22907 79 Jan. 28, 1998 79 RTA00000199AF.p.4.1 M00003985C:F01 10282 80 Jan. 28, 1998 80 RTA00000196AF.p.13.2 M00001432A:E06 6125 81 Jan. 28, 1998 81 RTA00000196AF.b.15.1 M00001347B:E01 5102 82 Jan. 28, 1998 82 RTA00000183AF.l.18.1 M00001535D:C01 3484 83 Jan. 28, 1998 83 RTA00000186AF.f.24.2 M00001629B:E06 0 84 Jan. 28, 1998 84 RTA00000191AF.h.14.1 M00004056B:D09 13553 85 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 86 Jan. 28, 1998 86 RTA00000189AF.l.22.1 M00003879C:G10 33333 87 Feb. 24, 1998 245 RTA00000195AF.d.20.1 M00004117A:D11 37574 87 Jan. 28, 1998 87 RTA00000195AF.d.20.1 M00004117A:D11 37574 88 Jan. 28, 1998 88 RTA00000197AF.e.23.1 M00001456B:C09 37157 89 Jan. 28, 1998 89 RTA00000177AF.n.8.3 M00001356D:F06 4188 90 Jan. 28, 1998 90 RTA00000199F.f.15.2 M00003845A:H12 8772 91 Jan. 28, 1998 91 RTA00000198AF.j.19.1 M00001653C:F12 38914 92 Jan. 28, 1998 92 RTA00000198AF.j.18.1 M00001653B:G07 22759 93 Jan. 28, 1998 93 RTA00000200F.o.11.1 M00004270A:F11 0 94 Jan. 28, 1998 94 RTA00000195AF.b.4.1 M00001490C:D07 0 95 Jan. 28, 1998 95 RTA00000180AF.g.3.1 M00001425A:C11 9024 96 Jan. 28, 1998 96 RTA00000197AF.j.20.1 M00001496C:C11 4915 97 Jan. 28, 1998 97 RTA00000197AF.o.2.1 M00001541C:B07 5739 98 Jan. 28, 1998 98 RTA00000200AF.f.14.1 M00004115D:C08 22051 99 Jan. 28, 1998 99 RTA00000184AF.d.8.1 M00001548A:A08 4393 100 Jan. 28, 1998 100 RTA00000200R.f.14.1 M00004115D:C08 22051 101 Jan. 28, 1998 101 RTA00000191AF.d.08.2 M00003997B:G07 970 102 Jan. 28, 1998 102 RTA00000199R.j.08.1 M00003884D:G07 37844 103 Jan. 28, 1998 103 RTA00000199F.e.10.1 M00003822A:F02 22906 104 Jan. 28, 1998 104 RTA00000196R.h.03.1 M00001381A:D02 6636 105 Jan. 28, 1998 105 RTA00000179AF.g.12.3 M00001398A:G03 36390 106 Jan. 28, 1998 106 RTA00000197AF.n.21.1 M00001540B:C09 0 107 Jan. 28, 1998 107 RTA00000196R.i.13.1 M00001390A:A09 9857 108 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 109 Jan. 28, 1998 109 RTA00000197AF.d.12.1 M00001451D:C10 39546 110 Jan. 28, 1998 110 RTA00000197R.h.01.1 M00001470A:H01 13075 111 Jan. 28, 1998 111 RTA00000198AF.o.12.1 M00003751D:B02 22038 112 Jan. 28, 1998 112 RTA00000177AF.m.8.1 M00001354C:C10 8010 113 Jan. 28, 1998 113 RTA00000196AF.d.09.1 M00001354B:B10 16934 114 Jan. 28, 1998 114 RTA00000200R.f.02.1 M00004108A:A09 7138 115 Jan. 28, 1998 115 RTA00000179AR.o.20.3 M00001409D:F11 2409 116 Jan. 28, 1998 116 RTA00000181AR.k.24.3 M00001454B:C12 7005 117 Jan. 28, 1998 117 RTA00000199AF.j.18.1 M00003889D:B09 5140 118 Jan. 28, 1998 118 RTA00000199F.b.24.2 M00003794A:B03 0 119 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 120 Jan. 28, 1998 120 RTA00000178AR.m.19.5 M00001384D:H07 0 121 Jan. 28, 1998 121 RTA00000199AF.o.16.1 M00003979A:F03 16721 122 Jan. 28, 1998 122 RTA00000197AF.l.15.1 M00001517B:G08 4947 123 Jan. 28, 1998 123 RTA00000191AF.k.6.1 M00004078B:A11 5451 124 Jan. 28, 1998 124 RTA00000199AR.m.06.1 M00003933C:D06 19122 125 Jan. 28, 1998 125 RTA00000197AF.k.15.1 M00001504D:D11 22750 126 Jan. 28, 1998 126 RTA00000201F.d.16.1 M00004338B:A08 0 127 Jan. 28, 1998 127 RTA00000178AF.k.18.1 M00001382A:F04 9755 128 Jan. 28, 1998 128 RTA00000196F.i.12.1 M00001389D:G11 38800 129 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 130 Jan. 28, 1998 130 RTA00000196AF.h.23.1 M00001386A:C02 13357 131 Jan. 28, 1998 131 RTA00000185AF.d.11.2 M00001579D:C03 6539 132 Jan. 28, 1998 132 RTA00000178AF.f.20.3 M00001372C:F07 39881 133 Jan. 28, 1998 133 RTA00000181AR.n.20.3 M00001457B:E03 0 134 Jan. 28, 1998 134 RTA00000197F.e.11.1 M00001454B:G03 2306 135 Jan. 28, 1998 135 RTA00000196AF.c.22.1 M00001352D:C05 22548 136 Jan. 28, 1998 136 RTA00000197AF.c.10.1 M00001448B:F06 10400 137 Jan. 28, 1998 137 RTA00000181AF.m.4.3 M00001455A:E09 13238 138 Jan. 28, 1998 138 RTA00000182AF.a.3.3 M00001462B:A10 0 139 Jan. 28, 1998 139 RTA00000191AF.d.01.2 M00003996A:A06 7031 140 Jan. 28, 1998 140 RTA00000199F.a.2.1 M00003772A:D07 12674 141 Jan. 28, 1998 141 RTA00000196AF.c.6.1 M00001350A:D06 23148 142 Jan. 28, 1998 142 RTA00000198AF.k.19.1 M00001660B:C04 75879 143 Jan. 28, 1998 143 RTA00000199R.h.09.1 M00003867C:H09 76020 144 Jan. 28, 1998 144 RTA00000198AF.o.18.1 M00003755A:A09 13018 145 Jan. 28, 1998 145 RTA00000178AF.h.24.1 M00001376B:C06 6745 146 Jan. 28, 1998 146 RTA00000185AF.a.19.2 M00001571C:H06 5749 147 Jan. 28, 1998 147 RTA00000185AF.c.24.2 M00001578B:E04 23001 148 Jan. 28, 1998 148 RTA00000199F.h.17.2 M00003871A:A05 36254 149 Jan. 28, 1998 149 RTA00000181AR.h.06.3 M00001450D:D04 87226 150 Jan. 28, 1998 150 RTA00000184F.k.09.1 M00001557C:H07 7065 151 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 152 Jan. 28, 1998 152 RTA00000196AF.c.20.1 M00001352C:H02 8934 153 Jan. 28, 1998 153 RTA00000200F.n.17.2 M00004252C:E03 19064 154 Jan. 28, 1998 154 RTA00000196F.e.7.1 M00001360D:E11 1039 155 Jan. 28, 1998 155 RTA00000197F.e.8.1 M00001454A:C11 3135 156 Jan. 28, 1998 156 RTA00000199R.o.12.1 M00003977A:E04 16128 157 Jan. 28, 1998 157 RTA00000188AF.n.01.1 M00003801A:B10 36412 158 Jan. 28, 1998 158 RTA00000198AF.k.03.1 M00001655A:F06 22765 159 Jan. 28, 1998 159 RTA00000182AF.l.12.1 M00001487A:A05 1027 160 Jan. 28, 1998 160 RTA00000192AF.b.20.1 M00004118D:E08 0 161 Jan. 28, 1998 161 RTA00000183AF.e.23.2 M00001506D:A09 0 162 Jan. 28, 1998 162 RTA00000201F.e.15.1 M00004444B:D11 9960 163 Jan. 28, 1998 163 RTA00000192AR.e.13.3 M00004142A:B12 9457 164 Jan. 28, 1998 164 RTA00000193AR.i.14.4 M00004307C:A06 9457 165 Jan. 28, 1998 165 RTA00000192AF.g.23.1 M00004157C:A09 6455 166 Jan. 28, 1998 166 RTA00000198AF.f.21.1 M00001614D:D09 22676 167 Jan. 28, 1998 167 RTA00000179AF.d.22.3 M00001394C:C11 7955 168 Jan. 28, 1998 168 RTA00000177AR.k.23.1 M00001352D:D02 35550 169 Jan. 28, 1998 169 RTA00000196AF.g.24.1 M00001380C:F02 8685 170 Jan. 28, 1998 170 RTA00000197AF.d.23.1 M00001453A:E11 16130 171 Jan. 28, 1998 171 RTA00000198R.c.07.1 M00001575D:G05 19181 172 Jan. 28, 1998 172 RTA00000186AF.p.09.2 M00001655C:E04 6879 173 Jan. 28, 1998 173 RTA00000200AR.b.07.1 M00004039C:C01 17125 174 Jan. 28, 1998 174 RTA00000181AF.e.22.3 M00001448D:F09 3442 175 Jan. 28, 1998 175 RTA00000200F.i.5.1 M00004156B:A12 22892 176 Jan. 28, 1998 176 RTA00000183AF.h.19.1 M00001528A:A01 5175 177 Jan. 28, 1998 177 RTA00000197AF.c.3.1 M00001447C:C01 3145 178 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 179 Jan. 28, 1998 179 RTA00000179AF.f.20.3 M00001397B:B09 16154 180 Jan. 28, 1998 180 RTA00000199AF.j.12.1 M00003887A:A06 22461 181 Jan. 28, 1998 181 RTA00000198AF.d.2.1 M00001585A:F07 0 182 Jan. 28, 1998 182 RTA00000196AF.h.16.1 M00001384C:E03 39895 183 Jan. 28, 1998 183 RTA00000198AF.c.17.1 M00001579C:E08 6923 184 Jan. 28, 1998 184 RTA00000197AF.f.7.1 M00001457C:C11 19261 185 Feb. 24, 1998 234 RTA00000195AF.d.4.1 M00003881D:D06 22766 185 Jan. 28, 1998 185 RTA00000195AF.d.4.1 M00003881D:D06 22766 186 Jan. 28, 1998 186 RTA00000198R.p.09.1 M00003761D:E02 10473 187 Jan. 28, 1998 187 RTA00000180AR.j.04.4 M00001429C:G12 22300 188 Jan. 28, 1998 188 RTA00000188AF.o.05.1 M00003806D:G05 4668 189 Jan. 28, 1998 189 RTA00000197AF.h.10.1 M00001476B:F10 15554 190 Jan. 28, 1998 190 RTA00000134A.c.7.1 M00001528A:A01 5175 191 Jan. 28, 1998 191 RTA00000187AF.p.23.1 M00003748B:F02 39804 192 Jan. 28, 1998 192 RTA00000185AF.m.7.1 M00001605C:D12 39804 193 Jan. 28, 1998 193 RTA00000199AF.n.3.1 M00003946D:C11 0 194 Jan. 28, 1998 194 RTA00000200R.k.01.1 M00004188C:A09 40049 195 Jan. 28, 1998 195 RTA00000198AF.c.10.1 M00001577B:H02 77149 196 Jan. 28, 1998 196 RTA00000198F.e.10.1 M00001599B:E09 9727 197 Jan. 28, 1998 197 RTA00000198F.l.12.1 M00001669C:B01 8592 198 Jan. 28, 1998 198 RTA00000197AR.e.07.1 M00001453D:G12 86969 199 Jan. 28, 1998 199 RTA00000199R.c.09.1 M00003800A:C09 16824 200 Jan. 28, 1998 200 RTA00000182AF.f.2.1 M00001469D:D02 4794 201 Jan. 28, 1998 201 RTA00000198AF.p.18.1 M00003769B:D03 23081 202 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 203 Jan. 28, 1998 203 RTA00000201F.d.09.1 M00004380B:A05 1827 204 Jan. 28, 1998 204 RTA00000180AR.o.5.2 M00001437D:C04 7848 205 Jan. 28, 1998 205 RTA00000189AF.g.11.1 M00003858D:F12 0 206 Jan. 28, 1998 206 RTA00000181AF.o.04.2 M00001457C:C12 22205 207 Jan. 28, 1998 207 RTA00000199AF.l.19.1 M00003924B:D04 22460 208 Jan. 28, 1998 208 RTA00000198AF.h.22.1 M00001635C:A03 22366 209 Jan. 28, 1998 209 RTA00000182AF.c.5.1 M00001464D:F06 6397 210 Jan. 28, 1998 210 RTA00000189AR.b.12.1 M00003829B:G03 17233 211 Jan. 28, 1998 211 RTA00000199AF.m.15.1 M00003939A:A02 10101 212 Jan. 28, 1998 212 RTA00000197AF.j.9.1 M00001494B:C01 13236 213 Jan. 28, 1998 213 RTA00000200F.o.04.1 M00004260D:C12 12514 214 Jan. 28, 1998 214 RTA00000200AF.f.22.1 M00004121C:F06 16521 215 Jan. 28, 1998 215 RTA00000192AR.e.14.3 M00004142A:D08 3300 216 Jan. 28, 1998 216 RTA00000188AF.g.9.1 M00003774B:B08 4959 217 Jan. 28, 1998 217 RTA00000198AF.h.3.1 M00001625D:C07 22562 218 Jan. 28, 1998 218 RTA00000188AF.o.18.1 M00003811D:A12 13678 219 Jan. 28, 1998 219 RTA00000198AF.m.19.1 M00001680D:D02 40041 220 Jan. 28, 1998 220 RTA00000200AF.h.01.2 M00004141D:A09 0 221 Jan. 28, 1998 221 RTA00000189AF.i.17.1 M00003868C:H10 16814 222 Jan. 28, 1998 222 RTA00000185AF.i.4.1 M00001594A:B12 13942 223 Jan. 28, 1998 223 RTA00000197F.i.9.1 M00001488D:C10 0 224 Jan. 28, 1998 224 RTA00000188AF.m.11.1 M00003799A:D09 0 225 Jan. 28, 1998 225 RTA00000189AF.b.5.1 M00003828A:E04 3784 226 Jan. 28, 1998 226 RTA00000191AR.o.09.4 M00004096A:G02 0 227 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 228 Jan. 28, 1998 228 RTA00000187AR.h.15.2 M00001679A:A06 6660 229 Jan. 28, 1998 229 RTA00000198AF.g.3.1 M00001615C:F03 0 230 Jan. 28, 1998 230 RTA00000185AR.b.18.1 M00001575B:C09 12171 231 Jan. 28, 1998 231 RTA00000192AF.l.13.2 M00004185C:C03 11443 232 Jan. 28, 1998 232 RTA00000186AF.j.03.2 M00001638A:E07 0 233 Jan. 28, 1998 233 RTA00000197AF.l.8.1 M00001511B:C06 39954 234 Jan. 28, 1998 234 RTA00000191AF.f.8.1 M00004035A:A04 6541 235 Jan. 28, 1998 235 RTA00000201AF.a.02.1 M00004295B:D02 35362 236 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 237 Jan. 28, 1998 237 RTA00000197AF.k.10.1 M00001500D:B11 0 238 Jan. 28, 1998 238 RTA00000187AR.k.12.1 M00001679D:F02 78415 239 Jan. 28, 1998 239 RTA00000201R.d.02.1 M00004375A:H01 2599 240 Jan. 28, 1998 240 RTA00000178AF.e.1.1 M00001369A:H12 2664 241 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 242 Jan. 28, 1998 242 RTA00000198AF.m.17.1 M00001679D:F06 77992 243 Jan. 28, 1998 243 RTA00000181AF.m.15.3 M00001455D:A11 12081 244 Jan. 28, 1998 244 RTA00000199F.f.12.2 M00003844C:A08 8131 245 Jan. 28, 1998 245 RTA00000200AF.k.7.1 M00004193C:G11 0 246 Jan. 28, 1998 246 RTA00000199AF.l.4.1 M00003911D:B04 4410 247 Jan. 28, 1998 247 RTA00000198AF.k.08.1 M00001656C:G08 17436 248 Jan. 28, 1998 248 RTA00000198R.c.14.1 M00001578D:C04 39814 249 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 250 Jan. 28, 1998 250 RTA00000192AF.j.21.1 M00004176D:B12 2289 251 Jan. 28, 1998 251 RTA00000192AF.n.13.1 M00004197D:H01 8210 252 Jan. 28, 1998 252 RTA00000181AF.e.18.3 M00001448D:C09 8 253 Jan. 28, 1998 253 RTA00000181AF.e.17.3 M00001448D:C09 8 254 Jan. 28, 1998 254 RTA00000178AF.n.2.1 M00001385C:H11 17083 255 Jan. 28, 1998 255 RTA00000199AF.j.17.1 M00003889A:D10 5121 256 Jan. 28, 1998 256 RTA00000184AR.e.15.1 M00001549C:E06 16347 257 Jan. 28, 1998 257 RTA00000198AF.e.20.1 M00001604C:E09 9810 258 Jan. 28, 1998 258 RTA00000199F.h.12.2 M00003868B:D12 16621 259 Jan. 28, 1998 259 RTA00000197AF.j.4.1 M00001492D:A11 17209 260 Jan. 28, 1998 260 RTA00000198R.m.17.1 M00001679D:F06 77992 261 Jan. 28, 1998 261 RTA00000192AF.a.24.1 M00004114C:F11 13183 262 Jan. 28, 1998 262 RTA00000186AF.c.17.1 M00001619D:G05 8551 263 Jan. 28, 1998 263 RTA00000190AF.n.6.1 M00003965A:B11 0 264 Jan. 28, 1998 264 RTA00000179AF.k.3.3 M00001401A:H07 0 265 Jan. 28, 1998 265 RTA00000177AF.e.14.1 M00001343D:H07 23255 266 Jan. 28, 1998 266 RTA00000199F.f.21.2 M00003847C:E09 13344 267 Jan. 28, 1998 267 RTA00000186AF.g.11.2 M00001630B:H09 5214 268 Jan. 28, 1998 268 RTA00000186AF.h.01.2 M00001632A:F12 0 269 Jan. 28, 1998 269 RTA00000183AF.k.13.1 M00001534B:C12 0 270 Jan. 28, 1998 270 RTA00000178R.l.08.1 M00001383A:C03 39648 271 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00004375A:H01 2599 272 Jan. 28, 1998 272 RTA00000199F.g.08.2 M00003853D:G08 0 273 Jan. 28, 1998 273 RTA00000201F.c.08.1 M00004353C:H07 0 274 Jan. 28, 1998 274 RTA00000191AF.o.17.1 M00004102A:H02 5957 275 Jan. 28, 1998 275 RTA00000191AF.o.17.2 M00004102A:H02 5957 276 Jan. 28, 1998 276 RTA00000198AF.j.15.1 M00001653B:E09 4369 277 Jan. 28, 1998 277 RTA00000198AR.i.08.1 M00001639A:F10 9807 278 Jan. 28, 1998 278 RTA00000198AF.p.16.1 M00003768A:E02 71877 279 Jan. 28, 1998 279 RTA00000196AF.h.24.1 M00001386A:D11 7308 280 Jan. 28, 1998 280 RTA00000193AF.b.18.1 M00004233C:H09 7542 281 Jan. 28, 1998 281 RTA00000188AF.n.10.1 M00003802D:B11 10283 282 Jan. 28, 1998 282 RTA00000193AF.c.15.1 M00004248B:E08 3726 283 Jan. 28, 1998 283 RTA00000177AF.i.8.4 M00001350A:H01 7187 284 Jan. 28, 1998 284 RTA00000199F.d.10.2 M00003808C:B05 22049 285 Jan. 28, 1998 285 RTA00000181AR.j.14.3 M00001453B:E10 5399 286 Jan. 28, 1998 286 RTA00000181AR.k.2.3 M00001453C:A11 0 287 Jan. 28, 1998 287 RTA00000200AF.b.07.1 M00004039C:C01 17125 288 Jan. 28, 1998 288 RTA00000181AR.i.06.3 M00001452A:C07 19119 289 Jan. 28, 1998 289 RTA00000196F.k.07.1 M00001399C:D09 22443 290 Jan. 28, 1998 290 RTA00000201F.f.10.1 M00004498D:D05 5231 291 Jan. 28, 1998 291 RTA00000200AF.e.16.1 M00004101C:G08 12068 292 Jan. 28, 1998 292 RTA00000199AF.m.18.1 M00003939C:F04 0 293 Jan. 28, 1998 293 RTA00000197AF.e.13.1 M00001454C:F02 662 294 Jan. 28, 1998 294 RTA00000198AF.k.23.1 M00001661B:C08 8995 295 Jan. 28, 1998 295 RTA00000181AR.i.19.2 M00001452C:B06 16970 296 Jan. 28, 1998 296 RTA00000196AF.f.20.1 M00001371D:G01 22774 297 Jan. 28, 1998 297 RTA00000178AF.f.9.3 M00001371C:E09 7172 298 Jan. 28, 1998 298 RTA00000197AR.e.11.1 M00001454B:G03 2306 299 Jan. 28, 1998 299 RTA00000196AF.f.5.1 M00001366D:G02 11937 300 Feb. 24, 1998 464 RTA00000195AF.c.12.1 M00003818B:G12 37582 300 Jan. 28, 1998 300 RTA00000195AF.c.12.1 M00003818B:G12 37582 301 Jan. 28, 1998 301 RTA00000181AR.i.19.3 M00001452C:B06 16970 302 Jan. 28, 1998 302 RTA00000186AF.d.1.2 M00001621C:C08 40044 303 Jan. 28, 1998 303 RTA00000186AR.e.03.3 M00001623D:C10 22110 304 Jan. 28, 1998 304 RTA00000182AR.c.5.1 M00001464D:F06 6397 305 Jan. 28, 1998 305 RTA00000200AF.b.15.1 M00004040D:F01 10627 306 Jan. 28, 1998 306 RTA00000199AF.p.12.1 M00003989A:H11 12578 307 Jan. 28, 1998 307 RTA00000200F.n.05.2 M00004246C:A09 18989 308 Jan. 28, 1998 308 RTA00000178AF.j.20.1 M00001380C:E05 15066 309 Jan. 28, 1998 309 RTA00000198AF.h.12.1 M00001632C:A02 9503 310 Jan. 28, 1998 310 RTA00000188AF.m.08.1 M00003798D:H08 22155 311 Jan. 28, 1998 311 RTA00000191AR.j.4.2 M00004071D:A10 5198 312 Jan. 28, 1998 312 RTA00000193AF.h.2.1 M00004290A:B03 3273 313 Jan. 28, 1998 313 RTA00000183AF.o.11.1 M00001540D:D02 0 314 Jan. 28, 1998 314 RTA00000182AF.o.5.1 M00001493B:D09 5007 315 Jan. 28, 1998 315 RTA00000199R.d.23.1 M00003815D:H09 37477 316 Jan. 28, 1998 316 RTA00000198AF.h.24.1 M00001636C:C01 8390 317 Jan. 28, 1998 317 RTA00000198AF.p.09.1 M00003761D:E02 10473 318 Jan. 28, 1998 318 RTA00000200AF.g.17.1 M00004138A:H09 0 319 Jan. 28, 1998 319 RTA00000200F.n.05.1 M00004246C:A09 18989 320 Jan. 28, 1998 320 RTA00000196AF.m.13.1 M00001415B:E09 16290 321 Jan. 28, 1998 321 RTA00000181AR.b.21.1 M00001444C:D05 3266 322 Jan. 28, 1998 322 RTA00000184AR.b.21.1 M00001546B:B02 39788 323 Jan. 28, 1998 323 RTA00000182AF.m.21.1 M00001490C:C12 18699 324 Jan. 28, 1998 324 RTA00000184F.j.06.1 M00001556B:G02 11294 325 Jan. 28, 1998 325 RTA00000182AF.d.18.4 M00001467D:H05 37435 326 Jan. 28, 1998 326 RTA00000197AR.e.19.1 M00001455D:A09 8047 327 Jan. 28, 1998 327 RTA00000182AF.i.1.3 M00001479B:A01 7033 328 Jan. 28, 1998 328 RTA00000200AF.g.09.1 M00004131B:H09 22785 329 Jan. 28, 1998 329 RTA00000186AF.b.9.1 M00001616C:F07 0 330 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 331 Jan. 28, 1998 331 RTA00000197AR.c.20.1 M00001449D:A06 16282 332 Jan. 28, 1998 332 RTA00000193AR.n.04.3 M00004375C:D01 9850 333 Jan. 28, 1998 333 RTA00000196F.k.15.1 M00001400A:F06 8320 334 Jan. 28, 1998 334 RTA00000181AR.b.21.3 M00001444C:D05 3266 335 Jan. 28, 1998 335 RTA00000182AF.e.3.2 M00001468B:H06 0 336 Jan. 28, 1998 336 RTA00000186AF.f.24.1 M00001629B:E06 0 337 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 338 Jan. 28, 1998 338 RTA00000184AF.i.1.1 M00001554B:C07 0 339 Jan. 28, 1998 339 RTA00000193AF.d.1.1 M00004250D.D10 0 340 Jan. 28, 1998 340 RTA00000185AF.n.8.1 M00001608B:A03 0 341 Jan. 28, 1998 341 RTA00000181AF.l.06.2 M00001454C:C08 0 342 Jan. 28, 1998 342 RTA00000196AF.d.10.1 M00001354C:B06 22256 343 Jan. 28, 1998 343 RTA00000201F.a.18.1 M00004314B:G07 16837 344 Jan. 28, 1998 344 RTA00000198AF.o.02.1 M00003748A:B07 68756 345 Jan. 28, 1998 345 RTA00000187AF.h.21.1 M00001679A:F01 39171 346 Jan. 28, 1998 346 RTA00000197AR.k.22.1 M00001505C:H01 11394 347 Jan. 28, 1998 347 RTA00000199F.b.03.2 M00003779B:E12 38340 348 Jan. 28, 1998 348 RTA00000200F.n.07.2 M00004247C:C12 8663 349 Jan. 28, 1998 349 RTA00000191AF.j.15.1 M00004073B:B01 6308 350 Jan. 28, 1998 350 RTA00000193AR.c.7.2 M00004241D:F11 9850 351 Jan. 28, 1998 351 RTA00000179AF.c.22.1 M00001393B:B09 22515 352 Jan. 28, 1998 352 RTA00000197AF.p.3.1 M00001550A:A03 7239 353 Jan. 28, 1998 353 RTA00000198F.a.9.1 M00001557D:C08 0 354 Jan. 28, 1998 354 RTA00000198R.k.03.1 M00001655A:F06 22765 355 Jan. 28, 1998 355 RTA00000184AR.b.24.1 M00001546B:C05 5777 356 Jan. 28, 1998 356 RTA00000180AF.l.12.2 M00001433B:H11 0 357 Jan. 28, 1998 357 RTA00000184AF.o.15.1 M00001564D:C09 0 358 Jan. 28, 1998 358 RTA00000198AF.g.7.1 M00001616C:C09 13386 359 Jan. 28, 1998 359 RTA00000196AF.b.17.1 M00001348A:D04 12193 360 Jan. 28, 1998 360 RTA00000198F.i.5.1 M00001638A:D10 39989 361 Jan. 28, 1998 361 RTA00000177AR.g.16.4 M00001347A:B10 13576 362 Jan. 28, 1998 362 RTA00000197AR.c.24.1 M00001450A:B12 82498 363 Jan. 28, 1998 363 RTA00000196AF.e.14.1 M00001362C:A10 12850 364 Jan. 28, 1998 364 RTA00000187AF.g.13.1 M00001676C:C11 2991 365 Jan. 28, 1998 365 RTA00000196F.l.20.2 M00001410B:G05 22678 366 Jan. 28, 1998 366 RTA00000192AF.o.19.1 M00004208D:H08 3549 367 Jan. 28, 1998 367 RTA00000196F.i.24.1 M00001392C:D10 4233 368 Jan. 28, 1998 368 RTA00000198AF.k.18.1 M00001660A:C12 17432 369 Jan. 28, 1998 369 RTA00000196F.m.3.1 M00001413A:F02 10453 370 Jan. 28, 1998 370 RTA00000179AF.c.15.3 M00001392D:H06 2995 371 Jan. 28, 1998 371 RTA00000197F.e.7.1 M00001453D:G12 86969 372 Jan. 28, 1998 372 RTA00000186AF.d.23.1 M00001623B:G07 22187 373 Jan. 28, 1998 373 RTA00000196F.e.12.1 M00001361C:H11 10147 374 Jan. 28, 1998 374 RTA00000178AF.l.11.1 M00001383A:G04 23286 375 Jan. 28, 1998 375 RTA00000177AF.m.18.1 M00001355B:G11 0 376 Jan. 28, 1998 376 RTA00000177AF.m.18.3 M00001355B:G11 0 377 Jan. 28, 1998 377 RTA00000178AF.m.19.1 M00001384D:H07 0 378 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 379 Jan. 28, 1998 379 RTA00000180AF.l.06.2 M00001433A:G07 5625 380 Jan. 28, 1998 380 RTA00000182AF.k.24.1 M00001485D:B10 5625 381 Jan. 28, 1998 381 RTA00000199AF.m.14.1 M00003938A:B04 10580 382 Jan. 28, 1998 382 RTA00000200AF.j.6.1 M00004176B:E08 22902 383 Jan. 28, 1998 383 RTA00000199F.f.20.2 M00003847B:G03 0 384 Jan. 28, 1998 384 RTA00000196AF.h.17.1 M00001384C:F12 39215 385 Jan. 28, 1998 385 RTA00000201F.c.24.1 M00004374D:E10 35731 386 Jan. 28, 1998 386 RTA00000197AR.j.04.1 M00001492D:A11 17209 387 Feb. 24, 1998 632 RTA00000191AF.j.14.1 M00004073A:H12 1002 387 Jan. 28, 1998 387 RTA00000191AF.j.14.1 M00004073A:H12 1002 388 Jan. 28, 1998 388 RTA00000185AF.n.17.1 M00001609B:A11 5336 389 Jan. 28, 1998 389 RTA00000181AR.k.2.2 M00001453C:A11 0 390 Jan. 28, 1998 390 RTA00000197AR.f.07.1 M00001457C:C11 19261 391 Jan. 28, 1998 391 RTA00000179AF.e.20.3 M00001396A:C03 4009 392 Jan. 28, 1998 392 RTA00000185AF.b.11.2 M00001573C:D03 9024 393 Jan. 28, 1998 393 RTA00000188AF.b.14.1 M00003754D:D02 0 394 Jan. 28, 1998 394 RTA00000198AF.p.22.1 M00003771A:G10 0 395 Jan. 28, 1998 395 RTA00000196R.c.21.2 M00001352C:H10 0 396 Jan. 28, 1998 396 RTA00000179AR.b.02.3 M00001391B:G12 0 397 Jan. 28, 1998 397 RTA00000198AF.b.22.1 M00001571B:E03 38956 398 Jan. 28, 1998 398 RTA00000177AR.l.13.3 M00001353A:G12 8078 399 Jan. 28, 1998 399 RTA00000186AF.m.15.2 M00001649C:B10 40122 400 Jan. 28, 1998 400 RTA00000186AR.e.07.3 M00001623D:G03 4175 401 Jan. 28, 1998 491 RTA00000195F.e.04.1 M00004465B:D04 6731 402 Jan. 28, 1998 402 RTA00000177AF.b.21.4 M00001341A:F12 4443 403 Jan. 28, 1998 403 RTA00000184AF.f.13.1 M00001550D:H02 3784 404 Jan. 28, 1998 404 RTA00000195AF.b.6.1 M00001496C:G10 39490 405 Jan. 28, 1998 405 RTA00000197AF.b.24.1 M00001446C:D09 23171 406 Jan. 28, 1998 406 RTA00000199F.f.09.2 M00003842B:D09 22907 407 Jan. 28, 1998 407 RTA00000178AF.e.20.1 M00001370D:E12 3135 408 Jan. 28, 1998 408 RTA00000183AR.l.15.1 M00001535C:E01 39383 409 Jan. 28, 1998 409 RTA00000180AF.d.1.3 M00001418D:B06 8526 410 Jan. 28, 1998 410 RTA00000201F.a.20.1 M00004316A:G09 22639 411 Jan. 28, 1998 411 RTA00000179AF.j.13.3 M00001400B:H06 0 412 Feb. 24, 1998 678 RTA00000195AF.c.24.1 M00003860D:H07 0 412 Jan. 28, 1998 412 RTA00000195AF.c.24.1 M00003860D:H07 0 413 Jan. 28, 1998 413 RTA00000200F.a.12.1 M00004031D:B05 16751 414 Jan. 28, 1998 414 RTA00000185AR.b.15.1 M00001573D:F04 39813 415 Jan. 28, 1998 415 RTA00000200AF.f.09.1 M00004111C:E11 12863 416 Jan. 28, 1998 416 RTA00000199F.a.5.1 M00003773B:G01 22134 417 Jan. 28, 1998 417 RTA00000200R.d.16.1 M00004085A:B02 39875 418 Jan. 28, 1998 418 RTA00000187AR.k.01.1 M00001679D:B05 78356 419 Jan. 28, 1998 419 RTA00000182AF.j.20.1 M00001483B:D03 4769 420 Jan. 28, 1998 420 RTA00000181AF.c.11.1 M00001445D:A06 4769 421 Jan. 28, 1998 421 RTA00000200AF.i.21.1 M00004167D:A07 5316 422 Jan. 28, 1998 422 RTA00000189AF.b.12.1 M00003829B:G03 17233 423 Jan. 28, 1998 423 RTA00000188AR.b.17.1 M00003755A:B03 10662 424 Jan. 28, 1998 424 RTA00000187AR.j.24.1 M00001679D:B05 78356 425 Jan. 28, 1998 425 RTA00000200AF.c.16.1 M00004064D:A11 23433 426 Jan. 28, 1998 426 RTA00000199AF.o.19.1 M00003980D:E09 36927 427 Jan. 28, 1998 427 RTA00000187AR.d.9.2 M00001664D:G07 5483 428 Jan. 28, 1998 428 RTA00000185AF.b.15.2 M00001573D:F04 39813 429 Jan. 28, 1998 429 RTA00000196F.i.19.1 M00001390C:C11 39498 430 Jan. 28, 1998 430 RTA00000198R.k.23.1 M00001661B:C08 8995 431 Jan. 28, 1998 431 RTA00000199AF.k.15.1 M00003905C:G10 8275 432 Jan. 28, 1998 432 RTA00000198AF.o.05.1 M00003750A:D01 26702 433 Jan. 28, 1998 433 RTA00000198R.j.18.1 M00001653B:G07 22759 434 Jan. 28, 1998 434 RTA00000187AR.d.2.2 M00001664C:H10 4892 435 Jan. 28, 1998 435 RTA00000182AR.c.22.1 M00001467A:D08 16283 436 Jan. 28, 1998 436 RTA00000200AF.k.11.1 M00004197C:F03 9796 437 Jan. 28, 1998 437 RTA00000198R.a.23.1 M00001563B:D11 10700 438 Jan. 28, 1998 438 RTA00000180AR.g.03.4 M00001425A:C11 9024 439 Jan. 28, 1998 439 RTA00000185AF.d.14.2 M00001579D:G07 8071 440 Jan. 28, 1998 440 RTA00000177AR.f.13.4 M00001345A:G11 104°0 441 Jan. 28, 1998 441 RTA00000185AF.e.6.1 M00001583B:E10 0 442 Jan. 28, 1998 442 RTA00000191AF.l.9.1 M00004081C:H06 0 443 Jan. 28, 1998 443 RTA00000197AR.i.17.1 M00001490A:E11 3516 444 Jan. 28, 1998 444 RTA00000189AF.l.16.1 M00003879A:G05 0 445 Jan. 28, 1998 445 RTA00000196AF.n.13.1 M00001422C:F12 8396 446 Jan. 28, 1998 446 RTA00000182AF.a.23.3 M00001463A:F06 9755 447 Jan. 28, 1998 447 RTA00000198AF.d.8.1 M00001587A:H03 0 448 Jan. 28, 1998 448 RTA00000200AF.j.9.1 M00004177C:A01 8608 449 Jan. 28, 1998 449 RTA00000181AF.m.22.3 M00001455D:F09 9283 450 Jan. 28, 1998 450 RTA00000181AF.m.21.3 M00001455D:F09 9283 451 Jan. 28, 1998 451 RTA00000200AF.b.20.1 M00004043A:D02 40403 452 Jan. 28, 1998 452 RTA00000199F.d.19.2 M00003813D:H12 6707 453 Jan. 28, 1998 453 RTA00000199AF.i.20.1 M00003881A:D09 9544 454 Jan. 28, 1998 454 RTA00000200R.d.04.1 M00004078A:A06 5506 455 Jan. 28, 1998 455 RTA00000198AF.d.12.1 M00001589A:C01 21142 456 Jan. 28, 1998 456 RTA00000200AF.b.12.1 M00004040B:F10 22053 457 Jan. 28, 1998 457 RTA00000191AR.l.7.2 M00004081C:D12 14391 458 Jan. 28, 1998 458 RTA00000199R.d.16.1 M00003812C:A05 24191 459 Jan. 28, 1998 459 RTA00000179AF.c.22.3 M00001393B:B09 22515 460 Jan. 28, 1998 460 RTA00000179AF.c.15.1 M00001392D:H06 2995 461 Jan. 28, 1998 461 RTA00000190AF.e.13.1 M00003908A:H09 38961 462 Jan. 28, 1998 462 RTA00000196AF.n.17.1 M00001423D:A09 12477 463 Jan. 28, 1998 463 RTA00000177AR.k.23.4 M00001352D:D02 35550 464 Jan. 28, 1998 464 RTA00000199AF.i.14.1 M00003917A:D02 22865 465 Jan. 28, 1998 465 RTA00000187AF.k.20.1 M00001680B:C01 3648 466 Jan. 28, 1998 466 RTA00000177AF.p.20.1 M00001361A:A05 4141 467 Jan. 28, 1998 467 RTA00000195AF.b.19.1 M00001589A:D12 77678 468 Jan. 28, 1998 468 RTA00000198AF.a.18.1 M00001561C:E11 0 469 Jan. 28, 1998 469 RTA00000190AF.n.2.1 M00003963A:E03 5650 470 Jan. 28, 1998 470 RTA00000198AF.f.16.1 M00001614A:E06 0 471 Jan. 28, 1998 471 RTA00000188AF.e.2.1 M00003763B:H01 0 472 Jan. 28, 1998 472 RTA00000192AF.p.17.1 M00004214C:H05 11451 473 Jan. 28, 1998 473 RTA00000196F.i.3.1 M00001387A:E10 0 474 Jan. 28, 1998 474 RTA00000192AR.d.1.3 M00004130D:H01 14507 475 Jan. 28, 1998 475 RTA00000187AR.m.3.3 M00001682C:B12 17055 476 Jan. 28, 1998 476 RTA00000200R.g.15.1 M00004135B:G01 22898 477 Jan. 28, 1998 477 RTA00000180AR.e.22.2 M00001423A:G05 7714 478 Jan. 28, 1998 478 RTA00000192AR.o.24.2 M00004210B:B05 7191 479 Jan. 28, 1998 479 RTA00000197R.l.22.1 M00001528A:C11 6962 480 Jan. 28, 1998 480 RTA00000181AF.o.08.2 M00001457C:H12 849 481 Jan. 28, 1998 481 RTA00000179AR.l.22.2 M00001405B:E09 4314 482 Jan. 28, 1998 482 RTA00000187AF.j.7.1 M00001679C:F01 78091 483 Jan. 28, 1998 483 RTA00000192AF.h.19.1 M00004162C:A07 4642 484 Jan. 28, 1998 484 RTA00000199F.g.20.2 M00003860D:A01 15767 485 Jan. 28, 1998 485 RTA00000196AF.c.14.1 M00001352B:F04 23105 486 Jan. 28, 1998 486 RTA00000190AR.p.22.2 M00003979A:E11 16368 487 Jan. 28, 1998 487 RTA00000198F.i.8.1 M00001639A:F10 9807 488 Jan. 28, 1998 488 RTA00000179AR.l.22.4 M00001405B:E09 4314 489 Jan. 28, 1998 489 RTA00000186AF.h.22.1 M00001634B:C10 16485 490 Jan. 28, 1998 490 RTA00000198AF.n.05.1 M00001687A:G01 24157 491 Jan. 28, 1998 491 RTA00000196F.k.11.1 M00001399C:H12 3 492 Jan. 28, 1998 492 RTA00000198AF.b.8.1 M00001567C:H12 22636 493 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 494 Jan. 28, 1998 494 RTA00000200AF.k.1.1 M00004188C:A09 40049 495 Jan. 28, 1998 495 RTA00000185AF.j.21.1 M00001597A:E12 0 496 Jan. 28, 1998 496 RTA00000190AF.p.3.1 M00003975B:F03 2378 497 Jan. 28, 1998 497 RTA00000198AF.o.09.1 M00003751B:A05 4310 498 Jan. 28, 1998 498 RTA00000190AF.h.12.1 M00003917C:D03 12977 499 Jan. 28, 1998 499 RTA00000199F.b.22.2 M00003791C:E09 17018 500 Jan. 28, 1998 500 RTA00000179AR.m.07.5 M00001405D:D11 0 501 Jan. 28, 1998 501 RTA00000200R.k.11.1 M00004197C:F03 9796 502 Jan. 28, 1998 502 RTA00000197AF.o.23.1 M00001549A:A09 12682 503 Jan. 28, 1998 503 RTA00000197AF.k.9.1 M00001500C:C08 3138 504 Jan. 28, 1998 504 RTA00000198AF.g.2.1 M00001615C:D02 16640 505 Jan. 28, 1998 505 RTA00000188AF.n.03.1 M00003801B:B10 9443 506 Jan. 28, 1998 506 RTA00000198R.o.09.1 M00003751B:A05 4310 507 Jan. 28, 1998 507 RTA00000198AF.c.5.1 M00001573D:F10 53802 508 Jan. 28, 1998 508 RTA00000187AF.i.14.2 M00001679B:H07 19406 509 Jan. 28, 1998 509 RTA00000183AF.p.17.1 M00001543A:H12 5158 510 Jan. 28, 1998 510 RTA00000178AF.n.23.1 M00001387B:E02 3298 511 Jan. 28, 1998 511 RTA00000196AF.g.10.1 M00001376B:A02 12498 512 Jan. 28, 1998 512 RTA00000191AF.c.3.1 M00003987D:D06 3549 513 Jan. 28, 1998 513 RTA00000197AF.h.14.1 M00001477B:F04 7045 514 Jan. 28, 1998 514 RTA00000196AF.n.02.1 M00001417D:A04 39260 515 Jan. 28, 1998 515 RTA00000196AF.f.18.1 M00001370D:A12 14506 516 Jan. 28, 1998 516 RTA00000200AF.e.23.1 M00004107B:A06 14686 517 Jan. 28, 1998 517 RTA00000184AF.e.14.1 M00001549C:D02 16347 518 Jan. 28, 1998 518 RTA00000199AF.n.22.1 M00003971A:A06 23064 519 Jan. 28, 1998 519 RTA00000183AF.a.24.2 M00001499B:A11 10539 520 Jan. 28, 1998 520 RTA00000195AF.c.8.1 M00001678B:H01 0 520 Feb. 24, 1998 958 RTA00000195AF.c.8.1 M00001678B:H01 0 521 Jan. 28, 1998 521 RTA00000197AF.p.12.1 M00001552B:G05 0 522 Jan. 28, 1998 522 RTA00000178AR.h.17.2 M00001376A:C05 23824 523 Jan. 28, 1998 523 RTA00000198AF.d.4.1 M00001586D:E02 22435 524 Jan. 28, 1998 524 RTA00000191AF.j.24.1 M00004076B:G03 0 525 Jan. 28, 1998 525 RTA00000198AF.c.7.1 M00001575D:G05 19181 526 Jan. 28, 1998 526 RTA00000185AF.e.20.1 M00001585A:D06 5865 527 Jan. 28, 1998 527 RTA00000198R.m.23.1 M00001684B:G03 38469 528 Jan. 28, 1998 528 RTA00000200F.n.09.2 M00004249D:B08 12391 529 Jan. 28, 1998 529 RTA00000178AF.b.13.1 M00001364A:E11 3114 530 Jan. 28, 1998 530 RTA00000185AF.d.24.2 M00001582D:F05 0 531 Jan. 28, 1998 531 RTA00000195F.a.3.1 M00001368A:A03 27179 532 Jan. 28, 1998 532 RTA00000177AF.o.4.1 M00001358C:C06 0 533 Jan. 28, 1998 533 RTA00000177AR.m.13.4 M00001355A:C12 4175 534 Jan. 28, 1998 534 RTA00000201AF.e.01.1 M00004405D:C04 11397 535 Jan. 28, 1998 535 RTA00000196AF.n.19.1 M00001423D:D12 6881 536 Jan. 28, 1998 536 RTA00000193AR.a.2.3 M00004216D:D03 0 537 Jan. 28, 1998 537 RTA00000188AF.g.14.1 M00003774C:D02 0 538 Jan. 28, 1998 538 RTA00000177AR.m.13.3 M00001355A:C12 4175 539 Jan. 28, 1998 539 RTA00000197AR.b.13.1 M00001445B:E04 9560 540 Jan. 28, 1998 540 RTA00000179AF.b.10.3 M00001391D:D10 0 541 Jan. 28, 1998 541 RTA00000197AR.b.16.1 M00001445C:A08 0 542 Jan. 28, 1998 542 RTA00000198R.p.12.1 M00003763D:E10 8878 543 Jan. 28, 1998 543 RTA00000200AF.l.19.1 M00004167A:H03 14722 544 Jan. 28, 1998 544 RTA00000196F.j.13.1 M00001396D:B03 23170 545 Jan. 28, 1998 545 RTA00000196F.a.2.1 M00001338B:E02 3575 546 Jan. 28, 1998 546 RTA00000197F.i.6.1 M00001487C:D06 12149 547 Jan. 28, 1998 547 RTA00000196AF.g.8.1 M00001375B:G12 39665 548 Jan. 28, 1998 548 RTA00000179AF.f.23.3 M00001397B:G03 35258 549 Jan. 28, 1998 549 RTA00000198AF.c.16.1 M00001579C:B11 26801 550 Jan. 28, 1998 550 RTA00000183AF.g.14.1 M00001513D:A03 0 551 Jan. 28, 1998 551 RTA00000200AR.c.24.1 M00004076D:D04 15972 552 Jan. 28, 1998 552 RTA00000193AF.b.24.1 M00004237D:D08 35 553 Jan. 28, 1998 553 RTA00000201F.b.22.1 M00004344B:H04 35728 554 Jan. 28, 1998 554 RTA00000186AR.e.07.4 M00001623D:G03 4175 555 Jan. 28, 1998 555 RTA00000198AF.j.08.1 M00001651B:A11 10983 556 Jan. 28, 1998 556 RTA00000199F.f.17.2 M00003845D:B04 22905 557 Jan. 28, 1998 557 RTA00000198AF.d.9.1 M00001587D:A10 8841 558 Jan. 28, 1998 558 RTA00000186AR.h.14.1 M00001632D:H07 0 559 Jan. 28, 1998 559 RTA00000197AF.p.20.1 M00001554B:B07 22795 560 Jan. 28, 1998 560 RTA00000184AF.i.23.3 M00001556A:F11 1577 561 Jan. 28, 1998 561 RTA00000185AR.d.10.1 M00001579C:H10 0 562 Jan. 28, 1998 562 RTA00000196F.j.12.1 M00001396A:H03 19294 563 Jan. 28, 1998 563 RTA00000192AR.o.16.2 M00004208B:F05 9061 564 Jan. 28, 1998 564 RTA00000200AF.g.18.1 M00004138B:B11 1600 565 Jan. 28, 1998 565 RTA00000191AF.c.10.1 M00003989B:F11 40422 566 Jan. 28, 1998 566 RTA00000195F.a.4.1 M00001372C:G12 20470 567 Jan. 28, 1998 567 RTA00000177AR.m.13.1 M00001355A:C12 4175 568 Jan. 28, 1998 568 RTA00000196AF.p.01.2 M00001430A:A02 87143 569 Jan. 28, 1998 569 RTA00000196AF.l.23.1 M00001412A:E04 12052 570 Jan. 28, 1998 570 RTA00000183AF.a.19.2 M00001499A:A05 3788 571 Jan. 28, 1998 571 RTA00000198AF.b.14.1 M00001569C:B06 801 572 Jan. 28, 1998 572 RTA00000181AF.l.16.2 M00001454D:E05 13532 573 Jan. 28, 1998 573 RTA00000196AF.b.7.1 M00001344A:G07 7774 574 Jan. 28, 1998 574 RTA00000192AF.f.3.1 M00004146C:C11 5257 575 Jan. 28, 1998 575 RTA00000186AF.l.12.2 M00001645A:C12 19267 576 Jan. 28, 1998 576 RTA00000196AF.c.7.1 M00001350B:G11 0 577 Jan. 28, 1998 577 RTA00000190AF.a.24.2 M00003901B:A05 0 578 Jan. 28, 1998 578 RTA00000180AF.g.17.1 M00001426A:A09 16653 579 Jan. 28, 1998 579 RTA00000200F.i.7.1 M00004157D:B03 22322 580 Jan. 28, 1998 580 RTA00000197F.a.12.1 M00001438B:B09 7895 581 Jan. 28, 1998 581 RTA00000191AF.p.3.2 M00004104B:F11 17 582 Jan. 28, 1998 582 RTA00000178AR.d.12.4 M00001368A:D07 2476 583 Jan. 28, 1998 583 RTA00000190AR.h.12.2 M00003917C:D03 12977 584 Jan. 28, 1998 584 RTA00000190AR.c.03.1 M00003904C:A08 0 585 Jan. 28, 1998 585 RTA00000198AF.n.18.1 M00001771A:A07 16715 586 Jan. 28, 1998 586 RTA00000199R.o.11.1 M00003976C:A10 23172 587 Jan. 28, 1998 587 RTA00000199F.a.3.1 M00003772D:E10 16617 588 Jan. 28, 1998 588 RTA00000191AF.b.4.1 M00003983C:F03 14936 589 Jan. 28, 1998 589 RTA00000192AF.l.1.1 M00004183C:D07 16392 590 Jan. 28, 1998 590 RTA00000190AF.d.2.1 M00003906B:F12 2444 591 Jan. 28, 1998 591 RTA00000197AF.h.1.1 M00001470A:H01 13075 592 Jan. 28, 1998 592 RTA00000186AF.e.18.1 M00001624C:A06 0 593 Jan. 28, 1998 593 RTA00000196R.c.14.2 M00001352B:F04 23105 594 Jan. 28, 1998 594 RTA00000181AR.e.04.3 M00001448A:G09 11825 595 Jan. 28, 1998 595 RTA00000195R.a.06.1 M00001394A:E04 35265 595 Feb. 24, 1998 1065 RTA00000195R.a.06.1 M00001394A:E04 35265 596 Jan. 28, 1998 596 RTA00000184AF.d.9.1 M00001548A:B11 6515 597 Jan. 28, 1998 597 RTA00000198F.a.4.1 M00001557A:F01 9635 598 Jan. 28, 1998 598 RTA00000197F.e.10.1 M00001454B:D08 13154 599 Jan. 28, 1998 599 RTA00000179AF.o.5.1 M00001408D:D04 6172 600 Jan. 28, 1998 600 RTA00000177AF.g.4.1 M00001346B:B07 4119 601 Jan. 28, 1998 601 RTA00000184AF.i.10.2 M00001555A:B01 3744 602 Jan. 28, 1998 602 RTA00000195AF.b.21.1 M00001595B:A09 39055 602 Feb. 24, 1998 317 RTA00000195AF.b.21.1 M00001595B:A09 39055 603 Jan. 28, 1998 603 RTA00000183AR.d.11.3 M00001504D:G06 6420 604 Jan. 28, 1998 604 RTA00000200AF.j.15.1 M00004185D:E04 5849 605 Jan. 28, 1998 605 RTA00000196F.e.9.1 M00001361A:H07 23300 606 Jan. 28, 1998 606 RTA00000179AR.e.01.4 M00001395A:C09 2493 607 Jan. 28, 1998 607 RTA00000200AF.k.12.1 M00004198B:D02 7359 608 Jan. 28, 1998 608 RTA00000192AF.p.8.1 M00004212B:C07 2379 609 Jan. 28, 1998 609 RTA00000196AF.n.05.1 M00001418B:F07 12531 610 Jan. 28, 1998 610 RTA00000200AF.k.2.1 M00004188D:G08 35924 611 Jan. 28, 1998 611 RTA00000196F.i.13.2 M00001408A:H04 0 612 Jan. 28, 1998 612 RTA00000197AR.e.22.1 M00001456A:H02 78758 613 Jan. 28, 1998 613 RTA00000177AF.k.18.4 M00001352C:A05 53729 614 Jan. 28, 1998 614 RTA00000201F.f.03.1 M00004493B:D09 22633 615 Jan. 28, 1998 615 RTA00000197R.p.20.1 M00001554B:B07 22795 616 Jan. 28, 1998 616 RTA00000188AF.m.07.1 M00003798D:E03 23183 617 Jan. 28, 1998 617 RTA00000179AF.d.13.3 M00001394A:F01 6583 618 Jan. 28, 1998 618 RTA00000192AF.a.14.1 M00004111D:A08 6874 619 Jan. 28, 1998 619 RTA00000201F.g.08.1 M00004692A:E07 0 620 Jan. 28, 1998 620 RTA00000201R.g.08.1 M00004692A:E07 0 621 Jan. 28, 1998 621 RTA00000201R.g.08.2 M00004692A:E07 0 622 Jan. 28, 1998 622 RTA00000186AR.m.14.2 M00001649B:G12 9800 623 Jan. 28, 1998 623 RTA00000198R.b.24.1 M00001571D:B11 19047 624 Jan. 28, 1998 624 RTA00000200F.c.15.1 M00004275A:B03 7866 625 Jan. 28, 1998 625 RTA00000196AF.c.19.1 M00001352C:G09 5935 626 Jan. 28, 1998 626 RTA00000185AR.d.11.1 M00001579D:C03 6539 627 Jan. 28, 1998 627 RTA00000199F.h.15.2 M00003870A:C05 22269 628 Jan. 28, 1998 628 RTA00000198AF.g.16.1 M00001621D:D03 6602 629 Jan. 28, 1998 629 RTA00000199R.m.23.1 M00003945A:E09 40166 630 Jan. 28, 1998 630 RTA00000183AR.g.03.2 M00001512D:G09 3956 631 Jan. 28, 1998 631 RTA00000200AF.h.19.2 M00004151D:E03 0 632 Jan. 28, 1998 632 RTA00000183AR.g.03.1 M00001512D:G09 3956 633 Jan. 28, 1998 633 RTA00000197F.i.8.1 M00001488A:E01 6292 634 Jan. 28, 1998 634 RTA00000192AF.j.6.1 M00004172C:D08 11494 635 Jan. 28, 1998 635 RTA00000181AF.p.7.3 M00001460A:E01 38773 636 Jan. 28, 1998 636 RTA00000196F.k.20.1 M00001402B:F12 6324 637 Jan. 28, 1998 637 RTA00000200AF.g.15.1 M00004135B:G01 22898 638 Jan. 28, 1998 638 RTA00000193AF.l.05.2 M00004348A:A02 2815 639 Jan. 28, 1998 639 RTAC0000199AF.j.1.1 M00003881C:G09 6006 640 Jan. 28, 1998 640 RTA00000190AF.f.5.1 M00003909A:H04 5015 641 Jan. 28, 1998 641 RTA00000198F.a.10.1 M00001558A:E11 6695 642 Jan. 28, 1998 642 RTA00000189AF.i.14.1 M00003868B:G11 0 643 Jan. 28, 1998 643 RTA00000184AF.c.9.1 M00001546C:G10 16245 644 Jan. 28, 1998 644 RTA00000197F.i.12.1 M00001489B:A06 3605 645 Jan. 28, 1998 645 RTA00000177AF.k.9.1 M00001352A:E02 16245 646 Jan. 28, 1998 646 RTA00000186AF.d.24.1 M00001623C:H07 3114 647 Jan. 28, 1998 647 RTA00000197F.m.11.1 M00001530B:D10 16488 648 Jan. 28, 1998 648 RTA00000199F.i.9.1 M00003878C:E04 7 649 Jan. 28, 1998 649 RTA00000190AR.l.19.2 M00003946A:H10 88204 650 Jan. 28, 1998 650 RTA00000183AR.n.17.1 M00001539B:H06 9800 651 Jan. 28, 1998 651 RTA00000189AR.d.22.2 M00003844C:B11 6539 652 Jan. 28, 1998 652 RTA00000178AR.m.21.4 M00001385A:F12 7861 653 Jan. 28, 1998 653 RTA00000178AR.m.21.5 M00001385A:F12 7861 654 Jan. 28, 1998 654 RTA00000186AF.j.21.2 M00001639D:B07 22506 655 Jan. 28, 1998 655 RTA00000186AF.g.8.2 M00001630B:A11 8065 656 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 657 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 658 Jan. 28, 1998 658 RTA00000193AF.a.1.1 M00004216D:C03 16501 659 Jan. 28, 1998 659 RTA00000185AR.k.23.2 M00001601A:E09 0 660 Jan. 28, 1998 660 RTA00000197AF.p.16.1 M00001552D:G08 6013 661 Jan. 28, 1998 661 RTA00000198R.b.04.1 M00001565A:H09 0 662 Jan. 28, 1998 662 RTA00000201R.a.15.1 M000043128:H07 57347 663 Jan. 28, 1998 663 RTA00000199F.g.21.2 M00003861C:H02 34826 664 Jan. 28, 1998 664 RTA00000195R.a.23.1 M00001449C:H12 86432 665 Jan. 28, 1998 665 RTA00000197AF.l.22.1 M00001528A:C11 6962 666 Jan. 28, 1998 666 RTA00000198F.i.10.1 M00001640B:F03 12792 667 Jan. 28, 1998 667 RTA00000197AF.d.16.1 M00001452A:E07 23505 668 Jan. 28, 1998 668 RTA00000178AF.i.17.1 M00001377C:E12 0 669 Jan. 28, 1998 669 RTA00000192AF.c.2.1 M00004121B:G01 0 670 Jan. 28, 1998 670 RTA00000186AF.p.17.3 M00001656B:A07 38383 671 Jan. 28, 1998 671 RTA00000185AR.d.08.1 M00001579C:E09 6562 672 Jan. 28, 1998 672 RTA00000196AF.h.09.1 M00001382B:F12 8015 673 Jan. 28, 1998 673 RTA00000199F.m.3.1 M00003931B:A11 0 674 Jan. 28, 1998 674 RTA00000197AR.e.24.1 M00001456B:F10 39250 675 Jan. 28, 1998 675 RTA00000179AR.b.21.3 M00001392C:D05 4366 676 Jan. 28, 1998 676 RTA00000197AR.m.14.1 M00001531B:E09 14879 677 Jan. 28, 1998 677 RTA00000197AF.i.19.1 M00001490B:H11 39554 678 Jan. 28, 1998 678 RTA00000190AF.j.3.1 M00003922A:D02 2705 679 Jan. 28, 1998 679 RTA00000197AF.d.11.1 M00001451C:E01 27260 680 Jan. 28, 1998 680 RTA00006177AF.f.10.1 M00001345A:E01 6420 681 Jan. 28, 1998 681 RTA00000180AF.l.04.2 M00001432D:F05 11159 682 Jan. 28, 1998 682 RTA00000125A.j.16.1 M00001544A:E06 0 683 Jan. 28, 1998 683 RTA00000187AR.j.01.1 M00001679C:D01 79028 684 Jan. 28, 1998 684 RTA00000200AR.b.11.1 M00004040A:G12 12043 685 Jan. 28, 1998 685 RTA00000200F.i.9.1 M00004159C:F09 36756 686 Jan. 28, 1998 686 RTA00000201F.f.07.1 M00004497A:H03 51116 687 Jan. 28, 1998 687 RTA00000197AF.g.4.1 M00001464B:B03 8821 688 Jan. 28, 1998 688 RTA00000193AF.g.3.1 M00004050D:A06 5567 689 Jan. 28, 1998 689 RTA00000197AF.o.4.1 M00001542B:C06 4121 690 Jan. 28, 1998 690 RTA00000198R.l.21.1 M00601673A:A04 19194 691 Jan. 28, 1998 691 RTA00000195F.a.10.1 M00001401C:H03 6803 692 Jan. 28, 1998 692 RTA00000199F.e.4.1 M00003820B:C05 0 693 Jan. 28, 1998 693 RTA00000198F.m.12.1 M00001679C:D05 4 694 Jan. 28, 1998 694 RTA00000201R.c.19.1 M00004370A:G05 22357 695 Jan. 28, 1998 695 RTA00000197F.m.5.1 M00001528C:H04 10872 696 Jan. 28, 1998 696 RTA00000180AR.d.16.3 M00001419D:C10 11393 697 Jan. 28, 1998 697 RTA00000193AF.e.21.1 M00004271B:B06 0 698 Jan. 28, 1998 698 RTA00000179AF.g.1.3 M00001397C:A10 7588 699 Jan. 28, 1998 699 RTA00000178AF.a.12.1 M00001362B:H06 0 700 Jan. 28, 1998 700 RTA00000183AF.i.18.2 M00001529D:H02 40129 701 Jan. 28, 1998 701 RTA00000199AF.o.10.1 M00003974C:E04 0 702 Jan. 28, 1998 702 RTA00000177AR.b.8.5 M00001340B:A06 17062 703 Jan. 28, 1998 703 RTA00000198F.l.09.1 M00001664B:D06 3611 704 Jan. 28, 1998 704 RTA00000190AF.o.12.1 M00003972D:C09 3438 705 Jan. 28, 1998 705 RTA00000196F.i.5.1 M00001387B:A06 0 706 Jan. 28, 1998 706 RTA00000177AF.i.6.4 M00001350A:B08 0 707 Jan. 28, 1998 707 RTA00000179AF.p.15.1 M00001411D:F05 5622 708 Jan. 28, 1998 708 RTA00000201F.f.06.1 M00004496C:H03 23771 709 Jan. 28, 1998 709 RTA00000192AF.d.18.1 M00004135D:G02 0 710 Jan. 28, 1998 710 RTA00000196AF.l.3.1 M00001405B:D07 20864 711 Jan. 28, 1998 711 RTA00000198F.i.2.1 M00001637B:E07 8076 712 Jan. 28, 1998 712 RTA00000201F.b.21.1 M00004341B:G03 9071 713 Jan. 28, 1998 713 RTA00000198AF.g.21.1 M00001624A:F09 6273 714 Jan. 28, 1998 714 RTA00000199R.g.07.1 M00003853D:D03 0 715 Jan. 28, 1998 715 RTA00000197AR.k.11.1 M00001500D:E10 53758 716 Jan. 28, 1998 716 RTA00000200F.p.05.1 M00004285C:A08 3984 717 Jan. 28, 1998 717 RTA00000200F.o.10.2 M00004269B:C08 36432 718 Jan. 28, 1998 718 RTA00000196F.l.14.2 M00001408B:G06 23144 719 Jan. 28, 1998 719 RTA00000183AF.b.12.1 M00001500A:B02 0 720 Jan. 28, 1998 720 RTA00000197AF.f.14.1 M00001459B:C09 3732 721 Jan. 28, 1998 721 RTA00000180AF.c.4.1 M00001417B:C04 5415 722 Jan. 28, 1998 722 RTA00000199R.j.24.1 M00003895C:A10 0 723 Jan. 28, 1998 723 RTA00000183AF.p.24.1 M00001543C:F01 3116 724 Jan. 28, 1998 724 RTA00000177AR.f.15.4 M00001345B:E10 9062 725 Jan. 28, 1998 725 RTA00000197AF.b.1.1 M00001441D:E04 12134 726 Jan. 28, 1998 726 RTA00000200R.f.10.1 M00004111D:B07 4 727 Jan. 28, 1998 727 RTA00000184AF.n.12.2 M00001561D:C11 3727 728 Jan. 28, 1998 728 RTA00000177AR.f.17.4 M00001345C:B01 8594 729 Jan. 28, 1998 729 RTA00000184AF.a.19.1 M00001544C:C06 2628 730 Jan. 28, 1998 730 RTA00000192AF.o.11.1 M00004205D:F06 0 731 Jan. 28, 1998 731 RTA00000184F.k.02.1 M00001557B:H10 5192 732 Jan. 28, 1998 732 RTA00000186AF.p.01.2 M00001654D:G11 40440 733 Jan. 28, 1998 733 RTA00000200AF.d.20.1 M00004087A:G08 26600 734 Jan. 28, 1998 734 RTA00000200AF.d.21.1 M00004087C:D03 0 735 Jan. 28, 1998 735 RTA00000192AF.b.11.1 M00004117A:G01 40014 736 Jan. 28, 1998 736 RTA00000196AF.o.13.1 M00001428B:A09 0 737 Jan. 28, 1998 737 RTA00000189AR.m.9.1 M00003880B:C08 2917 738 Jan. 28, 1998 738 RTA00000183AF.o.8.1 M00001540C:B10 8927 739 Jan. 28, 1998 739 RTA00000181AF.p.12.3 M00001460C:H02 22204 740 Jan. 28, 1998 740 RTA00000198AF.d.15.1 M00001590C:H08 5997 741 Jan. 28, 1998 741 RTA00000196AF.n.22.1 M00001424B:H04 9572 742 Jan. 28, 1998 742 RTA00000177AF.m.1.1 M00001353D:D10 14929 743 Jan. 28, 1998 743 RTA00000178AF.k.9.1 M00001381B:F06 16342 744 Jan. 28, 1998 744 RTA00000196F.m.4.1 M00001413A:F03 7958 745 Jan. 28, 1998 745 RTA00000183AF.m.11.1 M00001536D:G02 8927 746 Jan. 28, 1998 746 RTA00000178AF.i.01.2 M00001376B:F03 4 747 Jan. 28, 1998 747 RTA00000190AF.c.6.1 M00003904D:D10 4780 748 Jan. 28, 1998 748 RTA00000198AF.b.24.1 M00001571D:B11 19047 749 Jan. 28, 1998 749 RTA00000178AR.i.13.4 M00001377B:H01 0 750 Jan. 28, 1998 750 RTA00000198AF.a.19.1 M00001561D:C05 0 751 Jan. 28, 1998 751 RTA00000179AF.c.4.3 M00001392D:B11 0 752 Jan. 28, 1998 752 RTA00000192AF.o.7.1 M00004204D:C03 5275 753 Jan. 28, 1998 753 RTA00000192AF.o.17.1 M00004208D:B10 5275 754 Jan. 28, 1998 754 RTA00000187AF.l.11.1 M00001681A:F03 4482 755 Jan. 28, 1998 755 RTA00000199F.c.21.2 M00003803C:D09 5070 756 Feb. 24, 1998 1 RTA00000404F.a.02.1 M00001589B:E12 9738 757 Feb. 24, 1998 2 RTA00000406F.d.16.1 M00003875C:G02 15040 758 Feb. 24, 1998 3 RTA00000420F.d.18.1 M00004105C:B05 63074 759 Feb. 24, 1998 4 RTA00000339F.i.20.1 M00001438D:C06 4356 760 Feb. 24, 1998 5 RTA00000408F.o.12.2 M00001572A:A10 78578 761 Feb. 24, 1998 6 RTA00000119A.j.15.1 M00001460A:E11 79623 762 Feb. 24, 1998 7 RTA00000413F.d.12.1 M00004088C:A12 66467 763 Feb. 24, 1998 8 RTA00000423F.i.12.1 M00003914D:E03 9118 764 Feb. 24, 1998 9 RTA00000406F.n.02.1 M00003918C:H10 15051 765 Feb. 24, 1998 10 RTA00000350R.c.12.1 M00001550D:A04 9728 766 Feb. 24, 1998 11 RTA00000411F.k.05.1 M00003850D:B05 64777 767 Feb. 24, 1998 12 RTA00000339F.b.17.1 M00001366D:E12 10020 768 Feb. 24, 1998 13 RTA00000406F.f.18.1 M00003879B:G02 38587 769 Feb. 24, 1998 14 RTA00000419F.b.09.1 M00001694C:F12 78128 770 Feb. 24, 1998 15 RTA00000419F.c.19.1 M00003820A:A08 64346 771 Feb. 24, 1998 16 RTA00000399F.a.02.1 M00001366D:C12 0 772 Feb. 24, 1998 17 RTA00000411F.m.15.1 M00003868D:B09 78014 773 Feb. 24, 1998 18 RTA00000420F.g.12.1 M00004895B:G04 0 774 Feb. 24, 1998 19 RTA00000123A.k.23.1 M00001533A:G05 80313 775 Feb. 24, 1998 20 RTA00000404F.m.04.2 M00001641A:A11 22720 776 Feb. 24, 1998 21 RTA00000411F.g.08.1 M00003822D:D04 45815 777 Feb. 24, 1998 22 RTA00000130A.m.15.1 M00001622A:H12 81630 778 Feb. 24, 1998 23 RTA00000411F.k.20.1 M00003854B:A07 64973 779 Feb. 24, 1998 24 RTA00000423F.l.09.1 M00004118A:H08 9752 780 Feb. 24, 1998 25 RTA00000418F.k.05.1 M00001637A:A06 73021 781 Feb. 24, 1998 26 RTA00000423F.h.18.1 M00003876C:D02 37972 782 Feb. 24, 1998 27 RTA00000420F.n.19.2 M00005259B:C01 0 783 Feb. 24, 1998 28 RTA00000422F.p.06.2 M00001661A:B11 39282 784 Feb. 24, 1998 29 RTA00000404F.n.16.2 M00001649C:D05 39095 785 Feb. 24, 1998 30 RTA00000411F.m.24.1 M00003870B:B08 77568 786 Feb. 24, 1998 31 RTA00000134A.j.10.1 M00001534A:G06 81383 787 Feb. 24, 1998 32 RTA00000409F.j.02.1 M00001611B:E06 76417 788 Feb. 24, 1998 33 RTA00000403F.j.15.1 M00001539B:G07 23840 789 Feb. 24, 1998 34 RTA00000411F.n.11.1 M00003875A:B01 77276 790 Feb. 24, 1998 35 RTA00000339F.i.13.1 M00001434A:B10 5970 791 Feb. 24, 1998 36 RTA00000414F.e.22.1 M00005257D:A06 0 792 Feb. 24, 1998 37 RTA00000406F.o.15.1 M00003988D:A08 37482 793 Feb. 24, 1998 38 RTA00000412F.g.04.2 M00003971B:B07 64457 794 Feb. 24, 1998 39 RTA00000187AF.l.7.1 M00001680D:F08 10539 795 Feb. 24, 1998 40 RTA00000352R.l.06.1 M00004187D:H06 40343 796 Feb. 24, 1998 41 RTA00000419F.b.12.1 M00003806B:C09 63148 797 Feb. 24, 1998 42 RTA00000423F.k.17.2 M00004038A:F02 37512 798 Feb. 24, 1998 43 RTA00000420F.g.04.1 M00004891B:B12 0 799 Feb. 24, 1998 44 RTA00000418F.k.14.1 M00001639A:H06 76133 800 Feb. 24, 1998 45 RTA00000409F.l.12.1 M00001615A:D06 26755 801 Feb. 24, 1998 46 RTA00000404F.c.20.1 M00001594A:D08 39088 802 Feb. 24, 1998 47 RTA00000423F.g.09.1 M00003904C:B06 38958 803 Feb. 24, 1998 48 RTA00000411F.b.24.1 M00001677B:A12 30041 804 Feb. 24, 1998 49 RTA00000406F.d.12.1 M00003875C:A01 38575 805 Feb. 24, 1998 50 RTA00000411F.f.02.1 M00003813A:D08 63386 806 Feb. 24, 1998 51 RTA00000129A.n.21.1 M00001604A:C11 79381 807 Feb. 24, 1998 52 RTA00000409F.m.12.1 M00001618B:D09 73490 808 Feb. 24, 1998 53 RTA00000410F.c.04.1 M00001633D:G09 74099 809 Feb. 24, 1998 54 RTA00000399F.o.01.1 M00001595C:E01 3055 810 Feb. 24, 1998 55 RTA00000406F.m.09.1 M00003914C:H05 26891 811 Feb. 24, 1998 56 RTA00000411F.b.06.1 M00001676C:A04 77884 812 Feb. 24, 1998 57 RTA00000409F.l.21.1 M00001615B:G07 73143 813 Feb. 24, 1998 58 RTA00000420F.m.18.1 M00005254D:A10 0 814 Feb. 24, 1998 59 RTA00000346F.j.08.1 M00003879B:A06 39951 815 Feb. 24, 1998 60 RTA00000413F.p.17.2 M00005136D:G06 0 816 Feb. 24, 1998 61 RTA00000410F.n.07.1 M00001662A:G01 78823 817 Feb. 24, 1998 62 RTA00000339F.n.10.1 M00001453B:F08 13719 818 Feb. 24, 1998 63 RTA00000404F.l.20.2 M00001639B:H05 38638 819 Feb. 24, 1998 64 RTA00000413F.d.18.1 M00004090B:B04 65305 820 Feb. 24, 1998 65 RTA00000404F.p.04.2 M00001652D:E05 39069 821 Feb. 24, 1998 66 RTA00000405F.g.19.2 M00001673A:G08 37150 822 Feb. 24, 1998 67 RTA00000409F.a.22.1 M00001583B:F02 75200 823 Feb. 24, 1998 68 RTA00000339F.n.03.1 M00001449B:B03 0 824 Feb. 24, 1998 69 RTA00000405F.o.18.1 M00003839A:D07 11016 825 Feb. 24, 1998 70 RTA00000409F.m.13.1 M00001618B:E05 0 826 Feb. 24, 1998 71 RTA00000120A.d.24.1 M00001464A:E10 5085 827 Feb. 24, 1998 72 RTA00000347F.a.08.1 M00001592C:G04 3135 828 Feb. 24, 1998 73 RTA00000413F.p.15.2 M00005136D:D06 0 829 Feb. 24, 1998 74 RTA00000408F.e.22.2 M00001476B:F08 26930 830 Feb. 24, 1998 75 RTA00000350R.i.22.1 M00001608B:A03 0 831 Feb. 24, 1998 76 RTA00000413F.d.16.1 M00004088C:F01 63331 832 Feb. 24, 1998 77 RTA00000420F.j.22.1 M00005173B:F01 0 833 Jan. 28, 1998 59 RTA00000195AF.b.13.1 M00001560D:A03 12605 833 Feb. 24, 1998 78 RTA00000195AF.b.13.1 M00001560D:A03 12605 834 Feb. 24, 1998 79 RTA00000419F.g.08.1 M00003842C:D11 66700 835 Feb. 24, 1998 80 RTA00000122A.g.16.1 M00001514A:B04 81366 836 Feb. 24, 1998 81 RTA00000419F.c.16.1 M00003819D:B01 65254 837 Feb. 24, 1998 82 RTA00000411F.b.03.1 M00001676B:E01 23634 838 Feb. 24, 1998 83 RTA00000405F.e.11.2 M00001663D:C06 9331 839 Feb. 24, 1998 84 RTA00000352R.i.15.1 M00004153B:B03 4363 840 Feb. 24, 1998 85 RTA00000339F.k.22.1 M00001427C:D01 5556 841 Feb. 24, 1998 86 RTA00000346F.g.22.1 M00003794D:G03 6371 842 Feb. 24, 1998 87 RTA00000403F.l.20.1 M00001573A:A06 18267 843 Feb. 24, 1998 88 RTA00000420F.i.24.1 M00005134B:E08 0 844 Feb. 24, 1998 89 RTA00000406F.c.08.1 M00003870C:A10 22387 845 Feb. 24, 1998 90 RTA00000411F.a.02.1 M00001675B:E02 78537 846 Feb. 24, 1998 91 RTA00000355R.e.15.1 M00004316A:G09 22639 847 Feb. 24, 1998 92 RTA00000412F.l.04.1 M00003989D:F12 66372 848 Feb. 24, 1998 93 RTA00000413F.p.24.1 M00005139A:H03 0 849 Feb. 24, 1998 94 RTA00000406F.a.23.1 M00003867B:D10 38712 850 Feb. 24, 1998 95 RTA00000423F.h.05.1 M00003906A:F04 14837 851 Feb. 24, 1998 96 RTA00000120A.n.19.3 M00001467A:H07 80004 852 Feb. 24, 1998 97 RTA00000403F.e.01.1 M00001473A:C11 38965 853 Feb. 24, 1998 98 RTA00000411F.l.03.1 M00003854D:A12 62702 854 Feb. 24, 1998 99 RTA00000420F.m.19.1 M00005254D:B08 0 855 Feb. 24, 1998 100 RTA00000339F.o.23.1 M00001473C:D09 7801 856 Feb. 24, 1998 101 RTA00000121A.m.2.1 M00001507A:A11 81064 857 Feb. 24, 1998 102 RTA00000420F.g.06.1 M00004891C:D04 0 858 Feb. 24, 1998 103 RTA00000418F.j.12.1 M00001626C:G08 73316 859 Feb. 24, 1998 104 RTA00000421F.n.03.1 M00001675C:A04 1638 860 Feb. 24, 1998 105 RTA00000346F.d.08.1 M00001671A:A10 39955 861 Feb. 24, 1998 106 RTA00000339F.f.11.1 M00001391C:H02 5832 862 Feb. 24, 1998 107 RTA00000125A.g.16.1 M00001544A:C09 21497 863 Feb. 24, 1998 108 RTA00000418F.o.18.1 M00001661B:F06 78676 864 Feb. 24, 1998 109 RTA00000422F.p.24.2 M00001658A:G09 5823 865 Feb. 24, 1998 110 RTA00000408F.k.14.1 M00001486B:E12 73856 866 Feb. 24, 1998 111 RTA00000128A.i.20.1 M00001560A:F03 9900 867 Feb. 24, 1998 112 RTA00000422F.c.11.1 M00003841D:A04 2643 868 Feb. 24, 1998 113 RTA00000401F.e.02.1 M00003805B:C04 0 869 Feb. 24, 1998 114 RTA00000341F.m.21.1 M00004051D:E01 0 870 Feb. 24, 1998 115 RTA00000418F.h.19.1 M00001590B:C05 0 871 Feb. 24, 1998 116 RTA00000403F.o.15.1 M00001582B:E12 39140 872 Feb. 24, 1998 117 RTA00000341F.m.13.1 M00003987B:E12 26502 873 Feb. 24, 1998 118 RTA00000408F.h.03.1 M00001479D:H03 78382 874 Feb. 24, 1998 119 RTA00000423F.k.05.1 M00004036D:F02 37472 875 Feb. 24, 1998 120 RTA00000401F.m.02.1 M00003907A:F01 1573 876 Feb. 24, 1998 121 RTA00000418F.p.19.1 M00001677D:B01 78544 877 Feb. 24, 1998 122 RTA00000420F.f.06.1 M00004115D:D08 64812 878 Feb. 24, 1998 123 RTA00000122A.j.18.1 M00001516A:D05 81317 879 Feb. 24, 1998 124 RTA00000420F.d.05.1 M00004092B:E05 64432 880 Feb. 24, 1998 125 RTA00000403F.m.18.1 M00001576A:B09 39185 881 Feb. 24, 1998 126 RTA00000422F.j.20.1 M00001653A:G07 22388 882 Feb. 24, 1998 127 RTA00000411F.j.05.1 M00003841C:F06 40709 883 Feb. 24, 1998 128 RTA00000403F.a.04.1 M00001448A:B12 23529 884 Feb. 24, 1998 129 RTA00000118A.d.24.1 M00001416A:H02 81488 885 Feb. 24, 1998 130 RTA00000406F.f.12.1 M00003879A:C11 21895 886 Feb. 24, 1998 131 RTA00000418F.g.22.1 M00001585B:F01 74837 887 Feb. 24, 1998 132 RTA00000418F.m.05.1 M00001650B:C10 73600 888 Feb. 24, 1998 133 RTA00000404F.l.20.1 M00001639B:H05 38638 889 Feb. 24, 1998 134 RTA00000408F.i.08.2 M00001482A:H05 75811 890 Feb. 24, 1998 135 RTA00000122A.d.5.1 M00001513A:F05 81155 891 Feb. 24, 1998 136 RTA00000419F.l.12.1 M00003901C:B01 75710 892 Feb. 24, 1998 137 RTA00000339R.a.06.1 M00001346A:E04 58694 893 Feb. 24, 1998 138 RTA00000406F.f.03.1 M00003878C:D08 38687 894 Feb. 24, 1998 139 RTA00000419F.b.19.1 M00003809A:C01 65534 895 Feb. 24, 1998 140 RTA00000128A.j.6.2 M00001560A:H10 5316 896 Feb. 24, 1998 141 RTA00000418F.k.19.1 M00001639C:C02 74932 897 Feb. 24, 1998 142 RTA00000420F.j.19.1 M00005140C:B10 0 898 Feb. 24, 1998 143 RTA00000420F.h.13.1 M00004899D:G06 0 899 Feb. 24, 1998 144 RTA00000349R.f.15.1 M00001472A:D08 75097 900 Feb. 24, 1998 145 RTA00000419F.g.12.1 M00003842C:G03 66171 901 Feb. 24, 1998 146 RTA00000404F.n.11.2 M00001649A:E11 38001 902 Feb. 24, 1998 147 RTA00000422F.c.02.1 M00004118B:A03 2902 903 Feb. 24, 1998 148 RTA00000419F.n.04.1 M00003975C:F07 13102 904 Feb. 24, 1998 149 RTA00000419F.o.24.1 M00004031A:F07 65092 905 Feb. 24, 1998 150 RTA00000419F.k.19.1 M00003877C:G12 75447 906 Feb. 24, 1998 151 RTA00000341F.c.21.1 M00003789C:F06 7899 907 Feb. 24, 1998 152 RTA00000127A.i.20.1 M00001555A:B12 81418 908 Feb. 24, 1998 153 RTA00000422F.g.22.1 M00001585B:A06 22561 909 Feb. 24, 1998 154 RTA00000340F.b.21.1 M00001533D:A08 8001 910 Feb. 24, 1998 155 RTA00000413F.h.13.1 M00004107A:D01 65190 911 Feb. 24, 1998 156 RTA00000125A.k.1.1 M00001545A:B12 0 912 Feb. 24, 1998 157 RTA00000339F.a.23.1 M00001361B:C07 4022 913 Feb. 24, 1998 158 RTA00000348R.j.16.1 M00001410A:D07 7005 914 Feb. 24, 1998 159 RTA00000348R.j.17.1 M00001391D:C06 2641 915 Feb. 24, 1998 160 RTA00000414F.f.19.1 M00005260B:E11 0 916 Feb. 24, 1998 161 RTA00000418F.n.22.1 M00001659D:B05 79062 917 Feb. 24, 1998 162 RTA00000406F.l.08.1 M00003908D:D12 39016 918 Feb. 24, 1998 163 RTA00000422F.l.23.1 M00001616D:C11 4240 919 Feb. 24, 1998 164 RTA00000345F.k.06.1 M00001475A:A12 0 920 Feb. 24, 1998 165 RTA00000409F.j.07.1 M00001611C:H11 75190 921 Feb. 24, 1998 166 RTA00000418F.m.19.1 M00001654D:A03 8890 922 Feb. 24, 1998 167 RTA00000399F.l.14.1 M00001590B:G08 3354 923 Feb. 24, 1998 168 RTA00000411F.e.22.1 M00003812B:D07 63638 924 Feb. 24, 1998 169 RTA00000347F.a.17.1 M00001366D:C06 16723 925 Feb. 24, 1998 170 RTA00000422F.n.08.1 M00001632B:E05 38655 926 Feb. 24, 1998 171 RTA00000404F.n.20.1 M00001650A:C11 26865 927 Feb. 24, 1998 172 RTA00000420F.i.17.1 M00005101C:B09 0 928 Feb. 24, 1998 173 RTA00000418F.d.13.1 M00001570A:H01 74309 929 Feb. 24, 1998 174 RTA00000404F.b.02.1 M00001591B:B12 38984 930 Feb. 24, 1998 175 RTA00000410F.d.09.1 M00001635B:R01 76964 931 Feb. 24, 1998 176 RTA00000403F.b.10.1 M00001455C:G07 73268 932 Feb. 24, 1998 177 RTA00000406F.i.12.1 M00003903D:H11 39080 933 Feb. 24, 1998 178 RTA00000406F.h.08.1 M00003901C:A08 6228 934 Feb. 24, 1998 179 RTA00000418F.i.19.1 M00001596D:E03 79180 935 Feb. 24, 1998 180 RTA00000400F.j.19.1 M00001653C:D10 4086 936 Feb. 24, 1998 181 RTA00000412F.h.21.1 M00003974D:F02 64348 937 Feb. 24, 1998 182 RTA00000404F.g.14.1 M00001614D:B08 8858 938 Feb. 24, 1998 183 RTA00000120A.g.18.1 M00001465A:C12 81255 939 Feb. 24, 1998 184 RTA00000133A.j.13.1 M00001507A:B02 16846 940 Feb. 24, 1998 185 RTA00000423F.j.05.1 M00003903C:C05 37958 941 Feb. 24, 1998 186 RTA00000132A.k.6.1 M00001464A:E07 81284 942 Feb. 24, 1998 187 RTA00000351R.g.11.1 M00003779D:E08 3077 943 Feb. 24, 1998 188 RTA00000406F.p.04.1 M00004030D:F11 37458 944 Feb. 24, 1998 189 RTA00000347F.a.13.1 M00001402D:F02 22446 945 Feb. 24, 1998 190 RTA00000419F.p.23.1 M00004039B:A05 64748 946 Feb. 24, 1998 191 RTA00000419F.d.17.1 M00003828B:F09 64353 947 Feb. 24, 1998 192 RTA00000421F.k.15.1 M00001613D:B03 2222 948 Feb. 24, 1998 193 RTA00000347F.b.10.1 M00001546C:C07 8044 949 Feb. 24, 1998 194 RTA00000124A.k.5.1 M00001538A:F12 80252 950 Feb. 24, 1998 195 RTA00000404F.h.22.1 M00001619C:C07 18735 951 Feb. 24, 1998 196 RTA00000418F.k.10.1 M00001639A:G07 74454 952 Feb. 24, 1998 197 RTA00000410F.o.05.1 M00001669A:B02 75262 953 Feb. 24, 1998 198 RTA00000339R.l.14.1 M00001452A:C07 19119 954 Feb. 24, 1998 199 RTA00000403F.m.13.2 M00001575D:A10 39077 955 Feb. 24, 1998 200 RTA00000339F.c.02.1 M00001381C:B08 12975 956 Feb. 24, 1998 201 RTA00000404F.l.09.1 M00001638B:E12 39176 957 Feb. 24, 1998 202 RTA00000419F.g.22.1 M00003845D:A09 64515 958 Feb. 24, 1998 203 RTA00000404F.g.21.1 M00001615C:A11 37947 959 Feb. 24, 1998 204 RTA00000351R.k.19.1 M00003841B:E03 936 960 Feb. 24, 1998 205 RTA00000138A.n.4.1 M00001624A:G11 21920 961 Feb. 24, 1998 206 RTA00000410F.b.15.1 M00001633C:F09 77100 962 Feb. 24, 1998 207 RTA00000414F.b.08.1 M00005212C:H02 0 963 Feb. 24, 1998 208 RTA00000419F.j.23.1 M00003871A:C11 74470 964 Feb. 24, 1998 209 RTA00000411F.j.02.1 M00003841C:D07 65310 965 Feb. 24, 1998 210 RTA00000419F.p.24.1 M00004039B:E12 63477 966 Feb. 24, 1998 211 RTA00000404F.a.19.1 M00001590B:C07 38624 967 Feb. 24, 1998 212 RTA00000408F.k.06.1 M00001485C:H10 78393 968 Feb. 24, 1998 213 RTA00000123A.f.3.1 M00001531A:H07 44017 969 Feb. 24, 1998 214 RTA00000404F.h.19.1 M00001619A:E05 8096 970 Feb. 24, 1998 215 RTA00000403F.j.18.1 M00001539D:E10 5790 971 Feb. 24, 1998 216 RTA00000420F.i.18.1 M00005101C:E09 0 972 Feb. 24, 1998 217 RTA00000399F.o.17.1 M00001599D:A09 1106 973 Feb. 24, 1998 218 RTA00000346F.e.13.1 M00001660B:D03 74653 974 Feb. 24, 1998 219 RTA00000419F.c.18.1 M00003819D:B11 41394 975 Feb. 24, 1998 220 RTA00000413F.k.02.1 M00004690A:G08 0 976 Feb. 24, 1998 221 RTA00000414F.f.13.1 M00005259D:H08 0 977 Feb. 24, 1998 222 RTA00000405F.e.09.1 M00001663C:F12 38978 978 Feb. 24, 1998 223 RTA00000404F.e.22.1 M00001610A:H05 11344 979 Feb. 24, 1998 224 RTA00000341F.g.21.1 M00003914C:F09 8823 980 Feb. 24, 1998 225 RTA00000414F.d.07.1 M00005229D:H09 0 981 Feb. 24, 1998 226 RTA00000125A.k.10.1 M00001545A:F02 81644 982 Feb. 24, 1998 227 RTA00000347F.c.06.1 M00001444D:C01 18846 983 Feb. 24, 1998 228 RTA00000411F.k.19.1 M00003852D:E08 64200 984 Feb. 24, 1998 229 RTA00000345F.i.09.1 M00001450A:D08 27250 985 Feb. 24, 1998 230 RTA00000423F.k.01.1 M00004034D:E09 40426 986 Feb. 24, 1998 231 RTA00000408F.d.06.1 M00001458D:C11 78997 987 Feb. 24, 1998 232 RTA00000128A.b.20.1 M00001558A:G09 79761 988 Feb. 24, 1998 233 RTA00000403F.i.08.1 M00001485C:B10 6176 989 Feb. 24, 1998 234 RTA00000195AF.d.4.1 M00003881D:D06 22766 989 Jan. 28, 1998 185 RTA00000195AF.d.4.1 M00003881D:D06 22766 990 Feb. 24, 1998 235 RTA00000126A.o.23.1 M00001551A:B10 6268 991 Feb. 24, 1998 236 RTA00000403F.h.12.1 M00001483C:G09 15205 992 Feb. 24, 1998 237 RTA00000119A.j.22.1 M00001460A:F07 80336 993 Feb. 24, 1998 238 RTA00000340F.j.12.1 M00001624A:B06 3277 994 Feb. 24, 1998 239 RTA00000346F.j.02.1 M00003832B:E01 5294 995 Feb. 24, 1998 240 RTA00000126A.n.7.2 M00001551A:D06 79557 996 Feb. 24, 1998 241 RTA00000339F.d.13.1 M00001395C:F11 0 997 Feb. 24, 1998 242 RTA00000404F.j.08.1 M00001629B:B08 39066 998 Feb. 24, 1998 243 RTA00000410F.c.14.1 M00001634A:H05 77809 999 Feb. 24, 1998 244 RTA00000120A.g.23.1 M00001465A:E10 81189 1000 Feb. 24, 1998 245 RTA00000195AF.d.20.1 M00004117A:D11 37574 1000 Jan. 28, 1998 87 RTA00000195AF.d.20.1 M00004117A:D11 37574 1001 Feb. 24, 1998 246 RTA00000414F.c.14.1 M00005218A:G05 0 1002 Feb. 24, 1998 247 RTA00000412F.j.17.1 M00003982C:G04 64071 1003 Feb. 24, 1998 248 RTA00000404F.k.24.1 M00001636A:C03 15256 1004 Feb. 24, 1998 249 RTA00000119A.j.10.1 M00001460A:C10 79646 1005 Feb. 24, 1998 250 RTA00000410F.o.12.1 M00001669A:G12 77376 1006 Feb. 24, 1998 251 RTA00000119A.i.9.1 M00001457A:G03 0 1007 Feb. 24, 1998 252 RTA00000412F.g.24.1 M00003973C:C03 28741 1008 Feb. 24, 1998 253 RTA00000400F.f.18.1 M00001637A:E10 3764 1009 Feb. 24, 1998 254 RTA00000341F.i.15.1 M00003986B:A08 5294 1010 Feb. 24, 1998 255 RTA00000419F.o.16.1 M00003989C:G05 62867 1011 Feb. 24, 1998 256 RTA00000404F.m.03.2 M00001640A:H02 11799 1012 Feb. 24, 1998 257 RTA00000411F.c.17.1 M00001678D:G03 77664 1013 Feb. 24, 1998 258 RTA00000406F.k.15.1 M00003907C:C04 38549 1014 Feb. 24, 1998 259 RTA00000406F.a.02.1 M00003855C:F10 37744 1015 Feb. 24, 1998 260 RTA00000414F.e.08.1 M00005236A:E04 0 1016 Feb. 24, 1998 261 RTA00000341F.b.06.1 M00003794A:E12 17008 1017 Feb. 24, 1998 262 RTA00000409F.n.14.1 M00001621B:G05 78190 1018 Feb. 24, 1998 263 RTA00000410F.p.17.1 M00001674D:C10 47425 1019 Feb. 24, 1998 264 RTA00000345F.j.08.1 M00001451B:A04 16731 1020 Feb. 24, 1998 265 RTA00000340F.k.16.1 M00001647B:C09 13157 1021 Feb. 24, 1998 266 RTA00000419F.g.15.1 M00003844D:A07 32519 1022 Feb. 24, 1998 267 RTA00000423F.a.19.1 M00001676D:A02 21396 1023 Feb. 24, 1998 268 RTA00000403F.e.23.1 M00001476A:D11 9626 1024 Feb. 24, 1998 269 RTA00000422F.e.08.1 M00001573A:E01 39020 1025 Feb. 24, 1998 270 RTA00000411F.d.15.1 M00001692A:B06 74890 1026 Feb. 24, 1998 271 RTA00000414F.e.16.1 M00005236B:H10 0 1027 Feb. 24, 1998 272 RTA00000411F.l.15.1 M00003857C:F11 66704 1028 Feb. 24, 1998 273 RTA00000400F.a.11.1 M00001612B:D11 0 1029 Feb. 24, 1998 274 RTA00000405F.e.08.1 M00001663C:F10 37916 1030 Feb. 24, 1998 275 RTA00000353R.j.24.1 M00001428B:D01 23089 1031 Feb. 24, 1998 276 RTA00000423F.a.18.1 M00001675A:G10 26761 1032 Feb. 24, 1998 277 RTA00000418F.o.06.1 M00001660C:D11 75930 1033 Feb. 24, 1998 278 RTA00000404F.c.10.1 M00001593B:E11 23534 1034 Feb. 24, 1998 279 RTA00000418F.i.21.1 M00001596D:E10 78728 1035 Feb. 24, 1998 280 RTA00000418F.p.15.1 M00001671C:C11 31066 1036 Feb. 24, 1998 281 RTA00000411F.l.13.1 M00003857C:C09 43114 1037 Feb. 24, 1998 282 RTA00000407F.a.24.1 M00004083A:E08 37560 1038 Feb. 24, 1998 283 RTA00000346F.n.06.1 M00004139C:A12 12439 1039 Feb. 24, 1998 284 RTA00000412F.l.21.1 M00004029C:G10 65183 1040 Feb. 24, 1998 285 RTA00000413F.i.02.1 M00004110D:A10 65857 1041 Feb. 24, 1998 286 RTA00000404F.i.19.1 M00001625B:C10 38698 1042 Feb. 24, 1998 287 RTA00000410F.n.09.1 M00001662C:A04 11736 1043 Feb. 24, 1998 288 RTA00000403F.a.11.1 M00001448C:F10 73109 1044 Feb. 24, 1998 289 RTA00000420F.n.08.1 M00005257A:H11 0 1045 Feb. 24, 1998 290 RTA00000411F.k.16.1 M00003852C:B06 64759 1046 Feb. 24, 1998 291 RTA00000405F.c.01.1 M00001657D:A04 19236 1047 Feb. 24, 1998 292 RTA00000423F.i.18.1 M00003918A:D08 14996 1048 Feb. 24, 1998 293 RTA00000403F.l.04.1 M00001571C:A04 39278 1049 Feb. 24, 1998 294 RTA00000405F.l.17.1 M00003805A:F02 17225 1050 Feb. 24, 1998 295 RTA00000406F.a.07.1 M00003856C:H09 26607 1051 Feb. 24, 1998 296 RTA00000347F.d.06.1 M00001457C:F02 39122 1052 Feb. 24, 1998 297 RTA00000419F.b.18.1 M00003808D:D08 67034 1053 Feb. 24, 1998 298 RTA00000406F.h.07.1 M00003901B:H04 38003 1054 Feb. 24, 1998 299 RTA00000405F.l.15.1 M00001694A:E03 19575 1055 Feb. 24, 1998 300 RTA00000406F.g.17.1 M00003881B:F10 37979 1056 Feb. 24, 1998 301 RTA00000401F.m.23.1 M00003914C:C02 2801 1057 Feb. 24, 1998 302 RTA00000356R.f.18.1 M00004692A:H10 0 1058 Feb. 24, 1998 303 RTA00000130A.h.22.1 M00001617A:D06 80933 1059 Feb. 24, 1998 304 RTA00000403F.n.18.2 M00001577D:H06 8811 1060 Feb. 24, 1998 305 RTA00000418F.p.06.1 M00001664A:F08 32628 1061 Feb. 24, 1998 306 RTA00000404F.d.13.1 M00001595D:A04 39036 1062 Feb. 24, 1998 307 RTA00000420F.l.12.2 M00005230B:H09 0 1063 Feb. 24, 1998 308 RTA00000353R.d.11.1 M00004692A:H08 0 1064 Feb. 24, 1998 309 RTA00000340F.n.01.1 M00001679A:G06 39081 1065 Feb. 24, 1998 310 RTA00000419F.d.06.1 M00003820B:D07 65496 1066 Feb. 24, 1998 311 RTA00000419F.n.09.1 M00003977C:A06 66070 1067 Feb. 24, 1998 312 RTA00000399F.i.08.1 M00001575D:B10 38927 1068 Feb. 24, 1998 313 RTA00000406F.g.07.1 M00003880C:E11 37925 1069 Feb. 24, 1998 314 RTA00000423F.g.13.1 M00003905A:E07 38028 1070 Feb. 24, 1998 315 RTA00000419F.p.12.1 M00004037A:E04 13767 1071 Feb. 24, 1998 316 RTA00000414F.a.02.1 M00005178D:H04 0 1072 Feb. 24, 1998 317 RTA00000195AF.b.21.1 M00001595B:A09 39055 1072 Jan. 28, 1998 602 RTA00000195AF.b.21.1 M00001595B:A09 39055 1073 Feb. 24, 1998 318 RTA00000403F.h.05.1 M00001482D:A04 39096 1074 Feb. 24, 1998 319 RTA00000420F.b.21.1 M00004088D:B10 65057 1075 Feb. 24, 1998 320 RTA00000422F.p.07.2 M00001661A:E06 39024 1076 Feb. 24, 1998 321 RTA00000339F.c.21.1 M00001389C:A08 5325 1077 Feb. 24, 1998 322 RTA00000339F.c.24.1 M00001364B:B06 5516 1078 Feb. 24, 1998 323 RTA00000421F.n.19.1 M00001679A:D10 16409 1079 Feb. 24, 1998 324 RTA00000340F.p.17.1 M00003750C:H05 0 1080 Feb. 24, 1998 325 RTA00000345F.k.21.1 M0b001464B:C11 40204 1081 Feb. 24, 1998 326 RTA00000419F.b.15.1 M00003806D:D11 43969 1082 Feb. 24, 1998 327 RTA00000405F.a.11.1 M00001655A:B11 39124 1083 Feb. 24, 1998 328 RTA00000423F.k.19.2 M00003985D:E10 17615 1084 Feb. 24, 1998 329 RTA00000413F.e.16.1 M00004093C:C02 63836 1085 Feb. 24, 1998 330 RTA00000403F.i.04.1 M00001485B:D09 8930 1086 Feb. 24, 1998 331 RTA00000404F.o.18.2 M00001651C:C05 39110 1087 Feb. 24, 1998 332 RTA00000409F.j.24.1 M00001611B:A09 76967 1088 Feb. 24, 1998 333 RTA00000399F.f.11.1 M00001487C:F01 40167 1089 Feb. 24, 1998 334 RTA00000408F.p.05.1 M00001575B:B02 9649 1090 Feb. 24, 1998 335 RTA00000413F.d.02.1 M00004087B:A12 66172 1091 Feb. 24, 1998 336 RTA00000340F.n.13.1 M00001688D:B10 17055 1092 Feb. 24, 1998 337 RTA00000340F.p.04.1 M00001679D:B02 78533 1093 Feb. 24, 1998 338 RTA00000411F.c.05.1 M00001677B:H06 73368 1094 Feb. 24, 1998 339 RTA00000403F.g.10.1 M00001481A:G06 20211 1095 Feb. 24, 1998 340 RTA00000408F.l.13.1 M00001530A:B12 4423 1096 Feb. 24, 1998 341 RTA00000412F.g.20.2 M00003972C:F08 25018 1097 Feb. 24, 1998 342 RTA00000404F.i.02.1 M00001619D:D10 39015 1098 Feb. 24, 1998 343 RTA00000422F.g.21.1 M00001583A:F07 17232 1099 Feb. 24, 1998 344 RTA00000403F.m.15.2 M00001575D:D12 26901 1100 Feb. 24, 1998 345 RTA00000412F.h.23.2 M00003974D:H04 65118 1101 Feb. 24, 1998 346 RTA00000418F.j.08.1 M00001626C:C11 73382 1102 Feb. 24, 1998 347 RTA00000125A.n.4.1 M00001546A:D08 81984 1103 Feb. 24, 1998 348 RTA00000412F.l.19.1 M00004029C:C05 65825 1104 Feb. 24, 1998 349 RTA00000404F.m.10.2 M00001641D:E02 779 1105 Feb. 24, 1998 350 RTA00000129A.p.3.1 M00001604A:B08 32644 1106 Feb. 24, 1998 351 RTA00000340F.p.20.1 M00003752B:C02 17008 1107 Feb. 24, 1998 352 RTA00000411F.a.10.1 M00001675C:G01 73073 1108 Feb. 24, 1998 353 RTA00000409F.n.17.1 M00001621C:C10 76725 1109 Feb. 24, 1998 354 RTA00000404F.c.03.2 M00001592C:F11 39198 1110 Feb. 24, 1998 355 RTA00000420F.a.19.1 M00004076A:D12 34192 1111 Feb. 24, 1998 356 RTA00000409F.m.24.1 M00001620D:H02 3942 1112 Feb. 24, 1998 357 RTA00000406F.n.16.1 M00003972A:G09 5660 1113 Feb. 24, 1998 358 RTA00000414F.e.06.1 M00005235A:A03 0 1114 Feb. 24, 1998 359 RTA00000420F.d.12.1 M00004096D:H03 64095 1115 Feb. 24, 1998 360 RTA00000409F.j.19.1 M00001613A:F03 73792 1116 Feb. 24, 1998 361 RTA00000422F.d.16.1 M00001570C:G03 39133 1117 Feb. 24, 1998 362 RTA00000418F.m.16.1 M00001653B:E06 74986 1118 Feb. 24, 1998 363 RTA00000405F.c.11.1 M00001659A:D12 39068 1119 Feb. 24, 1998 364 RTA00000404F.k.22.1 M00001635D:C12 39084 1120 Feb. 24, 1998 365 RTA00000418F.k.07.1 M00001637A:F10 75067 1121 Feb. 24, 1998 366 RTA00000403F.c.10.1 M00001456D:F05 75261 1122 Feb. 24, 1998 367 RTA00000401F.o.06.1 M00004029C:C12 2679 1123 Feb. 24, 1998 368 RTA00000346F.o.08.1 M00004149C:B02 0 1124 Feb. 24, 1998 369 RTA00000410F.m.05.1 M00001657B:B04 74964 1125 Feb. 24, 1998 370 RTA00000405F.i.20.1 M00001677A:G11 38532 1126 Feb. 24, 1998 371 RTA00000403F.j.17.1 M00001539D:B10 38563 1127 Feb. 24, 1998 372 RTA00000408F.p.24.1 M00001579A:E03 74286 1128 Feb. 24, 1998 373 RTA00000418F.k.18.1 M00001639C:A10 75385 1129 Feb. 24, 1998 374 RTA00000422F.m.04.1 M00001615B:A09 38702 1130 Feb. 24, 1998 375 RTA00000405F.g.16.2 M00001672D:D04 9021 1131 Feb. 24, 1998 376 RTA00000400F.k.22.1 M00001656A:B07 2512 1132 Feb. 24, 1998 377 RTA00000346F.i.01.1 M00003797A:D06 22260 1133 Feb. 24, 1998 378 RTA00000403F.a.07.1 M00001448B:F09 73559 1134 Feb. 24, 1998 379 RTA00000349R.j.07.1 M00001529B:C04 2642 1135 Feb. 24, 1998 380 RTA00000403F.b.19.1 M00001456B:A06 22327 1136 Feb. 24, 1998 381 RTA00000418F.m.23.1 M00001654D:F11 77195 1137 Feb. 24, 1998 382 RTA00000341F.h.10.1 M00003901B:G11 0 1138 Feb. 24, 1998 383 RTA00000404F.i.18.1 M00001621C:H12 21912 1139 Feb. 24, 1998 384 RTA00000422F.i.14.1 M00001487A:F10 39300 1140 Feb. 24, 1998 385 RTA00000418F.m.14.1 M00001651B:E06 75711 1141 Feb. 24, 1998 386 RTA00000406F.o.12.1 M00003986D:D02 37459 1142 Feb. 24, 1998 387 RTA00000411F.a.15.1 M00001675D:B08 73812 1143 Feb. 24, 1998 388 RTA00000411F.a.07.1 M00001675C:C03 74547 1144 Feb. 24, 1998 389 RTA00000411F.c.02.1 M00001677B:B04 72852 1145 Feb. 24, 1998 390 RTA00000355R.a.14.1 M00004187D:G09 10207 1146 Feb. 24, 1998 391 RTA00000130A.h.16.1 M00001617A:A08 80761 1147 Feb. 24, 1998 392 RTA00000410F.p.23.1 M00001675B:C01 73948 1148 Feb. 24, 1998 393 RTA00000418F.m.24.1 M00001654D:F12 77114 1149 Feb. 24, 1998 394 RTA00000420F.m.02.1 M00005233A:G08 0 1150 Feb. 24, 1998 395 RTA00000408F.j.19.2 M00001485C:C08 73752 1151 Feb. 24, 1998 396 RTA00000406F.e.21.1 M00003877D:G05 9090 1152 Feb. 24, 1998 397 RTA00000118A.d.17.1 M00001416A:D09 81921 1153 Feb. 24, 1998 398 RTA00000407F.b.04.1 M00004086D:B09 63221 1154 Feb. 24, 1998 399 RTA00000411F.e.07.1 M00003810C:A03 65008 1155 Feb. 24, 1998 400 RTA00000403F.f.08.1 M00001477A:G07 19107 1156 Feb. 24, 1998 401 RTA00000132A.c.11.1 M00001454A:G03 87278 1157 Feb. 24, 1998 402 RTA00000420F.e.16.1 M00004110A:E04 63639 1158 Feb. 24, 1998 403 RTA00000403F.d.22.1 M00001473A:A07 10692 1159 Feb. 24, 1998 404 RTA00000404F.b.11.1 M00001591D:F06 39079 1160 Feb. 24, 1998 405 RTA00000418F.k.17.1 M00001639C:A09 75390 1161 Feb. 24, 1998 406 RTA00000129A.k.12.1 M00001601A:A06 79322 1162 Feb. 24, 1998 407 RTA00000340R.m.07.1 M00001679D:F02 78415 1163 Feb. 24, 1998 408 RTA00000405F.d.14.1 M00001662A:C12 35209 1164 Feb. 24, 1998 409 RTA00000406F.f.11.1 M00003879A:B08 38601 1165 Feb. 24, 1998 410 RTA00000120A.h.5.1 M00001465A:G06 80344 1166 Feb. 24, 1998 411 RTA0000C420F.m.12.1 M00005234D:B04 0 1167 Feb. 24, 1998 412 RTA00000411F.g.06.1 M00003822D:C06 66065 1168 Feb. 24, 1998 413 RTA00000408F.d.16.1 M00001459B:D03 76318 1169 Feb. 24, 1998 414 RTA00000120A.p.18.1 M00001468A:C05 6478 1170 Feb. 24, 1998 415 RTA00000340R.f.05.1 M00001569B:G11 3202 1171 Feb. 24, 1998 416 RTA00000404F.c.19.1 M00001594A:D06 39026 1172 Feb. 24, 1998 417 RTA00000423F.l.02.1 M00003978C:A03 5639 1173 Feb. 24, 1998 418 RTA00000410F.a.01.1 M00001631D:B10 73354 1174 Feb. 24, 1998 419 RTA00000408F.h.08.1 M00001480A:D03 74575 1175 Feb. 24, 1998 420 RTA00000422F.b.16.1 M00003813B:A11 17045 1176 Feb. 24, 1998 421 RTA00000419F.f.10.1 M00003835D:G06 66193 1177 Feb. 24, 1998 422 RTA00000418F.l.04.1 M00001641C:D02 74140 1178 Feb. 24, 1998 423 RTA00000410F.a.16.1 M00001633A:E06 73548 1179 Feb. 24, 1998 424 RTA00000138A.e.13.1 M00001605A:E06 79608 1180 Feb. 24, 1998 425 RTA00000130A.b.5.1 M00001605A:E09 79579 1181 Feb. 24, 1998 426 RTA00000408F.j.15.2 M00001485B:F05 74759 1182 Feb. 24, 1998 427 RTA00000410F.m.20.1 M00001660B:E03 74285 1183 Feb. 24, 1998 428 RTA00000422F.f.14.1 M00001478B:D07 2036 1184 Feb. 24, 1998 429 RTA00000422F.c.17.1 M00004099D:F01 1360 1185 Feb. 24, 1998 430 RTA00000419F.e.04.1 M00003831C:G05 62963 1186 Feb. 24, 1998 431 RTA00000399F.j.15.1 M00001578C:G06 1261 1187 Feb. 24, 1998 432 RTA00000418F.g.05.1 M00001579C:H06 73075 1188 Feb. 24, 1998 433 RTA00000419F.n.02.1 M00003958B:H08 65963 1189 Feb. 24, 1998 434 RTA00000348R.b.16.1 M00001347B:H04 6510 1190 Feb. 24, 1998 435 RTA00000340F.b.02.1 M00001503C:G05 10185 1191 Feb. 24, 1998 436 RTA00000119A.m.15.1 M00001461A:E05 80989 1192 Feb. 24, 1998 437 RTA00000403F.m.20.2 M00001576A:F11 707 1193 Feb. 24, 1998 438 RTA00000195R.d.09.1 M00003981C:B04 8537 1194 Feb. 24, 1998 439 RTA00000413F.g.23.1 M00004103B:E09 40700 1195 Feb. 24, 1998 440 RTA00000403F.a.18.1 M00001448D:F12 75726 1196 Feb. 24, 1998 441 RTA00000404F.m.20.2 M00001647A:H08 39144 1197 Feb. 24, 1998 442 RTA00000347F.b.02.1 M00001450A:A02 39304 1198 Feb. 24, 1998 443 RTA00000414F.f.15.1 M00005260A:A12 0 1199 Feb. 24, 1998 444 RTA00000419F.h.04.1 M00003846A:D03 65034 1200 Feb. 24, 1998 445 RTA00000408F.d.12.1 M00001459B:A12 75782 1201 Feb. 24, 1998 446 RTA00000133A.m.19.2 M00001512A:G05 80167 1202 Feb. 24, 1998 447 RTA00000423F.b.04.3 M00001675D:E10 6311 1203 Feb. 24, 1998 448 RTA00000127A.a.3.1 M00001552A:H10 13232 1204 Feb. 24, 1998 449 RTA00000411F.j.16.1 M00003843A:E08 17237 1205 Feb. 24, 1998 450 RTA00000118A.a.23.1 M00001395A:H02 3500 1206 Feb. 24, 1998 451 RTA00000126A.o.22.1 M00001551A:A11 81752 1207 Feb. 24, 1998 452 RTA00000419F.n.13.1 M00003977D:A06 66026 1208 Feb. 24, 1998 453 RTA00000130A.h.13.1 M00001617A:A01 80790 1209 Feb. 24, 1998 454 RTA00000418F.n.19.1 M00001659C:F02 28761 1210 Feb. 24, 1998 455 RTA00000399F.d.23.1 M00001481B:A07 3310 1211 Feb. 24, 1998 456 RTA00000413F.o.06.1 M00005100A:B02 0 1212 Feb. 24, 1998 457 RTA00000411F.m.19.1 M00003868D:D11 74924 1213 Feb. 24, 1998 458 RTA00000130A.a.19.1 M00001605A:A06 0 1214 Feb. 24, 1998 459 RTA00000419F.k.06.1 M00003871D:A10 78493 1215 Feb. 24, 1998 460 RTA00000341F.j.12.1 M00003987C:G03 12195 1216 Feb. 24, 1998 461 RTA00000412F.d.16.1 M00003906B:H06 26829 1217 Feb. 24, 1998 462 RTA00000119A.j.23.1 M00001460A:G07 79835 1218 Feb. 24, 1998 463 RTA00000403F.o.22.1 M00001583A:D01 25076 1219 Feb. 24, 1998 464 RTA00000195AF.c.12.1 M00003818B:G12 37582 1219 Jan. 28, 1998 300 RTA00000195AF.c.12.1 M00003818B:G12 37582 1220 Feb. 24, 1998 465 RTA00000350R.p.18.1 M00001676B:F05 11460 1221 Feb. 24, 1998 466 RTA00000406F.i.24.1 M00003904D:B12 12767 1222 Feb. 24, 1998 467 RTA00000123A.n.13.2 M00001534A:D03 39167 1223 Feb. 24, 1998 468 RTA00000423F.c.19.1 M00001680B:E10 40472 1224 Feb. 24, 1998 469 RTA00000405F.g.24.1 M00001673D:D06 39076 1225 Feb. 24, 1998 470 RTA00000411F.j.06.1 M00003841C:H08 63545 1226 Feb. 24, 1998 471 RTA00000419F.c.11.1 M00003817B:C04 65504 1227 Feb. 24, 1998 472 RTA00000135A.f.14.2 M00001542A:G12 79969 1228 Feb. 24, 1998 473 RTA00000403F.a.05.1 M00001448A:E11 18808 1229 Feb. 24, 1998 474 RTA00000405F.e.17.1 M00001669A:C10 38662 1230 Feb. 24, 1998 475 RTA00000411F.d.05.1 M00001681C:A08 75812 1231 Feb. 24, 1998 476 RTA00000345F.h.01.1 M00001441B:D11 10834 1232 Feb. 24, 1998 477 RTA00000418F.d.03.1 M00001567B:G11 76824 1233 Feb. 24, 1998 478 RTA00000418F.h.08.1 M00001589B:E07 76401 1234 Feb. 24, 1998 479 RTA00000418F.m.10.1 M00001651A:H11 79110 1235 Feb. 24, 1998 480 RTA00000411F.i.15.1 M00003837C:G08 31612 1236 Feb. 24, 1998 481 RTA00000413F.i.23.1 M00004118B:F01 63073 1237 Feb. 24, 1998 482 RTA00000411F.e.24.1 M00003813A:B02 64781 1238 Feb. 24, 1998 483 RTA00000406F.g.22.1 M00003881D:C12 38590 1239 Feb. 24, 1998 484 RTA00000126A.n.13.2 M00001551A:H06 79735 1240 Feb. 24, 1998 485 RTA00000419F.a.02.1 M00001678A:F05 77993 1241 Feb. 24, 1998 486 RTA00000346F.l.13.1 M00003980B:C11 7542 1242 Feb. 24, 1998 487 RTA00000420F.g.05.1 M00004891B:D01 0 1243 Feb. 24, 1998 488 RTA00000339F.k.23.1 M00001429D:H12 0 1244 Feb. 24, 1998 489 RTA00000406F.j.19.1 M00003906A:F12 1685 1245 Feb. 24, 1998 490 RTA00000120A.d.15.1 M00001464A:B02 80533 1246 Feb. 24, 1998 491 RTA00000418F.f.21.1 M00001579B:F04 75157 1247 Feb. 24, 1998 492 RTA00000340F.o.18.1 M00001669D:C03 4261 1248 Feb. 24, 1998 493 RTA00000129A.d.1.2 M00001587A:F05 80058 1249 Feb. 24, 1998 494 RTA00000419F.k.12.1 M00003876C:F02 0 1250 Feb. 24, 1998 495 RTA00000400F.o.21.1 M00001669C:C08 16259 1251 Feb. 24, 1998 496 RTA00000419F.m.20.1 M00003914A:B07 76720 1252 Feb. 24, 1998 497 RTA00000350R.f.21.1 M00001610C:E07 22110 1253 Feb. 24, 1998 498 RTA00000406F.e.15.1 M00003877C:A11 39074 1254 Feb. 24, 1998 499 RTA00000126A.p.18.2 M00001552A:E10 80881 1255 Feb. 24, 1998 500 RTA00000411F.c.10.1 M00001678D:B11 73117 1256 Feb. 24, 1998 501 RTA00000414F.f.05.1 M00005257D:H11 0 1257 Feb. 24, 1998 502 RTA00000341F.d.08.1 M00003824C:D07 0 1258 Feb. 24, 1998 503 RTA00000420F.m.08.1 M00005233B:D04 0 1259 Feb. 24, 1998 504 RTA00000413F.d.05.1 M00004087C:A01 64788 1260 Feb. 24, 1998 505 RTA00000121A.o.3.1 M00001511A:A02 81437 1261 Feb. 24, 1998 506 RTA00000403F.f.09.1 M00001477B:C02 0 1262 Feb. 24, 1998 507 RTA00000420F.e.02.1 M00004107B:D07 40259 1263 Feb. 24, 1998 508 RTA00000420F.i.20.1 M00005101C:E12 0 1264 Feb. 24, 1998 509 RTA00000349R.g.10.1 M00001495B:B08 5777 1265 Feb. 24, 1998 510 RTA00000131A.g.16.2 M00001449A:F01 0 1266 Feb. 24, 1998 511 RTA00000341F.b.13.1 M00003762B:H09 0 1267 Feb. 24, 1998 512 RTA00000414F.c.16.1 M00005228A:B03 0 1268 Feb. 24, 1998 513 RTA00000126A.k.7.2 M00001550A:E07 79866 1269 Feb. 24, 1998 514 RTA00000404F.e.13.1 M00001608D:E09 12046 1270 Feb. 24, 1998 515 RTA00000419F.l.03.1 M00003879A:D02 79060 1271 Feb. 24, 1998 516 RTA00000339F.f.20.1 M00001399A:C03 6494 1272 Feb. 24, 1998 517 RTA00000P18A.a.2.1 M00001395A:A12 38067 1273 Feb. 24, 1998 518 RTA00000410F.m.18.1 M00001660B:A09 76365 1274 Feb. 24, 1998 519 RTA00000404F.l.10.1 M00001638B:F10 23136 1275 Feb. 24, 1998 520 RTA00000406F.c.20.1 M00003871D:G06 38578 1276 Feb. 24, 1998 521 RTA00000413F.b.14.1 M00004078A:C11 66591 1277 Feb. 24, 1998 522 RTA00000406F.c.18.1 M00003871C:F12 14368 1278 Feb. 24, 1998 523 RTA00000418F.j.09.1 M00001626C:D12 76352 1279 Feb. 24, 1998 524 RTA00000419F.f.23.1 M00003840D:H10 65002 1280 Feb. 24, 1998 525 RTA00000348R.d.24.1 M00001349B:G05 5774 1281 Feb. 24, 1998 526 RTA00000411F.a.05.1 M00001675B:H03 76699 1282 Feb. 24, 1998 527 RTA00000419F.m.21.1 M00003914A:E04 77947 1283 Feb. 24, 1998 528 RTA00000405F.n.16.1 M00003825B:B10 21503 1284 Feb. 24, 1998 529 RTA00000422F.o.19.2 M00001655C:E01 13084 1285 Feb. 24, 1998 530 RTA00000408F.n.02.2 M00001539A:E01 76993 1286 Feb. 24, 1998 531 RTA00000345F.n.12.1 M00001528A:C04 7337 1287 Feb. 24, 1998 532 RTA00000403F.a.24.1 M00001455B:A09 24128 1288 Feb. 24, 1998 533 RTA00000423F.e.11.1 M00003809B:E10 2566 1289 Feb. 24, 1998 534 RTA00000126A.g.7.1 M00001548A:H04 1902 1290 Feb. 24, 1998 535 RTA00000119A.g.7.1 M00001454A:F11 83580 1291 Feb. 24, 1998 536 RTA00000411F.i.02.1 M00003835B:H11 66975 1292 Feb. 24, 1998 537 RTA00000408F.l.09.1 M00001530A:A09 75487 1293 Feb. 24, 1998 538 RTA00000423F.g.04.1 M00003903D:C12 23012 1294 Feb. 24, 1998 539 RTA00000346F.m.15.1 M00004037B:C04 13553 1295 Feb. 24, 1998 540 RTA00000418F.i.18.1 M00001595C:B05 78024 1296 Feb. 24, 1998 541 RTA00000411F.h.15.1 M00003832A:A09 65160 1297 Feb. 24, 1998 542 RTA00000410F.i.19.1 M00001641B:C10 78988 1298 Feb. 24, 1998 543 RTA00000419F.k.24.1 M00003878C:G08 75596 1299 Feb. 24, 1998 544 RTA00000420F.l.21.2 M00005232A:H12 0 1300 Feb. 24, 1998 545 RTA00000420F.e.15.1 M00004110A:A10 20190 1301 Feb. 24, 1998 546 RTA00000409F.i.09.1 M00001610B:C07 75279 1302 Feb. 24, 1998 547 RTA00000419F.h.02.1 M00003845D:G08 63985 1303 Feb. 24, 1998 548 RTA00000413F.b.12.1 M00004077B:H11 64932 1304 Feb. 24, 1998 549 RTA00000121A.h.18.1 M00001471A:B04 16376 1305 Feb. 24, 1998 550 RTA00000411F.n.20.1 M00003875C:A09 75816 1306 Feb. 24, 1998 551 RTA00000340F.b.05.1 M00001513A:G07 0 1307 Feb. 24, 1998 552 RTA00000411F.n.12.1 M00003875A:C04 73308 1308 Feb. 24, 1998 553 RTA00000408F.j.12.2 M00001485B:C03 18226 1309 Feb. 24, 1998 554 RTA00000409F.i.03.1 M00001610A:E09 75968 1310 Feb. 24, 1998 555 RTA00000133A.d.22.1 M00001469A:G11 11797 1311 Feb. 24, 1998 556 RTA00000400F.i.11.1 M00001649C:H10 2587 1312 Feb. 24, 1998 557 RTA00000409F.j.05.1 M00001611C:C12 74128 1313 Feb. 24, 1998 558 RTA00000419F.m.04.1 M00003906C:C05 74367 1314 Feb. 24, 1998 559 RTA00000418F.k.03.1 M00001634D:G11 78901 1315 Feb. 24, 1998 560 RTA00000419F.d.16.1 M00003828B:E07 64357 1316 Feb. 24, 1998 561 RTA00000420F.e.10.1 M00004108D:G04 65899 1317 Feb. 24, 1998 562 RTA00000401F.j.17.1 M00003901B:C05 5483 1318 Feb. 24, 1998 563 RTA00000406F.b.08.1 M00003867D:A06 18258 1319 Feb. 24, 1998 564 RTA00000418F.k.08.1 M00001639A:C03 18259 1320 Feb. 24, 1998 565 RTA00000420F.k.17.2 M00005217B:A06 0 1321 Feb. 24, 1998 566 RTA00000414F.d.05.1 M00005229D:H03 0 1322 Feb. 24, 1998 567 RTA00000410F.c.02.1 M00001633D:D12 75055 1323 Feb. 24, 1998 568 RTA00000403F.m.03.1 M00001573D:D10 39179 1324 Feb. 24, 1998 569 RTA00000403F.h.18.1 M00001484C:A04 39241 1325 Feb. 24, 1998 570 RTA00000405F.n.13.1 M00003824A:G10 23810 1326 Feb. 24, 1998 571 RTA00000355R.c.14.1 M00004314B:G07 16837 1327 Feb. 24, 1998 572 RTA00000422F.l.03.1 M00001610D:D05 39147 1328 Feb. 24, 1998 573 RTA00000414F.c.23.1 M00005229B:G12 0 1329 Feb. 24, 1998 574 RTA00000403F.o.14.1 M00001579D:H09 38971 1330 Feb. 24, 1998 575 RTA00000345F.a.18.1 M00001351C:B06 5517 1331 Feb. 24, 1998 576 RTA00000401F.d.15.2 M00001693C:C12 5297 1332 Feb. 24, 1998 577 RTA00000419F.e.11.1 M00003833B:C12 36780 1333 Feb. 24, 1998 578 RTA00000127A.f.11.1 M00001554A:A08 81463 1334 Feb. 24, 1998 579 RTA00000413F.m.16.1 M00004898C:F03 0 1335 Feb. 24, 1998 580 RTA00000403F.o.07.1 M00001579C:A01 39037 1336 Feb. 24, 1998 581 RTA00000403F.d.19.1 M00001472C:A01 39243 1337 Feb. 24, 1998 582 RTA00000414F.e.14.1 M00005236B:F10 0 1338 Feb. 24, 1998 583 RTA00000406F.i.17.1 M00003904B:C03 37902 1339 Feb. 24, 1998 584 RTA00000418F.d.22.1 M00001573B:C06 75324 1340 Feb. 24, 1998 585 RTA00000340R.o.12.1 M00003746C:E02 53732 1341 Feb. 24, 1998 586 RTA00000125A.g.24.1 M00001544A:F05 80397 1342 Feb. 24, 1998 587 RTA00000130A.o.21.1 M00001623A:F04 80218 1343 Feb. 24, 1998 588 RTA00000420F.a.23.1 M00004078B:F12 42158 1344 Feb. 24, 1998 589 RTA00000411F.m.18.1 M00003868D:D09 75629 1345 Feb. 24, 1998 590 RTA00000407F.b.22.1 M00004108B:B02 37487 1346 Feb. 24, 1998 591 RTA00000409F.a.16.1 M00001583A:A05 73990 1347 Feb. 24, 1998 592 RTA00000421F.p.18.1 M00003877B:H10 750 1348 Feb. 24, 1998 593 RTA00000341F.k.12.1 M00004103C:D04 62985 1349 Feb. 24, 1998 594 RTA00000129A.c.18.2 M00001587A:B10 37216 1350 Feb. 24, 1998 595 RTA00000410F.d.10.1 M00001635B:H02 77561 1351 Feb. 24, 1998 596 RTA00000351R.i.03.1 M00003846B:D06 6874 1352 Feb. 24, 1998 597 RTA00000135A.l.1.2 M00001545A:B10 39426 1353 Feb. 24, 1998 598 RTA00000420F.b.18.1 M00004086D:G08 66136 1354 Feb. 24, 1998 599 RTA00000401F.k.14.1 M00003903A:H09 211 1355 Feb. 24, 1998 600 RTA00000406F.m.04.1 M00003914B:A11 14959 1356 Feb. 24, 1998 601 RTA00000403F.o.13.1 M00001579D:F04 39049 1357 Feb. 24, 1998 602 RTA00000411F.f.06.1 M00003813B:E09 64186 1358 Feb. 24, 1998 603 RTA00000399F.o.19.1 M00001607A:F11 2594 1359 Feb. 24, 1998 604 RTA00000351R.c.13.1 M00003747D:C05 11476 1360 Feb. 24, 1998 605 RTA00000403F.c.14.1 M00001457D:A07 0 1361 Feb. 24, 1998 606 RTA00000420F.l.20.2 M00005232A:C10 0 1362 Feb. 24, 1998 607 RTA00000420F.d.16.1 M00004103D:F10 64485 1363 Feb. 24, 1998 608 RTA00000404F.i.12.1 M00001620D:G11 39001 1364 Feb. 24, 1998 609 RTA00000404F.o.10.2 M00001651B:B12 16785 1365 Feb. 24, 1998 610 RTA00000419F.d.07.1 M00003820B:D10 21421 1366 Feb. 24, 1998 611 RTA00000404F.p.02.2 M00001652D:A06 39097 1367 Feb. 24, 1998 612 RTA00000125A.k.14.1 M00001545A:G05 79457 1368 Feb. 24, 1998 613 RTA00000122A.j.22.1 M00001516A:F06 81151 1369 Feb. 24, 1998 614 RTA00000406F.i.13.1 M00003904A:C04 37904 1370 Feb. 24, 1998 615 RTA00000135A.b.23.1 M00001538A:D12 35241 1371 Feb. 24, 1998 616 RTA00006423F.c.11.1 M00001677D:B02 0 1372 Feb. 24, 1998 617 RTA00000423F.f.23.1 M00003816C:E09 15390 1373 Feb. 24, 1998 618 RTA00000423F.l.04.1 M00004039B:G08 14320 1374 Feb. 24, 1998 619 RTA00000420F.b.04.1 M00004081A:E02 63820 1375 Feb. 24, 1998 620 RTA00000420F.a.07.1 M00004072C:F08 63405 1376 Feb. 24, 1998 621 RTA00000408F.i.18.2 M00001482C:D02 74410 1377 Feb. 24, 1998 622 RTA00000404F.l.07.1 M00001637C:C06 10798 1378 Feb. 24, 1998 623 RTA00000341F.j.05.1 M00003963D:B05 36177 1379 Feb. 24, 1998 624 RTA00000420F.a.16.1 M00004075D:C10 63345 1380 Feb. 24, 1998 625 RTA00000126A.h.22.2 M00001549A:F01 0 1381 Feb. 24, 1998 626 RTA00000410F.j.01.1 M00001641B:F12 73399 1382 Feb. 24, 1998 627 RTA00000408F.p.21.1 M00001579A:C03 77930 1383 Feb. 24, 1998 628 RTA00000412F.d.19.1 M00003907B:C03 75743 1384 Feb. 24, 1998 629 RTA00000352R.c.04.1 M00003924A:D08 71976 1385 Feb. 24, 1998 630 RTA00000413F.f.19.1 M00004100B:C07 65189 1386 Feb. 24, 1998 631 RTA00000411F.e.03.1 M00001694D:C12 73648 1387 Feb. 24, 1998 632 RTA00000191AF.j.14.1 M00004073A:H12 1002 1387 Jan. 28, 1998 387 RTA00000191AF.j.14.1 M00004073A:H12 1002 1388 Feb. 24, 1998 633 RTA00000341F.d.02.1 M00003797A:G03 4706 1389 Feb. 24, 1998 634 RTA00000418F.c.04.1 M00001487B:A11 41587 1390 Feb. 24, 1998 635 RTA00000418F.o.17.1 M00001661B:F03 79069 1391 Feb. 24, 1998 636 RTA00000418F.e.21.1 M00001577B:A03 74773 1392 Feb. 24, 1998 637 RTA00000419F.d.14.1 M00003828A:D05 64945 1393 Feb. 24, 1998 638 RTA00000418F.b.09.1 M00001478B:H08 19700 1394 Feb. 24, 1998 639 RTA00000414F.d.09.1 M00005231C:B01 0 1395 Feb. 24, 1998 640 RTA00000405F.f.02.1 M00001669B:G02 38665 1396 Feb. 24, 1998 641 RTA00000410F.j.20.1 M00001642D:G10 73601 1397 Feb. 24, 1998 642 RTA00000341F.h.19.1 M00003916C:C05 0 1398 Feb. 24, 1998 643 RTA00000420F.l.14.2 M00005230D:F06 0 1399 Feb. 24, 1998 644 RTA00000119A.j.9.1 M00001460A:B12 82060 1400 Feb. 24, 1998 645 RTA00000422F.p.12.2 M00001661C:F10 9840 1401 Feb. 24, 1998 646 RTA00000421F.m.14.1 M00001642A:F03 3524 1402 Feb. 24, 1998 647 RTA00000418F.b.23.1 M00001485A:C05 28767 1403 Feb. 24, 1998 648 RTA00000340F.i.13.1 M00001624B:B10 79299 1404 Feb. 24, 1998 649 RTA00000412F.g.03.1 M00003971B:A10 64740 1405 Feb. 24, 1998 650 RTA00000122A.g.17.1 M00001514A:B08 32655 1406 Feb. 24, 1998 651 RTA00000403F.g.11.1 M00001481A:H08 24238 1407 Feb. 24, 1998 652 RTA00000419F.n.12.1 M00003977D:A03 66086 1408 Feb. 24, 1998 653 RTA00000352R.m.12.1 M00004212B:C07 2379 1409 Feb. 24, 1998 654 RTA00000421F.a.05.1 M00001570C:G06 5278 1410 Feb. 24, 1998 655 RTA00000351R.p.14.1 M00003915C:H04 13166 1411 Feb. 24, 1998 656 RTA00000403F.e.08.1 M00001473D:B11 19126 1412 Feb. 24, 1998 657 RTA00000124A.k.20.1 M00001538A:C08 80913 1413 Feb. 24, 1998 658 RTA00000121A.n.2.1 M00001511A:A05 33585 1414 Feb. 24, 1998 659 RTA00000422F.m.24.1 M00001641D:C04 39159 1415 Feb. 24, 1998 660 RTA00000408F.e.24.2 M00001476:C11 75002 1416 Feb. 24, 1998 661 RTA00000341F.l.16.1 M00003986D:C08 8479 1417 Feb. 24, 1998 662 RTA00000339F.o.07.1 M00001473D:G01 2566 1418 Feb. 24, 1998 663 RTA00000403F.b.12.1 M00001455D:A06 78775 1419 Feb. 24, 1998 664 RTA00000404F.a.09.1 M00001589C:E06 38985 1420 Feb. 24, 1998 665 RTA00000419F.p.20.1 M00004039A:C03 9458 1421 Feb. 24, 1998 666 RTA00000403F.o.19.1 M00001582D:F02 78615 1422 Feb. 24, 1998 667 RTA00000405F.h.07.2 M00001674A:G11 4984 1423 Feb. 24, 1998 668 RTA00000408F.m.05.2 M00001530C:G10 23384 1424 Feb. 24, 1998 669 RTA00000410F.b.10.1 M00001633C:B09 74504 1425 Feb. 24, 1998 670 RTA0G000131A.i.6.1 M00001450A:B08 0 1426 Feb. 24, 1998 671 RTA00000413F.h.12.1 M00004107A:A12 66929 1427 Feb. 24, 1998 672 RTA00000406F.k.14.1 M00003907C:C02 38651 1428 Feb. 24, 1998 673 RTA00000406F.d.09.1 M00003875B:F12 38591 1429 Feb. 24, 1998 674 RTA00000411F.f.17.1 M00003814B:F12 65661 1430 Feb. 24, 1998 675 RTA00000411F.k.10.1 M00003850D:H11 64506 1431 Feb. 24, 1998 676 RTA00000411F.g.21.1 M00003823D:G05 64500 1432 Feb. 24, 1998 677 RTA00000119A.h.24.1 M00001457A:C05 82266 1433 Jan. 28, 1998 412 RTA00000195AF.c.24.1 M00003860D:H07 0 1433 Feb. 24, 1998 678 RTA00000195AF.c.24.1 M00003860D:H07 0 1434 Feb. 24, 1998 679 RTA00000408F.m.22.2 M00001539A:C12 72949 1435 Feb. 24, 1998 680 RTA00000345F.e.11.1 M00001391C:C04 4392 1436 Feb. 24, 1998 681 RTA00000120A.c.24.1 M00001464A:D03 34278 1437 Feb. 24, 1998 682 RTA00000410F.i.17.1 M00001641B:B01 78147 1438 Feb. 24, 1998 683 RTA00000403F.j.21.1 M00001540D:E02 24723 1439 Feb. 24, 1998 684 RTA00000339F.k.20.1 M00001426D:D12 6662 1440 Feb. 24, 1998 685 RTA00000129A.a.13.2 M00001582A:A03 79780 1441 Feb. 24, 1998 686 RTA00000129A.k.21.1 M00001601A:E12 82067 1442 Feb. 24, 1998 687 RTA00000350R.g.10.1 M00001587C:C10 9026 1443 Feb. 24, 1998 688 RTA00000413F.d.23.1 M00004090B:H06 66030 1444 Feb. 24, 1998 689 RTA00000419F.p.03.1 M00004035A:G10 1937 1445 Feb. 24, 1998 690 RTA00000341F.b.05.1 M00003793D:A11 0 1446 Feb. 24, 1998 691 RTA00000354R.n.08.1 M00003835A:A09 8802 1447 Feb. 24, 1998 692 RTA00000411F.d.10.1 M00001681D:C12 76445 1448 Feb. 24, 1998 693 RTA00000404F.b.19.1 M00001592B:A04 39281 1449 Feb. 24, 1998 694 RTA00000418F.c.07.1 M00601529D:C05 73245 1450 Feb. 24, 1998 695 RTA00000418F.j.15.1 M00001632C:H07 74855 1451 Feb. 24, 1998 696 RTA00000404F.p.12.2 M00001653B:C06 0 1452 Feb. 24, 1998 697 RTA00000412F.d.14.1 M00003905D:C08 76757 1453 Feb. 24, 1998 698 RTA00000413F.b.16.1 M00004078A:E05 65126 1454 Feb. 24, 1998 699 RTA00000340F.l.05.1 M00001644B:D06 38935 1455 Feb. 24, 1998 700 RTA00000350R.m.14.1 M00001644C:B07 39171 1456 Feb. 24, 1998 701 RTA00000418F.l.11.1 M00001641C:H07 77158 1457 Feb. 24, 1998 702 RTA00000130A.d.5.1 M00001605A:H03 82051 1458 Feb. 24, 1998 703 RTA00000339F.n.05.1 M00001449D:B01 39648 1459 Feb. 24, 1998 704 RTA00000355R.a.12.1 M00004159C:F09 36756 1460 Feb. 24, 1998 705 RTA00000407F.a.23.1 M00004081C:A10 23489 1461 Feb. 24, 1998 706 RTA00000403F.a.09.1 M00001448B:H05 77820 1462 Feb. 24, 1998 707 RTA00000403F.h.11.1 M00001483B:D04 39219 1463 Feb. 24, 1998 708 RTA00000406F.j.13.1 M00003905D:B08 38688 1464 Feb. 24, 1998 709 RTA00000352R.p.09.1 M00004228C:H03 16915 1465 Feb. 24, 1998 710 RTA00G00413F.g.24.1 M00004104D:A04 65481 1466 Feb. 24, 1998 711 RTA00000404F.l.03.2 M00001636B:G11 40272 1467 Feb. 24, 1998 712 RTA00000407F.b.18.1 M00004102C:D09 37569 1468 Feb. 24, 1998 713 RTA00000414F.b.10.1 M00005212D:D09 0 1469 Feb. 24, 1998 714 RTA00000420F.a.08.1 M00004073A:D10 19473 1470 Feb. 24, 1998 715 RTA00000418F.b.01.1 M00001475C:G11 76040 1471 Feb. 24, 1998 716 RTA00000420F.l.03.2 M00005217D:F12 0 1472 Feb. 24, 1998 717 RTA00000404F.i.22.1 M00001625C:G05 39082 1473 Feb. 24, 1998 718 RTA00000124A.k.23.1 M00001538A:D03 81350 1474 Feb. 24, 1998 719 RTA00000404F.e.11.1 M00001608C:E11 38991 1475 Feb. 24, 1998 720 RTA00000129A.d.2.4 M00001587A:G06 80119 1476 Feb. 24, 1998 721 RTA00000422F.k.14.1 M00001649D:A08 0 1477 Feb. 24, 1998 722 RTA00000411F.l.22.1 M00003858B:G05 64439 1478 Feb. 24, 1998 723 RTA00000419F.o.15.1 M00003989C:D03 32487 1479 Feb. 24, 1998 724 RTA00000119A.m.17.1 M00001461A:F05 79536 1480 Feb. 24, 1998 725 RTA00000410F.b.07.1 M00001633C:A05 78916 1481 Feb. 24, 1998 726 RTA00000420F.b.19.1 M00004088D:A11 36873 1482 Feb. 24, 1998 727 RTA00000414F.d.02.1 M00005229B:H06 0 1483 Feb. 24, 1998 728 RTA00000411F.b.21.1 M00001677B:A02 10051 1484 Feb. 24, 1998 729 RTA00000403F.m.20.1 M00001576A:F11 707 1485 Feb. 24, 1998 730 RTA00000356R.c.16.1 M00004294C:C08 16915 1486 Feb. 24, 1998 731 RTA00000119A.d.17.1 M00001453A:B01 0 1487 Feb. 24, 1998 732 RTA00000412F.h.11.1 M00003974B:B11 63175 1488 Feb. 24, 1998 733 RTA00000405F.d.18.1 M00001662C:B02 10494 1489 Feb. 24, 1998 734 RTA00000414F.e.09.1 M00005236A:G10 0 1490 Feb. 24, 1998 735 RTA00000420F.a.11.1 M00004073C:D04 66460 1491 Feb. 24, 1998 736 RTA00000120A.c.7.1 M00001462A:D03 80985 1492 Feb. 24, 1998 737 RTA00000404F.e.15.1 M00001609B:C09 39101 1493 Feb. 24, 1998 738 RTA00000422F.n.20.1 M00001669B:B12 38676 1494 Feb. 24, 1998 739 RTA00000423F.h.20.1 M00003914A:G06 38639 1495 Feb. 24, 1998 740 RTA00000399F.l.19.1 M00001590D:G07 40145 1496 Feb. 24, 1998 741 RTA00000414F.b.12.1 M00005212D:H01 0 1497 Feb. 24, 1998 742 RTA00000410F.b.18.1 M00001633C:H11 76701 1498 Feb. 24, 1998 743 RTA00000345F.i.08.1 M00001449D:G10 0 1499 Feb. 24, 1998 744 RTA00000423F.g.15.1 M00003905A:F09 35173 1500 Feb. 24, 1998 745 RTA00000413F.b.04.1 M00004076D:H07 66427 1501 Feb. 24, 1998 746 RTA00000345F.e.02.1 M00001395A:E03 0 1502 Feb. 24, 1998 747 RTA00000413F.n.24.1 M00004960C:E10 0 1503 Feb. 24, 1998 748 RTA00000346F.f.11.1 M00003793C:D09 38528 1504 Feb. 24, 1998 749 RTA00000351R.i.13.1 M00003858D:F12 0 1505 Feb. 24, 1998 750 RTA00000403F.c.05.1 M00001456C:C11 74935 1506 Feb. 24, 1998 751 RTA00000422F.i.02.1 M00001456C:B12 76436 1507 Feb. 24, 1998 752 RTA00000410F.a.08.1 M00001632A:B10 73324 1508 Feb. 24, 1998 753 RTA00000345F.o.13.1 M00001546B:F12 11500 1509 Feb. 24, 1998 754 RTA00000419F.e.02.1 M00003830C:A03 65010 1510 Feb. 24, 1998 755 RTA00000423F.d.17.1 M00001663A:C11 20630 1511 Feb. 24, 1998 756 RTA00000403F.g.13.1 M00001481B:D09 38718 1512 Feb. 24, 1998 757 RTA00000423F.h.13.1 M00003871A:B09 14398 1513 Feb. 24, 1998 758 RTA00000407F.a.01.1 M00004039A:H11 12501 1514 Feb. 24, 1998 759 RTA00000399F.o.06.1 M00001595D:G03 13574 1515 Feb. 24, 1998 760 RTA00000423F.d.04.1 M00001694A:B12 11307 1516 Feb. 24, 1998 761 RTA00000411F.f.14.1 M00003814B:C12 62984 1517 Feb. 24, 1998 762 RTA00000411F.c.04.1 M00001677B:E06 76858 1518 Feb. 24, 1998 763 RTA00000135A.m.18.1 M00001545A:C03 19255 1519 Feb. 24, 1998 764 RTA00000413F.c.17.1 M00004085B:B05 36831 1520 Feb. 24, 1998 765 RTA00000137A.j.15.4 M00001559A:C08 4213 1521 Feb. 24, 1998 766 RTA00000404F.j.01.1 M00001625D:G10 26859 1522 Feb. 24, 1998 767 RTA00000138A.p.10.1 M00001644A:H01 81625 1523 Feb. 24, 1998 768 RTA00000121A.k.5.1 M00001507A:E04 17530 1524 Feb. 24, 1998 769 RTA00000340F.i.10.1 M00001618A:F10 38561 1525 Feb. 24, 1998 770 RTA00000421F.f.05.1 M00001477B:E02 5266 1526 Feb. 24, 1998 771 RTA00000423F.h.07.1 M00003911B:F08 37933 1527 Feb. 24, 1998 772 RTA00000413F.e.04.1 M00004090C:C07 64176 1528 Feb. 24, 1998 773 RTA00000406F.h.03.1 M00003901B:A09 38585 1529 Feb. 24, 1998 774 RTA00000403F.e.24.1 M00001476B:D10 16432 1530 Feb. 24, 1998 775 RTA00000405F.c.22.1 M00001660C:B06 39053 1531 Feb. 24, 1998 776 RTA00000403F.i.11.1 M00001485D:E05 23535 1532 Feb. 24, 1998 777 RTA00000419F.g.02.1 M00003842A:A03 62839 1533 Feb. 24, 1998 778 RTA00000347F.e.05.1 M00001578D:C04 39814 1534 Feb. 24, 1998 779 RTA00000408F.l.16.1 M00001530A:F12 73468 1535 Feb. 24, 1998 780 RTA00000405F.l.11.1 M00001693D:E08 2055 1536 Feb. 24, 1998 781 RTA00000423F.f.09.1 M00003808C:A05 64823 1537 Feb. 24, 1998 782 RTA00000419F.k.03.1 M00003871C:B05 40822 1538 Feb. 24, 1998 783 RTA00000406F.b.02.1 M00003867B:G08 38744 1539 Feb. 24, 1998 784 RTA00000418F.o.14.1 M00001661B:B05 33524 1540 Feb. 24, 1998 785 RTA00000404F.l.03.1 M00001636B:G11 40272 1541 Feb. 24, 1998 786 RTA00000404F.b.09.1 M00001591D:C07 39166 1542 Feb. 24, 1998 787 RTA00000345F.i.24.1 M00001449C:C05 0 1543 Feb. 24, 1998 788 RTA00000419F.i.04.1 M00003860B:F11 65791 1544 Feb. 24, 1998 789 RTA00000423F.b.13.1 M00001676C:E07 20619 1545 Feb. 24, 1998 790 RTA00000345F.n.08.1 M00001517A:B11 0 1546 Feb. 24, 1998 791 RTA00000399F.n.15.1 M00001594D:C03 3213 1547 Feb. 24, 1998 792 RTA00000406F.k.11.1 M00003907B:D05 38715 1548 Feb. 24, 1998 793 RTA00000414F.e.21.1 M00005257C:G01 0 1549 Feb. 24, 1998 794 RTA00000406F.c.06.1 M00003870C:A01 37924 1550 Feb. 24, 1998 795 RTA00000418F.n.07.1 M00001658B:A07 76316 1551 Feb. 24, 1998 796 RTA00000419F.n.15.1 M00003977D:D04 63484 1552 Feb. 24, 1998 797 RTA00000408F.n.06.2 M00001539A:H12 76642 1553 Feb. 24, 1998 798 RTA00000420F.c.04.1 M00004089A:B08 65007 1554 Feb. 24, 1998 799 RTA00000411F.j.15.1 M00003843A:E04 66871 1555 Feb. 24, 1998 800 RTA00000403F.m.12.1 M00001575D:A02 16933 1556 Feb. 24, 1998 801 RTA00000128A.m.23.1 M00001561A:D01 81441 1557 Feb. 24, 1998 802 RTA00000406F.g.03.1 M00003880B:D11 38690 1558 Feb. 24, 1998 803 RTA00000405F.h.05.2 M00001674A:G07 75706 1559 Feb. 24, 1998 804 RTA00000129A.n.24.1 M00001604A:C07 81409 1560 Feb. 24, 1998 805 RTA00000406F.j.08.1 M00003905B:C06 6688 1561 Feb. 24, 1998 806 RTA00000345F.f.08.1 M00001413B:H09 0 1562 Feb. 24, 1998 807 RTA00000418F.n.11.1 M00001658D:G12 78977 1563 Feb. 24, 1998 808 RTA00000418F.p.08.1 M00001669D:D06 73983 1564 Feb. 24, 1998 809 RTA00000420F.i.23.1 M00005134A:D11 0 1565 Feb. 24, 1998 810 RTA00000120A.h.9.1 M00001465A:B12 80736 1566 Feb. 24, 1998 811 RTA00000413F.a.12.1 M00004072D:F09 63403 1567 Feb. 24, 1998 812 RTA00000412F.o.05.1 M00004034A:A01 63575 1568 Feb. 24, 1998 813 RTA00000346F.o.06.1 M00004136D:B02 4937 1569 Feb. 24, 1998 814 RTA00000408F.l.24.1 M00001530B:G09 34263 1570 Feb. 24, 1998 815 RTA00000403F.a.17.1 M00001448D:E12 13686 1571 Feb. 24, 1998 816 RTA00000354R.n.04.1 M00003808C:B05 22049 1572 Feb. 24, 1998 817 RTA00000420F.l.08.2 M00005228C:C05 0 1573 Feb. 24, 1998 818 RTA00000406F.h.05.1 M00003901B:C03 38542 1574 Feb. 24, 1998 819 RTA00000410F.b.24.1 M00001633D:D09 75104 1575 Feb. 24, 1998 820 RTA00000423F.d.11.1 M00001678C:C06 38950 1576 Feb. 24, 1998 821 RTA00000420F.h.16.1 M00004927A:E06 0 1577 Feb. 24, 1998 822 RTA00000419F.o.21.1 M00004031A:E01 10336 1578 Feb. 24, 1998 823 RTA00000119A.k.1.1 M00001460A:H11 81282 1579 Feb. 24, 1998 824 RTA00000420F.f.07.1 M00004119A:C09 66312 1580 Feb. 24, 1998 825 RTA00000404F.k.22.2 M00001635D:C12 39084 1581 Feb. 24, 1998 826 RTA00000422F.e.07.1 M00001579C:G05 38964 1582 Feb. 24, 1998 827 RTA00000410F.f.12.1 M00001637C:E03 73883 1583 Feb. 24, 1998 828 RTA00000419F.n.05.1 M00003976C:D06 63713 1584 Feb. 24, 1998 829 RTA00000411F.m.11.1 M00003867A:D12 73196 1585 Feb. 24, 1998 830 RTA00000347F.b.08.1 M00001541B:E05 17591 1586 Feb. 24, 1998 831 RTA00000420F.d.21.1 M00004107B:B04 65313 1587 Feb. 24, 1998 832 RTA00000403F.o.10.2 M00001579C:G05 38964 1588 Feb. 24, 1998 833 RTA00000420F.j.20.1 M00005140D:C06 0 1589 Feb. 24, 1998 834 RTA00000407F.b.11.1 M00004090C:C10 0 1590 Feb. 24, 1998 835 RTA00000413F.c.10.1 M00004083B:C01 65600 1591 Feb. 24, 1998 836 RTA00000411F.b.17.1 M00001676D:B02 72893 1592 Feb. 24, 1998 837 RTA00000420F.h.01.1 M00004897C:D06 0 1593 Feb. 24, 1998 838 RTA00000408F.k.19.1 M00001487C:G03 77593 1594 Feb. 24, 1998 839 RTA00000414F.b.01.1 M00005212B:A02 0 1595 Feb. 24, 1998 840 RTA00000420F.b.20.1 M00004088D:B05 0 1596 Feb. 24, 1998 841 RTA00000119A.i.8.1 M00001457A:G12 82593 1597 Feb. 24, 1998 842 RTA00000401F.n.23.1 M00003982A:B06 1552 1598 Feb. 24, 1998 843 RTA00000418F.g.03.1 M00001579C:E06 78737 1599 Feb. 24, 1998 844 RTA00000411F.a.09.1 M00001675C:F01 78629 1600 Feb. 24, 1998 845 RTA00000348R.b.04.1 M00001342B:E01 1890 1601 Feb. 24, 1998 846 RTA00000419F.j.11.1 M00003868C:C07 73183 1602 Feb. 24, 1998 847 RTA00000403F.l.11.1 M00001571D:F05 25073 1603 Feb. 24, 1998 848 RTA00000404F.n.18.2 M00001649C:E11 37169 1604 Feb. 24, 1998 849 RTA00000122A.n.16.1 M00001517A:G08 80553 1605 Feb. 24, 1998 850 RTA00000420F.c.07.1 M00004089A:E02 65555 1606 Feb. 24, 1998 851 RTA00000423F.d.07.1 M00001678B:B12 0 1607 Feb. 24, 1998 852 RTA00000414F.f.03.1 M00005257D:G07 0 1608 Feb. 24, 1998 853 RTA00000408F.j.13.2 M00001485B:D10 42275 1609 Feb. 24, 1998 854 RTA00000345F.a.07.1 M00001338C:E10 0 1610 Feb. 24, 1998 855 RTA00000423F.a.01.1 M00001659C:F10 39103 1611 Feb. 24, 1998 856 RTA00000408F.d.02.1 M00001458D:A01 79169 1612 Feb. 24, 1998 857 RTA00000404F.e.09.1 M00001608B:A09 39121 1613 Feb. 24, 1998 858 RTA00000341F.e.20.1 M00003891D:B10 67422 1614 Feb. 24, 1998 859 RTA00000419F.m.22.1 M00003914A:G09 75600 1615 Feb. 24, 1998 860 RTA00000419F.m.23.1 M00003958B:E11 64263 1616 Feb. 24, 1998 861 RTA00000419F.b.06.1 M00001694B:B08 76728 1617 Feb. 24, 1998 862 RTA00000414F.c.07.1 M00005216A:H01 0 1618 Feb. 24, 1998 863 RTA00000406F.p.08.1 M00004032C:B02 37573 1619 Feb. 24, 1998 864 RTA00000129A.n.17.1 M00001604A:A09 79811 1620 Feb. 24, 1998 865 RTA00000414F.c.03.1 M00005216A:D09 0 1621 Feb. 24, 1998 866 RTA00000407F.b.08.1 M00004088D:B03 37513 1622 Feb. 24, 1998 867 RTA000G0339F.l.21.1 M00001455D:D11 9781 1623 Feb. 24, 1998 868 RTA00000406F.i.08.1 M00003903C:E12 37946 1624 Feb. 24, 1998 869 RTA00000403F.h.07.1 M00001482D:H11 26856 1625 Feb. 24, 1998 870 RTA00000418F.n.24.1 M00001659D:C09 73153 1626 Feb. 24, 1998 871 RTA00000403F.f.23.1 M00001479C:E01 39223 1627 Feb. 24, 1998 872 RTA00000409F.l.20.1 M00001615B:G01 74394 1628 Feb. 24, 1998 873 RTA00000418F.l.06.1 M00001641C:F01 73317 1629 Feb. 24, 1998 874 RTA00000346F.o.22.1 M00004300C:H09 7381 1630 Feb. 24, 1998 875 RTA00000129A.k.22.1 M00001601A:E02 79639 1631 Feb. 24, 1998 876 RTA00000423F.d.16.1 M00001678D:C11 39173 1632 Feb. 24, 1998 877 RTA00000418F.m.22.1 M00001654D:E12 74567 1633 Feb. 24, 1998 878 RTA00000413F.c.12.1 M00004083B:G03 65334 1634 Feb. 24, 1998 879 RTA00000409F.b.19.1 M00001584D:H02 14479 1635 Feb. 24, 1998 880 RTA00000418F.g.20.1 M00001585B:C03 74626 1636 Feb. 24, 1998 881 RTA00000413F.d.15.1 M00004088C:E04 64943 1637 Feb. 24, 1998 882 RTA00000355R.c.03.1 M00004244C:G07 3986 1638 Feb. 24, 1998 883 RTA00000406F.c.09.1 M00003870C:E10 5671 1639 Feb. 24, 1998 884 RTA00000412F.c.10.1 M00003903C:C04 76372 1640 Feb. 24, 1998 885 RTA00000122A.j.17.1 M00001516A:D02 62736 1641 Feb. 24, 1998 886 RTA00000420F.m.15.1 M00005235B:F10 0 1642 Feb. 24, 1998 887 RTA00000339F.p.06.1 M00001484A:A10 4880 1643 Feb. 24, 1998 888 RTA00000339R.c.04.1 M00001362D:H01 1805 1644 Feb. 24, 1998 889 RTA00000346F.b.16.1 M00001615C:G05 16485 1645 Feb. 24, 1998 890 RTA00000418F.j.19.1 M00001634D:D02 78399 1646 Feb. 24, 1998 891 RTA00000137A.p.12.1 M00001587A:B01 80614 1647 Feb. 24, 1998 892 RTA00000339F.m.17.1 M00001453B:H12 20854 1648 Feb. 24, 1998 893 RTA0000041BF.p.10.1 M00001669D:F05 75323 1649 Feb. 24, 1998 894 RTA00000408F.k.12.1 M00001486B:D07 77246 1650 Feb. 24, 1998 895 RTA00000137A.j.11.4 M00001559A:A11 79752 1651 Feb. 24, 1998 896 RTA00000423F.l.20.1 M00004105C:E09 12580 1652 Feb. 24, 1998 897 RTA00000419F.n.24.1 M00003980A:F04 65995 1653 Feb. 24, 1998 898 RTA00000418F.l.03.1 M00001641C:C06 79058 1654 Feb. 24, 1998 899 RTA00000406F.h.10.1 M00003901C:F09 22732 1655 Feb. 24, 1998 900 RTA00000419F.m.13.1 M00003908A:F12 79052 1656 Feb. 24, 1998 901 RTA00000418F.j.14.1 M00001632C:B10 32623 1657 Feb. 24, 1998 902 RTA00000403F.a.10.1 M00001448C:E11 73952 1658 Feb. 24, 1998 903 RTA00000420F.a.21.1 M00004078B:C11 66241 1659 Feb. 24, 1998 904 RTA00000127A.e.6.1 M00001553A:E07 5885 1660 Feb. 24, 1998 905 RTA00000405F.g.21.2 M00001673B:F07 38966 1661 Feb. 24, 1998 906 RTA00000405F.g.21.1 M00001673B:F07 38966 1662 Feb. 24, 1998 907 RTA00000419F.m.06.1 M00003906C:D06 75749 1663 Feb. 24, 1998 908 RTA00000423F.g.03.1 M00003905C:G11 38007 1664 Feb. 24, 1998 909 RTA00000420F.i.04.1 M00004959D:H12 0 1665 Feb. 24, 1998 910 RTA00000418F.f.03.1 M00001577B:F10 78911 1666 Feb. 24, 1998 911 RTA00000406F.p.13.1 M00004034C:G02 8584 1667 Feb. 24, 1998 912 RTA00000404F.g.13.1 M00001614C:E06 9436 1668 Feb. 24, 1998 913 RTA00000120A.c.20.1 M00001464A:B07 43235 1669 Feb. 24, 1998 914 RTA00000138A.m.15.1 M00001624A:A03 41603 1670 Feb. 24, 1998 915 RTA00000408F.f.14.2 M00001476D:F03 73024 1671 Feb. 24, 1998 916 RTA00000418F.p.20.1 M00001677D:B07 78023 1672 Feb. 24, 1998 917 RTA00000423F.e.21.1 M00003806B:G05 66961 1673 Feb. 24, 1998 918 RTA00000419F.j.22.1 M00003871A:A02 73525 1674 Feb. 24, 1998 919 RTA00000410F.d.18.1 M00001635D:D05 75458 1675 Feb. 24, 1998 920 RTA00000403F.b.24.1 M00001456B:G01 78838 1676 Feb. 24, 1998 921 RTA00000422F.j.02.1 M00001594D:B08 10368 1677 Feb. 24, 1998 922 RTA00000410F.e.09.1 M00001636A:F08 76093 1678 Feb. 24, 1998 923 RTA00000126A.d.19.1 M00001548A:G01 79474 1679 Feb. 24, 1998 924 RTA00000354R.m.02.1 M00003890B:C08 12766 1680 Feb. 24, 1998 925 RTA00000353R.h.10.1 M00001390C:C11 39498 1681 Feb. 24, 1998 926 RTA00000399F.k.20.1 M00001505C:D10 3003 1682 Feb. 24, 1998 927 RTA00000411F.d.21.1 M00001692B:E01 74794 1683 Feb. 24, 1998 928 RTA00000340F.m.04.1 M00001679B:H07 19406 1684 Feb. 24, 1998 929 RTA00000411F.n.09.1 M00003875A:A07 78962 1685 Feb. 24, 1998 930 RTA00000127A.h.22.2 M00001554A:E04 13155 1686 Feb. 24, 1998 931 RTA00000420F.e.09.1 M00004108D:E07 66325 1687 Feb. 24, 1998 932 RTA00000405F.p.03.1 M00003844A:A11 11346 1688 Feb. 24, 1998 933 RTA00000419F.a.18.1 M00001680A:B02 78484 1689 Feb. 24, 1998 934 RTA00000414F.e.01.1 M00005233D:H07 0 1690 Feb. 24, 1998 935 RTA00000420F.i.07.1 M00004960A:B08 0 1691 Feb. 24, 1998 936 RTA00000121A.n.23.1 M00001511A:G01 26981 1692 Feb. 24, 1998 937 RTA00000121A.n.15.1 M00001511A:G08 40849 1693 Feb. 24, 1998 938 RTA00000403F.i.23.1 M00001487B:E10 11364 1694 Feb. 24, 1998 939 RTA00000405F.a.03.1 M00001654C:E04 39065 1695 Feb. 24, 1998 940 RTA00000414F.f.17.1 M00005260A:F04 0 1696 Feb. 24, 1998 941 RTA00000419F.p.08.1 M00004036D:B04 65560 1697 Feb. 24, 1998 942 RTA00000126A.n.6.2 M00001551A:D04 79917 1698 Feb. 24, 1998 943 RTA00000413F.c.03.1 M00004081D:H09 64527 1699 Feb. 24, 1998 944 RTA00000422F.k.24.1 M00001610C:E06 39118 1700 Feb. 24, 1998 945 RTA00000412F.c.17.1 M00003905A:A06 75620 1701 Feb. 24, 1998 946 RTA00000414F.b.07.1 M00005212C:D02 0 1702 Feb. 24, 1998 947 RTA00000347F.g.08.1 M00004096B:F05 23121 1703 Feb. 24, 1998 948 RTA00000419F.o.06.1 M00003986C:D09 64643 1704 Feb. 24, 1998 949 RTA00000340R.j.07.1 M00001654C:D05 38954 1705 Feb. 24, 1998 950 RTA00000423F.j.02.1 M00003903B:C02 38617 1706 Feb. 24, 1998 951 RTA00000419F.c.04.1 M00003815C:D12 63749 1707 Feb. 24, 1998 952 RTA00000411F.a.01.1 M00001675B:D02 74524 1708 Feb. 24, 1998 953 RTA00000406F.f.05.1 M00003878C:F06 22961 1709 Feb. 24, 1998 954 RTA00000410F.n.05.1 M00001662A:C07 77830 1710 Feb. 24, 1998 955 RTA00000404F.e.06.1 M00001607D:F06 39315 1711 Feb. 24, 1998 956 RTA00000423F.l.06.1 M00004062A:H06 38136 1712 Feb. 24, 1998 957 RTA00000411F.c.03.1 M00001677B:B06 79280 1713 Feb. 24, 1998 958 RTA00000195AF.c.8.1 M00001678B:H01 0 1713 Jan. 28, 1998 520 RTA00000195AF.c.8.1 M00001678B:H01 0 1714 Feb. 24, 1998 959 RTA00000340F.g.20.1 M00001609D:G10 4089 1715 Feb. 24, 1998 960 RTA00000404F.l.19.2 M00001639B:H01 16196 1716 Feb. 24, 1998 961 RTA00000420F.n.21.2 M00005259B:D12 0 1717 Feb. 24, 1998 962 RTA00000404F.p.05.2 M00001652D:E09 1896 1718 Feb. 24, 1998 963 RTA00000405F.l.07.1 M00001693C:E09 38636 1719 Feb. 24, 1998 964 RTA00000423F.l.15.1 M00004075B:G09 11219 1720 Feb. 24, 1998 965 RTA00000411F.n.06.1 M00003871D:E11 73886 1721 Feb. 24, 1998 966 RTA00000422F.k.15.1 M00001594A:G09 19253 1722 Feb. 24, 1998 967 RTA00000406F.h.16.1 M00003902B:D06 38618 1723 Feb. 24, 1998 968 RTA00000419F.f.24.1 M00003841B:E06 18717 1724 Feb. 24, 1998 969 RTA00000411F.d.18.1 M00001692A:G06 76063 1725 Feb. 24, 1998 970 RTA00000414F.e.15.1 M00005236B:G03 0 1726 Feb. 24, 1998 971 RTA00000411F.i.11.1 M00003837C:E05 66849 1727 Feb. 24, 1998 972 RTA00000408F.d.15.1 M00001459B:C1 78467 1728 Feb. 24, 1998 973 RTA00000339F.b.22.1 M00001373D:B03 6867 1729 Feb. 24, 1998 974 RTA00000340F.h.07.1 M00001608D:D11 19254 1730 Feb. 24, 1998 975 RTA00000411F.n.02.1 M00003870B:F04 78049 1731 Feb. 24, 1998 976 RTA00000419F.b.17.1 M00003808D:D04 63261 1732 Feb. 24, 1998 977 RTA00000350R.p.12.1 M00001657C:C07 0 1733 Feb. 24, 1998 978 RTA00000130A.e.20.1 M00001606A:H09 79502 1734 Feb. 24, 1998 979 RTA00000345F.b.17.1 M00001362C:H11 945 1735 Feb. 24, 1998 980 RTA00000411F.i.13.1 M00003837C:F10 66138 1736 Feb. 24, 1998 981 RTA00000420F.e.20.1 M00004110B:A07 64762 1737 Feb. 24, 1998 982 RTA00000126A.p.23.2 M00001552A:F06 80915 1738 Feb. 24, 1998 983 RTA00000423F.f.11.1 M00003809A:H04 0 1739 Feb. 24, 1998 984 RTA00000406F.g.08.1 M00003880C:H03 37963 1740 Feb. 24, 1998 985 RTA00000409F.a.08.1 M00001582D:B01 74978 1741 Feb. 24, 1998 986 RTA00000406F.d.24.1 M00003876B:C05 37997 1742 Feb. 24, 1998 987 RTA00000422F.b.22.1 M00004117B:A12 2368 1743 Feb. 24, 1998 988 RTA00000407F.a.22.1 M00004081A:G01 15570 1744 Feb. 24, 1998 989 RTA00000418F.i.12.1 M00001592A:E02 78971 1745 Feb. 24, 1998 990 RTA00000121A.h.19.1 M00001471A:D04 80334 1746 Feb. 24, 1998 991 RTA00000419F.b.10.1 M00001694C:G04 78566 1747 Feb. 24, 1998 992 RTA00000406F.m.10.1 M00003914D:B02 38004 1748 Feb. 24, 1998 993 RTA00000406F.o.05.1 M00003985B:G04 37894 1749 Feb. 24, 1998 994 RTA00000408F.b.04.2 M00001455A:F04 39933 1750 Feb. 24, 1998 995 RTA00000411F.k.04.1 M00003850D:A05 65407 1751 Feb. 24, 1998 996 RTA00000423F.j.03.1 M00003903B:D03 5391 1752 Feb. 24, 1998 997 RTA00000134A.l.9.1 M00001535A:D10 81814 1753 Feb. 24, 1998 998 RTA00000341F.g.22.1 M00003914D:D10 0 1754 Feb. 24, 1998 999 RTA00000418F.k.04.1 M00001637A:A03 75864 1755 Feb. 24, 1998 1000 RTA00000351R.j.21.1 M00003859D:C05 31604 1756 Feb. 24, 1998 1001 RTA00000413F.p.07.2 M00005102C:D03 0 1757 Feb. 24, 1998 1002 RTA00000419F.p.18.1 M00004038D:G06 63002 1758 Feb. 24, 1998 1003 RTA00000420F.k.08.2 M00005176C:C09 0 1759 Feb. 24, 1998 1004 RTA00000419F.a.24.1 M00001680B:D02 79290 1760 Feb. 24, 1998 1005 RTA00000339F.e.17.1 M00001397D:G08 7568 1761 Feb. 24, 1998 1006 RTA00000129A.e.14.1 M00001587A:F08 80053 1762 Feb. 24, 1998 1007 RTA00000404F.a.01.1 M00001589B:B08 19251 1763 Feb. 24, 1998 1008 RTA00000414F.f.07.1 M00005250C:B05 0 1764 Feb. 24, 1998 1009 RTA00000399F.o.24.1 M00001607D:A11 2272 1765 Feb. 24, 1998 1010 RTA00000408F.n.16.2 M00001540C:B03 73720 1766 Feb. 24, 1998 1011 RTA00000400F.c.04.1 M00001618A:F08 6445 1767 Feb. 24, 1998 1012 RTA00000403F.g.06.1 M00001480C:A05 10505 1768 Feb. 24, 1998 1013 RTA00000404F.b.18.1 M00001592A:H05 13669 1769 Feb. 24, 1998 1014 RTA00000412F.l.14.1 M00004029B:F01 62792 1770 Feb. 24, 1998 1015 RTA00000129A.b.6.2 M00001582A:H01 39111 1771 Feb. 24, 1998 1016 RTA00000406F.n.12.1 M00003960A:G07 37517 1772 Feb. 24, 1998 1017 RTA00000418F.e.03.1 M00001573B:G08 73442 1773 Feb. 24, 1998 1018 RTA00000413F.j.21.1 M00004688A:A02 0 1774 Feb. 24, 1998 1019 RTA00000403F.g.03.1 M00001479D:G06 23537 1775 Feb. 24, 1998 1020 RTA00000412F.p.06.1 M00004038B:H10 65485 1776 Feb. 24, 1998 1021 RTA00000419F.b.21.1 M00003809A:F01 65366 1777 Feb. 24, 1998 1022 RTA00000401F.j.15.1 M00003901A:C09 3061 1778 Feb. 24, 1998 1023 RTA00000404F.f.12.1 M00001611B:A05 39209 1779 Feb. 24, 1998 1024 RTA00000351R.j.16.1 M00003857B:F07 64773 1780 Feb. 24, 1998 1025 RTA00000118A.j.24.1 M00001450A:B03 18 1781 Feb. 24, 1998 1026 RTA00000419F.f.18.1 M00003839D:E11 64047 1782 Feb. 24, 1998 1027 RTA00000423F.i.16.1 M00003907D:A12 38604 1783 Feb. 24, 1998 1028 RTA00000346F.d.12.1 M00001676B:B09 11777 1784 Feb. 24, 1998 1029 RTA00000411F.f.04.1 M00003813A:G04 64526 1785 Feb. 24, 1998 1030 RTA00000125A.c.17.1 M00001542A:E04 80619 1786 Feb. 24, 1998 1031 RTA00000404F.g.08.1 M00001613D:H10 38980 1787 Feb. 24, 1998 1032 RTA00000423F.c.13.1 M00001678A:A11 39059 1788 Feb. 24, 1998 1033 RTA00000414F.e.19.1 M00005257C:E05 0 1789 Feb. 24, 1998 1034 RTA00000124A.f.16.3 M00001536A:F11 47430 1790 Feb. 24, 1998 1035 RTA00000404F.k.15.1 M00001634A:B04 8225 1791 Feb. 24, 1998 1036 RTA00000339F.k.08.1 M00001439B:A10 8133 1792 Feb. 24, 1998 1037 RTA00000339F.l.12.1 M00001450A:G11 7711 1793 Feb. 24, 1998 1038 RTA00000406F.b.01.1 M00003867B:G07 39006 1794 Feb. 24, 1998 1039 RTA00000407F.c.08.1 M00004118D:B05 37549 1795 Feb. 24, 1998 1040 RTA00000348R.o.12.1 M00001433C:F10 2263 1796 Feb. 24, 1998 1041 RTA00000403F.b.05.1 M00001455B:E07 74300 1797 Feb. 24, 1998 1042 RTA00000339F.g.10.1 M00001400C:D02 6327 1798 Feb. 24, 1998 1043 RTA00000423F.b.17.1 M00001662B:F06 8200 1799 Feb. 24, 1998 1044 RTA00000419F.n.11.1 M00003977C:B03 66477 1800 Feb. 24, 1998 1045 RTA00000408F.j.05.2 M00001483C:G06 73878 1801 Feb. 24, 1998 1046 RTA00000346F.j.06.1 M00003879A:A02 5767 1802 Feb. 24, 1998 1047 RTA00000419F.c.14.1 M00003819B:G01 65727 1803 Feb. 24, 1998 1048 RTA00000413F.o.07.2 M00005100A:C01 0 1804 Feb. 24, 1998 1049 RTA00000405F.f.05.1 M00001669C:D09 14359 1805 Feb. 24, 1998 1050 RTA00000405F.f.05.2 M00001669C:D09 14359 1806 Feb. 24, 1998 1051 RTA00000346F.h.24.1 M00003797A:C11 4379 1807 Feb. 24, 1998 1052 RTA00000420F.b.02.1 M00004081A:A08 64013 1808 Feb. 24, 1998 1053 RTA00000413F.b.24.1 M00004080A:F01 65117 1809 Feb. 24, 1998 1054 RTA00000412F.d.08.1 M00003905C:B02 75328 1810 Feb. 24, 1998 1055 RTA00000346F.a.04.1 M00001607B:C05 5382 1811 Feb. 24, 1998 1056 RTA00000419F.m.18.1 M00003908C:G09 76014 1812 Feb. 24, 1998 1057 RTA00000419F.l.24.1 M00003904D:B10 74628 1813 Feb. 24, 1998 1058 RTA00000408F.c.06.1 M00001456D:E08 78619 1814 Feb. 24, 1998 1059 RTA00000405F.h.21.2 M00001675C:D12 39072 1815 Feb. 24, 1998 1060 RTA00000346F.g.02.1 M00003792A:B10 6901 1816 Feb. 24, 1998 1061 RTA00000405F.g.05.2 M00001671D:E10 38987 1817 Feb. 24, 1998 1062 RTA00000411F.f.20.1 M00003816C:C01 63501 1818 Feb. 24, 1998 1063 RTA00000132A.n.7.1 M00001466A:F08 0 1819 Feb. 24, 1998 1064 RTA00000420F.d.19.1 M00004105C:C08 43146 1820 Jan. 28, 1998 595 RTA00000195R.a.06.1 M00001394A:E04 35265 1820 Feb. 24, 1998 1065 RTA00000195R.a.06.1 M00001394A:E04 35265 1821 Feb. 24, 1998 1066 RTA00000123A.f.2.1 M00001531A:H03 80379 1822 Feb. 24, 1998 1067 RTA00000411F.j.11.1 M00003841D:F06 66154 1823 Feb. 24, 1998 1068 RTA00000341F.f.03.1 M00003850A:F06 0 1824 Feb. 24, 1998 1069 RTA00000346F.k.05.1 M00003904C:A08 0 1825 Feb. 24, 1998 1070 RTA00000346F.n.22.1 M00004137A:D06 0 1826 Feb. 24, 1998 1071 RTA00000404F.k.18.2 M00001635A:C06 5475 1827 Feb. 24, 1998 1072 RTA00000419F.j.03.1 M00003868B:G06 77578 1828 Feb. 24, 1998 1073 RTA00000418F.a.10.1 M00001475B:C04 15245 1829 Feb. 24, 1998 1074 RTA00000423F.h.11.1 M00003867C:E11 38977 1830 Feb. 24, 1998 1075 RTA00000413F.b.17.1 M00004078A:F07 21704 1831 Feb. 24, 1998 1076 RTA00000423F.k.09.1 M00004035B:H09 26630 1832 Feb. 24, 1998 1077 RTA00000414F.e.11.1 M00005236B:A12 0 1833 Feb. 24, 1998 1078 RTA00000423F.f.03.1 M00003829C:D10 63852 1834 Feb. 24, 1998 1079 RTA00000419F.e.10.1 M00003833B:B03 63225 1835 Feb. 24, 1998 1080 RTA00000351R.g.06.1 M00003771D:G05 0 1836 Feb. 24, 1998 1081 RTA00000403F.d.02.1 M00001458D:D01 39224 1837 Feb. 24, 1998 1082 RTA00000137A.o.22.1 M00001587A:D01 0 1838 Feb. 24, 1998 1083 RTA00000418F.j.20.1 M00001634D:D04 77101 1839 Feb. 24, 1998 1084 RTA00000403F.o.22.2 M00001583A:D01 25076 1840 Feb. 24, 1998 1085 RTA00000403F.n.22.1 M00001578B:B05 26775 1841 Feb. 24, 1998 1086 RTA00000403F.n.22.2 M00001578B:B05 26775 1842 Feb. 24, 1998 1087 RTA00000401F.o.13.1 M00004040C:A01 3220 1843 Feb. 24, 1998 1088 RTA00000339R.b.02.1 M00001344B:F12 0 1844 Feb. 24, 1998 1089 RTA00000406F.j.21.1 M00003906A:H07 17822 1845 Feb. 24, 1998 1090 RTA00000405F.g.22.1 M00001673C:A02 527 1846 Feb. 24, 1998 1091 RTA00000356R.h.05.1 M00004107C:C02 35052 1847 Feb. 24, 1998 1092 RTA00000125A.c.2.1 M00001542A:F06 40148 1848 Feb. 24, 1998 1093 RTA00000340F.i.15.1 M00001629C:E07 26815 1849 Feb. 24, 1998 1094 RTA00000405F.h.03.2 M00001673D:F10 20633 1850 Feb. 24, 1998 1095 RTA00000345F.c.12.1 M00001376A:C05 23824 1851 Feb. 24, 1998 1096 RTA00000421F.a.06.1 M00001589C:A11 2385 1852 Feb. 24, 1998 1097 RTA00000412F.o.03.1 M00004033D:D07 65039 1853 Feb. 24, 1998 1098 RTA00000409F.d.16.1 M00001590C:F10 76090 1854 Feb. 24, 1998 1099 RTA00000400F.m.16.1 M00001660B:E04 3307 1855 Feb. 24, 1998 1100 RTA00000414F.a.12.1 M00005210A:E06 0 1856 Feb. 24, 1998 1101 RTA00000408F.j.17.2 M00001485B:H03 78935 1857 Feb. 24, 1998 1102 RTA00000126A.j.15.2 M00001549A:H11 40425 1858 Feb. 24, 1998 1103 RTA00000346F.a.16.1 M00001593A:B07 12082 1859 Feb. 24, 1998 1104 RTA00000126A.b.10.1 M00001547A:F06 0 1860 Feb. 24, 1998 1105 RTA00000340F.p.18.1 M00003751C:A04 287 1861 Feb. 24, 1998 1106 RTA00000410F.b.17.1 M00001633C:H05 77458 1862 Feb. 24, 1998 1107 RTA00000419F.l.22.1 M00003903D:C06 78444 1863 Feb. 24, 1998 1108 RTA00000346F.c.16.1 M00001652B:G10 9579 1864 Feb. 24, 1998 1109 RTA00000422F.f.22.1 M00001584A:G03 38703 1865 Feb. 24, 1998 1110 RTA00000404F.j.24.1 M00001631D:G05 39067 1866 Feb. 24, 1998 1111 RTA00000406F.m.20.1 M00003918C:C12 38038 1867 Feb. 24, 1998 1112 RTA00000418F.c.05.1 M00001487B:F02 76475 1868 Feb. 24, 1998 1113 RTA00000418F.p.21.1 M00001677D:F03 78068 1869 Feb. 24, 1998 1114 RTA00000340F.f.22.1 M00001594B:F12 1720 1870 Feb. 24, 1998 1115 RTA00000340F.i.08.1 M00001615B:F07 12005 1871 Feb. 24, 1998 1116 RTA00000410F.o.04.1 M00001664D:F04 79018 1872 Feb. 24, 1998 1117 RTA00000411F.l.16.1 M00003857C:G01 16122 1873 Feb. 24, 1998 1118 RTA00000411F.j.03.1 M00003841C:F01 66263 1874 Feb. 24, 1998 1119 RTA00000126A.k.24.1 M00001550A:F07 39428 1875 Feb. 24, 1998 1120 RTA00000353R.l.23.1 M00001418B:F07 12531 1876 Feb. 24, 1998 1121 RTA00000120A.m.10.3 M00001467A:B03 81376 1877 Feb. 24, 1998 1122 RTA00000419F.f.16.1 M00003839D:E02 64679 1878 Feb. 24, 1998 1123 RTA00000408F.c.23.1 M00001458C:D10 42261 1879 Feb. 24, 1998 1124 RTA00000123A.h.22.1 M00001532A:C01 17124 1880 Feb. 24, 1998 1125 RTA00000118A.n.5.1 M00001451A:C10 0 1881 Feb. 24, 1998 1126 RTA00000136A.h.6.1 M00001550A:D09 81620 1882 Feb. 24, 1998 1127 RTA00000401F.g.22.1 M00003871A:G09 1147 1883 Feb. 24, 1998 1128 RTA00000423F.a.02.3 M00001656B:A08 39210 1884 Feb. 24, 1998 1129 RTA00000401F.m.07.1 M00003907D:F11 2893 1885 Feb. 24, 1998 1130 RTA00000354R.p.01.1 M00004104C:H12 0 1886 Feb. 24, 1998 1131 RTA00000418F.e.20.1 M00001576C:G05 73741 1887 Feb. 24, 1998 1132 RTA00000119A.c.12.1 M00001453A:D08 4882 1888 Feb. 24, 1998 1133 RTA00000405F.l.03.1 M00001692D:B01 38580 1889 Feb. 24, 1998 1134 RTA00000418F.m.02.1 M00001650A:A12 74550 1890 Feb. 24, 1998 1135 RTA00000346F.o.16.1 M00004358D:C02 176 1891 Feb. 24, 1998 1136 RTA00000406F.c.05.1 M00003870A:H01 22077 1892 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 1893 Feb. 24, 1998 1138 RTA00000411F.k.21.1 M00003854B:D04 65349 1894 Feb. 24, 1998 1139 RTA00000404F.h.20.1 M00001619B:A09 15564 1895 Feb. 24, 1998 1140 RTA00000339F.c.05.1 M00001365A:H10 3908 1896 Feb. 24, 1998 1141 RTA00000347F.f.08.1 M00003972D:H02 5948 1897 Feb. 24, 1998 1142 RTA00000418F.i.06.1 M00001591B:B06 75151 1898 Feb. 24, 1998 1143 RTA00000423F.a.03.1 M00001656B:D05 26796 1899 Feb. 24, 1998 1144 RTA00000345F.j.09.1 M00001451B:F01 13 1900 Feb. 24, 1998 1145 RTA00000423F.k.21.2 M00003984D:B08 37499 1901 Feb. 24, 1998 1146 RTA00000347F.h.02.1 M00004072D:H12 562 1902 Feb. 24, 1998 1147 RTA00000404F.c.18.1 M00001594A:C01 38982 1903 Feb. 24, 1998 1148 RTA00000345F.d.23.1 M00001390D:E03 5862 1904 Feb. 24, 1998 1149 RTA00000339F.b.02.1 M00001344B:F12 0 1905 Feb. 24, 1998 1150 RTA00000411F.g.24.1 M00003825B:B11 65233 1906 Feb. 24, 1998 1151 RTA00000405F.g.18.2 M00001672D:E08 5255 1907 Feb. 24, 1998 1152 RTA00000405F.m.07.1 M00003809B:B02 37733 1908 Feb. 24, 1998 1153 RTA00000411F.j.07.1 M00003841C:H11 66963 1909 Feb. 24, 1998 1154 RTA00000403F.m.09.2 M00001575B:G01 26814 1910 Feb. 24, 1998 1155 RTA00000353R.h.04.1 M00001375B:C06 17123 1911 Feb. 24, 1998 1156 RTA00000408F.f.10.2 M00001476D:C05 75309 1912 Feb. 24, 1998 1157 RTA00000422F.m.18.1 M00001647B:E04 23829 1913 Feb. 24, 1998 1158 RTA00000405F.o.03.1 M00003829C:H05 37575 1914 Feb. 24, 1998 1159 RTA00000413F.b.18.1 M00004078C:F04 39873 1915 Feb. 24, 1998 1160 RTA00000400F.g.02.1 M00001638B:E03 1508 1916 Feb. 24, 1998 1161 RTA00000346F.m.05.1 M00003983B:C08 5644 1917 Feb. 24, 1998 1162 RTA00000408F.c.10.1 M00001458A:A11 18247 1918 Feb. 24, 1998 1163 RTA00000341F.b.14.1 M00003763A:C01 5992 1919 Feb. 24, 1998 1164 RTA00000405F.m.21.1 M00003815C:C06 24218 1920 Feb. 24, 1998 1165 RTA00000408F.c.08.1 M00001456D:G11 73473 1921 Feb. 24, 1998 1166 RTA00000347F.h.01.1 M00004040A:G12 12043 1922 Feb. 24, 1998 1167 RTA00000410F.c.06.1 M00001633D:H06 77784 1923 Feb. 24, 1998 1168 RTA00000421F.b.06.1 M00001567A:B09 2113 1924 Feb. 24, 1998 1169 RTA00000405F.b.08.1 M00001656B:E01 39182 1925 Feb. 24, 1998 1170 RTA00000409F.l.24.1 M00001616C:A02 73174 1926 Feb. 24, 1998 1171 RTA00000406F.j.06.1 M00003905A:F10 38952 1927 Feb. 24, 1998 1172 RTA00000423F.h.03.1 M00003875D:D09 37903 1928 Feb. 24, 1998 1173 RTA00000339R.b.07.1 M00001360A:G10 6826 1929 Feb. 24, 1998 1174 RTA00000121A.k.22.1 M00001507A:C05 79523 1930 Feb. 24, 1998 1175 RTA00000414F.b.04.1 M00005212B:E01 0 1931 Feb. 24, 1998 1176 RTA00000411F.m.06.1 M00003858D:G06 24195 1932 Feb. 24, 1998 1177 RTA00000126A.b.9.1 M00001547A:F11 81279 1933 Feb. 24, 1998 1178 RTA00000400F.f.11.1 M00001636A:E07 4088 1934 Feb. 24, 1998 1179 RTA00000341F.o.12.1 M00004144A:F04 2883 1935 Feb. 24, 1998 1180 RTA00000404F.l.05.1 M00001636D:F09 38671 1936 Feb. 24, 1998 1181 RTA00000346F.f.14.1 M00003800B:F03 16998 1937 Feb. 24, 1998 1182 RTA00000346F.d.21.1 M00001670B:G12 6641 1938 Feb. 24, 1998 1183 RTA00000346F.j.21.1 M00003879D:A08 3095 1939 Feb. 24, 1998 1184 RTA00000345F.h.08.1 M00001419D:C10 11393 1940 Feb. 24, 1998 1185 RTA00000413F.b.20.1 M00004079D:G08 66063 1941 Feb. 24, 1998 1186 RTA00060419F.p.10.1 M00004036D:B09 41448 1942 Feb. 24, 1998 1187 RTA00000120A.c.19.1 M00001464A:B03 81016 1943 Feb. 24, 1998 1188 RTA00000341F.o.18.1 M00004169D:B11 37189 1944 Feb. 24, 1998 1189 RTA00000339F.o.18.1 M00001469B:B01 6641 1945 Feb. 24, 1998 1190 RTA00000405F.g.02.2 M00001671B:G05 10567 1946 Feb. 24, 1998 1191 RTA00000340F.i.05.1 M00001614B:E08 0 1947 Feb. 24, 1998 1192 RTA00000406F.m.17.1 M00003918A:F09 0 1948 Feb. 24, 1998 1193 RTA00000411F.k.14.1 M00003851A:C10 63987 1949 Feb. 24, 1998 1194 RTA00000420F.e.05.1 M00004107D:E12 63908 1950 Feb. 24, 1998 1195 RTA00000422F.e.23.1 M00001567D:B03 19246 1951 Feb. 24, 1998 1196 RTA00000413F.l.18.1 M00004895D:G07 0 1952 Feb. 24, 1998 1197 RTA00000128A.j.10.1 M00001560A:H06 80085 1953 Feb. 24, 1998 1198 RTA00000412F.f.10.2 M00003959A:A03 65405 1954 Feb. 24, 1998 1199 RTA00000401F.j.23.1 M00003901C:D03 570 1955 Feb. 24, 1998 1200 RTA00000422F.k.17.1 M00001652A:A01 38955 1956 Feb. 24, 1998 1201 RTA00000409F.m.02.1 M00001616C:A11 9157 1957 Feb. 24, 1998 1202 RTA00000347F.h.10.1 M00004206A:E02 22779 1958 Feb. 24, 1998 1203 RTA00000413F.e.10.1 M00004092C:B03 31033 1959 Feb. 24, 1998 1204 RTA00000419F.l.02.1 M00003879A:C01 75736 1960 Feb. 24, 1998 1205 RTA00000419F.k.05.1 M00003871C:E04 11757 1961 Feb. 24, 1998 1206 RTA00000418F.b.20.1 M00001484D:G05 73560 1962 Feb. 24, 1998 1207 RTA00000401F.j.21.1 M00003901B:F10 0 1963 Feb. 24, 1998 1208 RTA00000347F.e.24.1 M00003823B:F07 8188 1964 Feb. 24, 1998 1209 RTA00000408F.n.05.2 M00001539A:H02 77883 1965 Feb. 24, 1998 1210 RTA00000419F.o.09.1 M00003987B:F08 66396 1966 Feb. 24, 1998 1211 RTA00000399F.f.14.1 M00001487D:C11 11483 1967 Feb. 24, 1998 1212 RTA00000349R.o.03.1 M00001551D:H07 23006 1968 Feb. 24, 1998 1213 RTA00000135A.a.23.1 M00001537A:H05 27054 1969 Feb. 24, 1998 1214 RTA00000339F.j.07.1 M00001428D:B10 5673 1970 Feb. 24, 1998 1215 RTA00000422F.o.08.2 M00001659D:D03 26832 1971 Feb. 24, 1998 1216 RTA00000404F.e.07.1 M00001608A:D03 9034 1972 Feb. 24, 1998 1217 RTA00000410F.j.17.1 M00001642D:F02 72912 1973 Feb. 24, 1998 1218 RTA00000418F.m.18.1 M00001653B:G10 76479 1974 Feb. 24, 1998 1219 RTA00000347F.e.20.1 M00003771B:E05 39911 1975 Feb. 24, 1998 1220 RTA00000419F.e.23.1 M00003834B:G04 65772 1976 Feb. 24, 1998 1221 RTA00000403F.o.17.1 M00001582D:A02 23085 1977 Feb. 24, 1998 1222 RTA00000423F.e.13.1 M00003848A:C09 10998 1978 Feb. 24, 1998 1223 RTA00000347F.a.14.1 M00001429D:F11 7421 1979 Feb. 24, 1998 1224 RTA00000122A.h.24.1 M00001514A:A12 48 1980 Feb. 24, 1998 1225 RTA00000346F.j.13.1 M00003841C:E04 5337 1981 Feb. 24, 1998 1226 RTA00000414F.c.12.1 M00005218A:F09 0 1982 Feb. 24, 1998 1227 RTA00000411F.g.05.1 M00003822D:B10 64664 1983 Feb. 24, 1998 1228 RTA00000404F.h.10.1 M00001618A:A03 37148 1984 Feb. 24, 1998 1229 RTA00000422F.n.14.1 M00001642C:G02 26787 1985 Feb. 24, 1998 1230 RTA00000399F.j.14.1 M00001578C:F05 16942 1986 Feb. 24, 1998 1231 RTA00000120A.m.13.3 M00001467A:C10 80608 1987 Feb. 24, 1998 1232 RTA00000412F.i.03.1 M00003975D:C06 65617 1988 Feb. 24, 1998 1233 RTA00000418F.l.02.1 M00001641C:C05 39316 1989 Feb. 24, 1998 1234 RTA00000352R.c.20.1 M00003982A:B12 7339 1990 Feb. 24, 1998 1235 RTA00000411F.j.04.1 M00003841C:F03 66219 1991 Feb. 24, 1998 1236 RTA00000414F.b.06.1 M00005212C:C03 0 1992 Feb. 24, 1998 1237 RTA00000414F.c.24.1 M00005229B:H04 0 1993 Feb. 24, 1998 1238 RTA00000420F.g.09.1 M00004895B:E12 0 1994 Feb. 24, 1998 1239 RTA00000340F.o.22.1 M00001673B:B07 7356 1995 Feb. 24, 1998 1240 RTA00000404F.a.18.1 M00001590B:B02 36267 1996 Feb. 24, 1998 1241 RTA00000408F.l.14.1 M00001530A:E10 12001 1997 Feb. 24, 1998 1242 RTA00000405F.d.10.1 M00001661C:F11 39000 1998 Feb. 24, 1998 1243 RTA00000404F.j.19.1 M00001630D:H10 0 1999 Feb. 24, 1998 1244 RTA00000418F.h.23.1 M00001591A:B05 75153 2000 Feb. 24, 1998 1245 RTA00000422F.k.22.1 M00001592C:E05 4098 2001 Feb. 24, 1998 1246 RTA00000418F.j.11.1 M00001626C:E04 73853 2002 Feb. 24, 1998 1247 RTA00000408F.o.13.1 M00001572A:B05 74895 2003 Feb. 24, 1998 1248 RTA00000419F.o.07.1 M00003986C:E09 14059 2004 Feb. 24, 1998 1249 RTA00000419F.n.17.1 M00003978D:G04 63186 2005 Feb. 24, 1998 1250 RTA00000403F.f.15.1 M00001477D:F10 22768 2006 Feb. 24, 1998 1251 RTA00000408F.d.03.1 M00001458D:A02 22768 2007 Feb. 24, 1998 1252 RTA00000400F.g.08.1 M00001639A:C11 1275 2008 Feb. 24, 1998 1253 RTA00000346F.f.02.1 M00003772C:B12 62757 2009 Feb. 24, 1998 1254 RTA00000341F.p.11.1 M00004159C:G12 0 2010 Feb. 24, 1998 1255 RTA00000413F.i.21.1 M00004118B:B04 64066 2011 Feb. 24, 1998 1256 RTA00000401F.k.19.1 M00003903D:D10 799 2012 Feb. 24, 1998 1257 RTA00000419F.h.21.1 M00003856C:B08 64828 2013 Feb. 24, 1998 1258 RTA00000403F.p.05.2 M00001583D:B08 24528 2014 Feb. 24, 1998 1259 RTA00000420F.l.19.2 M00005231A:H04 0 2015 Feb. 24, 1998 1260 RTA00000422F.f.18.1 M00001583D:B08 24528 2016 Feb. 24, 1998 1261 RTA00000404F.m.17.2 M00001643B:E05 0 2017 Feb. 24, 1998 1262 RTA0D000122A.h.4.1 M00001514A:G03 33576 2018 Feb. 24, 1998 1263 RTA00000341F.i.22.1 M00003911A:F10 7825 2019 Feb. 24, 1998 1264 RTA00000345F.e.13.1 M00001392C:D05 4366 2020 Feb. 24, 1998 1265 RTA00000340F.d.07.1 M00001532D:A06 0 2021 Feb. 24, 1998 1266 RTA00000121A.a.2.1 M00001468A:H10 81843 2022 Mar. 24, 1998 1 RTA00000527F.g.13.1 M00003845D:A04 36035 2023 Mar. 24, 1998 2 RTA00000523F.d.19.1 M00003824A:A06 26489 2024 Mar. 24, 1998 3 RTA00000528F.b.23.1 M00001479C:F10 1605 2025 Mar. 24, 1998 4 RTA00000426F.h.11.1 M00003905B:H05 75479 2026 Mar. 24, 1998 5 RTA00000426F.p.04.1 M000040298:H08 34149 2027 Mar. 24, 1998 6 RTA00000523F.l.10.1 M00005134B:E01 0 2028 Mar. 24, 1998 7 RTA00000523F.o.20.1 M00005177B:H02 0 2029 Mar. 24, 1998 8 RTA00000428F.b.06.1 M00005228A:A09 0 2030 Mar. 24, 1998 9 RTA00000522F.b.22.1 M00001573B:H12 75181 2031 Mar. 24, 1998 10 RTA00000527F.f.12.1 M00003829D:D12 5945 2032 Mar. 24, 1998 11 RTA00000427F.l.11.1 M00005139A:F01 0 2033 Mar. 24, 1998 12 RTA00000522F.a.23.1 M00001570C:A05 38613 2034 Mar. 24, 1998 13 RTA00000528F.m.16.1 M00003845D:C03 4468 2035 Mar. 24, 1998 14 RTA00000523F.b.02.1 M00003806C:A06 65163 2036 Mar. 24, 1998 15 RTA00000425F.j.14.1 M00001639D:C12 73397 2037 Mar. 24, 1998 16 RTA00000426F.m.22.1 M00003983A:G02 30002 2038 Mar. 24, 1998 17 RTA00000527F.p.06.1 M00004029B:G10 1292 2039 Mar. 24, 1998 18 RTA00000522F.e.16.1 M00001590A:C08 75283 2040 Mar. 24, 1998 19 RTA00000527F.j.02.2 M00003856A:B07 4896 2041 Mar. 24, 1998 20 RTA00000522F.o.06.1 M00001659D:A09 26860 2042 Mar. 24, 1998 21 RTA00000523F.h.17.1 M00003852A:B03 65586 2043 Mar. 24, 1998 22 RTA00000527F.k.15.1 M00003982A:G03 22688 2044 Mar. 24, 1998 23 RTA00000522F.p.07.1 M00001670A:C11 76888 2045 Mar. 24, 1998 24 RTA00000522F.n.08.1 M00001656A:D10 76343 2046 Mar. 24, 1998 25 RTA00000425F.c.06.1 M00001585D:D11 78041 2047 Mar. 24, 1998 26 RTA00000427F.b.23.1 M00003973D:F08 64297 2048 Mar. 24, 1998 27 RTA00000527F.p.02.1 M00004029B:A01 36844 2049 Mar. 24, 1998 28 RTA00000427F.d.08.1 M00003980C:E12 63967 2050 Mar. 24, 1998 29 RTA00000524F.b.03.1 M00005212A:D10 0 2051 Mar. 24, 1998 30 RTA00000426F.m.07.1 M00004028A:G03 63504 2052 Mar. 24, 1998 31 RTA00000427F.c.10.1 M00003976B:E06 65478 2053 Mar. 24, 1998 32 RTA00000424F.n.14.1 M00001584D:C11 73008 2054 Mar. 24, 1998 33 RTA00000524F.b.21.1 M00005216C:B09 0 2055 Mar. 24, 1998 34 RTA00000424F.m.15.1 M00001612D:F06 73759 2056 Mar. 24, 1998 35 RTA00000426F.f.11.1 M00003823C:B01 63102 2057 Mar. 24, 1998 36 RTA00000428F.a.16.1 M00005212D:F08 0 2058 Mar. 24, 1998 37 RTA00000426F.f.20.1 M00003854C:F01 65134 2059 Mar. 24, 1998 38 RTA00000528F.i.22.1 M00001661D:D05 2478 2060 Mar. 24, 1998 39 RTA00000527F.c.23.1 M00003822C:A07 37742 2061 Mar. 24, 1998 40 RTA00000426F.h.23.1 M00003911A:D12 75964 2062 Mar. 24, 1998 41 RTA00000525F.b.17.1 M00004037B:A04 24715 2063 Mar. 24, 1998 42 RTA00000527F.i.19.2 M00003853C:C06 38089 2064 Mar. 24, 1998 43 RTA00000527F.p.07.1 M00004029C:B03 23343 2065 Mar. 24, 1998 44 RTA00000527F.p.17.1 M00004030C:D12 17223 2066 Mar. 24, 1998 45 RTA00000528F.m.12.1 M00003842D:F08 5768 2067 Mar. 24, 1998 46 RTA00000523F.c.09.1 M00003813C:D08 47389 2068 Mar. 24, 1998 47 RTA00000523F.e.18.1 M00003829D:A11 62898 2069 Mar. 24, 1998 48 RTA00000527F.k.21.1 M00003982B:H10 36051 2070 Mar. 24, 1998 49 RTA00000527F.n.22.1 M00004027A:A08 24175 2071 Mar. 24, 1998 50 RTA00000522F.k.15.1 M00001652D:G06 76866 2072 Mar. 24, 1998 51 RTA00000522F.n.02.1 M00001655D:E08 74959 2073 Mar. 24, 1998 52 RTA00000523F.l.07.1 M00004927C:H11 0 2074 Mar. 24, 1998 53 RTA00000525F.c.17.1 M00004040A:C08 38160 2075 Mar. 24, 1998 54 RTA00000425F.f.19.1 M00001653D:G07 32635 2076 Mar. 24, 1998 55 RTA00000528F.e.23.1 M00001593B:D10 19242 2077 Mar. 24, 1998 56 RTA00000522F.n.16.1 M00001657D:A10 26769 2078 Mar. 24, 1998 57 RTA00000427F.c.20.1 M00003978A:E01 26527 2079 Mar. 24, 1998 58 RTA00000527F.k.06.1 M00003981B:B12 12469 2080 Mar. 24, 1998 59 RTA00000427F.n.14.1 M00004960B:D12 0 2081 Mar. 24, 1998 60 RTA00000523F.i.06.1 M00003855A:A01 66341 2082 Mar. 24, 1998 61 RTA00000427F.f.21.1 M00004118B:C11 36853 2083 Mar. 24, 1998 62 RTA00000427F.j.19.1 M00004077A:G12 41395 2084 Mar. 24, 1998 63 RTA00000522F.b.01.1 M00001570C:B02 75691 2085 Mar. 24, 1998 64 RTA00000424F.j.24.1 M00001596A:G06 79101 2086 Mar. 24, 1998 65 RTA00000523F.c.91.1 M00003810A:A02 65710 2087 Mar. 24, 1998 66 RTA00000427F.b.15.1 M00003971C:F09 66891 2088 Mar. 24, 1998 67 RTA00000527F.e.03.1 M00003825D:F01 25560 2089 Mar. 24, 1998 68 RTA00000523F.n.04.1 M00005138B:D12 0 2090 Mar. 24, 1998 69 RTA00000522F.j.15.2 M00001651C:G12 76535 2091 Mar. 24, 1998 70 RTA00000525F.e.07.1 M00004115C:G03 38147 2092 Mar. 24, 1998 71 RTA00000527F.j.20.2 M00003860D:E06 37603 2093 Mar. 24, 1998 72 RTA00000426F.f.19.1 M00003854C:C09 66701 2094 Mar. 24, 1998 73 RTA00000524F.b.12.1 M00005213C:G01 0 2095 Mar. 24, 1998 74 RTA00000527F.d.19.1 M00003825B:F10 486 2096 Mar. 24, 1998 75 RTA00000523F.j.22.1 M00003857A:E12 64688 2097 Mar. 24, 1998 76 RTA00000523F.l.18.1 M00005134D:A06 0 2098 Mar. 24, 1998 77 RTA00000425F.i.17.1 M00001633A:F11 43213 2099 Mar. 24, 1998 78 RTA00000427F.o.05.1 M00004958B:D01 0 2100 Mar. 24, 1998 79 RTA00000523F.l.15.1 M00005134C:E11 0 2101 Mar. 24, 1998 80 RTA00000425F.p.12.1 M00001638C:G01 73219 2102 Mar. 24, 1998 81 RTA00000427F.j.07.1 M00004105A:B10 64819 2103 Mar. 24, 1998 82 RTA00000523F.h.15.1 M00003851C:F09 65137 2104 Mar. 24, 1998 83 RTA00000527F.i.05.2 M00003851C:B06 37481 2105 Mar. 24, 1998 84 RTA00000527F.k.18.1 M00003982B:C10 11332 2106 Mar. 24, 1998 85 RTA00000427F.m.21.1 M00004900C:E11 0 2107 Mar. 24, 1998 86 RTA00000523F.k.01.1 M00003966C:F03 41437 2108 Mar. 24, 1998 87 RTA00000425F.j.11.1 M00001637C:H12 76667 2109 Mar. 24, 1998 88 RTA00000424F.b.22.4 M00001530A:F11 72971 2110 Mar. 24, 1998 89 RTA00000527F.n.02.1 M00003986C:G11 24190 2111 Mar. 24, 1998 90 RTA00000525F.a.03.1 M00004031D:F05 36786 2112 Mar. 24, 1998 91 RTA00000527F.j.21.2 M00003855A:F01 37490 2113 Mar. 24, 1998 92 RTA00000424F.a.24.4 M00001448D:E11 73951 2114 Mar. 24, 1998 93 RTA00000522F.k.14.1 M00001652D:G02 74280 2115 Mar. 24, 1998 94 RTA00000522F.n.05.1 M00001655D:H11 73260 2116 Mar. 24, 1998 95 RTA00000523F.c.18.1 M00003817C:A10 66179 2117 Mar. 24, 1998 96 RTA00000523F.b.13.1 M00003809B:A03 66330 2118 Mar. 24, 1998 97 RTA00000522F.j.14.2 M00001651C:D11 73123 2119 Mar. 24, 1998 98 RTA00000527F.p.16.1 M00004030C:C02 23798 2120 Mar. 24, 1998 99 RTA00000425F.c.20.1 M00001626D:A02 73581 2121 Mar. 24, 1998 100 RTA00000424F.i.21.1 M00001596A:E07 73482 2122 Mar. 24, 1998 101 RTA00000523F.j.19.1 M00003966B:D02 65910 2123 Mar. 24, 1998 102 RTA00000522F.g.19.1 M00001595C:A01 78119 2124 Mar. 24, 1998 103 RTA00000424F.b.22.1 M00001530A:F11 72971 2125 Mar. 24, 1998 104 RTA00000527F.b.18.1 M00003810D:H09 37469 2126 Mar. 24, 1998 105 RTA00000526F.d.01.1 M00004104B:A02 4468 2127 Mar. 24, 1998 106 RTA00000424F.j.14.1 M00001592B:B02 74311 2128 Mar. 24, 1998 107 RTA00000523F.n.20.1 M00005174D:H02 0 2129 Mar. 24, 1998 108 RTA00000525F.e.16.1 M00004117B:G01 36837 2130 Mar. 24, 1998 109 RTA00000424F.a.01.4 M00001575A:D05 43214 2131 Mar. 24, 1998 110 RTA00000522F.d.08.1 M00001578B:A06 74284 2132 Mar. 24, 1998 111 RTA00000425F.d.08.1 M00001631A:F06 74350 2133 Mar. 24, 1998 112 RTA00000523F.n.12.1 M00005173C:A02 0 2134 Mar. 24, 1998 113 RTA00000527F.g.07.1 M00003840C:C02 37488 2135 Mar. 24, 1998 114 RTA00000524F.a.23.1 M00005211C:E09 0 2136 Mar. 24, 1998 115 RTA00000525F.b.05.1 M00004034C:F05 21116 2137 Mar. 24, 1998 116 RTA00000425F.n.05.1 M00001647D:G07 73965 2138 Mar. 24, 1998 117 RTA00000523F.d.18.1 M00003822B:G01 64072 2139 Mar. 24, 1998 118 RTA00000525F.a.02.1 M00004031C:H10 37454 2140 Mar. 24, 1998 119 RTA00000523F.p.06.1 M00005177D:F09 0 2141 Mar. 24, 1998 120 RTA00000426F.h.09.1 M00003905B:G03 78797 2142 Mar. 24, 1998 121 RTA00000427F.n.02.1 M00004900D:B10 0 2143 Mar. 24, 1998 122 RTA00000523F.o.12.1 M00005177A:B06 0 2144 Mar. 24, 1998 123 RTA00000427F.g.05.1 M00004069C:C05 63138 2145 Mar. 24, 1998 124 RTA00000424F.m.12.1 M00001586C:H07 77675 2146 Mar. 24, 1998 125 RTA00000424F.a.01.1 M00001575A:D05 43214 2147 Mar. 24, 1998 126 RTA00000527F.m.05.1 M00003985A:C01 17240 2148 Mar. 24, 1998 127 RTA00000523F.n.10.1 M00005140D:G09 0 2149 Mar. 24, 1998 128 RTA00000428F.c.02.1 M00005229D:H07 0 2150 Mar. 24, 1998 129 RTA00000527F.p.18.1 M00004030D:B06 31635 2151 Mar. 24, 1998 130 RTA00000427F.h.12.1 M00004092C:D08 36894 2152 Mar. 24, 1998 131 RTA00000523F.c.15.1 M00003813D:G06 36935 2153 Mar. 24, 1998 132 RTA00000427F.k.17.1 M00004101A:F07 64965 2154 Mar. 24, 1998 133 RTA00000425F.f.04.1 M00001607A:B06 24633 2155 Mar. 24, 1998 134 RTA00000424F.c.14.3 M00001476D:A09 76614 2156 Mar. 24, 1998 135 RTA00000522F.k.10.2 M00001652D:B09 77619 2157 Mar. 24, 1998 136 RTA00000424F.m.22.1 M00001614C:E11 72943 2158 Mar. 24, 1998 137 RTA00000527F.h.17.1 M00003848D:G02 37799 2159 Mar. 24, 1998 138 RTA00000527F.c.22.1 M00003822B:G12 37496 2160 Mar. 24, 1998 139 RTA00000425F.k.22.1 M00001633C:E12 78123 2161 Mar. 24, 1998 140 RTA00000424F.m.14.1 M00001612D:D12 77491 2162 Mar. 24, 1998 141 RTA00000522F.k.19.1 M00001653A:A05 32625 2163 Mar. 24, 1998 142 RTA00000523F.i.18.1 M00003856B:C04 64463 2164 Mar. 24, 1998 143 RTA00000425F.j.22.1 M00001633B:E03 73882 2165 Mar. 24, 1998 144 RTA00000527F.g.23.1 M00003846C:F08 37538 2166 Mar. 24, 1998 145 RTA00000426F.m.24.1 M00003981A:A07 63943 2167 Mar. 24, 1998 146 RTA00000527F.i.17.2 M00003853B:C08 37539 2168 Mar. 24, 1998 147 RTA00000425F.d.21.1 M00001631B:H04 78920 2169 Mar. 24, 1998 148 RTA00000427F.n.18.1 M00004891D:C11 0 2170 Mar. 24, 1998 149 RTA00000424F.d.04.3 M00001478A:F12 76505 2171 Mar. 24, 1998 150 RTA00000424F.d.04.1 M00001478A:F12 76505 2172 Mar. 24, 1998 151 RTA00000427F.c.12.1 M00003976B:H07 66995 2173 Mar. 24, 1998 152 RTA00000425F.d.07.1 M00001631A:F12 43197 2174 Mar. 24, 1998 153 RTA00000527F.l.13.1 M00003983C:F10 36904 2175 Mar. 24, 1998 154 RTA00000522F.h.13.1 M00001596C:F09 40823 2176 Mar. 24, 1998 155 RTA00000424F.l.19.1 M00001609C:A12 75454 2177 Mar. 24, 1998 156 RTA00000525F.b.22.1 M00004037C:D07 16679 2178 Mar. 24, 1998 157 RTA00000523F.g.10.1 M00003848B:E07 40694 2179 Mar. 24, 1998 158 RTA00000427F.a.06.1 M00004036A:A11 66550 2180 Mar. 24, 1998 159 RTA00000525F.c.19.1 M00004040B:F07 38159 2181 Mar. 24, 1998 160 RTA00000523F.f.06.1 M00003833D:H08 62871 2182 Mar. 24, 1998 161 RTA00000424F.h.10.1 M00001485C:G06 72925 2183 Mar. 24, 1998 162 RTA00000522F.a.12.1 M00001567A:H05 33515 2184 Mar. 24, 1998 163 RTA00000522F.h.01.1 M00001595C:E05 75010 2185 Mar. 24, 1998 164 RTA00000523F.n.17.1 M00005174D:B02 0 2186 Mar. 24, 1998 165 RTA00000425F.e.21.1 M00001629D:D10 77203 2187 Mar. 24, 1998 166 RTA00000523F.f.07.1 M00003833D:H10 62799 2188 Mar. 24, 1998 167 RTA00000424F.i.20.1 M00001596A:D01 44010 2189 Mar. 24, 1998 168 RTA00000424F.j.12.1 M00001594C:E05 73827 2190 Mar. 24, 1998 169 RTA00000425F.f.05.1 M00001607A:D10 24090 2191 Mar. 24, 1998 170 RTA00000523F.d.12.1 M00003822B:D08 64888 2192 Mar. 24, 1998 171 RTA00000523F.e.10.1 M00003829A:F03 62878 2193 Mar. 24, 1998 172 RTA00000425F.f.11.1 M00001656C:C04 79275 2194 Mar. 24, 1998 173 RTA00000426F.m.18.1 M00003986D:G07 62974 2195 Mar. 24, 1998 174 RTA00000424F.b.21.4 M00001530A:B02 24686 2196 Mar. 24, 1998 175 RTA00000528F.d.18.1 M00001582C:E01 2684 2197 Mar. 24, 1998 176 RTA00000522F.g.15.1 M00001595B:G07 76536 2198 Mar. 24, 1998 177 RTA00000522F.n.12.1 M00001656A:H12 74117 2199 Mar. 24, 1998 178 RTA00000428F.a.12.1 M00005179B:H02 0 2200 Mar. 24, 1998 179 RTA00000424F.d.10.3 M00001530D:A11 73110 2201 Mar. 24, 1998 180 RTA00000523F.k.02.1 M00004687A:C03 0 2202 Mar. 24, 1998 181 RTA00000523F.b.06.1 M00003808A:F09 28736 2203 Mar. 24, 1998 182 RTA00000524F.b.17.1 M00005214B:A06 0 2204 Mar. 24, 1998 183 RTA00000527F.c.04.1 M00003813C:H08 23090 2205 Mar. 24, 1998 184 RTA00000524F.b.18.1 M00005214B:D11 0 2206 Mar. 24, 1998 185 RTA00000527F.h.23.1 M00003850C:G09 37630 2207 Mar. 24, 1998 186 RTA00000425F.c.07.1 M00001585D:F03 76042 2208 Mar. 24, 1998 187 RTA00000428F.b.23.1 M00005231D:H10 0 2209 Mar. 24, 1998 188 RTA00000525F.c.15.1 M00004040A:A07 7692 2210 Mar. 24, 1998 189 RTA00000424F.d.22.3 M00001448B:G07 76189 2211 Mar. 24, 1998 190 RTA00000523F.h.12.1 M00003851C:D07 65745 2212 Mar. 24, 1998 191 RTA00000522F.g.22.1 M00001595C:B12 77504 2213 Mar. 24, 1998 192 RTA00000523F.m.02.1 M00005134D:H03 0 2214 Mar. 24, 1998 193 RTA00000428F.b.12.1 M00005231C:B07 0 2215 Mar. 24, 1998 194 RTA00000522F.j.12.2 M00001651C:A04 74341 2216 Mar. 24, 1998 195 RTA00000523F.i.08.1 M00003855A:C12 65099 2217 Mar. 24, 1998 196 RTA00000523F.f.12.1 M00003840A:C10 63751 2218 Mar. 24, 1998 197 RTA00000425F.j.20.1 M00001633B:A12 26760 2219 Mar. 24, 1998 198 RTA00000523F.o.05.1 M00005175B:H04 0 2220 Mar. 24, 1998 199 RTA00000427F.f.24.1 M00004076D:B09 64572 2221 Mar. 24, 1998 200 RTA00000527F.a.13.1 M00003805D:E06 37740 2222 Mar. 24, 1998 201 RTA00000427F.n.17.1 M00004891D:A07 0 2223 Mar. 24, 1998 202 RTA00000528F.j.11.1 M00001669B:C12 1070 2224 Mar. 24, 1998 203 RTA00000427F.p.10.2 M00005102C:F09 0 2225 Mar. 24, 1998 204 RTA00000424F.a.09.4 M00001575C:C11 77833 2226 Mar. 24, 1998 205 RTA00000426F.h.12.1 M00003905C:F12 78093 2227 Mar. 24, 1998 206 RTA00000525F.f.07.1 M00004119A:A06 37500 2228 Mar. 24, 1998 207 RTA00000424F.j.07.1 M00001596B:C11 79211 2229 Mar. 24, 1998 208 RTA00000424F.m.10.1 M00001586C:E06 34251 2230 Mar. 24, 1998 209 RTA00000427F.g.16.1 M00004069A:E12 63011 2231 Mar. 24, 1998 210 RTA00000522F.g.06.1 M00001594D:G11 78221 2232 Mar. 24, 1998 211 RTA00000424F.h.03.1 M00001487C:G09 74447 2233 Mar. 24, 1998 212 RTA00000424F.n.06.1 M00001613A:D02 74737 2234 Mar. 24, 1998 213 RTA00000427F.c.22.1 M00003978A:E09 63990 2235 Mar. 24, 1998 214 RTA00000424F.k.12.1 M00001610C:B07 77666 2236 Mar. 24, 1998 215 RTA00000425F.f.02.1 M00001607A:A01 76982 2237 Mar. 24, 1998 216 RTA00000427F.h.11.1 M00004092C:B12 26494 2238 Mar. 24, 1998 217 RTA00000425F.j.16.1 M00001639D:F02 75631 2239 Mar. 24, 1998 218 RTA00000427F.i.19.1 M00004102C:D01 64206 2240 Mar. 24, 1998 219 RTA00000427F.f.17.1 M00004115A:B12 63803 2241 Mar. 24, 1998 220 RTA00000522F.o.18.1 M00001669B:H06 76366 2242 Mar. 24, 1998 221 RTA00000427F.j.22.1 M00004097D:B05 66367 2243 Mar. 24, 1998 222 RTA00000426F.p.10.1 M00004033D:C05 65845 2244 Mar. 24, 1998 223 RTA00000522F.m.02.1 M00001654C:G07 76834 2245 Mar. 24, 1998 224 RTA00000527F.k.09.1 M00003981C:F05 213 2246 Mar. 24, 1998 225 RTA00000527F.d.09.1 M00003824A:G11 10848 2247 Mar. 24, 1998 226 RTA00000425F.e.15.1 M00001608D:F11 75921 2248 Mar. 24, 1998 227 RTA00000427F.j.11.1 M00004097C:H08 26635 2249 Mar. 24, 1998 228 RTA00000523F.o.14.1 M00005177A:H09 0 2250 Mar. 24, 1998 229 RTA00000424F.n.13.1 M00001584D:B06 74942 2251 Mar. 24, 1998 230 RTA00000424F.g.14.1 M00001572A:B06 74879 2252 Mar. 24, 1998 231 RTA00000426F.e.17.1 M00003810C:B06 64089 2253 Mar. 24, 1998 232 RTA00000527F.j.13.2 M00003852B:G04 2924 2254 Mar. 24, 1998 233 RTA00000426F.f.13.1 M00003851A:A06 65384 2255 Mar. 24, 1998 234 RTA00000524F.c.16.1 M00005218D:G10 0 2256 Mar. 24, 1998 235 RTA00000427F.g.19.1 M00004087A:B05 64611 2257 Mar. 24, 1998 236 RTA00000527F.o.01.1 M00004027A:D06 19088 2258 Mar. 24, 1998 237 RTA00000522F.c.01.1 M00001576A:C11 74938 2259 Mar. 24, 1998 238 RTA00000522F.g.17.1 M00001595B:G10 76486 2260 Mar. 24, 1998 239 RTA00000523F.j.17.1 M00003966B:A04 63610 2261 Mar. 24, 1998 240 RTA00000522F.n.14.1 M00001657C:C11 73410 2262 Mar. 24, 1998 241 RTA00000527F.o.12.1 M00004028B:G08 688 2263 Mar. 24, 1998 242 RTA00000523F.e.20.1 M00003829D:F03 65164 2264 Mar. 24, 1998 243 RTA00000424F.c.15.3 M00001476D:F12 73533 2265 Mar. 24, 1998 244 RTA00000426F.p.09.1 M00004033D:B07 66665 2266 Mar. 24, 1998 245 RTA00000522F.p.09.1 M00001670A:F09 75204 2267 Mar. 24, 1998 246 RTA00000426F.m.21.1 M00003983A:F06 64915 2268 Mar. 24, 1998 247 RTA00000425F.j.21.1 M00001633B:B11 77373 2269 Mar. 24, 1998 248 RTA00000527F.l.14.1 M00003983D:A09 14935 2270 Mar. 24, 1998 249 RTA00000523F.h.21.1 M00003853B:C10 41440 2271 Mar. 24, 1998 250 RTA00000427F.h.24.1 M00004091B:H09 65193 2272 Mar. 24, 1998 251 RTA00000425F.f.24.1 M00001656D:C04 40841 2273 Mar. 24, 1998 252 RTA00000425F.m.03.1 M00001642D:G08 76045 2274 Mar. 24, 1998 253 RTA00000426F.m.08.1 M00004030B:A12 63781 2275 Mar. 24, 1998 254 RTA00000523F.d.24.1 M00003824D:D08 64799 2276 Mar. 24, 1998 255 RTA00000523F.c.14.1 M00003813D:C02 66015 2277 Mar. 24, 1998 256 RTA00000523F.b.20.1 M00003809C:H07 66492 2278 Mar. 24, 1998 257 RTA00000522F.h.07.1 M00001595D:C11 75149 2279 Mar. 24, 1998 258 RTA00000527F.g.10.1 M00003845A:E12 37820 2280 Mar. 24, 1998 259 RTA00000528F.m.04.1 M00003830D:H11 10815 2281 Mar. 24, 1998 260 RTA00000524F.b.02.1 M00005212A:A02 0 2282 Mar. 24, 1998 261 RTA00000427F.i.22.1 M00004104D:B05 63199 2283 Mar. 24, 1998 262 RTA00000424F.k.03.1 M00001590D:B04 21289 2284 Mar. 24, 1998 263 RTA00000527F.n.07.1 M00003986D:H12 15939 2285 Mar. 24, 1998 264 RTA00000425F.e.09.1 M00001608C:G04 75550 2286 Mar. 24, 1998 265 RTA00000427F.h.02.1 M00004085B:G01 63652 2287 Mar. 24, 1998 266 RTA00000426F.f.16.1 M00003813B:F02 65613 2288 Mar. 24, 1998 267 RTA00000425F.i.21.1 M00001635B:B02 75305 2289 Mar. 24, 1998 268 RTA00000427F.k.19.1 M00004103B:B07 62851 2290 Mar. 24, 1998 269 RTA00000427F.p.02.2 M00005100B:D02 0 2291 Mar. 24, 1998 270 RTA00000426F.g.16.1 M00003814B:C01 41446 2292 Mar. 24, 1998 271 RTA00000527F.l.05.1 M00003983A:D02 13016 2293 Mar. 24, 1998 272 RTA00000426F.m.02.1 M00004034C:C06 66237 2294 Mar. 24, 1998 273 RTA00000424F.a.02.4 M00001575A:D06 78806 2295 Mar. 24, 1998 274 RTA00000523F.h.06.1 M00003851B:D03 28745 2296 Mar. 24, 1998 275 RTA00000522F.l.22.1 M00001654C:D10 75801 2297 Mar. 24, 1998 276 RTA00000427F.h.19.1 M00004092D:B11 63047 2298 Mar. 24, 1998 277 RTA00000427F.e.08.1 M00003974D:E01 47387 2299 Mar. 24, 1998 278 RTA00000522F.g.21.1 M00001595C:A09 77310 2300 Mar. 24, 1998 279 RTA00000528F.b.03.1 M00001455A:D10 2078 2301 Mar. 24, 1998 280 RTA00000522F.g.20.1 M00001595C:A05 77688 2302 Mar. 24, 1998 281 RTA00000527F.k.20.1 M00003982B:H07 17148 2303 Mar. 24, 1998 282 RTA00000427F.h.22.1 M00004108C:E01 64547 2304 Mar. 24, 1998 283 RTA00000425F.k.20.1 M00001633C:A08 74048 2305 Mar. 24, 1998 284 RTA00000524F.b.19.1 M00005216B:D02 0 2306 Mar. 24, 1998 285 RTA00000522F.b.07.1 M00001570D:E05 78634 2307 Mar. 24, 1998 286 RTA00000426F.g.19.1 M00003858B:G02 63672 2308 Mar. 24, 1998 287 RTA00000525F.d.19.1 M00004114B:D09 36860 2309 Mar. 24, 1998 288 RTA00000427F.l.04.1 M00005136D:C01 0 2310 Mar. 24, 1998 289 RTA00000427F.d.10.1 M00003978C:A12 40685 2311 Mar. 24, 1998 290 RTA00000427F.l.03.1 M00005136D:B07 0 2312 Mar. 24, 1998 291 RTA00000523F.o.23.1 M00005177C:G04 0 2313 Mar. 24, 1998 292 RTA00000424F.a.05.4 M00001575B:C0: 77976 2314 Mar. 24, 1998 293 RTA00000525F.c.02.1 M00004038A:E05 14618 2315 Mar. 24, 1998 294 RTA00000424F.a.05.1 M00001575B:C01 77976 2316 Mar. 24, 1998 295 RTA00000522F.l.15.1 M00001654B:A01 74691 2317 Mar. 24, 1998 296 RTA00000425F.e.02.1 M00001625C:F10 76143 2318 Mar. 24, 1998 297 RTA00000525F.c.11.1 M00004039C:E02 37895 2319 Mar. 24, 1998 298 RTA00000527F.e.08.1 M00003826B:B04 19015 2320 Mar. 24, 1998 299 RTA00000522F.c.14.1 M00001577A:A03 75449 2321 Mar. 24, 1998 300 RTA00000424F.m.08.1 M00001584A:A07 19402 2322 Mar. 24, 1998 301 RTA00000527F.f.18.1 M00003830D:B11 37577 2323 Mar. 24, 1998 302 RTA00000427F.p.04.2 M00005100B:H07 0 2324 Mar. 24, 1998 303 RTA00000522F.a.06.1 M00001567A:C11 73662 2325 Mar. 24, 1998 304 RTA00000525F.d.13.1 M00004110C:E03 349 2326 Mar. 24, 1998 305 RTA00000523F.n.16.1 M00005173D:H02 0 2327 Mar. 24, 1998 306 RTA00000522F.d.23.1 M00001579D:F02 73868 2328 Mar. 24, 1998 307 RTA00000427F.p.03.2 M00005100B:G11 0 2329 Mar. 24, 1998 308 RTA00000424F.k.23.1 M00001614A:B10 31061 2330 Mar. 24, 1998 309 RTA00000523F.j.10.1 M00003860B:G09 63384 2331 Mar. 24, 1998 310 RTA00000527F.p.08.1 M00004029C:F02 36013 2332 Mar. 24, 1998 311 RTA00000428F.b.02.1 M00005214D:D10 0 2333 Mar. 24, 1998 312 RTA00000426F.f.17.1 M00003811C:C02 66334 2334 Mar. 24, 1998 313 RTA00000523F.j.21.1 M00003966C:A12 36925 2335 Mar. 24, 1998 314 RTA00000522F.e.09.1 M00001589D:A01 32599 2336 Mar. 24, 1998 315 RTA00000427F.n.19.1 M00004891D:E07 0 2337 Mar. 24, 1998 316 RTA00000523F.h.16.1 M00003851D:H11 66031 2338 Mar. 24, 1998 317 RTA00000428F.a.01.1 M00004897D:G05 0 2339 Mar. 24, 1998 318 RTA00000523F.a.01.1 M00001671C:F11 74923 2340 Mar. 24, 1998 319 RTA00000523F.p.15.1 M00005178B:H01 0 2341 Mar. 24, 1998 320 RTA00000427F.j.06.1 M00004102D:B05 63676 2342 Mar. 24, 1998 321 RTA00000424F.m.04.1 M00001609C:G05 79017 2343 Mar. 24, 1998 322 RTA00000523F.i.17.1 M00003856B:A12 65779 2344 Mar. 24, 1998 323 RTA00000524F.c.12.1 M00005218B:D09 0 2345 Mar. 24, 1998 324 RTA00000523F.o.09.1 M00005176A:C12 0 2346 Mar. 24, 1998 325 RTA00000525F.c.18.1 M00004040B:C05 24208 2347 Mar. 24, 1998 326 RTA00000527F.e.09.1 M00003826B:E11 37521 2348 Mar. 24, 1998 327 RTA00000424F.j.08.1 M00001596B:D09 73972 2349 Mar. 24, 1998 328 RTA00000523F.n.01.1 M00005137A:E01 0 2350 Mar. 24, 1998 329 RTA00000527F.c.09.1 M00003817C:G06 64859 2351 Mar. 24, 1998 330 RTA00000523F.d.23.1 M00003824C:A10 63633 2352 Mar. 24, 1998 331 RTA00000528F.k.10.1 M00001678C:F09 1981 2353 Mar. 24, 1998 332 RTA00000523F.c.03.1 M00003810B:B11 36913 2354 Mar. 24, 1998 333 RTA00000427F.k.21.1 M00004090D:F12 62880 2355 Mar. 24, 1998 334 RTA00000427F.n.11.1 M00004960B:A09 0 2356 Mar. 24, 1998 335 RTA00000427F.d.09.1 M00003980C:F12 66486 2357 Mar. 24, 1998 336 RTA00000426F.n.17.1 M00004039D:B10 66572 2358 Mar. 24, 1998 337 RTA00000525F.e.08.1 M00004115C:H04 24193 2359 Mar. 24, 1998 338 RTA00000523F.e.15.1 M00003829C:E08 7919 2360 Mar. 24, 1998 339 RTA00000426F.m.03.1 M00004034C:E08 66480 2361 Mar. 24, 1998 340 RTA00000424F.h.06.1 M00001485C:D07 77552 2362 Mar. 24, 1998 341 RTA00000425F.d.06.1 M00001631A:D03 77660 2363 Mar. 24, 1998 342 RTA00000427F.e.12.1 M00003959C:G06 62813 2364 Mar. 24, 1998 343 RTA00000527F.c.11.1 M00003817D:D12 37484 2365 Mar. 24, 1998 344 RTA00000425F.p.15.1 M00001638C:R07 31680 2366 Mar. 24, 1998 345 RTA00000426F.n.23.1 M00004030C:A08 18176 2367 Mar. 24, 1998 346 RTA00000522F.m.19.1 M00001655C:C07 41544 2368 Mar. 24, 1998 347 RTA00000522F.a.05.1 M00001567A:C04 32611 2369 Mar. 24, 1998 348 RTA00000427F.i.09.1 M00004097C:E03 65916 2370 Mar. 24, 1998 349 RTA00000424F.j.09.1 M00001596B:H05 74387 2371 Mar. 24, 1998 350 RTA00000424F.n.11.1 M00001582C:C04 73874 2372 Mar. 24, 1998 351 RTA00000523F.l.03.1 M00004927A:A02 0 2373 Mar. 24, 1998 352 RTA00000527F.e.13.1 M00003826C:F05 37588 2374 Mar. 24, 1998 353 RTA00000428F.a.18.1 M00005214C:A09 0 2375 Mar. 24, 1998 354 RTA00000425F.j.19.1 M00001639D:006 77925 2376 Mar. 24, 1998 355 RTA00000522F.g.12.1 M00001595A:E07 78783 2377 Mar. 24, 1998 356 RTA00000523F.g.07.1 M00001693A:H06 75804 2378 Mar. 24, 1998 357 RTA00000425F.e.19.1 M00001629D:B10 73409 2379 Mar. 24, 1998 358 RTA00000425F.n.19.1 M00001638B:C08 78324 2380 Mar. 24, 1998 359 RTA00000523F.d.21.1 M00003824B:C09 33424 2381 Mar. 24, 1998 360 RTA00000521F.j.03.1 M00003860A:A08 64535 2382 Mar. 24, 1998 361 RTA00000523F.p.08.1 M00005178A:A07 0 2383 Mar. 24, 1998 362 RTA00000523F.p.09.1 M00005178A:A08 0 2384 Mar. 24, 1998 363 RTA00000427F.k.07.1 M00004099A:F11 63742 2385 Mar. 24, 1998 364 RTA00000523F.m.07.1 M00005136A:D10 0 2386 Mar. 24, 1998 365 RTA00000527F.k.16.1 M00003982B:B06 1015 2387 Mar. 24, 1998 366 RTA00000522F.a.17.1 M00001567C:B08 79032 2388 Mar. 24, 1998 361 RTA00000527F.l.19.1 M00003983D:E08 36856 2389 Mar. 24, 1998 368 RTA00000424F.i.11.1 M00001485D:A05 41569 2390 Mar. 24, 1998 369 RTA00000524F.c.08.1 M00005217C:C01 0 2391 Mar. 24, 1998 370 RTA00000424F.d.19.3 M00001448B:A07 73180 2392 Mar. 24, 1998 371 RTA00000522F.j.09.2 M00001650D:F11 78522 2393 Mar. 24, 1998 372 RTA00000424F.m.24.1 M00001614C:G07 77045 2394 Mar. 24, 1998 373 RTA00000522F.j.19.2 M00001652B:D06 76224 2395 Mar. 24, 1998 374 RTA00000528F.f.10.1 M00001596C:G05 3600 2396 Mar. 24, 1998 375 RTA00000427F.p.19.2 M00004895C:G05 0 2397 Mar. 24, 1998 376 RTA00000525F.b.21.1 M00004037C:D04 9486 2398 Mar. 24, 1998 377 RTA00000527F.j.12.2 M00003857C:E05 37503 2399 Mar. 24, 1998 378 RTA00000522F.g.11.1 M00001595A:D12 75432 2400 Mar. 24, 1998 379 RTA00000522F.k.02.2 M00001652C:B09 77622 2401 Mar. 24, 1998 380 RTA00000427F.e.13.1 M00003959D:A04 66080 2402 Mar. 24, 1998 381 RTA00000426F.f.18.1 M00003854C:C02 63271 2403 Mar. 24, 1998 382 RTA00000427F.a.12.1 M00003982C:H10 63377 2404 Mar. 24, 1998 383 RTA00000424F.b.23.4 M00001530A:H05 77322 2405 Mar. 24, 1998 384 RTA00000527F.p.03.1 M00004029B:A06 5940 2406 Mar. 24, 1998 385 RTA00000426F.f.12.1 M00003823C:C04 19096 2407 Mar. 24, 1998 386 RTA00000523F.l.16.1 M00005134C:G04 0 2408 Mar. 24, 1998 387 RTA00000427F.f.02.1 M00004118D:A11 36822 2409 Mar. 24, 1998 388 RTA00000526F.d.17.1 M00004235A:A12 2757 2410 Mar. 24, 1998 389 RTA00000424F.i.15.1 M00001596A:A02 78043 2411 Mar. 24, 1998 390 RTA00000524F.a.11.1 M00005210D:C09 0 2412 Mar. 24, 1998 391 RTA00000522F.m.03.1 M00001654C:G09 79194 2413 Mar. 24, 1998 392 RTA00000522F.a.20.1 M00001567C:E07 74070 2414 Mar. 24, 1998 393 RTA00000424F.b.15.4 M00001539B:B10 74958 2415 Mar. 24, 1998 394 RTA00000527F.g.14.1 M00003845D:B02 37532 2416 Mar. 24, 1998 395 RTA00000522F.d.06.1 M00001578B:A02 74809 2417 Mar. 24, 1998 396 RTA00000528F.g.05.2 M00001615C:E07 3770 2418 Mar. 24, 1998 397 RTA00000427F.e.10.1 M00003974D:H07 64599 2419 Mar. 24, 1998 398 RTA00000527F.c.16.1 M00003821A:H09 22908 2420 Mar. 24, 1998 399 RTA00000524F.c.07.1 M00005217A:G10 0 2421 Mar. 24, 1998 400 RTA00000523F.f.17.1 M00003840B:E08 63984 2422 Mar. 24, 1998 401 RTA00000525F.c.16.1 M00004040A:B04 38209 2423 Mar. 24, 1998 402 RTA00000527F.p.24.1 M00004031B:A06 36832 2424 Mar. 24, 1998 403 RTA00000425F.n.17.1 M00001636A:H12 78304 2425 Mar. 24, 1998 404 RTA00000522F.b.18.1 M00001573B:A06 3460 2426 Mar. 24, 1998 405 RTA00000425F.c.07.1 M00001608C:D02 75992 2427 Mar. 24, 1998 406 RTA00000523F.o.07.1 M00005176A:A05 0 2428 Mar. 24, 1998 407 RTA00000523F.h.08.1 M00003851B:E01 62893 2429 Mar. 24, 1998 408 RTA00000522F.o.10.1 M00001660D:E05 78798 2430 Mar. 24, 1998 409 RTA00000425F.l.10.1 M00001638A:C08 26893 2431 Mar. 24, 1998 410 RTA00000427F.f.16.1 M00004119D:H06 64122 2432 Mar. 24, 1998 411 RTA00000424F.n.12.1 M00001582C:G02 41589 2433 Mar. 24, 1998 412 RTA00000425F.i.11.1 M00001664B:F06 21716 2434 Mar. 24, 1998 413 RTA00000425F.i.10.1 M00001664B:E05 78736 2435 Mar. 24, 1998 414 RTA00000426F.m.12.1 M00004030B:D08 63740 2436 Mar. 24, 1998 415 RTA00000527F.g.12.1 M00003845C:D04 37746 2437 Mar. 24, 1998 416 RTA00000527F.i.12.2 M00003852B:D11 0 2438 Mar. 24, 1998 417 RTA00000524F.b.10.1 M00005213C:A01 0 2439 Mar. 24, 1998 418 RTA00000425F.i.18.1 M00001633A:G10 42255 2440 Mar. 24, 1998 419 RTA00000428F.b.22.1 M00005231D:B09 0 2441 Mar. 24, 1998 420 RTA00000424F.j.13.1 M00001594C:H03 74485 2442 Mar. 24, 1998 421 RTA00000523F.i.10.1 M00003855B:B09 64876 2443 Mar. 24, 1998 422 RTA00000527F.f.03.1 M00003829A:B08 17788 2444 Mar. 24, 1998 423 RTA00000427F.p.06.2 M00005102C:C01 0 2445 Mar. 24, 1998 424 RTA00000424F.k.10.1 M00001592D:H02 73232 2446 Mar. 24, 1998 425 RTA00000522F.i.07.2 M00001649A:E10 78377 2447 Mar. 24, 1998 426 RTA00000424F.k.21.1 M00001614A:A04 73197 2448 Mar. 24, 1998 427 RTA00000522F.b.08.1 M00001570D:E06 26915 2449 Mar. 24, 1998 428 RTA00000522F.l.08.1 M00001654A:E08 78781 2450 Mar. 24, 1998 429 RTA00000525F.a.14.1 M00004033B:C02 37566 2451 Mar. 24, 1998 430 RTA00000424F.g.08.1 M00001482C:F09 74928 2452 Mar. 24, 1998 431 RTA00000425F.l.09.1 M00001638A:B04 75251 2453 Mar. 24, 1998 432 RTA00000522F.o.20.1 M00001669C:B09 74853 2454 Mar. 24, 1998 433 RTA00000527F.j.04.2 M00003856A:G04 11809 2455 Mar. 24, 1998 434 RTA00000522F.c.11.1 M00001576C:H02 31064 2456 Mar. 24, 1998 435 RTA00000523F.c.13.1 M00003813D:B12 40668 2457 Mar. 24, 1998 436 RTA00000427F.i.21.1 M00004102C:F03 65540 2458 Mar. 24, 1998 437 RTA00000427F.n.10.1 M00004960B:A08 0 2459 Mar. 24, 1998 438 RTA00000522F.h.02.1 M00001595C:E09 74947 2460 Mar. 24, 1998 439 RTA00000522F.g.10.1 M00001595A:C07 74294 2461 Mar. 24, 1998 440 RTA00000523F.o.22.1 M00005177C:B04 0 2462 Mar. 24, 1998 441 RTA00000528F.g.22.2 M00001630C:F09 920 2463 Mar. 24, 1998 442 RTA00000425F.d.14.1 M00001629A:H09 13417 2464 Mar. 24, 1998 443 RTA00000425F.k.16.1 M00001640A:F05 75282 2465 Mar. 24, 1998 444 RTA00000525F.b.09.1 M00004035B:F05 23472 2466 Mar. 24, 1998 445 RTA00000522F.j.08.2 M00001650D:D10 76613 2467 Mar. 24, 1998 446 RTA00000425F.f.20.1 M00001653D:H07 74071 2468 Mar. 24, 1998 447 RTA00000523F.f.19.1 M00003840B:F05 34169 2469 Mar. 24, 1998 448 RTA00000425F.j.18.1 M00001639D:G12 75561 2470 Mar. 24, 1998 449 RTA00000426F.m.04.1 M00004028A:B10 36865 2471 Mar. 24, 1998 450 RTA00000527F.g.21.1 M00003846B:C05 36028 2472 Mar. 24, 1998 451 RTA00000527F.i.15.2 M00003852C:F07 14235 2473 Mar. 24, 1998 452 RTA00000525F.a.22.1 M00004033D:G06 36848 2474 Mar. 24, 1998 453 RTA00000522F.p.22.1 M00001671B:F02 73322 2475 Mar. 24, 1998 454 RTA00000424F.d.12.2 M00001530D:E06 74342 2476 Mar. 24, 1998 455 RTA00000424F.g.24.1 M00001487C:A11 79156 2477 Mar. 24, 1998 456 RTA00000427F.a.10.1 M00004038B:D01 65370 2478 Mar. 24, 1998 457 RTA00000426F.h.20.1 M00003905A:H11 23187 2479 Mar. 24, 1998 458 RTA00000424F.d.12.3 M00001530D:E06 74342 2480 Mar. 24, 1998 459 RTA00000425F.c.03.1 M00001585D:B12 74643 2481 Mar. 24, 1998 460 RTA00000523F.f.16.1 M00003840B:E07 26522 2482 Mar. 24, 1998 461 RTA00000427F.f.15.1 M00004119D:A07 66734 2483 Mar. 24, 1998 462 RTA00000427F.p.13.2 M00004695B:E04 0 2484 Mar. 24, 1998 463 RTA00000523F.p.16.1 M00005179D:B03 0 2485 Mar. 24, 1998 464 RTA00000522F.p.18.1 M00001671A:H06 76376 2486 Mar. 24, 1998 465 RTA00000528F.d.04.1 M00001570D:E07 2395 2487 Mar. 24, 1998 466 RTA00000427F.d.06.1 M00003980B:C06 33446 2488 Mar. 24, 1998 467 RTA00000528F.h.02.2 M00001632C:D08 1701 2489 Mar. 24, 1998 468 RTA00000524F.a.18.1 M00005211A:E09 0 2490 Mar. 24, 1998 469 RTA00000522F.e.20.1 M00001590B:H10 26770 2491 Mar. 24, 1998 470 RTA00000427F.p.24.2 M00004897D:F03 0 2492 Mar. 24, 1998 471 RTA00000528F.c.11.1 M00001486D:D12 1701 2493 Mar. 24, 1998 472 RTA00000522F.g.18.1 M00001595B:H11 73226 2494 Mar. 24, 1998 473 RTA00000523F.o.21.1 M00005177C:A01 0 2495 Mar. 24, 1998 474 RTA00000522F.h.05.1 M00001595C:H11 73358 2496 Mar. 24, 1998 475 RTA00000427F.i.06.1 M00004097B:D03 41450 2497 Mar. 24, 1998 476 RTA00000425F.n.16.1 M00001636A:C02 18265 2498 Mar. 24, 1998 477 RTA00000527F.l.21.1 M00003983D:H02 36439 2499 Mar. 24, 1998 478 RTA00000527F.p.09.1 M00004029C:F05 7694 2500 Mar. 24, 1998 479 RTA00000527F.l.23.1 M00003984A:B06 36018 2501 Mar. 24, 1998 480 RTA00000424F.d.17.3 M00001455A:E11 73958 2502 Mar. 24, 1998 481 RTA00000523F.j.02.1 M00003857A:H10 62853 2503 Feb. 24, 1998 1132 RTA00000119A.c.12.1 M00001453A:D08 4882 2504 Feb. 24, 1998 6 RTA00000119A.j.15.1 M00001460A:E11 79623 2505 Feb. 24, 1998 1041 RTA00000403F.b.05.1 M00001455B:E07 74300 2506 Feb. 24, 1998 994 RTA00000408F.b.04.2 M00001455A:F04 39933 2507 Feb. 24, 1998 401 RTA00000132A.c.11.1 M00001454A:G03 87278 2508 Feb. 24, 1998 535 RTA00000119A.g.7.1 M00001454A:F11 83580 2509 Feb. 24, 1998 867 RTA00000339F.l.21.1 M00001455D:D11 9781 2510 Feb. 24, 1998 62 RTA00000339F.n.10.1 M00001453B:F08 13719 2511 Feb. 24, 1998 380 RTA00000403F.b.19.1 M00001456B:A06 22327 2512 Jan. 28, 1998 288 RTA00000181AR.i.06.3 M00001452A:C07 19119 2512 Feb. 24, 1998 198 RTA00000339R.l.14.1 M00001452A:C07 19119 2513 Jan. 28, 1998 288 RTA00000181AR.i.06.3 M00001452A:C07 19119 2513 Feb. 24, 1998 198 RTA00000339R.l.14.1 M00001452A:C07 19119 2514 Feb. 24, 1998 264 RTA00000345F.j.08.1 M00001451B:A04 16731 2515 Feb. 24, 1998 1125 RTA00000118A.n.5.1 M00001451A:C10 0 2516 Feb. 24, 1998 229 RTA00000345F.i.09.1 M00001450A:D08 27250 2517 Feb. 24, 1998 670 RTA00000131A.i.6.1 M00001450A:B08 0 2518 Feb. 24, 1998 892 RTA00000339F.m.17.1 M00001453B:H12 20854 2519 Feb. 24, 1998 1123 RTA00000408F.c.23.1 M00001458C:D10 42261 2520 Feb. 24, 1998 680 RTA00000345F.e.11.1 M00001391C:C04 4392 2521 Feb. 24, 1998 644 RTA00000119A.j.9.1 M00001460A:B12 82060 2522 Feb. 24, 1998 972 RTA00000408F.d.15.1 M00001459B:C11 78467 2523 Feb. 24, 1998 1081 RTA00000403F.d.02.1 M00001458D:D01 39224 2524 Feb. 24, 1998 231 RTA00000408F.d.06.1 M00001458D:C11 78997 2525 Feb. 24, 1998 663 RTA00000403F.b.12.1 M00001455D:A06 78775 2526 Feb. 24, 1998 856 RTA00000408F.d.02.1 M00001458D:A01 79169 2527 Feb. 24, 1998 743 RTA00000345F.i.08.1 M00001449D:G10 0 2528 Feb. 24, 1998 1162 RTA00000408F.c.10.1 M00001458A:A11 18247 2529 Feb. 24, 1998 841 RTA00000119A.i.8.1 M00001457A:G12 82593 2530 Feb. 24, 1998 677 RTA00000119A.h.24.1 M00001457A:C05 82266 2531 Feb. 24, 1998 750 RTA00000403F.c.05.1 M00001456C:C11 74935 2532 Feb. 24, 1998 751 RTA00000422F.i.02.1 M00001456C:B12 76436 2533 Feb. 24, 1998 920 RTA00000403F.b.24.1 M00001456B:G01 78838 2534 Feb. 24, 1998 1251 RTA00000408F.d.03.1 M00001458D:A02 22768 2535 Feb. 24, 1998 450 RTA00000118A.a.23.1 M00001395A:H02 3500 2536 Feb. 24, 1998 85 RTA00000339F.k.22.1 M00001427C:D01 5556 2537 Feb. 24, 1998 684 RTA00000339F.k.20.1 M00001426D:D12 6662 2538 Feb. 24, 1998 129 RTA00000118A.d.24.1 M00001416A:H02 81488 2539 Feb. 24, 1998 397 RTA00000118A.d.17.1 M00001416A:D09 81921 2540 Feb. 24, 1998 158 RTA00000348R.j.16.1 M00001410A:D07 7005 2541 Feb. 24, 1998 1025 RTA00000118A.j.24.1 M00001450A:B03 18 2542 Feb. 24, 1998 1005 RTA00000339F.e.17.1 M00001397D:G08 7568 2543 Feb. 24, 1998 1040 RTA00000348R.o.12.1 M00001433C:F10 2263 2544 Feb. 24, 1998 746 RTA00000345F.e.02.1 M00001395A:E03 0 2545 Feb. 24, 1998 517 RTA00000118A.a.2.1 M00001395A:A12 38067 2546 Feb. 24, 1998 1065 RTA00000195R.a.06.1 M00001394A:E04 35265 2546 Jan. 28, 1998 595 RTA00000195R.a.06.1 M00001394A:E04 35265 2547 Jan. 28, 1998 595 RTA00000195R.a.06.1 M00001394A:E04 35265 2547 Feb. 24, 1998 1065 RTA00000195R.a.06.1 M00001394A:E04 35265 2548 Jan. 28, 1998 675 RTA00000179AR.b.21.3 M00001392C:D05 4366 2548 Feb. 24, 1998 1264 RTA00000345F.e.13.1 M00001392C:D05 4366 2549 Jan. 28, 1998 562 RTA00000196F.j.12.1 M00001396A:H03 19294 2550 Feb. 24, 1998 1042 RTA00000339F.g.10.1 M00001400C:D02 6327 2551 Feb. 24, 1998 706 RTA00000403F.a.09.1 M00001448B:H05 77820 2552 Feb. 24, 1998 823 RTA00000119A.k.1.1 M00001460A:H11 81282 2553 Feb. 24, 1998 703 RTA00000339F.n.05.1 M00001449D:B01 39648 2554 Feb. 24, 1998 787 RTA00000345F.i.24.1 M00001449C:C05 0 2555 Feb. 24, 1998 68 RTA00000339F.n.03.1 M00001449B:B03 0 2556 Feb. 24, 1998 440 RTA00000403F.a.18.1 M00001448D:F12 75726 2557 Feb. 24, 1998 815 RTA00000403F.a.17.1 M00001448D:E12 13686 2558 Feb. 24, 1998 275 RTA00000353R.j.24.1 M00001428B:D01 23089 2559 Feb. 24, 1998 902 RTA00000403F.a.10.1 M00001448C:E11 73952 2560 Feb. 24, 1998 1214 RTA00000339F.j.07.1 M00001428D:B10 5673 2561 Feb. 24, 1998 378 RTA00000403F.a.07.1 M00001448B:F09 73559 2562 Feb. 24, 1998 473 RTA00000403F.a.05.1 M00001448A:E11 18808 2563 Feb. 24, 1998 128 RTA00000403F.a.04.1 M00001448A:B12 23529 2564 Feb. 24, 1998 227 RTA00000347F.c.06.1 M00001444D:C01 18846 2565 Feb. 24, 1998 35 RTA00000339F.i.13.1 M00001434A:B10 5970 2566 Feb. 24, 1998 442 RTA00000347F.b.02.1 M00001450A:A02 39304 2567 Feb. 24, 1998 288 RTA00000403F.a.11.1 M00001448C:F10 73109 2568 Feb. 24, 1998 853 RTA00000408F.j.13.2 M00001485B:D10 42275 2569 Feb. 24, 1998 249 RTA00000119A.j.10.1 M00001460A:C10 79646 2570 Feb. 24, 1998 634 RTA00000418F.c.04.1 M00001487B:A11 41587 2571 Feb. 24, 1998 110 RTA00000408F.k.14.1 M00001486B:E12 73856 2572 Feb. 24, 1998 894 RTA00000408F.k.12.1 M00001486B:D07 77246 2573 Feb. 24, 1998 395 RTA00000408F.j.19.2 M00001485C:C08 73752 2574 Feb. 24, 1998 509 RTA00000349R.g.10.1 M00001495B:B08 5777 2575 Feb. 24, 1998 426 RTA00000408F.j.15.2 M00001485B:F05 74759 2576 Feb. 24, 1998 101 RTA00000121A.m.2.1 M00001507A:A11 81064 2577 Feb. 24, 1998 330 RTA00000403F.i.04.1 M00001485B:D09 8930 2578 Feb. 24, 1998 647 RTA00000418F.b.23.1 M00001485A:C05 28767 2579 Feb. 24, 1998 569 RTA00000403F.h.18.1 M00001484C:A04 39241 2580 Feb. 24, 1998 236 RTA00000403F.h.12.1 M00001483C:G09 15205 2581 Feb. 24, 1998 707 RTA00000403F.h.11.1 M00001483B:D04 39219 2582 Feb. 24, 1998 869 RTA00000403F.h.07.1 M00001482D:H11 26856 2583 Feb. 24, 1998 1101 RTA00000408F.j.17.2 M00001485B:H03 78935 2584 Feb. 24, 1998 344 RTA00000403F.m.15.2 M00001575D:D12 26901 2585 Feb. 24, 1998 768 RTA00000121A.k.5.1 M00001507A:E04 17530 2586 Feb. 24, 1998 1174 RTA00000121A.k.22.1 M00001507A:C05 79523 2587 Feb. 24, 1998 184 RTA00000133A.j.13.1 M00001507A:B02 16846 2588 Feb. 24, 1998 1230 RTA00000399F.j.14.1 M00001578C:F05 16942 2589 Feb. 24, 1998 304 RTA00000403F.n.18.2 M00001577D:H06 8811 2590 Feb. 24, 1998 938 RTA00000403F.i.23.1 M00001487B:E10 11364 2591 Feb. 24, 1998 1131 RTA00000418F.e.20.1 M00001576C:G05 73741 2592 Feb. 24, 1998 651 RTA00000403F.g.11.1 M00001481A:H08 24238 2593 Feb. 24, 1998 312 RTA00000399F.j.08.1 M00001575D:B10 38927 2594 Feb. 24, 1998 800 RTA00000403F.m.12.1 M00001575D:A02 16933 2595 Feb. 24, 1998 1017 RTA00000418F.e.03.1 M000015738:G08 73442 2596 Feb. 24, 1998 269 RTA00000422F.e.08.1 M00001573A:E01 39020 2597 Feb. 24, 1998 1247 RTA00000408F.o.13.1 M00001572A:B05 74895 2598 Feb. 24, 1998 847 RTA00000403F.l.11.1 M00001571D:F05 25073 2599 Feb. 24, 1998 910 RTA00000418F.f.03.1 M00001577B:F10 78911 2600 Feb. 24, 1998 244 RTA00000120A.g.23.1 M00001465A:E10 81189 2601 Feb. 24, 1998 1189 RTA00000339F.o.18.1 M00001469B:B01 6641 2602 Feb. 24, 1998 1266 RTA00000121A.a.2.1 M00001468A:H10 81843 2603 Feb. 24, 1998 414 RTA00000120A.p.18.1 M00001468A:C05 6478 2604 Feb. 24, 1998 96 RTA00000120A.n.19.3 M00001467A:H07 80004 2605 Feb. 24, 1998 1231 RTA00000120A.m.13.3 M00001467A:C10 80608 2606 Feb. 24, 1998 134 RTA00000408F.i.08.2 M00001482A:H05 75811 2607 Feb. 24, 1998 410 RTA00000120A.h.5.1 M00001465A:G06 80344 2608 Feb. 24, 1998 403 RTA00000403F.d.22.1 M00001473A:A07 10692 2609 Feb. 24, 1998 183 RTA00000120A.g.18.1 M00001465A:C12 81255 2610 Feb. 24, 1998 810 RTA00000120A.h.9.1 M00001465A:B12 80736 2611 Feb. 24, 1998 71 RTA00000120A.d.24.1 M00001464A:E10 5085 2612 Feb. 24, 1998 490 RTA00000120A.d.15.1 M00001464A:B02 80533 2613 Feb. 24, 1998 736 RTA00000120A.c.7.1 M00001462A:D03 80985 2614 Feb. 24, 1998 724 RTA00000119A.m.17.1 M00001461A:F05 79536 2615 Feb. 24, 1998 1063 RTA00000132A.n.7.1 M00001466A:F08 0 2616 Feb. 24, 1998 74 RTA00000408F.e.22.2 M00001476B:F08 26930 2617 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 2617 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 2617 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 2618 Feb. 24, 1998 1012 RTA00000403F.g.06.1 M00001480C:A05 10505 2619 Feb. 24, 1998 419 RTA00000408F.h.08.1 M00001480A:D03 74575 2620 Feb. 24, 1998 871 RTA00000403F.f.23.1 M00001479C:E01 39223 2621 Feb. 24, 1998 638 RTA00000418F.b.09.1 M00001478B:H08 19700 2622 Feb. 24, 1998 770 RTA00000421F.f.05.1 M00001477B:E02 5266 2623 Feb. 24, 1998 549 RTA00000121A.h.18.1 M00001471A:B04 16376 2624 Feb. 24, 1998 660 RTA00000408F.e.24.2 M00001476C:C11 75002 2625 Feb. 24, 1998 144 RTA00000349R.f.15.1 M00001472A:D08 75097 2626 Feb. 24, 1998 774 RTA00000403F.e.24.1 M00001476B:D10 16432 2627 Feb. 24, 1998 268 RTA00000403F.e.23.1 M00001476A:D11 9626 2628 Feb. 24, 1998 715 RTA00000418F.b.01.1 M00001475C:G11 76040 2629 Feb. 24, 1998 1073 RTA00000418F.a.10.1 M00001475B:C04 15245 2630 Feb. 24, 1998 100 RTA00000339F.o.23.1 M00001473C:D09 7801 2631 Feb. 24, 1998 756 RTA00000403F.g.13.1 M00001481B:D09 38718 2632 Feb. 24, 1998 915 RTA00000408F.f.14.2 M00001476D:F03 73024 2633 Jan. 28, 1998 389 RTA00000181AR.k.2.2 M00001453C:A11 0 2633 Jan. 28, 1998 286 RTA00000181AR.k.2.3 M00001453C:A11 0 2634 Jan. 28, 1998 565 RTA00000191AF.c.10.1 M00003989B:F11 40422 2635 Jan. 28, 1998 449 RTA00000181AF.m.22.3 M00001455D:F09 9283 2635 Jan. 28, 1998 450 RTA00000181AF.m.21.3 M00001455D:F09 9283 2636 Jan. 28, 1998 449 RTA00000181AF.m.22.3 M00001455D:F09 9283 2636 Jan. 28, 1998 450 RTA00000181AF.m.21.3 M00001455D:F09 9283 2637 Jan. 28, 1998 449 RTA00000181AF.m.22.3 M00001455D:F09 9283 2637 Jan. 28, 1998 450 RTA00000181AF.m.21.3 M00001455D:F09 9283 2638 Jan. 28, 1998 449 RTA00000181AF.m.22.3 M00001455D:F09 9283 2638 Jan. 28, 1998 450 RTA00000181AF.m.21.3 M00001455D:F09 9283 2639 Jan. 28, 1998 390 RTA00000197AR.f.07.1 M00001457C:C11 19261 2639 Jan. 28, 1998 184 RTA00000197AF.f.7.1 M00001457C:C11 19261 2640 Jan. 28, 1998 598 RTA00000197F.e.10.1 M00001454B:D08 13154 2641 Jan. 28, 1998 184 RTA00000197AF.f.7.1 M00001457C:C11 19261 2641 Jan. 28, 1998 390 RTA00000197AR.f.07.1 M00001457C:C11 19261 2642 Jan. 28, 1998 286 RTA00000181AR.k.2.3 M00001453C:A11 0 2642 Jan. 28, 1998 389 RTA00000181AR.k.2.2 M00001453C:A11 0 2643 Jan. 28, 1998 667 RTA00000197AF.d.16.1 M00001452A:E07 23505 2644 Jan. 28, 1998 679 RTA00000197AF.d.11.1 M00001451C:E01 27260 2645 Jan. 28, 1998 664 RTA00000195R.a.23.1 M00001449C:H12 86432 2646 Jan. 28, 1998 594 RTA00000181AR.e.04.3 M00001448A:G09 11825 2647 Jan. 28, 1998 405 RTA00000197AF.b.24.1 M00001446C.D09 23171 2648 Jan. 28, 1998 572 RTA00000181AF.l.16.2 M00001454D:E05 13532 2649 Jan. 28, 1998 590 RTA00000190AF.d.2.1 M00003906B:F12 2444 2650 Jan. 28, 1998 675 RTA00000179AR.b.21.3 M00001392C:D05 4366 2650 Feb. 24, 1998 1264 RTA00000345F.e.13.1 M00001392C:D05 4366 2651 Jan. 28, 1998 486 RTA00000190AR.p.22.2 M00003979A:E11 16368 2652 Jan. 28, 1998 701 RTA00000199AF.o.10.1 M00003974C:E04 0 2653 Jan. 28, 1998 704 RTA00000190AF.o.12.1 M00003972D:C09 3438 2654 Jan. 28, 1998 469 RTA00000190AF.n.2.1 M00003963A:E03 5650 2655 Jan. 28, 1998 612 RTA00000197AR.e.22.1 M00001456A:H02 78758 2656 Jan. 28, 1998 640 RTA00000190AF.f.5.1 M00003909A:H04 5015 2657 Jan. 28, 1998 539 RTA00000197AR.b.13.1 M00001445B:E04 9560 2658 Jan. 28, 1998 431 RTA00000199AF.k.15.1 M00003905C:G10 8275 2659 Jan. 28, 1998 747 RTA00000190AF.c.6.1 M00003904D:D10 4780 2660 Jan. 28, 1998 584 RTA00000190AR.c.03.1 M00003904C:A08 0 2660 Feb. 24, 1998 1069 RTA00000346F.k.05.1 M00003904C:A08 0 2661 Jan. 28, 1998 584 RTA00000190AR.c.03.1 M00003904C:A08 0 2661 Feb. 24, 1998 1069 RTA00000346F.k.05.1 M00003904C:A08 0 2662 Jan. 28, 1998 577 RTA00000190AF.a.24.2 M00003901B:A05 0 2663 Jan. 28, 1998 639 RTA00000199AF.j.1.1 M00003881C:G09 6006 2664 Jan. 28, 1998 649 RTA00000190AR.l.19.2 M00003946A:H10 88204 2665 Jan. 28, 1998 488 RTA00000179AR.l.22.4 M00001405B:E09 4314 2665 Jan. 28, 1998 481 RTA00000179AR.l.22.2 M00001405B:E09 4314 2666 Jan. 28, 1998 721 RTA00000180AF.c.4.1 M00001417B:C04 5415 2667 Jan. 28, 1998 744 RTA00000196F.m.4.1 M00001413A:F03 7958 2668 Jan. 28, 1998 569 RTA00000196AF.l.23.1 M00001412A:E04 12052 2669 Jan. 28, 1998 707 RTA00000179AF.p.15.1 M00001411D:F05 5622 2670 Jan. 28, 1998 599 RTA00000179AF.o.5.1 M00001408D:D04 6172 2671 Jan. 28, 1998 420 RTA00000181AF.c.11.1 M00001445D:A06 4769 2672 Jan. 28, 1998 500 RTA00000179AR.m.07.5 M00001405D:D11 0 2673 Jan. 28, 1998 609 RTA00000196AF.n.05.1 M00001418B:F07 12531 2673 Feb. 24, 1998 1120 RTA00000353R.l.23.1 M00001418B:F07 12531 2674 Jan. 28, 1998 481 RTA00000179AR.l.22.2 M00001405B:E09 4314 2674 Jan. 28, 1998 488 RTA00000179AR.l.22.4 M00001405B:E09 4314 2675 Jan. 28, 1998 481 RTA00000179AR.l.22.2 M00001405B:E09 4314 2675 Jan. 28, 1998 488 RTA00000179AR.l.22.4 M00001405B:E09 4314 2676 Jan. 28, 1998 481 RTA00000179AR.l.22.2 M00001405B:E09 4314 2676 Jan. 28, 1998 488 RTA00000179AR.l.22.4 M00001405B:E09 4314 2677 Jan. 28, 1998 636 RTA00000196F.k.20.1 M00001402B:F12 6324 2678 Jan. 28, 1998 691 RTA00000195F.a.10.1 M00001401C:H03 6803 2679 Feb. 24, 1998 161 RTA00000418F.n.22.1 M00001659D:B05 79062 2680 Jan. 28, 1998 611 RTA00000196F.l.13.2 M00001408A:H04 0 2681 Jan. 28, 1998 535 RTA00000196AF.n.19.1 M00001423D:D12 6881 2682 Jan. 28, 1998 413 RTA00000200F.a.12.1 M00004031D:B05 16751 2683 Jan. 28, 1998 580 RTA00000197F.a.12.1 M00001438B:B09 7895 2684 Jan. 28, 1998 681 RTA00000180AF.l.04.2 M00001432D:F05 11159 2685 Jan. 28, 1998 568 RTA00000196AF.p.01.2 M00001430A:A02 87143 2686 Jan. 28, 1998 736 RTA00000196AF.o.13.1 M00001428B:A09 0 2687 Jan. 28, 1998 438 RTA00000180AR.g.03.4 M00001425A:C11 9024 2687 Jan. 28, 1998 95 RTA00000180AF.g.3.1 M00001425A:C11 9024 2688 Jan. 28, 1998 514 RTA00000196AF.n.02.1 M00001417D:A04 39260 2689 Jan. 28, 1998 741 RTA00000196AF.n.22.1 M00001424B:H04 9572 2690 Jan. 28, 1998 609 RTA00000196AF.n.05.1 M00001418B:F07 12531 2690 Feb. 24, 1998 1120 RTA00000353R.l.23.1 M00001418B:F07 12531 2691 Jan. 28, 1998 462 RTA00000196AF.n.17.1 M00001423D:A09 12477 2692 Jan. 28, 1998 477 RTA00000180AR.e.22.2 M00001423A:G05 7714 2693 Jan. 28, 1998 445 RTA00000196AF.n.13.1 M00001422C:F12 8396 2694 Jan. 28, 1998 696 RTA00000180AR.d.16.3 M00001419D:C10 11393 2694 Feb. 24, 1998 1184 RTA00000345F.h.08.1 M00001419D:C10 11393 2695 Jan. 28, 1998 696 RTA00000180AR.d.16.3 M00001419D:C10 11393 2695 Feb. 24, 1998 1184 RTA00000345F.h.08.1 M00001419D:C10 11393 2696 Jan. 28, 1998 541 RTA00000197AR.b.16.1 M00001445C:A08 0 2697 Jan. 28, 1998 95 RTA00000180AF.g.3.1 M00001425A:C11 9024 2697 Jan. 28, 1998 438 RTA00000180AR.g.03.4 M00001425A:C11 9024 2698 Jan. 28, 1998 536 RTA00000193AR.a.2.3 M00004216D:D03 0 2699 Jan. 28, 1998 588 RTA00000191AF.b.4.1 M00003983C:F03 14936 2700 Jan. 28, 1998 401 RTA00000195F.e.04.1 M00004465B:D04 6731 2701 Feb. 24, 1998 91 RTA00000355R.e.15.1 M00004316A:G09 22639 2701 Jan. 28, 1998 410 RTA00000201F.a.20.1 M00004316A:G09 22639 2702 Jan. 28, 1998 410 RTA00000201F.a.20.1 M00004316A:G09 22639 2702 Feb. 24, 1998 91 RTA00000355R.e.15.1 M00004316A:G09 22639 2703 Jan. 28, 1998 716 RTA00000200F.p.05.1 M00004285C:A08 3984 2704 Feb. 24, 1998 434 RTA00000348R.b.16.1 M00001347B:H04 6510 2705 Jan. 28, 1998 528 RTA00000200F.n.09.2 M00004249D:B08 12391 2706 Feb. 24, 1998 575 RTA00000345F.a.18.1 M00001351C:B06 5517 2707 Jan. 28, 1998 658 RTA00000193AF.a.1.1 M00004216D:C03 16501 2708 Jan. 28, 1998 472 RTA00000192AF.p.17.1 M00004214C:H05 11451 2709 Jan. 28, 1998 478 RTA00000192AR.o.24.2 M00004210B:B05 7191 2710 Jan. 28, 1998 753 RTA00000192AF.o.17.1 M00004208D:B10 5275 2711 Jan. 28, 1998 563 RTA00000192AR.o.16.2 M00004208B:F05 9061 2712 Jan. 28, 1998 730 RTA00000192AF.o.11.1 M00004205D:F06 0 2713 Jan. 28, 1998 624 RTA00000200F.o.15.1 M00004275A:B03 7866 2714 Feb. 24, 1998 169 RTA00000347F.a.17.1 M00001366D:C06 16723 2715 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 2715 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 2715 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 2716 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 2716 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 2716 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 2717 Jan. 28, 1998 522 RTA00000178AR.h.17.2 M00001376A:C05 23824 2717 Feb. 24, 1998 1095 RTA00000345F.c.12.1 M00001376A:C05 23824 2718 Jan. 28, 1998 522 RTA00000178AR.h.17.2 M00001376A:C05 23824 2718 Feb. 24, 1998 1095 RTA00000345F.c.12.1 M00001376A:C05 23824 2719 Feb. 24, 1998 1155 RTA00000353R.h.04.1 M00001375B:C06 17123 2720 Jan. 28, 1998 614 RTA00000201F.f.03.1 M00004493B:D09 22633 2721 Feb. 24, 1998 16 RTA00000399F.a.02.1 M00001366D:C12 0 2722 Jan. 28, 1998 436 RTA00000200AF.k.11.1 M00004197C:F03 9796 2722 Jan. 28, 1998 501 RTA00000200R.k.11.1 M00004197C:F03 9796 2723 Feb. 24, 1998 1140 RTA00000339F.c.05.1 M00001365A:H10 3908 2724 Feb. 24, 1998 322 RTA00000339F.c.24.1 M00001364B:B06 5516 2725 Feb. 24, 1998 888 RTA00000339R.c.04.1 M00001362D:H01 1805 2726 Jan. 28, 1998 33 RTA00000178AR.a.20.1 M00001362C:H11 945 2726 Feb. 24, 1998 979 RTA00000345F.b.17.1 M00001362C:H11 945 2727 Jan. 28, 1998 33 RTA00000178AR.a.20.1 M00001362C:H11 945 2727 Feb. 24, 1998 979 RTA00000345F.b.17.1 M00001362C:H11 945 2728 Feb. 24, 1998 1173 RTA00000339R.b.07.1 M00001360A:G10 6826 2729 Feb. 24, 1998 973 RTA00000339F.b.22.1 M00001373D:B03 6867 2730 Jan. 28, 1998 581 RTA00000191AF.p.3.2 M00004104B:F11 17 2731 Jan. 28, 1998 637 RTA00000200AF.g.15.1 M00004135B:G01 22898 2731 Jan. 28, 1998 476 RTA00000200R.g.15.1 M00004135B:G01 22898 2732 Jan. 28, 1998 637 RTA00000200AF.g.15.1 M00004135B:G01 22898 2732 Jan. 28, 1998 476 RTA00000200R.g.15.1 M00004135B:G01 22898 2733 Jan. 28, 1998 474 RTA00000192AR.d.1.3 M00004130D:H01 14507 2734 Jan. 28, 1998 735 RTA00000192AF.b.11.1 M00004117A:G01 40014 2735 Jan. 28, 1998 726 RTA00000200R.f.10.1 M00004111D:B07 4 2736 Jan. 28, 1998 752 RTA00000192AF.o.7.1 M00004204D:C03 5275 2737 Jan. 28, 1998 516 RTA00000200AF.e.23.1 M00004107B:A06 14686 2738 Jan. 28, 1998 685 RTA00000200F.i.9.1 M00004159C:F09 36756 2738 Feb. 24, 1998 704 RTA00000355R.a.12.1 M00004159C:F09 36756 2739 Jan. 28, 1998 417 RTA00000200R.d.16.1 M00004085A:B02 39875 2740 Jan. 28, 1998 454 RTA00000200R.d.04.1 M00004078A:A06 5506 2741 Jan. 28, 1998 551 RTA00000200AR.c.24.1 M00004076D:D04 15972 2742 Jan. 28, 1998 524 RTA00000191AF.j.24.1 M00004076B:G03 0 2743 Feb. 24, 1998 1166 RTA00000347F.h.01.1 M00004040A:G12 12043 2743 Jan. 28, 1998 684 RTA00000200AR.b.11.1 M00004040A:G12 12043 2744 Feb. 24, 1998 1166 RTA00000347F.h.01.1 M00004040A:G12 12043 2744 Jan. 28, 1998 684 RTA00000200AR.b.11.1 M00004040A:G12 12043 2745 Jan. 28, 1998 415 RTA00000200AF.f.09.1 M00004111C:E11 12863 2746 Jan. 28, 1998 448 RTA00000200AF.j.9.1 M00004177C:A01 8608 2747 Feb. 24, 1998 446 RTA00000133A.m.19.2 M00001512A:G05 80167 2748 Jan. 28, 1998 436 RTA00000200AF.k.11.1 M00004197C:F03 9796 2748 Jan. 28, 1998 501 RTA00000200R.k.11.1 M00004197C:F03 9796 2749 Jan. 28, 1998 436 RTA00000200AF.k.11.1 M00004197C:F03 9796 2749 Jan. 28, 1998 501 RTA00000200R.k.11.1 M00004197C:F03 9796 2750 Jan. 28, 1998 436 RTA00000200AF.k.11.1 M00004197C:F03 9796 2750 Jan. 28, 1998 501 RTA00000200R.k.11.1 M00004197C:F03 9796 2751 Jan. 28, 1998 610 RTA00000200AF.k.2.1 M00004188D:G08 35924 2752 Jan. 28, 1998 494 RTA00000200AF.k.1.1 M00004188C:A09 40049 2752 Jan. 28, 1998 194 RTA00000200R.k.01.1 M00004188C:A09 40049 2753 Jan. 28, 1998 574 RTA00000192AF.f.3.1 M00004146C:C11 5257 2754 Jan. 28, 1998 604 RTA00000200AF.j.15.1 M00004185D:E04 5849 2755 Jan. 28, 1998 579 RTA00000200F.i.7.1 M00004157D:B03 22322 2756 Jan. 28, 1998 634 RTA00000192AF.j.6.1 M00004172C:D08 11494 2757 Jan. 28, 1998 421 RTA00000200AF.i.21.1 M00004167D:A07 5316 2758 Jan. 28, 1998 543 RTA00000200AF.i.19.1 M00004167A:H03 14722 2759 Jan. 28, 1998 483 RTA00000192AF.h.19.1 M00004162C:A07 4642 2760 Feb. 24, 1998 704 RTA00000355R.a.12.1 M00004159C:F09 36756 2760 Jan. 28, 1998 685 RTA00000200F.i.9.1 M00004159C:F09 36756 2761 Jan. 28, 1998 607 RTA00000200AF.k.12.1 M00004198B:D02 7359 2762 Jan. 28, 1998 494 RTA00000200AF.k.1.1 M00004188C:A09 40049 2762 Jan. 28, 1998 194 RTA00000200R.k.01.1 M00004188C:A09 40049 2763 Feb. 24, 1998 554 RTA00000409F.i.03.1 M00001610A:E09 75968 2764 Feb. 24, 1998 1228 RTA00000404F.h.10.1 M00001618A:A03 37148 2765 Feb. 24, 1998 332 RTA00000409F.i.24.1 M00001611B:A09 76967 2766 Feb. 24, 1998 1023 RTA00000404F.f.12.1 M00001611B:A05 39209 2767 Feb. 24, 1998 572 RTA00000422F.l.03.1 M00001610D:D05 39147 2768 Feb. 24, 1998 497 RTA00000350R.f.21.1 M00001610C:E07 22110 2769 Feb. 24, 1998 557 RTA00000409F.j.05.1 M00001611C:C12 74128 2770 Feb. 24, 1998 223 RTA00000404F.e.22.1 M00001610A:H05 11344 2771 Feb. 24, 1998 165 RTA00000409F.j.07.1 M00001611C:H11 75190 2772 Feb. 24, 1998 959 RTA00000340F.g.20.1 M00001609D:G10 4089 2773 Feb. 24, 1998 737 RTA00000404F.e.15.1 M00001609B:C09 39101 2774 Feb. 24, 1998 974 RTA00000340F.h.07.1 M00001608D:D11 19254 2775 Feb. 24, 1998 857 RTA00000404F.e.09.1 M00001608B:A09 39121 2776 Jan. 28, 1998 340 RTA00000185AF.n.8.1 M00001608B:A03 0 2776 Feb. 24, 1998 75 RTA00000350R.i.22.1 M00001608B:A03 0 2777 Jan. 28, 1998 340 RTA00000185AF.n.8.1 M00001608B:A03 0 2777 Feb. 24, 1998 75 RTA00000350R.i.22.1 M00001608B:A03 0 2778 Feb. 24, 1998 546 RTA00000409F.i.09.1 M00001610B:C07 75279 2779 Feb. 24, 1998 374 RTA00000422F.m.04.1 M00001615B:A09 38702 2780 Feb. 24, 1998 505 RTA00000121A.o.3.1 M00001511A:A02 81437 2781 Feb. 24, 1998 453 RTA00000130A.h.13.1 M00001617A:A01 80790 2782 Feb. 24, 1998 163 RTA00000422F.l.23.1 M00001616D:C11 4240 2783 Feb. 24, 1998 889 RTA00000346F.b.16.1 M00001615C:G05 16485 2784 Feb. 24, 1998 203 RTA00000404F.g.21.1 M00001615C:A11 37947 2785 Feb. 24, 1998 32 RTA00000409F.j.02.1 M00001611B:E06 76417 2786 Feb. 24, 1998 872 RTA00000409F.l.20.1 M00001615B:G01 74394 2787 Feb. 24, 1998 978 RTA00000130A.e.20.1 M00001606A:H09 79502 2788 Feb. 24, 1998 45 RTA00000409F.l.12.1 M00001615A:D06 26755 2789 Feb. 24, 1998 182 RTA00000404F.g.14.1 M00001614D:B08 8858 2790 Feb. 24, 1998 912 RTA00000404F.g.13.1 M00001614C:E06 9436 2791 Feb. 24, 1998 1191 RTA00000340F.i.05.1 M00001614B:E08 0 2792 Feb. 24, 1998 192 RTA00000421F.k.15.1 M00001613D:B03 2222 2793 Feb. 24, 1998 360 RTA00000409F.j.19.1 M00001613A:F03 73792 2794 Feb. 24, 1998 57 RTA00000409F.l.21.1 M00001615B:G07 73143 2795 Feb. 24, 1998 354 RTA00000404F.c.03.2 M00001592C:F11 39198 2796 Feb. 24, 1998 791 RTA00000399F.n.15.1 M00001594D:C03 3213 2797 Feb. 24, 1998 921 RTA00000422F.j.02.1 M00001594D:B08 10368 2798 Feb. 24, 1998 1114 RTA00000340F.f.22.1 M00001594B:F12 1720 2799 Feb. 24, 1998 966 RTA00000422F.k.15.1 M00001594A:G09 19253 2800 Feb. 24, 1998 46 RTA00000404F.c.20.1 M00001594A:D08 39088 2801 Feb. 24, 1998 955 RTA00000404F.e.06.1 M00001607D:F06 39315 2802 Feb. 24, 1998 1103 RTA00000346F.a.16.1 M00001593A:B07 12082 2803 Feb. 24, 1998 540 RTA00000418F.i.18.1 M00001595C:B05 78024 2804 Feb. 24, 1998 1245 RTA00000422F.k.22.1 M00001592C:E05 4098 2805 Feb. 24, 1998 693 RTA00000404F.b.19.1 M00001592B:A04 39281 2806 Feb. 24, 1998 1013 RTA00000404F.b.18.1 M00001592A:H05 13669 2807 Feb. 24, 1998 989 RTA00000418F.i.12.1 M00001592A:E02 78971 2808 Feb. 24, 1998 404 RTA00000404F.b.11.1 M00001591D:F06 39079 2809 Feb. 24, 1998 786 RTA00000404F.b.09.1 M00001591D:C07 39166 2810 Feb. 24, 1998 1147 RTA00000404F.c.18.1 M00001594A:C01 38982 2811 Feb. 24, 1998 686 RTA00000129A.k.21.1 M00001601A:E12 82067 2812 Feb. 24, 1998 1011 RTA00000400F.c.04.1 M00001618A:F08 6445 2813 Feb. 24, 1998 702 RTA00000130A.d.5.1 M00001605A:H03 82051 2814 Feb. 24, 1998 425 RTA00000130A.b.5.1 M00001605A:E09 79579 2815 Feb. 24, 1998 458 RTA00000130A.a.19.1 M00001605A:A06 0 2816 Feb. 24, 1998 51 RTA00000129A.n.21.1 M00001604A:C11 79381 2817 Feb. 24, 1998 804 RTA00000129A.n.24.1 M00001604A:C07 81409 2818 Feb. 24, 1998 317 RTA00000195AF.b.21.1 M00001595B:A09 39055 2818 Jan. 28, 1998 602 RTA00000195AF.b.21.1 M00001595B:A09 39055 2819 Feb. 24, 1998 864 RTA00000129A.n.17.1 M00001604A:A09 79811 2820 Feb. 24, 1998 317 RTA00000195AF.b.21.1 M00001595B:A09 39055 2820 Jan. 28, 1998 602 RTA00000195AF.b.21.1 M00001595B:A09 39055 2821 Feb. 24, 1998 875 RTA00000129A.k.22.1 M00001601A:E02 79639 2822 Feb. 24, 1998 406 RTA00000129A.k.12.1 M00001601A:A06 79322 2823 Feb. 24, 1998 179 RTA00000418F.i.19.1 M00001596D:E03 79180 2824 Feb. 24, 1998 759 RTA00000399F.o.06.1 M00001595D:G03 13574 2825 Feb. 24, 1998 306 RTA00000404F.d.13.1 M00001595D:A04 39036 2826 Feb. 24, 1998 1055 RTA00000346F.a.04.1 M00001607B:C05 5382 2827 Feb. 24, 1998 350 RTA00000129A.p.3.1 M00001604A:B08 32644 2828 Feb. 24, 1998 721 RTA00000422F.k.14.1 M00001649D:A08 0 2829 Feb. 24, 1998 391 RTA00000130A.h.16.1 M00001617A:A08 80761 2830 Feb. 24, 1998 962 RTA00000404F.p.05.2 M00001652D:E09 1896 2831 Feb. 24, 1998 65 RTA00000404F.p.04.2 M00001652D:E05 39069 2832 Feb. 24, 1998 1108 RTA00000346F.c.16.1 M00001652B:G10 9579 2833 Feb. 24, 1998 1200 RTA00000422F.k.17.1 M00001652A:A01 38955 2834 Feb. 24, 1998 1218 RTA00000418F.m.18.1 M00001653B:G10 76479 2835 Feb. 24, 1998 171 RTA00000404F.n.20.1 M00001650A:C11 26865 2836 Feb. 24, 1998 180 RTA00000400F.j.19.1 M00001653C:D10 4086 2837 Feb. 24, 1998 556 RTA00000400F.i.11.1 M00001649C:H10 2587 2838 Feb. 24, 1998 848 RTA00000404F.n.18.2 M00001649C:E11 37169 2839 Feb. 24, 1998 29 RTA00000404F.n.16.2 M00001649C:D05 39095 2840 Feb. 24, 1998 146 RTA00000404F.n.11.2 M00001649A:E11 38001 2841 Feb. 24, 1998 700 RTA00000350R.m.14.1 M00001644C:B07 39171 2842 Feb. 24, 1998 699 RTA00000340F.l.05.1 M00001644B:D06 38935 2843 Feb. 24, 1998 479 RTA00000418F.m.10.1 M00001651A:H11 79110 2844 Feb. 24, 1998 1169 RTA00000405F.b.08.1 M00001656B:E01 39182 2845 Feb. 24, 1998 855 RTA00000423F.a.01.1 M00001659C:F10 39103 2846 Feb. 24, 1998 363 RTA00000405F.c.11.1 M00001659A:D12 39068 2847 Feb. 24, 1998 807 RTA00000418F.n.11.1 M00001658D:G12 78977 2848 Feb. 24, 1998 795 RTA00000418F.n.07.1 M00001658B:A07 76316 2849 Feb. 24, 1998 109 RTA00000422F.p.24.2 M00001658A:G09 5823 2850 Feb. 24, 1998 696 RTA00000404F.p.12.2 M00001653B:C06 0 2851 Feb. 24, 1998 369 RTA00000410F.m.05.1 M00001657B:B04 74964 2852 Feb. 24, 1998 1229 RTA00000422F.n.14.1 M00001642C:G02 26787 2853 Feb. 24, 1998 529 RTA00000422F.o.19.2 M00001655C:E01 13084 2854 Feb. 24, 1998 327 RTA00600405F.a.11.1 M00001655A:B11 39124 2855 Feb. 24, 1998 393 RTA00000418F.m.24.1 M00001654D:F12 77114 2856 Feb. 24, 1998 381 RTA00000418F.m.23.1 M00001654D:F11 77195 2857 Feb. 24, 1998 877 RTA00000418F.m.22.1 M00001654D:E12 74567 2858 Feb. 24, 1998 166 RTA00000418F.m.19.1 M00001654D:A03 8890 2859 Feb. 24, 1998 291 RTA00000405F.c.01.1 M00001657D:A04 19236 2860 Feb. 24, 1998 356 RTA00000409F.m.24.1 M00001620D:H02 3942 2861 Feb. 24, 1998 717 RTA00000404F.i.22.1 M00001625C:G05 39082 2862 Feb. 24, 1998 648 RTA00000340F.i.13.1 M00001624B:B10 79299 2863 Feb. 24, 1998 914 RTA00000138A.m.15.1 M00001624A:A03 41603 2864 Feb. 24, 1998 587 RTA00000130A.o.21.1 M00001623A:F04 80218 2865 Feb. 24, 1998 22 RTA00000130A.m.15.1 M00001622A:H12 81630 2866 Feb. 24, 1998 767 RTA00000138A.p.10.1 M00001644A:H01 81625 2867 Feb. 24, 1998 262 RTA00000409F.n.14.1 M00001621B:G05 78190 2868 Feb. 24, 1998 960 RTA00000404F.l.19.2 M00001639B:H01 16196 2869 Feb. 24, 1998 608 RTA00000404F.i.12.1 M00001620D:G11 39001 2870 Feb. 24, 1998 342 RTA00000404F.i.02.1 M00001619D:D10 39015 2871 Feb. 24, 1998 195 RTA00000404F.h.22.1 M00001619C:C07 18735 2872 Feb. 24, 1998 214 RTA00000404F.h.19.1 M00001619A:E05 8096 2873 Feb. 24, 1998 52 RTA00000409F.m.12.1 M00001618B:D09 73490 2874 Feb. 24, 1998 769 RTA00000340F.i.10.1 M0000161°A:F10 3°561 2875 Feb. 24, 1998 383 RTA00000404F.i.18.1 M00001621C:H12 21912 2876 Feb. 24, 1998 256 RTA00000404F.m.03.2 M00001640A:H02 11799 2877 Feb. 24, 1998 519 RTA00000404F.l.10.1 M00001638B:F10 23136 2878 Feb. 24, 1998 646 RTA00000421F.m.14.1 M00001642A:F03 3524 2879 Feb. 24, 1998 659 RTA00000422F.m.24.1 M00001641D:C04 39159 2880 Feb. 24, 1998 701 RTA00000418F.l.11.1 M00001641C:H07 77158 2881 Feb. 24, 1998 873 RTA00000418F.l.06.1 M00001641C:F01 73317 2882 Feb. 24, 1998 422 RTA00000418F.l.04.1 M00001641C:D02 74140 2883 Feb. 24, 1998 766 RTA00000404F.j.01.1 M00001625D:G10 26859 2884 Feb. 24, 1998 20 RTA00000404F.m.04.2 M00001641A:A11 22720 2885 Feb. 24, 1998 346 RTA00000418F.j.08.1 M00001626C:C11 73382 2886 Feb. 24, 1998 141 RTA00000418F.k.19.1 M00001639C:C60 74932 2887 Feb. 24, 1998 373 RTA00000418F.k.18.1 M00001639C:A10 75385 2888 Feb. 24, 1998 405 RTA00000418F.k.17.1 M00001639C:A09 75390 2889 Feb. 24, 1998 63 RTA00000404F.l.20.2 M00001639B:H05 38638 2889 Feb. 24, 1998 133 RTA00000404F.l.20.1 M00001639B:H05 38638 2890 Feb. 24, 1998 133 RTA00000404F.l.20.1 M00001639B:H05 38638 2890 Feb. 24, 1998 63 RTA00000404F.l.20.2 M00001639B:H05 38638 2891 Feb. 24, 1998 1261 RTA00000404F.m.17.2 M00001643B:E05 0 2892 Feb. 24, 1998 626 RTA00000410F.j.01.1 M00001641B:F12 73399 2893 Feb. 24, 1998 982 RTA00000126A.p.23.2 M00001552A:F06 80915 2894 Feb. 24, 1998 196 RTA00000418F.k.10.1 M00001639A:G07 74454 2895 Feb. 24, 1998 765 RTA00000137A.j.15.4 M00001559A:C08 4213 2896 Feb. 24, 1998 895 RTA00000137A.j.11.4 M00001559A:A11 79752 2897 Feb. 24, 1998 232 RTA00000128A.b.20.1 M00001558A:G09 79761 2898 Feb. 24, 1998 152 RTA00000127A.i.20.1 M00001555A:B12 81418 2899 Feb. 24, 1998 78 RTA00000195AF.b.13.1 M00001560D:A03 12605 2899 Jan. 28, 1998 59 RTA00000195AF.b.13.1 M00001560D:A03 12605 2900 Feb. 24, 1998 448 RTA00000127A.a.3.1 M00001552A:H10 13232 2901 Feb. 24, 1998 801 RTA00000128A.m.23.1 M00001561A:D01 81441 2902 Feb. 24, 1998 499 RTA00000126A.p.18.2 M00001552A:E10 80881 2903 Feb. 24, 1998 1212 RTA00000349R.o.03.1 M00001551D:H07 23006 2904 Feb. 24, 1998 484 RTA00000126A.n.13.2 M00001551A:H06 79735 2905 Feb. 24, 1998 240 RTA00000126A.n.7.2 M00001551A:D06 79557 2906 Feb. 24, 1998 451 RTA00000126A.o.22.1 M00001551A:A11 81752 2907 Feb. 24, 1998 513 RTA00000126A.k.7.2 M00001550A:E07 79866 2908 Feb. 24, 1998 578 RTA00000127A.f.11.1 M00001554A:A08 81463 2909 Feb. 24, 1998 372 RTA00000408F.p.24.1 M00001579A:E03 74286 2910 Feb. 24, 1998 985 RTA00000409F.a.08.1 M00001582D:B01 74978 2911 Feb. 24, 1998 685 RTA00000129A.a.13.2 M00001582A:A03 79780 2912 Feb. 24, 1998 574 RTA00000403F.o.14.1 M00001579D:H09 38971 2913 Feb. 24, 1998 601 RTA00000403F.o.13.1 M00001579D:F04 39049 2914 Feb. 24, 1998 432 RTA00000418F.g.05.1 M00001579C:H06 73075 2915 Jan. 28, 1998 59 RTA00000195AF.b.13.1 M00001560D:A03 12605 2915 Feb. 24, 1998 78 RTA00000195AF.b.13.1 M00001560D:A03 12605 2916 Feb. 24, 1998 491 RTA00000418F.f.21.1 M00001579B:F04 75157 2917 Feb. 24, 1998 612 RTA00000125A.k.14.1 M00001545A:G05 79457 2918 Jan. 28, 1998 248 RTA00000198R.c.14.1 M00001578D:C04 39814 2918 Feb. 24, 1998 778 RTA00000347F.e.05.1 M00001578D:C04 39814 2919 Jan. 28, 1998 248 RTA00000198R.c.14.1 M00001578D:C04 39814 2919 Feb. 24, 1998 778 RTA00000347F.e.05.1 M00001578D:C04 39814 2920 Feb. 24, 1998 361 RTA00000422F.d.16.1 M00001570C:G03 39133 2921 Feb. 24, 1998 173 RTA00000418F.d.13.1 M00001570A:H01 74309 2922 Feb. 24, 1998 1195 RTA00000422F.e.23.1 M00001567D:B03 19246 2923 Feb. 24, 1998 1168 RTA00000421F.b.06.1 M00001567A:B09 2113 2924 Feb. 24, 1998 580 RTA00000403F.o.07.1 M00001579C:A01 39037 2925 Feb. 24, 1998 531 RTA00000345F.n.12.1 M00001528A:C04 7337 2926 Feb. 24, 1998 154 RTA00000340F.b.21.1 M00001533D:A08 8001 2927 Feb. 24, 1998 19 RTA00000123A.k.23.1 M00001533A:G05 80313 2928 Feb. 24, 1998 1265 RTA00000340F.d.07.1 M00001532D:A06 0 2929 Feb. 24, 1998 1124 RTA00000123A.h.22.1 M00001532A:C01 17124 2930 Feb. 24, 1998 1241 RTA00000408F.l.14.1 M00001530A:E10 12001 2931 Feb. 24, 1998 534 RTA00000126A.g.7.1 M00001548A:H04 1902 2932 Feb. 24, 1998 694 RTA00000418F.c.07.1 M00001529D:C05 73245 2933 Feb. 24, 1998 1034 RTA00000124A.f.16.3 M00001536A:F11 47430 2934 Feb. 24, 1998 790 RTA00000345F.n.08.1 M00001517A:B11 0 2935 Feb. 24, 1998 613 RTA00000122A.j.22.1 M00001516A:F06 81151 2936 Feb. 24, 1998 885 RTA00000122A.j.17.1 M00001516A:D02 62736 2937 Feb. 24, 1998 1262 RTA00000122A.h.4.1 M00001514A:G03 33576 2938 Feb. 24, 1998 135 RTA00000122A.d.5.1 M00001513A:F05 81155 2939 Jan. 28, 1998 391 RTA00000179AF.e.20.3 M00001396A:C03 4009 2940 Feb. 24, 1998 537 RTA00000408F.l.09.1 M00001530A:A09 75487 2941 Feb. 24, 1998 683 RTA00000403F.j.21.1 M00001540D:E02 24723 2942 Feb. 24, 1998 343 RTA00000422F.g.21.1 M00001583A:F07 17232 2943 Feb. 24, 1998 226 RTA00000125A.k.10.1 M00001545A:F02 81644 2944 Feb. 24, 1998 763 RTA00000135A.m.18.1 M00001545A:C03 19255 2945 Feb. 24, 1998 156 RTA00000125A.k.1.1 M00001545A:B12 0 2946 Feb. 24, 1998 597 RTA00000135A.l.1.2 M00001545A:B10 39426 2947 Feb. 24, 1998 586 RTA00000125A.g.24.1 M00001544A:F05 80397 2948 Feb. 24, 1998 467 RTA00000123A.n.13.2 M00001534A:D03 39167 2949 Feb. 24, 1998 830 RTA00000347F.b.08.1 M00001541B:E05 17591 2950 Feb. 24, 1998 997 RTA00000134A.l.9.1 M00001535A:D10 81814 2951 Feb. 24, 1998 371 RTA00000403F.j.17.1 M00001539D:B10 38563 2952 Feb. 24, 1998 33 RTA00000403F.j.15.1 M00001539B:G07 23840 2953 Feb. 24, 1998 1209 RTA00000408F.n.05.2 M00001539A:H02 77883 2954 Feb. 24, 1998 530 RTA00000408F.n.02.2 M00001539A:E01 76993 2955 Feb. 24, 1998 1213 RTA00000135A.a.23.1 M00001537A:H05 27054 2956 Feb. 24, 1998 347 RTA00000125A.n.4.1 M00001546A:D08 81984 2957 Feb. 24, 1998 472 RTA00000135A.f.14.2 M00001542A:G12 79969 2958 Feb. 24, 1998 243 RTA00000410F.c.14.1 M00001634A:H05 77809 2959 Feb. 24, 1998 919 RTA00000410F.d.18.1 M00001635D:D05 75458 2960 Feb. 24, 1998 825 RTA00000404F.k.22.2 M00001635D:C12 39084 2960 Feb. 24, 1998 364 RTA00000404F.k.22.1 M00001635D:C12 39084 2961 Feb. 24, 1998 825 RTA00000404F.k.22.2 M00001635D:C12 39084 2961 Feb. 24, 1998 364 RTA00000404F.k.22.1 M00001635D:C12 39084 2962 Feb. 24, 1998 595 RTA00000410F.d.10.1 M00001635B:H02 77561 2963 Feb. 24, 1998 175 RTA00000410F.d.09.1 M00001635B:H01 76964 2964 Feb. 24, 1998 206 RTA00000410F.b.15.1 M00001633C:F09 77100 2965 Feb. 24, 1998 1083 RTA00000418F.j.20.1 M00001634D:D04 77101 2966 Feb. 24, 1998 922 RTA00000410F.e.09.1 M00001636A:F08 76093 2967 Feb. 24, 1998 1035 RTA00000404F.k.15.1 M00001634A:B04 18225 2968 Feb. 24, 1998 1167 RTA00000410F.c.06.1 M00001633D:H06 77784 2969 Feb. 24, 1998 53 RTA00000410F.c.04.1 M00001633D:G09 74099 2970 Feb. 24, 1998 567 RTA00000410F.c.02.1 M00001633D:D12 75055 2971 Feb. 24, 1998 819 RTA00000410F.b.24.1 M00001633D:D09 75104 2972 Feb. 24, 1998 666 RTA00000403F.o.19.1 M00001582D:F02 78615 2973 Feb. 24, 1998 559 RTA00000418F.k.03.1 M00001634D:G11 78901 2974 Feb. 24, 1998 999 RTA00000418F.k.04.1 M00001637A:A03 75864 2975 Feb. 24, 1998 936 RTA00000121A.n.23.1 M00001511A:G01 26981 2976 Feb. 24, 1998 201 RTA00000404F.l.09.1 M00001638B:E12 39176 2977 Feb. 24, 1998 1160 RTA00000400F.g.02.1 M00001638B:E03 1508 2978 Feb. 24, 1998 827 RTA00000410F.f.12.1 M00001637C:E03 73883 2979 Feb. 24, 1998 622 RTA00000404F.l.07.1 M00001637C:C06 10798 2980 Feb. 24, 1998 365 RTA00000418F.k.07.1 M00001637A:F10 75067 2981 Feb. 24, 1998 248 RTA00000404F.k.24.1 M00001636A:C03 15256 2982 Feb. 24, 1998 25 RTA00000418F.k.05.1 M00001637A:A06 73021 2983 Feb. 24, 1998 1178 RTA00000400F.f.11.1 M00001636A:E07 4088 2984 Feb. 24, 1998 1180 RTA00000404F.l.05.1 M00001636D:F09 38671 2985 Feb. 24, 1998 711 RTA00000404F.l.03.2 M00001636B:G11 40272 2985 Feb. 24, 1998 785 RTA00000404F.l.03.1 M00001636B:G11 40272 2986 Feb. 24, 1998 785 RTA00000404F.l.03.1 M00001636B:G11 40272 2986 Feb. 24, 1998 711 RTA00000404F.l.03.2 M00001636B:G11 40272 2987 Feb. 24, 1998 711 RTA00000404F.l.03.2 M00001636B:G11 40272 2987 Feb. 24, 1998 785 RTA00000404F.l.03.1 M00001636B:G11 40272 2988 Feb. 24, 1998 711 RTA00000404F.l.03.2 M00001636B:G11 40272 2988 Feb. 24, 1998 785 RTA00000404F.l.03.1 M00001636B:G11 40272 2989 Feb. 24, 1998 1106 RTA00000410F.b.17.1 M00001633C:H05 77458 2990 Feb. 24, 1998 253 RTA00000400F.f.18.1 M00001637A:E10 3764 2991 Feb. 24, 1998 562 RTA00000401F.j.17.1 M00003901B:C05 5483 2992 Feb. 24, 1998 1082 RTA00000137A.o.22.1 M00001587A:D01 0 2993 Feb. 24, 1998 594 RTA00000129A.c.18.2 M00001587A:B10 37216 2994 Feb. 24, 1998 891 RTA00000137A.p.12.1 M00001587A:B01 80614 2995 Feb. 24, 1998 131 RTA00000418F.g.22.1 M00001585B:F01 74837 2996 Feb. 24, 1998 880 RTA00000418F.g.20.1 M00001585B:C03 74626 2997 Feb. 24, 1998 742 RTA00000410F.b.18.1 M00001633C:H11 76701 2998 Feb. 24, 1998 879 RTA00000409F.b.19.1 M00001584D:H02 14479 2999 Feb. 24, 1998 167 RTA00000399F.l.14.1 M00001590B:G08 3354 3000 Feb. 24, 1998 1260 RTA00000422F.f.18.1 M00001583D:B08 24528 3000 Feb. 24, 1998 1258 RTA00000403F.p.05.2 M00001553D:B08 24528 3001 Feb. 24, 1998 1260 RTA00000422F.f.18.1 M00001583D:B08 24528 3001 Feb. 24, 1998 1258 RTA00000403F.p.05.2 M00001583D:B08 24528 3002 Feb. 24, 1998 1260 RTA00000422F.f.18.1 M00001583D:B08 24528 3002 Feb. 24, 1998 1258 RTA00000403F.p.05.2 M00001583D:B08 24528 3003 Feb. 24, 1998 1260 RTA00000422F.f.18.1 M00001583D:B08 24528 3003 Feb. 24, 1998 1258 RTA00000403F.p.05.2 M00001583D:B08 24528 3004 Feb. 24, 1998 67 RTA00000409F.a.22.1 M00001583B:F02 75200 3005 Feb. 24, 1998 564 RTA00000418F.k.08.1 M00001639A:C03 18259 3006 Jan. 28, 1998 282 RTA00000193AF.c.15.1 M00004248B:E08 3726 3007 Feb. 24, 1998 242 RTA00000404F.j.08.1 M00001629B:B08 39066 3008 Feb. 24, 1998 669 RTA00000410F.b.10.1 M00001633C:B09 74504 3009 Feb. 24, 1998 725 RTA00000410F.b.07.1 M00001633C:A05 78916 3010 Feb. 24, 1998 423 RTA00000410F.a.16.1 M00001633A:E06 73548 3011 Feb. 24, 1998 695 RTA00000418F.j.15.1 M00001632C:H07 74855 3012 Feb. 24, 1998 901 RTA00000418F.j.14.1 M00001632C:B10 32623 3013 Feb. 24, 1998 752 RTA00000410F.a.08.1 M00001632A:B10 73324 3014 Feb. 24, 1998 1007 RTA00000404F.a.01.1 M00001589B:B08 19251 3015 Feb. 24, 1998 1093 RTA00000340F.i.15.1 M00001629C:E07 26815 3016 Feb. 24, 1998 664 RTA00000404F.a.09.1 M00001589C:E06 38985 3017 Feb. 24, 1998 1246 RTA00000418F.j.11.1 M00001626C:E04 73853 3018 Feb. 24, 1998 174 RTA00000404F.b.02.1 M00001591B:B12 38984 3019 Feb. 24, 1998 1142 RTA00000418F.i.06.1 M00001591B:B06 75151 3020 Feb. 24, 1998 740 RTA00000399F.l.19.1 M00001590D:G07 40145 3021 Feb. 24, 1998 1098 RTA00000409F.d.16.1 M00001590C:F10 76090 3022 Feb. 24, 1998 591 RTA00000409F.a.16.1 M00001583A:A05 73990 3023 Feb. 24, 1998 1110 RTA00000404F.j.24.1 M00001631D:G05 39067 3024 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3024 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3024 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3025 Jan. 28, 1998 68 RTA00000184F.k.19.1 M00001558B:D08 8022 3025 Jan. 28, 1998 63 RTA00000184AF.k.19.1 M00001558B:D08 8022 3026 Jan. 28, 1998 269 RTA00000183AF.k.13.1 M00001534B:C12 0 3027 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3027 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3027 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3028 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3028 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3028 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3029 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3029 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3029 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3030 Jan. 28, 1998 34 RTA00000197AF.n.8.1 M00001536D:A12 4101 3031 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3031 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3031 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3032 Jan. 28, 1998 106 RTA00000197AF.n.21.1 M00001540B:C09 0 3033 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3033 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3033 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3034 Jan. 28, 1998 108 RTA00000183AR.h.232 M00001528A:F09 18957 3034 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3034 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3035 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3035 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3035 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3036 Jan. 28, 1998 233 RTA00000197AF.l.8.1 M00001511B:C06 39954 3037 Jan. 28, 1998 323 RTA00000182AF.m.21.1 M00001490C:C12 18699 3038 Jan. 28, 1998 223 RTA00000197F.i.9.1 M00001488D:C10 0 3039 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3039 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3039 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3040 Jan. 28, 1998 352 RTA00000197AF.p.3.1 M00001550A:A03 7239 3041 Jan. 28, 1998 301 RTA00000181AR.i.19.3 M00001452C:B06 16970 3041 Jan. 28, 1998 295 RTA00000181AR.i.19.2 M00001452C:B06 16970 3042 Jan. 28, 1998 68 RTA00000184F.k.19.1 M00001558B:D08 8022 3042 Jan. 28, 1998 63 RTA00000184AF.k.19.1 M00001558B:D08 8022 3043 Jan. 28, 1998 63 RTA00000184AF.k.19.1 M00001558B:D08 8022 3043 Jan. 28, 1998 68 RTA00000184F.k.19.1 M000015588:D08 8022 3044 Jan. 28, 1998 41 RTA00000184F.k.12.1 M00001557D:D09 8761 3045 Jan. 28, 1998 150 RTA00000184F.k.09.1 M00001557C:H07 7065 3046 Jan. 28, 1998 82 RTA00000183AF.l.18.1 M00001535D:C01 3484 3047 Jan. 28, 1998 338 RTA00000184AF.i.1.1 M00001554B:C07 0 3048 Jan. 28, 1998 327 RTA00000182AF.i.1.3 M00001479B:A01 7033 3049 Jan. 28, 1998 256 RTA00000184AR.e.15.1 M00001549C:E06 16347 3050 Jan. 28, 1998 99 RTA00000184AF.d.8.1 M00001548A:A08 4393 3051 Jan. 28, 1998 355 RTA00000184AR.b.24.1 M00001546B:C05 5777 3052 Jan. 28, 1998 322 RTA00000184AR.b.21.1 M00001546B:B02 39788 3053 Jan. 28, 1998 97 RTA00000197AF.o.2.1 M00001541C:B07 5739 3054 Jan. 28, 1998 313 RTA00000183AF.o.11.1 M00001540D:D02 0 3055 Jan. 28, 1998 42 RTA00000184F.j.21.1 M00001557A:D02 7065 3056 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 3056 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 3056 Jan. 28, 1998 116 RTA00000181AR.k.24.3 M00001454B:C12 7005 3057 Jan. 28, 1998 134 RTA00000197F.e.11.1 M00001454B:G03 2306 3057 Jan. 28, 1998 298 RTA00000197AR.e.11.1 M00001454B:G03 2306 3058 Jan. 28, 1998 134 RTA00000J97F.e.11.1 M00001454B:G03 2306 3058 Jan. 28, 1998 298 RTA00000197AR.e.11.1 M00001454B:G03 2306 3059 Jan. 28, 1998 134 RTA00000197F.e.11.1 M00001454B:G03 2306 3059 Jan. 28, 1998 298 RTA00000197AR.e.11.1 M00001454B:G03 2306 3060 Jan. 28, 1998 116 RTA000G0181AR.k.24.3 M00001454B:C12 7005 3060 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 3060 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 3061 Jan. 28, 1998 116 RTA00000181AR.k.24.3 M00001454B:C12 7005 3061 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 3061 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 3062 Jan. 28, 1998 159 RTA00000182AF.l.12.1 M00001487A:A05 1027 3063 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 3063 Jan. 28, 1998 116 RTA00000181AR.k.24.3 M00001454B:C12 7005 3063 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 3064 Jan. 28, 1998 341 RTA00000181AF.l.06.2 M00001454C:C08 0 3065 Jan. 28, 1998 116 RTA00000181AR.k.24.3 M00001454B:C12 7005 3065 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 3065 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 3066 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 3066 Jan. 28, 1998 116 RTA00000181AR.k.24.3 M00001454B:C12 7005 3066 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 3067 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 3067 Jan. 28, 1998 116 RTA00000181AR.k.24.3 M00001454B:C12 7005 3067 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 3068 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 3068 Jan. 28, 1998 116 RTA00000181AR.k.24.3 M00001454B:C12 7005 3068 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 3069 Jan. 28, 1998 170 RTA00000197AF.d.23.1 M00001453A:E11 16130 3070 Jan. 28, 1998 491 RTA00000196F.k.11.1 M00001399C:H12 3 3071 Jan. 28, 1998 119 RTA00000181AR.k.24.2 M00001454B:C12 7005 3071 Jan. 28, 1998 378 RTA00000181AF.k.24.3 M00001454B:C12 7005 3071 Jan. 28, 1998 116 RTA0000D181AR.k.24.3 M00001454B:C12 7005 3072 Jan. 28, 1998 674 RTA00000197AR.e.24.1 M00001456B:F10 39250 3072 Jan. 28, 1998 3 RTA00000197AF.e.24.1 M00001456B:F10 39250 3073 Feb. 24, 1998 78 RTA00000195AF.b.13.1 M00001560D:A03 12605 3073 Jan. 28, 1998 59 RTA00000195AF.b.13.1 M00001560D:A03 12605 3074 Jan. 28, 1998 189 RTA00000197AF.h.10.1 M00001476B:F10 15554 3075 Jan. 28, 1998 46 RTA00000182AF.f.13.1 M00001470C:B10 8010 3076 Jan. 28, 1998 200 RTA00000182AF.f.2.1 M00001469D:D02 4794 3077 Jan. 28, 1998 325 RTA00000182AF.d.18.4 M00001467D:H05 37435 3078 Jan. 28, 1998 45 RTA00000197AR.f.12.1 M00001458C:E01 3513 3079 Jan. 28, 1998 298 RTA00000197AR.e.11.1 M00001454B:G03 2306 3079 Jan. 28, 1998 134 RTA00000197F.e.11.1 M00001454B:G03 2306 3080 Jan. 28, 1998 37 RTA00000181AF.n.15.2 M00001457A:B07 86128 3081 Jan. 28, 1998 7 RTA00000197AR.e.12.1 M00001454B:G07 22095 3082 Jan. 28, 1998 674 RTA00000197AR.e.24.1 M00001456B:F10 39250 3082 Jan. 28, 1998 3 RTA00000197AF.e.24.1 M00001456B:F10 39250 3083 Jan. 28, 1998 88 RTA00000197AF.e.23.1 M00001456B:C09 37157 3084 Jan. 28, 1998 243 RTA00000181AF.m.15.3 M00001455D:A11 12081 3085 Jan. 28, 1998 326 RTA00000197AR.e.19.1 M00001455D:A09 8047 3086 Jan. 28, 1998 293 RTA00000197AF.e.13.1 M00001454C:F02 662 3087 Jan. 28, 1998 380 RTA00000182AF.k.24.1 M00001485D:B10 5625 3088 Jan. 28, 1998 206 RTA00000181AF.o.04.2 M00001457C:C12 22205 3089 Jan. 28, 1998 228 RTA00000187AR.h.15.2 M00001679A:A06 6660 3090 Jan. 28, 1998 68 RTA00000184F.k.19.1 M00001558B:D08 8022 3090 Jan. 28, 1998 63 RTA00000184AF.k.19.1 M00001558B:D08 8022 3091 Jan. 28, 1998 191 RTA00000187AF.p.23.1 M00003748B:F02 39804 3092 Jan. 28, 1998 10 RTA00000198AF.n.16.1 M00001694C:H10 3721 3093 Jan. 28, 1998 219 RTA00000198AF.m.19.1 M00001680D:D02 40041 3093 Jan. 28, 1998 32 RTA00000198R.m.19.1 M00001680D:D02 40041 3094 Jan. 28, 1998 32 RTA00000198R.m.19.1 M00001680D:D02 40041 3094 Jan. 28, 1998 219 RTA00000198AF.m.19.1 M00001680D:D02 40041 3095 Jan. 28, 1998 317 RTA00000198AF.p.09.1 M00003761D:E02 10473 3095 Jan. 28, 1998 186 RTA00000198R.p.09.1 M00003761D:E02 10473 3096 Jan. 28, 1998 219 RTA00000198AF.m.19.1 M00001680D:D02 40041 3096 Jan. 28, 1998 32 RTA00000198R.m.19.1 M00001680D:D02 40041 3097 Jan. 28, 1998 64 RTA00000198AF.p.12.1 M00003763D:E10 8878 3097 Jan. 28, 1998 542 RTA00000198R.p.12.1 M00003763D:E10 8878 3098 Jan. 28, 1998 364 RTA00000187AF.g.13.1 M00001676C:C11 2991 3099 Jan. 28, 1998 430 RTA00000198R.k.23.1 M00001661B:C08 8995 3099 Jan. 28, 1998 294 RTA00000198AF.k.23.1 M00001661B:C08 8995 3100 Jan. 28, 1998 430 RTA00000198R.k.23.1 M00001661B:C08 8995 3100 Jan. 28, 1998 294 RTA00000198AF.k.23.1 M00001661B:C08 8995 3101 Jan. 28, 1998 57 RTA00000198AF.k.20.1 M00001660C:B12 22553 3102 Jan. 28, 1998 368 RTA00000198AF.k.18.1 M00001660A:C12 17432 3103 Jan. 28, 1998 247 RTA00000198AF.k.08.1 M00001656C:G08 17436 3104 Jan. 28, 1998 219 RTA00000198AF.m.19.1 M00001680D:D02 40041 3104 Jan. 28, 1998 32 RTA00000198R.m.19.1 M00001680D:D02 40041 3105 Jan. 28, 1998 199 RTA00000199R.c.09.1 M00003800A:C09 16824 3105 Jan. 28, 1998 66 RTA00000199F.c.09.2 M00003800A:C09 16824 3106 Jan. 28, 1998 225 RTA00000189AF.b.5.1 M00003828A:E04 3784 3107 Jan. 28, 1998 5 RTA00000195R.c.11.1 M00003811A:E03 66087 3108 Jan. 28, 1998 284 RTA00000199F.d.10.2 M00003808C:B05 22049 3108 Feb. 24, 1998 816 RTA00000354R.n.04.1 M00003808C:B05 22049 3109 Jan. 28, 1998 284 RTA00000199F.d.10.2 M00003808C:B05 22049 3109 Feb. 24, 1998 816 RTA00000354R.n.04.1 M00003808C:B05 22049 3110 Jan. 28, 1998 2 RTA00000188AF.n.15.1 M00003804A:H04 0 3111 Jan. 28, 1998 317 RTA00000198AF.p.09.1 M00003761D:E02 10473 3111 Jan. 28, 1998 186 RTA00000198R.p.09.1 M00003761D:E02 10473 3112 Jan. 28, 1998 199 RTA00000199R.c.09.1 M00003800A:C09 16824 3112 Jan. 28, 1998 66 RTA00000199F.c.09.2 M00003800A:C09 16824 3113 Jan. 28, 1998 487 RTA00000198F.i.8.1 M00001639A:F10 9807 3113 Jan. 28, 1998 277 RTA00000198AR.i.08.1 M00001639A:F10 9807 3114 Jan. 28, 1998 66 RTA00000199F.c.09.2 M00003800A:C09 16824 3114 Jan. 28, 1998 199 RTA00000199R.c.09.1 M00003800A:C09 16824 3115 Jan. 28, 1998 224 RTA00000188AF.m.11.1 M00003799A:D09 0 3116 Jan. 28, 1998 58 RTA00000199F.b.01.2 M00003778A:D08 19118 3117 Jan. 28, 1998 216 RTA00000188AF.g.9.1 M00003774B:B08 4959 3118 Jan. 28, 1998 201 RTA00000198AF.p.18.1 M00003769B:D03 23081 3119 Jan. 28, 1998 542 RTA00000198R.p.12.1 M00003763D:E10 8878 3119 Jan. 28, 1998 64 RTA00000198AF.p.12.1 M00003763D:E10 8878 3120 Jan. 28, 1998 199 RTA00000199R.c.09.1 M00003800A:C09 16824 3120 Jan. 28, 1998 66 RTA00000199F.c.09.2 M00003800A:C09 16824 3121 Jan. 28, 1998 146 RTA00000185AF.a.19.2 M00001571C:H06 5749 3122 Jan. 28, 1998 248 RTA00000198R.c.14.1 M00001578D:C04 39814 3122 Feb. 24, 1998 778 RTA00000347F.e.05.1 M00001578D:C04 39814 3123 Jan. 28, 1998 248 RTA00000198R.c.14.1 M00001578D:C04 39814 3123 Feb. 24, 1998 778 RTA00000347F.e.05.1 M00001578D:C04 39814 3124 Jan. 28, 1998 147 RTA00000185AF.c.24.2 M00001578B:E04 23001 3125 Jan. 28, 1998 195 RTA00000198AF.c.10.1 M00001577B:H02 77149 3126 Jan. 28, 1998 171 RTA00000198R.c.07.1 M00001575D:G05 19181 3126 Jan. 28, 1998 525 RTA00000198AF.c.7.1 M00001575D:G05 19181 3127 Jan. 28, 1998 172 RTA00000186AF.p.09.2 M00001655C:E04 6879 3128 Jan. 28, 1998 230 RTA00000185AR.b.18.1 M00001575B:C09 12171 3129 Jan. 28, 1998 192 RTA00000185AF.m.7.1 M00001605C:D12 39804 3130 Jan. 28, 1998 19 RTA00000185AF.a.8.1 M00001570D:A03 4868 3131 Jan. 28, 1998 492 RTA00000198AF.b.8.1 M00001567C:H12 22636 3131 Jan. 28, 1998 23 RTA00000198R.b.08.1 M00001567C:H12 22636 3132 Jan. 28, 1998 23 RTA00000198R.b.08.1 M00001567C:H12 22636 3132 Jan. 28, 1998 492 RTA00000198AF.b.8.1 M00001567C:H12 22636 3133 Jan. 28, 1998 357 RTA00000184AF.o.15.1 M00001564D:C09 0 3134 Jan. 28, 1998 30 RTA00000184AR.n.07.2 M00001561C:F06 0 3135 Jan. 28, 1998 59 RTA00000195AF.b.13.1 M00001560D:A03 12605 3135 Feb. 24, 1998 78 RTA00000195AF.b.13.1 M00001560D:A03 12605 3136 Jan. 28, 1998 525 RTA00000198AF.c.7.1 M00001575D:G05 19181 3136 Jan. 28, 1998 171 RTA00000198R.c.07.1 M00001575D:G05 19181 3137 Jan. 28, 1998 303 RTA00000186AR.e.03.3 M00001623D:C10 22110 3138 Jan. 28, 1998 295 RTA00000181AR.i.19.2 M00001452C:B06 16970 3138 Jan. 28, 1998 301 RTA00000181AR.i.19.3 M00001452C:B06 16970 3139 Jan. 28, 1998 232 RTA00000186AF.j.03.2 M00001638A:E07 0 3140 Jan. 28, 1998 309 RTA00000198AF.h.12.1 M00001632C:A02 9503 3141 Jan. 28, 1998 268 RTA00000186AF.h.01.2 M00001632A:F12 0 3142 Jan. 28, 1998 267 RTA00000186AF.g.11.2 M00001630B:H09 5214 3143 Jan. 28, 1998 83 RTA00000186AF.f.24.2 M00001629B:E06 0 3143 Jan. 28, 1998 336 RTA00000186AF.f.24.1 M00001629B:E06 0 3144 Jan. 28, 1998 222 RTA00000185AF.i.4.1 M00001594A:B12 13942 3145 Jan. 28, 1998 217 RTA00000198AF.h.3.1 M00001625D:C07 22562 3146 Jan. 28, 1998 196 RTA00000198F.e.10.1 M00001599B:E09 9727 3147 Jan. 28, 1998 372 RTA00000186AF.d.23.1 M00001623B:G07 22187 3148 Jan. 28, 1998 302 RTA00000186AF.d.1.2 M00001621C:C08 40044 3149 Jan. 28, 1998 262 RTA00000186AF.c.17.1 M00001619D:G05 8551 3150 Jan. 28, 1998 358 RTA00000198AF.g.7.1 M00001616C:C09 13386 3151 Jan. 28, 1998 166 RTA00000198AF.f.21.1 M00001614D:D09 22676 3152 Jan. 28, 1998 277 RTA00000198AR.i.08.1 M00001639A:F10 9807 3152 Jan. 28, 1998 487 RTA00000195F.i.8.1 M00001639A:F10 9807 3153 Jan. 28, 1998 336 RTA00000186AF.f.24.1 M00001629B:E06 0 3153 Jan. 28, 1998 83 RTA00000186AF.f.24.2 M00001629B:E06 0 3154 Jan. 28, 1998 352 RTA00000197AF.p.3.1 M00001550A:A03 7239 3155 Jan. 28, 1998 251 RTA00000192AF.n.13.1 M00004197D:H01 8210 3156 Jan. 28, 1998 41 RTA00000184F.k.12.1 M00001557D:D09 8761 3157 Jan. 28, 1998 731 RTA00000184F.k.02.1 M00001557B:H10 5192 3158 Jan. 28, 1998 42 RTA00000184F.j.21.1 M00001557A:D02 7065 3159 Jan. 28, 1998 42 RTA00000184F.j.21.1 M00001557A:D02 7065 3160 Jan. 28, 1998 302 RTA00000186AF.d.1.2 M00001621C:C08 40044 3161 Jan. 28, 1998 560 RTA00000184AF.i.23.3 M00001556A:F11 1577 3162 Jan. 28, 1998 558 RTA00000186AR.h.14.1 M00001632D:H07 0 3163 Jan. 28, 1998 256 RTA00000184AR.e.15.1 M00001549C:E06 16347 3164 Jan. 28, 1998 682 RTA00000125A.j.16.1 M00001544A:E06 0 3165 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3165 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3165 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3166 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3166 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3166 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3167 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3167 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3167 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3168 Feb. 24, 1998 531 RTA00000345F.n.12.1 M00001528A:C04 7337 3169 Jan. 28, 1998 324 RTA90000184F.j.06.1 M00001556B:G02 11294 3170 Feb. 24, 1998 604 RTA00000351R.c.13.1 M00003747D:C05 11476 3171 Jan. 28, 1998 301 RTA00000181AR.i.19.3 M00001452C:B06 16970 3171 Jan. 28, 1998 295 RTA00000181AR.i.19.2 M00001452C:B06 16970 3172 Jan. 28, 1998 231 RTA00000192AF.l.13.2 M00004185C:C03 11443 3173 Jan. 28, 1998 634 RTA00000192AF.j.6.1 M00004172C:D08 11494 3174 Jan. 28, 1998 165 RTA00000192AF.g.23.1 M00004157C:A09 6455 3175 Jan. 28, 1998 574 RTA00000192AF.f.3.1 M00004146C:C11 5257 3176 Jan. 28, 1998 146 RTA00000185AF.a.19.2 M00001571C:H06 5749 3177 Jan. 28, 1998 651 RTA00000189AR.d.22.2 M00003844C:B11 6539 3178 Jan. 28, 1998 161 RTA00000183AF.e.23.2 M00001506D:A09 0 3179 Jan. 28, 1998 475 RTA00000187AR.m.3.3 M00001682C:B12 17055 3180 Feb. 24, 1998 39 RTA00000187AF.l.7.1 M00001680D:F08 10539 3181 Jan. 28, 1998 228 RTA00000187AR.h.15.2 M00001679A:A06 6660 3182 Feb. 24, 1998 465 RTA00000350R.p.18.1 M00001676B:F05 11460 3183 Jan. 28, 1998 575 RTA00000186AF.l.12.2 M00001645A:C12 19267 3184 Feb. 24, 1998 700 RTA00000350R.m.14.1 M00001644C:B07 39171 3185 Jan. 28, 1998 261 RTA00000192AF.a.24.1 M00004114C:F11 13183 3186 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3186 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3186 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3187 Jan. 28, 1998 398 RTA00000177AR.l.13.3 M00001353A:G12 8078 3188 Jan. 28, 1998 645 RTA00000177AF.k.9.1 M00001352A:E02 16245 3189 Jan. 28, 1998 283 RTA00000177AF.i.8.4 M00001350A:H01 7187 3190 Jan. 28, 1998 361 RTA00000177AR.g.16.4 M00001347A:B10 13576 3191 Jan. 28, 1998 680 RTA00000177AF.f.10.1 M00001345A:E01 6420 3192 Jan. 28, 1998 632 RTA00000183AR.g.03.1 M00001512D:G09 3956 3192 Jan. 28, 1998 630 RTA00000183AR.g.03.2 M00001512D:G09 3956 3193 Jan. 28, 1998 702 RTA00000177AR.b.8.5 M00001340B:A06 17062 3194 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3194 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3194 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3195 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3195 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3195 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3196 Jan. 28, 1998 129 RTA00000134A.d.10.1 M00001528A:F09 18957 3196 Jan. 28, 1998 236 RTA00000183AR.h.23.1 M00001528A:F09 18957 3196 Jan. 28, 1998 108 RTA00000183AR.h.23.2 M00001528A:F09 18957 3197 Jan. 28, 1998 435 RTA00000182AR.c.22.1 M00001467A:D08 16283 3198 Jan. 28, 1998 635 RTA00000181AF.p.7.3 M00001460A:E01 38773 3199 Jan. 28, 1998 362 RTA00000197AR.c.24.1 M00001450A:B12 82498 3200 Feb. 24, 1998 442 RTA00000347F.b.02.1 M00001450A:A02 39304 3201 Jan. 28, 1998 265 RTA00000177AF.e.14.1 M00001343D:H07 23255 3202 Jan. 28, 1998 270 RTA00000178R.l.08.1 M00001383A:C03 39648 3203 Jan. 28, 1998 472 RTA00000192AF.p.17.1 M00004214C:H05 11451 3204 Jan. 28, 1998 603 RTA00000183AR.d.11.3 M00001504D:G06 6420 3205 Jan. 28, 1998 519 RTA00000183AF.a.24.2 M00001499B:A11 10539 3206 Jan. 28, 1998 435 RTA00000182AR.c.22.1 M00001467A:D08 16283 3207 Feb. 24, 1998 158 RTA00000348R.j.16.1 M00001410A:D07 7005 3208 Jan. 28, 1998 411 RTA00000179AF.j.13.3 M00001400B:H06 0 3209 Jan. 28, 1998 742 RTA00000177AF.m.1.1 M00001353D:D10 14929 3210 Jan. 28, 1998 270 RTA00000178R.l.08.1 M00001383A:C03 39648 3211 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3211 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3211 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3212 Jan. 28, 1998 297 RTA00000178AF.f.9.3 M00001371C:E09 7172 3213 Jan. 28, 1998 33 RTA00000178AR.a.20.1 M00001362C:H11 945 3213 Feb. 24, 1998 979 RTA00000345F.b.17.1 M00001362C:H11 945 3214 Jan. 28, 1998 33 RTA00000178AR.a.20.1 M00001362C:H11 945 3214 Feb. 24, 1998 979 RTA00000345F.b.17.1 M00001362C:H11 945 3215 Jan. 28, 1998 466 RTA00000177AF.p.20.1 M00001361A:A05 4141 3216 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3216 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3216 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3217 Jan. 28, 1998 632 RTA00000183AR.g.03.1 M00001512D:G09 3956 3217 Jan. 28, 1998 630 RTA00000183AR.g.03.2 M00001512D:G09 3956 3218 Jan. 28, 1998 391 RTA00000179AF.e.20.3 M00001396A:C03 4009 3219 Jan. 28, 1998 370 RTA00000179AF.c.15.3 M00001392D:H06 2995 3219 Jan. 28, 1998 460 RTA00000179AF.c.15.1 M00001392D:H06 2995 3220 Jan. 28, 1998 47 RTA00000192AF.m.12.1 M00004191D:B11 0 3221 Jan. 28, 1998 438 RTA00000180AR.g.03.4 M00001425A:C11 9024 3221 Jan. 28, 1998 95 RTA00000180AF.g.3.1 M00001425A:C11 9024 3222 Jan. 28, 1998 438 RTA00000180AR.g.03.4 M00001425A:C11 9024 3222 Jan. 28, 1998 95 RTA00000180A1F.g.3.1 M00001425A:C11 9024 3223 Jan. 28, 1998 320 RTA00000196AF.m.13.1 M00001415B:E09 16290 3224 Jan. 28, 1998 365 RTA00000196F.l.20.2 M00001410B:G05 22678 3225 Jan. 28, 1998 80 RTA00000196AF.p.13.2 M00001432A:E06 6125 3226 Jan. 28, 1998 179 RTA00000179AF.f.20.3 M00001397B:B09 16154 3227 Jan. 28, 1998 379 RTA00000180AF.l.06.2 M00001433A:G07 5625 3228 Jan. 28, 1998 460 RTA00000179AF.c.15.1 M00001392D:H06 2995 3228 Jan. 28, 1998 370 RTA00000179AF.c.15.3 M00001392D:H06 2995 3229 Jan. 28, 1998 107 RTA00000196R.i.13.1 M00001390A:A09 9857 3230 Jan. 28, 1998 120 RTA00000178AR.m.19.5 M00001384D:H07 0 3230 Jan. 28, 1998 377 RTA00000178AF.m.19.1 M00001384D:H07 0 3231 Jan. 28, 1998 120 RTA00000178AR.m.19.5 M00001384D:H07 0 3231 Jan. 28, 1998 377 RTA00000178AF.m.19.1 M00001384D:H07 0 3232 Jan. 28, 1998 384 RTA00000196AF.h.17.1 M00001384C:F12 39215 3233 Jan. 28, 1998 182 RTA00000196AF.h.16.1 M00001384C:E03 39895 3234 Jan. 28, 1998 105 RTA00000179AF.g.12.3 M00001398A:G03 36390 3235 Jan. 28, 1998 252 RTA00000181AF.e.18.3 M00001448D:C09 8 3235 Jan. 28, 1998 253 RTA00000181AF.e.17.3 M00001448D:C09 8 3236 Jan. 28, 1998 301 RTA00000181AR.i.19.3 M00001452C:B06 16970 3236 Jan. 28, 1998 295 RTA00000181AR.i.19.2 M00001452C:B06 16970 3237 Jan. 28, 1998 288 RTA00000181AR.i.06.3 M00001452A:C07 19119 3237 Feb. 24, 1998 198 RTA00000339R.l.14.1 M00001452A:C07 19119 3238 Jan. 28, 1998 288 RTA00000181AR.i.06.3 M00001452A:C07 19119 3238 Feb. 24, 1998 198 RTA00000339R.l.14.1 M00001452A:C07 19119 3239 Jan. 28, 1998 109 RTA00000197AF.d.12.1 M00001451D:C10 39546 3240 Jan. 28, 1998 149 RTA00000181AR.h.06.3 M00001450D:D04 87226 3241 Jan. 28, 1998 75 RTA00000180AR.h.19.2 M00001428A:H10 84182 3242 Jan. 28, 1998 21 RTA00000131A.g.19.2 M00001449A:G10 36535 3243 Jan. 28, 1998 308 RTA00000178AF.j.20.1 M00001380C:E05 15066 3244 Jan. 28, 1998 253 RTA00000181AF.e.17.3 M00001448D:C09 8 3244 Jan. 28, 1998 252 RTA00000181AF.e.18.3 M00001448D:C09 8 3245 Jan. 28, 1998 252 RTA00000181AF.e.18.3 M00001448D:C09 8 3245 Jan. 28, 1998 253 RTA00000181AF.e.17.3 M00001448D:C09 8 3246 Jan. 28, 1998 253 RTA00000181AF.e.17.3 M00001448D:C09 8 3246 Jan. 28, 1998 252 RTA00000181AF.e.18.3 M00001448D:C09 8 3247 Jan. 28, 1998 136 RTA00000197AF.c.10.1 M00001448B:F06 10400 3248 Jan. 28, 1998 177 RTA00000197AF.c.3.1 M00001447C:C01 3145 3249 Jan. 28, 1998 204 RTA00000180AR.o.5.2 M00001437D:C04 7848 3250 Jan. 28, 1998 362 RTA00000197AR.c.24.1 M00001450A:B12 82498 3251 Jan. 28, 1998 81 RTA00000196AF.b.15.1 M00001347B:E01 5102 3252 Jan. 28, 1998 342 RTA00000196AF.d.10.1 M00001354C:B06 22256 3253 Jan. 28, 1998 113 RTA00000196AF.d.09.1 M00001354B:B10 16934 3254 Jan. 28, 1998 463 RTA00000177AR.k.23.4 M00001352D:D02 35550 3254 Jan. 28, 1998 168 RTA00000177AR.k.23.1 M00001352D:D02 35550 3255 Jan. 28, 1998 463 RTA00000177AR.k.23.4 M00001352D:D02 35550 3255 Jan. 28, 1998 168 RTA00000177AR.k.23.1 M00001352D:D02 35550 3256 Jan. 28, 1998 135 RTA00000196AF.c.22.1 M00001352D:C05 22548 3257 Jan. 28, 1998 270 RTA00000178R.l.08.1 M00001383A:C03 39648 3258 Jan. 28, 1998 359 RTA00000196AF.b.17.1 M00001348A:D04 12193 3259 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3259 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3259 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M000013558:G10 14391 3260 Jan. 28, 1998 361 RTA00000177AR.g.16.4 M00001347A:B10 13576 3261 Jan. 28, 1998 265 RTA00000177AF.e.14.1 M00001343D:H07 23255 3262 Jan. 28, 1998 56 RTA00000177AF.e.9.1 M00001343D:C04 37442 3263 Jan. 28, 1998 48 RTA00000177AR.a.23.5 M00001339D:G02 6995 3264 Feb. 24, 1998 308 RTA00000353R.d.11.1 M00004692A:H08 0 3265 Jan. 28, 1998 164 RTA00000193AR.i.14.4 M00004307C:A06 9457 3266 Jan. 28, 1998 283 RTA00000177AF.i.8.4 M00001350A:H01 7187 3267 Jan. 28, 1998 15 RTA00000177AR.n.8.1 M00001356D:F06 4188 3267 Jan. 28, 1998 89 RTA00000177AF.n.8.3 M00001356D:F06 4188 3268 Jan. 28, 1998 383 RTA00000199F.f.20.2 M00003847B:G03 0 3269 Jan. 28, 1998 132 RTA00000178AF.f.20.3 M00001372C:F07 39881 3270 Jan. 28, 1998 296 RTA00000196AF.f.20.1 M00001371D:G01 22774 3271 Jan. 28, 1998 297 RTA00000178AF.f.9.3 M00001371C:E09 7172 3272 Jan. 28, 1998 240 RTA00000178AF.e.1.1 M00001369A:H12 2664 3273 Jan. 28, 1998 16 RTA00000196AF.e.16.1 M00001363C:H02 39252 3274 Jan. 28, 1998 112 RTA00000177AF.m.8.1 M00001354C:C10 8010 3275 Jan. 28, 1998 154 RTA00000196F.e.7.1 M00001360D:E11 1039 3276 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3276 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3276 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3277 Jan. 28, 1998 89 RTA00000177AF.n.8.3 M00001356D:F06 4188 3277 Jan. 28, 1998 15 RTA00000177AR.n.8.1 M00001356D:F06 4188 3278 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3278 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3278 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3279 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3279 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3279 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3280 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3280 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3280 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3281 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M000013558:G10 14391 3281 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3281 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3282 Jan. 28, 1998 169 RTA00000196AF.g.24.1 M00001380C:F02 8685 3283 Jan. 28, 1998 363 RTA00000196AF.e.14.1 M00001362C:A10 12850 3284 Jan. 28, 1998 92 RTA00000198AF.j.18.1 M00001653B:G07 22759 3284 Jan. 28, 1998 433 RTA00000198R.j.18.1 M00001653B:G07 22759 3285 Jan. 28, 1998 537 RTA00000188AF.g.14.1 M00003774C:D02 0 3286 Jan. 28, 1998 434 RTA00000187AR.d.2.2 M00001664C:H10 4892 3287 Jan. 28, 1998 703 RTA00000198F.l.09.1 M00001664B:D06 3611 3288 Jan. 28, 1998 430 RTA00000198R.k.23.1 M00001661B:C08 8995 3288 Jan. 28, 1998 294 RTA00000198AF.k.23.1 M00001661B:C08 8995 3289 Jan. 28, 1998 294 RTA00000198AF.k.23.1 M00001661B:C08 8995 3289 Jan. 28, 1998 430 RTA00000198R.k.23.1 M00001661B:C08 8995 3290 Jan. 28, 1998 754 RTA00000187AF.l.11.1 M00001681A:F03 4482 3291 Jan. 28, 1998 732 RTA00000186AF.p.01.2 M00001654D:G11 40440 3292 Jan. 28, 1998 475 RTA00000187AR.m.3.3 M00001682C:B12 17055 3293 Jan. 28, 1998 433 RTA00000198R.j.18.1 M00001653B:G07 22759 3293 Jan. 28, 1998 92 RTA00000198AF.j.18.1 M00001653B:G07 22759 3294 Jan. 28, 1998 555 RTA00000198AF.j.08.1 M00001651B:A11 10983 3295 Jan. 28, 1998 399 RTA00000186AF.m.15.2 M00001649C:B10 40122 3296 Jan. 28, 1998 575 RTA00000186AF.l.12.2 M00001645A:C12 19267 3297 Jan. 28, 1998 666 RTA00000198F.i.10.1 M00001640B:F03 12792 3298 Jan. 28, 1998 654 RTA00000186AF.j.21.2 M00001639D:B07 22506 3299 Jan. 28, 1998 670 RTA00000186AF.p.17.3 M00001656B:A07 38383 3300 Jan. 28, 1998 393 RTA00000188AF.b.14.1 M00003754D:D02 0 3301 Jan. 28, 1998 422 RTA00000189AF.b.12.1 M00003829B:G03 17233 3301 Jan. 28, 1998 210 RTA00000189AR.b.12.1 M00003829B:G03 17233 3302 Jan. 28, 1998 587 RTA00000199F.a.3.1 M00003772D:E10 16617 3303 Jan. 28, 1998 394 RTA00000198AF.p.22.1 M00003771A:G10 0 3304 Jan. 28, 1998 542 RTA00000198R.p.12.1 M00003763D:E10 8878 3304 Jan. 28, 1998 64 RTA00000198AF.p.12.1 M00003763D:E10 8878 3305 Jan. 28, 1998 64 RTA00000198AF.p.12.1 M00003763D:E10 8878 3305 Jan. 28, 1998 542 RTA00000198R.p.12.1 M00003763D:E10 8878 3306 Jan. 28, 1998 465 RTA00000187AF.k.20.1 M00001680B:C01 3648 3307 Jan. 28, 1998 423 RTA00000188AR.b.17.1 M00003755A:B03 10662 3308 Jan. 28, 1998 711 RTA00000198F.i.2.1 M00001637B:E07 8076 3309 Jan. 28, 1998 497 RTA00000198AF.o.09.1 M00003751B:A05 4310 3309 Jan. 28, 1998 506 RTA00000198R.o.09.1 M00003751B:A05 4310 3310 Jan. 28, 1998 506 RTA00000198R.o.09.1 M00003751B:A05 4310 3310 Jan. 28, 1998 497 RTA00000198AF.o.09.1 M00003751B:A05 4310 3311 Jan. 28, 1998 432 RTA00000198AF.o.05.1 M00003750A:D01 26702 3311 Jan. 28, 1998 49 RTA00000198R.o.05.1 M00003750A:D01 26702 3312 Jan. 28, 1998 49 RTA00000198R.o.05.1 M00003750A:D01 26702 3312 Jan. 28, 1998 432 RTA00000198AF.o.05.1 M00003750A:D01 26702 3313 Jan. 28, 1998 585 RTA00000198AF.n.18.1 M00001771A:A07 16715 3314 Jan. 28, 1998 527 RTA00000198R.m.23.1 M00001684B:G03 38469 3315 Jan. 28, 1998 471 RTA00000188AF.e.2.1 M00003763B:H01 0 3316 Jan. 28, 1998 171 RTA00000198R.c.07.1 M00001575D:G05 19181 3316 Jan. 28, 1998 525 RTA00000198AF.c.7.1 M00001575D:G05 19181 3317 Jan. 28, 1998 557 RTA00000198AF.d.9.1 M00001587D:A10 8841 3318 Jan. 28, 1998 523 RTA00000198AF.d.4.1 M00001586D:E02 22435 3319 Jan. 28, 1998 441 RTA00000185AF.e.6.1 M00001583B:E10 0 3320 Jan. 28, 1998 439 RTA00000185AF.d.14.2 M00001579D:G07 8071 3321 Jan. 28, 1998 561 RTA00000185AR.d.10.1 M00001579C:H10 0 3322 Jan. 28, 1998 277 RTA00000198AR.i.08.1 M00001639A:F10 9807 3322 Jan. 28, 1998 487 RTA00000198F.i.8.1 M00001639A:F10 9807 3323 Jan. 28, 1998 525 RTA00000198AF.c.7.1 M00001575D:G05 19181 3323 Jan. 28, 1998 171 RTA00000198R.c.07.1 M00001575D:G05 19181 3324 Feb. 24, 1998 317 RTA00000195AF.b.21.1 M00001595B:A09 39055 3324 Jan. 28, 1998 602 RTA00000195AF.b.21.1 M00001595B:A09 39055 3325 Jan. 28, 1998 507 RTA00000198AF.c.5.1 M00001573D:F10 53802 3326 Jan. 28, 1998 414 RTA00000185AR.b.15.1 M00001573D:F04 39813 3326 Jan. 28, 1998 428 RTA00000185AF.b.15.2 M00001573D:F04 39813 3327 Jan. 28, 1998 428 RTA00000185AF.b.15.2 M00001573D:F04 39813 3327 Jan. 28, 1998 414 RTA00000185AR.b.15.1 M00001573D:F04 39813 3328 Jan. 28, 1998 414 RTA00000155AR.b.15.1 M00001573D:F04 39813 3328 Jan. 28, 1998 428 RTA00000185AF.b.15.2 M00001573D:F04 39813 3329 Jan. 28, 1998 428 RTA00000185AF.b.15.2 M00001573D:F04 39813 3329 Jan. 28, 1998 414 RTA00000185AR.b.15.1 M00001573D:F04 39813 3330 Jan. 28, 1998 392 RTA00000185AF.b.11.2 M00001573C:D03 9024 3331 Jan. 28, 1998 549 RTA00000198AF.c.16.1 M00001579C:B11 26801 3332 Jan. 28, 1998 628 RTA00000198AF.g.16.1 M00001621D:D03 6602 3333 Jan. 28, 1998 616 RTA00000188AF.m.07.1 M00003798D:E03 23183 3334 Jan. 28, 1998 489 RTA00000186AF.h.22.1 M00001634B:C10 16485 3335 Jan. 28, 1998 655 RTA00000186AF.g.8.2 M00001630B:A11 8065 3336 Jan. 28, 1998 592 RTA00000186AF.e.18.1 M00001624C:A06 0 3337 Jan. 28, 1998 713 RTA00000198AF.g.21.1 M00001624A:F09 6273 3338 Jan. 28, 1998 554 RTA00000186AR.e.07.4 M00001623D:G03 4175 3338 Jan. 28, 1998 400 RTA00000186AR.e.07.3 M00001623D:G03 4175 3339 Jan. 28, 1998 467 RTA00000195AF.b.19.1 M00001589A:D12 77678 3340 Jan. 28, 1998 646 RTA00000186AF.d.24.1 M00001623C:H07 3114 3341 Jan. 28, 1998 740 RTA00000198AF.d.15.1 M00001590C:H08 5997 3342 Jan. 28, 1998 504 RTA00000198AF.g.2.1 M00001615C:D02 16640 3343 Jan. 28, 1998 470 RTA00000198AF.f.16.1 M00001614A:E06 0 3344 Jan. 28, 1998 388 RTA00000185AF.n.17.1 M00001609B:A11 5336 3345 Jan. 28, 1998 495 RTA00000185AF.j.21.1 M00001597A:E12 0 3346 Feb. 24, 1998 317 RTA00000195AF.b.21.1 M00001595B:A09 39055 3346 Jan. 28, 1998 602 RTA00000195AF.b.21.1 M00001595B:A09 39055 3347 Jan. 28, 1998 487 RTA00000198F.i.8.1 M00001639A:F10 9807 3347 Jan. 28, 1998 277 RTA00000198AR.i.08.1 M00001639A:F10 9807 3348 Jan. 28, 1998 554 RTA00000186AR.e.07.4 M00001623D:G03 4175 3348 Jan. 28, 1998 400 RTA00000186AR.e.07.3 M00001623D:G03 4175 3349 Jan. 28, 1998 699 RTA00000178AF.a.12.1 M00001362B:H06 0 3350 Jan. 28, 1998 416 RTA00000199F.a.5.1 M00003773B:G01 22134 3351 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 3351 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 3351 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 3352 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 3352 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 3352 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 3353 Jan. 28, 1998 522 RTA00000178AR.h.17.2 M00001376A:C05 23824 3353 Feb. 24, 1998 1095 RTA00000345F.c.12.1 M00001376A:C05 23824 3354 Jan. 28, 1998 522 RTA00000178AR.h.17.2 M00001376A:C05 23824 3354 Feb. 24, 1998 1095 RTA00000345F.c.12.1 M00001376A:C05 23824 3355 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 3355 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 3355 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 3356 Jan. 28, 1998 566 RTA00000195F.a.4.1 M00001372C:G12 20470 3357 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 3357 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 3357 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 3358 Jan. 28, 1998 605 RTA00000196F.e.9.1 M00001361A:H07 23300 3359 Jan. 28, 1998 532 RTA00000177AF.o.4.1 M00001358C:C06 0 3360 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3360 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3360 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3361 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3361 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3361 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3362 Jan. 28, 1998 337 RTA00000177AR.m.17.3 M00001355B:G10 14391 3362 Jan. 28, 1998 493 RTA00000177AF.m.17.1 M00001355B:G10 14391 3362 Jan. 28, 1998 330 RTA00000177AR.m.17.4 M00001355B:G10 14391 3363 Jan. 28, 1998 742 RTA00000177AF.m.1.1 M00001353D:D10 14929 3364 Jan. 28, 1998 547 RTA00000196AF.g.8.1 M00001375B:G12 39665 3365 Jan. 28, 1998 510 RTA00000178AF.n.23.1 M00001387B:E02 3298 3366 Jan. 28, 1998 606 RTA00000179AR.e.01.4 M00001395A:C09 2493 3367 Feb. 24, 1998 1065 RTA00000195R.a.06.1 M00001394A:E04 35265 3367 Jan. 28, 1998 595 RTA00000195R.a.06.1 M00001394A:E04 35265 3368 Feb. 24, 1998 1065 RTA00000195R.a.06.1 M00001394A:E04 35265 3368 Jan. 28, 1998 595 RTA00000195R.a.06.1 M00001394A:E04 35265 3369 Jan. 28, 1998 370 RTA00000179AF.c.15.3 M00001392D:H06 2995 3369 Jan. 28, 1998 460 RTA00000179AF.c.15.1 M00001392D:H06 2995 3370 Jan. 28, 1998 370 RTA00000179AF.c.15.3 M00001392D:H06 2995 3370 Jan. 28, 1998 460 RTA00000179AF.c.15.1 M00001392D:H06 2995 3371 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 3371 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 3371 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 3372 Jan. 28, 1998 675 RTA00000179AR.b.21.3 M00001392C:D05 4366 3372 Feb. 24, 1998 1264 RTA00000345F.e.13.1 M00001392C:D05 4366 3373 Jan. 28, 1998 168 RTA00000177AR.k.23.1 M00001352D:D02 35550 3373 Jan. 28, 1998 463 RTA00000177AR.k.23.4 M00001352D:D02 35550 3374 Jan. 28, 1998 652 RTA00000178AR.m.21.4 M00001385A:F12 786 3374 Jan. 28, 1998 653 RTA00000178AR.m.21.5 M00001385A:F12 7861 3375 Jan. 28, 1998 653 RTA00000178AR.m.21.5 M00001385A:F12 7861 3375 Jan. 28, 1998 652 RTA00000178AR.m.21.4 M00001385A:F12 7861 3376 Jan. 28, 1998 672 RTA00000196AF.h.09.1 M00001382B:F12 8015 3377 Jan. 28, 1998 668 RTA00000178AF.i.17.1 M00001377C:E12 0 3378 Jan. 28, 1998 746 RTA00000178AF.i.01.2 M00001376B:F03 4 3379 Jan. 28, 1998 656 RTA00000178AR.h.22.3 M00001376B:A08 19230 3379 Jan. 28, 1998 657 RTA00000178AR.h.22.2 M00001376B:A08 19230 3379 Feb. 24, 1998 1137 RTA00000345F.d.03.1 M00001376B:A08 19230 3380 Jan. 28, 1998 675 RTA00000179AR.b.21.3 M00001392C:D05 4366 3380 Feb. 24, 1998 1264 RTA00000345F.e.13.1 M00001392C:D05 4366 3381 Jan. 28, 1998 651 RTA00000189AR.d.22.2 M00003844C:B11 6539 3382 Jan. 28, 1998 444 RTA00000189AF.l.16.1 M00003879A:G05 0 3383 Jan. 28, 1998 648 RTA00000199F.i.9.1 M00003878C:E04 7 3384 Feb. 24, 1998 678 RTA00000195AF.c.24.1 M00003860D:H07 0 3384 Jan. 28, 1998 412 RTA00000195AF.c.24.1 M00003860D:H07 0 3385 Jan. 28, 1998 412 RTA00000195AF.c.24.1 M00003860D:H07 0 3385 Feb. 24, 1998 678 RTA00000Z95AF.c.24.1 M00003860D:H07 0 3386 Jan. 28, 1998 484 RTA00000199F.g.20.2 M00003860D:A01 15767 3387 Jan. 28, 1998 398 RTA00000177AR.l.13.3 M00001353A:G12 8078 3388 Jan. 28, 1998 556 RTA00000199F.f.17.2 M00003845D:B04 22905 3389 Jan. 28, 1998 545 RTA00000196F.a.2.1 M00001338B:E02 3575 3390 Jan. 28, 1998 406 RTA00000199F.f.09.2 M00003842B:D09 22907 3390 Jan. 28, 1998 78 RTA00000199R.f.09.1 M00003842B:D09 22907 3391 Jan. 28, 1998 78 RTA00000199R.f.09.1 M00003842B:D09 22907 3391 Jan. 28, 1998 406 RTA00000199F.f.09.2 M00003842B:D09 22907 3392 Jan. 28, 1998 692 RTA00000199F.e.4.1 M00003820B:C05 0 3393 Jan. 28, 1998 458 RTA00000199R.d.16.1 M00003812C:A05 24191 3394 Jan. 28, 1998 755 RTA00000199F.c.21.2 M00003803C:D09 5070 3395 Jan. 28, 1998 505 RTA00000188AF.n.03.1 M00003801B:B10 9443 3396 Jan. 28, 1998 714 RTA00000199R.g.07.1 M00003853D:D03 0 3397 Jan. 28, 1998 724 RTA00000177AR.f.15.4 M00001345B:E10 9062 3398 Jan. 28, 1998 623 RTA00000198R.b.24.1 M00001571D:B11 19047 3398 Jan. 28, 1998 748 RTA00000198AF.b.24.1 M00001571D:B11 19047 3399 Jan. 28, 1998 395 RTA00000196R.c.21.2 M00001352C:H10 0 3400 Jan. 28, 1998 593 RTA00000196R.c.14.2 M00001352B:F04 23105 3400 Jan. 28, 1998 485 RTA00000196AF.c.14.1 M00001352B:F04 23105 3401 Jan. 28, 1998 485 RTA00000196AF.c.14.1 M00001352B:F04 23105 3401 Jan. 28, 1998 593 RTA00000196R.c.14.2 M00001352B:F04 23105 3402 Jan. 28, 1998 645 RTA00000177AF.k.9.1 M00001352A:E02 16245 3403 Jan. 28, 1998 576 RTA00000196AF.c.7.1 M00001350B:G11 0 3404 Jan. 28, 1998 737 RTA00000189AR.m.9.1 M00003880B:C08 2917 3405 Jan. 28, 1998 728 RTA00000177AR.f.17.4 M00001345C:B01 8594 3406 Jan. 28, 1998 453 RTA00000199AF.i.20.1 M00003881A:D09 9544 3407 Jan. 28, 1998 440 RTA00000177AR.f.13.4 M00001345A:G11 10480 3408 Jan. 28, 1998 680 RTA00000177AF.f.10.1 M00001345A:E01 6420 3409 Jan. 28, 1998 573 RTA00000196AF.b.7.1 M00001344A:G07 7774 3410 Jan. 28, 1998 402 RTA00000177AF.b.21.4 M00001341A:F12 4443 3411 Jan. 28, 1998 702 RTA00000177AR.b.8.5 M00001340B:A06 17062 3412 Jan. 28, 1998 463 RTA00000177AR.k.23.4 M00001352D:D02 35550 3412 Jan. 28, 1998 168 RTA00000177AR.k.23.1 M00001352D:D02 35550 3413 Jan. 28, 1998 600 RTA00000177AF.g.4.1 M00001346B:B07 4119 3414 Jan. 28, 1998 280 RTA00000193AF.b.18.1 M00004233C:H09 7542 3415 Jan. 28, 1998 748 RTA00000198AF.b.24.1 M00001571D:B11 19047 3415 Jan. 28, 1998 623 RTA00000198R.b.24.1 M00001571D:B11 19047 3416 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 3416 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 3416 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 3417 Jan. 28, 1998 282 RTA00000193AF.c.15.1 M00004248B:E08 3726 3418 Jan. 28, 1998 307 RTA00000200F.n.05.2 M00004246C:A09 18989 3418 Jan. 28, 1998 319 RTA00000200F.n.05.1 M00004246C:A09 18989 3419 Jan. 28, 1998 319 RTA00000200F.n.05.1 M00004246C:A09 18989 3419 Jan. 28, 1998 307 RTA00000200F.n.05.2 M00004246C:A09 18989 3420 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 3420 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 3420 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 3421 Jan. 28, 1998 307 RTA00000200F.n.05.2 M00004246C:A09 18989 3421 Jan. 28, 1998 319 RTA00000200F.n.05.1 M00004246C:A09 18989 3422 Jan. 28, 1998 50 RTA00000201R.a.02.1 M00004295B:D02 35362 3422 Jan. 28, 1998 235 RTA00000201AF.a.02.1 M00004295B:D02 35362 3423 Jan. 28, 1998 251 RTA00000192AF.n.13.1 M00004197D:H01 8210 3424 Jan. 28, 1998 47 RTA00000192AF.m.12.1 M00004191D:B11 0 3425 Jan. 28, 1998 494 RTA00000200AF.k.1.1 M00004188C:A09 40049 3425 Jan. 28, 1998 194 RTA00000200R.k.01.1 M00004188C:A09 40049 3426 Jan. 28, 1998 494 RTA00000200AF.k.1.1 M00004188C:A09 40049 3426 Jan. 28, 1998 194 RTA00000200R.k.01.1 M00004185C:A09 40049 3427 Jan. 28, 1998 231 RTA00000192AF.l.13.2 M00004185C:C03 11443 3428 Jan. 28, 1998 382 RTA00000200AF.j.6.1 M00004176B:E08 22902 3429 Jan. 28, 1998 307 RTA00000200F.n.05.2 M00004246C:A09 18989 3429 Jan. 28, 1998 319 RTA00000200F.n.05.1 M00004246C:A09 18989 3430 Jan. 28, 1998 52 RTA00000201R.b.02.1 M00004319D:G09 22660 3431 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00004375A:H01 2599 3431 Jan. 28, 1998 239 RTA00000201R.d.02.1 M00004375A:H01 2599 3431 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 3432 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 3432 Jan. 28, 1998 239 RTA00000201R.d.02.1 M00004375A:H01 2599 3432 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00004375A:H01 2599 3433 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 3433 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00064375A:H01 2599 3433 Jan. 28, 1998 239 RTA00000201R.d.02.1 M00004375A:H01 2599 3434 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00004375A:H01 2599 3434 Jan. 28, 1998 239 RTA01000201R.d.02.1 M00004375A:H01 2599 3434 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 3435 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 3435 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00004375A:H01 2599 3435 Jan. 28, 1998 239 RTA00000201R.d.02.1 M00004375A:H01 2599 3436 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 3436 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 3436 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 3437 Jan. 28, 1998 273 RTA00000201F.c.08.1 M00004353C:H07 0 3438 Jan. 28, 1998 328 RTA00000200AF.g.09.1 M00004131B:H09 22785 3438 Jan. 28, 1998 26 RTA00000200R.g.09.1 M00004131B:H09 22785 3439 Feb. 24, 1998 571 RTA00000355R.e.14.1 M00004314B:G07 16837 3439 Jan. 28, 1998 343 RTA00000201F.a.18.1 M00004314B:G07 16837 3440 Jan. 28, 1998 343 RTA00000201F.a.18.1 M00004314B:G07 16837 3440 Feb. 24, 1998 571 RTA00000355R.e.14.1 M00004314B:G07 16837 3441 Jan. 28, 1998 164 RTA00000193AR.i.14.4 M00004307C:A06 9457 3442 Jan. 28, 1998 50 RTA00000201R.a.02.1 M00004295B:D02 35362 3442 Jan. 28, 1998 235 RTA00000201AF.a.02.1 M00004295B:D02 35362 3443 Jan. 28, 1998 235 RTA00000201AF.a.02.1 M00004295B:D02 35362 3443 Jan. 28, 1998 50 RTA00000201R.a.02.1 M00004295B:D02 35362 3444 Jan. 28, 1998 50 RTA00000201R.a.02.1 M00004295B:D02 35362 3444 Jan. 28, 1998 235 RTA00000201AF.a.02.1 M00004295B:D02 35362 3445 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 3445 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00004375A:H01 2599 3445 Jan. 28, 1998 239 RTA00000201R.d.02.1 M00004375A:H01 2599 3446 Jan. 28, 1998 13 RTA00000190AF.i.5.1 M00003919A:A10 0 3447 Jan. 28, 1998 72 RTA00000200F.a.6.1 M00004029B:F11 36952 3448 Jan. 28, 1998 101 RTA00000191AF.d.08.2 M00003997B:G07 970 3449 Jan. 28, 1998 79 RTA00000199AF.p.4.1 M00003985C:F01 10282 3450 Jan. 28, 1998 121 RTA00000199AF.o.16.1 M00003979A:F03 16721 3451 Jan. 28, 1998 193 RTA00000199AF.n.3.1 M00003946D:C11 0 3452 Jan. 28, 1998 165 RTA00000192AF.g.23.1 M00004157C:A09 6455 3453 Jan. 28, 1998 381 RTA00000199AF.m.14.1 M00003938A:B04 10580 3454 Jan. 28, 1998 123 RTA00000191AF.k.6.1 M00004078B:A11 5451 3455 Jan. 28, 1998 102 RTA00000199R.j.08.1 M00003884D:G07 37844 3456 Jan. 28, 1998 86 RTA00000189AF.l.22.1 M00003879C:G10 33333 3457 Jan. 28, 1998 148 RTA00000199F.h.17.2 M00003871A:A05 36254 3458 Jan. 28, 1998 143 RTA00000199R.h.09.1 M00003867C:H09 76020 3459 Jan. 28, 1998 266 RTA00000199F.f.21.2 M00003847C:E09 13344 3460 Feb. 24, 1998 153 RTA00000422F.g.22.1 M00001585B:A06 22561 3461 Jan. 28, 1998 292 RTA00000199AF.m.18.1 M00003939C:F04 0 3462 Jan. 28, 1998 275 RTA00000191AF.o.17.2 M00004102A:H02 5957 3462 Jan. 28, 1998 274 RTA00000191AF.o.17.1 M00004102A:H02 5957 3463 Jan. 28, 1998 239 RTA00000201R.d.02.1 M00004375A:H01 2599 3463 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00004375A:H01 2599 3463 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 3464 Jan. 28, 1998 328 RTA00000200AF.g.09.1 M00004131B:H09 22785 3464 Jan. 28, 1998 26 RTA00000200R.g.09.1 M00004131B:H09 22785 3465 Jan. 28, 1998 214 RTA00000200AF.f.22.1 M00004121C:F06 16521 3466 Jan. 28, 1998 160 RTA00000192AF.b.20.1 M00004118D:E08 0 3467 Jan. 28, 1998 98 RTA00000200AF.f.14.1 M00004115D:C08 22051 3467 Jan. 28, 1998 100 RTAG0000200R.f.14.1 M00004115D:C08 22051 3468 Jan. 28, 1998 98 RTA00000200AF.f.14.1 M00004115D:C08 22051 3468 Jan. 28, 1998 100 RTA00000200R.f.14.1 M00004115D:C08 22051 3469 Jan. 28, 1998 305 RTA00000200AF.b.15.1 M00004040D:F01 10627 3470 Jan. 28, 1998 98 RTA00000200AF.f.14.1 M00004115D:C08 22051 3470 Jan. 28, 1998 100 RTA00000200R.f.14.1 M00004115D:C08 22051 3471 Jan. 28, 1998 29 RTA00000200AF.b.19.1 M00004042D:H02 22847 3472 Jan. 28, 1998 274 RTA00000191AF.o.17.1 M00004102A:H02 5957 3472 Jan. 28, 1998 275 RTA00000191AF.o.17.2 M00004102A:H02 5957 3473 Jan. 28, 1998 274 RTA00000191AF.o.17.1 M00004102A:H02 5957 3473 Jan. 28, 1998 275 RTA00000191AF.o.17.2 M00004102A:H02 5957 3474 Jan. 28, 1998 275 RTA00000191AF.o.17.2 M00004102A:H02 5957 3474 Jan. 28, 1998 274 RTA00000191AF.o.17.1 M00004102A:H02 5957 3475 Jan. 28, 1998 226 RTA00000191AR.o.09.4 M00004096A:G02 0 3476 Jan. 28, 1998 40 RTA00000200AR.e.02.1 M00004090A:F09 36059 3477 Jan. 28, 1998 175 RTA00000200F.i.5.1 M00004156B:A12 22892 3478 Jan. 28, 1998 98 RTA00000200AF.f.14.1 M00004115D:C08 22051 3478 Jan. 28, 1998 100 RTA00000200R.f.14.1 M00004115D:C08 22051 3479 Jan. 28, 1998 643 RTA00000184AF.c.9.1 M00001546C:G10 16245 3480 Jan. 28, 1998 615 RTA00000197R.p.20.1 M00001554B:B07 22795 3480 Jan. 28, 1998 559 RTA00000197AF.p.20.1 M00001554B:B07 22795 3481 Jan. 28, 1998 660 RTA00000197AF.p.16.1 M00001552D:G08 6013 3482 Jan. 28, 1998 521 RTA00000197AF.p.12.1 M00001552B:G05 0 3483 Jan. 28, 1998 403 RTA00000184AF.f.13.1 M00001550D:H02 3784 3484 Jan. 28, 1998 517 RTA00000184AF.e.14.1 M00001549C:D02 16347 3485 Jan. 28, 1998 676 RTA00000197AR.m.14.1 M00001531B:E09 14879 3486 Jan. 28, 1998 596 RTA00000184AF.d.9.1 M00001548A:B11 6515 3487 Jan. 28, 1998 559 RTA00000197AF.p.20.1 M00001554B:B07 22795 3487 Jan. 28, 1998 615 RTA00000197R.p.20.1 M00001554B:B07 22795 3488 Jan. 28, 1998 729 RTA00000184AF.a.19.1 M00001544C:C06 2628 3489 Jan. 28, 1998 682 RTA00000125A.j.16.1 M00001544A:E06 0 3490 Jan. 28, 1998 723 RTA00000183AF.p.24.1 M00001543C:F01 3116 3491 Jan. 28, 1998 509 RTA00000183AF.p.17.1 M00001543A:H12 5158 3492 Jan. 28, 1998 738 RTA00000183AF.o.8.1 M00001540C:B10 8927 3493 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 3493 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00004375A:H01 2599 3493 Jan. 28, 1998 239 RTA00000201R.d.02.1 M00004375A:H01 2599 3494 Jan. 28, 1998 502 RTA00000197AF.o.23.1 M00001549A:A09 12682 3495 Jan. 28, 1998 468 RTA00000198AF.a.18.1 M00001561C:E11 0 3496 Jan. 28, 1998 210 RTA00000189AR.b.12.1 M00003829B:G03 17233 3496 Jan. 28, 1998 422 RTA00000189AF.b.12.1 M00003829B:G03 17233 3497 Jan. 28, 1998 748 RTA00000198AF.b.24.1 M00001571D:B11 19047 3497 Jan. 28, 1998 623 RTA00000198R.b.24.1 M00001571D:B11 19047 3498 Jan. 28, 1998 397 RTA00000198AF.b.22.1 M00001571B:E03 38956 3499 Jan. 28, 1998 571 RTA00000198AF.b.14.1 M00001569C:B06 801 3500 Jan. 28, 1998 492 RTA00000198AF.b.8.1 M00001567C:H12 22636 3500 Jan. 28, 1998 23 RTA00000198R.b.08.1 M00001567C:H12 22636 3501 Jan. 28, 1998 492 RTA00000198AF.b.8.1 M00001567C:H12 22636 3501 Jan. 28, 1998 23 RTA00000198R.b.08.1 M00001567C:H12 22636 3502 Jan. 28, 1998 559 RTA00000197AF.p.20.1 M00001554B:B07 22795 3502 Jan. 28, 1998 615 RTA00000197R.p.20.1 M00001554B:B07 22795 3503 Jan. 28, 1998 727 RTA00000184AF.n.12.2 M00001561D:C11 3727 3504 Jan. 28, 1998 559 RTA00000197AF.p.20.1 M00001554B:B07 22795 3504 Jan. 28, 1998 615 RTA00000197R.p.20.1 M00001554B:B07 22795 3505 Jan. 28, 1998 641 RTA00000198F.a.10.1 M00001558A:E11 6695 3506 Jan. 28, 1998 731 RTA00000184F.k.02.1 M00001557B:H10 5192 3507 Jan. 28, 1998 597 RTA00000198F.a.4.1 M00001557A:F01 9635 3508 Jan. 28, 1998 560 RTA00000184AF.i.23.3 M00001556A:F11 1577 3509 Jan. 28, 1998 601 RTA00000184AF.i.10.2 M00001555A:B01 3744 3510 Jan. 28, 1998 700 RTA00000183AF.i.18.2 M00001529D:H02 40129 3511 Jan. 28, 1998 437 RTA00000198R.a.23.1 M00001563B:D11 10700 3512 Jan. 28, 1998 591 RTA00000197AF.h.1.1 M00001470A:H01 13075 3512 Jan. 28, 1998 110 RTA00000197R.h.01.1 M00001470A:H01 13075 3513 Jan. 28, 1998 259 RTA00000197AF.j.4.1 M00001492D:A11 17209 3513 Jan. 28, 1998 386 RTA00000197AR.j.04.1 M00001492D:A11 17209 3514 Jan. 28, 1998 386 RTA00000197AR.j.04.1 M00001492D:A11 17209 3514 Jan. 28, 1998 259 RTA00000197AF.j.4.1 M00001492D:A11 17209 3515 Jan. 28, 1998 644 RTA00000197F.i.12.1 M00001489B:A06 3605 3516 Jan. 28, 1998 633 RTA00000197F.i.8.1 M00001488A:E01 6292 3517 Jan. 28, 1998 546 RTA00000197F.i.6.1 M00001487C:D06 12149 3518 Jan. 28, 1998 650 RTA00000183AR.n.17.1 M00001539B:H06 9800 3519 Jan. 28, 1998 513 RTA00000197AF.h.14.1 M00001477B:F04 7045 3520 Jan. 28, 1998 519 RTA00000183AF.a.24.2 M00001499B:A11 10539 3521 Jan. 28, 1998 110 RTA00000197R.h.01.1 M00001470A:H01 13075 3521 Jan. 28, 1998 591 RTA00000197AF.h.1.1 M00001470A:H01 13075 3522 Jan. 28, 1998 446 RTA00000182AF.a.23.3 M00001463A:F06 9755 3523 Jan. 28, 1998 739 RTA00000181AF.p.12.3 M00001460C:H02 22204 3524 Jan. 28, 1998 635 RTA00000181AF.p.7.3 M00001460A:E01 38773 3525 Jan. 28, 1998 720 RTA00000197AF.f.14.1 M00001459B:C09 3732 3526 Jan. 28, 1998 623 RTA00000198R.b.24.1 M00001571D:B11 19047 3526 Jan. 28, 1998 748 RTA00000198AF.b.24.1 M00001571D:B11 19047 3527 Jan. 28, 1998 419 RTA00000182AF.j.20.1 M00001483B:D03 4769 3528 Jan. 28, 1998 632 RTA00000183AR.g.03.1 M00001512D:G09 3956 3528 Jan. 28, 1998 630 RTA00000183AR.g.03.2 M00001512D:G09 3956 3529 Jan. 28, 1998 695 RTA00000197F.m.5.1 M00001528C:H04 10872 3530 Jan. 28, 1998 479 RTA00000197R.l.22.1 M00001528A:C11 6962 3530 Jan. 28, 1998 665 RTA00000197AF.l.22.1 M00001528A:C11 6962 3531 Jan. 28, 1998 479 RTA00000197R.l.22.1 M00001528A:C11 6962 3531 Jan. 28, 1998 665 RTA00000197AF.l.22.1 M00001528A:C11 6962 3532 Jan. 28, 1998 479 RTA00000197R.l.22.1 M00001528A:C11 6962 3532 Jan. 28, 1998 665 RTA00000197AF.l.22.1 M00001528A:C11 6962 3533 Jan. 28, 1998 479 RTA00000197R.l.22.1 M00001528A:C11 6962 3533 Jan. 28, 1998 665 RTA00000197AF.l.22.1 M00001528A:C11 6962 3534 Jan. 28, 1998 550 RTA00000183AF.g.14.1 M00001513D:A03 0 3535 Jan. 28, 1998 404 RTA00000195AF.b.6.1 M00001496C:G10 39490 3536 Jan. 28, 1998 630 RTA00000183AR.g.03.2 M00001512D:G09 3956 3536 Jan. 28, 1998 632 RTA00000183AR.g.03.1 M00001512D:G09 3956 3537 Jan. 28, 1998 570 RTA00000183AF.a.19.2 M00001499A:A05 3788 3538 Jan. 28, 1998 630 RTA00000183AR.g.03.2 M00001512D:009 3956 3538 Jan. 28, 1998 632 RTA00000183AR.g.03.1 M00001512D:G09 3956 3539 Jan. 28, 1998 603 RTA00000183AR.d.11.3 M00001504D:G06 6420 3540 Jan. 28, 1998 715 RTA00000197AR.k.11.1 M00001500D:E10 53758 3541 Jan. 28, 1998 503 RTA00000197AF.k.9.1 M00001500C:C08 3138 3542 Jan. 28, 1998 719 RTA00000183AF.b.12.1 M00001500A:B02 0 3543 Jan. 28, 1998 271 RTA00000201F.d.02.1 M00004375A:H01 2599 3543 Jan. 28, 1998 239 RTA00000201R.d.02.1 M00004375A:H01 2599 3543 Jan. 28, 1998 227 RTA00000201R.d.02.2 M00004375A:H01 2599 3544 Jan. 28, 1998 630 RTA00000183AR.g.03.2 M00001512D:G09 3956 3544 Jan. 28, 1998 632 RTA00000183AR.g.03.1 M00001512D:G09 3956 3545 Mar. 24, 1998 15 RTA00000425F.j.14.1 M00001639D:C12 73397 3546 Mar. 24, 1998 111 RTA00000425F.d.08.1 M00001631A:F06 74350 3547 Mar. 24, 1998 152 RTA00000425F.d.07.1 M00001631A:F12 43197 3548 Mar. 24, 1998 147 RTA00000425F.d.21.1 M00001631B:H04 78920 3549 Mar. 24, 1998 77 RTA00000425F.i.17.1 M00001633A:F11 43213 3550 Mar. 24, 1998 418 RTA00000425F.i.18.1 M00001633A:G10 42255 3551 Mar. 24, 1998 197 RTA00000425F.j.20.1 M00001633B:A12 26760 3552 Mar. 24, 1998 143 RTA00000425F.j.22.1 M00001633B:E03 73882 3553 Mar. 24, 1998 283 RTA00000425F.k.20.1 M00001633C:A08 74048 3554 Mar. 24, 1998 139 RTA00000425F.k.22.1 M00001633C:E12 78123 3555 Feb. 24, 1998 870 RTA00000418F.n.24.1 M00001659D:C09 73153 3556 Mar. 24, 1998 403 RTA00000425F.n.17.1 M00001636A:H12 78304 3557 Feb. 24, 1998 1109 RTA00000422F.f.22.1 M00001584A:G03 38703 3558 Mar. 24, 1998 150 RTA00000424F.d.04.1 M00001478A:F12 76505 3558 Mar. 24, 1998 149 RTA00000424F.d.04.3 M00001478A:F12 76505 3559 Mar. 24, 1998 358 RTA00000425F.n.19.1 M00001638B:C08 78324 3560 Mar. 24, 1998 165 RTA00000425F.e.21.1 M00001629D:D10 77203 3561 Mar. 24, 1998 443 RTA00000425F.k.16.1 M00001640A:F05 75282 3562 Mar. 24, 1998 252 RTA00000425F.m.03.1 M00001642D:G08 76045 3563 Mar. 24, 1998 116 RTA00000425F.n.05.1 M00001647D:G07 73965 3564 Mar. 24, 1998 425 RTA00000522F.i.07.2 M00001649A:E10 78377 3565 Mar. 24, 1998 445 RTA00000522F.j.08.2 M00001650D:D10 76613 3566 Mar. 24, 1998 371 RTA00000522F.j.09.2 M00001650D:F11 78522 3567 Mar. 24, 1998 97 RTA00000522F.j.14.2 M00001651C:D11 73123 3568 Mar. 24, 1998 69 RTA00000522F.j.15.2 M00001651C:G12 76535 3569 Mar. 24, 1998 373 RTA00000522F.j.19.2 M00001652B:D06 76224 3570 Mar. 24, 1998 93 RTA00000522F.k.14.1 M00001652D:G02 74280 3571 Mar. 24, 1998 50 RTA00000522F.k.15.1 M00001652D:G06 76866 3572 Mar. 24, 1998 141 RTA00000522F.k.19.1 M00001653A:A05 32625 3573 Mar. 24, 1998 409 RTA00000425F.l.10.1 M00001638A:C08 26893 3574 Feb. 24, 1998 443 RTA00000414F.f.15.1 M00005260A:A12 0 3575 Feb. 24, 1998 886 RTA00000420F.m.15.1 M00005235B:F10 0 3576 Feb. 24, 1998 260 RTA00000414F.e.08.1 M00005236A:E04 0 3577 Feb. 24, 1998 734 RTA00000414F.e.09.1 M00005236A:G10 0 3578 Feb. 24, 1998 1077 RTA00000414F.e.11.1 M00005236B:A12 0 3579 Feb. 24, 1998 970 RTA00000414F.e.15.1 M00005236B:G03 0 3580 Feb. 24, 1998 271 RTA00000414F.e.16.1 M00005236B:H10 0 3581 Feb. 24, 1998 58 RTA00000420F.m.18.1 M00005254D:A10 0 3582 Feb. 24, 1998 289 RTA00000420F.n.08.1 Mb0005257A:H11 0 3583 Feb. 24, 1998 1033 RTA00000414F.e.19.1 M00005257C:E05 0 3584 Feb. 24, 1998 793 RTA00000414F.e.21.1 M00005257C:G01 0 3585 Feb. 24, 1998 36 RTA00000414F.e.22.1 M00005257D:A06 0 3586 Feb. 24, 1998 852 RTA00000414F.f.03.1 M00005257D:G07 0 3587 Mar. 24, 1998 341 RTA00000425F.d.06.1 M00001631A:D03 77660 3588 Feb. 24, 1998 961 RTA00000420F.n.21.2 M00005259B:D12 0 3589 Mar. 24, 1998 441 RTA00000528F.g.22.2 M00001630C:F09 920 3590 Feb. 24, 1998 940 RTA00000414F.f.17.1 M00005260A:F04 0 3591 Feb. 24, 1998 160 RTA00000414F.f.19.1 M00005260B:E11 0 3592 Mar. 24, 1998 140 RTA00000424F.m.14.1 M00001612D:D12 77491 3593 Mar. 24, 1998 34 RTA00000424F.m.15.1 M00001612D:F06 73759 3594 Mar. 24, 1998 212 RTA00000424F.n.06.1 M00001613A:D02 74737 3595 Mar. 24, 1998 308 RTA00000424F.k.23.1 M00001614A:B10 31061 3596 Mar. 24, 1998 372 RTA00000424F.m.24.1 M00001614C:G07 77045 3597 Mar. 24, 1998 396 RTA00000528F.g.05.2 M00001615C:E07 3770 3598 Mar. 24, 1998 296 RTA00000425F.e.02.1 M00001625C:F10 76141 3599 Mar. 24, 1998 99 RTA00000425F.c.20.1 M00001626D:A02 73581 3600 Mar. 24, 1998 442 RTA00000425F.d.14.1 M00001629A:H09 13417 3601 Mar. 24, 1998 357 RTA00000425F.e.19.1 M00001629D:B10 73409 3602 Feb. 24, 1998 210 RTA00000419F.p.24.1 M00004039B:E12 63477 3603 Feb. 24, 1998 501 RTA00000414F.f.05.1 M00005257D:H11 0 3604 Feb. 24, 1998 561 RTA00000420F.e.10.1 M00004108D:G04 65899 3605 Feb. 24, 1998 758 RTA00000407F.a.01.1 M00004039A:H11 12501 3606 Feb. 24, 1998 688 RTA00000413F:d.23.1 M00004090B:H06 66030 3607 Feb. 24, 1998 124 RTA00000420F.d.05.1 M00004092B:E05 64432 3608 Feb. 24, 1998 329 RTA00000413F.e.16.1 M00004093C:C02 63836 3609 Feb. 24, 1998 359 RTA00000420F.d.12.1 M00004096D:H03 64095 3610 Feb. 24, 1998 429 RTA00000422F.c.17.1 M00004099D:F01 1360 3611 Feb. 24, 1998 630 RTA00000413F.f.19.1 M00004100B:C07 65189 3612 Feb. 24, 1998 439 RTA00000413F.g.23.1 M00004103B:E09 40700 3613 Feb. 24, 1998 3 RTA00000420F.d.18.1 M00004105C:B05 63074 3614 Feb. 24, 1998 1064 RTA00000420F.d.19.1 M00004105C:C08 43146 3615 Feb. 24, 1998 671 RTA00000413F.h.12.1 M00004107A:A12 66929 3616 Feb. 24, 1998 507 RTA00000420F.e.02.1 M00004107B:D07 40259 3617 Feb. 24, 1998 319 RTA00000420F.b.21.1 M00004088D:B10 65057 3618 Feb. 24, 1998 931 RTA00000420F.e.09.1 M00004108D:E07 66325 3619 Feb. 24, 1998 840 RTA00000420F.b.20.1 M00004088D:B05 0 3620 Feb. 24, 1998 545 RTA00000420F.e.15.1 M00004110A:A10 20190 3621 Feb. 24, 1998 981 RTA00000420F.e.20.1 M00004110B:A07 64762 3622 Mar. 24, 1998 370 RTA00000424F.d.19.3 M00001448B:A07 73180 3623 Mar. 24, 1998 370 RTA00000424F.d.19.3 M00001448B:A07 73180 3624 Mar. 24, 1998 189 RTA00000424F.d.22.3 M00001448B:G07 76189 3625 Mar. 24, 1998 189 RTA00000424F.d.22.3 M00001448B:G07 76189 3626 Mar. 24, 1998 92 RTA00000424F.a.24.4 M00001448D:E11 73951 3627 Mar. 24, 1998 92 RTA00000424F.a.24.4 M00001448D:E11 73951 3628 Mar. 24, 1998 279 RTA00000528F.b.03.1 M00001455A:D10 2078 3629 Mar. 24, 1998 279 RTA00000528F.b.03.1 M00001455A:D10 2078 3630 Mar. 24, 1998 480 RTA00000424F.d.17.3 M00001455A:E11 73958 3631 Mar. 24, 1998 480 RTA00000424F.d.17.3 M00001455A:E11 73958 3632 Feb. 24, 1998 583 RTA00000406F.i.17.1 M00003904B:C03 37902 3633 Feb. 24, 1998 590 RTA00000407F.b.22.1 M00004105B:B02 37487 3634 Feb. 24, 1998 1075 RTA00000413F.b.17.1 M00004078A:F07 21704 3635 Feb. 24, 1998 544 RTA00000420F.l.21.2 M00005232A:H12 0 3636 Jan. 28, 1998 684 RTA00000200AR.b.11.1 M00004040A:G12 12043 3636 Feb. 24, 1998 1166 RTA00000347F.h.01.1 M00004040A:G12 12043 3637 Jan. 28, 1998 684 RTA00000200AR.b.11.1 M00004040A:G12 12043 3637 Feb. 24, 1998 1166 RTA00000347F.h.01.1 M00004040A:G12 12043 3638 Feb. 24, 1998 1087 RTA00000401F.o.13.1 M00004040C:A01 3220 3639 Feb. 24, 1998 114 RTA00000341F.m.21.1 M00004051D:E01 0 3640 Feb. 24, 1998 811 RTA00000413F.a.12.1 M00004072D:F09 63403 3641 Feb. 24, 1998 714 RTA00000420F.a.08.1 M00004073A:D10 19473 3642 Jan. 28, 1998 387 RTA00000191AF.j.14.1 M00004073A:H12 1002 3642 Feb. 24, 1998 632 RTA00000191AF.j.14.1 M00004073A:H12 1002 3643 Jan. 28, 1998 387 RTA00000191AF.j.14.1 M00004073A:H12 1002 3643 Feb. 24, 1998 632 RTA00000191AF.j.14.1 M00004073A:H12 1002 3644 Feb. 24, 1998 964 RTA00000423F.l.15.1 M00004075B:G09 11219 3645 Feb. 24, 1998 355 RTA00000420F.a.19.1 M00004076A:D12 34192 3646 Feb. 24, 1998 745 RTA00000413F.b.04.1 M00004076D:H07 66427 3647 Feb. 24, 1998 64 RTA00000413F.d.18.1 M00004090B:B04 65305 3648 Feb. 24, 1998 698 RTA00000413F.b.16.1 M00004078A:E05 65126 3649 Feb. 24, 1998 190 RTA00000419F.p.23.1 M00004039B:A05 64748 3650 Feb. 24, 1998 903 RTA00000420F.a.21.1 M00004078B:C11 66241 3651 Feb. 24, 1998 588 RTA00000420F.a.23.1 M00004078B:F12 42158 3652 Feb. 24, 1998 1185 RTA00000413F.b.20.1 M00004079D:G08 66063 3653 Feb. 24, 1998 619 RTA00000420F.b.04.1 M00004081A:E02 63820 3654 Feb. 24, 1998 988 RTA00000407F.a.22.1 M00004081A:G01 15570 3655 Feb. 24, 1998 705 RTA00000407F.a.23.1 M00004081C:A10 23489 3656 Feb. 24, 1998 282 RTA00000407F.a.24.1 M00004083A:E08 37560 3657 Feb. 24, 1998 835 RTA00000413F.c.10.1 M00004083B:C01 65600 3658 Feb. 24, 1998 598 RTA00000420F.b.18.1 M00004086D:G08 66136 3659 Feb. 24, 1998 335 RTA00000413F.d.02.1 M00004087B:A12 66172 3660 Feb. 24, 1998 504 RTA00000413F.d.05.1 M00004087C:A01 64788 3661 Feb. 24, 1998 76 RTA00000413F.d.16.1 M00004088C:F01 63331 3662 Feb. 24, 1998 726 RTA00000420F.b.19.1 M00004088D:A11 36873 3663 Feb. 24, 1998 521 RTA00000413F.b.14.1 M00004078A:C11 66591 3664 Feb. 24, 1998 255 RTA00000419F.o.16.1 M00003989C:G05 62867 3665 Feb. 24, 1998 665 RTA00000419F.p.20.1 M00004039A:C03 9458 3666 Feb. 24, 1998 1234 RTA00000352R.c.20.1 M00003982A:B12 7339 3667 Feb. 24, 1998 247 RTA00000412F.j.17.1 M00003982C:G04 64071 3668 Feb. 24, 1998 1145 RTA00000423F.k.21.2 M00003984D:B08 37499 3669 Feb. 24, 1998 993 RTA00000406F.o.05.1 M00003985B:G04 37894 3670 Feb. 24, 1998 328 RTA00000423F.k.19.2 M00003985D:E10 17615 3671 Feb. 24, 1998 254 RTA00000341F.l.15.1 M00003986B:A08 5294 3672 Feb. 24, 1998 948 RTA00000419F.o.06.1 M00003986C:D09 64643 3673 Feb. 24, 1998 661 RTA00000341F.l.16.1 M00003986D:C08 8479 3674 Feb. 24, 1998 117 RTA00000341F.m.13.1 M00003987B:E12 26502 3675 Feb. 24, 1998 1210 RTA00000419F.o.09.1 M00003987B:F08 66396 3676 Feb. 24, 1998 460 RTA00000341F.j.12.1 M00003987C:G03 12195 3677 Feb. 24, 1998 486 RTA00000346F.l.13.1 M00003980B:C11 7542 3678 Feb. 24, 1998 723 RTA00000419F.o.15.1 M00003989C:D03 32487 3679 Feb. 24, 1998 897 RTA00000419F.n.24.1 M00003980A:F04 65995 3680 Feb. 24, 1998 92 RTA00000412F.l.04.1 M00003989D:F12 66372 3681 Feb. 24, 1998 1014 RTA00000412F.l.14.1 M00004029B:F01 62792 3682 Feb. 24, 1998 348 RTA00000412F.l.19.1 M00004029C:C05 65825 3683 Feb. 24, 1998 284 RTA00000412F.l.21.1 M00004029C:G10 65183 3684 Feb. 24, 1998 188 RTA00000406F.p.04.1 M00004030D:F11 37458 3685 Feb. 24, 1998 812 RTA00000412F.o.05.1 M00004034A:A01 63575 3686 Feb. 24, 1998 911 RTA00000406F.p.13.1 M00004034C:G02 8584 3687 Feb. 24, 1998 230 RTA00000423F.k.01.1 M00004034D:E09 40426 3688 Feb. 24, 1998 1076 RTA00000423F.k.09.1 M00004035B:H09 26630 3689 Feb. 24, 1998 941 RTA00000419F.p.08.1 M00004036D:B04 65560 3690 Feb. 24, 1998 1186 RTA00000419F.p.10.1 M00004036D:B09 41448 3691 Feb. 24, 1998 42 RTA00000423F.k.17.2 M00004038A:F02 37512 3692 Feb. 24, 1998 934 RTA00000414F.e.01.1 M00005233D:H07 0 3693 Feb. 24, 1998 37 RTA00000406F.o.15.1 M00003988D:A08 37482 3694 Feb. 24, 1998 1016 RTA00000406F.n.12.1 M00003960A:G07 37517 3695 Jan. 28, 1998 584 RTA00000190AR.c.03.1 M00003904C:A08 0 3695 Feb. 24, 1998 1069 RTA00000346F.k.05.1 M00003904C:A08 0 3696 Jan. 28, 1998 584 RTA00000190AR.c.03.1 M00003904C:A08 0 3696 Feb. 24, 1998 1069 RTA00000346F.k.05.1 M00003904C:A08 0 3697 Feb. 24, 1998 489 RTA00000406F.j.19.1 M00003906A:F12 1685 3698 Feb. 24, 1998 461 RTA00000412F.d.16.1 M00003906B:H06 26829 3699 Feb. 24, 1998 558 RTA00000419F.m.04.1 M00003906C:C05 74367 3700 Feb. 24, 1998 120 RTA00000401F.m.02.1 M00003907A:F01 1573 3701 Feb. 24, 1998 628 RTA00000412F.d.19.1 M00003907B:C03 75743 3702 Feb. 24, 1998 792 RTA00000406F.k.11.1 M00003907B:D05 38715 3703 Feb. 24, 1998 292 RTA00000423F.i.18.1 M00003918A:D08 14996 3704 Feb. 24, 1998 1192 RTA00000406F.m.17.1 M00003918A:F09 0 3705 Feb. 24, 1998 9 RTA00000406F.n.02.1 M00003918C:H10 15051 3706 Feb. 24, 1998 629 RTA00000352R.c.04.1 M00003924A:D08 71976 3707 Feb. 24, 1998 438 RTA00000195R.d.09.1 M00003981C:B04 8537 3708 Feb. 24, 1998 433 RTA00000419F.n.02.1 M00003958B:H08 65963 3709 Feb. 24, 1998 147 RTA00000422F.c.02.1 M00004118B:A03 2902 3710 Feb. 24, 1998 649 RTA00000412F.g.03.1 M00003971B:A10 64740 3711 Feb. 24, 1998 1141 RTA00000347F.f.08.1 M00003972D:H02 5948 3712 Feb. 24, 1998 252 RTA00000412F.g.24.1 M00003973C:C03 28741 3713 Feb. 24, 1998 732 RTA00000412F.h.11.1 M00003974B:B11 63175 3714 Feb. 24, 1998 181 RTA00000412F.h.21.1 M00003974D:F02 64348 3715 Feb. 24, 1998 345 RTA00000412F.h.23.2 M00003974D:H04 65118 3716 Feb. 24, 1998 148 RTA00000419F.n.04.1 M00003975C:F07 13102 3717 Feb. 24, 1998 311 RTA00000419F.n.09.1 M00003977C:A06 66070 3718 Feb. 24, 1998 1044 RTA00000419F.n.11.1 M00003977C:B03 66477 3719 Feb. 24, 1998 652 RTA00000419F.n.12.1 M00003977D:A03 66086 3720 Feb. 24, 1998 452 RTA00000419F.n.13.1 M00003977D:A06 66026 3721 Feb. 24, 1998 796 RTA00000419F.n.15.1 M00003977D:D04 63484 3722 Feb. 24, 1998 1249 RTA00000419F.n.17.1 M00003978D:G04 63186 3723 Feb. 24, 1998 860 RTA00000419F.m.23.1 M00003958B:E11 64263 3724 Feb. 24, 1998 713 RTA00000414F.b.10.1 M00005212D:D09 0 3725 Feb. 24, 1998 1002 RTA00000419F.p.18.1 M00004038D:G06 63002 3726 Feb. 24, 1998 1048 RTA00000413F.o.07.2 M00005100A:C01 0 3727 Feb. 24, 1998 508 RTA00000420F.i.20.1 M00005101C:E12 0 3728 Feb. 24, 1998 1001 RTA00000413F.p.07.2 M00005102C:D03 0 3729 Feb. 24, 1998 88 RTA00000420F.i.24.1 M00005134B:E08 0 3730 Feb. 24, 1998 93 RTA00000413F.p.24.1 M00005139A:H03 0 3731 Feb. 24, 1998 142 RTA00000420F.j.19.1 M00005140C:B10 0 3732 Feb. 24, 1998 833 RTA00000420F.j.20.1 M00005140D:C06 0 3733 Feb. 24, 1998 316 RTA00000414F.a.02.1 M00005178D:H04 0 3734 Feb. 24, 1998 1100 RTA00000414F.a.12.1 M00005210A:E06 0 3735 Feb. 24, 1998 1175 RTA00000414F.b.04.1 M00005212B:E01 0 3736 Feb. 24, 1998 1236 RTA00000414F.b.06.1 M00005212C:C03 0 3737 Feb. 24, 1998 747 RTA00000413F.n.24.1 M00004960C:E10 0 3738 Feb. 24, 1998 207 RTA00000414F.b.08.1 M00005212C:H02 0 3739 Feb. 24, 1998 935 RTA00000420F.i.07.1 M00004960A:B08 0 3740 Feb. 24, 1998 741 RTA00000414F.b.12.1 M00005212D:H01 0 3741 Feb. 24, 1998 865 RTA00000414F.c.03.1 M00005216A:D09 0 3742 Feb. 24, 1998 862 RTA00000414F.c.07.1 M00005216A:H01 0 3743 Feb. 24, 1998 565 RTA00000420F.k.17.2 M00005217B:A06 0 3744 Feb. 24, 1998 1226 RTA00000414F.c.12.1 M00005218A:F09 0 3745 Feb. 24, 1998 512 RTA00000414F.c.16.1 M00005228A:B03 0 3746 Feb. 24, 1998 817 RTA00000420F.l.08.2 M00005228C:C05 0 3747 Feb. 24, 1998 573 RTA00000414F.c.23.1 M00005229B:G12 0 3748 Feb. 24, 1998 1237 RTA00000414F.c.24.1 M00005229B:H04 0 3749 Feb. 24, 1998 727 RTA00000414F.d.02.1 M00005229B:H06 0 3750 Feb. 24, 1998 566 RTA00000414F.d.05.1 M00005229D:H03 0 3751 Feb. 24, 1998 307 RTA00000420F.l.12.2 M00005230B:H09 0 3752 Mar. 24, 1998 149 RTA00000424F.d.04.3 M00001478A:F12 76505 3752 Mar. 24, 1998 150 RTA00000424F.d.04.1 M00001478A:F12 76505 3753 Feb. 24, 1998 946 RTA00000414F.b.07.1 M00005212C:D02 0 3754 Jan. 28, 1998 343 RTA00000201F.a.18.1 M00004314B:G07 16837 3754 Feb. 24, 1998 571 RTA00000355R.e.14.1 M00004314B:G07 16837 3755 Feb. 24, 1998 481 RTA00000413F.i.23.1 M00004118B:F01 63073 3756 Feb. 24, 1998 1039 RTA00000407F.c.08.1 M00004118D:B05 37549 3757 Feb. 24, 1998 824 RTA00000420F.f.07.1 M00004119A:C09 66312 3758 Feb. 24, 1998 813 RTA00000346F.o.06.1 M00004136D:B02 4937 3759 Feb. 24, 1998 1070 RTA00000346F.n.22.1 M00004137A:D06 0 3760 Feb. 24, 1998 283 RTA00000346F.n.06.1 M00004139C:A12 12439 3761 Feb. 24, 1998 368 RTA00000346F.o.08.1 M00004149C:B02 0 3762 Feb. 24, 1998 704 RTA00000355R.a.12.1 M00004159C:F09 36756 3762 Jan. 28, 1998 685 RTA00000200F.i.9.1 M00004159C:F09 36756 3763 Jan. 28, 1998 685 RTA00000200F.i.9.1 M00004159C:F09 36756 3763 Feb. 24, 1998 704 RTA00000355R.a.12.1 M00004159C:F09 36756 3764 Feb. 24, 1998 1254 RTA00000341F.p.11.1 M00004159C:G12 0 3765 Feb. 24, 1998 1188 RTA00000341F.o.18.1 M00004169D:B11 37189 3766 Feb. 24, 1998 40 RTA00000352R.l.06.1 M00004187D:H06 40343 3767 Feb. 24, 1998 456 RTA00000413F.o.06.1 M00005100A:B02 0 3768 Feb. 24, 1998 882 RTA00000355R.c.03.1 M00004244C:G07 3986 3769 Feb. 24, 1998 503 RTA00000420F.m.08.1 M00005233B:D04 0 3770 Feb. 24, 1998 571 RTA00000355R.e.14.1 M00004314B:G07 16837 3770 Jan. 28, 1998 343 RTA00000201F.a.18.1 M00004314B:G07 16837 3771 Feb. 24, 1998 91 RTA00000355R.e.15.1 M00004316A:G09 22639 3771 Jan. 28, 1998 410 RTA00000201F.a.20.1 M00004316A:G09 22639 3772 Feb. 24, 1998 91 RTA00000355R.e.15.1 M00004316A:G09 22639 3772 Jan. 28, 1998 410 RTA00000201F.a.20.1 M00004316A:G09 22639 3773 Feb. 24, 1998 1135 RTA00000346F.o.16.1 M00004358D:C02 176 3774 Feb. 24, 1998 220 RTA00000413F.k.02.1 M00004690A:G08 0 3775 Feb. 24, 1998 487 RTA00000420F.g.05.1 M00004891B:D01 0 3776 Feb. 24, 1998 102 RTA00000420F.g.06.1 M00004891C:D04 0 3777 Feb. 24, 1998 1238 RTA00000420F.g.09.1 M00004895B:E12 0 3778 Feb. 24, 1998 18 RTA00000420F.g.12.1 M00004895B:G04 0 3779 Feb. 24, 1998 1196 RTA00000413F.l.18.1 M00004895D:G07 0 3780 Feb. 24, 1998 579 RTA00000413F.m.16.1 M00004898C:F03 0 3781 Feb. 24, 1998 143 RTA00000420F.h.13.1 M00004899D:G06 0 3782 Feb. 24, 1998 909 RTA00000420F.i.04.1 M00004959D:H12 0 3783 Feb. 24, 1998 709 RTA00000352R.p.09.1 M00004228C:H03 16915 3784 Mar. 24, 1998 221 RTA00000427F.j.22.1 M00004097D:B05 66367 3785 Mar. 24, 1998 188 RTA00000525F.c.15.1 M00004040A:A07 7692 3786 Mar. 24, 1998 401 RTA00000525F.c.16.1 M00004040A:B04 38209 3787 Mar. 24, 1998 53 RTA00000525F.c.17.1 M00004040A:C08 38160 3788 Mar. 24, 1998 325 RTA00000525F.c.18.1 M00004040B:C05 24208 3789 Mar. 24, 1998 159 RTA00000525F.c.19.1 M00004040B:F07 38159 3790 Mar. 24, 1998 209 RTA00000427F.g.16.1 M00004069A:E12 63011 3791 Mar. 24, 1998 123 RTA00000427F.g.05.1 M00004069C:C08 63138 3792 Mar. 24, 1998 62 RTA00000427F.j.19.1 M00004077A:G12 41395 3793 Mar. 24, 1998 265 RTA00000427F.h.02.1 M00004085B:G01 63652 3794 Mar. 24, 1998 235 RTA00000427F.g.19.1 M00004087A:B05 64611 3795 Mar. 24, 1998 333 RTA00000427F.k.21.1 M00004090D:F12 62880 3796 Mar. 24, 1998 130 RTA00000427F.h.12.1 M00004092C:D08 36894 3797 Mar. 24, 1998 243 RTA00000424F.c.15.3 M00001476D:F12 73533 3798 Mar. 24, 1998 227 RTA00000427F.i.11.1 M00004097C:H08 26635 3799 Mar. 24, 1998 456 RTA00000427F.a.10.1 M00004038B:D01 65370 3800 Mar. 24, 1998 7 RTA00000523F.o.20.1 M00005177B:H02 0 3801 Mar. 24, 1998 291 RTA00000523F.o.23.1 M00005177C:G04 0 3802 Mar. 24, 1998 119 RTA00000523F.p.06.1 M00005177D:F09 0 3803 Mar. 24, 1998 178 RTA00000428F.a.12.1 M00005179B:H02 0 3804 Mar. 24, 1998 463 RTA00000523F.p.16.1 M00005179D:B03 0 3805 Mar. 24, 1998 390 RTA00000524F.a.11.1 M00005210D:C09 0 3806 Mar. 24, 1998 468 RTA00000524F.a.18.1 M00005211A:E09 0 3807 Mar. 24, 1998 114 RTA00000524F.a.23.1 M00005211C:E09 0 3808 Mar. 24, 1998 29 RTA00000524F.b.03.1 M00005212A:D10 0 3809 Mar. 24, 1998 36 RTA00000428F.a.16.1 M00005212D:F08 0 3810 Mar. 24, 1998 417 RTA00000524F.b.10.1 M00005213C:A01 0 3811 Mar. 24, 1998 182 RTA00000524F.b.17.1 M00005214B:A06 0 3812 Mar. 24, 1998 348 RTA00000427F.i.09.1 M00004097C:E03 65916 3813 Mar. 24, 1998 384 RTA00000527F.p.03.1 M00004029B:A06 5940 3814 Mar. 24, 1998 84 RTA00000527F.k.18.1 M00003982B:C10 11332 3815 Mar. 24, 1998 48 RTA00000527F.k.21.1 M00003982B:H10 36051 3816 Mar. 24, 1998 271 RTA00000527F.l.05.1 M00003983A:D02 13016 3817 Mar. 24, 1998 246 RTA00000426F.m.21.1 M00003983A:F06 64915 3818 Mar. 24, 1998 16 RTA00000426F.m.22.1 M00003983A:G02 30002 3819 Mar. 24, 1998 367 RTA00000527F.l.19.1 M00003983D:E08 36856 3820 Mar. 24, 1998 477 RTA00000527F.l.21.1 M00003983D:H02 36439 3821 Mar. 24, 1998 126 RTA00000527F.m.05.1 M00003985A:C01 17240 3822 Mar. 24, 1998 89 RTA00000527F.n.02.1 M00003986C:G11 24190 3823 Mar. 24, 1998 263 RTA00000527F.n.07.1 M00003986D:H12 15939 3824 Mar. 24, 1998 49 RTA00000527F.n.22.1 M00004027A:A08 24175 3825 Mar. 24, 1998 449 RTA00000426F.m.04.1 M00004028A:B10 36865 3826 Mar. 24, 1998 336 RTA00000426F.n.17.1 M00004039D:B10 66572 3827 Mar. 24, 1998 27 RTA00000527F.p.02.1 M00004029B:A01 36844 3828 Mar. 24, 1998 297 RTA00000525F.c.11.1 M00004039C:E02 37895 3829 Mar. 24, 1998 17 RTA00000527F.p.06.1 M00004029B:G10 1292 3830 Mar. 24, 1998 310 RTA00000527F.p.08.1 M00004029C:F02 36013 3831 Mar. 24, 1998 478 RTA00000527F.p.09.1 M00004029C:F05 7694 3832 Mar. 24, 1998 253 RTA00000426F.m.08.1 M00004030B:A12 63781 3833 Mar. 24, 1998 414 RTA00000426F.m.12.1 M00004030B:D08 63740 3834 Mar. 24, 1998 345 RTA00000426F.n.23.1 M00004030C:A08 18176 3835 Mar. 24, 1998 98 RTA00000527F.p.16.1 M00004030C:C02 23798 3836 Mar. 24, 1998 115 RTA00000525F.b.05.1 M00004034C:F05 21116 3837 Mar. 24, 1998 444 RTA00000525F.b.09.1 M00004035B:F05 23472 3838 Mar. 24, 1998 158 RTA00000427F.a.06.1 M00004036A:A11 66550 3839 Mar. 24, 1998 376 RTA00000525F.b.21.1 M00004037C:D04 9486 3840 Mar. 24, 1998 293 RTA00000525F.c.02.1 M00004038A:E05 14618 3841 Mar. 24, 1998 138 RTA00000527F.c.22.1 M00003822B:G12 37496 3842 Mar. 24, 1998 30 RTA00000426F.m.07.1 M00004028A:G03 63504 3843 Mar. 24, 1998 322 RTA00000523F.i.17.1 M00003856B:A12 65779 3844 Mar. 24, 1998 311 RTA00000428F.b.02.1 M00005214D:D10 0 3845 Mar. 24, 1998 233 RTA00000426F.f.13.1 M00003851A:A06 65384 3846 Mar. 24, 1998 274 RTA00000523F.h.06.1 M00003851B:D03 28745 3847 Mar. 24, 1998 407 RTA00000523F.h.08.1 M00003851B:E01 62893 3848 Mar. 24, 1998 82 RTA00000523F.h.15.1 M00003851C:F09 65137 3849 Mar. 24, 1998 316 RTA00000523F.h.16.1 M00003851D:H11 66031 3850 Mar. 24, 1998 232 RTA00000527F.i.13.2 M00003852B:G04 2924 3851 Mar. 24, 1998 451 RTA00000527F.i.15.2 M00003852C:F07 14235 3852 Mar. 24, 1998 249 RTA00000523F.h.21.1 M00003853B:C10 41440 3853 Mar. 24, 1998 72 RTA00000426F.f.19.1 M00003854C:C09 66701 3854 Mar. 24, 1998 60 RTA00000523F.i.06.1 M00003855A:A01 66341 3855 Mar. 24, 1998 91 RTA00000527F.i.21.2 M00003855A:F01 37490 3856 Mar. 24, 1998 137 RTA00000527F.h.17.1 M00003848D:G02 37799 3857 Mar. 24, 1998 433 RTA00000527F.j.04.2 M00003856A:G04 11809 3858 Mar. 24, 1998 157 RTA00000523F.g.10.1 M00003848B:E07 40694 3859 Mar. 24, 1998 75 RTA00000523F.i.22.1 M00003857A:E12 64688 3860 Mar. 24, 1998 481 RTA00000523F.j.02.1 M00003857A:H10 62853 3861 Mar. 24, 1998 377 RTA00000527F.j.12.2 M00003857C:E05 37503 3862 Mar. 24, 1998 286 RTA00000426F.g.19.1 M00003858B:G02 63672 3863 Mar. 24, 1998 71 RTA00000527F.j.20.2 M00003860D:E06 37603 3864 Mar. 24, 1998 205 RTA00000426F.h.12.1 M00003905C:F12 78093 3865 Mar. 24, 1998 40 RTA00000426F.h.23.1 M00003911A:D12 75964 3866 Mar. 24, 1998 369 RTA00000524F.c.08.1 M00005217C:C01 0 3867 Mar. 24, 1998 234 RTA00000524F.c.16.1 M00005218D:G10 0 3868 Mar. 24, 1998 8 RTA00000428F.b.06.1 M00005228A:A09 0 3869 Mar. 24, 1998 193 RTA00000428F.b.12.1 M00005231C:B07 0 3870 Mar. 24, 1998 419 RTA0000042BF.b.22.1 M00005231D:B09 0 3871 Feb. 24, 1998 486 RTA00000346F.l.13.1 M00003980B:C11 7542 3872 Mar. 24, 1998 421 RTA00000523F.i.10.1 M00003855B:B09 64876 3873 Mar. 24, 1998 10 RTA00000527F.f.12.1 M00003829D:D12 5945 3874 Mar. 24, 1998 145 RTA00000426F.m.24.1 M00003981A:A07 63943 3875 Mar. 24, 1998 39 RTA00000527F.c.23.1 M00003822C:A07 37742 3876 Mar. 24, 1998 35 RTA00000426F.f.11.1 M00003823C:B01 63102 3877 Mar. 24, 1998 385 RTA00000426F.f.12.1 M00003823C:C04 19096 3878 Mar. 24, 1998 2 RTA00000523F.d.19.1 M00003824A:A06 26489 3879 Mar. 24, 1998 225 RTA00000527F.d.09.1 M00003824A:G11 10848 3880 Mar. 24, 1998 359 RTA00000523F.d.21.1 M00003824B:C09 33424 3881 Mar. 24, 1998 330 RTA00000523F.d.23.1 M00003824C:A10 63633 3882 Mar. 24, 1998 254 RTA00000523F.d.24.1 M00003824D:D08 64799 3883 Mar. 24, 1998 74 RTA00000527F.d.19.1 M00003825B:F10 486 3884 Mar. 24, 1998 67 RTA00000527F.e.03.1 M00003825D:F01 25560 3885 Mar. 24, 1998 352 RTA00000527F.e.13.1 M00003826C:F05 37588 3886 Mar. 24, 1998 185 RTA00000527F.h.21.1 M00003850C:G09 37630 3887 Mar. 24, 1998 338 RTA00000523F.e.15.1 M00003829C:E08 7919 3888 Mar. 24, 1998 284 RTA00000524F.b.19.1 M00005216B:D02 0 3889 Mar. 24, 1998 242 RTA00000523F.e.20.1 M00003829D:F03 65164 3890 Mar. 24, 1998 301 RTA00000527F.f.18.1 M00003830D:B11 37577 3891 Mar. 24, 1998 259 RTA00000528F.m.04.1 M00003830D:H11 10815 3892 Mar. 24, 1998 160 RTA00000523F.f.06.1 M00003833D:H08 62871 3893 Mar. 24, 1998 166 RTA00000523F.f.07.1 M00003833D:H10 62799 3894 Mar. 24, 1998 196 RTA00000523F.f.12.1 M00003840A:C10 63751 3895 Mar. 24, 1998 447 RTA00000523F.f.19.1 M00003840B:F05 34169 3896 Mar. 24, 1998 113 RTA00000527F.g.07.1 M00003840C:C02 37488 3897 Mar. 24, 1998 45 RTA00000528F.m.12.1 M00003842D:F08 5768 3898 Mar. 24, 1998 415 RTA00000527F.g.12.1 M00003845C:D04 37746 3899 Mar. 24, 1998 1 RTA00000527F.g.13.1 M00003845D:A04 36035 3900 Mar. 24, 1998 450 RTA00000527F.g.21.1 M00003846B:C05 36028 3901 Mar. 24, 1998 144 RTA00000527F.g.23.1 M00003846C:F08 37538 3902 Mar. 24, 1998 422 RTA00000527F.f.03.1 M00003829A:B08 17788 3903 Mar. 24, 1998 176 RTA00000522F.g.15.1 M00001595B:G07 76536 3904 Mar. 24, 1998 264 RTA00000425F.e.09.1 M00001608C:G04 75550 3905 Mar. 24, 1998 32 RTA00000424F.n.14.1 M00001584D:C11 73008 3906 Mar. 24, 1998 459 RTA00000425F.c.03.1 M00001585D:B12 74643 3907 Mar. 24, 1998 124 RTA00000424F.m.12.1 M00001586C:H07 77675 3908 Mar. 24, 1998 314 RTA00000522F.e.09.1 M00001589D:A01 32599 3909 Mar. 24, 1998 262 RTA00000424F.k.03.1 M00001590D:B04 21289 3910 Mar. 24, 1998 106 RTA00000424F.j.14.1 M00001592B:B02 74311 3911 Mar. 24, 1998 424 RTA00000424F.k.10.1 M00001592D:H02 73232 3912 Mar. 24, 1998 168 RTA00000424F.j.12.1 M00001594C:E05 73827 3913 Mar. 24, 1998 420 RTA00000424F.j.13.1 M00001594C:H03 74485 3914 Mar. 24, 1998 210 RTA00000522F.g.06.1 M00001594D:G11 78221 3915 Mar. 24, 1998 439 RTA00000522F.g.10.1 M00001595A:C07 74294 3916 Mar. 24, 1998 300 RTA00000424F.m.08.1 M00001584A:A07 19402 3917 Mar. 24, 1998 355 RTA00000522F.g.12.1 M00001595A:E07 78783 3918 Mar. 24, 1998 411 RTA00000424F.n.12.1 M00001582C:G02 41589 3919 Mar. 24, 1998 238 RTA00000522F.g.17.1 M00001595B:G10 76486 3920 Mar. 24, 1998 472 RTA00000522F.g.18.1 M00001595B:H11 73226 3921 Mar. 24, 1998 102 RTA00000522F.g.19.1 M00001595C:A01 78119 3922 Mar. 24, 1998 280 RTA00000522F.g.20.1 M00001595C:A05 77688 3923 Mar. 24, 1998 191 RTA00000522F.g.22.1 M00001595C:B12 77504 3924 Mar. 24, 1998 163 RTA00000522F.h.01.1 M00001595C:E05 75010 3925 Mar. 24, 1998 438 RTA00000522F.h.02.1 M00001595C:E09 74947 3926 Mar. 24, 1998 257 RTA00000522F.h.07.1 M00001595D:C11 75149 3927 Mar. 24, 1998 389 RTA00000424F.i.15.1 M00001596A:A02 78043 3928 Mar. 24, 1998 167 RTA00000424F.i.20.1 M00001596A:D01 44010 3929 Mar. 24, 1998 374 RTA00000528F.f.10.1 M00001596C:G05 3600 3930 Mar. 24, 1998 215 RTA00000425F.f.02.1 M00001607A:A01 76982 3931 Mar. 24, 1998 22 RTA00000527F.k.15.1 M00003982A:G03 22688 3932 Mar. 24, 1998 378 RTA00000522F.g.11.1 M00001595A:D12 75432 3933 Mar. 24, 1998 63 RTA00000522F.b.01.1 M00001570C:B02 75691 3934 Mar. 24, 1998 430 RTA00000424F.g.08.1 M00001482C:F09 74928 3935 Mar. 24, 1998 340 RTA00000424F.h.06.1 M00001485C:D07 77552 3936 Mar. 24, 1998 161 RTA00000424F.h.10.1 M00001485C:G06 72925 3937 Mar. 24, 1998 368 RTA00000424F.i.11.1 M00001485D:A05 41569 3938 Mar. 24, 1998 455 RTA00000424F.g.24.1 M00001487C:A11 79156 3939 Mar. 24, 1998 211 RTA00000424F.h.03.1 M00001487C:G09 74447 3940 Mar. 24, 1998 174 RTA00000424F.b.21.4 M00001530A:B02 24686 3941 Mar. 24, 1998 383 RTA00000424F.b.23.4 M00001530A:H05 77322 3942 Mar. 24, 1998 179 RTA00000424F.d.10.3 M00001530D:A11 73110 3943 Mar. 24, 1998 393 RTA00000424F.b.15.4 M00001539B:B10 74958 3944 Mar. 24, 1998 347 RTA00000522F.a.05.1 M00001567A:C04 32611 3945 Mar. 24, 1998 303 RTA00000522F.a.06.1 M00001567A:C11 73662 3946 Mar. 24, 1998 229 RTA00000424F.n.13.1 M00001584D:B06 74942 3947 Mar. 24, 1998 392 RTA00000522F.a.20.1 M00001567C:E07 74070 3948 Mar. 24, 1998 226 RTA00000425F.e.15.1 M00001608D:F11 75921 3949 Mar. 24, 1998 285 RTA00000522F.b.07.1 M00001570D:E05 78634 3950 Mar. 24, 1998 465 RTA00000528F.d.04.1 M00001570D:E07 2395 3951 Mar. 24, 1998 404 RTA00000522F.b.18.1 M00001573B:A06 3460 3952 Mar. 24, 1998 9 RTA00000522F.b.22.1 M00001573B:H12 75181 3953 Mar. 24, 1998 109 RTA00000424F.a.01.4 M00001575A:D05 43214 3953 Mar. 24, 1998 125 RTA00000424F.a.01.1 M00001575A:D05 43214 3954 Mar. 24, 1998 125 RTA00000424F.a.01.1 M00001575A:D05 43214 3954 Mar. 24, 1998 109 RTA00000424F.a.01.4 M00001575A:D05 43214 3955 Mar. 24, 1998 294 RTA00000424F.a.05.1 M00001575B:C01 77976 3955 Mar. 24, 1998 292 RTA00000424F.a.05.4 M00001575B:C01 77976 3956 Mar. 24, 1998 292 RTA00000424F.a.05.4 M00001575B:C01 77976 3956 Mar. 24, 1998 294 RTA00000424F.a.05.1 M00001575B:C01 77976 3957 Mar. 24, 1998 434 RTA00000522F.c.11.1 M00001576C:H02 31064 3958 Mar. 24, 1998 299 RTA00000522F.c.14.1 M00001577A:A03 75449 3959 Mar. 24, 1998 110 RTA00000522F.d.08.1 M00001578B:A06 74284 3960 Mar. 24, 1998 306 RTA00000522F.d.23.1 M00001579D:F02 73868 3961 Mar. 24, 1998 350 RTA00000424F.n.11.1 M00001582C:C04 73874 3962 Mar. 24, 1998 366 RTA00000522F.a.17.1 M00001567C:B08 79032 3963 Mar. 24, 1998 239 RTA00000523F.j.17.1 M00003966B:A04 63610 3964 Mar. 24, 1998 405 RTA00000425F.e.07.1 M00001608C:D02 75992 3965 Mar. 24, 1998 231 RTA00000426F.e.17.1 M00003810C:B06 64089 3966 Mar. 24, 1998 104 RTA00000527F.b.18.1 M00003810D:H09 37469 3967 Mar. 24, 1998 312 RTA00000426F.f.17.1 M00003811C:C02 66334 3968 Mar. 24, 1998 266 RTA00000426F.f.16.1 M00003813B:F02 65613 3969 Mar. 24, 1998 183 RTA00000527F.c.04.1 M00003813C:H08 23090 3970 Mar. 24, 1998 435 RTA00000523F.c.13.1 M00003813D:B12 40668 3971 Mar. 24, 1998 255 RTA00000523F.c.14.1 M00003813D:C02 66015 3972 Mar. 24, 1998 131 RTA00000523F.c.15.1 M00003813D:G06 36935 3973 Mar. 24, 1998 270 RTA00000426F.g.16.1 M00003814B:C01 41446 3974 Mar. 24, 1998 95 RTA00000523F.c.18.1 M00003817C:A10 66179 3975 Mar. 24, 1998 329 RTA00000527F.c.09.1 M00003817C:G06 64859 3976 Mar. 24, 1998 65 RTA00000523F.c.01.1 M00003810A:A02 65710 3977 Mar. 24, 1998 398 RTA00000527F.c.16.1 M00003821A:H09 22908 3978 Mar. 24, 1998 96 RTA00000523F.b.13.1 M00003809B:A03 66330 3979 Mar. 24, 1998 313 RTA00000523F.j.21.1 M00003966C:A12 36925 3980 Mar. 24, 1998 86 RTA00000523F.k.01.1 M00003966C:F03 41437 3981 Mar. 24, 1998 26 RTA00000427F.b.23.1 M00003973D:F08 64297 3982 Mar. 24, 1998 277 RTA00000427F.e.08.1 M00003974D:E01 47387 3983 Mar. 24, 1998 397 RTA00000427F.e.10.1 M00003974D:H07 64599 3984 Mar. 24, 1998 31 RTA00000427F.c.10.1 M00003976B:E06 65478 3985 Mar. 24, 1998 151 RTA00000427F.c.12.1 M00003976B:H07 66995 3986 Mar. 24, 1998 57 RTA00000427F.c.20.1 M00003978A:E01 26527 3987 Mar. 24, 1998 213 RTA00000427F.c.22.1 M00003978A:E09 63990 3988 Mar. 24, 1998 289 RTA00000427F.d.10.1 M00003978C:A12 40685 3989 Mar. 24, 1998 28 RTA00000427F.d.08.1 M00003980C:E12 63967 3990 Mar. 24, 1998 335 RTA00000427F.d.09.1 M00003980C:F12 66486 3991 Mar. 24, 1998 267 RTA00000425F.i.21.1 M00001635B:B02 75305 3992 Mar. 24, 1998 343 RTA00000527F.c.11.1 M00003817D:D12 37484 3993 Mar. 24, 1998 251 RTA00000425F.f.24.1 M00001656D:C04 40841 3994 Mar. 24, 1998 155 RTA00000424F.l.19.1 M00001609C:A12 75454 3995 Mar. 24, 1998 321 RTA00000424F.m.04.1 M00001609C:G05 79017 3996 Mar. 24, 1998 214 RTA00000424F.k.12.1 M00001610C:B07 77666 3997 Mar. 24, 1998 446 RTA00000425F.f.20.1 M00001653D:H07 74071 3998 Mar. 24, 1998 428 RTA00000522F.l.08.1 M00001654A:E08 78781 3999 Mar. 24, 1998 295 RTA00000522F.l.15.1 M00001654B:A01 74691 4000 Mar. 24, 1998 275 RTA00000522F.l.22.1 M00001654C:D10 75801 4001 Mar. 24, 1998 223 RTA00000522F.m.02.1 M00001654C:G07 76834 4002 Mar. 24, 1998 391 RTA00000522F.m.03.1 M00001654C:G09 79194 4003 Mar. 24, 1998 346 RTA00000522F.m.19.1 M00001655C:C07 41544 4004 Mar. 24, 1998 51 RTA00000522F.n.02.1 M00001655D:E08 74959 4005 Mar. 24, 1998 94 RTA00000522F.n.05.1 M00001655D:H11 73260 4006 Mar. 24, 1998 332 RTA00000523F.c.03.1 M00003810B:B11 36913 4007 Mar. 24, 1998 172 RTA00000425F.f.11.1 M00001656C:C04 79275 4008 Mar. 24, 1998 58 RTA00000527F.k.06.1 M00003981B:B12 12469 4009 Mar. 24, 1998 240 RTA00000522F.n.14.1 M00001657C:C11 73410 4010 Mar. 24, 1998 56 RTA00000522F.n.16.1 M00001657D:A10 26769 4011 Mar. 24, 1998 20 RTA00000522F.0.06.1 M00001659D:A09 26860 4012 Mar. 24, 1998 38 RTA00000528F.i.22.1 M00001661D:D05 2478 4013 Mar. 24, 1998 413 RTA00000425F.i.10.1 M00001664B:E08 78736 4014 Mar. 24, 1998 412 RTA00000425F.i.11.1 M00001664B:F06 21716 4015 Mar. 24, 1998 202 RTA00000528F.j.11.1 M00001669B:C12 1070 4016 Mar. 24, 1998 432 RTA00000522F.o.20.1 M00001669C:B09 74853 4017 Mar. 24, 1998 245 RTA00000522F.p.09.1 M00001670A:F09 75204 4018 Mar. 24, 1998 331 RTA00000528F.k.10.1 M00001678C:F09 1981 4019 Mar. 24, 1998 356 RTA00000523F.a.07.1 M00001693A:H06 75804 4020 Mar. 24, 1998 200 RTA00000527F.a.13.1 M00003805D:E06 37740 4021 Mar. 24, 1998 14 RTA00000523F.b.02.1 M00003806C:A06 65163 4022 Mar. 24, 1998 177 RTA00000522F.n.12.1 M00001656A:H12 74117 4023 Feb. 24, 1998 1158 RTA00000405F.o.03.1 M00003829C:H05 37575 4024 Feb. 24, 1998 1181 RTA00000346F.f.14.1 M00003800B:F03 16998 4025 Feb. 24, 1998 610 RTA00000419F.d.07.1 M00003820B:D10 21421 4026 Feb. 24, 1998 1227 RTA00000411F.g.05.1 M00003822D:B10 64664 4027 Feb. 24, 1998 412 RTA00000411F.g.06.1 M00003822D:C06 66065 4028 Feb. 24, 1998 21 RTA00000411F.g.08.1 M00003822D:D04 45815 4029 Feb. 24, 1998 1208 RTA00000347F.e.24.1 M00003823B:F07 8188 4030 Feb. 24, 1998 502 RTA00000341F.d.08.1 M00003824C:D07 0 4031 Feb. 24, 1998 528 RTA00000405F.n.16.1 M00003825B:B10 21503 4032 Feb. 24, 1998 15 RTA00000419F.c.19.1 M00003820A:A08 64346 4033 Feb. 24, 1998 637 RTA00000419F.d.14.1 M00003828A:D05 64945 4034 Feb. 24, 1998 81 RTA00000419F.c.16.1 M00003819D:B01 65254 4035 Feb. 24, 1998 754 RTA00000419F.e.02.1 M00003830C:A03 65010 4036 Feb. 24, 1998 430 RTA00000419F.e.04.1 M00003831C:G05 62963 4037 Feb. 24, 1998 541 RTA00000411F.h.15.1 M00003832A:A09 65160 4038 Feb. 24, 1998 1079 RTA00000419F.e.10.1 M00003833B:B03 63225 4039 Feb. 24, 1998 577 RTA00000419F.e.11.1 M00003833B:C12 36780 4040 Feb. 24, 1998 1220 RTA00000419F.e.23.1 M00003834B:G04 65772 4041 Feb. 24, 1998 691 RTA00000354R.n.08.1 M00003835A:A09 8802 4042 Feb. 24, 1998 536 RTA00000411F.i.02.1 M00003835B:H11 66975 4043 Feb. 24, 1998 421 RTA00000419F.f.10.1 M00003835D:G06 66193 4044 Feb. 24, 1998 1150 RTA00000411F.g.24.1 M00003825B:B11 65233 4045 Feb. 24, 1998 533 RTA00000423F.e.11.1 M00003809B:E10 2566 4046 Feb. 24, 1998 520 RTA00000406F.c.20.1 M00003871D:G06 38578 4047 Feb. 24, 1998 41 RTA00000419F.b.12.1 M00003806B:C09 63148 4048 Feb. 24, 1998 917 RTA00000423F.e.21.1 M00003806B:G05 66961 4049 Feb. 24, 1998 326 RTA00000419F.b.15.1 M00003806D:D11 43969 4050 Feb. 24, 1998 297 RTA00000419F.b.18.1 M00003808D:D08 67034 4051 Feb. 24, 1998 139 RTA00000419F.b.19.1 M00003809A:C01 65534 4052 Feb. 24, 1998 1021 RTA00000419F.b.21.1 M00003809A:F01 65366 4053 Feb. 24, 1998 1152 RTA00000405F.m.07.1 M00003809B:B02 37733 4054 Feb. 24, 1998 310 RTA00000419F.d.06.1 M00003820B:D07 65496 4055 Feb. 24, 1998 120 RTA00000401F.m.02.1 M00003907A:F01 1573 4056 Feb. 24, 1998 69 RTA00000405F.o.18.1 M00003839A:D07 11016 4057 Feb. 24, 1998 482 RTA00000411F.e.24.1 M00003813A:B02 64781 4058 Feb. 24, 1998 50 RTA00000411F.f.02.1 M00003813A:D08 63386 4059 Feb. 24, 1998 602 RTA00000411F.f.06.1 M00003813B:E09 64186 4060 Feb. 24, 1998 761 RTA00000411F.f.14.1 M00003814B:C12 62984 4061 Feb. 24, 1998 674 RTA00000411F.f.17.1 M00003814B:F12 65661 4062 Feb. 24, 1998 1164 RTA00000405F.m.21.1 M00003815C:C06 24218 4063 Feb. 24, 1998 951 RTA00000419F.c.04.1 M00003815C:D12 63749 4064 Feb. 24, 1998 471 RTA00000419F.c.11.1 M00003817B:C04 65504 4065 Feb. 24, 1998 1047 RTA00000419F.c.14.1 M00003819B:G01 65727 4066 Feb. 24, 1998 1178 RTA00000400F.f.11.1 M00001636A:E07 4088 4067 Feb. 24, 1998 89 RTA00000406F.c.08.1 M00003870C:A10 22387 4068 Feb. 24, 1998 94 RTA00000406F.a.23.1 M00003867B:D10 38712 4069 Feb. 24, 1998 1038 RTA00000406F.b.01.1 M00003867B:G07 39006 4070 Feb. 24, 1998 783 RTA00000406F.b.02.1 M00003867B:G08 38744 4071 Feb. 24, 1998 563 RTA00000406F.b.08.1 M00003867D:A06 18258 4072 Feb. 24, 1998 1072 RTA00000419F.j.03.1 M00003868B:G06 77578 4073 Feb. 24, 1998 846 RTA00000419F.j.11.1 M00003868C:C07 73183 4074 Feb. 24, 1998 17 RTA00000411F.m.15.1 M00003868D:B09 78014 4075 Feb. 24, 1998 589 RTA00000411F.m.18.1 M00003868D:D09 75629 4076 Feb. 24, 1998 971 RTA00000411F.i.11.1 M00003837C:E05 66849 4077 Feb. 24, 1998 794 RTA00000406F.c.06.1 M00003870C:A01 37924 4078 Feb. 24, 1998 788 RTA00000419F.i.04.1 M00003860B:F11 65791 4079 Feb. 24, 1998 883 RTA00000406F.c.09.1 M00003870C:E10 5671 4080 Feb. 24, 1998 918 RTA00000419F.j.22.1 M00003871A:A02 73525 4081 Feb. 24, 1998 757 RTA00000423F.h.13.1 M00003871A:B09 14398 4082 Feb. 24, 1998 208 RTA00000419F.j.23.1 M00003871A:C11 74470 4083 Feb. 24, 1998 1127 RTA00000401F.g.22.1 M00003871A:G09 1147 4084 Feb. 24, 1998 1205 RTA00000419F.k.05.1 M00003871C:E04 11757 4085 Feb. 24, 1998 522 RTA00000406F.c.18.1 M00003871C:F12 14368 4086 Feb. 24, 1998 459 RTA00000419F.k.06.1 M00003871D:A10 78493 4087 Feb. 24, 1998 965 RTA00000411F.n.06.1 M00003871D:E11 73886 4088 Feb. 24, 1998 457 RTA00000411F.m.19.1 M00003868D:D11 74924 4089 Feb. 24, 1998 145 RTA00000419F.g.12.1 M00003842C:G03 66171 4090 Feb. 24, 1998 633 RTA00000341F.d.02.1 M00003797A:G03 4706 4091 Feb. 24, 1998 1026 RTA00000419F.f.18.1 M00003839D:E11 64047 4092 Feb. 24, 1998 524 RTA00000419F.f.23.1 M00003840D:H10 65002 4093 Feb. 24, 1998 204 RTA00000351R.k.19.1 M00003841B:E03 936 4094 Feb. 24, 1998 968 RTA00000419F.f.24.1 M00003841B:E06 18717 4095 Feb. 24, 1998 209 RTA00000411F.j.02.1 M00003841C:D07 65310 4096 Feb. 24, 1998 1118 RTA00000411F.j.03.1 M00003841C:F01 66263 4097 Feb. 24, 1998 470 RTA00000411F.j.06.1 M00003841C:H08 63545 4098 Feb. 24, 1998 1153 RTA00000411F.j.07.1 M00003841C:H11 66963 4099 Jan. 28, 1998 412 RTA00000195AF.c.24.1 M00003860D:H07 0 4099 Feb. 24, 1998 678 RTA00000195AF.c.24.1 M00003860D:H07 0 4100 Feb. 24, 1998 777 RTA00000419F.g.02.1 M00003842A:A03 62839 4101 Feb. 24, 1998 678 RTA00000195AF.c.24.1 M00003860D:H07 0 4101 Jan. 28, 1998 412 RTA00000195AF.c.24.1 M00003860D:H07 0 4102 Feb. 24, 1998 799 RTA00000411F.j.15.1 M00003843A:E04 66871 4103 Feb. 24, 1998 932 RTA00000405F.p.03.1 M00003844A:A11 11346 4104 Feb. 24, 1998 266 RTA00000419F.g.15.1 M00003844D:A07 32519 4105 Feb. 24, 1998 547 RTA00000419F.h.02.1 M00003845D:G08 63985 4106 Feb. 24, 1998 290 RTA00000411F.k.16.1 M00003852C:B06 64759 4107 Feb. 24, 1998 23 RTA00000411F.k.20.1 M00003854B:A07 64973 4108 Feb. 24, 1998 1138 RTA00000411F.k.21.1 M00003854B:D04 65349 4109 Feb. 24, 1998 1000 RTA00000351R.j.21.1 M00003859D:C05 31604 4110 Feb. 24, 1998 980 RTA00000411F.i.13.1 M00003837C:F10 66138 4111 Feb. 24, 1998 112 RTA00000422F.c.11.1 M00003841D:A04 2643 4112 Feb. 24, 1998 905 RTA00000405F.g.21.2 M00001673B:F07 38966 4112 Feb. 24, 1998 906 RTA00000405F.g.21.1 M00001673B:F07 38966 4113 Feb. 24, 1998 294 RTA00000405F.l.17.1 M00003805A:F02 17225 4114 Feb. 24, 1998 105 RTA00000346F.d.08.1 M00001671A:A10 39955 4115 Feb. 24, 1998 1190 RTA00000405F.g.02.2 M00001671B:G05 10567 4116 Feb. 24, 1998 280 RTA00000418F.p.15.1 M00001671C:C11 31066 4117 Feb. 24, 1998 1151 RTA00000405F.g.18.2 M00001672D:E08 5255 4118 Feb. 24, 1998 66 RTA00000405F.g.19.2 M00001673A:G08 37150 4119 Feb. 24, 1998 1239 RTA00000340F.o.22.1 M00001673B:B07 7356 4120 Feb. 24, 1998 906 RTA00000405F.g.21.1 M00001673B:F07 38966 4120 Feb. 24, 1998 905 RTA00000405F.g.21.2 M00001673B:F07 38966 4121 Feb. 24, 1998 893 RTA00000418F.p.10.1 M00001669D:F05 75323 4122 Feb. 24, 1998 906 RTA00000405F.g.21.1 M00001673B:F07 38966 4122 Feb. 24, 1998 905 RTA00000405F.g.21.2 M00001673B:F07 38966 4123 Feb. 24, 1998 808 RTA00000418F.p.08.1 M00001669D:D06 73983 4124 Feb. 24, 1998 469 RTA00000405F.g.24.1 M00001673D:D06 39076 4125 Feb. 24, 1998 1094 RTA00000405F.h.03.2 M00001673D:F10 20633 4126 Feb. 24, 1998 803 RTA00000405F.h.05.2 M00001674A:G07 75706 4127 Feb. 24, 1998 667 RTA00000405F.h.07.2 M00001674A:G11 4984 4128 Feb. 24, 1998 276 RTA00000423F.a.18.1 M00001675A:G10 26761 4129 Feb. 24, 1998 1050 RTA00000405F.f.05.2 M00001669C:D09 14359 4129 Feb. 24, 1998 1049 RTA00000405F.f.05.1 M00001669C:D09 14359 4130 Feb. 24, 1998 1050 RTA00000405F.f.05.2 M00001669C:D09 14359 4130 Feb. 24, 1998 1049 RTA00000405F.f.05.1 M00001669C:D09 14359 4131 Feb. 24, 1998 104 RTA00000421F.n.03.1 M00001675C:A04 1638 4132 Feb. 24, 1998 388 RTA00000411F.a.07.1 M00001675C:C03 74547 4133 Feb. 24, 1998 906 RTA00000405F.g.21.1 M00001673B:F07 38966 4133 Feb. 24, 1998 905 RTA00000405F.g.21.2 M00001673B:F07 38966 4134 Feb. 24, 1998 222 RTA00000405F.e.09.1 M00001663C:F12 38978 4135 Feb. 24, 1998 518 RTA00000410F.m.18.1 M00001660B:A09 76365 4136 Feb. 24, 1998 218 RTA00000346F.e.13.1 M00001660B:D03 74653 4137 Feb. 24, 1998 427 RTA00000410F.m.20.1 M00001660B:E03 74285 4138 Feb. 24, 1998 1099 RTA00000400F.m.16.1 M00001660B:E04 3307 4139 Feb. 24, 1998 775 RTA00000405F.c.22.1 M00001660C:B06 39053 4140 Feb. 24, 1998 28 RTA00000422F.p.06.2 M00001661A:B11 39282 4141 Feb. 24, 1998 108 RTA00000418F.o.18.1 M00001661B:F06 78676 4142 Feb. 24, 1998 954 RTA00000410F.n.05.1 M00001662A:C07 77830 4143 Feb. 24, 1998 1182 RTA00000346F.d.11.1 M00001670B:G12 6641 4144 Feb. 24, 1998 1043 RTA00000423F.b.17.1 M00001662B:F06 8200 4145 Feb. 24, 1998 447 RTA00000423F.b.04.3 M00001675D:E10 6311 4146 Feb. 24, 1998 305 RTA00000418F.p.06.1 M00001664A:F08 32628 4147 Feb. 24, 1998 1116 RTA00000410F.o.04.1 M00001664D:F04 79018 4148 Feb. 24, 1998 320 RTA00000422F.p.07.2 M00001661A:E06 39024 4149 Feb. 24, 1998 197 RTA00000410F.o.05.1 M00001669A:B02 75262 4150 Feb. 24, 1998 738 RTA00000422F.n.20.1 M00001669B:B12 38676 4151 Feb. 24, 1998 495 RTA00000400F.0.21.1 M00001669C:C08 16259 4152 Feb. 24, 1998 1050 RTA00000405F.f.05.2 M00001669C:D09 14359 4152 Feb. 24, 1998 1049 RTA00000405F.f.05.1 M00001669C:D09 14359 4153 Feb. 24, 1998 1049 RTA00000405F.f.05.1 M00001669C:D09 14359 4153 Feb. 24, 1998 1050 RTA00000405F.f.05.2 M00001669C:D09 14359 4154 Feb. 24, 1998 492 RTA00000340F.o.18.1 M00001669D:C03 4261 4155 Feb. 24, 1998 61 RTA00000410F.n.07.1 M00001662A:G01 78823 4156 Feb. 24, 1998 299 RTA00000405F.l.15.1 M00001694A:E03 19575 4157 Feb. 24, 1998 475 RTA00000411F.d.05.1 M00001681C:A08 75812 4158 Feb. 24, 1998 692 RTA00000411F.d.10.1 M00001681D:C12 76445 4159 Feb. 24, 1998 336 RTA00000340F.n.13.1 M00001688D:B10 17055 4160 Feb. 24, 1998 270 RTA00000411F.d.15.1 M00001692A:B06 74890 4161 Feb. 24, 1998 969 RTA00000411F.d.18.1 M00001692A:G06 76063 4162 Feb. 24, 1998 927 RTA00000411F.d.21.1 M00001692B:E01 74794 4163 Feb. 24, 1998 1133 RTA00000405F.l.03.1 M00001692D:B01 38580 4164 Feb. 24, 1998 576 RTA00000401F.d.15.2 M00001693C:C12 5297 4165 Feb. 24, 1998 1059 RTA00000405F.h.21.2 M00001675C:D12 39072 4166 Feb. 24, 1998 780 RTA00000405F.l.11.1 M00001693D:E08 2055 4167 Feb. 24, 1998 933 RTA00000419F.a.18.1 M00001680A:B02 78484 4168 Feb. 24, 1998 631 RTA00000411F.e.03.1 M00001694D:C12 73648 4169 Feb. 24, 1998 585 RTA00000340R.o.12.1 M00003746C:E02 53732 4170 Feb. 24, 1998 604 RTA00000351R.c.13.1 M00003747D:C05 11476 4171 Feb. 24, 1998 187 RTA00000351R.g.11.1 M00003779D:E08 3077 4172 Feb. 24, 1998 1060 RTA00000346F.g.02.1 M00003792A:B10 6901 4173 Feb. 24, 1998 690 RTA00000341F.b.05.1 M00003793D:A11 0 4174 Feb. 24, 1998 86 RTA00000346F.g.22.1 M00003794D:G03 6371 4175 Feb. 24, 1998 1051 RTA00000346F.h.24.1 M00003797A:C11 4379 4176 Feb. 24, 1998 377 RTA00000346F.i.01.1 M00003797A:D06 22260 4177 Feb. 24, 1998 963 RTA00000405F.i.07.1 M00001693C:E09 38636 4178 Feb. 24, 1998 121 RTA00000418F.p.19.1 M00001677D:B01 78544 4179 Feb. 24, 1998 781 RTA00000423F.f.09.1 M00003808C:A05 64823 4180 Feb. 24, 1998 1028 RTA00000346F.d.12.1 M00001676B:B09 11777 4181 Feb. 24, 1998 82 RTA00000411F.b.03.1 M00001676B:E01 23634 4182 Feb. 24, 1998 465 RTA00000350R.p.18.1 M00001676B:F05 11460 4183 Feb. 24, 1998 56 RTA00000411F.b.06.1 M00001676C:A04 77884 4184 Feb. 24, 1998 789 RTA00000423F.b.13.1 M00001676C:E07 20619 4185 Feb. 24, 1998 267 RTA00000423F.a.19.1 M00001676D:A02 21396 4186 Feb. 24, 1998 836 RTA00000411F.b.17.1 M00001676D:B02 72893 4187 Feb. 24, 1998 370 RTA00000405F.i.20.1 M00001677A:G11 38532 4188 Feb. 24, 1998 39 RTA00000187AF.l.7.1 M00001680D:F08 10539 4189 Feb. 24, 1998 389 RTA00000411F.c.02.1 M00001677B:B04 72852 4190 Feb. 24, 1998 1004 RTA00000419F.a.24.1 M00001680B:D02 79290 4191 Feb. 24, 1998 958 RTA00000195AF.c.8.1 M00001678B:H01 0 4191 Jan. 28, 1998 520 RTA00000195AF.c.8.1 M00001678B:H01 0 4192 Feb. 24, 1998 958 RTA00000195AF.c.8.1 M00001678B:H01 0 4192 Jan. 28, 1998 520 RTA00000195AF.c.8.1 M00001678B:H01 0 4193 Feb. 24, 1998 500 RTA00000411F.c.10.1 M00001678D:B11 73117 4194 Feb. 24, 1998 323 RTA00000421F.n.19.1 M00001679A:D10 16409 4195 Feb. 24, 1998 309 RTA00000340F.n.01.1 M00001679A:G06 39081 4196 Feb. 24, 1998 337 RTA00000340F.p.04.1 M00001679D:B02 78533 4197 Jan. 28, 1998 238 RTA00000187AR.k.12.1 M00001679D:F02 78415 4197 Feb. 24, 1998 407 RTA00000340R.m.07.1 M00001679D:F02 78415 4198 Jan. 28, 1998 238 RTA00000187AR.k.12.1 M00001679D:F02 78415 4198 Feb. 24, 1998 407 RTA00000340R.m.07.1 M00001679D:F02 78415 4199 Feb. 24, 1998 387 RTA00000411F.a.15.1 M00001675D:B08 73812 4200 Feb. 24, 1998 48 RTA00000411F.b.24.1 M00001677B:A12 30041 4201 Feb. 24, 1998 234 RTA00000195AF.d.4.1 M00003881D:D06 22766 4201 Jan. 28, 1998 185 RTA00000195AF.d.4.1 M00003881D:D06 22766 4202 Feb. 24, 1998 130 RTA00000406F.f.12.1 M00003879A:C11 21895 4203 Feb. 24, 1998 953 RTA00000406F.f.05.1 M00003878C:F06 22961 4204 Feb. 24, 1998 138 RTA00000406F.f.03.1 M00003878C:D08 38687 4205 Feb. 24, 1998 673 RTA00000406F.d.09.1 M00003875B:F12 38591 4206 Feb. 24, 1998 136 RTA00000419F.l.12.1 M00003901C:B01 75710 4207 Feb. 24, 1998 300 RTA00000406F.g.17.1 M00003881B:F10 37979 4208 Feb. 24, 1998 2 RTA00000406F.d.16.1 M00003875C:G02 15040 4209 Feb. 24, 1998 1207 RTA00000401F.j.21.1 M00003901B:F10 0 4210 Feb. 24, 1998 494 RTA00000419F.k.12.1 M00003876C:F02 0 4211 Feb. 24, 1998 515 RTA00000419F.l.03.1 M00003879A:D02 79060 4212 Feb. 24, 1998 26 RTA00000423F.h.18.1 M00003876C:D02 37972 4213 Feb. 24, 1998 49 RTA00000406F.d.12.1 M00003875C:A01 38575 4214 Feb. 24, 1998 986 RTA00000406F.d.24.1 M00003876B:C05 37997 4215 Feb. 24, 1998 150 RTA00000419F.k.19.1 M00003877C:G12 75447 4216 Feb. 24, 1998 538 RTA00000423F.g.04.1 M00003903D:C12 23012 4217 Feb. 24, 1998 1046 RTA00000346F.j.06.1 M00003879A:A02 5767 4218 Feb. 24, 1998 868 RTA00000406F.i.08.1 M00003903C:E12 37946 4219 Feb. 24, 1998 409 RTA00000406F.f.11.1 M00003879A:B08 38601 4220 Feb. 24, 1998 924 RTA00000354R.m.02.1 M00003890B:C08 12766 4221 Feb. 24, 1998 543 RTA00000419F.k.24.1 M00003878C:G08 75596 4222 Jan. 28, 1998 185 RTA00000195AF.d.4.1 M00003881D:D06 22766 4222 Feb. 24, 1998 234 RTA00000195AF.d.4.1 M00003881D:D06 22766 4223 Feb. 24, 1998 382 RTA00000341F.h.10.1 M00003901B:G11 0 4224 Feb. 24, 1998 550 RTA00000411F.n.20.1 M00003875C:A09 75816 4225 Feb. 24, 1998 614 RTA00000406F.i.13.1 M00003904A:C04 37904 4226 Feb. 24, 1998 13 RTA00000406F.f.18.1 M00003879B:G02 38587 4227 Feb. 24, 1998 1256 RTA00000401F.k.19.1 M00003903D:D10 799 4228 Feb. 24, 1998 185 RTA00000423F.j.05.1 M00003903C:C05 37958 4229 Feb. 24, 1998 177 RTA00000406F.i.12.1 M00003903D:H11 39080 4230 Feb. 24, 1998 802 RTA00000406F.g.03.1 M00003880B:D11 38690 4231 Feb. 24, 1998 34 RTA00000411F.n.11.1 M00003875A:B01 77276 4232 Feb. 24, 1998 498 RTA00000406F.e.15.1 M00003877C:A11 39074 4233 Feb. 24, 1998 929 RTA00000411F.n.09.1 M00003875A:A07 78962 4234 Feb. 24, 1998 984 RTA00000406F.g.08.1 M00003880C:H03 37963 4235 Feb. 24, 1998 818 RTA00000406F.h.05.1 M00003901B:C03 38542 4236 Feb. 24, 1998 592 RTA00000421F.p.18.1 M00003877B:H10 750 4237 Feb. 24, 1998 313 RTA00000406F.g.07.1 M00003880C:E11 37925 4238 Jan. 28, 1998 324 RTA00000184F.j.06.1 M00001556B:G02 11294 4239 Feb. 24, 1998 773 RTA00000406F.h.03.1 M00003901B:A09 38585 4240 Mar. 24, 1998 244 RTA00000426F.p.09.1 M00004033D:B07 66665 4241 Mar. 24, 1998 222 RTA00000426F.p.10.1 M00004033D:C05 65845 4242 Jan. 28, 1998 181 RTA00000198AF.d.2.1 M00001585A:F07 0 4243 Jan. 28, 1998 77 RTA00000197AF.n.2.1 M00001535A:D02 6229 4244 Feb. 24, 1998 844 RTA00000411F.a.09.1 M00001675C:F01 78629 4245 Feb. 24, 1998 352 RTA00000411F.a.10.1 M00001675C:G01 73073 4246 Mar. 24, 1998 272 RTA00000426F.m.02.1 M00004034C:C06 66237 4247 Mar. 24, 1998 429 RTA00000525F.a.14.1 M00004033B:C02 37566 4248 Feb. 24, 1998 118 RTA00000408F.h.03.1 M00001479D:H03 78382 4249 Mar. 24, 1998 156 RTA00000525F.b.22.1 M00004037C:D07 16679 4250 Feb. 24, 1998 70 RTA00000409F.m.13.1 M00001618B:E05 0 4251 Feb. 24, 1998 1198 RTA00000412F.f.10.2 M00003959A:A03 65405 4252 Feb. 24, 1998 1139 RTA00000404F.h.20.1 M00001619B:A09 15564 4253 Mar. 24, 1998 41 RTA00000525F.b.17.1 M00004037B:A04 24715 4254 Mar. 24, 1998 452 RTA00000525F.a.22.1 M00004033D:G06 36848 4255 Feb. 24, 1998 1019 RTA00000403F.g.03.1 M00001479D:G06 23537 4256 Feb. 24, 1998 532 RTA00000403F.a.24.1 M00001455B:A09 24128 4257 Mar. 24, 1998 5 RTA00000426F.p.04.1 M00004029B:H08 34149 4258 Mar. 24, 1998 43 RTA00000527F.p.07.1 M00004029C:B03 23343 4259 Feb. 24, 1998 562 RTA00000401F.j.17.1 M00003901B:C05 5483 4260 Feb. 24, 1998 303 RTA00000130A.h.22.1 M00001617A:D06 80933 4261 Feb. 24, 1998 1201 RTA00000409F.m.02.1 M00001616C:A11 9157 4262 Mar. 24, 1998 241 RTA00000527F.o.12.1 M00004028B:G08 688 4263 Feb. 24, 1998 1170 RTA00000409F.l.24.1 M00001616C:A02 73174 4264 Feb. 24, 1998 176 RTA00000403F.b.10.1 M00001455C:G07 73268 4265 Jan. 28, 1998 131 RTA00000185AF.d.11.2 M00001579D:C03 6539 4265 Jan. 28, 1998 626 RTA00000185AR.d.11.1 M00001579D:C03 6539 4266 Jan. 28, 1998 190 RTA00000134A.c.7.1 M00001528A:A01 5175 4266 Jan. 28, 1998 176 RTA00000183AF.h.19.1 M00001528A:A01 5175 4267 Mar. 24, 1998 90 RTA00000525F.a.03.1 M00004031D:F05 36786 4268 Mar. 24, 1998 236 RTA00000527F.o.01.1 M00004027A:D06 19088 4269 Mar. 24, 1998 339 RTA00000426F.m.03.1 M00004034C:E08 66480 4270 Jan. 28, 1998 183 RTA00000198AF.c.17.1 M00001579C:E08 6923 4271 Mar. 24, 1998 44 RTA00000527F.p.17.1 M00004030C:D12 17223 4272 Mar. 24, 1998 129 RTA00000527F.p.18.1 M00004030D:B06 31635 4273 Mar. 24, 1998 402 RTA00000527F.p.24.1 M00004031B:A06 36832 4274 Mar. 24, 1998 118 RTA00000525F.a.02.1 M00004031C:H10 37454 4275 Jan. 28, 1998 353 RTA00000198F.a.9.1 M00001557D:C08 0 4276 Feb. 24, 1998 1250 RTA00000403F.f.15.1 M00001477D:F10 22768 4277 Jan. 28, 1998 131 RTA00000185AF.d.11.2 M00001579D:C03 6539 4277 Jan. 28, 1998 626 RTA00000185AR.d.11.1 M00001579D:C03 6539 4278 Feb. 24, 1998 428 RTA00000422F.f.14.1 M00001478B:D07 2036 4279 Jan. 28, 1998 209 RTA00000182AF.c.5.1 M00001464D:F06 6397 4279 Jan. 28, 1998 304 RTA00000182AR.c.5.1 M00001464D:F06 6397 4280 Feb. 24, 1998 205 RTA00000138A.n.4.1 M00001624A:G11 21920 4281 Feb. 24, 1998 251 RTA00000119A.i.9.1 M00001457A:G03 0 4282 Mar. 24, 1998 250 RTA00000427F.h.24.1 M00004091B:H09 65193 4283 Jan. 28, 1998 61 RTA00000197AF.h.11.1 M00001476D:G03 22264 4284 Mar. 24, 1998 216 RTA00000427F.h.11.1 M00004092C:B12 26494 4285 Jan. 28, 1998 110 RTA00000197R.h.01.1 M00001470A:H01 13075 4285 Jan. 28, 1998 591 RTA00000197AF.h.1.1 M00001470A:H01 13075 4286 Jan. 28, 1998 110 RTA00000197R.h.01.1 M00001470A:H01 13075 4286 Jan. 28, 1998 591 RTA00000197AF.h.1.1 M00001470A:H01 13075 4287 Mar. 24, 1998 276 RTA00000427F.h.19.1 M00004092D:B11 63047 4288 Jan. 28, 1998 335 RTA00000182AF.e.3.2 M00001468B:H06 0 4289 Mar. 24, 1998 475 RTA00000427F.i.06.1 M00004097B:D03 41450 4290 Feb. 24, 1998 286 RTA00000404F.i.19.1 M00001625B:C10 38698 4291 Jan. 28, 1998 209 RTA00000182AF.c.5.1 M00001464D:F06 6397 4291 Jan. 28, 1998 304 RTA00000182AR.c.5.1 M00001464D:F06 6397 4292 Feb. 24, 1998 1165 RTA00000408F.c.08.1 M00001456D:G11 73473 4293 Jan. 28, 1998 304 RTA00000182AR.c.5.1 M00001464D:F06 6397 4293 Jan. 28, 1998 209 RTA00000182AF.c.5.1 M00001464D:F06 6397 4294 Jan. 28, 1998 138 RTA00000182AF.a.3.3 M00001462B:A10 0 4295 Jan. 28, 1998 36 RTA00000181AF.p.4.3 M00001460A:A03 40392 4296 Feb. 24, 1998 523 RTA00000418F.j.09.1 M00001626C:D12 76352 4297 Feb. 24, 1998 296 RTA00000347F.d.06.1 M00001457C:F02 39122 4298 Jan. 28, 1998 390 RTA00000197AR.f.07.1 M00001457C:C11 19261 4298 Jan. 28, 1998 184 RTA00000197AF.f.7.1 M00001457C:C11 19261 4299 Jan. 28, 1998 184 RTA00000197AF.f.7.1 M00001457C:C11 19261 4299 Jan. 28, 1998 390 RTA00000197AR.f.07.1 M00001457C:C11 19261 4300 Jan. 28, 1998 133 RTA00000181AR.n.20.3 M00001457B:E03 0 4301 Mar. 24, 1998 132 RTA00000427F.k.17.1 M00004101A:F07 64965 4302 Mar. 24, 1998 218 RTA00000427F.i.19.1 M00004102C:D01 64206 4303 Mar. 24, 1998 436 RTA00000427F.i.21.1 M00004102C:F03 65540 4304 Jan. 28, 1998 209 RTA00000182AF.c.5.1 M00001464D:F06 6397 4304 Jan. 28, 1998 304 RTA00000182AR.c.5.1 M00001464D:F06 6397 4305 Jan. 28, 1998 176 RTA00000183AF.h.19.1 M00001528A:A01 5175 4305 Jan. 28, 1998 190 RTA00000134A.c.7.1 M00001528A:A01 5175 4306 Jan. 28, 1998 12 RTA00000183AF.i.15.2 M00001529B:C04 2642 4306 Feb. 24, 1998 379 RTA00000349R.j.07.1 M00001529B:C04 2642 4307 Feb. 24, 1998 1156 RTA00000408F.f.10.2 M00001476D:C05 75309 4308 Feb. 24, 1998 366 RTA00000403F.c.10.1 M00001456D:F05 75261 4309 Feb. 24, 1998 353 RTA00000409F.n.17.1 M00001621C:C10 76725 4310 Feb. 24, 1998 526 RTA00000411F.a.05.1 M00001675B:H03 76699 4311 Feb. 24, 1998 90 RTA00000411F.a.02.1 M00001675B:E02 78537 4312 Feb. 24, 1998 952 RTA00000411F.a.01.1 M00001675B:D02 74524 4313 Feb. 24, 1998 392 RTA00000410F.p.23.1 M00001675B:C01 73948 4314 Feb. 24, 1998 238 RTA00000340F.j.12.1 M00001624A:B06 3277 4315 Jan. 28, 1998 176 RTA00000183AF.h.19.1 M00001528A:A01 5175 4315 Jan. 28, 1998 190 RTA00000134A.c.7.1 M00001528A:A01 5175 4316 Feb. 24, 1998 298 RTA00000406F.h.07.1 M00003901B:H04 38003 4317 Jan. 28, 1998 190 RTA00000134A.c.7.1 M00001528A:A01 5175 4317 Jan. 28, 1998 176 RTA00000183AF.h.19.1 M00001528A:A01 5175 4318 Jan. 28, 1998 12 RTA00000183AF.i.15.2 M00001529B:C04 2642 4318 Feb. 24, 1998 379 RTA00000349R.j.07.1 M00001529B:C04 2642 4319 Jan. 28, 1998 122 RTA00000197AF.l.15.1 M00001517B:G08 4947 4320 Mar. 24, 1998 199 RTA00000427F.f.24.1 M00004076D:B09 64572 4321 Jan. 28, 1998 161 RTA00000183AF.e.23.2 M00001506D:A09 0 4322 Jan. 28, 1998 17 RTA00000183AR.e.14.2 M00001506B:D09 17437 4323 Jan. 28, 1998 346 RTA00000197AR.k.22.1 M00001505C:H01 11394 4324 Jan. 28, 1998 125 RTA00000197AF.k.15.1 M00001504D:D11 22750 4325 Jan. 28, 1998 212 RTA00000197AF.j.9.1 M00001494B:C01 13236 4326 Jan. 28, 1998 314 RTA00000182AF.o.5.1 M00001493B:D09 5007 4327 Jan. 28, 1998 386 RTA00000197AR.j.04.1 M00001492D:A11 17209 4327 Jan. 28, 1998 259 RTA00000197AF.j.4.1 M00001492D:A11 17209 4328 Jan. 28, 1998 259 RTA00000197AF.j.4.1 M00001492D:A11 17209 4328 Jan. 28, 1998 386 RTA00000197AR.j.04.1 M00001492D:A11 17209 4329 Jan. 28, 1998 94 RTA00000195AF.b.4.1 M00001490C:D07 0 4330 Jan. 28, 1998 336 RTA00000186AF.f.24.1 M00001629B:E06 0 4330 Jan. 28, 1998 83 RTA00000186AF.f.24.2 M00001629B:E06 0 4331 Feb. 24, 1998 1037 RTA00000339F.l.12.1 M00001450A:G11 7711 4332 Jan. 28, 1998 432 RTA00000198AF.o.05.1 M00003750A:D01 26702 4332 Jan. 28, 1998 49 RTA00000198R.o.05.1 M00003750A:D01 26702 4333 Feb. 24, 1998 468 RTA00000423F.c.19.1 M00001680B:E10 40472 4334 Feb. 24, 1998 1009 RTA00000399F.o.24.1 M00001607D:A11 2272 4335 Jan. 28, 1998 281 RTA00000188AF.n.10.1 M00003802D:B11 10283 4336 Jan. 28, 1998 157 RTA00000188AF.n.01.1 M00003801A:B10 36412 4337 Feb. 24, 1998 842 RTA00000401F.n.23.1 M00003982A:B06 1552 4338 Feb. 24, 1998 1216 RTA00000404F.e.07.1 M00001608A:D03 9034 4339 Feb. 24, 1998 1045 RTA00000408F.j.05.2 M00001483C:G06 73878 4340 Feb. 24, 1998 483 RTA00000406F.g.22.1 M00003881D:C12 38590 4341 Jan. 28, 1998 310 RTA00000188AF.m.08.1 M00063798D:H08 22155 4342 Jan. 28, 1998 118 RTA00000199F.b.24.2 M00003794A:B03 0 4343 Jan. 28, 1998 218 RTA00000188AF.o.18.1 M00003811D:A12 13678 4344 Mar. 24, 1998 380 RTA00000427F.e.13.1 M00003959D:A04 66080 4345 Jan. 28, 1998 315 RTA00000199R.d.23.1 M00003815D:H09 37477 4346 Jan. 28, 1998 140 RTA00000199F.a.2.1 M00003772A:D07 12674 4347 Mar. 24, 1998 101 RTA00000523F.j.19.1 M00003966B:D02 65910 4348 Jan. 28, 1998 278 RTA00000198AF.p.16.1 M00003768A:E02 71877 4349 Feb. 24, 1998 514 RTA00000404F.e.13.1 M00001608D:E09 12046 4350 Jan. 28, 1998 508 RTA00000187AF.i.14.2 M00001679B:H07 19406 4350 Feb. 24, 1998 928 RTA00000340F.m.04.1 M00001679B:H07 19406 4351 Jan. 28, 1998 317 RTA00000198AF.p.09.1 M00003761D:E02 10473 4351 Jan. 28, 1998 186 RTA00000198R.p.09.1 M00003761D:E02 10473 4352 Jan. 28, 1998 317 RTA00000198AF.p.09.1 M00003761D:E02 10473 4352 Jan. 28, 1998 186 RTA00000198R.p.09.1 M00003761D:E02 10473 4353 Mar. 24, 1998 66 RTA00000427F.b.15.1 M00003971C:F09 66891 4354 Mar. 24, 1998 508 RTA00000187AF.i.14.2 M00001679B:H07 19406 4354 Feb. 24, 1998 928 RTA00000340F.m.04.1 M00001679B:H07 19406 4355 Jan. 28, 1998 144 RTA00000198AF.o.18.1 M00003755A:A09 13018 4356 Mar. 24, 1998 248 RTA00000527F.l.14.1 M00003983D:A09 14935 4357 Jan. 28, 1998 347 RTA00000199F.b.03.2 M00003779B:E12 38340 4358 Jan. 28, 1998 272 RTA00000199F.g.08.2 M00003853D:G08 0 4359 Jan. 28, 1998 263 RTA00000190AF.n.6.1 M00003965A:B11 0 4360 Feb. 24, 1998 1183 RTA00000346F.j.21.1 M00003879D:A08 3095 4361 Feb. 24, 1998 553 RTA00000408F.j.12.2 M00001485B:C03 18226 4362 Mar. 24, 1998 181 RTA00000523F.b.06.1 M00003808A:F09 28736 4363 Jan. 28, 1998 246 RTA00000199AF.l.4.1 M00003911D:B04 4410 4364 Jan. 28, 1998 51 RTA00000199R.k.07.1 M00003901C:A03 12973 4365 Jan. 28, 1998 62 RTA00000190AF.a.18.2 M00003900D:B10 0 4366 Jan. 28, 1998 117 RTA00000199AF.j.18.1 M00003889D:B09 5140 4367 Jan. 28, 1998 255 RTA00000199AF.j.17.1 M00003889A:D10 5121 4368 Jan. 28, 1998 180 RTA00000199AF.j.12.1 M00003887A:A06 22461 4369 Mar. 24, 1998 256 RTA00000523F.b.20.1 M00003809C:H07 66492 4370 Feb. 24, 1998 603 RTA00000399F.o.19.1 M00001607A:F11 2594 4371 Feb. 24, 1998 510 RTA00000131A.g.16.2 M00001449A:F01 0 4372 Jan. 28, 1998 49 RTA00000198R.o.05.1 M00003750A:D01 26702 4372 Jan. 28, 1998 432 RTA00000198AF.o.05.1 M00003750A:D01 26702 4373 Feb. 24, 1998 424 RTA00000138A.e.13.1 M00001605A:E06 79608 4374 Jan. 28, 1998 90 RTA00000199F.f.15.2 M00003845A:H12 8772 4375 Jan. 28, 1998 244 RTA00000199F.f.12.2 M00003844C:A08 8131 4376 Jan. 28, 1998 78 RTA00000199R.f.09.1 M00003842B:D09 22907 4376 Jan. 28, 1998 406 RTA00000199F.f.09.2 M00003842B:D09 22907 4377 Jan. 28, 1998 406 RTA00000199F.f.09.2 M00003842B:D09 22907 4377 Jan. 28, 1998 78 RTA00000199R.f.09.1 M00003842B:D09 22907 4378 Jan. 28, 1998 44 RTA00000199F.f.08.2 M00003841D:E03 12445 4379 Jan. 28, 1998 39 RTA00000189AR.b.19.1 M00003832B:E01 5294 4379 Feb. 24, 1998 239 RTA00000346F.j.02.1 M00003832B:E01 5294 4380 Jan. 28, 1998 39 RTA00000189AR.b.19.1 M00003832B:E01 5294 4380 Feb. 24, 1998 239 RTA00000346F.j.02.1 M00003832B:E01 5294 4381 Feb. 24, 1998 1161 RTA00000346F.m.05.1 M00003983B:C08 5644 4382 Feb. 24, 1998 887 RTA00000339F.p.06.1 M00001484A:A10 4880 4383 Mar. 24, 1998 46 RTA00000523F.c.09.1 M00003813C:D08 47389 4384 Feb. 24, 1998 1206 RTA00000418F.b.20.1 M00001484D:G05 73560 4385 Jan. 28, 1998 336 RTA00000186AF.f.24.1 M00001629B:E06 0 4385 Jan. 28, 1998 83 RTA00000186AF.f.24.2 M00001629B:E06 0 4386 Jan. 28, 1998 111 RTA00000198AF.o.12.1 M00003751D:B02 22038 4387 Mar. 24, 1998 365 RTA00006527F.k.16.1 M00003982B:B06 1015 4388 Feb. 24, 1998 1113 RTA00000418F.p.21.1 M00001677D:F03 78068 4389 Mar. 24, 1998 281 RTA00000527F.k.20.1 M00003982B:H07 17148 4390 Jan. 28, 1998 360 RTA00000198F.i.5.1 M00001638A:D10 39989 4391 Jan. 28, 1998 55 RTA00000186AF.i.21.1 M00001636C:H09 6033 4392 Jan. 28, 1998 316 RTA00000198AF.h.24.1 M00001636C:C01 8390 4393 Jan. 28, 1998 208 RTA00000198AF.h.22.1 M00001635C:A03 22366 4394 Feb. 24, 1998 1031 RTA00000404F.g.08.1 M00001613D:H10 38980 4395 Mar. 24, 1998 382 RTA00000427F.a.12.1 M00003982C:H10 63377 4396 Feb. 24, 1998 916 RTA00000418F.p.20.1 M00001677D:B07 78023 4397 Jan. 28, 1998 91 RTA00000198AF.j.19.1 M00001653C:F12 38914 4398 Feb. 24, 1998 858 RTA00000341F.e.20.1 M00003891D:B10 67422 4399 Jan. 28, 1998 354 RTA00000198R.k.03.1 M00001655A:F06 22765 4399 Jan. 28, 1998 158 RTA00000198AF.k.03.1 M00001655A:F06 22765 4400 Mar. 24, 1998 219 RTA00000427F.f.17.1 M00004115A:B12 63803 4401 Mar. 24, 1998 153 RTA00000527F.l.13.1 M00003983C:F10 36904 4402 Mar. 24, 1998 320 RTA00000427F.j.06.1 M00004102D:B05 63676 4403 Feb. 24, 1998 762 RTA00000411F.c.04.1 M00001677B:E06 76858 4404 Feb. 24, 1998 957 RTA00000411F.c.03.1 M00001677B:B06 79280 4405 Mar. 24, 1998 479 RTA00000527F.l.23.1 M00003984A:B06 36018 4406 Jan. 28, 1998 329 RTA00000186AF.b.9.1 M00001616C:F07 0 4407 Feb. 24, 1998 1115 RTA00000340F.i.08.1 M00001615B:F07 12005 4408 Feb. 24, 1998 1022 RTA00000401F.j.15.1 M00003901A:C09 3061 4409 Jan. 28, 1998 4 RTA00000198R.f.04.1 M00001607D:F07 5023 4410 Mar. 24, 1998 173 RTA00000426F.m.18.1 M00003986D:G07 62974 4411 Feb. 24, 1998 616 RTA00000423F.c.11.1 M00001677D:B02 0 4412 Jan. 28, 1998 345 RTA00000187AF.h.21.1 M00001679A:F01 39171 4413 Feb. 24, 1998 621 RTA000004118F.i.18.2 M00001482C:D02 74410 4414 Jan. 28, 1998 344 RTA00000198AF.o.02.1 M00003748A:B07 68756 4415 Feb. 24, 1998 257 RTA00000411F.c.17.1 M00001678D:G03 77664 4416 Feb. 24, 1998 944 RTA00000422F.k.24.1 M00001610C:E06 39118 4417 Feb. 24, 1998 876 RTA00000423F.d.16.1 M00001678D:C11 39173 4418 Feb. 24, 1998 1144 RTA00000345F.j.09.1 M00001451B:F01 13 4419 Jan. 28, 1998 242 RTA00000198AF.m.17.1 M00001679D:F06 77992 4419 Jan. 28, 1998 260 RTA00000198R.m.17.1 M00001679D:F06 77992 4420 Jan. 28, 1998 260 RTA00000198R.m.17.1 M00001679D:F06 77992 4420 Jan. 28, 1998 242 RTA00000198AF.m.17.1 M00001679D:F06 77992 4421 Jan. 28, 1998 242 RTA00000198AF.m.17.1 M00001679D:F06 77992 4421 Jan. 28, 1998 260 RTA00000198R.m.17.1 M00001679D:F06 77992 4422 Jan. 28, 1998 260 RTA00000198R.m.17.1 M00001679D:F06 77992 4422 Jan. 28, 1998 242 RTA00000198AF.m.17.1 M00001679D:F06 77992 4423 Jan. 28, 1998 238 RTA00000187AR.k.12.1 M00001679D:F02 78415 4423 Feb. 24, 1998 407 RTA00000340R.m.07.1 M00001679D:F02 78415 4424 Jan. 28, 1998 276 RTA00000198AF.j.15.1 M00001653B:E09 4369 4425 Jan. 28, 1998 65 RTA00000198AF.m.16.1 M00001679D:D05 51 4426 Jan. 28, 1998 257 RTA00000198AF.e.20.1 M00001604C:E09 9810 4427 Feb. 24, 1998 820 RTA00000423F.d.11.1 M00001678C:C06 38950 4428 Mar. 24, 1998 466 RTA00000427F.d.06.1 M00003980B:C06 33446 4429 Feb. 24, 1998 455 RTA00000399F.d.23.1 M00001481B:A07 3310 4430 Feb. 24, 1998 851 RTA00000423F.d.07.1 M00001678B:B12 0 4431 Jan. 28, 1998 142 RTA00000198AF.k.19.1 M00001660B:C04 75879 4432 Feb. 24, 1998 485 RTA00000419F.a.02.1 M00001678A:F05 77993 4433 Mar. 24, 1998 224 RTA00000527F.k.09.1 M00003981C:F05 213 4434 Feb. 24, 1998 1032 RTA00000423F.c.13.1 M00001678A:A11 39059 4435 Jan. 28, 1998 354 RTA00000198R.k.03.1 M00001655A:F06 22765 4435 Jan. 28, 1998 158 RTA00000198AF.k.03.1 M00001655A:F06 22765 4436 Jan. 28, 1998 354 RTA00000198R.k.03.1 M00001655A:F06 22765 4436 Jan. 28, 1998 158 RTA00000198AF.k.03.1 M00001655A:F06 22765 4437 Jan. 28, 1998 158 RTA00000198AF.k.03.1 M00001655A:F06 22765 4437 Jan. 28, 1998 354 RTA00000198R.k.03.1 M00001655A:F06 22765 4438 Jan. 28, 1998 238 RTA00000187AR.k.12.1 M00001679D:F02 78415 4438 Feb. 24, 1998 407 RTA00000340R.m.07.1 M00001679D:F02 78415 4439 Jan. 28, 1998 669 RTA00000192AF.c.2.1 M00004121B:G01 0 4440 Mar. 24, 1998 394 RTA00000527F.g.14.1 M00003845D:B02 37532 4441 Jan. 28, 1998 608 RTA0000092AF.p.8.1 M00004212B:C07 2379 4441 Feb. 24, 1998 653 RTA00000352R.m.12.1 M00004212B:C07 2379 4442 Jan. 28, 1998 608 RTA00000192AF.p.8.1 M00004212B:C07 2379 4442 Feb. 24, 1998 653 RTA00000352R.m.12.1 M00004212B:C07 2379 4443 Jan. 28, 1998 730 RTA00000192AF.o.11.1 M00004205D:F06 0 4444 Feb. 24, 1998 1157 RTA00000422F.m.18.1 M00001647B:E04 23829 4445 Feb. 24, 1998 1187 RTA00000120A.c.19.1 M00001464A:B03 81016 4446 Feb. 24, 1998 913 RTA00000120A.c.20.1 M00001464A:B07 43235 4447 Jan. 28, 1998 589 RTA00000192AF.l.1.1 M00004183C:D07 16392 4448 Feb. 24, 1998 640 RTA00000405F.f.02.1 M00001669B:G02 38665 4449 Jan. 28, 1998 27 RTA00000192AF.i.12.1 M00004169C:C12 5319 4450 Feb. 24, 1998 681 RTA00000120A.c.24.1 M00001464A:D03 34278 4451 Feb. 24, 1998 265 RTA00000340F.k.16.1 M00001647B:C09 13157 4452 Jan. 28, 1998 70 RTA00000192AF.e.3.1 M00004138B:H02 13272 4453 Mar. 24, 1998 171 RTA00000523F.e.10.1 M00003829A:F03 62878 4454 Feb. 24, 1998 1134 RTA00000418F.m.02.1 M00001650A:A12 74550 4455 Jan. 28, 1998 618 RTA00000192AF.a.14.1 M00004111D:A08 6874 4456 Jan. 28, 1998 457 RTA00000191AR.l.7.2 M00004081C:D12 14391 4457 Feb. 24, 1998 596 RTA00000351R.i.03.1 M00003846B:D06 6874 4458 Mar. 24, 1998 460 RTA00000523F.f.16.1 M00003840B:E07 26522 4459 Mar. 24, 1998 400 RTA00000523F.f.17.1 M00003840B:E08 63984 4460 Feb. 24, 1998 1129 RTA00000401F.m.07.1 M00003907D:F11 2893 4461 Feb. 24, 1998 132 RTA00000418F.m.05.1 M00001650B:C10 73600 4462 Jan. 28, 1998 482 RTA00000187AF.j.7.1 M00001679C:F01 78091 4463 Feb. 24, 1998 1107 RTA00000419F.l.22.1 M00003903D:C06 78444 4464 Feb. 24, 1998 609 RTA00000404F.o.10.2 M00001651B:B12 16785 4465 Jan. 28, 1998 376 RTA00000177AF.m.18.3 M00001355B:G11 0 4465 Jan. 28, 1998 375 RTA00000177AF.m.18.1 M00001355B:G11 0 4466 Feb. 24, 1998 186 RTA00000132A.k.6.1 M00001464A:E07 81284 4467 Jan. 28, 1998 18 RTA00000196AF.c.17.1 M00001352C:F06 39602 4468 Mar. 24, 1998 282 RTA00000427F.h.22.1 M00004108C:E01 64547 4469 Feb. 24, 1998 859 RTA00000419F.m.22.1 M00003914A:G09 75600 4470 Mar. 24, 1998 33 RTA00000524F.b.21.1 M00005216C:B09 0 4471 Mar. 24, 1998 170 RTA00000523F.d.12.1 M00003822B:D08 64888 4472 Mar. 24, 1998 117 RTA00000523F.d.18.1 M00003822B:G01 64072 4473 Feb. 24, 1998 739 RTA00000423F.h.20.1 M00003914A:G06 38639 4474 Feb. 24, 1998 527 RTA00000419F.m.21.1 M00003914A:E04 77947 4475 Feb. 24, 1998 237 RTA00000119A.j.22.1 M00001460A:F07 80336 4476 Feb. 24, 1998 349 RTA00000404F.m.10.2 M00001641D:E02 779 4477 Feb. 24, 1998 462 RTA00000119A.j.23.1 M00001460A:G07 79835 4478 Feb. 24, 1998 1263 RTA00000341F.i.22.1 M00003911A:F10 7825 4479 Mar. 24, 1998 47 RTA00000523F.e.18.1 M00003829D:A11 62898 4480 Jan. 28, 1998 152 RTA00000196AF.c.20.1 M00001352C:H02 8934 4481 Mar. 24, 1998 13 RTA00000528F.m.16.1 M00003845D:C03 4468 4482 Jan. 28, 1998 14 RTA00000196R.c.11.2 M00001352A:E12 13658 4483 Feb. 24, 1998 641 RTA00000410F.j.20.1 M00001642D:G10 73601 4484 Jan. 28, 1998 141 RTA00000196AF.c.6.1 M00001350A:D06 23148 4485 Jan. 28, 1998 25 RTA00000196AF.c.1.1 M00001349C:C05 8171 4486 Feb. 24, 1998 436 RTA00000119A.m.15.1 M00001461A:E05 80989 4487 Jan. 28, 1998 9 RTA00000177AF.g.22.1 M00001347C:G08 7031 4488 Feb. 24, 1998 162 RTA00000406F.l.08.1 M00003908D:D12 39016 4489 Feb. 24, 1998 1056 RTA00000419F.m.18.1 M00003908C:G09 76014 4490 Jan. 28, 1998 73 RTA00000177AF.e.21.3 M00001344A:H07 4306 4491 Mar. 24, 1998 326 RTA00000527F.e.09.1 M00003826B:E11 37521 4492 Feb. 24, 1998 900 RTA00000419F.m.13.1 M00003908A:F12 79052 4493 Feb. 24, 1998 441 RTA00000404F.m.20.2 M00001647A:H08 39144 4494 Feb. 24, 1998 1217 RTA00000410F.j.17.1 M00001642D:F02 72912 4495 Mar. 24, 1998 309 RTA00000523F.j.10.1 M00003860B:G09 63384 4496 Feb. 24, 1998 385 RTA00000418F.m.14.1 M00001651B:E06 75711 4497 Feb. 24, 1998 1121 RTA00000120A.m.10.3 M00001467A:B03 81376 4498 Jan. 28, 1998 617 RTA00000179AF.d.13.3 M00001394A:F01 6583 4499 Feb. 24, 1998 1242 RTA00000405F.d.10.1 M00001661C:F11 39000 4500 Mar. 24, 1998 19 RTA00000527F.j.02.2 M00003856A:B07 4896 4501 Feb. 24, 1998 645 RTA00000422F.p.12.2 M00001661C:F10 9840 4502 Mar. 24, 1998 142 RTA00000523F.i.18.1 M00003856B:C04 64463 4503 Feb. 24, 1998 376 RTA00000400F.k.22.1 M00001656A:B07 2512 4504 Jan. 28, 1998 532 RTA00000177AF.o.4.1 M00001358C:C06 0 4505 Feb. 24, 1998 1128 RTA00000423F.a.02.3 M00001656B:A08 39210 4506 Feb. 24, 1998 1143 RTA00000423F.a.03.1 M00001656B:D05 26796 4507 Feb. 24, 1998 408 RTA00000405F.d.14.1 M00001662A:C12 35209 4508 Mar. 24, 1998 360 RTA00000523F.j.03.1 M00003860A:A08 64535 4509 Jan. 28, 1998 409 RTA00000180AF.d.1.3 M00001418D:B06 8526 4510 Feb. 24, 1998 784 RTA00000418F.o.14.1 M00001661B:B05 33524 4511 Mar. 24, 1998 120 RTA00000426F.h.09.1 M00003905B:G03 78797 4512 Jan. 28, 1998 706 RTA00000177AF.i.6.4 M00001350A:B08 0 4513 Mar. 24, 1998 4 RTA00000426F.h.11.1 M00003905B:H05 75479 4514 Feb. 24, 1998 697 RTA00000412F.d.14.1 M00003905D:C08 76757 4515 Feb. 24, 1998 908 RTA00000423F.g.03.1 M00003905C:G11 38007 4516 Mar. 24, 1998 342 RTA00000427F.e.12.1 M00003959C:G06 62813 4517 Feb. 24, 1998 97 RTA00000403F.e.01.1 M00001473A:C11 38965 4518 Feb. 24, 1998 555 RTA00000133A.d.22.1 M00001469A:G11 11797 4519 Feb. 24, 1998 454 RTA00000418F.n.19.1 M00001659C:F02 28761 4520 Feb. 24, 1998 562 RTA00000401F.j.17.1 M00003901B:C05 5483 4521 Feb. 24, 1998 1215 RTA00000422F.o.08.2 M00001659D:D03 26832 4522 Feb. 24, 1998 635 RTA00000418F.o.17.1 M00001661B:F03 79069 4523 Mar. 24, 1998 190 RTA00000523F.h.12.1 M00003851C:D07 65745 4524 Jan. 28, 1998 267 RTA00000186AF.g.11.2 M00001630B:H09 5214 4525 Feb. 24, 1998 238 RTA00000340F.j.12.1 M00001624A:B06 3277 4526 Feb. 24, 1998 331 RTA00000404F.o.18.2 M00001651C:C05 39110 4527 Jan. 28, 1998 626 RTA00000185AR.d.11.1 M00001579D:C03 6539 4527 Jan. 28, 1998 131 RTA00000185AF.d.11.2 M00001579D:C03 6539 4528 Jan. 28, 1998 626 RTA00000185AR.d.11.1 M00001579D:C03 6539 4528 Jan. 28, 1998 131 RTA00000185AF.d.11.2 M00001579D:C03 6539 4529 Jan. 28, 1998 147 RTA00000185AF.c.24.2 M00001578B:E04 23001 4530 Feb. 24, 1998 164 RTA00000345F.k.06.1 M00001475A:A12 0 4531 Feb. 24, 1998 611 RTA00000404F.p.02.2 M00001652D:A06 39097 4532 Feb. 24, 1998 274 RTA00000405F.e.08.1 M00001663C:F10 37916 4533 Feb. 24, 1998 755 RTA00000423F.d.17.1 M00001663A:C11 20630 4534 Feb. 24, 1998 126 RTA00000422F.j.20.1 M00001653A:G07 22388 4535 Mar. 24, 1998 195 RTA00000523F.i.08.1 M00001855A:C12 65099 4536 Mar. 24, 1998 83 RTA00000527F.i.05.2 M00003851C:B06 37481 4537 Jan. 28, 1998 375 RTA00000177AF.m.18.1 M00001355B:G11 0 4537 Jan. 28, 1998 376 RTA00000177AF.m.18.3 M00001355B:G11 0 4538 Feb. 24, 1998 763 RTA00000135A.m.18.1 M00001545A:C03 19255 4539 Feb. 24, 1998 362 RTA00000418F.m.16.1 M00001653B:E06 74986 4540 Feb. 24, 1998 287 RTA00000410F.n.09.1 M00001662C:A04 11736 4541 Mar. 24, 1998 416 RTA00000527F.i.12.2 M00003852B:D11 0 4542 Feb. 24, 1998 662 RTA00000339F.o.07.1 M00001473D:G01 2566 4543 Feb. 24, 1998 949 RTA00000340R.j.07.1 M00001654C:D05 38954 4544 Mar. 24, 1998 146 RTA00000527F.i.17.2 M00003853B:C08 37539 4545 Feb. 24, 1998 939 RTA00000405F.a.03.1 M00001654C:E04 39065 4546 Mar. 24, 1998 42 RTA00000527F.i.19.2 M00003853C:C06 38089 4547 Mar. 24, 1998 381 RTA00000426F.f.18.1 M00003854C:C02 63271 4548 Feb. 24, 1998 656 RTA00000403F.e.08.1 M00001473D:B11 19126 4549 Mar. 24, 1998 37 RTA00000426F.f.20.1 M00003854C:F01 65134 4550 Feb. 24, 1998 733 RTA00000405F.d.18.1 M00001662C:B02 10494 4551 Jan. 28, 1998 334 RTA00000181AR.b.21.3 M00001444C:D05 3266 4551 Jan. 28, 1998 321 RTA00000181AR.b.21.1 M00001444C:D05 3266 4552 Mar. 24, 1998 198 RTA00000523F.o.05.1 M00005175B:H04 0 4553 Mar. 24, 1998 302 RTA00000427F.p.04.2 M00005100B:H07 0 4554 Mar. 24, 1998 203 RTA000004Z7F.p.10.2 M00005102C:F09 0 4555 Jan. 28, 1998 331 RTA00000197AR.c.20.1 M00001449D:A06 16282 4556 Mar. 24, 1998 6 RTA00000523F.l.10.1 M00005134B:E01 0 4557 Jan. 28, 1998 174 RTA00000181AF.e.22.3 M00001448D:F09 3442 4558 Mar. 24, 1998 79 RTA00000523F.l.15.1 M00005134C:E11 0 4559 Mar. 24, 1998 386 RTA00000523F.l.16.1 M00005134C:G04 0 4560 Mar. 24, 1998 76 RTA00000523F.l.18.1 M00005134D:A06 0 4561 Mar. 24, 1998 192 RTA00000523F.m.02.1 M00005134D:H03 0 4562 Mar. 24, 1998 290 RTA00000427F.l.03.1 M00005136D:B07 0 4563 Mar. 24, 1998 269 RTA00000427F.p.02.2 M00005100B:D02 0 4564 Jan. 28, 1998 321 RTA00000181AR.b.21.1 M00001444C:D05 3266 4564 Jan. 28, 1998 334 RTA00000181AR.b.21.3 M00001444C:D05 3266 4565 Mar. 24, 1998 334 RTA00000427F.n.11.1 M00004960B:A09 0 4566 Jan. 28, 1998 334 RTA00000181AR.b.21.3 M00001444C:D05 3266 4566 Jan. 28, 1998 321 RTA00000181AR.b.21.1 M00001444C:D05 3266 4567 Jan. 28, 1998 334 RTA00000181AR.b.21.3 M00001444C:D05 3266 4567 Jan. 28, 1998 321 RTA00000181AR.b.21.1 M00001444C:D05 3266 4568 Mar. 24, 1998 328 RTA00000523F.n.01.1 M00005137A:E01 0 4569 Jan. 28, 1998 356 RTA00000180AF.l.12.2 M00001433B:H11 0 4570 Mar. 24, 1998 68 RTA00000523F.n.04.1 M00005138B:D12 0 4571 Mar. 24, 1998 127 RTA00000523F.n.10.1 M00005140D:G09 0 4572 Jan. 28, 1998 187 RTA00000180AR.j.04.4 M00001429C:G12 22300 4573 Mar. 24, 1998 112 RTA00000523F.n.12.1 M00005173C:A02 0 4574 Mar. 24, 1998 305 RTA00000523F.n.16.1 M00005173D:H02 0 4575 Mar. 24, 1998 164 RTA00000523F.n.17.1 M00005174D:B02 0 4576 Mar. 24, 1998 107 RTA00000523F.n.20.1 M00005174D:H02 0 4577 Feb. 24, 1998 898 RTA00000418F.l.03.1 M00001641C:C06 79058 4578 Mar. 24, 1998 288 RTA00000427F.l.04.1 M00005136D:C01 0 4579 Mar. 24, 1998 462 RTA00000427F.p.13.2 M00004695B:E04 0 4580 Jan. 28, 1998 137 RTA00000181AF.m.4.3 M00001455A:E09 13238 4581 Jan. 28, 1998 20 RTA00000181AF.l.14.2 M00001454D:D06 2364 4582 Mar. 24, 1998 105 RTA00000526F.d.01.1 M00004104B:A02 4468 4583 Mar. 24, 1998 261 RTA00000427F.i.22.1 M00004104D:B05 63199 4584 Mar. 24, 1998 81 RTA00000427F.j.07.1 M00004105A:B10 64819 4585 Mar. 24, 1998 287 RTA00000525F.d.19.1 M00004114B:D09 36860 4586 Jan. 28, 1998 311 RTA00000191AR.j.4.2 M00004071D:A10 5198 4587 Mar. 24, 1998 337 RTA00000525F.e.08.1 M00004115C:H04 24193 4588 Mar. 24, 1998 206 RTA00000525F.f.07.1 M00004119A:A06 37500 4589 Mar. 24, 1998 461 RTA00000427F.f.15.1 M00004119D:A07 66734 4590 Mar. 24, 1998 410 RTA00000427F.f.16.1 M00004119D:H06 64122 4591 Mar. 24, 1998 307 RTA00000427F.p.03.2 M00005100B:G11 0 4592 Mar. 24, 1998 180 RTA00000523F.k.02.1 M00004687A:C03 0 4593 Jan. 28, 1998 115 RTA00000179AR.o.20.3 M00001409D:F11 2409 4594 Mar. 24, 1998 315 RTA00000427F.n.19.1 M00004891D:E07 0 4595 Mar. 24, 1998 375 RTA00000427F.p.19.2 M00004895C:G05 0 4596 Mar. 24, 1998 470 RTA00000427F.p.24.2 M00004897D:F03 0 4597 Jan. 28, 1998 155 RTA00000197F.e.8.1 M00001454A:C11 3135 4598 Jan. 28, 1998 286 RTA00000181AR.k.2.3 M00001453C:A11 0 4598 Jan. 28, 1998 389 RTA00000181AR.k.2.2 M00001453C:A11 0 4599 Jan. 28, 1998 286 RTA00000181AR.k.2.3 M00001453C:A11 0 4599 Jan. 28, 1998 389 RTA00000181AR.k.2.2 M00001453C:A11 0 4600 Jan. 28, 1998 285 RTA00000181AR.j.14.3 M00001453B:E10 5399 4601 Mar. 24, 1998 317 RTA00000428F.a.01.1 M00004897D:G05 0 4602 Mar. 24, 1998 85 RTA00000427F.m.21.1 M00004900C:E11 0 4603 Mar. 24, 1998 121 RTA00000427F.n.02.1 M00004900D:B10 0 4604 Mar. 24, 1998 78 RTA00000427F.o.05.1 M00004958B:D01 0 4605 Mar. 24, 1998 437 RTA00000427F.n.10.1 M00004960B:A08 0 4606 Mar. 24, 1998 388 RTA00000526F.d.17.1 M00004235A:A12 2757 4607 Jan. 28, 1998 299 RTA00000196AF.f.5.1 M00001366D:G02 11937 4608 Jan. 28, 1998 369 RTA00000196F.m.3.1 M00001413A:F02 10453 4609 Mar. 24, 1998 319 RTA00000523F.p.15.1 M00005178B:H01 0 4610 Jan. 28, 1998 374 RTA00000178AF.l.11.1 M00001383A:G04 23286 4611 Feb. 24, 1998 1090 RTA00000405F.g.22.1 M00001673C:A02 527 4612 Jan. 28, 1998 127 RTA00000178AF.k.18.1 M00001382A:F04 9755 4613 Jan. 28, 1998 104 RTA00000196R.h.03.1 M00001381A:D02 6636 4614 Feb. 24, 1998 642 RTA00000341F.h.19.1 M00003916C:C05 0 4615 Feb. 24, 1998 655 RTA00000351R.p.14.1 M00003915C:H04 13166 4616 Jan. 28, 1998 145 RTA00000178AF.h.24.1 M00001376B:C06 6745 4617 Feb. 24, 1998 224 RTA00000341F.g.21.1 M00003914C:F09 8823 4618 Feb. 24, 1998 301 RTA00000401F.m.23.1 M00003914C:C02 2801 4619 Feb. 24, 1998 133 RTA00000404F.l.20.1 M00001639B:H05 38638 4619 Feb. 24, 1998 63 RTA00000404F.l.20.2 M00001639B:H05 38638 4620 Feb. 24, 1998 542 RTA00000410F.i.19.1 M00001641B:C10 78988 4621 Feb. 24, 1998 63 RTA00000404F.l.20.2 M00001639B:H05 38638 4621 Feb. 24, 1998 133 RTA00000404F.l.20.1 M00001639B:H05 38638 4622 Feb. 24, 1998 600 RTA00000406F.m.04.1 M00003914B:A11 14959 4623 Jan. 28, 1998 33 RTA00000178AR.a.20.1 M00001362C:H11 945 4623 Feb. 24, 1998 979 RTA00000345F.b.17.1 M00001362C:H11 945 4624 Jan. 28, 1998 33 RTA00000178AR.a.20.1 M00001362C:H11 945 4624 Feb. 24, 1998 979 RTA00000345F.b.17.1 M00001362C:H11 945 4625 Mar. 24, 1998 73 RTA00000524F.b.12.1 M00005213C:G01 0 4626 Jan. 28, 1998 373 RTA00000196F.e.12.1 M00001361C:H11 10147 4627 Feb. 24, 1998 1233 RTA00000418F.l.02.1 M00001641C:C05 39316 4628 Mar. 24, 1998 184 RTA00000524F.b.18.1 M00005214B:D11 0 4629 Mar. 24, 1998 353 RTA00000428F.a.18.1 M00005214C:A09 0 4630 Jan. 28, 1998 89 RTA00000177AF.n.8.3 M00001356D:F06 4188 4630 Jan. 28, 1998 15 RTA00000177AR.n.8.1 M00001356D:F06 4188 4631 Jan. 28, 1998 89 RTA00000177AF.n.8.3 M00001356D:F06 4188 4631 Jan. 28, 1998 15 RTA00000177AR.n.8.1 M00001356D:F06 4188 4632 Jan. 28, 1998 375 RTA00000177AF.m.18.1 M00001355B:G11 0 4632 Jan. 28, 1998 376 RTA00000177AF.m.18.3 M00001355B:G11 0 4633 Jan. 28, 1998 375 RTA00000177AF.m.18.1 M00001355B:G11 0 4633 Jan. 28, 1998 376 RTA00000177AF.m.18.3 M00001355B:G11 0 4634 Feb. 24, 1998 682 RTA00000410F.i.17.1 M00001641B:B01 78147 4635 Jan. 28, 1998 367 RTA00000196F.i.24.1 M00001392C:D10 4233 4636 Jan. 28, 1998 264 RTA00000179AF.k.3.3 M00001401A:H07 0 4637 Jan. 28, 1998 333 RTA00000196F.k.15.1 M00001400A:F06 8320 4638 Jan. 28, 1998 38 RTA00000196R.k.07.1 M00001399C:D09 22443 4638 Jan. 28, 1998 289 RTA00000196F.k.07.1 M00001399C:D09 22443 4639 Jan. 28, 1998 38 RTA00000196R.k.07.1 M00001399C:D09 22443 4639 Jan. 28, 1998 289 RTA00000196F.k.07.1 M00001399C:D09 22443 4640 Jan. 28, 1998 289 RTA00000196F.k.07.1 M00001399C:D09 22443 4640 Jan. 28, 1998 38 RTA00000196R.k.07.1 M00001399C:D09 22443 4641 Jan. 28, 1998 38 RTA00000196R.k.07.1 M00001399C:D09 22443 4641 Jan. 28, 1998 289 RTA00000196F.k.07.1 M00001399C:D09 22443 4642 Mar. 24, 1998 324 RTA00000523F.o.09.1 M00005176A:C12 0 4643 Mar. 24, 1998 122 RTA00000523F.o.12.1 M00005177A:B06 0 4644 Jan. 28, 1998 167 RTA00000179AF.d.22.3 M00001394C:C11 7955 4645 Jan. 28, 1998 351 RTA00000179AF.c.22.1 M00001393B:B09 22515 4645 Jan. 28, 1998 459 RTA00000179AF.c.22.3 M00001393B:B09 22515 4646 Jan. 28, 1998 351 RTA00000179AF.c.22.1 M00001393B:B09 22515 4646 Jan. 28, 1998 459 RTA00000179AF.c.22.3 M00001393B:B09 22515 4647 Mar. 24, 1998 361 RTA00000523F.p.08.1 M00005178A:A07 0 4648 Jan. 28, 1998 43 RTA00000179AF.c.14.3 M00001392D:H04 0 4649 Mar. 24, 1998 268 RTA00000427F.k.19.1 M00004103B:B07 62851 4650 Mar. 24, 1998 473 RTA00000523F.o.21.1 M00005177C:A01 0 4651 Jan. 28, 1998 60 RTA00000196AR.i.12.3 M00001389D:G11 38800 4651 Jan. 28, 1998 128 RTA00000196F.i.12.1 M00001389D:G11 38800 4652 Jan. 28, 1998 128 RTA00000196F.i.12.1 M00001389D:G11 38800 4652 Jan. 28, 1998 60 RTA00000196AR.i.12.3 M00001389D:G11 38800 4653 Jan. 28, 1998 60 RTA00000196AR.i.12.3 M00001389D:G11 38800 4653 Jan. 28, 1998 128 RTA00000196F.i.12.1 M00001389D:G11 38800 4654 Jan. 28, 1998 60 RTA00000196AR.i.12.3 M00001389D:G11 38800 4654 Jan. 28, 1998 128 RTA00000196F.i.12.1 M00001389D:G11 38800 4655 Jan. 28, 1998 28 RTA00000178AR.o.01.5 M00001387B:H07 0 4656 Jan. 28, 1998 279 RTA00000196AF.h.24.1 M00001386A:D11 7308 4657 Jan. 28, 1998 130 RTA00000196AF.h.23.1 M00001386A:C02 13357 4658 Jan. 28, 1998 254 RTA00000178AF.n.2.1 M00001385C:H11 17083 4659 Jan. 28, 1998 74 RTA00000196AF.h.20.1 M00001385B:F10 0 4660 Jan. 28, 1998 377 RTA00000178AF.m.19.1 M00001384D:H07 0 4660 Jan. 28, 1998 120 RTA00000178AR.m.19.5 M00001384D:H07 0 4661 Jan. 28, 1998 377 RTA00000178AF.m.19.1 M00001384D:H07 0 4661 Jan. 28, 1998 120 RTA00000178AR.m.19.5 M00001384D:H07 0 4662 Mar. 24, 1998 228 RTA00000523F.o.14.1 M00005177A:H09 0 4663 Jan. 28, 1998 567 RTA00000177AR.m.13.1 M00001355A:C12 4175 4663 Jan. 28, 1998 538 RTA00000177AR.m.13.3 M00001355A:C12 4175 4663 Jan. 28, 1998 533 RTA00000177AR.m.13.4 M00001355A:C12 4175 4664 Jan. 28, 1998 511 RTA00000196AF.g.10.1 M00001376B:A02 12498 4665 Jan. 28, 1998 620 RTA00000201R.g.08.1 M00004692A:E07 0 4665 Jan. 28, 1998 619 RTA00000201F.g.08.1 M00004692A:E07 0 4665 Jan. 28, 1998 621 RTA00000201R.g.08.2 M00004692A:E07 0 4666 Mar. 24, 1998 194 RTA00000522F.j.12.2 M00001651C:A04 74341 4667 Feb. 24, 1998 79 RTA00000419F.g.08.1 M00003842C:D11 66700 4668 Jan. 28, 1998 619 RTA00000201F.g.08.1 M00004692A:E07 0 4668 Jan. 28, 1998 620 RTA00000201R.g.08.1 M00004692A:E07 0 4668 Jan. 28, 1998 621 RTA00000201R.g.08.2 M00004692A:E07 0 4669 Jan. 28, 1998 529 RTA00000178AF.b.13.1 M00001364A:E11 3114 4670 Feb. 24, 1998 111 RTA00000128A.i.20.1 M00001560A:F03 9900 4671 Mar. 24, 1998 379 RTA00000522F.k.02.2 M00001652C:B09 77622 4672 Mar. 24, 1998 135 RTA00000522F.k.10.2 M00001652D:B09 77619 4673 Feb. 24, 1998 1197 RTA00000128A.j.10.1 M00001560A:H06 80085 4674 Feb. 24, 1998 140 RTA00000128A.j.6.2 M00001560A:H10 5316 4675 Mar. 24, 1998 247 RTA00000425F.j.21.1 M00001633B:B11 77373 4676 Jan. 28, 1998 538 RTA00000177AR.m.13.3 M00001355A:C12 4175 4676 Jan. 28, 1998 567 RTA00000177AR.m.13.1 M00001355A:C12 4175 4676 Jan. 28, 1998 533 RTA00000177AR.m.13.4 M00001355A:C12 4175 4677 Feb. 24, 1998 729 RTA00000403F.m.20.1 M00001576A:F11 707 4677 Feb. 24, 1998 437 RTA00000403F.m.20.2 M00001576A:F11 707 4678 Jan. 28, 1998 533 RTA00000177AR.m.13.4 M00001355A:C12 4175 4678 Jan. 28, 1998 538 RTA00000177AR.m.13.3 M00001355A:C12 4175 4678 Jan. 28, 1998 567 RTA00000177AR.m.13.1 M00001355A:C12 4175 4679 Jan. 28, 1998 533 RTA00000177AR.m.13.4 M00001355A:C12 4175 4679 Jan. 28, 1998 538 RTA00000177AR.m.13.3 M00001355A:C12 4175 4679 Jan. 28, 1998 567 RTA00000177AR.m.13.1 M00001355A:C12 4175 4680 Jan. 28, 1998 538 RTA00000177AR.m.13.3 M00001355A:C12 4175 4680 Jan. 28, 1998 567 RTA00000177AR.m.13.1 M00001355A:C12 4175 4680 Jan. 28, 1998 533 RTA00000177AR.m.13.4 M00001355A:C12 4175 4681 Jan. 28, 1998 533 RTA00000177AR.m.13.4 M00001355A:C12 4175 4681 Jan. 28, 1998 538 RTA00000177AR.m.13.3 M00001355A:C12 4175 4681 Jan. 28, 1998 567 RTA00000177AR.m.13.1 M00001355A:C12 4175 4682 Jan. 28, 1998 620 RTA00000201R.g.08.1 M00004692A:E07 0 4682 Jan. 28, 1998 621 RTA00000201R.g.08.2 M00004692A:E07 0 4682 Jan. 28, 1998 619 RTA00000201F.g.08.1 M00004692A:E07 0 4683 Feb. 24, 1998 845 RTA00000348R.b.04.1 M00001342B:E01 1890 4684 Feb. 24, 1998 1088 RTA00000339R.b.02.1 M00001344B:F12 0 4684 Feb. 24, 1998 1149 RTA00000339F.b.02.1 M00001344B:F12 0 4685 Feb. 24, 1998 618 RTA00000423F.l.04.1 M00004039B:G08 14320 4686 Feb. 24, 1998 1235 RTA00000411F.j.04.1 M00003841C:F03 66219 4687 Feb. 24, 1998 415 RTA00000340R.f.05.1 M00001569B:G11 3202 4688 Feb. 24, 1998 1088 RTA00000339R.b.02.1 M00001344B:F12 0 4688 Feb. 24, 1998 1149 RTA00000339F.b.02.1 M00001344B:F12 0 4689 Feb. 24, 1998 1067 RTA00000411F.j.11.1 M00003841D:F06 66154 4690 Jan. 28, 1998 429 RTA00000196F.i.19.1 M00001390C:C11 39498 4690 Feb. 24, 1998 925 RTA00000353R.h.10.1 M00001390C:C11 39498 4691 Jan. 28, 1998 508 RTA00000187AF.i.14.2 M00001679B:H07 19406 4691 Feb. 24, 1998 928 RTA00000340F.m.04.1 M00001679B:H07 19406 4692 Feb. 24, 1998 10 RTA00000350R.c.12.1 M00001550D:A04 9728 4693 Jan. 28, 1998 553 RTA00000201F.b.22.1 M00004344B:H04 35728 4694 Jan. 28, 1998 459 RTA00000179AF.c.22.3 M00001393B:B09 22515 4694 Jan. 28, 1998 351 RTA00000179AF.c.22.1 M00001393B:B09 22515 4695 Jan. 28, 1998 351 RTA00000179AF.c.22.1 M00001393B:B09 22515 4695 Jan. 28, 1998 459 RTA00000179AF.c.22.3 M00001393B:B09 22515 4696 Feb. 24, 1998 235 RTA00000126A.o.23.1 M00001551A:B10 6268 4697 Feb. 24, 1998 942 RTA00000126A.n.6.2 M00001551A:D04 79917 4698 Feb. 24, 1998 228 RTA00000411F.k.19.1 M00003852D:E08 64200 4699 Jan. 28, 1998 638 RTA00000193AF.l.05.2 M00004348A:A02 2815 4700 Mar. 24, 1998 143 RTA00000425F.l.09.1 M00001638A:B04 75251 4701 Jan. 28, 1998 540 RTA00000179AF.b.10.3 M00001391D:D10 0 4702 Feb. 24, 1998 390 RTA00000355R.a.14.1 M00004187D:G09 10207 4703 Jan. 28, 1998 429 RTA00000196F.i.19.1 M00001390C:C11 39498 4703 Feb. 24, 1998 925 RTA00000353R.h.10.1 M00001390C:C11 39498 4704 Feb. 24, 1998 930 RTA00000127A.h.22.2 M00001554A:E04 13155 4705 Feb. 24, 1998 1193 RTA00000411F.k.14.1 M00003851A:C10 63987 4706 Jan. 28, 1998 694 RTA00000201R.c.19.1 M00004370A:G05 22357 4707 Mar. 24, 1998 80 RTA00000425F.p.12.1 M00001638C:G01 73219 4708 Mar. 24, 1998 344 RTA00000425F.p.15.1 M00001638C:H07 31680 4709 Jan. 28, 1998 743 RTA00000178AF.k.9.1 M00001381B:F06 16342 4710 Feb. 24, 1998 202 RTA00000419F.g.22.1 M00003845D:A09 64515 4711 Jan. 28, 1998 749 RTA00000178AR.i.13.4 M00001377B:H01 0 4712 Mar. 24, 1998 217 RTA00000425F.j.16.1 M00001639D:F02 75631 4713 Mar. 24, 1998 448 RTA00000425F.j.18.1 M00001639D:G12 75561 4714 Jan. 28, 1998 385 RTA00000201F.c.24.1 M00004374D:E10 35731 4715 Feb. 24, 1998 904 RTA00000127A.e.6.1 M00001553A:E07 5885 4716 Feb. 24, 1998 620 RTA00000420F.a.07.1 M00004072C:F08 63405 4717 Jan. 28, 1998 396 RTA00000179AR.b.02.3 M00001391B:G12 0 4718 Feb. 24, 1998 463 RTA00000403F.o.22.1 M00001583A:D01 25076 4718 Feb. 24, 1998 1084 RTA00000403F.o.22.2 M00001583A:D01 25076 4719 Feb. 24, 1998 1225 RTA00000346F.j.13.1 M00003841C:E04 5337 4720 Feb. 24, 1998 1221 RTA00000403F.o.17.1 M00001582D:A02 23085 4721 Feb. 24, 1998 878 RTA00000413F.c.12.1 M00004083B:G03 65334 4722 Feb. 24, 1998 764 RTA00000413F.c.17.1 M00004085B:B05 36831 4723 Feb. 24, 1998 398 RTA00000407F.b.04.1 M00004086D:B09 63221 4724 Feb. 24, 1998 1179 RTA00000341F.o.12.1 M00004144A:F04 2883 4725 Feb. 24, 1998 7 RTA00000413F.d.12.1 M00004088C:A12 66467 4726 Feb. 24, 1998 881 RTA00000413F.d.15.1 M00004088C:E04 64943 4727 Feb. 24, 1998 463 RTA00000403F.o.22.1 M00001583A:D01 25076 4727 Feb. 24, 1998 1084 RTA00000403F.o.22.2 M00001583A:D01 25076 4728 Feb. 24, 1998 1084 RTA00000403F.o.22.2 M00001583A:D01 25076 4728 Feb. 24, 1998 463 RTA00000403F.o.22.1 M00001583A:D01 25076 4729 Jan. 28, 1998 506 RTA00000198R.o.09.1 M00003751B:A05 4310 4729 Jan. 28, 1998 497 RTA00000198AF.o.09.1 M00003751B:A05 4310 4730 Feb. 24, 1998 1015 RTA00000129A.b.6.2 M00001582A:H01 39111 4731 Feb. 24, 1998 866 RTA00000407F.b.08.1 M00004088D:B03 37513 4732 Feb. 24, 1998 943 RTA00000413F.c.03.1 M00004081D:H09 64527 4733 Feb. 24, 1998 463 RTA00000403F.o.22.1 M00001583A:D01 25076 4733 Feb. 24, 1998 1084 RTA00000403F.o.22.2 M00001583A:D01 25076 4734 Jan. 28, 1998 490 RTA00000198AF.n.05.1 M00001687A:G01 24157 4735 Feb. 24, 1998 798 RTA00000420F.c.04.1 M00004089A:B08 65007 4736 Feb. 24, 1998 850 RTA00000420F.c.07.1 M00004089A:E02 65555 4737 Feb. 24, 1998 199 RTA00000403F.m.13.2 M00001575D:A10 39077 4738 Jan. 28, 1998 424 RTA00000187AR.j.24.1 M00001679D:B05 78356 4738 Jan. 28, 1998 418 RTA00000187AR.k.01.1 M00001679D:B05 78356 4739 Jan. 28, 1998 424 RTA00000187AR.j.24.1 M00001679D:B05 78356 4739 Jan. 28, 1998 418 RTA00000187AR.k.01.1 M00001679D:B05 78356 4740 Jan. 28, 1998 418 RTA00000187AR.k.01.1 M00001679D:B05 78356 4740 Jan. 28, 1998 424 RTA00000187AR.j.24.1 M00001679D:B05 78356 4741 Jan. 28, 1998 424 RTA00000187AR.j.24.1 M00001679D:B05 78356 4741 Jan. 28, 1998 418 RTA00000187AR.k.01.1 M00001679D:B05 78356 4742 Jan. 28, 1998 482 RTA00000187AF.j.7.1 M00001679C:F01 78091 4743 Jan. 28, 1998 693 RTA00000198F.m.12.1 M00001679C:D05 4 4744 Mar. 24, 1998 23 RTA00000522F.p.07.1 M00001670A:C11 76888 4745 Jan. 28, 1998 497 RTA00000198AF.o.09.1 M00003751B:A05 4310 4745 Jan. 28, 1998 506 RTA00000198R.o.09.1 M00003751B:A05 4310 4746 Jan. 28, 1998 642 RTA00000189AF.i.14.1 M00003868B:G11 0 4747 Feb. 24, 1998 1119 RTA00000126A.k.24.1 M00001550A:F07 39428 4748 Feb. 24, 1998 654 RTA00000421F.a.05.1 M00001570C:G06 5278 4749 Feb. 24, 1998 1146 RTA00000347F.h.02.1 M00004072D:H12 562 4750 Feb. 24, 1998 137 RTA00000339R.a.06.1 M00001346A:E04 58694 4751 Feb. 24, 1998 729 RTA00000403F.m.20.1 M00001576A:F11 707 4751 Feb. 24, 1998 437 RTA00000403F.m.20.2 M00001576A:F11 707 4752 Feb. 24, 1998 627 RTA00000408F.p.21.1 M00001579A:C03 77930 4753 Feb. 24, 1998 735 RTA00000420F.a.11.1 M00004073C:D04 66460 4754 Feb. 24, 1998 525 RTA00000348R.d.24.1 M00001349B:G05 5774 4755 Feb. 24, 1998 624 RTA00000420F.a.16.1 M00004075D:C10 63345 4756 Feb. 24, 1998 437 RTA00000403F.m.20.2 M00001576A:F11 707 4756 Feb. 24, 1998 729 RTA00000403F.m.20.1 M00001576A:F11 707 4757 Feb. 24, 1998 437 RTA00000403F.m.20.2 M00001576A:F11 707 4757 Feb. 24, 1998 729 RTA00000403F.m.20.1 M00001576A:F11 707 4758 Jan. 28, 1998 499 RTA00000199F.b.22.2 M00003791C:E09 17018 4759 Feb. 24, 1998 843 RTA00000418F.g.03.1 M00001579C:E06 78737 4760 Feb. 24, 1998 956 RTA00000423F.l.06.1 M00004062A:H06 38136 4761 Feb. 24, 1998 826 RTA00000422F.e.07.1 M00001579C:G05 38964 4761 Feb. 24, 1998 832 RTA00000403F.o.10.2 M00001579C:G05 38964 4762 Feb. 24, 1998 826 RTA00000422F.e.07.1 M00001579C:G05 38964 4762 Feb. 24, 1998 832 RTA00000403F.o.10.2 M00001579C:G05 38964 4763 Feb. 24, 1998 826 RTA00000422F.e.07.1 M00001579C:G05 38964 4763 Feb. 24, 1998 832 RTA00000403F.o.10.2 M00001579C:G05 38964 4764 Feb. 24, 1998 826 RTA00000422F.e.07.1 M00001579C:G05 38964 4764 Feb. 24, 1998 832 RTA00000403F.o.10.2 M00001579C:G05 38964 4765 Feb. 24, 1998 1159 RTA00000413F.b.18.1 M00004078C:F04 39873 4766 Feb. 24, 1998 1122 RTA00000419F.f.16.1 M00003839D:E02 64679 4767 Feb. 24, 1998 1053 RTA00000413F.b.24.1 M00004080A:F01 65117 4768 Feb. 24, 1998 1052 RTA00000420F.b.02.1 M00004081A:A08 64013 4769 Feb. 24, 1998 157 RTA00000339F.a.23.1 M00001361B:C07 4022 4770 Jan. 28, 1998 452 RTA00000199F.d.19.2 M00003813D:H12 6707 4771 Feb. 24, 1998 480 RTA00000411F.i.15.1 M00003837C:G08 31612 4772 Feb. 24, 1998 125 RTA00000403F.m.18.1 M00001576A:B09 39185 4773 Feb. 24, 1998 548 RTA00000413F.b.12.1 M00004077B:H11 64932 4774 Feb. 24, 1998 814 RTA00000408F.l.24.1 M00001530B:G09 34263 4775 Jan. 28, 1998 688 RTA00000193AF.g.3.1 M00004050D:A06 5567 4776 Jan. 28, 1998 451 RTA00000200AF.b.20.1 M00004043A:D02 40403 4777 Jan. 28, 1998 456 RTA00000200AF.b.12.1 M00004040B:F10 22053 4778 Feb. 24, 1998 849 RTA00000122A.n.16.1 M00001517A:G08 80553 4779 Jan. 28, 1998 12 RTA00000183AF.i.15.2 M00001529B:C04 2642 4779 Feb. 24, 1998 379 RTA00000349R.j.07.1 M00001529B:C04 2642 4780 Jan. 28, 1998 12 RTA00000183AF.i.15.2 M00001529B:C04 2642 4780 Feb. 24, 1998 379 RTA00000349R.j.07.1 M00001529B:C04 2642 4781 Jan. 28, 1998 512 RTA00000191AF.c.3.1 M00003987D:D06 3549 4782 Feb. 24, 1998 431 RTA00000399F.j.15.1 M00001578C:G06 1261 4783 Jan. 28, 1998 586 RTA00000199R.o.11.1 M00003976C:A10 23172 4784 Jan. 28, 1998 496 RTA00000190AF.p.3.1 M00003975B:F03 2378 4785 Feb. 24, 1998 340 RTA00000408F.l.13.1 M00001530A:B12 4423 4786 Jan. 28, 1998 617 RTA00000179AF.d.13.3 M00001394A:F01 6583 4787 Feb. 24, 1998 779 RTA00000408F.l.16.1 M00001530A:F12 73468 4788 Jan. 28, 1998 387 RTA00000191AF.j.14.1 M00004073A:H12 1002 4788 Feb. 24, 1998 632 RTAQ0000191AF.j.14.1 M00004073A:H12 1002 4789 Jan. 28, 1998 464 RTA00000199AF.l.14.1 M00003917A:D02 22865 4790 Feb. 24, 1998 668 RTA00000408F.m.05.2 M00001530C:G10 23384 4791 Feb. 24, 1998 1066 RTA00000123A.f.2.1 M00001531A:H03 80379 4792 Feb. 24, 1998 213 RTA00000123A.f.3.1 M00001531A:H07 44017 4793 Feb. 24, 1998 43 RTA00000420F.g.04.1 M00004891B:B12 0 4794 Feb. 24, 1998 302 RTA00000356R.f.18.1 M00004692A:H10 0 4795 Feb. 24, 1998 308 RTA00000353R.d.11.1 M00004692A:H08 0 4796 Feb. 24, 1998 975 RTA00000411F.n.02.1 M00003870B:F04 78049 4797 Jan. 28, 1998 722 RTA00000199R.j.24.1 M00003895C:A10 0 4798 Feb. 24, 1998 643 RTA00000420F.l.14.2 M00005230D:F06 0 4799 Jan. 28, 1998 480 RTA00000181AF.o.08.2 M00001457C:H12 849 4800 Jan. 28, 1998 518 RTA00000199AF.n.22.1 M00003971A:A06 23064 4801 Jan. 28, 1998 618 RTA00000192AF.a.14.1 M00004111D:A08 6874 4802 Feb. 24, 1998 937 RTA00000121A.n.15.1 M00001511A:G08 40849 4803 Feb. 24, 1998 821 RTA00000420F.h.16.1 M00004927A:E06 0 4804 Feb. 24, 1998 658 RTA00000121A.n.2.1 M00001511A:A05 33585 4805 Feb. 24, 1998 551 RTA00000340F.b.05.1 M00001513A:G07 0 4806 Feb. 24, 1998 172 RTA00000420F.i.17.1 M00005101C:B09 0 4807 Feb. 24, 1998 1224 RTA00000122A.h.24.1 M00001514A:A12 48 4808 Jan. 28, 1998 631 RTA00000200AF.h.19.2 M00004151D:E03 0 4809 Feb. 24, 1998 80 RTA00000122A.g.16.1 M00001514A:B04 81366 4810 Feb. 24, 1998 809 RTA00000420F.i.23.1 M00005134A:D11 0 4811 Feb. 24, 1998 650 RTA00000122A.g.17.1 M00001514A:B08 32655 4812 Feb. 24, 1998 73 RTA00000413F.p.15.2 M00005136D:D06 0 4813 Jan. 28, 1998 425 RTA00000200AF.c.16.1 M00004064D:A11 23433 4814 Feb. 24, 1998 60 RTA00000413F.p.17.2 M00005136D:G06 0 4815 Jan. 28, 1998 387 RTA00000191AF.j.14.1 M00004073A:H12 1002 4815 Feb. 24, 1998 632 RTA00000191AF.j.14.1 M00004073A:H12 1002 4816 Feb. 24, 1998 837 RTA00000420F.h.01.1 M00004897C:D06 0 4817 Feb. 24, 1998 123 RTA00000122A.j.18.1 M00001516A:D05 81317 4818 Feb. 24, 1998 77 RTA00000420F.j.22.1 M00005173B:F01 0 4819 Jan. 28, 1998 734 RTA00000200AF.d.21.1 M00004087C:D03 0 4820 Jan. 28, 1998 733 RTA00000200AF.d.20.1 M00004087A:G08 26600 4821 Feb. 24, 1998 1003 RTA00000420F.k.08.2 M00005176C:C09 0 4822 Jan. 28, 1998 442 RTA00000191AF.l.9.1 M00004081C:H06 0 4823 Jan. 28, 1998 457 RTA00000191AR.l.7.2 M00004081C:D12 14391 4824 Feb. 24, 1998 552 RTA00000411F.n.12.1 M00003875A:C04 73308 4825 Feb. 24, 1998 782 RTA00000419F.k.03.1 M00003871C:B05 40822 4826 Feb. 24, 1998 839 RTA00000414F.b.01.1 M00005212B:A02 0 4827 Jan. 28, 1998 674 RTA00000197AR.e.24.1 M00001456B:F10 39250 4827 Jan. 28, 1998 3 RTA00000197AF.e.24.1 M00001456B:F10 39250 4828 Jan. 28, 1998 669 RTA00000192AF.c.2.1 M00004121B:G01 0 4829 Jan. 28, 1998 718 RTA00000196F.l.14.2 M00001408B:G06 23144 4830 Feb. 24, 1998 1259 RTA00000420F.l.19.2 M00005231A:H04 0 4831 Jan. 28, 1998 717 RTA00000200F.o.10.2 M00004269B:C08 36432 4832 Feb. 24, 1998 107 RTA00000125A.g.16.1 M00001544A:C09 21497 4833 Jan. 28, 1998 697 RTA00000193AF.e.21.1 M00004271B:B06 0 4834 Feb. 24, 1998 829 RTA00000411F.m.11.1 M00003867A:D12 73196 4835 Jan. 28, 1998 409 RTA00000180AF.d.1.3 M00001418D:B06 8526 4836 Mar. 24, 1998 426 RTA00000424F.k.21.1 M00001614A:A04 73197 4837 Feb. 24, 1998 874 RTA00000346F.o.22.1 M00004300C:H09 7381 4838 Mar. 24, 1998 136 RTA00000424F.m.22.1 M00001614C:E11 72943 4839 Feb. 24, 1998 636 RTA00000418F.e.21.1 M00001577B:A03 74773 4840 Feb. 24, 1998 1202 RTA00000347F.h.10.1 M00004206A:E02 22779 4841 Feb. 24, 1998 1030 RTA00000125A.c.17.1 M00001542A:E04 80619 4842 Feb. 24, 1998 753 RTA00000345F.o.13.1 M00001546B:F12 11500 4843 Feb. 24, 1998 221 RTA00000414F.f.13.1 M00005259D:H08 0 4844 Feb. 24, 1998 193 RTA00000347F.b.10.1 M00001546C:C07 8044 4845 Feb. 24, 1998 1104 RTA00000126A.b.10.1 M00001547A:F06 0 4846 Feb. 24, 1998 1177 RTA00000126A.b.9.1 M00001547A:F11 81279 4847 Feb. 24, 1998 923 RTA00000126A.d.19.1 M00001548A:G01 79474 4848 Feb. 24, 1998 98 RTA00000411F.l.03.1 M00003854D:A12 62702 4849 Feb. 24, 1998 625 RTA00000126A.h.22.2 M00001549A:F01 0 4850 Jan. 28, 1998 710 RTA00000196AF.l.3.1 M00001405B:D07 20864 4851 Feb. 24, 1998 1102 RTA00000126A.j.15.2 M00001549A:H11 40425 4852 Mar. 24, 1998 467 RTA00000528F.h.02.2 M00001632C:D08 1701 4853 Jan. 28, 1998 411 RTA00000179AF.j.13.3 M00001400B:H06 0 4854 Feb. 24, 1998 1126 RTA00000136A.h.6.1 M00001550A:D09 81620 4855 Jan. 28, 1998 712 RTA00000201F.b.21.1 M00004341B:G03 9071 4856 Feb. 24, 1998 1257 RTA00000419F.h.21.1 M00003856C:B08 64828 4857 Feb. 24, 1998 194 RTA00000124A.k.5.1 M00001538A:F12 80252 4858 Jan. 28, 1998 508 RTA00000187AF.i.14.2 M00001679B:H07 19406 4858 Feb. 24, 1998 928 RTA00000340F.m.04.1 M00001679B:H07 19406 4859 Jan. 28, 1998 3 RTA00000197AF.e.24.1 M00001456B:F10 39250 4859 Jan. 28, 1998 674 RTA00000197AR.e.24.1 M00001456B:F10 39250 4860 Feb. 24, 1998 606 RTA00000420F.l.20.2 M00005232A:C10 0 4861 Feb. 24, 1998 30 RTA00000411F.m.24.1 M00003870B:B08 77568 4862 Feb. 24, 1998 31 RTA00000134A.j.10.1 M00001534A:G06 81383 4863 Feb. 24, 1998 1136 RTA00000406F.c.05.1 M00003870A:H01 22077 4864 Feb. 24, 1998 411 RTA00000420F.m.12.1 M00005234D:B04 0 4865 Feb. 24, 1998 1086 RTA00000403F.n.22.2 M00001578B:B05 26775 4865 Feb. 24, 1998 1085 RTA00000403F.n.22.1 M00001578B:B05 26775 4866 Feb. 24, 1998 1018 RTA00000413F.j.21.1 M00004688A:A02 0 4867 Feb. 24, 1998 657 RTA00000124A.k.20.1 M00001538A:C08 80913 4868 Feb. 24, 1998 718 RTA00000124A.k.23.1 M00001538A:D03 81350 4869 Feb. 24, 1998 1092 RTA00000125A.c.2.1 M00001542A:F06 40148 4870 Feb. 24, 1998 615 RTA00000135A.b.23.1 M00001538A:D12 35241 4871 Feb. 24, 1998 639 RTA00000414F.d.09.1 M00005231C:B01 0 4872 Feb. 24, 1998 1086 RTA00000403F.n.22.2 M00001578B:B05 26775 4872 Feb. 24, 1998 1085 RTA00000403F.n.22.1 M00001578B:B05 26775 4873 Feb. 24, 1998 99 RTA00000420F.m.19.1 M00005254D:B05 0 4874 Feb. 24, 1998 1085 RTA00000403F.n.22.1 M00001578B:B05 26775 4874 Feb. 24, 1998 1086 RTA00000403F.n.22.2 M00001578B:B05 26775 4875 Feb. 24, 1998 1086 RTA00000403F.n.22.2 M00001578B:B05 26775 4875 Feb. 24, 1998 1085 RTA00000403F.n.22.1 M00001578B:B05 26775 4876 Jan. 28, 1998 725 RTA00000197AF.b.1.1 M00001441D:E04 12134 4877 Feb. 24, 1998 215 RTA00000403F.j.18.1 M00001539D:E10 5790 4878 Feb. 24, 1998 1010 RTA00000408F.n.16.2 M00001540C:B03 73720 4879 Feb. 24, 1998 1074 RTA00000423F.h.11.1 M00003867C:E11 38977 4880 Feb. 24, 1998 27 RTA00000420F.n.19.2 M00005259B:C01 0 4881 Jan. 28, 1998 578 RTA00000180AF.g.17.1 M00001426A:A09 16653 4882 Feb. 24, 1998 1172 RTA00000423F.h.03.1 M00003875D:D09 37903 4883 Feb. 24, 1998 1008 RTA00000414F.f.07.1 M00005259C:B05 0 4884 Feb. 24, 1998 582 RTA00000414F.e.14.1 M00005236B:F10 0 4885 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 4885 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 4885 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 4886 Feb. 24, 1998 1223 RTA00000347F.a.14.1 M00001429D:F11 7421 4887 Feb. 24, 1998 488 RTA00000339F.k.23.1 M00001429D:H12 0 4888 Mar. 24, 1998 100 RTA00000424F.i.21.1 M00001596A:E07 73482 4889 Mar. 24, 1998 64 RTA00000424F.i.24.1 M00001596A:G06 79101 4890 Mar. 24, 1998 207 RTA00000424F.j.07.1 M00001596B:C11 79211 4891 Mar. 24, 1998 327 RTA00000424F.j.08.1 M00001596B:D09 73972 4892 Mar. 24, 1998 349 RTA00000424F.j.09.1 M00001596B:H05 74387 4893 Mar. 24, 1998 154 RTA00000522F.h.13.1 M00001596C:F09 40823 4894 Feb. 24, 1998 1252 RTA000004000F.g.08.1 M00001639A:C11 1275 4895 Feb. 24, 1998 261 RTA00000341F.b.06.1 M00003794A:E12 17008 4896 Jan. 28, 1998 312 RTA00000193AF.h.2.1 M00004290A:B03 3273 4897 Jan. 28, 1998 590 RTA00000190AF.d.2.1 M00003906B:F12 2444 4898 Jan. 28, 1998 213 RTA00000200F.o.04.1 M00004260D:C12 12514 4899 Feb. 24, 1998 333 RTA00000399F.f.11.1 M00001487C:F01 40167 4900 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 4900 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 4900 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 4901 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 4901 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 4901 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 4902 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 4902 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 4902 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 4903 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 4903 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 4903 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 4904 Jan. 28, 1998 249 RTA00000200R.o.03.2 M00004257C:H06 22807 4904 Jan. 28, 1998 85 RTA00000200R.o.03.1 M00004257C:H06 22807 4904 Jan. 28, 1998 178 RTA00000200F.o.03.1 M00004257C:H06 22807 4905 Mar. 24, 1998 133 RTA00000425F.f.04.1 M00001607A:B06 24633 4906 Mar. 24, 1998 169 RTA00000425F.f.05.1 M00001607A:D10 24090 4907 Feb. 24, 1998 44 RTA00000418F.k.14.1 M00001639A:H06 76133 4908 Feb. 24, 1998 1204 RTA00000419F.l.02.1 M00003879A:C01 75736 4909 Feb. 24, 1998 748 RTA00000346F.f.11.1 M00003793C:D09 38528 4910 Feb. 24, 1998 4 RTA00000339F.i.20.1 M00001438D:C06 4356 4911 Jan. 28, 1998 93 RTA00000200F.o.11.1 M00004270A:F11 0 4912 Jan. 28, 1998 435 RTA00000182AR.c.22.1 M00001467A:D08 16283 4913 Jan. 28, 1998 683 RTA00000187AR.j.01.1 M00001679C:D01 79028 4914 Mar. 24, 1998 469 RTA00000522F.e.20.1 M00001590B:H10 26770 4915 Jan. 28, 1998 172 RTA00000186AF.p.09.2 M00001655C:E04 6879 4916 Feb. 24, 1998 806 RTA00000345F.f.08.1 M00001413B:H09 0 4917 Jan. 28, 1998 677 RTA00000197AF.i.19.1 M00001490B:H11 39554 4918 Jan. 28, 1998 443 RTA00000197AR.i.17.1 M00001490A:E11 3516 4919 Feb. 24, 1998 863 RTA00000406F.p.08.1 M00004032C:B02 37573 4920 Mar. 24, 1998 55 RTA00000528F.e.23.1 M00001593B:D10 19242 4921 Feb. 24, 1998 1211 RTA00000399F.f.14.1 M00001487D:C11 11483 4922 Jan. 28, 1998 609 RTA00000196AF.n.05.1 M00001418B:F07 12531 4922 Feb. 24, 1998 1120 RTA00000353R.l.23.1 M00001418B:F07 12531 4923 Jan. 28, 1998 609 RTA00000196AF.n.05.1 M00001418B:F07 12531 4923 Feb. 24, 1998 1120 RTA00000353R.l.23.1 M00001418B:F07 12531 4924 Mar. 24, 1998 474 RTA00000522F.h.05.1 M00001595C:H11 73358 4925 Jan. 28, 1998 284 RTA00000199F.d.10.2 M00003808C:B05 22049 4925 Feb. 24, 1998 816 RTA00000354R.n.04.1 M00003808C:B05 22049 4926 Feb. 24, 1998 1112 RTA00000418F.c.05.1 M00001487B:F02 76475 4927 Jan. 28, 1998 687 RTA00000197AF.g.4.1 M00001464B:B03 8821 4928 Feb. 24, 1998 990 RTA00000121A.h.19.1 M00001471A:D04 80334 4929 Jan. 28, 1998 696 RTA00000180AR.d.16.3 M00001419D:C10 11393 4929 Feb. 24, 1998 1184 RTA00000345F.h.08.1 M00001419D:C10 11393 4930 Jan. 28, 1998 751 RTA00000179AF.c.4.3 M00001392D:B11 0 4931 Jan. 28, 1998 696 RTA00000180AR.d.16.3 M00001419D:C10 11393 4931 Feb. 24, 1998 1184 RTA00000345F.h.08.1 M00001419D:C10 11393 4932 Jan. 28, 1998 162 RTA00000201F.e.15.1 M00004444B:D11 9960 4933 Jan. 28, 1998 126 RTA00000201F.d.16.1 M00004388B:A08 0 4934 Jan. 28, 1998 332 RTA00000193AR.n.04.3 M00004375C:D01 9850 4935 Feb. 24, 1998 838 RTA00000408F.k.19.1 M00001487C:G03 77593 4936 Feb. 24, 1998 113 RTA00000401F.e.02.1 M00003805B:C04 0 4937 Mar. 24, 1998 278 RTA00000522F.g.21.1 M00001595C:A09 77310 4938 Mar. 24, 1998 54 RTA00000425F.f.19.1 M00001653D:G07 32635 4939 Feb. 24, 1998 976 RTA00000419F.b.17.1 M00003808D:D04 63261 4940 Feb. 24, 1998 59 RTA00000346F.j.08.1 M00003879B:A06 39951 4941 Feb. 24, 1998 151 RTA00000341F.c.21.1 M00003789C:F06 7899 4942 Jan. 28, 1998 67 RTA00000200AF.g.07.1 M00004128B:G01 0 4943 Feb. 24, 1998 324 RTA00000340F.p.17.1 M00003750C:H05 0 4944 Feb. 24, 1998 476 RTA00000345F.h.01.1 M00001441B:D11 10834 4945 Feb. 24, 1998 245 RTA00000195AF.d.20.1 M00004117A:D11 37574 4945 Jan. 28, 1998 87 RTA00000195AF.d.20.1 M00004117A:D11 37574 4946 Feb. 24, 1998 245 RTA00000195AF.d.20.1 M00004117A:D11 37574 4946 Jan. 28, 1998 87 RTA00000195AF.d.20.1 M00004117A:D11 37574 4947 Feb. 24, 1998 991 RTA00000419F.b.10.1 M00001694C:G04 78566 4948 Feb. 24, 1998 14 RTA00000419F.b.09.1 M00001694C:F12 78128 4949 Jan. 28, 1998 261 RTA00000192AF.a.24.1 M00004114C:F11 13183 4950 Jan. 28, 1998 24 RTA00000200AF.f.11.1 M00004111D:D11 0 4951 Mar. 24, 1998 408 RTA00000522F.o.10.1 M00001660D:E05 78798 4952 Jan. 28, 1998 328 RTA00000200AF.g.09.1 M00004131B:H09 22785 4952 Jan. 28, 1998 26 RTA00000200R.g.09.1 M00004131B:H09 22785 4953 Feb. 24, 1998 861 RTA00000419F.b.06.1 M00001694B:B08 76728 4954 Mar. 24, 1998 24 RTA00000522F.n.08.1 M00001656A:D10 76343 4955 Feb. 24, 1998 760 RTA00000423F.d.04.1 M00001694A:B12 11307 4956 Mar. 24, 1998 220 RTA00000522F.o.18.1 M00001669B:H06 76366 4957 Feb. 24, 1998 279 RTA00000418F.i.21.1 M00001596D:E10 78728 4958 Jan. 28, 1998 84 RTA00000191AF.h.14.1 M00004056B:D09 13553 4959 Jan. 28, 1998 284 RTA00000199F.d.10.2 M00003808C:B05 22049 4959 Feb. 24, 1998 816 RTA00000354R.n.04.1 M00003808C:B05 22049 4960 Feb. 24, 1998 217 RTA00000399F.o.17.1 M00001599D:A09 1106 4961 Jan. 28, 1998 287 RTA00000200AF.b.07.1 M00004039C:C01 17125 4961 Jan. 28, 1998 173 RTA00000200AR.b.07.1 M00004039C:C01 17125 4962 Jan. 28, 1998 287 RTA00000200AF.b.07.1 M00004039C:C01 17125 4962 Jan. 28, 1998 173 RTA00000200AR.b.07.1 M00004039C:C01 17125 4963 Jan. 28, 1998 287 RTA00000200AF.b.07.1 M00004039C:C01 17125 4963 Jan. 28, 1998 173 RTA00000200AR.b.07.1 M00004039C:C01 17125 4964 Jan. 28, 1998 287 RTA00000200AF.b.07.1 M00004039C:C01 17125 4964 Jan. 28, 1998 173 RTA00000200AR.b.07.1 M00004039C:C01 17125 4965 Mar. 24, 1998 464 RTA00000522F.p.18.1 M00001671A:H06 76376 4966 Mar. 24, 1998 453 RTA00000522F.p.22.1 M00001671B:F02 73322 4967 Feb. 24, 1998 54 RTA00000399F.o.01.1 M00001595C:E01 3055 4968 Feb. 24, 1998 1219 RTA00000347F.e.20.1 M00003771B:E05 39911 4969 Feb. 24, 1998 825 RTA00000404F.k.22.2 M00001635D:C12 39084 4969 Feb. 24, 1998 364 RTA00000404F.k.22.1 M00001635D:C12 39084 4970 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 4970 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 4970 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 4971 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 4971 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 4971 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 4972 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 4972 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 4972 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 4973 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 4973 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 4973 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 4974 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 4974 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 4974 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 4975 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 4975 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 4975 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 4976 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 4976 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 4976 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 4977 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 4977 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 4977 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 4978 Jan. 28, 1998 241 RTA00000200AF.l.17.1 M00004217C:D03 12771 4978 Jan. 28, 1998 151 RTA00000200R.l.17.1 M00004217C:D03 12771 4978 Jan. 28, 1998 202 RTA00000200R.l.17.2 M00004217C:D03 12771 4979 Jan. 28, 1998 366 RTA00000192AF.o.19.1 M00004208D:H08 3549 4980 Jan. 28, 1998 328 RTA00000200AF.g.09.1 M00004131B:H09 22785 4980 Jan. 28, 1998 26 RTA00000200R.g.09.1 M00004131B:H09 22785 4981 Jan. 28, 1998 245 RTA00000200AF.k.7.1 M00004193C:G11 0 4982 Feb. 24, 1998 1036 RTA00000339F.k.08.1 M00001439B:A10 8133 4983 Feb. 24, 1998 72 RTA00000347F.a.08.1 M00001592C:G04 3135 4984 Feb. 24, 1998 1163 RTA00000341F.b.14.1 M00003763A:C01 5992 4985 Feb. 24, 1998 278 RTA00000404F.c.10.1 M00001593B:E11 23534 4986 Jan. 28, 1998 250 RTA00000192AF.j.21.1 M00004176D:B12 2289 4987 Feb. 24, 1998 511 RTA00000341F.b.13.1 M00003762B:H09 0 4988 Jan. 28, 1998 27 RTA00000192AF.i.12.1 M00004619C:C12 5319 4989 Feb. 24, 1998 416 RTA00000404F.c.19.1 M00001594A:D06 39026 4990 Feb. 24, 1998 351 RTA00000340F.p.20.1 M00003752B:C02 17008 4991 Jan. 28, 1998 215 RTA00000192AR.e.14.3 M00004142A:D08 3300 4992 Jan. 28, 1998 163 RTA00000192AR.e.13.3 M00004142A:B12 9457 4993 Jan. 28, 1998 318 RTA00000200AF.g.17.1 M00004138A:H09 0 4994 Feb. 24, 1998 1105 RTA00000340F.p.18.1 M00003751C:A04 287 4995 Feb. 24, 1998 1080 RTA00000351R.g.06.1 M00003771D:G05 0 4996 Feb. 24, 1998 478 RTA00000418F.h.08.1 M00001589B:E07 76401 4997 Feb. 24, 1998 584 RTA00000418F.d.22.1 M00001573B:C06 75324 4998 Feb. 24, 1998 493 RTA00000129A.d.1.2 M00001587A:F05 80058 4999 Feb. 24, 1998 402 RTA00000420F.e.16.1 M00004110A:E04 63639 5000 Feb. 24, 1998 1006 RTA00000129A.e.14.1 M00001587A:F08 80053 5001 Feb. 24, 1998 285 RTA00000413F.i.02.1 M00004110D:A10 65857 5002 Jan. 28, 1998 659 RTA00000185AR.k.23.2 M00001601A:E09 0 5003 Feb. 24, 1998 122 RTA00000420F.f.06.1 M00004115D:D08 64812 5004 Feb. 24, 1998 245 RTA00000195AF.d.20.1 M00004117A:D11 37574 5004 Jan. 28, 1998 87 RTA00000195AF.d.20.1 M00004117A:D11 37574 5005 Jan. 28, 1998 87 RTA00000195AF.d.20.1 M00004117A:D11 37574 5005 Feb. 24, 1998 245 RTA00000195AF.d.20.1 M00004117A:D11 37574 5006 Feb. 24, 1998 720 RTA00000129A.d.2.4 M00001587A:G06 80119 5007 Feb. 24, 1998 687 RTA00000350R.g.10.1 M00001587C:C10 9026 5008 Mar. 24, 1998 18 RTA00000522F.e.16.1 M00001590A:C08 75283 5009 Jan. 28, 1998 447 RTA00000198AF.d.8.1 M00001587A:H03 0 5010 Jan. 28, 1998 554 RTA00000186AR.e.07.4 M00001623D:G03 4175 5010 Jan. 28, 1998 400 RTA00000186AR.e.07.3 M00001623D:G03 4175 5011 Jan. 28, 1998 526 RTA00000185AF.e.20.1 M00001585A:D06 5865 5012 Feb. 24, 1998 1 RTA00000404F.a.02.1 M00001589B:E12 9738 5013 Jan. 28, 1998 530 RTA00000185AF.d.24.2 M00001582D:F05 0 5014 Feb. 24, 1998 1096 RTA00000421F.a.06.1 M00001589C:A11 2385 5015 Jan. 28, 1998 131 RTA00000185AF.d.11.2 M00001579D:C03 6539 5015 Jan. 28, 1998 626 RTA00000185AR.d.11.1 M00001579D:C03 6539 5016 Jan. 28, 1998 626 RTA00000185AR.d.11.1 M00001579D:C03 6539 5016 Jan. 28, 1998 131 RTA00000185AF.d.11.2 M00001579D:C03 6539 5017 Feb. 24, 1998 1020 RTA00000412F.p.06.1 M00004038B:H10 65485 5018 Jan. 28, 1998 671 RTA00000185AR.d.08.1 M00001579C:E09 6562 5019 Feb. 24, 1998 1240 RTA00000404F.a.18.1 M00001590B:B02 36267 5020 Feb. 24, 1998 115 RTA00000418F.h.19.1 M00001590B:C05 0 5021 Feb. 24, 1998 211 RTA00000404F.a.19.1 M00001590B:C07 38624 5022 Jan. 28, 1998 455 RTA00000198AF.d.12.1 M00001589A:C01 21142 5023 Jan. 28, 1998 622 RTA00000186AR.m.14.2 M00001649B:G12 9800 5024 Feb. 24, 1998 958 RTA00000195AF.c.8.1 M00001678B:H01 0 5024 Jan. 28, 1998 520 RTA00000195AF.c.8.1 M00001678B:H01 0 5025 Jan. 28, 1998 520 RTA00000195AF.c.8.1 M00001678B:H01 0 5025 Feb. 24, 1998 958 RTA00000195AF.c.8.1 M00001678B:H01 0 5026 Jan. 28, 1998 690 RTA00000198R.l.21.1 M00001673A:A04 19194 5027 Feb. 24, 1998 772 RTA00000413F.e.04.1 M00004090C:C07 64176 5028 Feb. 24, 1998 834 RTA00000407F.b.11.1 M00004090C:C10 0 5029 Feb. 24, 1998 1154 RTA00000403F.m.09.2 M00001575B:G01 26814 5030 Feb. 24, 1998 1203 RTA00000413F.e.10.1 M00004092C:B03 31033 5031 Feb. 24, 1998 12 RTA00000339F.b.17.1 M00001366D:E12 10020 5032 Feb. 24, 1998 947 RTA00000347F.g.08.1 M00004096B:F05 23121 5033 Jan. 28, 1998 39 RTA00000189AR.b.19.1 M00003832B:E01 5294 5033 Feb. 24, 1998 239 RTA00000346F.j.02.1 M00003832B:E01 5294 5034 Jan. 28, 1998 39 RTA00000189AR.b.19.1 M00003832B:E01 5294 5034 Feb. 24, 1998 239 RTA00000346F.j.02.1 M00003832B:E01 5294 5035 Feb. 24, 1998 560 RTA00000419F.d.16.1 M00003828B:E07 64357 5036 Feb. 24, 1998 568 RTA00000403F.m.03.1 M00001573D:D10 39179 5037 Feb. 24, 1998 191 RTA00000419F.d.17.1 M00003828B:F09 64353 5038 Feb. 24, 1998 607 RTA00000420F.d.16.1 M00004103D:F10 64485 5039 Feb. 24, 1998 1130 RTA00000354R.p.01.1 M00004104C:H12 0 5040 Feb. 24, 1998 710 RTA00000413F.g.24.1 M00004104D:A04 65481 5041 Feb. 24, 1998 24 RTA00000423F.l.09.1 M00004118A:H08 9752 5042 Feb. 24, 1998 896 RTA00000423F.l.20.1 M00004105C:E09 12580 5043 Feb. 24, 1998 1078 RTA00000423F.f.03.1 M00003829C:D10 63852 5044 Jan. 28, 1998 558 RTA00000186AR.h.14.1 M00001632D:H07 0 5045 Feb. 24, 1998 155 RTA00000413F.h.13.1 M00004107A:D01 65190 5046 Feb. 24, 1998 926 RTA00000399F.k.20.1 M00001585C:D10 3003 5047 Feb. 24, 1998 1194 RTA00000420F.e.05.1 M00004107D:E12 63908 5048 Jan. 28, 1998 400 RTA00000186AR.e.07.3 M00001623D:G03 4175 5048 Jan. 28, 1998 554 RTA00000186AR.e.07.4 M00001623D:G03 4175 5049 Feb. 24, 1998 570 RTA00000405F.n.13.1 M00003824A:G10 23810 5050 Feb. 24, 1998 334 RTA00000408F.p.05.1 M00001575B:B02 9649 5051 Feb. 24, 1998 1029 RTA00000411F.f.04.1 M00003813A:G04 64526 5052 Mar. 24, 1998 134 RTA00000424F.c.14.3 M00001476D:A09 76614 5053 Feb. 24, 1998 396 RTA00000406F.e.21.1 M00003877D:G05 9090 5054 Mar. 24, 1998 230 RTA00000424F.g.14.1 M00001572A:B06 74879 5055 Feb. 24, 1998 617 RTA00000423F.f.23.1 M00003816C:E09 15390 5056 Feb. 24, 1998 5 RTA00000408F.o.12.2 M00001572A:A10 78578 5057 Feb. 24, 1998 689 RTA00000419F.p.03.1 M00004035A:G10 1937 5058 Mar. 24, 1998 273 RTA00000424F.a.02.4 M00001575A:D06 78806 5059 Feb. 24, 1998 241 RTA00000339F.d.13.1 M00001395C:F11 0 5060 Mar. 24, 1998 237 RTA00000522F.c.01.1 M00001576A:C11 74938 5061 Jan. 28, 1998 745 RTA00000183AF.m.11.1 M00001536D:G02 8927 5062 Jan. 28, 1998 408 RTA00000183AR.l.15.1 M00001535C:E01 39383 5063 Feb. 24, 1998 464 RTA00000195AF.c.12.1 M00003818B:G12 37582 5063 Jan. 28, 1998 300 RTA00000195AF.c.12.1 M00003818B:G12 37582 5064 Jan. 28, 1998 647 RTA00000197F.m.11.1 M00001530B:D10 16488 5065 Feb. 24, 1998 464 RTA00000195AF.c.12.1 M00003818B:G12 37582 5065 Jan. 28, 1998 300 RTA00000195AF.c.12.1 M00003818B:G12 37582 5066 Mar. 24, 1998 395 RTA00000522F.d.06.1 M00001578B:A02 74809 5067 Feb. 24, 1998 516 RTA00000339F.f.20.1 M00001399A:C03 6494 5068 Feb. 24, 1998 890 RTA00000418F.j.19.1 M00001634D:D02 78399 5069 Feb. 24, 1998 435 RTA00000340F.b.02.1 M00001503C:G05 10185 5070 Mar. 24, 1998 175 RTA00000528F.d.18.1 M00001582C:E01 2684 5071 Feb. 24, 1998 168 RTA00000411F.e.22.1 M00003812B:D07 63638 5072 Feb. 24, 1998 1071 RTA00000404F.k.18.2 M00001635A:C06 5475 5073 Feb. 24, 1998 189 RTA00000347F.a.13.1 M00001402D:F02 22446 5074 Feb. 24, 1998 825 RTA00000404F.k.22.2 M00001635D:C12 39084 5074 Feb. 24, 1998 364 RTA00000404F.k.22.1 M00001635D:C12 39084 5075 Mar. 24, 1998 25 RTA00000425F.c.06.1 M00001585D:D11 78041 5076 Mar. 24, 1998 186 RTA00000425F.c.07.1 M00001585D:F03 76042 5077 Mar. 24, 1998 208 RTA00000424F.m.10.1 M00001586C:E06 34251 5078 Feb. 24, 1998 420 RTA00000422F.b.16.1 M00003813B:A11 17045 5079 Mar. 24, 1998 103 RTA00000424F.b.22.1 M00001530A:F11 72971 5079 Mar. 24, 1998 88 RTA00000424F.b.22.4 M00001530A:F11 72971 5080 Mar. 24, 1998 318 RTA00000523F.a.01.1 M00001671C:F11 74923 5081 Feb. 24, 1998 676 RTA00000411F.g.21.1 M00003823D:G05 64500 5082 Mar. 24, 1998 3 RTA00000528F.b.23.1 M00001479C:F10 1605 5083 Feb. 24, 1998 1244 RTA00000418F.h.23.1 M00001591A:B08 75153 5084 Feb. 24, 1998 321 RTA00000339F.c.21.1 M00001389C:A08 5325 5085 Jan. 28, 1998 429 RTA00000196F.i.19.1 M00001390C:C11 39498 5085 Feb. 24, 1998 925 RTA00000353R.h.10.1 M00001390C:C11 39498 5086 Jan. 28, 1998 429 RTA00000196F.i.19.1 M00001390C:C11 39498 5086 Feb. 24, 1998 925 RTA00000353R.h.10.1 M00001390C:C11 39498 5087 Mar. 24, 1998 471 RTA00000528F.c.11.1 M00001486D:D12 1701 5088 Feb. 24, 1998 103 RTA00000418F.j.12.1 M00001626C:G08 73316 5089 Feb. 24, 1998 1148 RTA00000345F.d.23.1 M00001390D:E03 5862 5090 Feb. 24, 1998 87 RTA00000403F.l.20.1 M00001573A:A06 18267 5091 Mar. 24, 1998 427 RTA00000522F.b.08.1 M00001570D:E06 26915 5092 Jan. 28, 1998 661 RTA00000198R.b.04.1 M00001565A:H09 0 5093 Feb. 24, 1998 200 RTA00000339F.c.02.1 M00001381C:B08 12975 5094 Feb. 24, 1998 1243 RTA00000404F.j.19.1 M00001630D:H10 0 5095 Jan. 28, 1998 750 RTA00000198AF.a.19.1 M00001561D:C05 0 5096 Feb. 24, 1998 418 RTA00000410F.a.01.1 M00001631D:B10 73354 5097 Mar. 24, 1998 458 RTA00000424F.d.12.3 M00001530D:E06 74342 5097 Mar. 24, 1998 454 RTA00000424F.d.12.2 M00001530D:E06 74342 5098 Mar. 24, 1998 458 RTA00000424F.d.12.3 M00001530D:E06 74342 5098 Mar. 24, 1998 454 RTA00000424F.d.12.2 M00001530D:E06 74342 5099 Feb. 24, 1998 159 RTA00000348R.j.17.1 M00001391D:C06 2641 5100 Feb. 24, 1998 539 RTA00000346F.m.15.1 M00004037B:C04 13553 5101 Feb. 24, 1998 170 RTA00000422F.n.08.1 M00001632B:E05 38655 5102 Mar. 24, 1998 162 RTA00000522F.a.12.1 M00001567A:H05 33515 5103 Feb. 24, 1998 315 RTA00000419F.p.12.1 M00004037A:E04 13767 5104 Feb. 24, 1998 119 RTA00000423F.k.05.1 M00004036D:F02 37472 5105 Mar. 24, 1998 12 RTA00000522F.a.23.1 M00001570C:A05 38613 5106 Mar. 24, 1998 103 RTA00000424F.b.22.1 M00001530A:F11 72971 5106 Mar. 24, 1998 88 RTA00000424F.b.22.4 M00001530A:F11 72971 5107 Feb. 24, 1998 21 RTA00000411F.g.08.1 M00003822D:D04 45815 5108 Jan. 28, 1998 35 RTA00000191AF.n.17.1 M00004091B:D11 7848 5109 Mar. 24, 1998 39 RTA00000527F.c.23.1 M00003822C:A07 37742 5110 Jan. 28, 1998 43 RTA00000179AF.c.14.3 M00001392D:H04 0 5111 Feb. 24, 1998 54 RTA00000399F.o.01.1 M00001595C:E01 3055 5112 Feb. 24, 1998 63 RTA00000404F.l.20.2 M00001639B:H05 38638 5113 Jan. 28, 1998 82 RTA00000183AF.l.18.1 M00001535D:C01 3484 5114 Mar. 24, 1998 84 RTA00000527F.k.18.1 M00003982B:C10 11332 5115 Jan. 28, 1998 99 RTA00000184AF.d.8.1 M00001548A:A08 4393 5116 Feb. 24, 1998 99 RTA00000420F.m.19.1 M00005254D:B08 0 5117 Feb. 24, 1998 100 RTA00000339F.o.23.1 M00001473C:D09 7801 5118 Feb. 24, 1998 104 RTA00000421F.n.03.1 M00001675C:A04 1638 5119 Feb. 24, 1998 105 RTA00000346F.d.08.1 M00001671A:A10 39955 5120 Feb. 24, 1998 114 RTA00000341F.m.21.1 M00004051D:E01 0 5121 Jan. 28, 1998 137 RTA00000181AF.m.4.3 M00001455A:E09 13238 5122 Jan. 28, 1998 162 RTA00000201F.e.15.1 M00004444B:D11 9960 5123 Jan. 28, 1998 170 RTA00000197AF.d.23.1 M00001453A:E11 16130 5124 Jan. 28, 1998 206 RTA00000181AF.o.04.2 M00001457C:C12 22205 5125 Jan. 28, 1998 209 RTA00000182AF.c.5.1 M00001464D:F06 6397 5126 Feb. 24, 1998 215 RTA00000403F.j.18.1 M00001539D:E10 5790 5127 Feb. 24, 1998 219 RTA00000419F.c.18.1 M00003819D:B11 41394 5128 Jan. 28, 1998 229 RTA00000198AF.g.3.1 M00001615C:F03 0 5129 Jan. 28, 1998 230 RTA00000185AR.b.18.1 M00001575B:C09 12171 5130 Mar. 24, 1998 245 RTA00000522F.p.09.1 M00001670A:F09 75204 5131 Feb. 24, 1998 258 RTA00000406F.k.15.1 M00003907C:C04 38549 5132 Jan. 28, 1998 262 RTA00000186AF.c.17.1 M00001619D:G05 8551 5133 Jan. 28, 1998 269 RTA00000183AF.k.13.1 M00001534B:C12 0 5134 Jan. 28, 1998 276 RTA00000198AF.j.15.1 M00001653B:E09 4369 5135 Feb. 24, 1998 281 RTA00000411F.l.13.1 M00003857C:C09 43114 5136 Jan. 28, 1998 284 RTA00000199F.d.10.2 M00003808C:B05 22049 5137 Jan. 28, 1998 292 RTA00000199AF.m.18.1 M00003939C:F04 0 5138 Jan. 28, 1998 297 RTA00000178AF.f.9.3 M00001371C:E09 7172 5139 Feb. 24, 1998 301 RTA00000401F.m.23.1 M00003914C:C02 2801 5140 Jan. 28, 1998 302 RTA00000186AF.d.1.2 M00001621C:C05 40044 5141 Jan. 28, 1998 315 RTA00000199R.d.23.1 M00003815D:H09 37477 5142 Feb. 24, 1998 315 RTA00000419F.p.12.1 M00004037A:E04 13767 5143 Jan. 28, 1998 321 RTA00000181AR.b.21.1 M00001444C:D05 3266 5144 Mar. 24, 1998 323 RTA00000524F.c.12.1 M00005218B:D09 0 5145 Jan. 28, 1998 329 RTA00000186AF.b.9.1 M00001616C:F07 0 5146 Jan. 28, 1998 334 RTA00000181AR.b.21.3 M00001444C:D05 3266 5147 Feb. 24, 1998 334 RTA00000408F.p.05.1 M00001575B:B02 9649 5148 Jan. 28, 1998 335 RTA00000182AF.e.3.2 M00001468B:H06 0 5149 Jan. 28, 1998 336 RTA00000186AF.f.24.1 M00001629B:E06 0 5150 Feb. 24, 1998 341 RTA00000412F.g.20.2 M00003972C:F08 25018 5151 Feb. 24, 1998 343 RTA00000422F.g.21.1 M00001583A:F07 17232 5152 Jan. 28, 1998 347 RTA00000199F.b.03.2 M00003779B:E12 38340 5153 Feb. 24, 1998 354 RTA00000404F.c.03.2 M00001592C:F11 39198 5154 Jan. 28, 1998 361 RTA00000177AR.g.16.4 M00001347A:B10 13576 5155 Jan. 28, 1998 364 RTA00000187AF.g.13.1 M00001676C:C11 2991 5156 Feb. 24, 1998 377 RTA00000346F.i.01.1 M00003797A:D06 22260 5157 Feb. 24, 1998 389 RTA00000411F.c.02.1 M00001677B:B04 72852 5158 Feb. 24, 1998 403 RTA00000403F.d.22.1 M00001473A:A07 10692 5159 Jan. 28, 1998 407 RTA00000178AF.e.20.1 M00001370D:E12 3135 5160 Jan. 28, 1998 422 RTA00000189AF.b.12.1 M00003829B:G03 17233 5161 Feb. 24, 1998 429 RTA00000422F.c.17.1 M00004099D:F01 1360 5162 Feb. 24, 1998 431 RTA00000399F.j.15.1 M00001578C:G06 1261 5163 Jan. 28, 1998 439 RTA00000185AF.d.14.2 M00001579D:G07 8071 5164 Feb. 24, 1998 448 RTA00000127A.a.3.1 M00001552A:H10 13232 5165 Feb. 24, 1998 450 RTA00000118A.a.23.1 M00001395A:H02 3500 5166 Jan. 28, 1998 451 RTA00000200AF.b.20.1 M00004043A:D02 40403 5167 Feb. 24, 1998 455 RTA00000399F.d.23.1 M00001481B:A07 3310 5168 Jan. 28, 1998 475 RTA00000187AR.m.3.3 M00001682C:B12 17055 5169 Mar. 24, 1998 475 RTA00000427F.i.06.1 M00004097B:D03 41450 5170 Mar. 24, 1998 477 RTA00000527F.l.21.1 M00003983D:H02 36439 5171 Jan. 28, 1998 480 RTA00000181AF.o.08.2 M00001457C:H12 849 5172 Mar. 24, 1998 480 RTA00000424F.d.17.3 M00001455A:E11 73958 5173 Mar. 24, 1998 481 RTA00000523F.j.02.1 M00003857A:H10 62853 5174 Jan. 28, 1998 483 RTA00000192AF.h.19.1 M00004162C:A07 4642 5175 Feb. 24, 1998 489 RTA00000406F.j.19.1 M00003906A:F12 1685 5176 Jan. 28, 1998 501 RTA00000200R.k.11.1 M00004197C:F03 9796 5177 Feb. 24, 1998 502 RTA00000341F.d.08.1 M00003824C:D07 0 5178 Feb. 24, 1998 508 RTA00000420F.i.20.1 M00005101C:E12 0 5179 Jan. 28, 1998 510 RTA00000178AF.n.23.1 M00001387B:E02 3298 5180 Jan. 28, 1998 511 RTA00000196AF.g.10.1 M00001376B:A02 12498 5181 Feb. 24, 1998 519 RTA00000404F.l.10.1 M00001638B:F10 23136 5182 Feb. 24, 1998 524 RTA00000419F.f.23.1 M00003840D:H10 65002 5183 Jan. 28, 1998 525 RTA00000198AF.c.7.1 M00001575D:G05 19181 5184 Jan. 28, 1998 526 RTA00000185AF.e.20.1 M00001585A:D06 5865 5185 Jan. 28, 1998 527 RTA00000198R.m.23.1 M00001684B:G03 38469 5186 Jan. 28, 1998 529 RTA00000178AF.b.13.1 M00001364A:E11 3114 5187 Jan. 28, 1998 530 RTA00000185AF.d.24.2 M00001582D:F05 0 5188 Jan. 28, 1998 540 RTA00000179AF.b.10.3 M00001391D:D10 0 5189 Jan. 28, 1998 541 RTA00000197AR.b.16.1 M00001445C:A08 0 5190 Jan. 28, 1998 545 RTA00000196F.a.2.1 M00001338B:E02 3575 5191 Feb. 24, 1998 547 RTA00000419F.h.02.1 M00003845D:G08 63985 5192 Jan. 28, 1998 548 RTA00000179AF.f.23.3 M00001397B:G03 35258 5193 Jan. 28, 1998 550 RTA00000183AF.g.14.1 M00001513D:A03 0 5194 Feb. 24, 1998 555 RTA00000133A.d.22.1 M00001469A:G11 11797 5195 Jan. 28, 1998 569 RTA00000196AF.l.23.1 M00001412A:E04 12052 5196 Jan. 28, 1998 570 RTA00000183AF.a.19.2 M00001499A:A05 3788 5197 Jan. 28, 1998 574 RTA00000192AF.f.3.1 M00004146C:C11 5257 5198 Jan. 28, 1998 575 RTA00000186AF.l.12.2 M00001645A:C12 19267 5199 Jan. 28, 1998 576 RTA00000196AF.c.7.1 M00001350B:G11 0 5200 Feb. 24, 1998 579 RTA00000413F.m.16.1 M00004898C:F03 0 5201 Jan. 28, 1998 580 RTA00000197F.a.12.1 M00001438B:B09 7895 5202 Feb. 24, 1998 580 RTA00000403F.o.07.1 M00001579C:A01 39037 5203 Feb. 24, 1998 584 RTA00000418F.d.22.1 M00001573B:C06 75324 5204 Jan. 28, 1998 585 RTA00000198AF.n.18.1 M00001771A:A07 16715 5205 Jan. 28, 1998 601 RTA00000184AF.i.10.2 M00001555A:B01 3744 5206 Jan. 28, 1998 607 RTA00000200AF.k.12.1 M00004198B:D02 7359 5207 Jan. 28, 1998 613 RTA00000177AF.k.18.4 M00001352C:A05 53729 5208 Jan. 28, 1998 640 RTA00000190AF.f.5.1 M00003909A:H04 5015 5209 Feb. 24, 1998 645 RTA00000422F.p.12.2 M00001661C:F10 9840 5210 Jan. 28, 1998 654 RTA00000186AF.j.21.2 M00001639D:B07 22506 5211 Jan. 28, 1998 680 RTA00000177AF.f.10.1 M00001345A:E01 6420 5212 Jan. 28, 1998 699 RTA00000175AF.a.12.1 M00001362B:H06 0 5213 Jan. 28, 1998 703 RTA00000198F.l.09.1 M00001664B:D06 3611 5214 Jan. 28, 1998 704 RTA00000190AF.o.12.1 M00003972D:C09 3438 5215 Jan. 28, 1998 723 RTA00000183AF.p.24.1 M00001543C:F01 3116 5216 Feb. 24, 1998 733 RTA00000405F.d.18.1 M00001662C:B02 10494 5217 Jan. 28, 1998 739 RTA00000181AF.p.12.3 M00001460C:H02 22204 5218 Jan. 28, 1998 742 RTA00000177AF.m.1.1 M00001353D:D10 14929 5219 Feb. 24, 1998 774 RTA00000403F.e.24.1 M00001476B:D10 16432 5220 Feb. 24, 1998 775 RTA00000405F.c.22.1 M00001660C:B06 39053 5221 Feb. 24, 1998 790 RTA00000345F.n.08.1 M00001517A:B11 0 5222 Feb. 24, 1998 816 RTA00000354R.n.04.1 M00003808C:B05 22049 5223 Feb. 24, 1998 829 RTA00000411F.m.11.1 M00003867A:D12 73196 5224 Feb. 24, 1998 851 RTA00000423F.d.07.1 M00001678B:B12 0 5225 Feb. 24, 1998 871 RTA00000403F.f.23.1 M00001479C:E01 39223 5226 Feb. 24, 1998 877 RTA00000418F.m.22.1 M00001654D:E12 74567 5227 Feb. 24, 1998 914 RTA00000138A.m.15.1 M00001624A:A03 41603 5228 Feb. 24, 1998 923 RTA00000126A.d.19.1 M00001548A:G01 79474 5229 Feb. 24, 1998 924 RTA00000354R.m.02.1 M00003890B:C08 12766 5230 Feb. 24, 1998 940 RTA00000414F.f.17.1 M00005260A:F04 0 5231 Feb. 24, 1998 1005 RTA00000339F.e.17.1 M00001397D:G08 7568 5232 Feb. 24, 1998 1013 RTA00000404F.b.18.1 M00001592A:H05 13669 5233 Feb. 24, 1998 1037 RTA00000339F.l.12.1 M00001450A:G11 7711 5234 Feb. 24, 1998 1055 RTA00000346F.a.04.1 M00001607B:C05 5382 5235 Feb. 24, 1998 1070 RTA00000346F.n.22.1 M00004137A:D06 0 5236 Feb. 24, 1998 1096 RTA00000421F.a.06.1 M00001589C:A11 2385 5237 Feb. 24, 1998 1125 RTA00000118A.n.5.1 M00001451A:C10 0 5238 Feb. 24, 1998 1128 RTA00000423F.a.02.3 M00001656B:A08 39210 5239 Feb. 24, 1998 1129 RTA00000401F.m.07.1 M00003907D:F11 2893 5240 Feb. 24, 1998 1136 RTA00000406F.c.05.1 M00003870A:H01 22077 5241 Feb. 24, 1998 1142 RTA00000418F.i.06.1 M00001591B:B06 75151 5242 Feb. 24, 1998 1145 RTA00000423F.k.21.2 M00003984D:B08 37499 5243 Feb. 24, 1998 1149 RTA00000339F.b.02.1 M00001344B:F12 0 5244 Feb. 24, 1998 1166 RTA00000347F.h.01.1 M00004040A:G12 12043 5245 Feb. 24, 1998 1177 RTA00000126A.b.9.1 M00001547A:F11 81279 5246 Feb. 24, 1998 1187 RTA00000120A.c.19.1 M00001464A:B03 81016 5247 Feb. 24, 1998 1203 RTA00000413F.e.10.1 M00004092C:B03 31033 5248 Feb. 24, 1998 1205 RTA00000419F.k.05.1 M00003871C:E04 11757 5249 Feb. 24, 1998 1230 RTA00000399F.j.14.1 M00001578C:F05 16942 5250 Feb. 24, 1998 1233 RTA00000418F.l.02.1 M00001641C:C05 39316 5251 Feb. 24, 1998 1248 RTA00000419F.o.07.1 M00003986C:E09 14059 5252 Feb. 24, 1998 1261 RTA00000404F.m.17.2 M00001643B:E05 0

TABLE 2 Nearest Neighbor Nearest Neighbor SEQ (BlastN vs. Genbank (BlastX vs. Non-Redundant Proteins) ID ACCESSION DESCRIPTION P VALUE ACCESSION DESCRIPTION P VALUE 2503 AB011149 Homo sapiens 0 3043678 (AB011149) 1e-096 mRNA for KIAA0577 protein KIAA0577 [Homo sapiens] protein, complete cds 2504 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 2505 Z59973 H. sapiens CpG 1e-009 <NONE> <NONE> <NONE> DNA, clone 184b10, forward read cpg184b10.ft1a. 2506 AJ000742 Homo Sapiens 2e-016 <NONE> <NONE> <NONE> hisH1 gene, 5′ UTR 2507 U10324 Human nuclear 3e-009 1729881 TETRACYCLINE 9.3 factor NF90 RESISTANCE mRNA, complete PROTEIN, cds. CLASS H (TETA(H)) >gi|392873 (U00792) tetracycline resistance protein [Pasteurella multocida] 2508 U95094 Xenopus laevis 3e-010 1890128 (U89949) folate 7.3 XL-INCENP binding protein (XL-INCENP) [Sus scrofa] mRNA, complete cds 2509 M15657 Human aldolase 0.002 <NONE> <NONE> <NONE> B (ALDOB) gene, exons 2 through 6. 2510 U95094 Xenopus laevis 8e-008 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2511 U39722 Mycoplasma 0.043 2773162 (AF039595) 10 genitalium sulfonylurea section 44 of 51 receptor 1B of the complete [Rattus genome norvegicus] 2512 AB012174 Homo sapiens 7e-017 <NONE> <NONE> <NONE> DNA, anonymous heat-stable fragment RP7-1B 2513 AB012174 Homo sapiens 7e-017 <NONE> <NONE> <NONE> DNA, anonymous heat-stable fragment RP7-1B 2514 U95094 Xenopus laevis 7e-007 2984585 (AC004472) 1e-013 XL-INCENP P1.11659_4 (XL-INCENP) [Homo sapiens] mRNA, complete cds 2515 AF061016 Homo sapiens 0 3127127 (AF061016) UDP- 7e-035 UDP-glucose glucose dehydrogenase dehydrogenase (UGDH) mRNA, [Homo sapiens] complete cds dehydrogenase [Homo sapiens] 2516 U95102 Xenopus laevis 6e-005 2983872 (AE000742) 1.5 mitotic putative protein phosphoprotein [Aquifex aeolicus] 90 mRNA, complete cds 2517 X13293 Human mRNA 3e-019  127584 MYB-RELATED 0.0002 for B-myb gene PROTEIN B(B- MYB) human >gi|29472 (X13293) B-myb protein (AA 1- 700) [Homo sapiens] 2518 Y10183 H. sapiens mRNA 0 3882036 (AJ010405) 2.5 for MEMD hypothetical protein protein 2519 M90297 Human 4e-023 2851668 HYPOTHETICAL 7.8 glucokinase OUTER (GCK) gene, MEMBRANE exon 1 and 5′ USHER flanking region. PROTEIN IN RIBB-GLGS INTERGENIC REGION PRECURSOR 2520 V00436 Gallus gallus 4.4 <NONE> <NONE> <NONE> fragment of gene X of ovalbumin family coding for the first leader exon. 2521 U95094 Xenopus laevis 6e-006 3800811 (AF072251) 6.9 XL-INCENP methyl-CpG (XL-INCENP) binding protein 2 mRNA, complete [Mus musculus] cds 2522 Y09540 H. sapiens AHSG 2e-007 2135357 HLA class I alpha 3.1 gene, partial chain - human (fragment) sapiens] 2523 U95098 Xenopus laevis 3e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 2524 D87438 Human mRNA 1e-011 <NONE> <NONE> <NONE> for KIAA0251 gene, partial cds 2525 AE001203 Treponema 0.42 <NONE> <NONE> <NONE> pallidum section 19 of 87 of the complete genome 2526 U47322 Cloning vector 2e-036  987050 (X65335) lacZ 4e-008 DNA, complete gene product sequence. [unidentified cloning vector] 2527 M97287 Human 0  417747 DNA-BINDING 2e-009 MAR/SAR DNA PROTEIN SATB1 binding protein (SPECIAL AT- (SATB1) mRNA, RICH complete cds. > :: SEQUENCE gb|I58691|I58691 BINDING Sequence 1 from PROTEIN 1) U.S. Pat. No. protein SATB1 - 5,652,340 human >gi|337811 (M97287) putative [Homo sapiens] 2528 AF005355 Oryctolagus 1e-094 3253159 (AF005355) 2e-084 cuniculus translation translation initiation factor initiation factor eIF2C eIF2C mRNA, complete cds 2529 L16978 Anadara trapezia 0.11 <NONE> <NONE> <NONE> beta globin gene, complete cds. 2530 M24191 Human beta 0.013 3878519 (Z92806) 0.6 globulin K10G4.7 pseudogene, [Caenorhabditis clone 46B elegans] 2531 AF047611 Euroglyphus 0.12 <NONE> <NONE> <NONE> maynei group 1 allergen Eur m 1 0102 2532 AE001372 Plasmodium 0.002 <NONE> <NONE> <NONE> falciparum chromosome 2, section 9 of 73 of the complete sequence 2533 J04700 Homo sapiens 0.014 <NONE> <NONE> <NONE> calcium- dependent protease large subunit (CANPmL) gene, promoter region and exon 1. 2534 AF038958 Homo sapiens 4e-086 2144098 SC2 - rat 1e-033 synaptic >gi|256994|bbs|11 glycoprotein SC2 5268 (S45663) spliced variant SC2 = synaptic mRNA, complete glycoprotein [rats, cds brain, Peptide, 308 aa] 2535 L13434 Human 8e-008 1085432 mucin (clone 4.3 chromosome PGM-2A) - pig 3p21.1 gene sequence, complete cds. 2536 U95094 Xenopus laevis 1e-011 3873713 (Z74026) cDNA 4e-010 XL-INCENP EST yk452h4.3 (XL-INCENP) comes from this mRNA, complete gene; cDNA EST cds yk452h4.5 comes from this gene 2537 U95102 Xenopus laevis 1e-011 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2538 U95102 Xenopus laevis 2e-006  386644 type la hair keratin 1.9 mitotic a3 [human, phosphoprotein Peptide, 404 aa] 90 mRNA, >gi|3724101|gnl|PI complete cds D|e1330425 (Y16788) keratin, type I [Homo sapiens] 2539 U95094 Xenopus laevis 0.0005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2540 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 2541 U79248 Human clone 6e-005 <NONE> <NONE> <NONE> 23826 mRNA sequence 2542 D44598 Saccharomyces 1e-010 2828280 (AL021687) 6e-060 cerevisiae putative protein chromosome VI [Arabidopsis phage 4121 thaliana] >gi|2832633|gnl|PI D|e1249651 (AL021711) putative protein [Arabidopsis thaliana] 2543 X64037 H. sapiens mRNA 0  35871 (X64002) RAP74 4e-049 for RNA [Homo sapiens] polymerase II >gi|228483|prf||18 associated protein 04353A RAP74 transcription factor RAP74 [Homo sapiens] 2544 M18857 A. californica 0.38 3169096 (AL023706) 3e-029 nuclear hypothetical polyhedrosis protein virus ORFs encoding a delayed early protein and two late protein, complete cds. 2545 U95102 Xenopus laevis 7e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2546 L22403 Homo sapiens 1e-020 <NONE> <NONE> <NONE> DNA sequence, repeat region. 2547 L22403 Homo sapiens 1e-020 <NONE> <NONE> <NONE> DNA sequence, repeat region. 2548 D38417 Mouse mRNA for 3e-028 <NONE> <NONE> <NONE> arylhydrocarbon receptor, complete cds 2549 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2550 X04754 Drosophila yolk 1e-012 2500649 PROBABLE RNA 1e-022 polypeptide gene 3′-TERMINAL YP3 PHOSPHATE CYCLASE (RNA- 3′-PHOSPHATE CYCLASE) (RNA CYCLASE) 2551 U95094 Xenopus laevis 3e-011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2552 U95102 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2553 U49169 Dictyostelium 0.13  586429 VERY 1.1 discoideum V- HYPOTHETICAL ATPase A 13.2 KD subunit (vatA) PROTEIN IN mRNA, complete PTC3-SAS3 cds INTERGENIC REGION >gi|626813|pir∥S4 5788 probable membrane protein YBL053w - yeast (Saccharomyces cerevisiae) >gi|536079 (Z35814) ORF YBL053w 2554 M22462 Chicken protein 1.1 2078531 (U89506) Mlark 5.6 p54 (ets-1) [Mus musculus] mRNA, complete cds. 2555 U73664 Human 0.37 2909381 (Y16569) ORF 3.3 t(11;14)(q13;q32) [Mycobacterium breakpoint tuberculosis] junction sequence 2556 U95102 Xenopus laevis 6e-006 3025166 PUTATIVE 1.4 mitotic NUCLEOSIDE phosphoprotein TRANSPORTER 90 mRNA, YEGT complete cds >gi|1736823|gnl|PI D|d1016692 (D90848) Nucleoside permease NupG (Nucleoside- transport system protein NupG). [Escherichia coli] >gi|1788415 (AE000299) putative nucleoside permease protein [Escherichia coli] 2557 U09210 Human vesicular 0.041 3176395 (AB015041) PIF1 1e-006 acetylcholine [Caenorhabditis transporter elegans] mRNA, complete cds. 2558 U95094 Xenopus laevis 0.002  540271 (U14635) similar 1e-020 XL-INCENP to GABA and (XL-INCENP) glycine receptors mRNA, complete cds 2559 U95102 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2560 U95102 Xenopus laevis 1e-010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2561 U95102 Xenopus laevis 3e-009 1788739 (AE000327) orf, 6.8 mitotic hypothetical phosphoprotein protein 90 mRNA, [Escherichia coli] complete cds 2562 AF073710 Homo sapiens 1e-013  728831 !!!! ALU 0.38 regulator of G- SUBFAMILY J protein signaling WARNING 9 mRNA, ENTRY complete cds 2563 U95102 Xenopus laevis 1e-011 2072296 (U95098) mitotic 5.1 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2564 U95102 Xenopus laevis 6e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2565 U95094 Xenopus laevis 5e-015 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2566 M98502 Mus musculus 2e-017 2370153 (Y13374) putative 7.3 protein encoding prenylated protein twelve zinc finger prenylated protein proteins (pMLZ- [Homo sapiens] 4) mRNA, >gi|3360403 complete cds. (AF052096) putative prenylated protein [Homo sapiens] 2567 U95102 Xenopus laevis 1e-009 2072296 (U95098) mitotic 2.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2568 U95094 Xenopus laevis 3e-008 2580433 (D76414) ppGpp 2.4 XL-INCENP hydrolase (XL-INCENP) [Staphylococcus mRNA, complete aureus] cds 2569 X82206 H. sapiens mRNA 4e-085 2909479 (AL021930) 1.4 for alpha- hypothetical centractin protein Rv0290 2570 Z68758 Human DNA 8e-009 1082778 secretory 7.1 sequence from phospholipase A2 cosmid cN85E10 receptor precursor, on chromosome transmembrane 22q11.2-qter form - human >gi|862375 2571 U95102 Xenopus laevis 0.0005 2583019 (AF022724) ARIX 0.64 mitotic homeodomain phosphoprotein protein [Homo 90 mRNA, sapiens] complete cds 2572 L19637 Arabidopsis 0.12 <NONE> <NONE> <NONE> thaliana adenine phosphoribosyltrans- ferase (apt) gene, complete cds. 2573 U95102 Xenopus laevis 2e-008  388057 (L22982) 6.9 mitotic merozoite surface phosphoprotein protein-1 90 mRNA, [Plasmodium complete cds chabaudi] 2574 U95098 Xenopus laevis 0.0005 3913436 PROBABLE 9.5 mitotic ATP- phosphoprotein DEPENDENT 44 mRNA, partial RNA HELICASE cds A (NUCLEAR DNA HELICASE II) (NDH II) 2575 AJ005698 Homo sapiens 3e-011 3776076 (AJ005698) 0.28 mRNA for poly(A)-specific poly(A)-specific ribonuclease ribonuclease [Homo sapiens] 2576 Z96602 H. sapiens 2e-006 2407641 (AF018956) 1.4 telomeric DNA neuropilin [Homo sequence, clone sapiens] 3QTEL015, read 3QTELOO015.seq 2577 U95102 Xenopus laevis 4e-012 3880672 (AL032633) 0.82 mitotic cDNA EST phosphoprotein EMBL:T00127 90 mRNA, comes from this complete cds gene; cDNA EST EMBL:T01189 comes from this gene [Caenorhabditis elegans] 2578 U95094 Xenopus laevis 4e-012 2088843 (AF00386) 3.5 XL-INCENP F59E12.9 gene (XL-INCENP) product mRNA, complete [Caenorhabditis cds elegans] 2579 U95315 Mycobacterium 3.8 <NONE> <NONE> <NONE> gordonae IS1511 transposase and Tn554 tpna transposase homolog genes, complete cds 2580 U95094 Xenopus laevis 6e-012 2072296 (U95098) mitotic 9.6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2581 U95102 Xenopus laevis 2e-013 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2582 U95094 Xenopus laevis 3e-008 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2583 U85193 Human nuclear 2e-038 <NONE> <NONE> <NONE> factor I-B2 (NFIB2) mRNA, complete cds 2584 U95102 Xenopus laevis 3e-009 2072296 (U95098) mitotic 5.2 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2585 U67532 Methanococcus 0.005 1938410 (U97000) No 4.5 jannaschii section definition line 74 of 150 of the found complete genome [Caenorhabditis elegans] 2586 X65319 Cloning vector 3e-081  987050 (X65335) lacZ 3e-015 pCAT-Enhancer gene product [unidentified cloning vector] 2587 AB006534 Homo sapiens e-103 2065529 (U78095) bikunin 3e-025 mRNA for [Homo sapiens] hepatocyte growth factor activator inhibitor type 2, complete cds 2588 U95094 Xenopus laevis 6e-006 3152559 (AC002986) 6e-008 XL-INCENP Similarity to A. (XL-INCENP) thaliana gene mRNA, complete product cds F21M12.20, gb|AC000132. EST gb|Z25651 comes from this gene. [Arabidopsis thaliana] 2589 X82829 B. taurus mRNA 9e-009 1353239 (U10245) putative 3e-017 for nuclear DNA RNA helicase A helicase II [Arabidopsis thaliana] 2590 AE001366 Plasmodium 0.047 <NONE> <NONE> <NONE> falciparum chromosome 2, section 3 of 73 of the complete sequence 2591 D78572 House mouse; 1e-041 1545807 (D78572) 1e-026 Musculus membrane domesticus glycoprotein [Mus mRNA for musculus] membrane glycoprotein, complete cds > :: dbj|E12950|E129 50 cDNA GA3- 43 encoding novel polypeptide which appear when differentiate from embryo-tumor cell P19 to nerve cell 2592 M77130 H. sapiens (clone 4e-011  629174 cellulose 1,4-beta- 1.5 B7) hY4 Ro RNA cellobiosidase (EC pseudogene. 3.2.1.91) - Clostridium thermocellum >gi|530014 (X80993) cellulose 1,4-beta- cellobiosidase [Clostridium thermocellum] 2593 M34661 Human 1 <NONE> <NONE> <NONE > chaperonin (HSP60) non- functional pseudogene 3. 2594 U95102 Xenopus laevis 6e-006 1723894 HYPOTHETICAL 9e-015 mitotic GTP-BINDING phosphoprotein PROTEIN IN 90 mRNA, SEH1-PRP20 complete cds INTERGENIC REGION >gi|2131584|pir∥S 64106 hypothetical protein YGL099w - yeast (Saccharomyces cerevisiae) >gi|1322637|gnl|PI D|e243302 (Z72621) ORF YGL099w [Saccharomyces cerevisiae] 2595 U95094 Xenopus laevis 9e-010 2072296 (U95098) mitotic 0.16 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2596 U95094 Xenopus laevis 1e-010 2072296 (U95098) mitotic 3.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2597 U57715 Rattus norvegicus 0 1518609 (U57715) FGF 2e-088 FGF receptor receptor activating activating protein protein FRAG1 FRAG1 (FRAG1) [Rattus mRNA, complete norvegicus] cds 2598 Z64776 H. sapiens CpG 0.0002 1777782 (U52513) ISG 2.4 DNA, clone family member 167d8, forward [Homo sapiens] read cpg167d8.ftlb. 2599 U95102 Xenopus laevis 3e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2600 AF022158 Homo sapiens 3e-010 2507553 ZINC FINGER 1e-016 KRAB domain PROTEIN 33A zinc finger (ZINC FINGER protein PROTEIN) KOX31) (KIAA0065) (HA0946) Kruppel-related. [Homo sapiens] 2601 Y07660 M. tuberculosis 2e-068  465847 HYPOTHETICAL 8e-075 accBC gene 66.5 KD PROTEIN F02A9.5 IN CHROMOSOME III >gi|280542|pir∥S2 8313 hypothetical protein F02A9.5 - Caenorhabditis elegans Genefinder; similar to Propionyl-CoA carboxylase beta chain; cDNA EST EMBL:M89018 comes from this gene; cDNA EST EMBL:D2806 2602 S51858 MO25 gene 0  547911 MO25 PROTEIN e-119 [mice, embryos, >gi|2143483|pir∥I5 mRNA, 2322 nt] 7997 hypothetical calcium-binding protein - mouse protein [mice, embryos, Peptide, 341 aa] [Mus sp.] 2603 AB018345 Homo sapiens e-131 3882325 (AB018345) e3-053 mRNA for KIAA0802 protein KIAA0802 [Homo sapiens] protein, partial cds 2604 L41560 Homo sapiens 2e-005 <NONE> <NONE> <NONE> (clones HGPCD2 and HGPCD15) pterin-4a- carbinolamine dehydratase (PCBD) gene, complete cds. 2605 AJ000041 Homo sapiens e-180  987050 (X65335) lacZ 0.001 mRNA for gene product HOXC11 [unidentified cloning vector] 2606 U55939 Expression vector 4e-043  987050 (X65335) lacZ 9e-009 pVP-Nco, gene product complete [unidentified sequence. cloning vector] 2607 U95094 Xenopus laevis 2e-014  124139 TRANS-ACTING 0.48 XL-INCENP TRANSCRIPTION- (XL-INCENP) AL PROTEIN mRNA, complete ICP0 cds >gi|73901|pir∥WZ BE61 gene 61 protein - human herpesvirus 3 >gi|60050 (X04370) ORF 61 (AA1-467) [Human herpesvirus 3] >gi|228664|prf∥18 08271A gene 61 protein 2608 U95094 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2609 U95102 Xenopus laevis 1e-013 3878130 (Z83112) 9 mitotic predicted using phosphoprotein Genefinder 90 mRNA, complete cds 2610 U95102 Xenopus laevis 3e-010 2072296 (U95098) mitotic 5.3 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2611 D14965 C. elegans gene 3.7 <NONE> <NONE> <NONE> for alpha-2 tubulin, complete cds 2612 Z61840 H. sapiens CpG 2e-080 3581872 (AL031541) 1.4 DNA, clone putative integral 59g12, forward membrane protein read [Streptomyces cpg59g12.ft1a. coelicolor] 2613 U59924 Sus scrofa nitric 1.1 <NONE> <NONE> <NONE> oxide synthase (NOS) mRNA, complete cds 2614 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2615 AF054625 Reporter vector 4e-065  987050 (X65335) lacZ 3e-015 pSRF-Luc, gene product complete [unidentified sequence cloning vector] 2616 U95094 Xenopus laevis 1e-011 2072296 (U95098) mitotic 3.1 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2617 AF031924 Homo sapiens e-161 2072296 (U95098) mitotic 5.5 homeobox phosphoprotein 44 transcription [Xenopus laevis] factor barx2 2618 U95102 Xenopus laevis 4e-012 2072296 (U95098) mitotic 5.6 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2619 U95094 Xenopus laevis 1e-009 2072296 (U95098) mitotic 5.6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2620 AF053461 Reporter vector 1e-013 1065484 (U40415) similar 0.49 pCRE-Luc, to S. cerevisiae complete LAG1 sequence (SP:P38703) 2621 U95094 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2622 AF013758 Homo sapiens 0 3046900 (AF013758) 3e-072 polyadenylate polyadenylate binding protein- binding protein- interacting interacting protein-1 (PAIP1) protein-1 [Homo mRNA, complete sapiens] cds 2623 D29808 Human mRNA 0.014 <NONE> <NONE> <NONE> for T-cell acute lymphoblastic leukemia associated antigen 1 (TALLA-1), complete cds 2624 U95094 Xenopus laevis 5e-013 2690005 (AE000794) B. 7.6 XL-INCENP burgdorferi (XL-INCENP) predicted coding mRNA, complete region BBF30 cds 2625 U95102 Xenopus laevis 0.041 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2626 Z12112 pWE15A cosmid 2e-067  987050 (X65335) lacZ 3e-008 vector DNA gene product [unidentified cloning vector] 2627 AB018326 Homo sapiens 0 3882287 (AB018326) 1e-073 mRNA for KIAA0783 protein KIAA0783 [Homo sapiens] protein, complete cds 2628 U95094 Xenopus laevis 1e-011 2072296 (U95098) mitotic 5.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2629 U95102 Xenopus laevis 2e-016 2072296 (U95098) mitotic 5.4 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2630 U95094 Xenopus laevis 2e-006 1001632 (D64002) 3.2 XL-INCENP hypothetical (XL-INCENP) protein mRNA, complete cds 2631 U95102 Xenopus laevis 3e-010 2072296 (U95098) mitotic 0.29 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2632 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2633 X05167 Barley gene for 0.13 1065515 (U4020) weak 9e-018 thiol protease similarity to aleurain procollagen alpha chain 1(V) chain [Caenorhabditis elegans] 2634 Z96177 H. sapiens 2e-060  987050 (X65335) lacZ 5e-010 telomeric DNA gene product sequence, clone [unidentified 10QTEL040, read cloning vector] 10QTELOO040.seq 2635 U95094 Xenopus laevis 2e-006  123432 ZERKNUELLT 3.4 XL-INCENP PROTEIN 1 (XL-INCENP) (ZEN-1) mRNA, complete cds 2636 U95094 Xenopus laevis 2e-006  123432 ZERKNUELLT 3.4 XL-INCENP PROTEIN 1 (XL-INCENP) (ZEN-1) mRNA, complete cds 2637 U95094 Xenopus laevis 5e-013 2072296 (U95098) mitotic 1.5 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2638 U95094 Xenopus laevis 5e-013 2072296 (U95098) mitotic 1.5 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2639 AF103734 Sindbis-like virus 3.5 <NONE> <NONE> <NONE> YN87448, complete genome 2640 M27280 H. influenzae lic-1 3.4 2529686 (AC002535) 6e-018 operon licA, licB, putative G-beta- licC and licD repeat containing genes, encoding protein, 5′ partial outer membrane [Arabidopsis lipopolysaccharide thaliana] phase variation, complete cds. 2641 AF103734 Sindbis-like virus 3.5 <NONE> <NONE> <NONE> YN87448, complete genome 2642 X05167 Barley gene for 0.13 1065515 (U40420) weak 9e-018 thiol protease similarity to aleurain procollagen alpha chain 1(V) chain [Caenorhabditis elegans] 2643 L76159 Homo sapiens 4e-032 1246233 (L76159) FRG1 1e-005 FRG1 mRNA, gene product complete cds. [Homo sapiens] 2644 AF086047 Homo sapiens 3e-008  628916 Delta-12 6 full length insert desaturases - cDNA clone Anabaena YX84A05 variabilis desaturase [Anabaena variabilis] 2645 AF086136 Homo sapiens 4e-021 3849864 (AJ007629) palI 4.6 full length insert protein cDNA clone [Emericella ZA89C06 nidulans] 2646 AB004818 Homo sapiens 1e-011 <NONE> <NONE> <NONE> mRNA for ENX- 2, complete cds 2647 D87686 Homo sapiens e-165 3540219 (D87686) 5e-054 mRNA for KIAA0017 protein KIAA0017 [Homo sapiens] protein, complete cds 2648 Z49218 S. cerevisiae 0.002 2984715 (AF053957) 0.33 chromosome XIII dynamin cosmid 7056 associated protein isoform Dap160-1 2649 U95094 Xenopus laevis 1e-009  868241 (U29488) 7e-030 XL-INCENP C56C10.3 gene (XL-INCENP) product mRNA, complete [Caenorhabditis cds elegans] 2650 D38417 Mouse mRNA for 3e-028 <NONE> <NONE> <NONE> arylhydrocarbon receptor, complete cds 2651 L29252 Human (clone 0.35 <NONE> <NONE> <NONE> D13-2) L-iditol-2- dehydrogenase gene, exon 4, exon 5, exon 6 and exon 7. 2652 U29171 Human casein 3e-063 1176666 HYPOTHETICAL 6.8 kinase I delta 139.1 KD mRNA, complete PROTEIN cds > C08B11.3 IN CHROMOSOME II >gi|3874171|gnl|PI D|e1343795 proteins; cDNA EST EMBL:T01154 comes from this gene; cDNA EST EMBL:T02016 comes from this gene; cDNA EST EMBL:D34307 comes from this gene; cDNA EST EMBL:D37339 comes from 2653 U63648 Mus musculus 6e-058 2645205 (U63648) p160 2e-038 p160 myb- myb-binding binding protein protein [Mus (P160) mRNA, musculus] complete cds 2654 U95102 Xenopus laevis 3e-010 2072296 (U95098) mitotic 5.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2655 Y11740 H. sapiens whn 0.12 <NONE> <NONE> <NONE> gene, exon 1a and 1b 2656 D26179 Rat mRNA for V- 2e-005 3879121 (Z70310) 8e-087 1 protein, predicted using complete cds Genefinder; Similarity to Mouse ankyrin (PIR Acc. No. S37771); cDNA EST EMBL:T01923 comes from this gene; cDNA EST EMBL:D32335 comes from this gene; cDNA EST EMBL:D32723 comes from this gene; cDNA ES . . . Genefinder; Similarity to M 2657 U67518 Methanococcus 1.2 3876465 (Z81071) 6e-011 jannaschii section predicted using 60 of 150 of the Genefinder; complete genome Similarity to Human small nuclear ribonucleoprotein E cDNA EST yk375g7.5 comes from this gene; cDNA EST yk435f5.3 comes from this gen . . . 2658 U95102 Xenopus laevis 3e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2659 U83176 Mus musculus 0 1778861 (U83176) e-101 ROSA 26 ROSA26AS [Mus transcription AS musculus] ROSA26AS mRNA, complete cds 2660 AB018374 Mus musculus 2e-065 3724364 (AB018374) 7e-010 GARP34 mRNA, GARP34 [Mus complete cds musculus] 2661 AB018374 Mus musculus 2e-065 3724364 (AB018374) 7e-010 GARP34 mRNA, GARP34 [Mus complete cds musculus] 2662 U95098 Xenopus laevis 4e-011 2072296 (U95098) mitotic 4.6 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 44 mRNA, partial cds 2663 AL022168 Human DNA 8e-008 <NONE> <NONE> <NONE> sequence from clone U247E12 on chromosome Xq22-23, complete sequence [Homo sapiens] 2664 M10277 Human 5e-063 <NONE> <NONE> <NONE> cytoplasmic beta- actin gene, complete cds. 2665 D83769 Homo sapiens 5e-014  763429 (U22961) putative 5.9 DNA, ORF; similar in corresponding part to the product sequence for encoded by human DHFR glycerol-3- phosphate dehydrogenase mRNA, GenBank Accession Number L34041; Method: conceptual translation supplied by author [Homo sapiens] 2666 U15426 Human 3e-071 1065484 (U40415) similar 3e-015 anonymous to S. cerevisiae mRNA sequence LAG1 with CCA repeat (SP:P38703) region. 2667 AF032900 Homo sapiens 0 3811295 (AF032900) 3e-061 timing protein timing protein CLK-1 mRNA, CLK-1; complete cds ubiquinone biosynthesis protein COQ7 [Homo sapiens] 2668 L39210 Homo sapiens e-111 2887425 (AB007885) 3e-036 inosine KIAA0425 [Homo monophosphate sapiens] dehydrogenase type II gene, complete cds 2669 U95102 Xenopus laevis 7.00E−07 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2670 X93016 S. scrofa mRNA 5e-045  101706 hypothetical 7.7 for cytosolic protein 2 - yeast malic enzyme (Saccharomyces NADP-dependent kluyveri) plasmid pSKL >gi|4870 (X54850) ORF 2, has similarity to DNA polymerase [Saccharomyces kluyveri] 2671 J03068 Human DNF1552 0.041 2414623 (Z99259) putative 7e-021 (lung) mRNA, phosphotransferase complete cds. 2672 X81372 H. sapiens mRNA 2e-016  728831 !!!! ALU 0.0001 for biphenyl SUBFAMILY J hydrolase-related WARNING protein ENTRY 2673 AB012130 Homo sapiens 0.00E+00 3097316 (AB012130) 3e-045 SBC2 mRNA for sodium sodium bicarbonate bicarbonate cotransporter2 cotransporter2, [Homo sapiens] complete cds 2674 D83769 Homo sapiens 5e-014  763429 (U22961) putative 5.9 DNA, ORF; similar in corresponding part to the product sequence for encoded by human DHFR glycerol-3- phosphate dehydrogenase mRNA, GenBank Accession Number L34041; Method: conceptual translation supplied by author [Homo sapiens] 2675 D38522 Human mRNA 1e-022  728831 !!!! ALU 0.002 for KIAA0080 SUBFAMILY J gene, partial cds WARNING ENTRY 2676 D38522 Human mRNA 1e-022  728831 !!!! ALU 0.002 for KIAA0080 SUBFAMILY J gene, partial cds WARNING ENTRY 2677 AF072810 Homo sapiens 0 4049922 (AF072810) 1e-070 transcription transcription factor factor WSTF WSTF [Homo mRNA, complete sapiens] cds 2678 U41767 Human e-130 1235674 (U41767) 1.00E−02 metargidin metargidin precursor mRNA, precursor [Homo complete cds sapiens] 2679 L81613 Homo sapiens 0.38 <NONE> <NONE> <NONE> (subclone 4_c7 from P1 H17) DNA sequence 2680 M68841 Human L1 9.00E−30  106322 hypothetical 8e-008 repetitive protein (L1H3′ sequence with a region) - human region homologous to a mouse ORF. 2681 U95094 Xenopus laevis 0.0005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2682 D87973 Mus musculus 0 4038076 (D87973) Impact 1e-095 Impact mRNA, [Mus musculus] complete cds 2683 M69175 Human H-protein 2e-017 <NONE> <NONE> <NONE> mRNA, complete cds. 2684 Z80361 H. sapiens HLA- 1e-082 1706108 MITOCHONDRI- 0.67 DRB pseudogene, AL CARNITINE repeat region; O- PALMITOYL- TRANSFERASE I, LIVER ISOFORM (CPTI) (CPTI-L) carnitine palmitoyltrans- ferase I [Homo sapiens] I [Homo sapiens] 2685 AF017044 Dictyostelium 0.014 <NONE> <NONE> <NONE> discoideum LTR- retrotransposon Skipper, partial genomic sequence, 3′ end 2686 U40825 Mus musculus e-118 1777577 (U40825) WW- 2.00E−29 WW-domain domain binding binding protein 1 protein 1 [Mus mRNA, complete musculus] cds 2687 U95094 Xenopus laevis 2e-005 2281149 (U58533) 4.6 XL-INCENP maturase [Carum (XL-INCENP) carvi] mRNA, complete cds 2688 U95102 Xenopus laevis 8e-008 3328840 (AE001314) 5.8 mitotic Putative outer phosphoprotein membrane protein 90 mRNA, A [Chlamydia complete cds trachomatis] 2689 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 2690 AB012130 Homo sapiens 0.00E+00 3097316 (AB012130) 3e-045 SBC2 mRNA for sodium sodium bicarbonate bicarbonate cotransporter2 cotransport2, [Homo sapiens] complete cds 2691 X69516 H. sapiens gene 3e-008 <NONE> <NONE> <NONE> for folate receptor 2692 U95094 Xenopus laevis 5.00E−04 1203965 (L42379) bone- 0.17 XL-INCENP derived growth (XL-INCENP) factor [Homo mRNA, complete sapiens] cds 2693 Z15027 H. sapiens HLA 3.00E−07  728836 !!!! ALU 3.6 class III DNA SUBFAMILY SP WARNING ENTRY 2694 U95098 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 2695 U95098 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 2696 X77775 G. gallus Gal beta 1e-022 3873839 (Z81029) 5.9 1,3 GalNAc- W05H12.2 specific GalNAc [Caenorhabditis alpha 2,6- elegans] sialyltransferase >gi|3880545|gnl|PI mRNA. D|e1350077 (Z82072) W05H12.2 2697 U95094 Xenopus laevis 2e-005 2281149 (U58533) 4.6 XL-INCENP maturase [Carum (XL-INCENP) carvi] mRNA, complete cds 2698 U33005 Mus musculus 3e-093 3893077 (Y17923) lyncein 1e-040 tbc1 mRNA, [Bos taurus] complete cds. > :: gb|I86429|I86429 Sequence 1 from U.S. Pat. No. 5,700,927 2699 U74651 Human DNA 1e-022  113667 !!!! ALU CLASS 0.002 polymerase B WARNING gamma (polg) ENTRY !!!! gene, promoter region and partial cds 2700 U95094 Xenopus laevis 9e-009 3064257 (AF043899) 0.87 XL-INCENP amphiphysin IIc1 (XL-INCENP) [Homo sapiens] mRNA, complete cds 2701 U43893 Mus musculs 0.005 3929529 (AF034611) 0.67 ATP synthase intrinsic factor- gamma-subunit B12 receptor gene, nuclear precursor; cubilin gene encoding a [Homo sapiens] mitochondrial protein, partial cds 2702 U43893 Mus musculus 0.005 3929529 (AF034611) 0.67 ATP synthase intrinsic factor- gamma-subunit B12 receptor gene, nuclear precursor; cubilin gene encoding a [Homo sapiens] mitochondrial protein, partial cds 2703 M30704 Human 0  113754 AMPHIREGULIN 4e-041 amphiregulin PRECURSOR (AR) mRNA, (AR) complete cds, clones lambda- AR1 and lambda- AR2. 2704 U95102 Xenopus laevis 9e-010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2705 U95102 Xenopus laevis 3e-011 2072296 (U95098) mitotic 5.2 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2706 U95094 Xenopus laevis 1e-009 2832664 (AL021710) 8e-020 XL-INCENP pollen-specific (XL-INCENP) protein-like mRNA, complete [Arabidopsis cds thaliana] 2707 U00684 Human unknown 2e-038 2500412 30S 1.3 mRNA. RIBOSOMAL PROTEIN S6 Mycoplasma pneumoniae (SGC3) (ATCC 29342) >gi|1674305 similar to Swiss- Prot Accession Number P02358, from E. coli [Mycoplasma pneumoniae] 2708 U95102 Xenopus laevis 5e-015  108693 glutamic acid-rich 0.067 mitotic protein, retinal - phosphoprotein bovine taurus] 90 mRNA, complete cds 2709 U95102 Xenopus laevis 1e-011  79703 hypothetical 32K 0.8 mitotic protein (frxC 5′ phosphoprotein region) - 90 mRNA, Synechocystis sp. complete cds (PCC 6803) >gi|217091|gnl|PI D|d1001745 2710 AF083395 Homo sapiens e-175 4106818 (AF083395) 4e-039 phospholipase phospholipase A2- A2-activating activating protein protein mRNA, [Homo sapiens] complete cds 2711 U95094 Xenopus laevis 3e-011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2712 AB019488 Homo sapiens 0  37403 (X03541) trk gene 1e-032 DNA for TRKA, product (aa 1-641) exon 17 and [Homo sapiens] complete cds 2713 X62570 H. sapiens mRNA e-105  32709 (X62570) IFP53 6e-033 for IFP53 [Homo sapiens] 2714 U95102 Xenopus laevis 0.005 1170056 GENERAL 4.3 mitotic SECRETION phosphoprotein PATHWAY 90 mRNA, PROTEIN F complete cds 2715 AF031924 Homo sapiens e-161 2072296 (U95098) mitotic 5.5 homeobox phosphoprotein 44 transcription [Xenopus laevis] factor barx2 2716 AF031924 Homo sapiens e-161 2072296 (U95098) mitotic 5.5 homeobox phosphoprotien 44 transcription [Xenopus laevis] factor barx2 2717 U95094 Xenopus laevis 9e-010 2072296 (U95098) mitotic 5.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2718 U95094 Xenopus laevis 9e-010 2072296 (U95098) mitotic 5.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2719 L20826 Human I-plastin e-163 2493466 I-PLASTIN 6e-069 mRNA, complete (INTESTINE- cds. SPECIFIC PLASTIN) >gi|1362892|pir∥A 56536 plastin, intestine-specific- human >gi|405230 (L20826) I-plastin 2720 Z54386 H. sapiens CpG 7e-059 1788180 (AE000281) biotin 5.8 DNA, clone sulfoxide 10g3, forward reductase 2 read cpg10g3.ft1a [Escherichia coli] 2721 AF086201 Homo sapiens 1e-085 2564332 (AB006630) 5.4 full length insert KIAA0292 [Homo cDNA clone sapiens] ZC42G09 2722 U95102 Xenopus laevis 4e-012 2072296 (U95098) mitotic 0.12 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2723 AJ006267 Homo sapiens 0 3688380 (AJ006267) ClpX- 1e-091 mRNA for ClpX- like protein [Homo like protein sapiens] 2724 AF064801 Homo sapiens 0 3395787 (AF064801) e-123 multiple multiple membrane membrane spanning receptor spanning receptor TRC8 (TRC8) TRC8 mRNA, complete cds 2725 U95102 Xenopus laevis 2e-006 2599526 (AF029331) 4.2 mitotic immunoglobulin phosphoprotein heavy chain V 90 mRNA, region [Homo complete cds sapiens] 2726 Y08013 S. salar. DNA 0.006 <NONE> <NONE> <NONE> segment containing GT repeat 2727 Y08013 S. salar DNA 0.006 <NONE> <NONE> <NONE> segment containing GT repeat 2728 AE000971 Archaeoglobus 0.041 <NONE> <NONE> <NONE> fulgidus section 136 of 172 of the complete genome 2729 U95094 Xenopus laevis 7e-007 1170586 RAS GTPASE- 9e-011 XL-INCENP ACTIVATING- (XL-INCENP) LIKE PROTEIN mRNA, complete IQGAP1 (P195) cds (KIAA0051) >gi|627594|pir∥A5 4854 Ras GTPase activating-related protein - human sapiens] >gi|536844 (L33075) ras GTPase- activating-like protein [Homo sapiens] 2730 M60858 Human nucleolin e-129 <NONE> <NONE> <NONE> gene, complete cds. 2731 M85145 Human tumor 2e-007 <NONE> <NONE> <NONE> necrosis factor receptor, 3′ flank. 2732 M85145 Human tumor 2e-007 <NONE> <NONE> <NONE> necrosis factor receptor, 3′ flank. 2733 U95102 Xenopus laevis 4e-013 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2734 L07063 Mus musculus 6e-089 2137294 FKBP65 binding 6e-024 FKBP65 binding protein - mosue protein mRNA, >gi|894162 complete cds 2735 X63432 H. sapiens ACTB e-112  987050 (X65335) lacZ 3e-014 mRNA for gene product mutant beta-actin [unidentified cloning vector] 2736 AF083395 Homo sapiens 0 4106818 (AF083395) 1e-094 phospholipase phospholipase A2- A2-activating activating protein protein mRNA, [Homo sapiens] complete cds 2737 AJ012449 Homo sapiens 3e-009 3165570 (AF067946) 4e-032 mRNA for NS1- similar to binding protein Drosophila ring canal protein 2738 M27878 Human DNA 3e-063 3702137 (AL031393) 1e-040 binding protein dJ733D15.1 (Zinc- (HPF2) mRNA, finger protein) complete cds. [Homo sapiens] 2739 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 2740 Y15230 Homo sapiens e-166 3170407 (AF046798) 1e-044 pygl gene, exon 5 glycogen and partial intron phosphorylase 4 and 5 [Homo sapiens] 2741 Z96177 H. sapiens 1e-053  987050 (X65335) lacZ 2e-005 telomeric DNA gene product sequence, clone [unidentified 10QTEL040, read cloning vector] 10QTELOO040.seq 2742 M90058 Human serglycin 3e-010 2072296 (U95098) mitotic 8.8 gene, exons 1, 2, phosphoprotein 44 and 3. [Xenopus laevis] 2743 X69878 H. sapiens Flt4 2e-088 <NONE> <NONE> <NONE> mRNA for transmembrane tyrosine kinase 2744 X69878 H. sapiens Flt4 2e-088 <NONE> <NONE> <NONE> mRNA for transmembrane tyrosine kinase 2745 AB007923 Homo sapiens 0 3413870 (AB007923) 1e-098 mRNA for KIAA0454 protein KIAA0454 [Homo sapiens] protein, partial cds 2746 AF042181 Homo sapiens 2e-047 2072296 (U95098) mitotic 3 testis-specific Y- phosphoprotein 44 encoded-like [Xenopus laevis] protein (TSPYL) mRNA, partial cds 2747 AL021173 Caenorhabditis 1.2 <NONE> <NONE> <NONE> elegans cosmid VK10D6R, complete sequence [Caenorhabditis elegans] 2748 U95102 Xenopus laevis 4e-012 2072296 (U95098) mitotic 0.12 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2749 U95102 Xenopus laevis 2e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2750 U95102 Xenopus laevis 2e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2751 M22970 Human 1e-032  113671 !!!! ALU CLASS 3e-066 pancreatic F WARNING phospholipase A- ENTRY !!!! 2 (PLA-2) gene, exons 1 to 3. 2752 U95094 Xenopus laevis 1e-011 2072296 (U95098) mitotic 5.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2753 U95102 Xenopus laevis 3e-011 3219914 HYPOTHETICAL 1e-011 mitotic 16.8 KD phosphoprotein PROTEIN 90 mRNA, C30D10.04 IN complete cds CHROMOSOME II >gi|2276353|gnl|PI D|e330328 pombe] 2754 U95094 Xenopus laevis 1e-011 3875246 (Z81490) similar 6e-078 XL-INCENP to WD domain, G- (XL-INCENP) beta repeats (2 mRNA, complete domains); cDNA cds EST EMBL:T00482 comes from this gene; cDNA EST EMBL:T00923 comes from this gene; cDNA EST yk449d4.3 comes from this gene; cDNA EST yk449d4.5 comes from this gen . . . 2755 D79205 Human mRNA 1e-086 1173044 60S 4e-009 for ribosomal RIBOSOMAL protein L39, PROTEIN L39 complete cds norvegicus] >gi|373419 (U57846) ribosomal protein L39 ribosomal protein L39 [Homo sapiens] 2756 AB014591 Homo sapiens 0 3327196 (AB014591) 1e-047 mRNA for KIAA0691 protein KIAA0691 [Homo sapiens] protein, complete cds 2757 U95102 Xenopus laevis 1e-012  115409 CUTICLE 0.031 mitotic COLLAGEN phosphoprotein ROL-6 elegans] 90 mRNA, >gi|3879235|gnl|PI complete cds D|e1348932 (Z66499) similar to cuticle collagen ROL-6; cDNA EST cm10c4 comes from this gene; cDNA EST EMBL:M88874 comes from this gene; cDNA EST yk265e2.3 comes from this gene; cDNA EST yk265e2.5 comes fro 2758 U78096 Human 4e-012  126296 LINE-1 0.0005 macrophage REVERSE colony TRANSCRIPTASE stimulating factor HOMOLOG receptor (c-fms) protein gene, exon 1A, 2 [Nycticebus and partial cds coucang] 2759 U95094 Xenopus laevis 3e-010 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2760 M27878 Human DNA 3e-063 3702137 (AL031393) 1e-040 binding protein dJ733D15.1 (Zinc- (HPF2) mRNA, finger protein) complete cds. [Homo sapiens] 2761 U43076 Mus musculus 2e-017  755484 (U20281) cell 8e-022 cdc37 homolog division cycle mRNA, complete control protein 37 cds [Gallus gallus] 2762 U95094 Xenopus laevis 1e-011 2072296 (U95098) mitotic 5.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2763 U95094 Xenopus laevis 2e-005 1171883 SODIUM- 2e-036 XL-INCENP INDEPENDENT (XL-INCENP) ORGANIC mRNA, complete ANION cds TRANSPORTER (ORGANIC ANION TRANSPORTING POLYPEPTIDE) anion - rat >gi|410311 (L19031) oatp [Rattus norvegicus] 2764 X54452 D. discoideum 3.3 <NONE> <NONE> <NONE> culmination spiA (Dd31) gene 2765 U95094 Xenopus laevis 4e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2766 AF053698 Reporter vector 3e-019  987050 (X65335) lacZ 0.2 pAP1-Luc, gene product complete [unidentified sequence cloning vector] 2767 U95102 Xenopus laevis 1e-012 3582428 (AB017257) 4.3 mitotic glycocyamine phosphoprotein kinase beta chain 90 mRNA, [Neanthes complete cds diversicolor] 2768 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 2769 U95098 Xenopus laevis 6e-006 3511122 (AF060503) zinc 5.3 mitotic finger protein phosphoprotein [Homo sapiens] 44 mRNA, partial cds 2770 U95094 Xenopus laevis 1e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2771 U95094 Xenopus laevis 1e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2772 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2773 U95094 Xenopus laevis 1e-013  804788 (M13002) 2855 is 0.64 XL-INCENP the position of the (XL-INCENP) first start codon in mRNA, complete ORF 2; putative cds [Mus musculus] 2774 U95098 Xenopus laevis 8e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 2775 M86526 Rat proline-rich 0.37 <NONE> <NONE> <NONE> protein (PRP) gene, 5′ end, and containing several Alu-like repetitive elements. 2776 Z22923 M. musculus 0.002 <NONE> <NONE> <NONE> alpha2 (IX) collagen gene, complete CDS. 2777 Z22923 M. musculus 0.002 <NONE> <NONE> <NONE> alpha2 (IX) collagen gene, complete CDS. 2778 U95102 Xenopus laevis 1e-012 2072296 (U95098) mitotic 5.4 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2779 Z74035 Caenorhabditis 3.4 2879805 (AL021813) 5.7 elegans cosmid hypothetical F47G9, complete protein sequence [Caenorhabditis elegans] 2780 U95094 Xenopus laevis 1e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2781 AG001356 Homo sapiens 2e-015 <NONE> <NONE> <NONE> genomic DNA, 21q region, clone: 9H11BG25 2782 D83006 Saccharomyces 1.2 <NONE> <NONE> <NONE> cerevisiae MNN4 gene, complete cds 2783 Z59640 H. sapiens CpG 0.12 <NONE> <NONE> <NONE> DNA, clone 167g11, forward read cpg167g11.ftlb. 2784 AF049069 Pinus radiata 1.1 1518141 (U66568) myocyte 3.1 PRE87 mRNA, enhancer factor 2A complete cds MEF2A [Danio rerio] 2785 U95094 Xenopus laevis 4e-012 2072296 (U95098) mitotic 5.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2786 AF031931 Hydra oligactis 0.13 <NONE> <NONE> <NONE> cyclic GMP- dependent protein kinase (hyGK) mRNA, complete cds 2787 Z96177 H. sapiens 3e-041  987050 (X65335) lacZ 0.015 telomeric DNA gene product sequence, clone [unidentified 10QTEL040, read cloning vector] 10QTELOO040.seq 2788 L48716 Homo sapiens 1.1  77657 hypothetical 30.1K 0.095 galactose-1- protein - phosphate uridyl Pseudomonas transferase aeruginosa (GALT) mutant F117S gene, exons 3 and 4 2789 U73902 Mus musculus 0.37  529773 (U06752) 0.009 emerin (Sta) Heterodimeric mRNA, complete complex cds composed of a mucin subunit, ASGP-1, which is predominantly O- glycosylated, and a cysteine-rich transmembrane subunit, ASGP-2, which is predominantly N- glycosylated [Rattus norvegicus] 2790 X54171 H. sapiens NG2-6 4e-021 <NONE> <NONE> <NONE> DNA 2791 M30519 Mouse mammary 0.12 1262926 (U51903) 4.3 tumor virus gag RasGAP-related gene, 3′ end, pol protein [Homo gene, 5′ end. sapiens] 2792 AJ223355 Rattus norvegicus 0.38  128059 NEGATIVE 2 mRNA for FACTOR (F- mitochondrial PROTEIN) (27 dicarboxylate KD PROTEIN) carrier (3′ORF) >gi|77283|pir∥S07 993 nef protein - simian immunodeficiency virus SIVsm (isolate F236) immunodeficiency virus] 2793 AF086022 Homo sapiens 6e-005 3402679 (AC004697) 9e-016 full length insert unknown protein cDNA clone [Arabidopsis YW23E02 thaliana] 2794 U47322 Cloning vector 9e-010 <NONE> <NONE> <NONE> DNA, complete sequence. 2795 U95094 Xenopus laevis 6e-006 3873667 (Z71178) similar 0.093 XL-INCENP to collagen (XL-INCENP) mRNA, complete cds 2796 U95102 Xenopus laevis 3e-009 2745961 (U51869) Bcd orf2 0.47 mitotic [Hom sapiens] phosphoprotein 90 mRNA, complete cds 2797 AF041209 Homo sapiens 0.0002 <NONE> <NONE> <NONE> midline 1 fetal kidney isoform 2 2798 AF092564 Homo sapiens 5e-056 4092846 (AB019987) 3e-017 chromosome- chromosome- associated associated protein-C polypeptide-C [Homo sapiens] 2799 U95094 Xenopus laevis 6e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2800 M95623 Homo sapiens 0.005 4007760 (AL034433) 4.2 hydroxymethyl- importin alpha bilane synthase subunit gene, complete cds. 2801 U95102 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2802 U95094 Xenopus laevis 6e-006 1065945 (U40799) coded 0.12 XL-INCENP for by C. elegans (XL-INCENP) cDNA yk28f2.3; mRNA, complete coded for by C. cds elegans cDNA yk12c10.3; coded for by C. elegans cDNA yk5a12.3; coded for by C. elegans cDNA yk49a8.3; coded for by C. elegans cDNA yk12c10.5; coded for by C. elegans cDNA yk28f2 . . . 2803 U95094 Xenopus laevis 0.04 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2804 M74558 Human SIL e-126 <NONE> <NONE> <NONE> mRNA, complete cds. > :: gb|G28581|G285 81 human STS SHGC-35335. 2805 M72885 Human GOS2 0.36 3873821 (Z68213) cDNA 1.8 gene, 5′ flank and EST yk2664c4.5 cds. comes from this gene; cDNA EST yk266c4.3 comes from this gene 2806 U27341 Bos taurus 6e-078 2136744 endothelin 3e-028 endothelin converting converting enzyme-2-bovine enzyme-2 Sequence 1 from U.S. Pat. No. 5,736,376 2807 U36756 Mus musculus 0.013 <NONE> <NONE> <NONE> thrombin receptor (Cf2r) gene, exon 1 2808 AJ003209 Human 0.12 <NONE> <NONE> <NONE> immunodeficiency virus type 1 mRNA for reverse transcriptase, isolate H-20, partial 2809 U95094 Xenopus laevis 1e-010 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2810 U95094 Xenopus laevis 8e-009 1272701 (L11900) 9.3 XL-INCENP cytochrome b (XL-INCENP) [Cratogeomys mRNA, complete bulleri] cds 2811 U95102 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2812 AB006572 Homo sapiens 0 3970833 (AB006572) 5e-037 RMP mRNA for RPB5 mediating RPB5 mediating protein [Homo protein, complete sapiens] cds 2813 U95102 Xenopus laevis 2e-006 1109865 (U41540) coded 2e-009 mitotic for by C. elegans phosphoprotein cDNA yk42d12.5; 90 mRNA, coded for by C. complete cds elegans cDNA yk27e10.5; coded for by C. elegans cDNA cm08h6; coded for by C. elegans cDNA yk88e12.5; coded for by C. elegans cDNA yk42d12.3; coded for by C. elegans cDNA yk27e1 . . . 2814 Z26259 H. sapiens isoform 3e-029 3426264 (AF037269) cell 0.47 1 gene for L-type division protein calcium channel, [Mycobacterium exon 4 smegmatis] 2815 U95102 Xenopus laevis 0.0002 2358285 (AF010403) ALR 0.27 mitotic [Homo sapiens] phosphoprotein 90 mRNA, complete cds 2816 AC004498 Homo sapiens 2e-006 <NONE> <NONE> <NONE> chromosome 5, P1 clone 1209C1 (LBNL H104), complete sequence [Homo sapiens] 2817 U95102 Xenopus laevis 3e-010 2072296 (U05098) mitotic 3.1 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2818 U43626 Human 2e-018 2197085 (AF003535) 0.0002 chromosome ORF2-like protein 15q11-q13 [Homo sapiens] putative DNA replication origin in the g- aminobutyric acid receptor b3 and a5 gene cluster 2819 Z96402 H. sapiens 0.001  386792 (M32334) 9.2 telomeric DNA intercellular sequence, clone adhesion molecule 18QTEL022, read 2 (ICAM-2) 18QTELOO022.seq [Homo sapiens] 2820 U43626 Human 2e-018 2197085 (AF003535) 0.0002 chromosome ORF2-like protein 15q11-q13 [Homo sapiens] putative DNA replication origin in the g- aminobutyric acid receptor b3 and a5 gene cluster 2821 U66534 Human beta4- 0.12 <NONE> <NONE> <NONE> integrin (ITGB4) gene, exon 14, 15, 16, 17 and 18 2822 U95094 Xenopus laevis 3e-009 2072296 (U95098) mitotic 3.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2823 AC001462 Homo sapiens 3e-011 2072296 (U95098) mitotic 7.1 (subclone 2_h10 phosphoprotein 44 from BAC H107) [Xenopus laevis] DNA sequence 2824 AE000464 Escherichia coli 6e-005 3879850 (Z81592) 2e-039 K-12 MG1655 predicted using section 354 of Genefinder 400 of the complete genome 2825 AB018304 Homo sapiens 3e-009 <NONE> <NONE> <NONE> mRNA for KIAA0761 protein, partial cds 2826 AL008982 Plasmodium 3.2 3880930 (AL021481) 5e-053 falciparum DNA similar to *** Phosphoglucomu- SEQUENCING tase and IN PROGRESS phosphomannomu- *** from contig tase phosphoserine; 3-52, complete cDNA EST sequence EMBL:D36168 comes from this gene; cDNA EST EMBL:D70697 comes from this gene; cDNA EST yk373h9.5 comes from this gene; cDNA EST EMBL:T008 . . . 2827 Z54196 S. cereale DNA 0.36 2500714 HYPOTHETICAL 4.1 for repeat unit 35.0 KD (D1100 family) PROTEIN F48E8.1 IN CHROMOSOME III >gi|746485 (U23514) similar to antigen domain of venom allergen (SP:VA52_DOLM A, P10736) and to antigen 5 (PIR:A37329) [Caenorhabditis elegans] 2828 Z95979 Homo sapiens 7e-017  113668 !!!! ALU CLASS 0.002 hRED1 gene, C WARNING exons 7, 8, 9 and ENTRY !!!! 10 2829 Z15030 H. sapiens gene 5e-024  565265 (M76741) biliary 9.2 for ventricular glycoprotein myosin light [Homo sapiens] chain 2 > :: gb|L01652|HUM VMLC Human ventricular myosin light chain 2 gene, seven exons. 2830 U56440 Human His-1 8e-007 <NONE> <NONE> <NONE> gene sequence 2831 AF009941 Tomocichla tuba 1.2 <NONE> <NONE> <NONE> cytochrome b (cytb) gene, mitochondrial gene encoding mitochondrial protein, complete cds 2832 X68011 H. sapiens ZNF81 3e-030 1731442 ZINC FINGER 1e-020 gene PROTEIN 81 human (fragment) >gi|454325 (X68011) ZNF81 gene product 2833 U36499 Human 1e-020 <NONE> <NONE> <NONE> lymphoid-specific SP100 homolog (LYSP100-A) mRNA, complete cds 2834 Z60692 H. sapiens CpG 3e-059 <NONE> <NONE> <NONE> DNA, clone 31f7, reverse read cpg31f7.rt1a. 2835 X92485 P. vivax pval 0.0002 <NONE> <NONE> <NONE> gene 2836 U95102 Xenopus laevis 0.0005  576257 Prostatic Acid 3e-009 mitotic Phosphatase phosphoprotein (E.C.3.1.3.2) 90 mRNA, Complexed With complete cds Tartaric Acid >gi|576258|pdb|1R PT|Prostatic Acid Phosphatase (E.C.3.1.3.2) Complexed With Vanadate 2837 U72372 Scandia 0.12 <NONE> <NONE> <NONE> geniculata 18S ribosomal RNA and 25S ribosomal RNA genes, partial sequence, and internal transcribed spacer 1, 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence 2838 D49425 Anabaena 3.2 <NONE> <NONE> <NONE> variabilis rbpD gene for RNA- binding protein, complete cds 2839 X95844 S. cerevisiae 3.5 <NONE> <NONE> <NONE> POP3 gene 2840 AE001425 Plasmodium 0.041 3880909 (AL032636) 5.5 falciparum Y40B1B.3 chromosome 2, [Caenorhabditis section 62 of 73 elegans] of the complete sequence 2841 U95102 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2842 X69064 M. musculus Ank- 1.3 <NONE> <NONE> <NONE> 1 mRNA for erythroid ankyrin 2843 U61950 Caenorhabditis 0.13 <NONE> <NONE> <NONE> elegans cosmid C45E5 2844 U73332 Human non- 1e-010 <NONE> <NONE> <NONE> coding genomic sequence upstream from unique L0 sequence in the alpha-globin gene cluster 2845 U21051 Human G 0.13 <NONE> <NONE> <NONE> protein-coupled receptor (GPR4) gene, complete cds. 2846 X57921 O. sativa random 4.1 <NONE> <NONE> <NONE> single-copy DNA fragment 12RG214R 2847 AF037219 Homo sapiens 0.043 <NONE> <NONE> <NONE> PIX1 mRNA sequence 2848 M55124 Human cystic 0.005 <NONE> <NONE> <NONE> fibrosis transmembrane conductance regulator (CFTR) gene, exon 17b 2849 AF035527 Mus musculus e-164 3138930 (AF035527) EHF 5e-084 EHF (Ehf) [Mus musculus] mRNA, complete cds 2850 AF052695 Rattus norvegicus 3.7 2894379 (Y14573) ring 8.2 cell cycle protein finger protein p55CDC gene, [Hordeum complete cds vulgare] 2851 <NONE> <NONE> <NONE> 3327112 (AB014549) 3.8 KIAA0649 protein [Homo sapiens] 2852 M34664 Human 0 2501737 TRANSCRIPTIO- 4.4 chaperonin NAL (HSP60) mRNA, ACTIVATOR complete cds. PROTEIN ACU- 15 >gi|1922895|gnl|PI D|e308394 (Y11565) transcriptional activator protein [Neurospora crassa] 2853 D49701 Aspergillus 0.042 3879556 (Z70756) 0.5 oryzae niaD gene T06E4.11 for nitrate [Caenorhabditis reductase, elegans] complete cds 2854 AF016266 Homo sapiens 1e-010  134846 SMALL 1.5 TRAIL receptor 2 PROLINE-RICH mRNA, complete PROTEIN II rich cds protein [Homo sapiens] 2855 U44862 Human Down 1.2 <NONE> <NONE> <NONE> Syndrome region of chromosome 21, clone A11E6- 2B6. 2856 X14503 Chlamydomonas 0.13 <NONE> <NONE> <NONE> eugametos petD gene for cytochrome b6/f complex subunit IV 2857 U95094 Xenopus laevis 2e-006 3228515 (U70256) SomA 4.6 XL-INCENP [Synechococcus (XL-INCENP) PCC6301] mNA, complete cds 2858 M25534 Chicken actin- 0.41 <NONE> <NONE> <NONE> capping protein (CapZ 36/32) alpha subunit mRNA, complete cds. 2859 X84372 D. melanogaster 1.1 <NONE> <NONE> <NONE> lethal(3)73Ah gene 2860 AF053551 Homo sapiens 0 3283049 (AF053551) 2e-089 metaxin 2 metaxin 2 [Homo (MTX2) mRNA, sapiens] nuclear gene encoding mitochondrial protein, complete cds 2861 U95102 Xenopus laevis 6e-005 3877358 (Z66520) similar 3e-005 mitotic to RBB3 like phosphoprotein protein; cDNA 90 mRNA, EST complete cds EMBL:C08891 comes from this gene; cDNA EST EMBL:C09371 comes from this gene; cDNA EST yk468f10.5 comes from this gene [Caenorhabditis elegans] 2862 AB002450 Homo sapiens 2e-014 3790760 (AF099922) No 2.5 mRNA from definition line chromosome found 5q21-22, [Caenorhabditis clone:A3-A elegans] 2863 AF053698 Reporter vector 1e-009 <NONE> <NONE> <NONE> pAP1-Luc, complete sequence 2864 AF045086 Drosophila 0.005 <NONE> <NONE> <NONE> prosaltans 14045- 0901.4 cytochrome oxidase II (COII) gene, mitochondrial gene encoding mitochondrial protein, complete cds 2865 Y09312 C. botulinum HA- 0.002 1171601 (X95276) rps8 5.7 70 gene (partial) [Plasmodium and HA-17 gene falciparum] 2866 AJ001597 Homo sapiens 0.005 1869883 (Z86099) RS1 0.52 gene encoding [human cAMP-dependent herpesvirus 2] protein kinase herpesvirus 2] gamma isoform 2867 AF022962 Mus musculus 1.1 <NONE> <NONE> <NONE> Sec8 mRNA, complete cds 2868 U95102 Xenopus laevis 0.0005 2499622 PROBABLE 3.5 mitotic SERINE/THREO- phosphoprotein NINE-PROTEIN 90 mRNA, KINASE complete cds YOL113W PROTEIN KINASE 75490 D) 2869 AJ005262 Dictyostelium 0.12 <NONE> <NONE> <NONE> discoideum gene encoding a novel glycoprotein 2870 U08214 Rattus sp. DNA 0.12 4033834 (AJ009556) 0.13 binding protein cytoskeleton (URE-B1) assembly control mRNA, complete protein S1a2p cds. [Candida albicans] 2871 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 2872 M31061 Human ornithine 2e-015 3808095 (Y08560) SCO- 0.098 decarboxylase spondin [Bos gene, complete taurus] cds. 2873 U21914 Human duplicate 0.002 <NONE> <NONE> <NONE> spinal muscular atrophy mRNA, clone 5G7, partial cds. 2874 <NONE> <NONE> <NONE> 1228047 (D83782) the 2.5 KIAA0199 gene is expressed ubiquitously.; the KIAA0199 protein shows similarity to sea urchin hydroxymethylglut- alyl-CoA reductase, and retains 8 hydrophobic domains. [Homo sapiens] 2875 U95102 Xenopus laevis 0.0002 4105505 (AF046914) 5.6 mitotic multiple inositol phosphoprotein polyphosphate 90 mRNA, phosphatase complete cds 2876 Z96120 H. sapiens 0.014 2347056 (AJ000085) 5.8 telomeric DNA Nedd4 protein sequence, clone [Xenopus laevis] 12PTEL057, read 12PTELOO057.seq 2877 U95094 Xenopus laevis 5e-013 2133693 masquerade 1.2 XL-INCENP precursor - fruit (XL-INCENP) fly (Drosophila mRNA, complete melanogaster) cds >gi|665545 (U18130) masquerade [Drosophila melanogaster] >gi|1095942|prf∥2 110286A masquerade gene 2878 X54252 C. elegans 0.38 <NONE> <NONE> <NONE> complete mitochondrial genome 2879 S81913 adrenocorticotro- 1.2 <NONE> <NONE> <NONE> pin receptor [Papio anubis = baboons, adrenal, mRNA Partial, 426 nt] 2880 X65997 M. musculus c-kit 0.13 <NONE> <NONE> <NONE> mRNA for truncated tyrosine-kinase 2881 AE000588 Helicobacter 1.1 <NONE> <NONE> <NONE> pylori section 66 of 134 of the complete genome 2882 U64861 Caenorhabditis 0.12 <NONE> <NONE> <NONE> elegans cosmid D47D2. 2883 U23173 Caenorhabditis 0.37 2854192 (AF045645) 7.2 elegans cosmid contains similarity K07E1 to microsomal triglyceride transfer proteins [Caenorhabditis elegans] 2884 AB014579 Homo sapiens 0 3327172 (AB014579) 2e-053 mRNA for KIAA0679 protein KIAA0679 [Homo sapiens] protein, partial cds 2885 U95102 Xenopus laevis 3e-009 1707032 (U80445) coded 0.17 mitotic for by C. elegans phosphoprotein cDNA yk13g5.3; 90 mRNA, coded for by C. complete cds elegans cDNA yk21g6.3; coded for by C. elegans cDNA CEMSE18F; coded for by C. elegans cDNA yk126b1.3; coded for by C. elegans cDNA yk65h8.3; coded for by C. elegans cDNA yk65h8 . . . 2886 Z22795 H. sapiens 6e-005 <NONE> <NONE> <NONE> microsatellite repeat. 2887 AE001061 Archaeoglobus 1.1 3738162 (AL031856) 2.4 fulgidus section putative 46 of 172 of the involvement in complete genome protein glycosylation in the golgi [Schizosaccharo- myces pombe] 2888 U95094 Xenopus laevis 6e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2889 Z96643 H. sapiens 0.0005 1363732 probable 4 telomeric DNA membrane protein sequence, clone YLR454w - yesst 5QTEL064, read 5QTELOO064.seq 2890 Z96643 H. sapiens 0.0005 1363732 probable 4 telomeric DNA membrane protein sequence, clone YLR454w - yeast 5QTEL064, read 5QTELOO064.seq 2891 X80169 M. musculus e-177 1717793 PROTEIN TSG24 5e-069 mRNA for 200 (MEIOTIC kD protein CHECK POINT REGULATOR) >gi|1083553|pir∥A 55117 tsg24 protein - mouse 2892 U95094 Xenopus laevis 9e-009 3832555 (AF077439) 4.4 XL-INCENP immunoglobulin (XL-INCENP) heavy chain mRNA, complete variable region cds 2893 AC002359 Homo sapiens 2e-007 3599342 (AF081112) ORF2 0.61 Xp22 Cosmid [Mus musculus U239B3 (from domesticus] Lawrence Livermore X library) complete sequence [Homo sapiens] 2894 U95094 Xenopus laevis 4e-011 3123058 HYPOTHETICAL 0.001 XL-INCENP WD-REPEAT (XL-INCENP) PROTEIN mRNA, complete SLL0163 cds >gi|1001440|gnl|PI D|d1010715 (D63999) beta transducin-like protein [Synechocystis sp.] 2895 U95102 Xenopus laevis 9e-010 2072296 (U95098) mitotic 5.2 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2896 Z46940 H. sapiens PRM1 0.013 <NONE> <NONE> <NONE> gene, PRM2 gene and TNP2 gene 2897 Z47735 H. sapiens 2e-008 <NONE> <NONE> <NONE> NFKB1 gene, exons 11 & 12 2898 U95098 Xenopus laevis 0.004 2224611 (AB002333) 4 mitotic KIAA0335 [Homo phosphoprotein sapiens] 44 mRNA, partial cds 2899 U95094 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2900 X00367 Chlamydomonas 0.12 <NONE> <NONE> <NONE> chloroplast DNA region with ARS element 03 (ARS = autonomously replicating sequence) 2901 U41222 Dictyostelium 0.35 <NONE> <NONE> <NONE> discoideum RacE (racE) gene, complete cds 2902 AB007504 Triticum 0.042 <NONE> <NONE> <NONE> aestivum TaMADS#11 mRNA for MADS box transcription factor, complete cds 2903 X65319 Cloning vector 7e-069  987050 (X65335) lacZ 7e-011 pCAT-Enhancer gene product [unidentified cloning vector] 2904 U95094 Xenopus laevis 0.0005 3924670 (AC004990) 6e-042 XL-INCENP supported by (XL-INCENP) Genscan and mRNA, complete several ESTs: cds C83049 2905 U95094 Xenopus laevis 0.041 2132051 hypothetical 3.3 XL-INCENP protein YOR083w - (XL-INCENP) yeast mRNA, complete cds 2906 Z12112 pWE15A cosmid 6e-068  987050 (X65335) lacZ 2e-009 vector DNA gene product [unidentified cloning vector] 2907 U95094 Xenopus laevis 2e-006 2995374 (AL022245) 5e-005 XL-INCENP hypothetical (XL-INCENP) protein mRNA, completc cds 2908 U47322 Cloning vector 3e-009 <NONE> <NONE> <NONE> DNA, complete sequence. 2909 X71623 H. sapiens 4e-012  113669 !!!! ALU CLASS 4.1 ZNF74-1 mRNA D WARNING > :: ENTRY !!!! gb|G27154|G271 54 human STS SHGC-31580. 2910 U43626 Human 7e-007 2394501 (AF024503) No 9.6 chromosome definition line 15q11-q13 found putative DNA [Caenorhabditis replication origin elegans] in the g- aminobutyric acid receptor b3 and a5 gene cluster 2911 U95094 Xenopus laevis 5e-014 2072296 (U95098) mitotic 5.3 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2912 U95094 Xenopus laevis 1e-012 2688749 (AE001179) 2.3 XL-INCENP conserved (XL-INCENP) hypothetical mRNA, complete protein [Borrelia cds burgdorferi]. 2913 U95102 Xenopus laevis 4e-013 2072296 (U95098) mitotic 3.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2914 U95094 Xenopus laevis 4e-013 2072296 (U95098) mitotic 4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2915 U95094 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2916 U95094 Xenopus laevis 0.004 1209842 (U45423) minus 0.092 XL-INCENP strand repeat (XL-INCENP) motif-containing mRNA, complete gene cds 2917 X80283 P. polycephalum 3.3 <NONE> <NONE> <NONE> genomic DNA containing Taq I repetitive element 2918 U95094 Xenopus laevis 6e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2919 U95094 Xenopus laevis 6e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2920 Z97333 Homo sapiens 9e-020  113667 !!!! ALU CLASS 4e-005 RHCE gene B WARNING ENTRY !!!! 2921 AF082350 Homo sapiens 1 <NONE> <NONE> <NONE> bone morphogenetic protein 15 precursor (BMP15) gene, exon 2 and complete cds 2922 L14684 Rattus norvegicus 0  585084 ELONGATON 9e-089 nuclear-encoded FACTOR G, mitochondrial MITOCHONDRI- elongation factor AL PRECURSOR G mRNA, (MEF-G) complete cds. >gi|543383|pir∥S4 0780 translation elongation factor G, mitochondrial - rat >gi|310102 2923 D78335 Human mRNA e-163 1718058 URIDINE 7e-072 for 5′-terminal KINASE region of UMK, (URIDINE complete cds MONOPHOSPHO- KINASE) >gi|471981 (L31783) uridine kinase 2924 U95094 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2925 U95094 Xenopus laevis 1e-013 1351922 AMINE 5.6 XL-INCENP OXIDASE (XL-INCENP) PRECURSOR mRNA, complete (MONAMINE cds OXIDASE) (TYRAMINE OXIDASE) >gi|419575|pir∥B4 1836 amine oxidase (flavin- containing) (EC 1.4.3.4) precursor - Klebsiella pneumoniae >gi|216723|gnl|PI D|d1001529 2926 U95094 Xenopus laevis 9e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2927 U95102 Xenopus laevis 1e-013 2072296 (U95098) mitotic 9.7 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 2928 AB018285 Homo sapiens 0 3882205 (AB018285) 2e-093 mRNA for KIAA0742 protein KIAA0742 [Homo sapiens] protein, partial cds 2929 U95102 Xenopus laevis 6e-006 3882183 (AB018274) 4e-049 mitotic KIAA0731 protein phosphoprotein [Homo sapiens] 90 mRNA, complete cds 2930 X94762 H. sapiens DNA 2e-068  631020 Kallmann 5.6 for Ki-67 antigen syndrome protein 5′-region (exon 1 homolog - chicken & 2) 2931 U95102 Xenopus laevis 2e-007 3522948 (AC004411) 2e-026 mitotic hypothetical phosphoprotein protein 90 mRNA, [Arabidopsis complete cds thaliana] 2932 U95094 Xenopus laevis 4e-011 2072296 (U95098) mitotic 6.5 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2933 U95102 Xenopus laevis 9e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2934 M18795 Gorilla pseudo- 7e-028 <NONE> <NONE> <NONE> beta- and delta- globin gene intergenic region with 2 Alu repeats. 2935 U95102 Xenopus laevis 0.0005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2936 U95094 Xenopus laevis 3e-007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2937 U09874 Mus musculus 2e-086 2493735 SKD3 PROTETN 6e-036 SKD3 mRNA, SKD3 [Mus complete cds. musculus] 2938 U95094 Xenopus laevis 1e-012 2072296 (U95098) mitotic 5.6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2939 D38417 Mouse mRNA for e-154 2072296 (U95098) mitotic 3.4 arylhydrocarbon phosphoprotein 44 receptor, [Xenopus laevis] complete cds 2940 U95102 Xenopus laevis 3e-008 3879062 (Z81576) 9.2 mitotic predicted using phosphoprotein Genefinder 90 mRNA, complete cds 2941 AE001368 Plasmodium 0.014 <NONE> <NONE> <NONE> falciparum chromosome 2, section 5 of 73 of the complete sequence 2942 U95094 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2943 U95102 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2944 AF083322 Homo sapiens e-133 3435244 (AF083322) 9e-015 centriole centriole associated protein associated protein CEP110 mRNA, CEP110 [Homo complete cds sapiens] 2945 U95102 Xenopus laevis 0.014 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2946 L07040 pFNeo eukaryotic 2e-038  987050 (X65335) lacZ 4e-005 expression vector, gene product complete [unidentified sequence. cloning vector] 2947 X65319 Cloning vector 2e-078  987050 (X65335) lacZ 1e-013 pCAT-Enhancer gene product [unidentified cloning vector] 2948 U95102 Xenopus laevis 3e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2949 AL031844 Human DNA 3.2 <NONE> <NONE> <NONE> sequence from clone 361H15 on chromosome 22q13.2-13.33, complete sequence [Homo sapiens] 2950 AC002186 Homo sapiens 2e-037 2072966 (U93570) p40 4e-013 (subclone 1_f12 [Homo sapiens] from P1 H115) DNA sequence 2951 U95102 Xenopus laevis 6e-005 4105414 (AF045593) ETS 1.4 mitotic DNA binding phosphoprotein protein Yan 90 mRNA, [Drosophila complete cds virilis] 2952 U95102 Xenopus laevis 3e-008  629692 hypothetical 4.3 mitotic protein - common phosphoprotein tobacco tabacum] 90 mRNA, complete cds 2953 S60885 LYAR = cell 5e-035 2498524 CELL GROWTH 5e-014 growth regulating REGULATING nucleolar protein NUCLEOLAR [mice, EL4 cells, PROTEIN mRNA, 1474 nt] >gi|423488|pir∥A4 0683 cell growth regulating nucleolar protein LYAR - mouse >gi|300372|bbs|13 1782 2954 U95102 Xenopus laevis 1e-012 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2955 Z23090 H. sapiens mRNA 1e-063 1709972 60S 3e-020 for 28 kDa heat RIBOSOMAL shock protein. PROTEIN L10A (CSA-19) 2956 X87817 M. musculus 0.0005 <NONE> <NONE> <NONE> mRNA for Ulip protein 2957 U87997 Enterococcus 1.2 <NONE> <NONE> <NONE> faecium enterocin B (entB) gene, complete cds 2958 U95098 Xenopus laevis 0.001 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 2959 U95102 Xenopus laevis 1e-011 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 2960 U95098 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 2961 U95098 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 2962 U95094 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2963 X62025 H. sapiens rod cG- 4e-034  728838 !!!! ALU 9e-006 PDE G gene for SUBFAMILY SX 3′,5′-cyclic WARNING nucleotide ENTRY phosphodiesterase 2964 AJ223364 Homo sapiens 1e-023 2072296 (U95098) mitotic 4.2 germ-line DNA phosphoprotein 44 upstream of [Xenopus laevis] Jkappa locus 2965 Z47046 Human cosmid 3e-020  804808 (M13100) 7e-005 QLL2C9 from unknown protein Xq28 [Rattus norvegicus] 2966 U95094 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2967 U95098 Xenopus laevis 9e-009  464502 PEROXISOMAL 9.5 mitotic TARGETING phosphoprotein SIGNAL 44 mRNA, partial RECEPTOR cds (PEROXISOMAL PROTEIN PAS10) (PEROXIN-5) (PTS1 RECEPTOR) >gi|1078412|pir∥A 49403 tetratricopeptide- repeat protein PAS10 - yeast tetratricopeptide- repeat protein [Saccharomyces cerevisiae] >gi|817830 (Z49701) Pas10p [Sa 2968 AF035940 Homo sapiens 3e-050 2306969 (AF007860) xl- 1e-041 MAGOH mRNA, Mago [Xenopus 2969 <NONE> complete cds laevis] <NONE> <NONE> <NONE> <NONE> <NONE> 2970 X66297 H. sapiens Alu 5e-014 <NONE> <NONE> <NONE> repeat (terminator 3) 2971 AB007934 Homo sapiens 0 3413892 (AB007934) e-118 mRNA for KIAA0465 protein KIAA0465 [Homo sapiens] protein, partial cds 2972 X15982 Ascobolus 0.042 <NONE> <NONE> <NONE> immersus DNA of linear mitochondrial plasmid pA12 with virus like replication 2973 U95094 Xenopus laevis 4e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2974 AC002181 Homo sapiens 2e-014 3879351 (Z35663) Short 0.69 (subclone 2_a12 region of from BAC H111) similarity with DNA sequence glucose-6- phosphate 1 - dehydrogenase from Plasmodium falciparum; cDNA EST EMBL:C12945 comes from this gene; cDNA EST yk251d3.3 comes from this gene; cDNA EST yk251d3.5 comes from this . . . 2975 U95094 Xenopus laevis 0.002 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 2976 U95094 Xenopus laevis 5e-013 3334221 4- 2e-012 XL-INCENP HYDROXYPHEN- (XL-INCENP) YLPYRUVATE mRNA, complete DIOXYGENASE cds 4- hydroxyphenylpy- ruvate dioxygenase [Mycosphaerella graminicola] 2977 S60885 LYAR = cell 8e-028 2498524 CELL GROWTH 0.72 growth regulating REGULATING nucleolar protein NUCLEOLAR PROTEIN >gi|423488|pir∥A4 0683 cell growth regulating nucleolar protein LYAR - mouse >gi|300372|bbs|13 1782 2978 U43958 Cloning vector 1e-010  335109 (M24873) major 1.1 pRcCMV-luc structural protein luciferase gene, [Rhesus macaque complete cds polyomavirus] 2979 U95102 Xenopus laevis 2e-014 399294 CYTOCHROME 3.5 mitotic P450 XXIA3 phosphoprotein (STEROID 21- 90 mRNA, HYDROXYLASE) complete cds (P450-C21) >gi|2117374|pir∥A 32525 steroid 21- monooxygenase (EC 1.14.99.10) cytochrome P450 21A1 - pig >gi|164560 (M83939) steroid 21-hydroxylase 2980 U95102 Xenopus laevis 0.0002 1169449 PROBABLE 1.9 mitotic EARLY E4 33 KD phosphoprotein PROTEIN 90 mRNA, complete cds 2981 U95094 Xenopus laevis 4e-011 2072296 (U95098) mitotic 3.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 2982 Z11711 H. sapiens gene 2e-014  728835 !!!! ALU 4.2 for alpha-2 SUBFAMILY SC macroglobulin, WARNING exon 1 ENTRY 2983 M76363 Human (Papua 1e-053 2072296 (U95098) mitotic 5.9 New Guinean) phosphoprotein 44 Mitochondrial [Xenopus laevis] DNA control region, sequence 130. 2984 U21228 Promoter-probe 3e-049 <NONE> <NONE> <NONE> vector pCG1408, complete sequence. 2985 X52994 Sheep mRNA for 0.005 1084987 cryptogene protein 2.6 CD3 gamma G4- subunit (partial) Sauroleishmania tarentolae (strain LEM125) 2986 X52994 Sheep mRNA for 0.005 1084987 cryptogene protein 2.6 CD3 gamma G4 - subunit (partial) Sauroleishmania tarentolae (strain LEM125) 2987 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 2988 <NONE> <NONE> <NONE> <NONE> <NONE> 2989 U95102 Xenopus laevis 3e-009  123398 OCTAMER- 3.2 mitotic BINDING phosphoprotein TRANSCRIPTION 90 mRNA, FACTOR 1 complete cds (OTF-1) (NF-A1) >gi|104811|pir∥A3 4873 transcription factor Oct-1, octamer-binding- chicken >gi|212467 2990 U95102 Xenopus laevis 1e-010 3881655 (Z82090) similar 6e-019 mitotic to Alpha-2- phosphoprotein macroglobulin 90 mRNA, family (3 complete cds domains); cDNA EST EMBL:D67694 comes from this gene [Caenorhabditis elegans] 2991 AB018270 Homo sapiens 0 2072296 (U95098) mitotic 2.5 mRNA for phosphoprotein 44 KIAA0727 [Xenopus laevis] protein, partial cds 2992 U58745 Caenorhabditis 1.2 2677839 (AF023476) 0.24 elegans cosmid meltrin-L C10G6. precursor [Homo sapiens] 2993 X17051 E. gracilis DNA 0.13 <NONE> <NONE> <NONE> for ribosomal protein operon 2994 Z14974 D. melanogaster 1.1 3021409 (Y12781) 6e-017 Cpo 61.1 gene for transducin (beta) couch potato like 1 protein protein. [Homo sapiens] 2995 U95098 Xenopus laevis 8e-008  417442 PARA- 4.2 mitotic AMINOBENZO- phosphoprotein ATE SYNTHASE 44 mRNA, partial Streptomyces cds griseus >gi|388263 (M93058) p- aminobenzoic acid synthase [Streptomyces griseus] 2996 U11270 Human 9e-020  113670 !!!! ALU CLASS 0.16 antithrombin III E WARNING gene, exon 1 and ENTRY !!!! partial cds. 2997 U95102 Xenopus laevis 1e-010 3024528 RAS-RELATED 1.1 mitotic PROTEIN phosphoprotein RAB2BV 90 mRNA, complete cds 2998 U95102 Xenopus laevis 4e-012  728831 !!!! ALU 0.17 mitotic SUBFAMILY J phosphoprotein WARNING 90 mRNA, ENTRY complete cds 2999 U51670 Barbus barbus x 0.13 <NONE> <NONE> <NONE> Barbus meridionalis microsatellite clone no.77 3000 U79776 Mus musculus 4e-094 1710382 (U79776) ajuba; 8e-037 ajuba (Ajuba) jub [Mus mRNA, complete musculus] cds 3001 U79776 Mus musculus 4e-094 1710382 (U79776) ajuba; 8e-037 ajuba (Ajuba) jub [Mus mRNA, complete musculus] cds 3002 U79776 Mus musculus e-100 1710382 (U79776) ajuba; 8e-019 ajuba (Ajuba) jub [Mus mRNA, complete musculus] cds 3003 U79776 Mus musculus e-100 1710382 (U79776) ajuba; 8e-019 ajuba (Ajuba) jub [Mus mRNA, complete musculus] cds 3004 U95102 Xenopus laevis 0.0005  482227 hypothetical 0.64 mitotic protein T07C4.9 - phosphoprotein Caenorhabditis 90 mRNA, elegans complete cds >gi|3879509|gnl|PI D|e1349070 (Z29443) similar to Annexin; cDNA EST EMBL:C10640 comes from this gene; cDNA EST EMBL:C12433 comes from this gene; cDNA EST yk192f7.5 comes from this gene; cDNA EST yk318c1 3005 U95094 Xenopus laevis 5e-013 1944590 (Z94121) 7.8 XL-INCENP hypothetical (XL-INCENP) protein Rv3899c mRNA, complete cds 3006 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3007 U40603 Rattus norvegicus 0.12 1082665 oligodendrocyte- 0.22 rat-slowpoke- specific proline- alpha mRNA, rich protein 2 - complete cds human >gi|1408050|gnl|PI D|d1006205 (D28114) MOBP [Homo sapiens] 3008 AF044081 Rattus norvegicus 1.1 2213519 (Z97050) sigG 3.1 steroidogenic [Mycobacterium acute regulatory tuberculosis] protein (StAR) mRNA, complete cds 3009 U95102 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3010 X13345 Human gene for 1e-009 <NONE> <NONE> <NONE> plasminogen activator inhibitor 1 3011 U95102 Xenopus laevis 4e-012  395338 (X66924) helix- 0.85 mitotic loop-helix protein phosphoprotein [Homo sapiens] 90 mRNA, complete cds 3012 U95094 Xenopus laevis 1e-011 2072296 (U95098) mitotic 5.6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3013 D78335 Human mRNA e-101 2072296 (U95098) mitotic 3.2 for 5′-terminal phosphoprotein 44 region of UMK, [Xenopus laevis] complete cds 3014 U03887 Human BXP20 6e-005 <NONE> <NONE> <NONE> gene. 3015 U43194 Mus musculus 4e-044 1176422 (U43194) 7e-020 rhophilin mRNA, rhophilin [Mus complete cds musculus] 3016 AC004507 Homo sapiens 1.2 <NONE> <NONE> <NONE> chromosome 5, P1 clone 798F12 (LBNL H82), complete sequence [Homo sapiens] 3017 X63436 B. taurus mRNA 0  464345 POLY(A) 6e-065 for poly(A) POLYMERASE polymerase (PAP) polynucleotide adenylyltransferase [Bos taurus] 3018 M98512 Human NFG 1e-021  728831 !!!! ALU 0.095 genomic SUBFAMILY J fragment. WARNING ENTRY 3019 AJ005016 Homo sapiens e-159 3005931 (AJ005016) ABC 2e-039 mRNA for transporter [Homo putative ABC sapiens] transporter, partial 3020 AJ006778 Homo sapiens 1e-053 <NONE> <NONE> <NONE> mRNA for DRIM protein 3021 X65319 Cloning vector 3e-081  987050 (X65335) lacZ 3e-015 pCAT-Enhancer gene product [unidentified cloning vector] 3022 U14698 Human Alu-Sb2 1e-040  728834 !!!! ALU 0.0001 repeat, clone SUBFAMILY HSB-8P. SB2 WARNING ENTRY 3023 U95094 Xenopus laevis 1e-010 3218396 (AL023860) 0.0003 XL-INCENP hypothetical (XL-INCENP) protein mRNA, complete cds 3024 U95098 Xenopus laevis 1.20E-01 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3025 Z59351 H.sapiens CpG 3e-020 1079063 deep orange 9.90E-02 DNA, clone protein-fruit fly 151a12, reverse (Drosophila read melanogaster) cpg151a12.rt1a. >gi|798832 (X86683) deep orange (dor) 3026 AB014564 Homo sapiens e-164 2498095 5E5 ANTIGEN 3.2 mRNA for >gi|1085558|pir∥J KIAA0664 C4163 DNA- protein, partial binding protein cds 5E5-rat norvegicus] >gi|1581020|prf∥2 116328A DNA- binding protein 5E5 [Rattus norvegicus] 3027 U95094 Xenopus laevis 1e-010 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3028 U95094 Xenopus laevis 1e-010 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3029 U95094 Xenopus laevis 1e-010 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3030 U95094 Xenopus laevis 4.00E-12 2072296 (U95098) mitotic 5.6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3031 U95098 Xenopus laevis 1.20E-01 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3032 AF070523 Homo sapiens 0.00E+00 <NONE> <NONE> <NONE> JWA protein mRNA, complete cds 3033 Z19055 B.aphidicola 0.41 <NONE> <NONE> <NONE> tryptophan operon 3034 Z19055 B.aphidicola 0.41 <NONE> <NONE> <NONE> tryptophan operon 3035 Z19055 B.aphidicola 0.41 <NONE> <NONE> <NONE> tryptophan operon 3036 U95098 Xenopus laevis 7.00E-07 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3037 U95094 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3038 AF064482 Homo sapiens 0 <NONE> <NONE> <NONE> natural resistance- associated macrophage protein 2 (NRAMP2) gene, exons 16 and 16A, alternatively spliced IRE form, complete cds 3039 U95098 Xenopus laevis 1.20E-01 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3041 U28153 Caenorhabditis 0.38 <NONE> <NONE> <NONE> elegans UNC-76 (unc-76) gene, complete cds. 3042 U95094 Xenopus laevis 5.00E-03 1079063 deep orange 0.23 XL-INCENP protein-fruit fly (XL-INCENP) (Drosophila mRNA, complete melanogaster) cds >gi|798832 (X86683) deep orange (dor) 3043 U95094 Xenopus laevis 5.00E-03 1079063 deep orange 0.23 XL-INCENP protein-fruit fly (XL-INCENP) (Drosophila mRNA, complete melanogaster) cds >gi|798832 (X86683) deep orange (dor) 3044 U95098 Xenopus laevis 2.00E-05 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3045 U95102 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3046 U63810 Homo sapiens 0.00E+00 3219331 (AC004020) 2e-097 WD40 protein Unknown gene Ciao 1 mRNA, product [Homo complete cds sapiens] 3047 M21533 Human MHC 2e-005 120467 V-FOS/FOX 9.9 class I TRANSFORMING lymphocyte PROTEIN antigen (HLA-E) murine osteosarcoma virus (provirus) (fragment) 3048 U95098 Xenopus laevis 6e-006 462702 NEUROFILAMENT 2.6 mitotic TRIPLET H phosphoprotein PROTEIN (200 44 mRNA, partial KD cds NEUROFILAMENT PROTEIN) (NF-H) 3049 U95102 Xenopus laevis 1e-010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3050 U95102 Xenopus laevis 4e-011 2072296 (U95098) mitotic 3.6 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3051 U95102 Xenopus laevis 5.00E-04 3116127 (AL023287) 6.9 mitotic hypothetical phosphoprotein protein 90 mRNA, complete cds 3052 U95094 Xenopus laevis 7.00E-06 586875 HYPOTHETICAL 2e-014 XL-INCENP 29.2 KD (XL-INCENP) PROTEIN IN mRNA, complete METS-KSGA cds INTERGENIC REGION >gi|2127033|pir∥S 66068 hypothetical protein-Bacillus subtilis subtilis] >gi|2632306|gnl|PI D|e1181972 (Z99104) similar to hypothetical proteins [Bacillus subtilis] 3053 U95102 Xenopus laevis 1e-010 1326350 (U58748) similar 0.035 mitotic to potential phosphoprotein transmembrane 90 mRNA, domains in S. complete cds cerevisiae nulcear division RFT1 protein (SP:P38206) 3054 Y10938 Homo sapiens 6e-016 2072296 (U95098) mitotic 4.4 retroviral-like phosphoprotein 44 sequence S71, [Xenopus laevis] 5LTR and env- like sequence 3055 U95094 Xenopus laevis 2.00E-05 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3056 AE000723 Aquifex aeolicus 1.20E+00 <NONE> <NONE> <NONE> section 55 of 109 of the complete genome 3057 U18055 Lycopersicon 1.10E+00 <NONE> <NONE> <NONE> esculentum 1- aminocyclo- propane-1- carboxylate synthase (LE-ACS3) DNA, partial cds 3058 AJ006025 Cicer arietinum 0.38 <NONE> <NONE> <NONE> mRNA for acyl- coA synthetase, partial 3059 AJ006025 Cicer arietinum 0.38 <NONE> <NONE> <NONE> mRNA for acyl- coA synthetase, partial 3060 U95102 Xenopus laevis 0.014 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3061 U95102 Xenopus laevis 0.014 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3062 U95102 Xenopus laevis 3.00E-10 3880303 (Z54238) T28C6.1 4.10E-02 mitotic [Caenorhabditis phosphoprotein elegans] 90 mRNA, complete cds 3063 AE000723 Aquifex aeolicus 1.20E+00 <NONE> <NONE> <NONE> section 55 of 109 of the complete genome 3064 Y14352 Gallus gallus 0.042 995644 (Z54206) UL38 1.9 gene encoding [Bovine neurofascin, herpesvirus 1] exons 31 & 31 >gi|1149580 (Z49078) UL38 [Bovine herpesvirus 1] >gi|2653309|gnl|PI D|e1187305 3065 AE000723 Aquifex aeolicus 1.20E+00 <NONE> <NONE> <NONE> section 55 of 109 of the complete genome 3066 U95102 Xenopus laevis 2.00E-03 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3067 U95102 Xenopus laevis 2.00E-03 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3068 U95102 Xenopus laevis 2.00E-03 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3069 U95094 Xenopus laevis 0.38 1395143 (D86080) aniline 9.00E-05 XL-INCENP dioxygenase (XL-INCENP) reductase mRNA, complete component cds [Acinetobacter sp.] dioxygenase reductase component [Acinetobacter sp.] 3070 AE001398 Plasmodium 0.0005 <NONE> <NONE> <NONE> falciparum chromosome 2, section 35 of 73 of the complete sequence 3071 U95102 Xenopus laevis 0.014 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3072 D16902 Human HepG2 3′ 2.00E-49 <NONE> <NONE> <NONE> region cDNA, clone hmd2h10 3073 Z26494 S.cerevisiae 1.1 3581891 (AL031540) 9.70E+00 genes for histone hypothetical wtf3 H2A and H2B, protein trehalase, and hexaprenyl pyrophosphate synthetase 3074 U95102 Xenopus laevis 2.00E-05 2224921 (AF000606) insect 1e-005 mitotic intestinal mucin phosphoprotein IIM22 90 mRNA, [Trichoplusia ni] complete cds 3075 U95094 Xenopus laevis 0.37 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3076 U18157 Human HLA 2.00E-05 <NONE> <NONE> <NONE> class I genomic survey sequence. 3077 U95094 Xenopus laevis 4.20E-02 2622750 (AE000921) DNA 2.5 XL-INCENP topoisomerase I (XL-INCENP) [Methanobacterium mRNA, complete thermoautotrophicum] cds 3078 AF022789 Homo sapiens 0.00E+00 <NONE> <NONE> <NONE> ubiquitin hydrolyzing enzyme I 3079 U18055 Lycopersicon 1.10E+00 <NONE> <NONE> <NONE> esculentum 1- aminocyclo- propane-1- carboxylate synthase (LE- ACS3) DNA, partial cds 3080 AF022388 Caenorhabditis 1.40E-02 3747107 (AF095741) 6e-012 elegans putative unknown [Rattus transcription norvegicus] factor MAB-3 (mab-3) gene, complete cds 3081 AF084594 Plasmodium 1.20E+00 3132802 (AF063223) po1 1.2 falciparum protein [Human erythrocyte immunodeficiency membrane virus type 1] protein 1 type w (var) gene, partial cds 3082 D16902 Human HepG2 3′ 2.00E-49 <NONE> <NONE> <NONE> region cDNA, clone hmd2h10 3083 X65709 A.carrageenovora 0.014 <NONE> <NONE> <NONE> gene for arylsulfatase 3084 AF060246 Mus musculus 2e-078 3372657 (AF060246) zinc 1e-031 strain C57BL/6 finger protein 106 zinc finger [Mus musculus] protein 106 (Zfp106) mRNA, H3a-a allele, complete cds 3085 AF037332 Homo sapiens 3.70E-01 <NONE> <NONE> <NONE> Eph-like receptor tyrosine kinase hEphB1b (EphB1) mRNA, complete cds 3086 U17579 Human growth 0.053 <NONE> <NONE> <NONE> hormone- releasing hormone receptor gene, alternatively spliced forms a, b, and c, partial cds 3087 U95102 Xenopus laevis 0.39 2950453 (AL022071) beta- 2.00E-05 mitotic transducin phosphoprotein 90 mRNA, complete cds 3088 U67479 Methanococcus 0.005 <NONE> <NONE> <NONE> jannaschii section 21 of 150 of the complete genome 3089 U95102 Xenopus laevis 9e-010 3283350 (AF062378) 3e-006 mitotic calmodulin- phosphoprotein binding protein 90 mRNA, SHA1 [Mus complete cds musculus] 3090 Z59351 H.sapiens CpG 3e-020 1079063 deep orange 9.90E-02 DNA, clone protein-fruit fly 151a12, reverse (Drosophila read melanogaster) cpg151a12.rt1a. >gi|798832 (X86683) deep orange (dor) 3091 U95102 Xenopus laevis 2e-005 1125753 (U42833) coded 1.00E-17 mitotic for by C. elegans phosphoprotein cDNA 90 mRNA, CEESN37F; complete cds Similar to ammonium transport protein. [Caenorhabditis elegans] 3092 AF021834 Homo sapiens e-172 125932 TISSUE FACTOR 9e-032 tissue factor PATHWAY pathway inhibitor INHIBITOR beta (TFPIbeta) PRECURSOR mRNA, complete (TFPI) cds (LIPOPROTEIN- ASSOCIATED COAGULATION INHIBITOR) (LACI) (EXTRINSIC PATHWAY INHIBITOR) (EPI) precursor- human >gi|180546 (J03225) lipoprotein- associated coagulation inhibitor precursor associated coagulation 3093 AJ006778 Homo sapiens 0.00E+00 3242214 (AJ006778) DRIM 3e-095 mRNA for DRIM protein [Homo protein sapiens] 3094 AJ006778 Homo sapiens 0.00E+00 3242214 (AJ006778) DRIM 3e.095 mRNA for DRIM protein [Homo protein sapiens] 3095 U95098 Xenopus laevis 6e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3096 AJ006778 Homo sapiens 0 3242214 (AJ006778) DRIM 8.00E-93 mRNA for DRIM protein [Homo protein sapiens] 3097 U95094 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3098 U95094 Xenopus laevis 3.00E-09 1850115 (Z86089) fadD2 1.4 XL-INCENP [Mycobacterium (XL-INCENP) tuberculosis] mRNA, complete cds 3099 U95094 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3100 U95094 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3101 U67986 Bacillus 1.1 2102696 (U72761) 1.90E+00 megaterium karyopherin beta 3 anthranilate [Homo sapiens] synthase (trpD) gene, partial cds, indole glycerol phosphate synthetase N- phosphoribosylan thranilate isomerase (trpF) gene partial cds 3102 U95102 Xenopus laevis 3e-010 2072296 (U95098) mitotic 5.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3103 U95102 Xenopus laevis 1.00E-10 135554 TETRACYCLINE 1.4 mitotic RESISTANCE phosphoprotein PROTEIN 90 mRNA, Bacillus cereus complete cds plasmid pBC16 >gi|72838|pir∥YTS OG tetracycline resistance protein- Streptococcus agalactiae plasmid pMV158 >gi|80428|pir∥JQ1 211 tetracycline resistance protein- Bacillus sp. plasmid pTB19 >gi|151696 (M63 3104 AJ006778 Homo sapiens 0 3242214 (AJ006778) DRIM 8.00E-93 mRNA for DRIM protein [Homo protein sapiens] 3105 U95102 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3106 M60562 Mus musculus 1.10E+00 <NONE> <NONE> <NONE> Mhc class II A beta polypeptide, partial cds (exons 3 and 4) 3107 U91985 Human DNA e-133 2810997 DNA 7e-013 fragmentation FRAGMENTATION factor-45 mRNA, FACTOR-45 complete cds factor-45 [Homo sapiens] 3108 Y11455 S.salar 3.50E-01 3879530 (Z49130) cDNA 0.0001 microsatellite EST yk486b9.3 DNA, CA-repeat comes from this (AC)11.5 gene; cDNA EST yk486b9.5 comes from this gene 3109 Y11455 S.salar 3.50E-01 3879530 (Z49130) cDNA 0.0001 microsatellite EST yk486b9.3 DNA, CA-repeat comes from this (AC)11.5 gene; cDNA EST yk486b9.5 comes from this gene 3110 AF052135 Homo sapiens 4e-033 4098124 (U73522) STAM 5e-033 clone 23625 SH3 domain mRNA sequence associating molecule [Homo sapiens] 3111 U95098 Xenopus laevis 6e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3112 U95102 Xenopus laevis 9e-009 1351538 HYPOTHETICAL 1.4 mitotic PROTEIN MG306 phosphoprotein Mycoplasma 90 mRNA, genitalium (SGC3) complete cds >gi|3844885 (U39711) conserved hypothetical protein [Mycoplasma genitalium] 3113 L78777 Homo sapiens 1.30E-01 <NONE> <NONE> <NONE> (subclone 2_b8 from P1 H49) DNA sequence 3114 U95102 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3115 U29917 Human AMP 3.00E-10 <NONE> <NONE> <NONE> deaminase (AMPD3) gene, exon 8 and 9. 3116 U95102 Xenopus laevis 9e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3117 AE001038 Archaeoglobus 0.14 <NONE> <NONE> <NONE> fulgidus section 69 of 172 of the complete genome 3118 AF042378 Homo sapiens 0 2801699 (AF042378) 4e-080 spindle pole body spindle pole body protein spc98 protein spc98 homolog GCP3 homolog GCP3 mRNA, complete cds 3119 U95094 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3120 U95102 Xenopus laevis 9e-009 1351538 HYPOTHETICAL 1.4 mitotic PROTEIN MG306 phosphoprotein Mycoplasma 90 mRNA, genitalium (SGC3) complete cds >gi|3844885 (U39711) conserved hypothetical protein [Mycoplasma genitalium] 3121 U95102 Xenopus laevis 7.00E-07 133361 DNA-DIRECTED 4.40E+00 mitotic RNA phosphoprotein POLYMERASE 90 mRNA, III 128 KD complete cds POLYPEPTIDE (RNA POLYMERASE III SUBUNIT 2) 2.7.7.6) III second-largest chain-fruit fly polymerase III second-largest subunit [Drosophila melanogaster] 3122 U95102 Xenopus laevis 2.00E-05 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3123 U95102 Xenopus laevis 2.00E-05 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3124 AJ011981 Homo sapiens 2.00E-69 461950 DPY-19 2e-026 mRNA sequence, PROTEIN elegans IMAGE clone >gi|156300 417820 (L12018) putative [Caenorhabditis elegans] 3125 U95102 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3126 U95102 Xenopus laevis 4e-011 2072296 (U95098) mitotic 3.60E+00 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3127 M26216 Rat (lambda 4.10E-02 205752 (M94288) 1.1 20BH0.1) L-type Nopp140 [Rattus 6-phosphofructo- norvegicus] 2-kinase/fructose- 2,6- bisphosphatase 3128 U95094 Xenopus laevis 5.00E-03 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3129 <NONE> <NONE> <NONE> 730888 OCTAPEPTIDE- 5.2 REPEAT PROTEIN T2 >gi|296382 3130 U95102 Xenopus laevis 5.00E-03 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3131 X65446 H.sapiens gene 6e-011 119110 EBNA-1 1e-005 locus DXS278 NUCLEAR (S232-RU2) PROTEIN DNA herpesvirus 4 (strain B95-8) >gi|1334880 (V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 3132 X65446 H.sapiens gene 6e-011 119110 EBNA-1 1e-005 locus DXS278 NUCLEAR (S232-RU2) PROTEIN DNA herpesvirus 4 (strain B95-8) >gi|1334880 (V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 3133 X72219 C.pasteurianum 0.015 <NONE> <NONE> <NONE> gap gene 3134 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3135 Z26494 S.cerevisiae 1.1 3581891 (AL031540) 9.70E+00 genes for histone hypothetical wtf3 H2A and H2B, protein trehalase, and hexaprenyl pyrophosphate synthetase 3136 U95102 Xenopus laevis 4e-011 2072296 (U95098) mitotic 3.60E+00 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3137 AL010234 Plasmodium 0.37 1213606 (X95910) ftsA 4.2 falciparum DNA [Campylobacter *** jejuni] SEQUENCING IN PROGRESS *** from contig 4-55, complete sequence 3138 U28153 Caenorhabditis 0.39 <NONE> <NONE> <NONE> elegans UNC-76 (unc-76) gene, complete cds. 3139 U95102 Xenopus laevis 8.00E-07 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3140 J05073 Human 1.00E-13 281501 phenylalanine-- 7 phosphoglycerate tRNA ligase (EC mutase (PGAM- 6.1.1.20) beta M) gene, chain-Thermus complete cds. aquaticus 3141 M90656 Human gamma- 0 1346190 GLUTAMATE-- 2.00E-71 glutamylcysteine CYSTEINE synthetase (GCS) LIGASE mRNA, complete CATALYTIC cds. SUBUNIT (GAMMA- GLUTAMYLCYS- TEINE SYNTHETASE) glutamate-- cysteine ligase (EC 6.3.2.2) heavy chain-human >gi|183039 (M90656) gamma- glutamylcysteine synthetase [Homo sapiens] 3142 U95098 Xenopus laevis 8e-006 951325 (U31517) nuclear 9.4 mitotic receptor XR78E/F phosphoprotein [Drosophila 44 mRNA, partial melanogaster] cds 3143 AF053551 Homo sapiens 0.00E+00 3283049 (AF053551) 1.00E-79 metaxin 2 metaxin 2 [Homo (MTX2) mRNA, sapiens] nuclear gene encoding mitochondrial protein, complete cds 3144 AF088034 Homo sapiens e-125 1353059 HYPOTHETICAL 9e-023 full length insert 27.4 KD cDNA clone PROTEIN IN ZC24F03 MER2-BNA1 INTERGENIC REGION >gi|1077874|pir∥S 57042 hypothetical protein YJR024c- yeast (Saccharomyces cerevisiae) >gi|1015663 (Z49524) ORF YJR024c gene product [Saccharomyces cerevisiae] 3145 AF087973 Homo sapiens 1e-033 <NONE> <NONE> <NONE> full length insert cDNA clone YU79H10 3146 AF032456 Homo sapiens 8.00E-07 <NONE> <NONE> <NONE> ubiquitin conjugating enzyme G2 3147 Y12259 R.norvegicus 6e-058 <NONE> <NONE> <NONE> mRNA for Kir3.1 protein 3148 U95102 Xenopus laevis 2.00E-07 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3149 X97154 D.willistoni 1.20E+00 3875246 (Z81490) similar 7e-016 mitochondrial to WD domain, G- 125 rRNA gene beta repeats (2 domains); cDNA EST EMBL:T00482 comes from this gene; cDNA EST EMBL:T00923 comes from this gene; cDNA EST yk449d4.3 comes from this gene; cDNA EST yk449d4.5 comes from this gen. . . 3150 U17247 Saccharomyces 1.20E-01 <NONE> <NONE> <NONE> cerevisiae chromosome XII cosmid L2142 3151 U95094 Xenopus laevis 2e-005 172012 (M12087) thr- 0.21 XL-INCENP tRNA-synthetase (XL-INCENP) [Saccharomyces mRNA, complete cerevisiae] cds 3152 L78777 Homo sapiens 1.30E-01 <NONE> <NONE> <NONE> (subclone 2_b8 from P1 H49) DNA sequence 3153 AF053551 Homo sapiens 0.00E+00 3283049 (AF053551) 1.00E-79 metaxin 2 metaxin 2 [Homo (MTX2) mRNA, sapiens] nuclear gene encoding mitochondrial protein, complete cds 3154 X53616 C.domesticus 1.1 <NONE> <NONE> <NONE> calnexin (pp90) mRNA 3155 U95094 Xenopus laevis 0.043 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3156 U95098 Xenopus laevis 0.002 3327080 (AB014533) 4.2 mitotic KIAA0633 protein phosphoprotein [Homo sapiens] 44 mRNA, partial cds 3157 U60337 Homo sapiens 0 3024091 BETA- 4e-068 beta-mannosidase MANNOSIDASE mRNA, complete PRECURSOR cds beta-mannosidase [Homo sapiens] 3158 U32790 Haemophilus 1.1 <NONE> <NONE> <NONE> influenzae Rd section 105 of 163 of the complete genome 3159 U95094 Xenopus laevis 0.12 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3160 U95102 Xenopus laevis 7e-007 1351696 HYPOTHETICAL 1.5 mitotic 30.4 KD phosphoprotein PROTEIN 90 mRNA, C3H1.13 IN complete cds CHROMOSOME I >gi|1103514 (Z68144) unknown 3161 U50535 Human BRCA2 4e-012 728831 !!!! ALU 4.5 region, mRNA SUBFAMILY J sequence CG006 WARNING ENTRY 3162 U95102 Xenopus laevis 3e-009 2132302 hypothetical 4e-022 mitotic protein YPR144c- phosphoprotein yeast similarity 90 mRNA, near C-terminus to complete cds RNA Polymerase beta subunit (Swiss Prot. accession number P11213) and CCAAT-binding transcription factor (PIR accession number A36368) [Saccharomyces cerevisiae] 3163 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3164 U95102 Xenopus laevis 3e-008 3123086 HYPOTHETICAL 1.3 mitotic PROTEIN phosphoprotein MJ1050 90 mRNA, Methanococcus complete cds jannaschii >gi|1499895 (U67548) conserved hypothetical protein [Methanococcus jannaschii] 3165 U95098 Xenopus laevis 0.005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3166 U95098 Xenopus laevis 0.005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3167 U95098 Xenopus laevis 0.005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3168 U95094 Xenopus laevis 1e-011 833783 (X14338) 0.17 XL-INCENP NADH:ubiquinone (XL-INCENP) oxidoreductase mRNA, complete (428 AA) [Bos cds taurus] 3169 M20918 C.thummi piger 0.12 2496813 HYPOTHETICAL 0.12 haemoglobin 59.9 KD (Hb) gene DNA, PROTEIN complete cds. B0304.5 IN CHROMOSOME II >gi|1041884 (U39472) B0304.5 gene product [Caenorhabditis elegans] 3170 U95094 Xenopus laevis 1e-011 100827 NADH 4.1 XL-INCENP dehydrogenase (XL-INCENP) (ubiquinone) (EC mRNA, complete 1.6.5.3) chain 4- cds wheat mitochondrion 3171 U28153 Caenorhabditis 0.38 <NONE> <NONE> <NONE> elegans UNC-76 (unc-76) gene, complete cds. 3172 AJ008065 Chrysolina bankii 0.045 <NONE> <NONE> <NONE> 16S rRNA gene, mitotype B2 3173 AB014591 Homo sapiens 7e-057 3327196 (AB014591) 8e-007 mRNA for KIAA0691 protein KIAA0691 [Homo sapiens] protein, complete cds 3174 U95102 Xenopus laevis 2e-007 3184082 (AL023781) N- 1e-036 mitotic terminal phosphoprotein acetyltransferase 1 90 mRNA, [Schizosaccharom complete cds yces pombe] 3175 U95102 Xenopus laevis 3e-009 3219914 HYPOTHETICAL 2e-011 mitotic 16.8 KD phosphoprotein PROTEIN 90 mRNA, C30D10.04 IN complete cds CHROMOSOME II >gi|2276353|gnl|PI D|e330328 pombe] 3176 U95094 Xenopus laevis 0.002 133361 DNA-DIRECTED 4.3 XL-INCENP RNA (XL-INCENP) POLYMERASE mRNA, complete III 128 KD cds POLYPEPTIDE (RNA POLYMERASE III SUBUNIT 2) 2.7.7.6) III second-largest chain-fruit fly polymerase III second-largest subunit [Drosophila melanogaster] 3177 U95098 Xenopus laevis 2e-006 2429362 (AF020261) 0.033 mitotic proline rich phosphoprotein protein [Santalum 44 mRNA, partial album] cds 3178 U95094 Xenopus laevis 7e-007 3641258 (AF064554) 0.68 XL-INCENP ventral anterior (XL-INCENP) homeobox- mRNA, complete containing protein cds 1 [Mus musculus] 3179 AB018323 Homo sapiens 3e-041 3327168 (AB014577) 2e-021 mRNA for KIAA0677 protein KIAA0780 [Homo sapiens] protein, partial cds 3180 U95102 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3181 U95094 Xenopus laevis 1e-011 3283350 (AF062378) 5e-006 XL-INCENP calmodulin- (XL-INCENP) binding protein mRNA, complete SHA1 [Mus cds musculus] 3182 Z96207 H.sapiens 8e-008 <NONE> <NONE> <NONE> telomeric DNA sequence, clone 12PTEL049, read 12PTELOO049.s eq 3183 AB017026 Mus musculus 0 3882265 (AB018315) 2e-091 mRNA for KIAA0772 protein oxysterol-binding [Homo sapiens] protein, complete cds 3184 U95102 Xenopus laevis 9e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3185 X05283 Drosophila 4.6 <NONE> <NONE> <NONE> melanogaster PKCG7 gene exons 7-14 for protein kinase C 3186 AF026069 Homo sapiens 0.42 <NONE> <NONE> <NONE> phosphomevalona te kinase (HUMPMKI) gene, partial cds 3187 AF052573 Homo sapiens 0 3510695 (AF052573) DNA 4e-011 DNA polymerase polymerase eta eta (POLH) [Homo sapiens] mRNA, complete cds 3188 M80198 Human FKBP-12 5e-014 2315521 (AF016452) 4e-027 pseudogene, similar to the beta clone lambda- transducin family 512, 5′ flank and complete cds. 3189 U95102 Xenopus laevis 8e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3190 AJ001296 Notophthalmus 0.38 1175412 HYPOTHETICAL 2e-020 viridescens 24.2 KD mRNA for PROTEIN cytokeratin 8 C13A11.03 IN CHROMOSOME I >gi|984224 (Z54096) unknown 3191 Z60048 H.sapiens CpG 4e-054 547662 HEPATOCYTE 1e-020 DNA, clone NUCLEAR 187a9, reverse FACTOR 3-BETA read HNF-3 beta- cpg187a9.rt1a. mouse >gi|402191 (X74937) HNF- 3beta [Mus musculus] 3192 U95760 Drosophila 3e-071 2078282 (U95760) Sno 3e-068 melanogaster [Drosophila strawberry notch melanogaster] (sno) mRNA, complete cds 3193 L09604 Homo sapiens 2e-035 <NONE> <NONE> <NONE> differentiation- dependent A4 protein mRNA, complete cds. 3194 AF054994 Homo sapiens 0.12 <NONE> <NONE> <NONE> clone 23832 mRNA sequence 3195 AF026069 Homo sapiens 0.42 <NONE> <NONE> <NONE> phosphomevalona te kinase (HUMPMKI) gene, partial cds 3196 AF026069 Homo sapiens 0.42 <NONE> <NONE> <NONE> phosphomevalona te kinase (HUMPMKI) gene, partial cds 3197 AB007918 Homo sapiens 0.015 138240 GLYCOPROTEIN 8.3 mRNA for E PRECURSOR I KIAA0449 >gi|59566|gnl|PID| protein, partial e312380 (X14112) cds virion glycoprotein E [human herpesvirus 1] >gi|59882 (X02138) glycoprotein gE (Us8) [Human herpesvirus 1] >gi|291496 (L00036) gE protein [Human herpesvirus 1] 3198 L07040 pFNeo eukaryotic 1e-052 2072972 (U93572) putative 1e-019 expression vector, p150 [Homo complete sapiens] sequence. 3199 U95098 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3200 M98502 Mus musculus 5e-014 <NONE> <NONE> <NONE> protein encoding twelve zinc finger proteins (pMLZ- 4) mRNA, complete cds. 3201 M95098 Bos taurus 1.1 3882205 (AB018285) 2e-034 lysozyme gene KIAA0742 protein (cow 2), complete [Homo sapiens] cds 3202 U49169 Dictyostelium 0.12 2126116 cymH protein- 4.2 discoideum V- Klebsiella oxytoca ATPase A >gi|854235 subunit (vatA) mRNA, complete cds 3203 U95102 Xenopus laevis 2e-006 2911548 (Y15173) E2 0.39 mitotic protein [Human phosphoprotein papillomavirus 90 mRNA, type 75] complete cds 3204 Z57610 H.sapiens CpG 7e-090 417134 HEPATOCYTE 5e-019 DNA, clone NUCLEAR 187a10, reverse FACTOR 3-BETA read norvegicus] cpg187a10.rt1a. 3205 U95102 Xenopus laevis 6e-006 4104093 (AF031642) urea 0.51 mitotic transporter UT4 phosphoprotein [Rattus 90 mRNA, norvegicus] complete cds 3206 U95098 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3207 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3208 <NONE> <NONE> <NONE> 2252814 (AF006492) FOG 3.4 [Mus musculus] 3209 AF035940 Homo sapiens e-131 2330011 (AF007862) mm- 4e-044 MAGOH mRNA, Mago [Mus complete cds musculus] >gi|2909828 (AF035939) similar to mago nashi [Mus musculus] >gi|2909830 3210 U49169 Dictyostelium 0.12 1942101 Porcine 1.1 discoideum V- Ribonuclease ATPase A Inhibitor subunit (vatA) Complexed With mRNA, complete Ribonuclease A cds 3211 AF054994 Homo sapiens 0.12 <NONE> <NONE> <NONE> clone 23832 mRNA sequence 3212 AF068627 Mus musculus 0.0005 1869835 (Z86099) protein 0.86 DNA cytosine-5 kinase [human methyltransferase herpesvirus 2] 3B2 (Dnmt3b) mRNA, alternatively spliced, complete cds 3213 X68553 C.elegans 0.41 854065 (X83413) U88 7e-007 repetitive DNA [Human sequence herpesvirus 6] 3214 X68553 C.elegans 0.41 854065 (X83413) U88 7e-007 repetitive DNA [Human sequence herpesvirus 6] 3215 U95098 Xenopus laevis 6e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3216 AF054994 Homo sapiens 0.12 <NONE> <NONE> <NONE> clone 23832 mRNA sequence 3217 U95760 Drosophila 3e-071 2078282 (U95760) Sno 3e-068 melanogaster [Drosophila strawberry notch melanogaster] (sno) mRNA, complete cds 3218 X96400 P.tetraurelia 0.38 <NONE> <NONE> <NONE> alpha-51D gene 3219 U95094 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3220 AF067212 Caenorhabditis 0.005 <NONE> <NONE> <NONE> elegans cosmid F37F2 3221 Y08844 L.esculentum 1.1 <NONE> <NONE> <NONE> PR1a2 gene 3222 Y08844 L.esculentum 1.1 <NONE> <NONE> <NONE> PR1a2 gene 3223 U95094 Xenopus laevis 6.00E-05 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3224 U08214 Rattus sp. DNA 1.1 477513 mesoderm 1.1 binding protein development (URE-B1) regulatory protein mRNA, complete Sna-mouse cds. >gi|54121 (X67253) sna [Mus musculus] 3225 L19713 Human dematin 0.051 <NONE> <NONE> <NONE> (HRD1) mRNA, complete cds. 3226 U95098 Xenopus laevis 0.043 2645389 (U83858) NADH 7.5 mitotic dehydrogenase phosphoprotein subunit 4 44 mRNA, partial [Onychomys cds leucogaster] 3227 U95102 Xenopus laevis 5.00E-03 2662477 (AF034804) 3e-011 mitotic LACK phosphoprotein [Leishmania 90 mRNA, major] complete cds 3228 U95094 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3229 U95102 Xenopus laevis 4e-012 2072296 (U95098) mitotic 6.20E+00 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3230 U95098 Xenopus laevis 0.0005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3231 U95098 Xenopus laevis 0.0005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3232 AF036685 Caenorhabditis 0.38 <NONE> <NONE> <NONE> elegans cosmid C05B10 3233 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3234 AL010153 Plasmodium 6e-005 <NONE> <NONE> <NONE> falciparum DNA *** SEQUENCING IN PROGRESS *** from contig 3-80, complete sequence 3235 U95098 Xenopus laevis 5.00E-04 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3236 U28153 Caenorhabditis 0.39 <NONE> <NONE> <NONE> elegans UNC-76 (unc-76) gene, complete cds. 3237 U95094 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3238 U95094 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3239 X65319 Cloning vector 5.00E-77 987050 (X65335) lacZ 3e-015 pCAT-Enhancer gene product [unidentified cloning vector] 3240 AG000140 Homo sapiens 1.60E-01 2494505 HEPATOCYTE 7.5 genomic DNA, NUCLEAR 21q region, clone: FACTOR 3 T171X2 FORKHEAD HOMOLOG 4 (HFH-4) >gi|2137385|pir∥I4 9734 HNF-3/fork- head homolog-4- mouse >gi|550488 (L13204) HNF- 3/fork-head homolog-4 [Mus musculus] 3241 L77886 Human protein 1.00E-21 139560 SATELLITE RNA 5.9 tyrosine 48 KD PROTEIN phosphatase mRNA, complete cds 3242 U95094 Xenopus laevis 8e-008 3879988 (Z68318) 7.9 XL-INCENP T21B10.4 (XL-INCENP) [Caenorhabditis mRNA, complete elegans] cds 3243 U95094 Xenopus laevis 7e-007 3184286 (AC004136) 7.7 XL-INCENP hypothetical (XL-INCENP) protein mRNA, complete [Arabidopsis cds thaliana] 3244 U95098 Xenopus laevis 5.00E-04 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3245 U95098 Xenopus laevis 0.005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3246 U95098 Xenopus laevis 0.005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3247 U95098 Xenopus laevis 2.00E-05 1050849 (X83742) MAP 4.5 mitotic kinase phosphoprotein phosphatase 44 mRNA, partial [Xenopus laevis] cds 3248 AF084186 Rattus norvegicus 0.39 3123155 HYPOTHETICAL 5.00E-29 alpha-fodrin 49.0 KD TRP- (A2A) mRNA, ASP REPEATS complete cds CONTAINING PROTEIN F55F8.5 IN CHROMOSOME 1 family [Caenorhabditis elegans] 3249 U95094 Xenopus laevis 5.00E-04 3293508 (AF069188) 0.3 XL-INCENP NADH (XL-INCENP) dehydrogenase 1 mRNA, complete [Ephedrus cds laevicollis] 3250 U95094 Xenopus laevis 3e-009 3243110 (AF034976) 4.6 XL-INCENP unknown (XL-INCENP) [Pilayella mRNA, complele littoralis] cds 3251 M77812 Rabbit myosin 0.58 3876408 (Z81069) 3.1 heavy chain Similarity to Yeast mRNA, complete hypothetical 65.2 cds. KD protein (SW:P36076); cDNA EST yk393e9.3 comes from this gene; cDNA EST yk393e9.5 comes from this gene [Caenorhabditis elegans] 3252 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3253 U95094 Xenopus laevis 7e-007 1351841 ISOCITRATE 6.00E+00 XL-INCENP LYASE (XL-INCENP) (ISOCITRASE) mRNA, complete lyase cds [Lycopersicon esculentum] 3254 Z50144 R.norvegicus 2.00E-76 1050752 (Z50144) 6e-033 mRNA for kynurenine/alpha- kynurenine/alpha- aminoadipate aminoadipate aminotransferase aminotransferase 3255 Z50144 R.norvegicus 2.00E-76 1050752 (Z50144) 6e-033 mRNA for kynurenine/alpha- kynurenine/alpha- aminoadipate aminoadipate aminotransferase aminotransferase 3256 U95102 Xenopus laevis 0.043 109340 pepsin (EC 4.5 mitotic 3.4.23.-) II-2/3 phosphoprotein precursor-rabbit 90 mRNA, complete cds 3257 U95102 Xenopus laevis 3e-007 3875769 (Z35662) similar 4.20E-01 mitotic to Approximately phosphoprotein 25 cadherin- 90 mRNA, repeats, 3 EGF complete cds domains and one Laminin G domain; cDNA EST EMBL:D27303 comes from this gene; cDNA EST EMBL:D27305 comes from this gene; cDNA EST EMBL:D27304 comes from this gene; . . . >gi|3876224|gnl|PI D|e134589 3258 AF041059 Homo sapiens 5.90E-02 <NONE> <NONE> <NONE> WSCR4 gene, exon 7 and partial cds 3259 AF054994 Homo sapiens 0.13 <NONE> <NONE> <NONE> clone 23832 mRNA sequence 3260 U87266 Arabidopsis 5.60E-01 1175412 HYPOTHETICAL 2e-009 thaliana 2,3- 24.2 KD oxidosqualene- PROTEIN triterpenoid C13A11.03 IN cyclase mRNA, CHROMOSOME complete cds 1 >gi|984224 (Z54096) unknown 3261 AL010240 Plasmodium 1.3 3882205 (AB018285) 5.00E-10 falciparum DNA KIAA0742 protein *** [Homo sapiens] SEQUENCING IN PROGRESS *** from contig 4-64, complete sequence 3262 L20566 Aspergillus niger 3.9 3777583 (AF084481) 5.00E+00 acid phospatase transmembrane complete cds. protein [Homo sapiens] 3263 U12202 Human ribosomal 3.80E+00 <NONE> <NONE> <NONE> protein S24 (rps24) gene, complete cds 3264 U70139 Mus musculus 0 2251234 (U70139) putative 6e-093 putative CCR4 CCR4 protein protein mRNA, [Mus musculus] partial cds 3265 AF055666 Mus musculus 0.53 3387889 (AF070532) emb- 0.56 kinesin light 5 [Homo sapiens] chain 2 (Klc2) mRNA, complete cds 3266 AF077618 Homo sapiens 0.4 127709 MYOBLAST 7.8 p73 gene, exon 3 DETERMINATION PROTEIN 1 3267 AF072250 Homo sapiens e-161 3800809 (AF072250) 2.00E-47 methyl-CpG methyl-CpG binding protein binding protein MBD4 MBD4 [Homo sapiens] 3268 U95098 Xenopus laevis 8e-009 886048 (U25686) E93 1.8 mitotic [Drosophila phosphoprotein melanogaster] 44 mRNA, partial cds 3269 AG001313 Homo sapiens 0.0005 <NONE> <NONE> <NONE> genomic DNA, 21q region, clone: 125H6N26 3270 U25846 Homarus 1.40E-02 <NONE> <NONE> <NONE> americanus clone LOB5 farnesoic acid o- methyltransferase mRNA, complete cds. 3271 AF068627 Mus musculus 0.0005 1698496 (U53444) LW- 4.40E+00 DNA cytosine-5 amid and MW- methyltransferase amid-containing 3B2 (Dnmt3b) preprohormone mRNA, alternatively spliced, complete cds 3272 U60022 Mus musculus 3.50E+00 2498941 SPLICEOSOME 0.23 antigen ASSOCIATED processing- PROTEIN 62 associated spliceosome- transporter associated protein TAP1-k mRNA, SAP 62-human complete cds >gi|409219 3273 U95102 Xenopus laevis 7e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3274 U24676 Drosophila 1.20E+00 <NONE> <NONE> <NONE> melanogaster twinstar (tsr) gene, complete cds 3275 U95098 Xenopus laevis 1.50E-02 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3276 AF054994 Homo sapiens 0.13 <NONE> <NONE> <NONE> clone 23832 mRNA sequence 3277 AF072250 Homo sapiens e-161 3800809 (AF072250) 2.00E-47 methyl-CpG methyl-CpG binding protein binding protein MBD4 MBD4 [Homo sapiens] 3278 AF054994 Homo sapiens 0.13 <NONE> <NONE> <NONE> clone 23832 mRNA sequence 3279 AF054994 Homo sapiens 0.13 <NONE> <NONE> <NONE> clone 23832 mRNA sequence 3280 AF054994 Homo sapiens 0.13 <NONE> <NONE> <NONE> clone 23832 mRNA sequence 3281 AF054994 Homo sapiens 0.13 <NONE> <NONE> <NONE> clone 23832 mRNA sequence 3282 U95098 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3283 U20281 Gallus gallus 0.017 2642625 (AF032118) 1.40E+00 clone pNG13 cell intersectin division cycle [Xenopus laevis] control protein 37 (cdc37) mRNA, complete cds. 3284 X65279 pWE15 cosmid 2e-059 987050 (X65335) lacZ 3e-015 vector DNA gene product [unidentified cloning vector] 3285 U95094 Xenopus laevis 4e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3286 D80005 Human mRNA 0 <NONE> <NONE> <NONE> for KIAA0183 gene, partial cds 3287 U27341 Bos taurus 1e-096 2136744 endothelin 2e-047 endothelin converting converting enzyme-2-bovine enzyme-2 Sequence 1 from U.S. Pat. No. 5736376 3288 M58417 Drosophila 0.35 1142698 (U26463) 6.8 melanogaster NADPH- laminin B2 gene, dependent complete cds. aldehyde reductase 3289 M58417 Drosophila 0.35 1142698 (U26463) 6.8 melanogaster NADPH- laminin B2 gene, dependent complete cds. aldehyde reductase 3290 AF020043 Homo sapiens 0 1785540 (U82626) e-112 chromosome- basement associated membrane- polypeptide associated chondroitin proteoglycan Bamacan [Rattus norvegicus] 3291 U57368 Mus musculus 0 1336628 (U57368) EGF e-101 EGF repeat repeat transmembrane transmembrane protein mRNA, protein [Mus complete cds. musculus] 3292 AB018323 Homo sapiens 3e-041 3327168 (AB014577) 1e-021 mRNA for KIAA0677 protein KIAA0780 [Homo sapiens] protein, partial cds 3293 X65279 pWE15 cosmid 2e-059 987050 (X65335) lacZ 3e-015 vector DNA gene product [unidentified cloning vector] 3294 X71642 M.musculus 3e-092 <NONE> <NONE> <NONE> GEG-154 mRNA 3295 U95094 Xenopus laevis 1e-009 3879362 (Z81113) similar 3e-005 XL-INCENP to DnaJ, (XL-INCENP) prokaryotic heat mRNA, complete shock protein, cds Zinc finger, C2H2 type; cDNA EST yk290e12.5 comes from this gene; cDNA EST yk290e12.3 comes from this gene; cDNA EST yk447h4.5 comes from this gene; cDNA EST yk474e4. . . 3296 AB017026 Mus musculus 0 3551523 (AB017026) e-103 mRNA for oxysterol-binding oxysterol-binding protein protein, complete cds 3297 U43431 Human DNA 0 2501242 DNA 6e-069 topoisomerase III TOPOISOMERASE mRNA, complete III >gi|1292912 cds. 3298 M35296 Human tyrosine 1.1 2135080 epithelial 1.8 kinase arg gene microtubule- mRNA. associated protein, 115K-human >gi|414115 (X73882) microtubule associated protein [Homo sapiens] 3299 D50646 Mouse mRNA for 1e-031 2136205 stromal cell- 4e-014 SDF2, complete derived factor 2- cds human sapiens] 3300 L34732 Homo sapiens T- 0.35 3875664 (Z83104) 3e-005 cell receptor beta predicted using (TCRB) mRNA Genefinder 3301 AF030558 Rattus norvegicus 1e-013 <NONE> <NONE> <NONE> phosphatidylinositol 5-phosphate 4- kinase gamma mRNA, complete cds 3302 X03100 Human HLA- 2e-018 <NONE> <NONE> <NONE> SB(DP) alpha gene 3303 U95094 Xenopus laevis 2e-006 2950243 (Z98204) extensin 2e-005 XL-INCENP [Hordeum (XL-INCENP) vulgare] mRNA, complete cds 3304 Y13631 Clostridium 1 <NONE> <NONE> <NONE> botulinum P-21, P-47 ntnh, bonT genes 3305 Y13631 Clostridium 1 <NONE> <NONE> <NONE> botulinum P-21, P-47 ntnh, bonT genes 3306 U95102 Xenopus laevis 3e-011 1655830 (U59446) 0.01 mitotic myrosinase- phosphoprotein binding protein 90 mRNA, related protein complete cds 3307 X17538 Butyrivibrio 0.12 1001811 (D64005) 5.2 fibrisolvens end1 hypothetical gene for protein endoglucanase 3308 D42053 Human mRNA 0 577309 (D42053) e-127 for KIAA0091 KIAA0091 gene gene, complete product is related cds to subtilisin. [Homo sapiens] 3309 L81800 Homo sapiens 2e-006 <NONE> <NONE> <NONE> (subclone 2_g9 from P1 H31) DNA sequence 3310 L81800 Homo sapiens 2e-006 <NONE> <NONE> <NONE> (subclone 2_g9 from P1 H31) DNA sequence 3311 K01641 Mouse Ig kappa 3.1 <NONE> <NONE> <NONE> active V-region from 70Z/3 cells. 3312 K01641 Mouse Ig kappa 3.1 <NONE> <NONE> <NONE> active V-region from 70Z/3 cells. 3313 U09954 Human ribosomal e-114 2136121 ribosomal protein 3e-027 protein L9 gene, L9-human 5′ region and >gi|607793 complete cds. 3314 M19735 Homo sapiens 0 179462 (M13519) N- 4e-075 beta- acetyl-beta- hexosaminidase glucosaminidase beta chain prepro-polypeptide mRNA, complete cds. 3315 M31760 Human 2e-016 2981631 (AB012223) 0.018 chromosome 9 ORF2 [Canis t(9;22) breakpoint familiaris] DNA. 3316 U95094 Xenopus laevis 4e-013 495696 (U00067) C. 2.5 XL-INCENP elegans PAR-3 (XL-INCENP) cell polarity mRNA, complete protein cds 3317 U61084 Human phorbolin 0 4097433 (U61084) 7e-099 3 mRNA, phorbolin 3 complete cds [Homo sapiens] 3318 X95161 H.sapiens brca2 5e-024 244126 uroporphyrinogen 0.12 gene exon 11 > :: III synthase, emb|A62786|A62 UROIIIS [human, 786 Sequence 27 Peptide Mutant, from Patent 265 aa] WO9719110 3319 U95094 Xenopus laevis 2e-013 2072296 (U95098) mitotic 3.9 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3320 U95102 Xenopus laevis 8e-008 2143490 LGL-1-mouse 7.2 mitotic >gi|1041889|bbs|1 phosphoprotein 69033 267 aa] 90 mRNA, [Mus sp.] complete cds 3321 U76112 Mus musculus 1e-013 729818 EUKARYOTIC 1.9 translation INITIATION repressor NAT1 FACTOR 4F mRNA, complete SUBUNIT P130 cds (EIF-4F) (MRNA CAP-BINDING PROTEIN COMPLEX SUBUNIT P130) >gi|539297|pir∥B4 8086 translation initiation factor eIF-4F TIF4632- yeast (Saccharomyces cerevisiae) >gi|295677 (L16924) p130 [Saccharomyces cerevisiae 3322 U95094 Xenopus laevis 3e-009 2072296 (U95098) mitotic 5.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3323 U95094 Xenopus laevis 4e-013 495696 (U00067) C. 2.5 XL-INCENP elegans PAR-3 (XL-INCENP) cell polarity mRNA, complete protein cds 3324 U43626 Human 2e-018 2197085 (AF003535) 0.0002 chromosome ORF2-like protein 15q11-q13 [Homo sapiens] putative DNA replication origin in the g- aminobutyric acid receptor b3 and a5 gene cluster 3325 U95102 Xenopus laevis 2e-010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3326 Z48561 E.coli perA, 0.38 2576325 (Y12239) env 7.4 perB, perC and [porcine perD genes endogenous retrovirus] 3327 Z48561 E.coli perA, 0.38 2576325 (Y12239) env 7.4 perB, perC and [porcine perD genes endogenous retrovirus] 3328 U95102 Xenopus laevis 0.002 2576325 (Y12239) env 7.4 mitotic [porcine phosphoprotein endogenous 90 mRNA, retrovirus] complete cds 3329 U95102 Xenopus laevis 0.002 2576325 (Y12239) env 7.4 mitotic [porcine phosphoprotein endogenous 90 mRNA, retrovirus] complete cds 3330 U95098 Xenopus laevis 1e-010 1362915 protein-tyrosine 0.5 mitotic kinase (EC phosphoprotein 2.7.1.112) STK-1 44 mRNA, partial precursor-human cds 3331 X65319 Cloning vector 3e-081 987050 (X65335) lacZ 3e-015 pCAT-Enhancer gene product [unidentified cloning vector] 3332 AB018304 Homo sapiens 0 3882243 (AB018304) 8e-098 mRNA for KIAA076 1 protein KIAA0761 [Homo sapiens] protein, partial cds 3333 Y08460 Mus musculus 1e-085 2225941 (Y08460) Mdes 8e-071 mRNA for Mdes protein [Mus transmembrane musculus] protein 3334 U95102 Xenopus laevis 8e-009 2072296 (U95098) mitotic 5.1 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3335 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3336 U95102 Xenopus laevis 2e-007 2687928 (AE001118) P115 5.2 mitotic protein [Borrelia phosphoprotein burgdorferi] 90 mRNA, complete cds 3337 U94831 Homo sapiens 0 2276460 (U94831) 5e-087 multispanning multispanning membrane membrane protein protein mRNA, [Homo sapiens] complete cds 3338 U14972 Human ribosomal 2e-059 133715 40S 0.0002 protein S10 RIBOSOMAL mRNA, complete PROTEIN S10 cds. 3339 K01254 Human gastrin 5e-005 <NONE> <NONE> <NONE> gene, complete cds. 3340 U08469 Glycine max 3- 3e-051 3876562 (Z81074) 1e-073 methylcrotonyl- Similarity to CoA carboxylase Soybean 3- mRNA, biotin- methylcrotonyl- carrier domain, CoA carboxylase partial cds. (TR:Q42777); cDNA EST EMBL:M75819 comes from this gene; cDNA EST EMBL:M89099 comes from this gene; cDNA EST EMBL:D32737 comes from this gene; cDNA EST EMBL:D327. . . 3341 AB011139 Homo sapiens 0 3043658 (AB011139) e-123 mRNA for KIAA0567 protein KIAA0567 [Homo sapiens] protein, partial cds 3342 U07615 Rattus norvegicus 2e-006 2506877 MUCIN 2 0.0007 mucin mRNA, PRECURSOR partial cds. (INTESTINAL MUCIN 2) >gi|454154 (L21998) mucin [Homo sapiens] 3343 AF061749 Homo sapiens e-154 3372677 (AF061749) 4e-060 tumorous tumorous imaginal imaginal discs discs protein protein Tid56 Tid56 homolog homolog (T1D1) mRNA, complete cds 3344 U95098 Xenopus laevis 0.001 2984587 (AC004472) 3e-008 mitotic P1.11659_3 phosphoprotein [Homo sapiens] 44 mRNA, partial cds 3345 U45998 Onchocerca 2e-008 3880433 (Z66521) similar 2e-051 volvulus to mitochondrial MRS3/MRS4 RNA splicing class MSR4 like mitochondrial protein; cDNA solute carrier EST mRNA, complete EMBL:C09217 cds comes from this gene [Caenorhabditis elegans] 3346 U43626 Human 2e-018 2197085 (AF003535) 0.0002 chromosome ORF2-like protein 15q11-q13 [Homo sapiens] putative DNA replication origin in the g- aminobutyric acid receptor b3 and a5 gene cluster 3347 U95094 Xenopus laevis 3e-009 2072296 (U95098) mitotic 5.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3348 U14972 Human ribosomal 2e-059 133715 40S 0.0002 protein S10 RIBOSOMAL mRNA, complete PROTEIN S10 cds. 3349 M80198 Human FKBP-12 1.00E-10 2315521 (AF016452) 1e-022 pseudogene, similar to the beta clone lambda- transducin family 512, 5′ flank and complete cds. 3350 AB011180 Homo sapiens 5e-077 3043740 (AB011180) 8e-071 mRNA for KIAA0608 protein KIAA0608 [Homo sapiens] protein, partial cds 3351 U45858 Zea mays 4.2 <NONE> <NONE> <NONE> glyceraldehyde-3- phosphate dehydrogenase 3352 U45858 Zea mays 4.2 <NONE> <NONE> <NONE> glyceraldehyde-3- phosphate dehydrogenase 3353 AF035940 Homo sapiens e-141 2330011 (AF007862) mm- 1e-075 MAGOH mRNA, Mago [Mus complete cds musculus] >gi|2909828 (AF035939) similar to mago nashi [Mus musculus] >gi|2909830 3354 AF035940 Homo sapiens e-141 2330011 (AF007862) mm- 1e-075 MAGOH mRNA, Mago [Mus complete cds musculus] >gi|2909828 (AF035939) similar to mago nashi [Mus musculus] >gi|2909830 3355 M24486 Human prolyl 4- e-147 3876769 (Z69637) 4e-012 hydroxylase Similarity to alpha subunit Human Prolyl 4- mRNA, complete hydroxylase alpha cds, clone PA-11. subunit (SW:P4HA_HUMAN); cDNA EST yk219g12.5 comes from this gene; cDNA EST yk319d8.5 comes from this gene; cDNA EST yk339d11.5 comes from this gene; cDNA EST yk371c9.3. . . 3356 Z50144 R.norvegicus 3.00E-93 1050752 (Z50144) 2e-043 mRNA for kynurenine/alpha- kynurenine/alpha- aminoadipate aminoadipate aminotransferase aminotransferase 3357 M24486 Human prolyl 4- e-147 3876769 (Z69637) 4e-012 hydroxylase Similarity to alpha subunit Human Prolyl 4- mRNA, complete hydroxylase alpha cds, clone PA-11. subunit (SW:P4HA_(—) HUMAN); cDNA EST yk219g12.5 comes from this gene; cDNA EST yk319d8.5 comes from this gene; cDNA EST yk339d11.5 comes from this gene; cDNA EST yk371c9.3. . . 3358 U83981 Homo sapiens 0 3258618 (U83981) 8.00E-24 apoptosis apoptosis associated protein associated protein (GADD34) [Homo sapiens] mRNA, complete cds 3359 U30817 Bos taurus very- 1e-010 2765125 (Y11770) very- 4e-013 long-chain acyl- long-chain acyl- CoA CoA dehydrogenase dehydrogenase mRNA, nuclear [Mus musculus] gene encoding mitochondrial protein, complete cds. 3360 Z35094 H.sapiens mRNA 5e-097 2498974 SURFEIT LOCUS 4e-046 for SURF-2 PROTEIN 2 3361 Z35094 H.sapiens mRNA 5e-097 2498974 SURFEIT LOCUS 4e-046 for SURF-2 PROTEIN 2 3362 Z35094 H.sapiens mRNA 5e-097 2498974 SURFEIT LOCUS 4e-046 for SURF-2 PROTEIN 2 3363 Z63829 H.sapiens CpG 5e-022 1050411 (L43146) nuclear 5.4 DNA, clone factor I-B1 90 h2, forward [Xenopus laevis] read cpg90h2.ft1a 3364 AF052573 Homo sapiens 0 3510695 (AF052573) DNA 4e-011 DNA polymerase polymerase eta eta (POLH) [Homo sapiens] mRNA, complete cds 3365 AF092564 Homo sapiens 0 3851586 (AF092564) 6e-052 chromosome- chromosome- associated associated protein- protein-C C [Homo sapiens] 3366 AF031924 Homo sapiens 2.00E-90 <NONE> <NONE> <NONE> homeobox transcription factor barx2 3367 U95102 Xenopus laevis 4e-011 419712 probable 2.6 mitotic transposase phosphoprotein (insertion 90 mRNA, sequence IS1138)- complete cds Mycoplasma pulmonis (SGC3) 3368 U95102 Xenopus laevis 4e-011 419712 probable 2.6 mitotic transposase phosphoprotein (insertion 90 mRNA, sequence IS1138)- complete cds Mycoplasma pulmonis (SGC3) 3369 M24487 Human prolyl 4- e-125 2507090 PROLYL 4- 1e-007 hydroxylase HYDROXYLASE alpha subunit ALPHA mRNA, complete SUBUNIT cds, clone PA-15. PRECURSOR >gi|66338|pir∥DA HUA2 procollagen- proline dioxygenase (EC 1.14.11.2) alpha chain precursor, splice form 2- human >gi|602675 (U14620) alpha- subunit of prolyl 4-hydroxylase [Homo sapiens] 3370 M24487 Human prolyl 4- e-125 2507090 PROLYL 4- 1e-007 hydroxylase HYDROXYLASE alpha subunit ALPHA mRNA, complete SUBUNIT cds, clone PA-15. PRECURSOR >gi|66338|pir∥DA HUA2 procollagen- proline dioxygenase (EC 1.14.11.2) alpha chain precursor, splice form 2- human >gi|602675 (U14620) alpha- subunit of prolyl 4-hydroxylase [Homo sapiens] 3371 U45858 Zea mays 4.2 <NONE> <NONE> <NONE> glyceraldehyde-3- phosphate dehydrogenase 3372 U95102 Xenopus laevis 7e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3373 D50930 Human mRNA 2e-046 <NONE> <NONE> <NONE> for KIAA0140 gene, complete cds 3374 X06461 Herpes simplex 3.00E-04 2924449 (AL022022) 4.00E-05 virus type I PE_PGRS immediate early [Mycobacterium (IE) gene 3 for tuberculosis] transcriptional activator IE175 (=ICP 4) 3375 X06461 Herpes simplex 3.00E-04 2924449 (AL022022) 4.00E-05 virus type I PE_PGRS immediate early [Mycobacterium (IE) gene 3 for tuberculosis] transcriptional activator IE175 (=ICP 4) 3376 X85753 Homo sapiens 7e-059 <NONE> <NONE> <NONE> mRNA for CDK8 protein kinase > :: emb|A61243|A61 243 Sequence 1 from Patent WO9709432 3377 X76192 Mycoplasma sp. 1.2 <NONE> <NONE> <NONE> munIM, munIC and munIR genes. 3378 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3379 M24486 Human prolyl 4- e-147 3876769 (Z69637) 4e-012 hydroxylase Similarity to alpha subunit Human Prolyl 4- mRNA, complete hydroxylase alpha cds, clone PA-11. subunit (SW:P4HA_HUMAN); cDNA EST yk219g12.5 comes from this gene; cDNA EST yk319d8.5 comes from this gene; cDNA EST yk339d11.5 comes from this gene; cDNA EST yk371c9.3. . . 3380 U95102 Xenopus laevis 7e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3381 U95094 Xenopus laevis 1e-010 2119163 collagen alpha 0.005 XL-INCENP 1(III) chain (XL-INCENP) precursor-mouse mRNA, complete cds 3382 AB009357 Homo sapiens 0 1167506 (D76446) TAK1 2e-033 mRNA for TGF- (TGF-beta- beta activated activated kinase) kinase 1b, [Mus musculus] complete cds 3383 D38112 Human 5e-052 14016 (X55654) 1e-014 mitochondrial cytochrome C DNA, complete oxidase II subunit sequence [Homo sapiens] 3384 Z96177 H.sapiens 7e-038 987050 (X65335) lacZ 0.035 telomeric DNA gene product sequence, clone [unidentified 10QTEL040, read cloning vector] 10QTELOO040.s eq 3385 Z96177 H.sapiens 7e-038 987050 (X65335) lacZ 0.035 telomeric DNA gene product sequence, clone [unidentified 10QTEL040, read cloning vector] 10QTELOO040.s eq 3386 U95094 Xenopus laevis 4e-011 2384956 (AF022985) No 6e-029 XL-INCENP definition line (XL-INCENP) found mRNA, complete [Caenorhabditis cds elegans] 3387 AF010484 Homo sapiens ICI 3e-010 <NONE> <NONE> <NONE> YAC 9IA12, right end sequence 3388 U95094 Xenopus laevis 5e-013 113667 !!!! ALU CLASS 0.68 XL-INCENP B WARNING (XL-INCENP) ENTRY !!!! mRNA, complete cds 3389 AJ009761 Homo sapiens 0 4050050 (AF102147) 4.00E-46 mRNA for putative putative dimethyladenosine dimethyladenosine transferase [Homo transferase, sapiens] partial 3390 U95102 Xenopus laevis 0.048 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3391 U95102 Xenopus laevis 0.048 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3392 AL022579 Homo sapiens 1e-070 <NONE> <NONE> <NONE> DNA sequence from clone 47K8 on chromosome Xp11.21-11.23, complete sequence [Homo sapiens] 3393 U37454 Human Down 0.12 <NONE> <NONE> <NONE> Syndrome region of chromosome 21 genomic sequence, clone A31D6-1H7. 3394 AF058954 Homo sapiens 0 3766199 (AF058954) GTP- e-122 GTP-specific specific succinyl- succinyl-CoA CoA synthetase synthetase beta beta subunit subunit (SCS) [Homo sapiens] mRNA, partial cds 3395 U95102 Xenopus laevis 3e-009 3043582 (AB011101) 2e-012 mitotic KIAA0529 protein phosphoprotein [Homo sapiens] 90 mRNA, complete cds 3396 Z23090 H.sapiens mRNA 3e-079 1709972 60S 2e-025 for 28 kDa heat RIBOSOMAL shock protein. PROTEIN L10A (CSA-19) 3397 D14657 Human mRNA 0 3183216 HYPOTHETICAL 2e-026 for KIAA0101 PROTEIN gene, complete KIAA0101 cds sapiens] 3398 D17577 Mouse mRNA for e-121 2497524 KINESIN-LIKE 1e-048 kinesin-like PROTEIN KIF1B protein (Kif1b), mouse complete cds >gi|407339|gnl|PI D|d1005029 (D17577) Kif1b [Mus musculus] 3399 AF091078 Homo sapiens 0 4050050 (AF102147) 1e-048 clone 559 putative unknown mRNA, dimethyladenosine complete transferase [Homo sequence sapiens] 3400 AC000043 Homo sapiens 7e-006 <NONE> <NONE> <NONE> Chromosome 22q13 Cosmid Clone p74a8, complete sequence [Homo sapiens] 3401 AC000043 Homo sapiens 7e-006 <NONE> <NONE> <NONE> Chromosome 22q13 Cosmid Clone p74a8, complete sequence [Homo sapiens] 3402 AF031924 Homo sapiens e-156 <NONE> <NONE> <NONE> homeobox transcription factor barx2 3403 AF031924 Homo sapiens e-157 3882305 (AB018335) 4.5 homeobox KIAA0792 protein transcription [Homo sapiens] factor barx2 3404 L22473 Human Bax alpha 0 728945 APOPTOSIS 9e-075 mRNA, complete REGULATOR cds. BAX, MEMBRANE ISOFORM ALPHA >gi|539664|pir∥A4 7538 bcl-2- associated protein bax alpha splice form-human >gi|388166 3405 U04709 Human adenine e-151 113668 !!!! ALU CLASS 0.91 phosphoribosyl- C WARNING transferase (APRT) ENTRY !!!! gene, 3′ flanking region 3406 U95094 Xenopus laevis 3e-008 3064146 (AF036408) 7.6 XL-INCENP mucin-like protein (XL-INCENP) [Trypanosoma mRNA, complete cruzi] cds 3407 AF093268 Rattus norvegicus e-171 1913909 (U92079) GLGF- 4e-046 homer-1c mRNA, domain protein complete cds Homer [Rattus norvegicus] 3408 U47322 Cloning vector 2.00E-38 987050 (X65335) lacZ 3.00E-03 DNA, complete gene product sequence. [unidentified cloning vector] 3409 U78109 Mus musculus 1.2 2506998 STANNIOCALCIN 1.2 prepro-neurturin (STC) mRNA, complete (CORPUSCLES cds OF STANNIUS PROTEIN) (CS) (HYPOCALCIN) (TELEOCALCIN) 3410 Z96177 H.sapiens 5e-013 <NONE> <NONE> <NONE> telomeric DNA sequence, clone 10QTEL040, read 10QTELOO040.s eq 3411 D50930 Human mRNA 0.00E+00 1235974 (X96713) collagen 5.8 for KIAA0140 [Globodera gene, complete pallida] cds 3412 D50930 Human mRNA 2e-046 <NONE> <NONE> <NONE> for KIAA0140 gene, complete cds 3413 U95102 Xenopus laevis 1e-010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3414 L01777 Yersinia 1.20E-01 <NONE> <NONE> <NONE> pseudotuberculosis (group IIA) rfb gene cluster 3415 D17577 Mouse mRNA for e-130 2497524 KINESIN-LIKE 1e-049 kinesin-like PROTEIN KIF1B protein (Kif1b), mouse complete cds >gi|407339|gnl|PI D|d1005029 (D17577) Kif1b [Mus musculus] 3416 AB014597 Homo sapiens 2e-067 3327208 (AB014597) 6e-050 mRNA for KIAA0697 protein KIAA0697 [Homo sapiens] protein, partial cds 3417 U95094 Xenopus laevis 1.00E-11 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3418 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3419 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3420 AB014597 Homo sapiens 2e-067 3327208 (AB014597) 6e-050 mRNA for KIAA0697 protein KIAA0697 [Homo sapiens] protein, partial cds 3421 U95102 Xenopus laevis 5e-014 2072296 (U95098) mitotic 5.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3422 U95094 Xenopus laevis 8.00E-08 1176456 (S79774) bile salt- 9.4 XL-INCENP dependent lipase, (XL-INCENP) BSDL {EC 3.1.1.-} mRNA, complete [human, fetal cds pancreas, Peptide Partial, 720 aa] [Homo sapiens] 3423 AF100661 Caenorhabditis 0.39 <NONE> <NONE> <NONE> elegans cosmid H20E11 3424 U95098 Xenopus laevis 2.00E-04 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3425 U95102 Xenopus laevis 9.00E-10 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3426 U95102 Xenopus laevis 9.00E−10 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3427 U95094 Xenopus laevis 2.00E−05 3056592 (AC004255) 10 XL-INCENP T1F9.13 (XL-INCENP) [Arabidopsis mRNA, complete thaliana] cds 3428 U89676 Candida albicans 0.12 <NONE> <NONE> <NONE> putative membrane protein (CSP37) gene, complete cds 3429 U95102 Xenopus laevis 5e−014 2072296 (U95098) mitotic 5.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3430 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3431 U95094 Xenopus laevis 2.00E−07 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3432 U95094 Xenopus laevis 2.00E−07 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3433 U95094 Xenopus laevis 2.00E−07 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3434 U95102 Xenopus laevis 4.00E−13 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3435 U95102 Xenopus laevis 4.00E−13 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3436 AB014597 Homo sapiens 2e−067 3327208 (AB014597) 6e−050 mRNA for KIAA0697 protein KIAA0697 [Homo sapiens] protein, partial cds 3437 U95094 Xenopus laevis 2.00E−06 1360669 collagen alpha 1.8 XL-INCENP 1(V) chain (XL-INCENP) precursor - human mRNA, complete sapiens] cds 3438 U65297 Geomys 3.50E+00 <NONE> <NONE> <NONE> breviceps cytochrome b (cytb) gene, mitochondrial gene encoding mitochondrial protein, complete cds 3439 U95094 Xenopus laevis 2.00E−06 3914965 TOXIN BMK-X 4 XL-INCENP PRECURSOR (XL-INCENP) (BMK10) (BMK mRNA, complete M10) cds (NEUROTOXIN M10) >gi|3138981 (AF062563) neurotoxin M10 precursor [Mesobuthus martensii] 3440 U95094 Xenopus laevis 2.00E−06 3914965 TOXIN BMK-X 4 XL-INCENP PRECURSOR (XL-INCENP) (BMK10) (BMK mRNA, complete M10) cds (NEUROTOXIN M10) >gi|3138981 (AF062563) neurotoxin M10 precursor [Mesobuthus martensii] 3441 U95102 Xenopus laevis 3e−011 3413900 (AB007938) 1.40E−02 mitotic KIAA0469 protein phosphoprotein [Homo sapiens] 90 mRNA, complete cds 3442 U95094 Xenopus laevis 1.00E−11 2072296 (U95098) mitotic 4.20E+00 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3443 U95094 Xenopus laevis 1.00E−11 2072296 (U95098) mitotic 4.20E+00 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3444 U95094 Xenopus laevis 8.00E−08 1176456 (S79774) bile salt- 9.4 XL-INCENP dependent lipase, (XL-INCENP) BSDL {EC 3.1.1.—} mRNA, complete (human, fetal cds pancreas, Peptide Partial, 720 aa] [Homo sapiens] 3445 U95102 Xenopus laevis 4.00E−13 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3446 U91543 Homo sapiens 1.00E−61 2961557 (AF050199) 3.70E+00 zinc-finger putative helicase (hZFH) peroxisome mRNA, complete microbody protein cds 175.1 3447 X75258 H. sapiens DNA 1.40E−02 1143020 (U28974) ORF1 9.5 from [Spiroplasma recombination virus] area 3448 U95098 Xenopus laevis 8.00E−08 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3449 U95094 Xenopus laevis 2.00E−07 631089 bat2 protein - 0.055 XL-INCENP human (XL-INCENP) mRNA, complete cds 3450 AL022321 Homo sapiens 1.10E+00 3063453 (AC003981) 7.2 DNA sequence F22O13.15 from PAC 20O8 [Arabidopsis on chromosome thaliana] 22q12.1-12.3. Contains exons 13 and 14 of the SLC5A1 (SGLT1) gene for solute carrier family 5 Sodium- Glucose Cot . . . 3451 AF060798 Homo sapiens 0.00E+00 3372666 (AF060798) 2e−067 myristilated and myristilated and palmitylated palmitylated serine-threonine serine-threonine kinase MPSK kinase MPSK (MPSK1) mRNA, [Homo sapiens] complete cds 3452 AF080399 Drosophila 1.1 3184082 (AL023781) N- 1e−033 melanogaster terminal mitotic acetyltransferase 1 checkpoint [Schizosaccharomyces control protein pombe] kinase BUB1 (Bub1) mRNA, complete cds 3453 AF041259 Homo sapiens 0.00E+00 3879065 (Z81576) R10E8.3 9.7 breast cancer [Caenorhabditis putative elegans] transcription factor (ZABC1) mRNA, complete cds 3454 U95094 Xenopus laevis 3.70E−01 549359 MINOR CAPSID 0.097 XL-INCENP PROTEIN L2 type (XL-INCENP) 26 >gi|396962 mRNA, complete (X74472) late cds protein [Human papillomavirus type 26] 3455 U95102 Xenopus laevis 2.00E−06 2746890 (AF040655) No 9.1 mitotic definition line phosphoprotein found 90 mRNA, [Caenorhabditis complete cds elegans] 3456 U95102 Xenopus laevis 2e−005 3874316 (Z81470) 6.8 mitotic predicted using phosphoprotein Genefinder 90 mRNA, complete cds 3457 V01399 Defective Semliki 0.98 2496616 HYPOTHETICAL 2.1 forest virus RNA. 38.5 KD Derived by serial PROTEIN Y4EE undiluted passaging of the virus in baby hamster kidney cells > :: gb|L00017|SFVD IB semliki forest virus defective interfering (18s di) rna di309. 3458 U95094 Xenopus laevis 4.60E−02 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3459 U95094 Xenopus laevis 6.00E−06 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3460 U95102 Xenopus laevis 0.014 630844 NADH 7.3 mitotic dehydrogenase phosphoprotein chain 2 - fruit fly 90 mRNA, dehydrogenase complete cds subunit 2 [Drosophila erecta] 3461 L49035 Gorilla gorilla 4.70E−01 2058691 (U94836) 4.3 ABC-transporter ERPROT 213-21 (TAP2) mRNA, [Homo Sapiens] complete cds 3462 U67524 Methanococcus 4.10E−02 140229 HYPOTHETICAL 7.3 jannaschii section 82 KD 66 of 150 of the A VIRULENCE complete genome PROTEIN IN A VRBS3 REGION >gi|77844|pir∥JQ0 317 hypothetical 82 K protein - Xanthomonas campestris pv. vesicatoria 3463 U95102 Xenopus laevis 4.00E−12 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3464 U65297 Geomys 3.50E+00 <NONE> <NONE> <NONE> breviceps cytochrome b (cytb) gene, mitochondrial gene encoding mitochondrial protein, complete cds 3465 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3466 U36266 Human beta- 1.20E+00 <NONE> <NONE> <NONE> prime-adaptin (BAM22) gene, exons 18 and 19 3467 AB018327 Homo sapiens 0 3882289 (AB018327)  e−103 mRNA for KIAA0784 protein KIAA0784 [Homo sapiens] protein, partial cds 3468 AB018327 Homo sapiens 0 3882289 (AB018327)  e−103 mRNA for KIAA0784 protein K1AA0784 [Homo sapiens] protein, partial cds 3469 U66789 Human laminin 4.80E−02 3873753 (Z66519) similar 3e−006 alpha 2 chain to phytoene (LAMA2) gene, synthase exon 57 precursor; cDNA EST yk340f7.3 comes from this gene; cDNA EST yk240f7.5 comes from this gene [Caenorhabditis elegans] 3470 AB018327 Homo sapiens 9.00E−88 3882289 (AB018327) 9e−022 mRNA for KIAA0784 protein KIAA0784 [Homo sapiens] protein, partial cds 3471 U95098 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3472 U67524 Methanococcus 4.10E−02 140229 HYPOTHETICAL 7.3 jannaschii section 82 KD 66 of 150 of the A VIRULENCE complete genome PROTEIN IN A VRBS3 REGION >gi|77844|pir∥JQ0 317 hypothetical 82 K protein - Xanthomonas campestris pv. vesicatoria 3473 L13972 Homo sapiens 0.005 <NONE> <NONE> <NONE> beta-galactoside alpha-2,3- sialyltransferase (SIAT4A) mRNA, complete cds 3474 L13972 Homo sapiens 0.005 <NONE> <NONE> <NONE> beta-galactoside alpha-2,3- sialyltransferase (SIAT4A) mRNA, complete cds 3475 AL031222 Caenorhabditis 1.10E−01 <NONE> <NONE> <NONE> elegans cosmid 6R55, complete sequence [Caenorhabditis elegans] 3476 AF070529 Homo sapiens 0 3879532 (Z49130) cDNA 1.56E+00 clone 24525 EST mRNA sequence EMBL:D74028 comes from this gene; cDNA EST EMBL:D71354 comes from this gene; cDNA EST EMBL:D76320 comes from this gene; cDNA EST yk486c7.3 comes from this gene; cDNA EST yk486c7.5 comes from this gene; cDNA . . . 3477 U02567 Mus musculus 1.30E−01 2414601 (Z99295) 5e−005 BALB/c T-cell phosphatidyl antigen 4-1BB synthase gene, complete cds. 3478 AB018327 Homo sapiens 9.00E−88 3882289 (AB018327) 9e−022 mRNA for KIAA0784 protein KIAA0784 [Homo sapiens] protein, partial cds 3479 U95102 Xenopus laevis 1e−011 2315521 (AF016452) 2e−006 mitotic similar to the beta phosphoprotein transducin family 90 mRNA, complete cds 3480 U95094 Xenopus laevis 9e−010 2072296 (U95098) mitotic 5.5 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3481 Y09077 H. sapiens mRNA 0 1235902 (U49844) FRAP- 3e−051 for atr gene > :: related protein gb|U76308|HSU7 [Homo sapiens] 6308 Human protein kinase ATR mRNA, complete cds > :: emb|A61385|A61 385 Sequence 1 from Patent WO9709433 3482 Z48633 H. sapiens mRNA  e−165 1177607 (X92485) pva1 1.9 for [Plasmodium retrotransposon vivax] 3483 U95102 Xenopus laevis 5e−013 111978 mucin-rat 2.6 mitotic phosphoprotein 90 mRNA, complete cds 3484 U95102 Xenopus laevis 3e−010 2072296 (U95098) mitotic 5.4 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3485 X77335 A. thaliana gene 0.13 1401051 (U24160) similar 3.5 for to Dv1-1 product methyltransferase encoded by GenBank Accession Number U10115; dishevelled segment polarity protein homolog [Mus musculus] 3486 AF038660 Homo sapiens  e−144 2995442 (Y12510) 9e−005 chromosome UDPGal:GlcNAc 1p33-p34 beta- b1,4 1,4- galactosyltransferase galactosyltrans- [Homo sapiens] ferase mRNA, complete cds 3487 U65960 Human kinase 1e−021 2120084 reverse 9.7 substrate transcriptase - HASPP28 gene, mouse >gi|558908 5′ flanking region and partial cds 3488 AF058907 Homo sapiens 8e−060 120806 GAG 5e−005 pleiotrophin POLYPROTEIN (PTN) gene, (CONTAINS: exons UV3, UV2 CORE PROTEIN and UV1 P15; INNER COAT PROTEIN P12; CORE SHELL PROTEIN P30) >gi|74562|pir∥FO VDA gag polyprotein - avian spleen necrosis virus (fragment) >gi|61758 (V01200) reading frame (gag?) [Spleen necrosis virus] 3489 U95094 Xenopus laevis 4e−011 3123086 HYPOTHETICAL 2.5 XL-INCENP PROTEIN (XL-INCENP) MJ1050 mRNA, complete Methanococcus cds jannaschii >gi|2499895 (U67548) conserved hypothetical protein [Methanococcus jannaschii] 3490 AF035940 Homo sapiens 5e−096 3879018 (Z81108) similar 5e−027 MAGOH mRNA, to MAGO NASHI complete cds PROTEIN; cDNA ESTyk415g7.3 comes from this gene; cDNA EST yk425g2.3 comes from this gene; cDNA EST yk425g2.5 comes from this gene; cDNA EST yk415g7.5 comes from this gene; cDNA EST yk376g9.3 c . . . 3491 U95102 Xenopus laevis 5e−013 3201662 (AF042191) 3.5 mitotic paraxial phosphoprotein protocadherin; 90 mRNA, PAPC [Danio complete cds rerio] 3492 S80107 membrane-  e−113 244503 (S80107) 2e−030 associated membrane- diazepam binding associated inhibitor diazepam binding inhibitor, MA-DB1 [cattle, brain, Peptide, 552 aa] [Bos taurus] 3493 U95102 Xenopus laevis 4.00E−12 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3494 U95094 Xenopus laevis 6e−015 728834 !!!! ALU 0.29 XL-INCENP SUBFAMILY (XL-INCENP) SB2 WARNING mRNA, complete ENTRY cds 3495 U32794 Haemophilus 1.3 2369865 (Y14131) RNA 5.1 influenzae Rd polymerase section 109 of [grapevine 163 of the leafroll-associated complete genome virus 2] 3496 AF030558 Rattus norvegicus 1e−013 <NONE> <NONE> <NONE> phosphatidylinositol 5-phosphate 4- kinase gamma mRNA, complete cds 3497 D17577 Mouse mRNA for e−121 2497524 KINESIN-LIKE 1e−048 kinesin-like PROTEIN KIF1B protein (Kif1b), mouse complete cds >gi|407339|gnl|PI D|d1005029 (D17577) Kif1b [Mus musculus] 3498 U95102 Xenopus laevis 6e−005 3881824 (Z73899) ZK829.5 1.5 mitotic [Caenorhabditis phosphoprotein elegans] 90 mRNA, complete cds 3499 L35657 Homo sapiens 2e−018 2072296 (U95098) mitotic 3.2 (subclone H8 phosphoprotein 44 5_a10 from P1 35 [Xenopus laevis] H5 C8) DNA sequence. 3500 U95094 Xenopus laevis 1e−009 2072296 (U95098) mitotic 5.6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3501 U95094 Xenopus laevis 1e−009 2072296 (U95098) mitotic 5.6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3502 U95094 Xenopus laevis 9e−010 2072296 (U95098) mitotic 5.5 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3503 U95094 Xenopus laevis 2e−006 2661842 (Y15732) DNA 4e−016 XL-INCENP polymerase beta (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3504 U65960 Human kinase 1e−021 2120084 reverse 9.7 substrate transcriptase - HASPP28 gene, mouse >gi|558908 5′ flanking region and partial cds 3505 L19031 Rattus norvegicus 3e−030 1171883 SODIUM- 2e−025 organic anion INDEPENDENT transporter ORGANIC ANION TRANSPORTER (ORGANIC ANION TAANSPORTING POLYPEPTIDE) anion - rat >gi|410311 (L19031) oatp [Rattus norvegicus] 3506 U60337 Homo sapiens 0 3024091 BETA- 2e−085 beta-mannosidase MANNOSIDASE mRNA, complete PRECURSOR cds beta-mannosidase [Homo sapiens] 3507 X92841 H. sapiens MICA 1e−055 106322 hypothetical 1e−009 gene protein (L1H 3′ region) - human 3508 U50535 Human BRCA2 4e−012 728831 !!!! ALU 4.2 region, mRNA SUBFAMILY J sequence CG006 WARNING ENTRY 3509 AF029984 Lycopersicon 5e−035 3121867 COP1 9e−052 esculentum COP1 REGULATORY homolog (COP1) PROTEIN mRNA, complete sativum] cds 3510 Z59258 H. sapiens CpG 2e−046 3219914 HYPOTHETICAL 2e−009 DNA, clone 16.8 KD 13d2, reverse PROTEIN read cpg13d2.rt1c C30D10.04 IN CHROMOSOME II >gi|2276353|gnl|PI D|e330328 pombe] 3511 U95094 Xenopus laevis 3e−008 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3512 AF004161 Oryctolagus 9e−030 2352427 (AF004161) 1e−025 cuniculus peroxisomal Ca- peroxisomal Ca- dependent solute dependent solute carrier carrier mRNA, complete cds 3513 U15643 Drosophila 0.13 <NONE> <NONE> <NONE> melanogaster ribosomal protein DL11 mRNA, complete cds 3514 U15643 Drosophila 0.13 <NONE> <NONE> <NONE> melanogaster ribosomal protein DL11 mRNA, complete cds 3515 X87212 H. sapiens mRNA e−103 1705632 DIPEPTIDYL- 3e−034 for cathepsin C PEPTIDASE I PRECURSOR TRANSFERASE) >gi|2146949|pir∥S 66504 dipeptidyl - peptidase I (EC 3.4.14.1) precursor - human sapiens] 3516 U28789 Mus musculus  e−101 <NONE> <NONE> <NONE> p53-associated cellular protein PACT mRNA, partial cds 3517 U95102 Xenopus laevis 1e−009 127112 MAK16 5e−022 mitotic PROTEIN phosphoprotein >gi|73269|pir∥BV 90 mRNA, BYK6 MAK16 complete cds protein - yeast (Saccharomyces cerevisiae) cerevisiae] >gi|595561 (U12980) Mak16p: putative nuclear protein [Saccharomyces cerevisiae] 3518 U95102 Xenopus laevis 9e−009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3519 U95094 Xenopus laevis 3e−010 2650142 (AE001070) A. 0.38 XL-INCENP fulgidus predicted (XL-INCENP) coding region mRNA, complete AF0495 cds 3520 U95094 Xenopus laevis 1e−012 2500418 40S 1.6 XL-INCENP RIBOSOMAL (XL-INCENP) PROTEIN S5 mRNA, complete >gi|1203905 cds 3521 AF004161 Oryctolagus 9e−030 2352427 (AF004161) 1e−025 cuniculus peroxisomal Ca- peroxisomal Ca- dependent solute dependent solute carrier carrier mRNA, complete cds 3522 U95102 Xenopus laevis 0.002 121743 GTPASE- 2.8 mitotic ACTIVATING phosphoprotein PROTEIN (GAP) 90 mRNA, (RAS P21 complete cds PROTEIN ACTIVATOR) (P120GAP) (RASGAP) human >gi|182972 (M23379) GTPase-activating protein activating protein [Homo sapiens] 3523 Z46372 R. norvegicus  e−131 3876360 (Z68315) 3e−011 RNA for DNA Similarity to topoisomerase II. Human MAP kinase phosphatase-1 (SW:PTN7_HUM AN) [Caenorhabditis elegans] 3524 X85060 B. taurus cosmid- 1e−051 2072972 (U93572) putative 1e−019 derived p150 [Homo microsatellite sapiens] DNA 3525 D86407 Homo sapiens 0 3322933 (AE001238) DNA 7.5 DNA for ligase (lig) apoER2, [Treponema complete cds, and pallidum] exon 19 3526 D17577 Mouse mRNA for  e−130 2497524 KINESIN-LIKE 1e−049 kinesin-like PROTEIN KIF1B protein (Kif1b), mouse complete cds >gi|407339|gnl|PI D|d1005029 (D17577) Kif1b [Mus musculus] 3527 U95094 Xenopus laevis 2e−007 2414623 (Z99259) putative 4e−009 XL-INCENP phosphotransferase (XL-INCENP) mRNA, complete cds 3528 U95760 Drosophila 1e−075 2076895 (AF002197) 8e−057 melanogaster F20H11.2 gene strawberry notch product (sno) mRNA, [Caenorbabditis complete cds elegans] 3529 X54326 H. sapiens mRNA 0 135104 MULTIFUNCTIONAL 3e−032 for glutaminyl- AMINOACYL- tRNA synthetase TRNA SYNTHETASE (CONTAINS: GLUTAMYL- TRNA SYNTHETASE glutamyl-prolyl- tRNA synthetase - human >gi|31958 3530 Z73360 Human DNA 3e−039 2072955 (U93566) p40 7.8 sequence from [Homo sapiens] cosmid 92M18, BRCA2 gene region chromosome 13q12-13. 3531 Z73360 Human DNA 3e−039 2072955 (U93566) p40 7.8 sequence from [Homo sapiens] cosmid 92M18, BRCA2 gene region chromosome 13q12-13. 3532 Z73360 Human DNA 1e−040 2072955 (U93566) p40 0.012 sequence from [Homo sapiens] cosmid 92M18, BRCA2 gene region chromosome 13q12-13. 3533 Z73360 Human DNA 1e−040 2072955 (U93566) p40 0.012 sequence from [Homo sapiens] cosmid 92M18, BRCA2 gene region chromosome 13q12-13. 3534 U95094 Xenopus laevis 1e−009 3808228 (AF039080) RNA 1.5 XL-INCENP dependent RNA (XL-INCENP) polymerase mRNA, complete [Sphaeropsis cds sapinea RNA virus 2] 3535 U95102 Xenopus laevis 2e−005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA1 complete cds 3536 U95760 Drosophila 3e−060 2078282 (U95760) Sno 1e−042 melanogaster [Drosophila strawberry notch melanogaster] (sno) mRNA, complete cds 3537 U95098 Xenopus laevis 0.13 2832777 (AL021086) 1- 4e−018 mitotic evidence = predicted phosphoprotein by match; 1- 44 mRNA, partial match_accession = cds A202870; 1- match_description = LD03215.5prime LD Drosophila melanogaster embryo BlueScript Drosophila melanogaster cDNA clone LD03215 5prime.; 1- match_species = Drosop . . . 3538 U95760 Drosophila 1e−075 2076895 (AF002197) 8e−057 melanogaster F20H11.2 gene strawberry notch product (sno) mRNA, [Caenorhabditis complete cds elegans] 3539 Z57610 H. sapiens CpG 9e−061 913042 hepatocyte nuclear 2e−014 DNA, clone factor 3 beta, 187a10, reverse HNF3 beta read cpg187a10.rt1a. 3540 X83416 H. sapiens PrP  e−169 1172651 PROTEASE 6.2 gene, exon 2 PRTH >gi|440338 (L27483) neutral protease large subunit [Porphyromonas gingivalis] 3541 AF061016 Homo sapiens 0 2072296 (U95098) mitotic 3.4 UDP-glucose phosphoprotein 44 dehydrogenase [Xenopus laevis] (UGDH) mRNA, complete cds 3542 X07290 Human HF.12 7e−080 1127843 (U41164) 1e−034 gene mRNA Cys2/His2 zinc finger protein [Rattus norvegicus] 3543 U95102 Xenopus laevis 4.00E−12 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3544 U95760 Drosophila 3e−060 2078282 (U95760) Sno 1e−042 melanogaster [Drosophila strawberry notch melanogaster] (sno) mRNA, complete cds 3546 U95094 Xenopus laevis 0.002 1255409 (U53153) similar 7.3 XL-INCENP to mouse bullous (XL-INCENP) pemphigoid mRNA, complete antigen, BPAG2 cds (PIR:A46053) [Caenorhabditis elegans] 3547 U95102 Xenopus laevis 8e−008 2072296 (U95098) mitotic 9.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3548 U95094 Xenopus laevis 2e−005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3549 U95094 Xenopus laevis 0.0002 84605 glycine-rich 4.4 XL-INCENP protein GRP33 - (XL-INCENP) brine shrimp mRNA, complete cds 3550 X83212 H. sapiens 5e−013 807677 (M13101) 0.39 tryptophan unknown protein hydroxylase gene, [Rattus promoter region norvegicus] 3551 U95102 Xenopus laevis 0.005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3552 U95094 Xenopus laevis 4e−012 310622 (L20249) 0.4 XL-INCENP homologous to (XL-INCENP) Saccharopolyspora mRNA, complete erythraea beta- cds ketoacyl synthase [Streptomyces coriofaciens] 3553 U95102 Xenopus laevis 7e−007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3554 U95094 Xenopus laevis 8e−007 2996640 (AC004500) GDF- 8.2 XL-INCENP 9 [Homo sapiens] (XL-INCENP) mRNA, complete cds 3555 Z35928 S. cerevisiae 0.043 2384728 (AF015883) 0.23 chromosome II hydroxyproline- reading frame rich glycoprotein ORF YBR059c gas28p precursor [Chlamydomonas reinhardtii] 3556 Z30174 M. domesticus 2e−037 543345 zinc finger protein 1e−020 (C57B1/6J) 30 - mouse mRNA for zinc domesticus] finger protein 30 3557 U95102 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3558 M36072 Human ribosomal 1e−054 133014 60S 0.019 protein L7a (surf RIBOSOMAL 3) large subunit PROTEIN L7A mRNA, complete (PLA-X cds. POLYPEPTIDE) (SURF-3) >gi|71116|pir∥R5H U7A ribosomal protein L7a - human >gi|71117|pir∥R5R T7A ribosomal protein L7a - rat >gi|34203 (X52138) L7a protein [Homo sapiens] >gi|35512 (X06705) PLA-X polypeptide [Homo sapiens] 3559 U84720 Homo sapiens 2e−037 <NONE> <NONE> <NONE> mRNA export protein (RAE1) mRNA, complete cds 3560 AE001054 Archaeoglobus 1.2 <NONE> <NONE> <NONE> filgidus section 53 of 172 of the complete genome 3561 U34683 Human 3e−052 1346191 GLUTATHIONE 1e−014 glutathione SYNTHETASE synthetase (GLUTATHIONE mRNA, complete SYNTHASE) cds (GSH SYNTHETASE) (GSH-S) sapiens] >gi|1236350 (U34683) glutathione synthetase 3562 U95102 Xenopus laevis 6e−015 1825695 (U88180) similar 4e−012 mitotic to molybdenum phosphoprotein cofactor 90 mRNA, biosynthesis complete cds protein E [Caenorhabditis elegans] 3563 AE001421 Plasmodium 0.005 <NONE> <NONE> <NONE> falciparum chromosome 2, section 58 of 73 of the complete sequence 3564 D10871 Human h NAT 5e−016 3915580 ZINC FINGER 0.96 allele 2—2 gene PROTEIN 186 for arylamine N- finger protein acetyltransferase [Homo sapiens] 3565 M32251 Cat LINE-1 DNA 2e−026 87765 hypothetical L1 2e−011 sequence region protein (third 1. intron of gene TS) - human >gi|364964|prf∥15 10254A L1 repetitive element ORF [Homo sapiens] 3566 Y12773 H. sapiens 3e−008 <NONE> <NONE> <NONE> TRIDENT/HFH1 1 gene, promoter sequence 3567 U95102 Xenopus laevis 3e−010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3568 U95102 Xenopus laevis 1e−010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3569 U95094 Xenopus laevis 9e−009 136821 HYPOTHETICAL 6 XL-INCENP PROTEIN UL13 (XL-INCENP) precursor - human mRNA, complete cytomegalovirus cds (strain AD169) 3570 AF039210 Homo sapiens  e−104 3347857 (AF064019) DNA 1e−024 caspase-activated fragmentation nuclease mRNA, factor 40 kDa complete cds subunit [Homo sapiens] >gi|3410909|gnl|PI D|d1033212 (AB013918) CAD 3571 U95102 Xenopus laevis 4e−012 2132458 probable 7.5 mitotic membrane protein phosphoprotein YDL211c - yeast 90 mRNA, complete cds 3572 U95094 Xenopus laevis 4e−011 2072296 (U95098) mitotic 0.39 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3573 U22233 Human 2e−015 2494053 5′- 0.02 methylthioadenosine METHYLTHIO- phosphorylase ADENOSINE (MTAP) mRNA, PHOSPHORYLASE complete cds. (MTA PHOSPHORYLASE) (MTAPASE) phosphorylase (EC 2.4.2.28) - human >gi|847724 (U22233) methylthioadenosine phosphorylase [Homo sapiens] 3574 X76122 A. majus cyclin-1 3.2 2135633 MHC cell surface 9 mRNA. glycoprotein - human sapiens] 3575 U95102 Xenopus laevis 1e−009 699508 (U20542) 0.64 mitotic lethal(1)1Bi phosphoprotein protein 90 mRNA, [Drosophila complete cds melanogaster] 3576 D13391 Human CYP19 2e−018 <NONE> <NONE> <NONE> gene for aromatase cytochrome P- 450, promoter region (containing two cis-acting transcriptional regulatory elements) 3577 U95102 Xenopus laevis 0.0002 532806 (U13875) C26E6.5 5e−045 mitotic gene product phosphoprotein [Caenorhabditis 90 mRNA, elegans] complete cds 3578 X63735 H. sapiens TRE5 4e−033 728831 !!!! ALU 9e−006 and TRE18 SUBFAMILY J sequence of the WARNING tre oncogene ENTRY 3579 AC004497 Homo sapiens 0.0005 <NONE> <NONE> <NONE> chromosome 21, P1 clone LBNL#6 3580 AB003095 Fruitfly strain 0.12 <NONE> <NONE> <NONE> S1259 mitochondrial DNA, A + T-rich region, partial sequence 3581 Z36019 S. cerevisiae 3.2 4107113 (AB007462) Pax- 5.3 chromosome II 2/5/8 [Ephydatia reading frame fluviatilis] ORF YBR150c 3582 Z56421 H. sapiens CpG 1e−033 3876101 (Z75536) similar 1e−040 DNA, clone to DnaJ domain; 117c7, reverse cDNA EST read yk398h12.5 comes cpg117c7.rt1a. from this gene; cDNA EST yk250d6.5 comes from this gene [Caenorhabditis elegans] 3583 U36499 Human 5e−015 1362890 phosphoprotein 75 - 1e−008 lymphoid-specific human SP100 homolog >gi|402148 (LYSP100-A) mRNA, complete cds 3584 U95098 Xenopus laevis 5e−005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3585 U95102 Xenopus laevis 0.002 1045228 (X92429) 0.84 mitotic Synthetase phosphoprotein [Streptomyces 90 mRNA, anulatus] complete cds 3586 D86963 Human mRNA 0.04 <NONE> <NONE> <NONE> for KIAA0208 gene, complete cds 3587 U95094 Xenopus laevis 1e−012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3588 AB012113 Homo sapiens 0.0002 1723187 112.3 KD 4.2 gene for CC PROTEIN IN chemokine PARC PYK1-SNC1 precursor, INTERGENIC complete cds REGION >gi|2131258|pir∥S 70292 FUN12 protein Fun12p: 97 kDa protein, function unknown [Saccharomyces cerevisiae] 3589 U95094 Xenopus laevis 3e−007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3590 U95098 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3591 U95098 Xenopus laevis 6e−005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3592 U95094 Xenopus laevis 1e−009 2072296 (U95098) mitotic 2.8 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3593 U95094 Xenopus laevis 3e−006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3594 M80938 Oryza sativa 16.9 1.5 <NONE> <NONE> <NONE> kDa heat shock protein gene, complete cds. 3595 U95094 Xenopus laevis 5e−014 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3596 U95094 Xenopus laevis 1e−012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3597 X67813 C. familiaris 4e−083 2072296 (U95098) mitotic 6.2 SRP72 mRNA phosphoprotein 44 for signal [Xenopus laevis] recognition particle 3598 AB007930 Homo sapiens 3e−038 3413884 (AB007930) 3e−016 mRNA for KIAA0461 KIAA0461 perotein [Homo perotein, partial sapiens] cds 3599 U95098 Xenopus laevis 8e−007 3093586 (AF018165) 2.7 mitotic amyloid precursor phosphoprotein protein [Tetraodon 44 mRNA, partial fluviatilis] cds 3600 Z35102 H. sapiens mRNA  e−126 2135799 Ndr protein kinase - 9e−086 for Ndr protein human kinase > :: >gi|854170 emb|A52140|A52 140 Sequence 6 from Patent WO9619579 3601 U95102 Xenopus laevis 2e−005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3602 X51544 Synthetic 0.13 1706266 SULFATE 5.8 hamster-human ADENYLATE hybrid cell TRANSFERASE (HCH-1) HSAG- SUBUNIT 2 2 gene Alu repeat (ATP- region. SULFURYLASE) >gi|1322409|gnl|PI D|e243270 3603 Z98237 H. sapiens DNA 3e−051 3979947 (AL034393) 6e−005 for exon trapped Y18D10A.15 sequence [Caenorhabditis elegans] 3604 U95098 Xenopus laevis 7e−005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3605 M57465 N. crassa 0.29 <NONE> <NONE> <NONE> phytoene dehydrogenase (a1-1) gene, complete cds. 3606 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3607 S71335 Aox1 = alternative 1.1 <NONE> <NONE> <NONE> oxidase {alternative pathway} suspension cells, mRNA, 1408 nt] 3608 U95098 Xenopus laevis 0.005 2621440 (AE000823) O- 5.7 mitotic antigen transporter phosphoprotein related protein 44 mRNA, partial cds 3609 U36199 Caenorhabditis 1.1 259519 (S48091) NSM 4.1 elegans CeMef-2 [tomato spotted (mef-2) gene, wilt virus TSWV, complete cds. Peptide, 302 aa] [Tomato spotted wilt virus] 3610 U95102 Xenopus laevis 0.35 3399767 (U76298) 0.35 mitotic uclacyanin I phosphoprotein [Arabidopsis 90 mRNA, thaliana] complete cds >gi|3831466 3611 AF000590 Homo sapiens 7e−026 <NONE> <NONE> <NONE> chromosome 21q11-q21 genomic clone SA-292 3612 U64195 HIV-1 isolate 1.2 <NONE> <NONE> <NONE> ZP36 from Australia, reverse transcriptase (pol) gene, partial cds. 3613 AB015331 Homo sapiens 1e−094 3970852 (AB015331) 0.0001 HRIHFB2017 HRIHFB2017 mRNA, partial [Homo sapiens] cds 3614 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3615 U95102 Xenopus laevis 1e−009 1743885 (U79716) Human 9.5 mitotic Reelin [Homo phosphoprotein sapiens] 90 mRNA, complete cds 3616 U95094 Xenopus laevis 3e−006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3617 <NONE> <NONE> <NONE> 2338034 (AF005370) 2e−008 putative immediate early protein [Alcelaphine herpesvirus 1) 3618 U95094 Xenopus laevis 0.006 2707286 (AF036316) cyclin 1.2 XL-INCENP [Prorocentrum (XL-INCENP) minimum] mRNA, complete cds 3619 X79810 R. norvegicus 0.049 2916892 (AL022004) 1 CYP2C13 gene PE_PGRS [Mycobacterium tuberculosis] 3620 AJ224516 Gallus gallus IL-2 1.4 <NONE> <NONE> <NONE> gene 3621 Z79044 H. sapiens flow- 0.42 <NONE> <NONE> <NONE> sorted chromosome 6 HindIII fragment, SC6pA21C9 3622 U39357 Ovis aries beta 2e−024 2072296 (U95098) mitotic 1.3 actin mRNA, phosphoprotein 44 complete cds [Xenopus laevis] 3623 U39357 Ovis aries beta 1e−043 940346 (U20963) ORF1; 5.6 actin mRNA, late mRNA [Suid complete cds herpesvirus 1] 3624 U95098 Xenopus laevis 3e−008 2702361 (AF036706) No 0.22 mitotic definition line phosphoprotein found 44 mRNA, partial [Caenorhabditis cds elegans] 3625 U95098 Xenopus laevis 0.041 244874 Glvr-1 product 1.9 mitotic [mice, Peptide, phosphoprotein 681 aa] 44 mRNA, partial cds 3626 U95094 Xenopus laevis 0.002 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3627 U95094 Xenopus laevis 0.002 1730141 FRAGILE X 9.4 XL-INCENP MENTAL (XL-INCENP) RETARDATION mRNA, complete SYNDROME cds RELATED PROTEIN 2 >gi|2135129|pir∥S 60173 fragile X mental retardation syndrome related protein - human >gi|1098637 (U31501) fragile X mental retardation syndrome related protein [Homo sapiens] 3628 U95094 Xenopus laevis 8e−008 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3629 U95094 Xenopus laevis 6e−006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3630 D87671 Rat mRNA for 0 1799570 (D87671) TIP120  e−112 TIP120, complete [Rattus cds norvegicus] 3631 D87671 Rat mRNA for 0 1799570 (D87671) TIP120  e−110 TIP120, complete [Rattus cds norvegicus] 3632 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3633 D88349 Chicken mRNA 0.12 2144081 luteinizing 9.3 for tyrosinase, hormone/chorionic complete cds gonadotropin receptor - rat >gi|252167|bbs|10 9910 (S40803) luteinizing hormone/chorionic gonadotropin receptor, LH/CG receptor {alternatively spliced, clone rLHR1834} 3634 X17206 Human mRNA 3e−025 2920827 (U92697) 0.0003 for LLRep3 ribosomal protein S2 [Rattus norvegicus] 3635 U95102 Xenopus laevis 4e−011 2072296 (U95098) mitotic 3.3 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3636 X69878 H. sapiens Flt4 2e−088 <NONE> <NONE> <NONE> mRNA for transmembrane tyrosine kinase 3637 X69878 H. sapiens Flt4 2e−088 <NONE> <NONE> <NONE> mRNA for transmembrane tyrosine kinase 3638 X15509 Human gene for 4e−011 <NONE> <NONE> <NONE> thymidine kinase, 5′ region (EC 2.7.1.21) 3639 U89744 Rattus norvegicus 0.39 1085432 mucin (clone 0.0006 putative cell PGM-2A) - pig surface antigen mRNA, complete cds 3640 L29252 Human (clone 3e−006 83981 NADH 2.4 D13-2) L-iditol-2 dehydrogenase dehydrogenase (ubiquinone) (EC gene, exon 4, 1.6.5.3) chain 4 - exon 5, exon 6 Sauroleishmania and exon 7. tarentolae mitochondrion 3641 Z35286 H. sapiens MDR3 0.016 <NONE> <NONE> <NONE> gene, exon1, exon2 3642 M11373 Simian T-cell 0.39 2773324 (AF040381) 5.9 leukemia virus, carbonic pol-env-pX-3′ anhydrase LTR region. [Erwinia carotovora] 3643 M11373 Simian T-cell 0.39 2773324 (AF040381) 5.9 leukemia virus, carbonic pol-env-pX-3′ anhydrase LTR region. [Erwinia carotovora] 3644 Z11763 O. granulifera 0.39 2138321 (U89012) dentin 2.6 gene for alpha- matrix acidic tubulin phosphoprotein 1 [Homo sapiens] 3645 <NONE> <NONE> <NONE> 1352944 HYPOTHETICAL 3.9 118.4 KD PROTEIN IN BAT2-DAL5 INTERGENIC REGION PRECURSOR YJR151c - yeast (Saccharomyces cerevisiae) >gi|1015903 3646 U18351 Drosophila 0.005 1468983 (U64830) protein 4e−012 melanogaster tyrosine kinase insulin receptor [Dictyostelium gene, complete discoideum] cds 3647 M28458 Human growth 1.2 2648877 (AE000987) A. 8.1 hormone receptor fulgidus predicted gene, exon 2. coding region AF1681 3648 AF069139 HIV-1 isolate 0.13 <NONE> <NONE> <NONE> DH12 clone 5 from the USA, vpr protein (vpr) gene, partial cds; tat protein (tat) and rev protein (rev) genes, complete cds; vpu pseudogene, complete sequence; envelope glycoprotein (env) and nef protein (n . . . 3649 U42627 Rattus norvegicus 0.41 1070602 collagen alpha 0.55 tyrosine 1(II) chain phosphatase precursor - human mRNA, complete cds. 3650 Y12851 Homo sapiens 0.005 <NONE> <NONE> <NONE> P2X7 gene, exon 1 and joined CDS 3651 U39706 Mycoplasma 0.39 465542 HYPOTHETICAL 2 genitalium 20.0 KD section 28 of 51 PROTEIN IN of the complete TRNP 5′REGION genome (ORF160) >gi|625956|pir∥S3 8599 hypothetical protein 160 (rpl20 5′ region) - euglenid (Astasia longa) plastid 3652 Z80361 H. sapiens HLA- 2e−048 <NONE> <NONE> <NONE> DRB pseudogene, repeat region; 3653 U12171 Oryza sativa IR54 3.5 <NONE> <NONE> <NONE> anther specific (RTS2) gene, complete cds. 3654 AG001163 Homo sapiens 5e−014 728831 !!!! ALU 0.004 genomic DNA, SUBFAMILY J 21q region, clone: WARNING Q94A10X26 ENTRY 3655 X04780 Human tRNA- 4.6 <NONE> <NONE> <NONE> Tyr-pseudogene (clone pHtT2) 3656 AF086264 Homo sapiens 0.002 <NONE> <NONE> <NONE> full length insert cDNA clone ZD43A10 3657 AB011118 Homo sapiens 0.002 1588661 tryptase [Bos 1.3 mRNA for taurus] KIAA0546 protein, partial cds 3658 Z46379 Homo sapiens 0.13 <NONE> <NONE> <NONE> mRNA for anti- Sm antibody VH chain 3659 Y12930 H. rustica CHD-W 0.39 3861232 (AJ235272) 1.2 gene, intron PROBABLE TRANSPORT ATP-BINDING PROTEIN MSBA (msbA2) [Rickettsia prowazekii] 3660 AF093267 Rattus norvegicus 0.005 <NONE> <NONE> <NONE> homer-1b mRNA, complete cds 3661 M34057 Human 0.043 <NONE> <NONE> <NONE> transforming growth factor- beta 1 binding protein mRNA, complete cds. 3662 X75418 H. sapiens TCR V 0.4 <NONE> <NONE> <NONE> Beta 13.2 gene (allele a). 3663 Z68758 Human DNA 2e−025 3399771 (AF041839) 0.39 sequence from Smad6 [Xenopus cosmid cN85E10 laevis] on chromosome 22q11.2-qter 3664 U95102 Xenopus laevis 2e−005 2078282 (U95760) Sno 0.0006 mitotic [Drosophila phosphoprotein melanogaster] 90 mRNA, complete cds 3665 Z75032 S. cerevisiae 0.14 <NONE> <NONE> <NONE> chromosome XV reading frame ORF YOR124c 3666 U28831 Human protein 0 896065 (U28831) protein  e−100 immuno-reactive that is immuno- with anti-PTH reactive with anti- polyclonal PTH polyclonal antibodies antibodies [Homo mRNA, partial sapiens] cds. > :: gb|I40055|I40055 Sequence 1 from U.S. Pat. No. 5618695 3667 U95098 Xenopus laevis 0.04 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3668 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3669 Z96359 H. sapiens 7e−006 2921609 (AF039037) 7.7 telomeric DNA 980219 -this used sequence, clone to be part of 17QTEL013, read R02C2.4 but was 17QTELOO013.s split into two eq genes based on protein similarities 3670 U95098 Xenopus laevis 8e−008 3342730 (AC005331) 2e−019 mitotic R31341_1 [Homo phosphoprotein sapiens] 44 mRNA, partial cds 3671 U22460 Ictalurus 1.2 2143951 Ras-related protein - 5e−009 punctatus heat rat >gi|498257 shock protein 70 (CF Hsp70) mRNA, complete cds. 3672 Y12259 R. norvegicus 0.005 135213 TYPE IIS 9.9 mRNA for Kir3.1 RESTRICTION protein ENZYME EC057I METHYLTRANS FERASE ACTIVITY >gi|281976|pir∥S2 6426 type II site- specific deoxyribonuclease (EC 3.1.21.4) Eco57I endonuclease [Escherichia coli] 3673 U95094 Xenopus laevis 8e−008 3006154 (AL022299) 4.5 XL-INCENP putative (XL-INCENP) cytochrome c1, mRNA, complete heme protein cds precursor [Schizosaccharomyces pombe] 3674 U95102 Xenopus laevis 6e−006 3915503 HYPOTHETICAL 2e−021 mitotic OXIDOREDUCTASE phosphoprotein IN CHEV- 90 mRNA, MOBA complete cds INTERGENIC REGION >gi|2632227|gnl|PI D|e1181911 1- dehydrogenase [Bacillus subtilis] 3675 U71363 Human zinc 3e−070 2689441 (AC003682) 4e−029 finger protein F18547_1 [Homo zfp6 (ZF6) sapiens] mRNA, partial cds 3676 AF042275 Oryza sativa 0.39 <NONE> <NONE> <NONE> anther-specific protein gene, complete cds 3677 M34601 P. berghei 0.13 <NONE> <NONE> <NONE> telomeric repeat region subfragment alpha DNA. 3678 U09368 Human zinc 6e−047 3445181 (AC005498) 4e−027 finger protein R31665_2 [Homo ZNF140 sapiens] 3679 D90345 Rat t complex 0.13 <NONE> <NONE> <NONE> polypeptide 1 (Tcp-1) mRNA 3680 AE000758 Aquifex aeolicus 0.38 134134 RYANODINE 9.8 section 90 of 109 RECEPTOR, of the complete SKELETAL genome MUSCLE muscle - rabbit >gi|1710 (X15750) ryanodine receptor (AA 1-5037) [Oryctolagus cuniculus] >gi|1714 (X15209) ryanodine receptor [Oryctolagus cuniculus] 3681 X60280 Vector plasmid 3e−040 2981631 (AB012223) 0.87 pLTRpoly DNA ORF2 [Canis familiaris] 3682 U95102 Xenopus laevis 3e−010 2072296 (U95098) mitotic 5.8 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3683 L81683 Homo sapiens 3e−019 113668 !!!! ALU CLASS 2 (subclone 1_d11 C WARNING from P1 H54) ENTRY !!!! 3684 U95102 DNA sequence Xenopus laevis 1e−012 2072296 (U95098) mitotic 9.7 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3685 U95102 Xenopus laevis 2e−012 2072296 (U95098) mitotic 6.8 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3686 X78261 H. sapiens mRNA 3e−010 728836 !!!! ALU 4.4 for TRE17 5′ SUBFAMILY SP extremity and WARNING unnamed adjacent ENTRY to TRE17, locus tre-1. 3687 AF093204 Gallus gallus 1e−011 3694883 (AF093204) 0.097 clone Ocya1 unknown [Gallus unknown mRNA gallus] 3688 L35664 Homo sapiens 3e−031 2072966 (U93570) p40 8e−006 (subclone H8 [Homo sapiens] 8_f5 from P1 35 H5 C8) DNA sequence. 3689 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3690 L10111 Octopus dofleini 0.14 <NONE> <NONE> <NONE> beta-tubulin mRNA, complete cds. 3691 S83333 CYP27 = sterol 3.5 <NONE> <NONE> <NONE> 27- hydroxylase/ cerebrotendinous xanthomatosis candidate gene {3′ region, intron 6 to intron 8} [human, Genomic, 1725 nt, segment 4 of 4] 3692 U95102 Xenopus laevis 4e−011 2072296 (U95098) mitotic 5.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3693 U95102 Xenopus laevis 9e−009 220578 (D00570) open 1.1 mitotic reading frame (251 phosphoprotein AA) 90 mRNA, complete cds 3694 U95102 Xenopus laevis 1e−010 416563 INTESTINAL 0.021 mitotic MEMBRANE A4 phosphoprotein PROTEIN A4 90 mRNA, differentiation- complete cds dependent protein [Homo sapiens] 3695 AB018374 Mus musculus 4e−074 3724364 (AB018374) 2e−017 GARP34 mRNA, GARP34 [Mus complete cds musculus] 3696 AB018374 Mus musculus 4e−074 3724364 (AB018374) 2e−017 GARP34 mRNA, GARP34 [Mus complete cds musculus] 3697 AB013721 Oryctolagus 4e−038 <NONE> <NONE> <NONE> cuniculus mRNA for mitsugumin 23, complete cds 3698 U33147 Human 1.1 1946371 (U93215) 2.5 mammaglobin regulatory protein mRNA, complete Viviparous-1 cds > :: isolog gb|I65735|I65735 Sequence I from U.S. Pat. No. 5668267 3699 U95098 Xenopus laevis 0.0006 2132981 probable 5.1 mitotic membrane protein phosphoprotein YPL105c - yeast 44 mRNA, partial cds 3700 U08802 HIV-1 sample 0.47 3880139 (Z68121) 7.3 026 clone 06 Similarity to Yeast from Thailand nitrogen partial cds. regulatory protein GLN3 (PIR Acc. No. S22280) 3701 U95094 Xenopus laevis 2e−011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3702 U95102 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3703 U95094 Xenopus laevis 1e−011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3704 Z56740 H. sapiens CpG 4e−043 2465332 (U92819) 0.007 DNA, clone unnamed HERV- 13b5, reverse H protein [Homo read cpg13b5.rt1c. sapiens] 3705 U95094 Xenopus laevis 1e−008 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3706 U95094 Xenopus laevis 3e−009 1293790 (U56248) Similar 2.9 XL-INCENP to polyketide (XL-INCENP) synthase. mRNA, complete [Caenorhabditis cds briggsae] 3707 AF023283 Chikungunya 0.39 3560261 (AL031535) RNA 4.5 virus S27 3′UTR binding protein 3708 U95102 Xenopus laevis 2e−006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3709 AF030944 Brugia malayi 0.12 <NONE> <NONE> <NONE> microfilarial sheath protein SHP3a 3710 AE000700 Aquifex aeolicus 0.15 <NONE> <NONE> <NONE> section 32 of 109 of the complete genome 3711 AJ001050 Homo sapiens 4e−042 1843434 (D88687) KM- 3e−038 mRNA for 102-derived thioredoxin reductase-like reductase factor [Homo sapiens] 3712 U95098 Xenopus laevis 0.002 625090 (U19464) outer 2.7 mitotic arm dynein beta phosphoprotein heavy chain 44 mRNA, partial [Paramecium cds tetraurelia] >gi|1588498|prf∥2 208428A dynein:SUBUNIT = heavy chain [Paramecium tetraurelia] 3713 AG001414 Homo sapiens 0.46 <NONE> <NONE> <NONE> genomic DNA, 21q region, clone: 9H11X4 3714 AB007930 Homo sapiens 0 3413884 (AB007930) 2e−068 mRNA for KIAA0461 KIAA0461 perotein [Homo perotein, partial sapiens] cds 3715 U95102 Xenopus laevis 9e−007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3716 Y09999 H. sapiens CHOP 2e−007 <NONE> <NONE> <NONE> gene, intron 1 3717 AF023461 Homo sapiens 0.13 2501500 ECDYSTEROID 5.6 FRA3B region UDP- sequence GLUCOSYL- TRANSFERASE PRECURSOR >gi|1563727|gnl|PI D|e267373 (Y08294) ecdysteroid UDP- glucosyltransferase [Lacanobia oleracea granulovirus] 3718 U95094 Xenopus laevis 2e−005 2330794 (Z98601) 0.004 XL-INCENP hypothetical (XL-INCENP) protein mRNA, complete 3719 U95102 Xenopus laevis 7e−007 1363246 TIFI protein - 5e−007 mitotic mouse phosphoprotein >gi|998815|bbs|16 90 mRNA, 7126 complete cds 3720 U95102 Xenopus laevis 6e−006 1314732 (U54640) 185 kDa 0.17 mitotic silk protein phosphoprotein [Chironomus 90 mRNA, pallidivittatus] complete cds 3721 U09933 Human 5e−025 3523099 (AF016271) Ksp- 7.6 urokinase-type cadherin [Mus plasminogen musculus] receptor, exon 3 3722 M30187 S. cerevisiae 0.13 218437 (D90352) myo- 7.3 mitochondrion inositol transporter Tyr-tRNA gene. 3723 X79703 O. aries gene for 0.043 141103 HYPOTHETICAL 4.5 beta-casein PROTEIN ORF- 1137 mouse 3724 U95094 Xenopus laevis 9e−009 2132008 hypothetical 9.9 XL-INCENP protein YOL072w - (XL-INCENP) yeast mRNA, complete cds 3725 L39210 Homo sapiens 2e−078 2224711 (AB002383) 2e−018 inosine KIAA0385 [Homo monophosphate sapiens] dehydrogenase type II gene, complete cds 3726 U52832 Homo sapiens 2e−005 <NONE> <NONE> <NONE> Cri-du-chat region mRNA, clone CSC3 3727 AF015043 Homo sapiens  e−169 2072296 (U95098) mitotic 3.4 EH-binding phosphoprotein 44 protein mRNA, [Xenopus laevis] partial cds 3728 D28485 Human MSMB 4e−011 <NONE> <NONE> <NONE> gene for beta- microseminoprotein (MSP), promoter region and exon1 3729 M33027 Human 0.043 <NONE> <NONE> <NONE> vasoactive intestinal peptide/PHM-27 gene, exons 1-6. 3730 X15377 Human gene for 2e−024 1346141 GLYCEROL 3e−011 the light and KINASE heavy chains of (ATP:GLYCEROL myeloperoxidase 3- PHOSPHOTRANS- FERASE) (GLYCERO- KINASE)(GK) Mycoplasma genitalium (SGC3) >gi|3844648 (U39683) glycerol kinase (glpK) [Mycoplasma genitalium] 3731 X57103 Human h-lys 0.0005 <NONE> <NONE> <NONE> gene for lysozyme (upstream region) 3732 U95102 Xenopus laevis 3e−010 3319482 (AF077546) No 9.8 mitotic definition line phosphoprotein found 90 mRNA, [Caenorhabditis complete cds elegans] 3733 U95102 Xenopus laevis 1e−012 2072296 (U95098) mitotic 5.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3734 U83857 Human Aac11 2e−027 2623755 (U35846) 3e−005 (aac11) mRNA, unknown [Mus complete cds musculus] 3735 U95102 Xenopus laevis 1e−013 2072296 (U95098) mitotic 2.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3736 U09367 Human zinc 1e−065 1731412 ZINC FINGER 7e−060 finger protein PROTEIN 136 ZNF136 human >gi|487785 (U09367) zinc finger protein ZNF136 3737 U95102 Xenopus laevis 6e−006 2507475 PAIRED 5.8 mitotic AMPHIPATHIC phosphoprotein HELIX PROTEIN 90 mRNA, complete cds 3738 U95102 Xenopus laevis 0.002 3702452 (X80031) type IV 1.5 mitotic collagen alpha 3 phosphoprotein chain 90 mRNA, complete cds 3739 AF086022 Homo sapiens 3.5 <NONE> <NONE> <NONE> full length insert cDNA clone YW23E02 3740 U95102 Xenopus laevis 0.0002 2960225 (AL022120) PPE 7.4 mitotic [Mycobacterium phosphoprotein tuberculosis] 90 mRNA, complete cds 3741 U95102 Xenopus laevis 2e−006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3742 AJ005866 Homo sapiens e−177 4008517 (AJ005866) Sqv- 9e−045 mRNA for 7-like protein putative Sqv-7- [Homo sapiens] like protein, partial 3743 AF043231 Emericella 1.1 <NONE> <NONE> <NONE> nidulans cAMP- dependent protein kinase regulatory subunit (pkaR) gene, complete cds 3744 AB002319 Human mRNA 5e−066 2224583 (AB002319) 2e−024 for KIAA0321 KIAA0321 [Homo gene, partial cds sapiens] 3745 M33132 Human 8e−018 113668 !!!! ALU CLASS 0.077 proliferating cell C WARNING nucleolar protein ENTRY !!!! P120 gene, exons 1-15. 3746 U95102 Xenopus laevis 9e−009 2394463 (AF024498) No 1.2 mitotic definition line phosphoprotein found 90 mRNA, [Caenorhabditis complete cds elegans] 3747 Z69944 S. pombe 4.4 <NONE> <NONE> <NONE> chromosome I cosmid c1F12. 3748 Z81014 Human DNA 4e−022 896065 (U28831) protein 0.075 sequence from that is immuno- cosmid U65A4, reactive with anti- between markers PTH polyclonal DXS366 and antibodies [Homo DXS87 on sapiens] chromosome X * 3749 U95102 Xenopus laevis 0.0002 3877203 (Z70780) similar 4.4 mitotic to initiation factor phosphoprotein IF-2; cDNA EST 90 mRNA, CEMSD25F complete cds comes from this gene 3750 U95094 Xenopus laevis 2e−007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3751 U95102 Xenopus laevis 3e−008 2065210 (Y12713) Pro-Pol- 2 mitotic dUTPase phosphoprotein polyprotein 90 mRNA, complete cds 3752 M36072 Human ribosomal 1e−054 133014 60S 0.019 protein L7a (surf RIBOSOMAL 3) large subunit PROTEIN L7A mRNA, complete (PLA-X cds. POLYPEPTIDE) (SURF-3) >gi|71116|pir∥R5H U7A ribosomal protein L7a- human >gi|71117|pir∥R5R T7A ribosomal protein L7a - rat >gi|34203 (X52138) L7a protein [Homo sapiens] >gi|35512 (X06705) PLA-X polypeptide [Homo sapiens] 3753 AB001615 Homo sapiens 6e−006 <NONE> <NONE> <NONE> DNA for cGMP- binding cGMP- specific phosphodiesterase (PDE5), exon 1 3754 X57103 Human h-lys 5e−015 113670 !!!! ALU CLASS 3.3 gene for E WARNING lysozyme ENTRY !!!! (upstream region) 3755 L09708 Homo sapiens 6e−005 1143705 (X89760) Hox2a 9.7 complement gene product [Zea component 2 (C2) mays] gene allele b, exons 10 through 18 and complete cds 3756 X73685 C. aethiops hsp70 2e−088 1322309 (U55176) heat 2e−025 mRNA shock cognate 70.II [Xenopus laevis] 3757 Z57594 H. sapiens CpG 0.002 <NONE> <NONE> <NONE> DNA, clone 186c5, reverse read cpg186c5.rt1b. 3758 AF095927 Rattus norvegicus e−117 3777604 (AF095927) 4e−040 protein protein phosphatase 2C phosphatase 2C mRNA, complete [Rattus cds norvegicus] 3759 U30788 Rattus norvegicus 5e−024 135576 LARGE 1.6 Tclone4 mRNA TEGUMENT PROTEIN (VIRION PROTEIN UL36) >gi|73851|pir∥WM BEH6 UL36 protein - human herpesvirus 1 (strain 17) >gi|59536|gnl|PID| e312351 1] 3760 Z96177 H. sapiens 3e−009 1082626 myosin heavy 5.8 telomeric DNA chain VA - human sequence, clone (fragment) 10QTEL040, read 10QTELOO040.s eq 3761 M37463 E. gracilis 0.38 2734883 (U75311) pyruvate 3.4 chloroplast decarboxylase 2 ribosomal protein [Pichia stipitis] genes rpl23, rpl2, rps19, rpl22, and rps3, complete cds. 3762 AF086241 Homo sapiens 4e−064 3702137 (AL031393) 1e−040 full length insert dJ733D15.1 (Zinc- cDNA clone finger protein) ZD29F04 [Homo sapiens] 3763 AF086241 Homo sapiens 4e−064 3702137 (AL031393) 1e−040 full length insert dJ733D15.1 (Zinc- cDNA clone finger protein) ZD29F04 [Homo sapiens] 3764 AF008227 Drosophila 3.6 2661842 (Y15732) DNA 2e−020 melanogaster odd polymerase beta Oz product (odz) [Xenopus laevis] gene, exons 3, 4, 5, 6, 7, and complete cds 3765 AF039688 Homo sapiens 0 3170176 (AF039688) 2e−073 antigen NY—CO-3 antigen NY—CO-3 (NY—CO-3) [Homo sapiens] mRNA, partial cds 3766 AF037332 Homo sapiens 0.37 1255919 (X96511) MAFB 5.6 Eph-like receptor protein [Coturnix tyrosine kinase japonica] hEpbB1b (EphB1) mRNA, complete cds 3767 U95094 Xenopus laevis 6e−006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3768 U95102 Xenopus laevis 0.005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3769 U95094 Xenopus laevis 3e−010 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3770 X57103 Human h-lys 5e−015 113670 !!!! ALU CLASS 3.3 gene for E WARNING lysozyme ENTRY !!!! (upstream region) 3771 U95102 Xenopus laevis 0.0002 2947096 (U81032) TniQ 0.86 mitotic [Pseudomonas phosphoprotein stutzeri] 90 mRNA, complete cds 3772 U95102 Xenopus laevis 0.0002 2947096 (U81032) TniQ 0.86 mitotic [Pseudomonas phosphoprotein stutzeri] 90 mRNA, complete cds 3773 M84326 Human ADP- 0 283748 collagen alpha 2(I) 0.14 ribosylation chain homolog - factor 1 mRNA, sea urchin complete cds (Strongylocentrotus purpuratus) >gi|161436 purpuratus] 3774 X82575 G. gallus mRNA 0.39 3327136 (AB014561) 3e−033 for Cnot KIAA0661 protein [Homo sapiens] 3775 L43001 Bos taurus 3e−072 1730238 GUANYLATE 1e−030 guanylyl cyclase− CYCLASE activating protein ACTIVATING 2 PROTEIN 2 (GCAP 2) (RETINAL GUANYLYL CYCLASE ACTIVATOR PROTEIN P24) >gi|2136762|pir∥A 57604 guanylate cyclase-activating protein 2 - bovine >gi|1002750 cyclase-activating protein 2 [Bos taurus] 3776 U47322 Cloning vector 7e−007 3335349 (AC004512) 9.2 DNA, complete Similar to sequence. gb|U46691 putative chromatin structure regulator (SUPT6H) from Homo sapiens. ESTs gb|T42908, gb|AA586170 and gb|AA395125 come from this gene. [Arabidopsis thaliana] 3777 L09647 Rattus norvegicus 2e−069 404764 (L10409) fork 3e−031 hepatocyte head related nuclear factor 3a protein [Mus musculus] 3778 U72756 Lycianthes 0.37 <NONE> <NONE> <NONE> heteroclita NADH dehydrogenase subunit protein, partial cds 3779 M94314 Homo sapiens 1e−073 3876073 (Z81505) similar 1.4 ribosomal protein to Zinc finger, L30 mRNA, C3HC4 type complete cds (RING finger); cDNA EST EMBL:D28025 comes from this gene; cDNA EST EMBL:D28024 comes from this gene; cDNA EST EMBL:D33210 comes from this gene; cDNA EST EMBL:D33441 comes from this . . . 3780 AF053315 Reporter vector 9e−019 987050 (X65335) lacZ 0.3 pNFkB-Luc, gene product complete [unidentified sequence cloning vector] 3781 U95094 Xenopus laevis 4e−011 2072296 (U95098) mitotic 4.5 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3782 U95094 Xenopus laevis 1e−013 1695957 (U78693) NADH 1.9 XL-INCENP dehydrogenase (XL-INCENP) [Holmskioldia mRNA, complete sanguinea] cds 3783 AF074990 Homo sapiens 0.005 1881709 (U89517) 9.6 full length insert polyprotein cDNA YH85A11 [Dengue virus type 2] 3784 U95102 Xenopus laevis 9e−009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3785 AF020038 Homo sapiens 4e−011 3647352 (Z97348) 9.6 NADP-dependent MAL3P1.11 isocitrate [Plasmodium dehydrogenase falciparum] (IDH) mRNA, complete cds 3786 Z75199 S. cerevisiae 8e−028 3880560 (Z70271) 7e−048 chromosome XV Similarity to Yeast reading frame E1-E2 ATPase ORF YOR291 w (SW:YED1_YEAST); cDNA EST EMBL:D37634 comes from this gene; cDNA EST EMBL:D34653 comes from this gene; cDNA EST EMBL:D34527 comes from this gene; cDNA EST EMBL:D32311 comes from this . . . 3787 U95102 Xenopus laevis 3e−008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3788 M86400 Human 5e−088 <NONE> <NONE> <NONE> phospholipase A2 mRNA, complete cds. > :: gb|I34404|I34404 Sequence 8 from U.S. Pat. No. 5597719 3789 X03100 Human HLA- 0.47 3941737 (AF109719) 2.4 SB(DP) alpha BAT2 [Mus gene musculus] 3790 U95094 Xenopus laevis 5e−015 3043662 (AB011141) 9.6 XL-INCENP KIAA0569 protein (XL-INCENP) [Homo sapiens] mRNA, complete cds 3791 U95094 Xenopus laevis 2e−014 2072296 (U95098) mitotic 0.29 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3792 U95102 Xenopus laevis 4e−012 345555 Ig light chain - 1.1 mitotic rainbow trout phosphoprotein (fragment) 90 mRNA, complete cds 3793 U95094 Xenopus laevis 5e−014 2072296 (U95098) mitotic 5.6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3794 AF064104 Homo sapiens 3e−030 2662463 (AF023158) 1e−008 Cdc14B1 tyrosine phosphatase phosphatase mRNA, complete [Homo sapiens] cds 3795 U29348 Salmonella 0.0005 2291118 (AF016414) No 9.6 enterica strain definition line s2978 invasion found protein SpaO [Caenorhabditis (spaO), SpaP elegans] (spaP) and SpaQ (spaQ) genes, complete cds 3796 U95102 Xenopus laevis 6e−016 2072296 (U95098) mitotic 5.6 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3797 U95094 Xenopus laevis 3e−010 1168719 C6.1A PROTEIN 0.004 XL-INCENP (XL-INCENP) mRNA, complete cds 3798 U95094 Xenopus laevis 2e−006 481236 hypothetical 3.4 XL-INCENP protein - (XL-INCENP) Madagascar mRNA, complete periwinkle roseus] cds 3799 U95094 Xenopus laevis 3e−008 423157 finger protein 4.3 XL-INCENP ZNF33A - human (XL-INCENP) (fragment) mRNA, complete cds 3800 U95102 Xenopus laevis 4e−012 2072296 (U95098) mitotic 5.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3801 U61950 Caenorhabditis 1.2 <NONE> <NONE> <NONE> elegans cosmid C45E5 3802 U95102 Xenopus laevis 3e−008 1703028 CLATHRIN 9.6 mitotic COAT phosphoprotein ASSEMBLY 90 mRNA, PROTEIN AP47 complete cds HOMOLOG 2 (CLATHRIN COAT ASSOCIATED PROTEIN AP47 HOMOLOG 2) (GOLGI ADAPTOR AP-1 47 KD PROTEIN HOMOLOG 2) (HA1 47 KD SUBUNIT HOMOLOG 2) (CLATHRIN ASSEMBLY PROTEIN ASSEMBLY PROTEIN COMPL . . . >gi|2134919|pir∥A 57170 clathri 3803 M31651 Homo sapiens sex 7e−017 <NONE> <NONE> <NONE> hormone-binding globulin (SHBG) gene, complete cds 3804 D00596 Homo sapiens 6e−038 <NONE> <NONE> <NONE> gene for thymidylate synthase, exons 1, 2, 3, 4, 5, 6, 7, complete cds 3805 U95102 Xenopus laevis 3e−010 2072296 (U95098) mitotic 3.7 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3806 D45906 Human mRNA 4e−096 <NONE> <NONE> <NONE> for LIMK-2, complete cds 3807 U95098 Xenopus laevis 2e−006 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3808 U95102 Xenopus laevis 0.004 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3809 AF045798 Xenopus laevis 0.36 3551167 (AB012131) Ich1 4.1 gremlin mRNA, [Coprinus complete cds cinereus] 3810 D78275 Human mRNA 8e-019 1709804 26S PROTEASE 0.001 for proteasome REGULATORY subunit p42, SUBUNIT S10B complete cds (P44) (CONSERVED ATPASE DOMAIN PROTEIN 44) 26S proteasome regulatory subunit [Homo sapiens] 3811 U95094 Xenopus laevis 4e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3812 U95102 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3813 U95102 Xenopus laevis 9e-014 3193162 (AF067618) No 1e-027 mitotic definition line phosphoprotein found 90 mRNA, [Caenorhabditis complete cds elegans] 3814 AF085858 Homo sapiens 1e-017 3329465 (AF064553) 4e-007 full length insert NSD1 protein cDNA clone [Mus musculus] YN49B07 3815 U95102 Xenopus laevis 3e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3816 U95094 Xenopus laevis 0.0003 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3817 U95102 Xenopus laevis 1e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3818 U95094 Xenopus laevis 2 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3819 U95094 Xenopus laevis 4e-006 416673 ATP SYNTHASE 1.3 XL-INCENP A CHAIN (XL-INCENP) (PROTEIN 6) mRNA, complele 3.6.1.34) protein 6 cds - liverwort (Marchantia polymorpha) mitochondrion >gi|786191 (M68929) atp6 [Marchantia polymorpha] 3820 L14684 Rattus norvegicus  e-115 585084 ELONGATION 5e-038 nuclear-encoded FACTOR G, mitochondrial MITOCHONDRI elongation factor AL PRECURSOR G mRNA, (MEF-G) complete cds. >gi|543383|pir∥S4 0780 translation elongation factor G, mitochondrial - rat >gi|310102 3821 U95094 Xenopus laevis 2e-012 2072296 (U95098) mitotic 2.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3822 U95094 Xenopus laevis 7e-012 1665789 (D87450) Similar 8.5 XL-INCENP to D. melanogaster (XL-INCENP) parallel sister mRNA, complete chromatids protein cds [Homo sapiens] 3823 U95094 Xenopus laevis 2e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3824 U95102 Xenopus laevis 3e-015 2072296 (U95098) mitotic 2.2 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3825 L48489 Homo sapiens N- 1e-038 728831 !!!! ALU 1e-008 acetylglucosamin SUBFAMILY J yltransferase III WARNING ENTRY 3826 U95102 Xenopus laevis 8e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3827 U95102 Xenopus laevis 1e-014 2072296 (U95098) mitotic 2.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3828 U95102 Xenopus laevis 1e-011 2072296 (U95098) mitotic 1.4 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3829 AB012162 Homo sapiens 1e-017 3894265 (AB012162) APC 0.45 mRNA for APC 2 2 protein [Homo protein, complete sapiens] cds 3830 U95094 Xenopus laevis 6e-010 1723680 HYPOTHETICAL 1.3 XL-INCENP 14.1 KD (XL-INCENP) PROTEIN IN mRNA, complete UPF3-SMD1 cds INTERGENIC REGION >gi|2132599|pir∥S 64368 probable membrane protein YGR073c - yeast (Saccharomyces cerevisiae) >gi|1323101|gnl|PI D|e243468 (Z72858) ORF YGR073c [Saccharomyccs cerevisiae] 3831 S54914 bup = 5′ of bmi-1  e-140 265569 (S54914) bup = 5′ of 2e-059 proviral insertion bmi-1 proviral locus [mice, insertion locus Genomic/mRNA, [mice, Peptide, 2022 nt] 195 aa] [Mus sp.] 3832 U95102 Xenopus laevis 2e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3833 U95094 Xenopus laevis 2e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3834 U95102 Xenopus laevis 1e-015 2072296 (U95098) mitotic 2.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3835 U95094 Xenopus laevis 4e-007 1805270 (U81983) 6.6 XL-INCENP endothelial PAS (XL-INCENP) domain protein 1 mRNA, complete [Mus musculus] cds 3836 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3837 X92814 H. sapiens mRNA 1e-032 1709969 H-REV 107 3e-013 for rat HREV107- PROTEIN like protein 3838 U95094 Xenopus laevis 1e-011 2183251 (AF002227) 0.015 XL-INCENP putative (XL-INCENP) polyprotein mRNA, complete [border disease cds virus strain C413] 3839 U95102 Xenopus laevis 1e-009 1142660 (U23502) POM1 7.3 mitotic [Plasmodium phosphoprotein chabaudi 90 mRNA, chabaudi] complete cds 3840 U95102 Xenopus laevis 4e-012 2072296 (U95098) mitotic 3.3 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3841 U47322 Cloning vector 2e-058 224398 ORF [Simian virus 4e-005 DNA, complete 40] sequence. 3842 U95094 Xenopus laevis 2e-012 2072296 (U95098) mitotic 2.9 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3843 U95102 Xenopus laevis 1e-011 2072296 (U95098) mitotic 3.3 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3844 Y15059 Homo sapiens 0.053 <NONE> <NONE> <NONE> hng/RC3 gene, exons 2, 3 & 4 3845 X99330 R. norvegicus 2e-027 <NONE> <NONE> <NONE> mRNA for IP63 protein 3846 AF100303 Caenorhabditis 0.53 <NONE> <NONE> <NONE> elegans cosmid Y7G10A 3847 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 3848 AF040094 Mus musculus 0.15 <NONE> <NONE> <NONE> inositol polyphosphate 5- phosphatase II (INPP5P) mRNA, complete cds 3849 Y15724 Homo sapiens 2e-013 <NONE> <NONE> <NONE> SERCA3 gene, exons 1-7 (and joined CDS) 3850 AB011144 Homo sapiens 0 3043668 (AB011144) 1e-080 mRNA for KIAA0572 protein KIAA0572 [Homo sapiens] protein, partial cds 3851 AF020762 Homo sapiens 0 2738927 (AF020762) 2.8 clone 1400 unknown protein unknown protein [Homo sapiens] mRNA, partial cds 3852 Z99706 Human DNA 0.0002 <NONE> <NONE> <NONE> sequence from cosmid U226D1 on chromosome X. Contains STS, complete sequence [Homo sapiens] 3853 M73700 Human 0.0002 <NONE> <NONE> <NONE> neutrophil lactoferrin mRNA, complete cds and 5′ promoter region. 3854 D31793 Human CD40 0.046 <NONE> <NONE> <NONE> ligand (CD40L) gene, 5′ flanking region and exon 1 3855 U16300 Human lysyl 0.0002 126363 LAMININ 0.18 hydroxylase ALPHA-1 CHAIN (PLOD) gene, PRECURSOR intron 9, precursor - human complete sequence. 3856 U61241 Homo sapiens 0.14 <NONE> <NONE> <NONE> p47-phox pseudogene, clone P41, exon 1 3857 D37791 Mouse mRNA for  e-105 3880102 (Z93390) similar 3e-021 beta-1,4- to FYVE zinc galactosyltransfer finger; cDNA EST ase yk26564.5 comes from this gene; cDNA EST yk359g9.5 comes from this gene; cDNA EST yk319c2.5 comes from this gene [Caenorhabditis elegans] zinc finger; cDNA EST yk26564.5 comes from this gene; cDNA EST yk359g9 3858 Z57667 H. sapiens CpG 1.2 <NONE> <NONE> <NONE> DNA, clone 18a8, reverse read cpg18a8.rt1b. 3859 U95102 Xenopus laevis 2e-014 2879809 (AJ223320) trp- 1.5 mitotic like protein phosphoprotein [Loligo forbesi] 90 mRNA, complete cds 3860 U22296 Rattus norvegicus  e-126 3024053 CASEIN KINASE 1e-061 casein kinase 1 I, GAMMA 1 gamma 1 isoform ISOFORM kinase mRNA, complete 1 gamma 1 cds isoform [Rattus norvegicus] 3861 U95094 Xenopus laevis 5e-014 113669 !!!! ALU CLASS 2.6 XL-INCENP D WARNING (XL-INCENP) ENTRY !!!! mRNA, complete cds 3862 U95102 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3864 U95102 Xenopus laevis 1e-010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3865 U95102 Xenopus laevis 1e-011 3182957 CGMP- 4.4 mitotic INHIBITED 3′,5′- phosphoprotein CYCLIC 90 mRNA, PHOSPHODIEST complete cds ERASE B (CYCLIC GMP INHIBITED PHOSPHODIEST ERASE B) (CGI- PDE B) (CGIPDE1). phophodiesterase- human >gi|1145302 (U38178) cyclic nucleotidc phophodiesterase [Homo sapiens] 3B [Homo sapiens] 3866 AF099004 Caenorhabditis 0.2 <NONE> <NONE> <NONE> elegans cosmid C07D2 3867 Z23091 H. sapiens GPV 5e-013 728836 !!!! ALU 0.82 gene encoding SUBFAMILY SP platelet WARNING glycoprotein V ENTRY precursor 3868 U95094 Xenopus laevis 3e-007 2291255 (AF016430) weak 8.4 XL-INCENP similarity to (XL-INCENP) Bacillus subtillis mRNA, complete spore coat protein cds precursor (GB: L42066) and Dictyostelium discoideum calcium binding protein (NID: g426313) in proline-rich regions [Caenorhabditis elegans] 3869 U58739 Caenorhabditis 0.33 <NONE> <NONE> <NONE> elegans cosmid F28C10. 3870 L48473 Homo sapiens 3e-008 <NONE> <NONE> <NONE> (subclone7_e11 from PI H16) DNA sequence. 3871 U95097 Xenopus laevis 0.015 <NONE> <NONE> <NONE> mitotic phosphoprotein 43 mRNA, partial cds 3872 Z73360 Human DNA 4e-020 <NONE> <NONE> <NONE> sequence from cosmid 92M18, BRCA2 gene region chromosome 13q12-13. 3873 Z71572 O. aries DNA for 1.2 1699130 (U80027) weak 6.1 immunoglobulin similarity to joining regions Arabadopsis thaliana phytochrome E (PIR: S41912) [Caenorhabditis elegans] 3874 U95102 Xenopus laevis 6e-010 2072296 (U95098) mitotic 1.7 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3875 AB018263 Homo sapiens 1.2 107240 oncogene 1 (tre-2 0.049 mRNA for locus) (clone 210) KIAA0720 - human protein, partial cds 3876 U87998 Mus musculus 0.14 <NONE> <NONE> <NONE> cyclin G1 gene, partial cds 3877 AE001408 Plasmodium 1.8 <NONE> <NONE> <NONE> falciparum chromosome 2, section 45 of 73 of the complete sequence 3878 AF061244 Agrocybe 0.16 3153241 (AF053004) class 5.8 aegerita B type I cytokine receptor DNA polymerase [Homo sapiens] (Mtpol) gene, complete cds; tRNA-Asn gene, complete sequence; and unknown genes, mitochondrial genes for mitochondrial products 3879 M73047 Homo sapiens 3e-028 136107 TRIPEPTIDYL- 0.35 tripeptidyl PEPTIDASE II peptidase II (TPP II) mRNA, complete tripeptidyl- cds. peptidase II (EC 3.4.14.10) - human sapiens] 3880 AB011393 Suncus murinus 0.17 107422 proline-rich 0.4 mitochondrial protein PRB3S DNA, D-loop (cys) - human region, partial sequence, isolate TKU-M205 3881 X69951 H. sapiens gene 1e-008 113668 !!!! ALU CLASS 0.54 for casein kinase C WARNING II alpha subunit> ENTRY !!!! subunit alpha [human, Genomic, 18862 nt] 3882 U54558 Human 3e-018 <NONE> <NONE> <NONE> translation initiation factor eIF3 p66 subunit mRNA, complete cds 3883 AB012259 Homo sapiens 5e-012 <NONE> <NONE> <NONE> DNA, anonymous heat-stable fragment RP12-8 3884 U44130 Xenopus laevis 0.15 3873716 (Z74026) similar 5.3 p58mRNA, to 1- partial cds aminocyclopropan e-1-carboxylate synthase; cDNA EST EMBL: D34239 comes from this gene; cDNA EST EMBL: D35575 comes from this gene; cDNA EST EMBL: D64242 comes from this gene; cDNA EST EMBL: D67126 comes from . . . 1- aminocyclopropan e-1-carbo 3885 AB007917 Homo sapiens 0.006 <NONE> <NONE> <NONE> mRNA for KIAA0448 protein, complete cds 3886 AJ223824 Lycopersicon 0.045 <NONE> <NONE> <NONE> esculentum cv Red River unknown sequence PCR random amplified RAPD band 9 3887 U47322 Cloning vector 3e-008 2183251 (AF002227) 0.67 DNA, complete putative sequence. polyprotein [border disease virus strain C413] 3888 U95102 Xenopus laevis 4e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3889 U67564 Methanococcus 1.3 2920535 (AF018081) type 0.73 jannaschii section XVIII collagen 106 of 150 of the [Homo sapiens] complete genome 3890 AE000720 Aquifex aeolicus 1.3 <NONE> <NONE> <NONE> section 52 of 109 of the complete genome 3891 AB011230 Zaglossus bruijni 3.6 <NONE> <NONE> <NONE> mitochondrial gene for NADH dehydrogenase subunit 1, partial cds 3892 Z96177 H. sapiens 1e-042 987050 (X65335) lacZ 0.0001 telomeric DNA gene product sequence, clone [unidentified 10QTEL040, read cloning vector] 10QTELOO040.s eq 3893 AF067646 Cloning vector 3e-029 987050 (X65335) lacZ 0.001 pCMV-scriptEX, gene product complete [unidentified sequence cloning vector] 3894 Z69919 Human DNA 3.8 <NONE> <NONE> <NONE> sequence from cosmid 91K3, Huntington's Disease Region, chromosome 4p16.3 contains CpG island. 3895 X75757 G. gallus cycB3 6e-036 729112 G2/MITOTIC- 4e-013 mRNA. SPECIFIC CYCLIN B3 3896 L27833 Bos taurus 0.48 854348 (X87336) DNA 7.5 pregnancy- endonuclease associated [Peperomia glycoprotein-1 polybotrya] 3897 U95102 Xenopus laevis 0.14 3169059 (AL023704) weak 5e-052 mitotic similarity to phosphoprotein B. subtilis spore 90 mRNA, outgrowth factor B complete cds [Schizosaccharom yces pombe] 3898 X64123 H. sapiens PVR 7e-006 2444416 (AF020484) 0.55 gene for NADH poliovirus debydrogenase- receptor (exon 8) like protein [Gleditsia fera] 3899 Z81043 Caenorhabditis 0.44 266459 P-SELECTIN 1.8 elegans cosmid PRECURSOR C29F3, complete (GRANULE sequence MEMBRANE [Caenorhabditis PROTEIN 140) elegans] (GMP-140) (PADGEM) (CD62P) mouse >gi|200553 (M87861) P- selectin [Mus musculus] 3900 AJ001235 Papio hamadryas 3e-050 3126961 (AF061747) cell 1.2 ERV-9 like LTR division protein insertion FtsZ homolog 3901 AE001314 Chlamydia 1.2 <NONE> <NONE> <NONE> trachomatis section 41 of 87 of the complete genome 3902 X82895 H. sapiens mRNA 2e-048 3659505 (AC005084) 1e-054 for DLG2 similar to mouse mCASK-A; similar to e1288039 3903 U95094 Xenopus laevis 2c-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3904 U95102 Xenopus laevis 9e-009 436923 (U01849) ORF1 0.08 mitotic [Trypanosoma phosphoprotein brucei] 90 mRNA, complete cds 3905 D88982 Clostridium 0.38 1082769 RNA helicase A - 5.6 botulinum DNA human for C2 toxin component-I and component-II, complete cds 3906 D50418 Mouse mRNA for 1e-041 2137398 homeotic protein 0.044 AREC3, partial AREC3 (clone cds SM) - mouse 3907 U95094 Xenopus laevis 6e-005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3908 U95102 Xenopus laevis 2e-007 2314677 (AE000648) 0.36 mitotic cation-transporting phosphoprotein ATPase, P-type 90 mRNA, (copA) complete cds 3909 U72745 Dictyostelium 0.014 <NONE> <NONE> <NONE> discoideum cysteine proteinase 3910 AJ011972 Homo sapiens 3e-081 <NONE> <NONE> <NONE> mRNA for histone deacetylase-like protein (JM21) 3911 U95094 Xenopus laevis 3e-011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3912 U95102 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3913 AC001032 Homo sapiens 9e-009 130402 RETROVIRUS- 3.2 (subclone 2_c211 RELATED POL from P1 H48) POLYPROTEIN DNA sequence 3914 J04830 S. cerevisiae 3.3 <NONE> <NONE> <NONE> CBP3 protein gene, complete cds. 3915 D78572 House mouse; 4e-044 1545807 (D78572) 1e-020 Musculus membrane domesticus glycoprotein [Mus mRNA for musculus] membrane glycoprotein, complete cds > :: dbj|E12950|E129 50 cDNA GA3- 43 encoding novel polypeptide which appear when differentiate from embryo-tumor cell P19 to nerve cell 3916 U95094 Xenopus laevis 1e-012 2072296 (U95098) mitotic 1.1 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 3917 U29923 Human AMP 0.04 3256504 (AP000001) 115aa 0.094 deaminase long hypothetical (AMPD3) gene, protein intron 1a and [Pyrococcus promoter 1b. horikoshii] 3918 Z68327 Human DNA 5e-015 <NONE> <NONE> <NONE> sequence from cosmid U25D11, between markers DXS366 and DXS87 on chromosome X. 3919 U95094 Xenopus laevis 1e-013 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3920 M89955 Human 5-HTID- 0 112819 5- 3e-053 type serotonin HYDROXYTRYP receptor gene, TAMINE ID complete cds. RECEPTOR human >gi|177772 (M89955) 5- HTID-type serotonin receptor receptor: ISOTYPE = ID-alpha [Homo sapiens] 3921 U95094 Xenopus laevis 2e-008 3879698 (Z78065) 9.1 XL-INCENP predicted using (XL-INCENP) Genefinder mRNA, complete cds 3922 U95094 Xenopus laevis 0.002 3184285 (AC004136) 9.5 XL-INCENP hypothetical (XL-INCENP) protein mRNA, complete [Arabidopsis cds thaliana] 3923 U95094 Xenopus laevis 0.005 139805 XFIN PROTEIN 1.9 XL-INCENP >gi|65234 (XL-INCENP) (X06021) Xfin mRNA, complete protein (AA 1- cds 1350) [Xenopus laevis] 3924 U95094 Xenopus laevis 4e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3925 AF013711 Homo sapiens 22 1e-020 103509 I factor 2 5.5 kDa actin-binding (transposon) - fruit protein fly protein [Drosophila teissieri] 3926 S83526 red photopigment 7e-006 <NONE> <NONE> <NONE> gene {Alu repeat region, long intron 1} [human, peripheral blood leucocytes, Genomic, 1987 nt] 3927 AB011542 Homo sapiens 0 3449310 (AB011542) 2e-095 mRNA for MEGF9 [Homo MEGF9, partial sapiens] cds 3928 U95102 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3929 X67312 P. pijperi 6e-006 <NONE> <NONE> <NONE> mitochondrion DNA for Vaccinia virus- like terminal loop structure 3930 U95094 Xenopus laevis 3e-010 3080474 (AL022602) cell 1.2 XL-INCENP divisin protein (XL-INCENP) FtsW mRNA, complete cds 3931 U95102 Xenopus laevis 4e-006 3769486 (AF074946) DNA 1.3 mitotic polymerase phosphoprotein [hemorrhagic 90 mRNA, enteritis virus] complete cds 3932 U95102 Xenopus laevis 3e-010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3933 U95102 Xenopus laevis 3e-008 1890266 (U88585) NADH- 4.2 mitotic dehydrogenase phosphoprotein subunit 1 [Quedius 90 mRNA, mesomelinus] complete cds 3934 Z12112 pWE15A cosmid 1e-051 987050 (X65335) lacZ 4e-009 vector DNA gene product [unidentified cloning vector] 3935 AF023180 Listeria 0.005 <NONE> <NONE> <NONE> monocytogenes low temperature requirement A protein (ltrA) gene, complete cds 3936 D10856 D. melanogaster 0.37 2315521 (AF016452) 1e-028 cyclin A gene similar to the beta transducin family 3937 U95102 Xenopus laevis 9e-009 3687507 (AL031788) C2H2 7.3 mitotic type zinc finger phosphoprotein protein 90 mRNA, [Schizosaccharom complete cds yces pombe] 3938 Z80361 H. sapiens HLA- 2e-078 <NONE> <NONE> <NONE> DRB pseudogene, repeat region; 3939 L22551 Plasmodium 1.2 <NONE> <NONE> <NONE> yoelii yoelii merozoite surface protein 1 gene, 5′ end. 3940 X74178 B. taurus 0.005 2291118 (AF016414) No 2.5 microsatellite definition line DNA INRA153 found [Caenorhabditis elegans] 3941 U95094 Xenopus laevis 9e-010 1354361 (U52008) Mrp50 0.48 XL-INCENP [Streptococcus (XL-INCENP) pyogenes] mRNA, complete cds 3942 U41635 Human OS-9 0.12 <NONE> <NONE> <NONE> precurosor mRNA, complete cds 3943 U95102 Xenopus laevis 1e-011 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3944 M37470 Human beta-N- 5e-025 728832 !!!! ALU 4.3 acetylhexosamini SUBFAMILY SB dase (HEXB) WARNING gene, deletion ENTRY junction. 3945 U95094 Xenopus laevis 6e-006 97885 salivary agglutinin 0.84 XL-INCENP receptor precursor (XL-INCENP) - Streptococcus mRNA, complete sanguis cds 3946 U95102 Xenopus laevis 3e-010 140550 HYPOTHETICAL 2.5 mitotic 259 KD PROTEIN phosphoprotein (ORF 2136) 90 mRNA, >gi|81341|pir∥A05 complete cds 037 hypothetical protein 2136 - liverwort (Marchantia polymorpha) chloroplast >gi|11665 3947 L13176 Papio anubis 0.0005 <NONE> <NONE> <NONE> apolipoprotein C- 1 gene, partail mRNA. 3948 U95102 Xenopus laevis 7e-006 580702 (X74410) fixP 2.9 mitotic gene product phosphoprotein [Azorhizobium 90 mRNA, caulinodans] complete cds 3949 X92987 B. primigenius 2e-036 1706000 COATOMER 2e-008 mRNA for coat GAMMA protein gamma- SUBUNIT cop (GAMMA-COAT PROTEIN) (GAMMA-COP) >gi|1066165 (X92987) coat protein gamma- cop [Bos primigenius] 3950 U95102 Xenopus laevis 8e-008 223232 protein src [Avian 0.37 mitotic sarcoma virus] phosphoprotein 90 mRNA, complete cds 3951 AF037350 Rattus norvegicus 1e-013 3004573 (AC004520) 8e-073 NF-E2-related similar to NFE2- factor 2 mRNA, related complete cds transcription factors; similar to I48694 (PID:g2137676) [Homo sapiens] 3952 AJ011972 Homo sapiens 8e-092 <NONE> <NONE> <NONE> mRNA for histone deacetylase-like protein (JM21) 3953 U95094 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3954 U95094 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3955 U95094 Xenopus laevis 3e-009 630444 CR5 protein - 4.3 XL-INCENP Trypanosoma (XL-INCENP) brucei >gi|468424 mRNA, complete cds 3956 U95094 Xenopus laevis 3e-009 630444 CR5 protein - 4.3 XL-INCENP Trypanosoma (XL-INCENP) brucei >gi|468424 mRNA, complete cds 3957 AF086172 Homo sapiens 9e-062 1172991 60S 9e-024 full length insert RIBOSOMAL cDNA clone PROTEIN L21 ZB89E10 sapiens] >gi|984143 (X89401) ribosomal protein L21 [Homo sapiens] >gi|1096939|prf∥2 113200B ribosomal protein L21 3958 D42084 Human mRNA 2e-058 1703270 PUTATIVE 1e-016 for KIAA0094 METHIONINE gene, partial cds AMINOPEPTIDA SE I (METAP I) (PEPTIDASE M 1) (KIAA0094) prcduct is related to S. cerevisiae methionine aminopeptidase. [Homo sapiens] 3959 AF634755 Homo sapiens 2e-005 <NONE> <NONE> <NONE> microphthalmia- associated transcription factor (MITF) gene, promoter region and partial cds 3960 Z96177 H. sapiens 3e-011 <NONE> <NONE> <NONE> telomeric DNA sequence, clone 10QTEL040, read 10QTELOO040.s eq 3961 U95094 Xenopus laevis 1e-012 141028 NADH- 1.1 XL-INCENP UBIQUINONE (XL-INCENP) OXIDOREDUCT mRNA, complete ASE CHAIN 5 cds >gi|76351|pir∥QQ UTC5 NADH dehydrogenase (ubiquinone) 3962 U93237 Human menin 0.37 134853 TRANSCRIPTIO 0.49 (MENI) gene, N INITIATION complete cds PROTEIN SPT5 yeast (Saccharomyces cerevisiae) >gi|172680 (M62882) SPT5 protein [Saccharomyces cerevisiae] >gi|854480 (Z49810) Spt5p [Saccharomyces cerevisiae] 3963 Z93782 Caenorhabditis 0.008 1171084 A/G-SPECIFIC 6.5 elegans cosmid ADENINE R12G8, complete GLYCOSYLASE sequence [Caenorhabditis elegans] 3964 U11270 Human 2e-023 728837 !!!! ALU 9e-006 antithrombin III SUBFAMILY SQ gene, exon 1 and WARNING partial cds. ENTRY 3965 U951027 Xenopus laevis 8e-007 3650488 (AF042273) signal 3.6 mitotic transducing phosphoprotein adaptor molecule 90 mRNA, 2A [Homo complete cds sapiens] 3966 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3967 AF086207 Homo sapiens 1e-009 1077301 probable 0.41 full length insert membrane protein cDNA clone YOL101c-yeast ZC48C05 similarity with bee NADH- ubiquinone oxidoreductssse chain 2 [Saccharomyces cerevisiae] >gi|1419955|gnl|PI D|e252291 3968 U95102 Xenopus laevis 4e-011 2072296 (U95098) mitotic 6.2 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3969 U95094 Xenopus laevis 2e-005 2274853 (AJ000502) iron 0.15 XL-INCENP regulatory protein (XL-INCENP) mRNA, complete cds 3970 U82165 Cercopithecus 2e-015 2735010 (U82166) CD99 0.011 aethiops type II-COS7 transmembrane [Cercopithecus glycoprotein aethiops] CD99-cos7 mRNA, partial cds 3971 U95094 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 3972 M87680 Human simple 3e-040 3874946 (Z79598) cDNA 1e-008 repeat EST polymorphism. EMBL: D34748 comes from this gene; cDNA EST yk218e6.5 comes from this gene; cDNA EST yk244e3.5 comes from this gene; cDNA EST yk248a4.5 comes from this gene; DNA EST yk250a3.5 comes from this gene; cDNA EST . . . 3973 U95094 Xenopus laevis 3e-010 119396 ENV 4.6 XL-INCENP POLYPROTEIN (XL-INCENP) (COAT mPNA, complete POLYPROTEIN) cds reticuloendothelios is virus >gi|61786 (X01455) env- protein (capsid protein) [Reticuloendotheli osis virus] >gi|209712 (K02537) envelope polyprotein [Avian reticuloendothelios is virus A] 3974 AB011143 Homo sapiens  e-151 1708199 HSC70- 4e-023 mRNA for INTERACTTNG KIAA0571 PROTEIN protein, complete cds 3975 AC001050 Homo sapiens 1e-019 728831 !!!! ALU 3e-006 (subclone 3_e9 SUBFAMILY J from P1 H55) WARNING DNA sequence ENTRY 3976 U95094 Xenopus laevis 3e-008 1077543 probable 5.9 XL-INCENP membrane protein (XL-INCENP) YDR198c - yeast mRNA, complete cds 3977 AJ00575 Drosophila virilis 0.056 <NONE> <NONE> <NONE> mRNA for GAGA factor class B-isoform 3978 U95102 Xenopus laevis 2e-014 478731 replication protein 1.5 mitotic - Butyrivibrio phosphoprotein fibrisolvens 90 mRNA, plasmid pRJF1 complete cds >gi|152515 (M94552) replication protein [Plasmid pRJF1] 3979 U95094 Xenopus laevis 1e-006 3319480 (AF077546) No 6.5 XL-INCENP definition tine (XL-INCENP) found mRNA, complete [Caenorhabditis cds elegans] 3980 U95102 Xenopus laevis 9e-0114 2072296 (U95098) mitotic 3 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3981 AF003350 Mus musculus 4e-007 1170261 OUTER 6.4 Npc1 gene, and MEMBRANE npc-nih intron USHER containing the PROTEIN HIFC MaLR inserted PRECURSOR sequence 3982 U95102 Xenopus laevis 0.001 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3983 U95102 Xenopus laevis 1e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3984 U95102 Xenopus laevis 4e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3985 AB007939 Homo sapiens  e-163 3413902 (AB007939) 2e-057 mRNA for KIAA0470 protein KIAA0470 [Homo sapiens] protein, complete cds 3986 U95102 Xenopus laevis 2e-010 2072296 (U95098) mitotic 2.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3987 U95102 Xenopus laevis 1e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3988 U95098 Xenopus laevis 1e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 3989 U95094 Xenopus laevis 0.008 2414527 (Z99263) 1.3 XL-INCENP hypothetical (XL-INCENP) protein mRNA, complete MLCB637.01c cds [Mycobacterium leprae] 3990 U95102 Xenopus laevis 0.074 464237 NADH- 2.2 mitotic UBIQUINONE phosphoprotein OXIDOREDUCT 90 mRNA, ASE CHAIN 4 complete cds 3991 U95094 Xenopus laevis 3e-010 3876367 (Z69360) Weak 7.7 XL-INCENP similarity to (XL-INCENP) Eimeria mRNA, complete thrombospondin cds (PIR Acc. No. A45517); cDNA EST EMBL: M89266 comes from this gene; cDNA EST yk295b9.5 comes from this gene [Caenorhabditis elegans] Eimeria thrombospondin (PIR Acc. No. A45517); cDNA EST EMBL: M89266 comes 3992 U95102 Xenopus laevis 0.0002 400624 SODIUM- AND 0.62 mitotic CHLORIDE- phosphoprotein DEPENDENT 90 mRNA, GABA complete cds TRANSPORTER 2 >gi|348413|pir∥A4 5078 gamma- aminobutyric acid transporter protein 2 - rat >gi|202523 (M95762) GABA transporter [Rattus norvegicus] 3993 U95102 Xenopus laevis 6e-015 2072296 (U95098) mitotic 5.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3994 U95102 Xenopus laevis 5e-012 2072296 (U95098) mitotic 6.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 3995 U95102 Xenopus laevis 3e-008 2286159 (AF007831) 6.3 mitotic glycoprotein H phosphoprotein [Human 90 mRNA, herpesvirus 7] complete cds 3996 U95102 Xenopus laevis 2e-014 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 3997 D16888 Human HepG2 3′  e-104 <NONE> <NONE> <NONE> region cDNA, clone hmd2c03 3998 U00995 Rattus norvegicus 1e-031 3639058 (AF077866) 1e-050 TA1 mRNA, amino acid complete cds. transporter E16 [Homo sapiens] 3999 AF037219 Homo sapiens 5e-013 586863 HYPOTHETICAL 2.7 PIX1 mRNA 9.2 KD PROTEIN sequence IN RECR-BOFA INTERGENIC REGION >gi|1075824|pir∥A 41869 bofA 5′- region hypothetical protein orf74- Bacillus subtilis subtilis] >gi|2632289|gn1|PI D|e1181955 (Z99104) yaaL 4000 U95102 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4001 U95094 Xenopus laevis 6e-015 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4002 U95094 Xenopus laevis 2e-013 549734 HYPOTHETICAL 3e-019 XL-INCENP 105.7 KD (XL-INCENP) PROTEIN IN mRNA, complete TPK3-PIR1 cds INTERGENIC REGION >gi|481105|pir∥S3 7786 hypothetical protein YKL165c - yeast (Saccharomyces cerevisiae) >gi|407483 (Z26877) unknown [Saccharomyces cerevisiae] >gi|486289 (Z28165) ORF YKL165c 4003 U95102 Xenopus laevis 2e-014 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4004 U95102 Xenopus laevis 9e-008 228110 T cell receptor 3.6 mitotic variable phosphoprotein region: SUBUNIT 90 mRNA, = beta: ISOTYPE = 1 complete cds 9 [Rattus norvegicus] 4005 U95094 Xenopus laevis 2e-014 930045 (X15332) alpha-1 0.52 XL-INCENP (III) collagen (XL-INCENP) [Homo sapiens] mRNA, complete cds 4006 U95094 Xenopus laevis 1e-010 2072296 (U95098) mitotic 6.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4007 U95102 Xenopus laevis 2e-015 2960195 (Y13051) tax 0.68 mitotic [Human T-cell phosphoprotein lymphotropic virus 90 mRNA, type 2b] complete cds 4008 U95102 Xenopus laevis 4e-007 3523099 (AF016271) Ksp- 6.6 mitotic cadherin [Mus phosphoprotein musculus] 90 mRNA, complete cds 4009 U95094 Xenopus laevis 6e-015 2072296 (U95098) mitotic 5.7 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4010 U95094 Xenopus laevis 6e-015 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4011 U95102 Xenopus laevis 3e-009 2121280 (AF000270) 1.5 mitotic lipoprotein phosphoprotein [Borrelia 90 mRNA, burgdorferi] complete cds 4012 U95102 Xenopus laevis 4e-012 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4013 L20489 Zea mays NADH 3.5 <NONE> <NONE> <NONE> dehydrogenase subunit 4 (complex I) (nad4) gene, exon 4. 4014 U95094 Xenopus laevis 2e-014 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4015 U95102 Xenopus laevis 2e-016 927407 (X89858) actin 0.02 mitotic binding protein phosphoprotein [Drosophila 90 mRNA, melanogaster] complete cds 4016 U05659 Human 17beta- 1e-092 1169300 ESTRADIOL 17 4e-029 hydroxysteroid BETA- dehydrogenase DEHYDROGENA type 3 mRNA, SE 3 complete cds DEHYDROGENA SE) >gi|1085271|pir∥S 43928 17-beta- hydroxysteroid dehydrogenase - human >gi|531162 hydroxysteroid dehydrogenase: IS OTYPE = 3 [Homo sapiens] 4017 U02428 Cloning vector 2e-066 987050 (X65335) lacZ 2e-009 pDR2, complete gene product sequence [unidentified cloning vector] 4018 U95094 Xenopus laevis 8e-018 3979938 (AL034393) 7e-009 XL-INCENP predicted using (XL-INCENP) Genefinder; cDNA mRNA, complete EST yk343c12.5 cds comes from this gene; cDNA EST yk402e12.5 comes from this gene; cDNA EST yk457e8.5 comes from this gene; cDNA EST yk470f2.5 comes from this gene; cDNA EST yk281e3.5 . . . 4019 U95102 Xenopus laevis 9e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4020 U95102 Xenopus laevis 1e-010 804806 (M13100) 5.7 mitotic unknown protein phosphoprotein [Rattus 90 mRNA, norvegicus] complete cds 4021 U95094 Xenopus laevis 2e-014 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4022 U95094 Xenopus laevis 1e-011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4023 U49974 Human mariner2  e-124 1698455 (U49974) mariner 2e-028 transposable transposase element, [Homo sapiens] complete consensus sequence 4024 L31840 Rattus norvegicus  e-175 1709212 NUCLEAR PORE 3e-093 nuclear pore COMPLEX complex protein PROTEIN NUP107 mRNA, NUP107 complete cds. 4025 AB001632 Homo sapiens 7e-007 <NONE> <NONE> <NONE> DNA for cGMP- binding cGMP- specific phosphodiesteras e (PDE5), exon 18 4026 X96401 H. sapiens mRNA 8e-070 <NONE> <NONE> <NONE> for ROX protein 4027 U95102 Xenopus laevis 0.015 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4028 U95094 Xenopus laevis 9e-010 2072296 (U95098) mitotic 3.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4029 AJ006064 Rattus norvegicus  e-124 3757680 (AJ006064) 2e-091 mRNA for coronin-like coronin-like protein [Rattus protein norvegicus] 4030 U95094 Xenopus laevis 1e-009 1184072 (U40766) COL-1 0.019 XL-INCENP [Meloidogyne (XL-INCENP) incognita] mRNA, complete cds 4031 U95094 Xenopus laevis 0.002 231721 T-CELL 5.8 XL-INCENP SURFACE (XL-INCENP) GLYCOPROTEIN mRNA, complete CD8 ALPHA cds CHAIN PRECURSOR (T- LYMPHOCYTE DIFFERENTIATI ON ANTIGEN T8/LEU-2) >gi|38145 (X60223) CD8 alpha chain 4032 U95102 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4033 U95098 Xenopus laevis 0.005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4034 U95094 Xenopus laevis 4e-011 1020391 (LA8340) alcohol 1.4 XL-INCENP dehydrogenase (XL-INCENP) [Methylobacteriu mRNA, complete m extorquens] cds 4035 U95102 Xenopus laevis 0.0002 2291282 (AF016433) 4.4 mitotic similarto C. phosphoprotein elegans olfactory 90 mRNA, receptor ODR-10 complete cds (NID: g1235900) [Caenorhabditis elegans] 4036 U95094 Xenopus laevis 1e-010 478993 DNA-binding 5e-006 XL-INCENP protein TAF-II (XL-INCENP) 250K - fruit fly mRNA, complete TATA-binding cds protein associated factor II 250, TBP associated factor II 250, TAFII250 {C-terminal} 4037 U95094 Xenopus laevis 1e-011 2072296 (U95098) mitotic 4.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4038 X03100 Human HLA- 2e-025 <NONE> <NONE> <NONE> SB(DP) alpha gene 4039 U95094 Xenopus laevis 8e-008 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4040 J03798 Human 2e-048 3874988 (Z74029) 5.6 autoantigen small Similarity to nuclear C. elegans alcohol ribonucleoprotein dehydrogenase Sm-DmRNA, (WP: C17G10.8); complete cds. cDNA EST EMBL: D66106 comes from this gene; cDNA EST EMBL: D69117 comes from this gene; cDNA EST EMBL: D69761 comes from this gene; cDNA EST EMBL: C12156 come . . . 4041 U95102 Xenopus laevis 6e-006 2292986 (AJ000496) cyclic 0.5 mitotic nucleotide-gated phosphoprotein channel beta 90 mRNA, subunit [Rattus complete cds norvegicus] 4042 U95102 Xenopus laevis 3e-010 2072296 (U95098) mitotic 2.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4043 AF020187 Amblyomma 1.2 <NONE> <NONE> <NONE> americanum ecdsyteroid receptor 4044 Z68758 Human DNA 2e-035 <NONE> <NONE> <NONE> sequence from cosmid cN85E10 on chromosome 22q11.2-qter 4045 U95102 Xenopus laevis 8e-008 2529632 (L78917) virion 4.6 mitotic protein [Rubella phosphopnotein virus] 90 mRNA, complete cds 4046 U95102 Xenopus laevis 6e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4047 AB007957 Homo sapiens 2e-016 728831 !!!! ALU 0.063 mRNA, SUBFAMILY J chromosome I WARNING specific transcript ENTRY KIAA0488 4048 M64716 Human ribosomal 3e-082 2660720 (AF029678) PHF1 7e-013 protein S25 [Homo sapiens] mRNA, complete cds. 4049 AB002437 Homo sapiens 6e-026 <NONE> <NONE> <NONE> mRNA from chromosome 5q21-22, clone: LI33 4050 Z74893 S. cerevisiae 0.13 <NONE> <NONE> <NONE> chromosome XV reading frame ORF YOL151w 4051 U95102 Xenopus laevis 7e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4052 U43416 Human 2e-056 728831 !!!! ALU 0.007 replication SUBFAMILY J control protein 1 WARNING (PARC1) mRNA, ENTRY complete cds. 4053 AF042346 Homo Sapiens 0 4104933 (AF042346)  e-123 putative putative phenylalanyl- phenylalanyl- tRNA synthetase tRNA synthetase beta-subunit beta-subunit; mRNA, complete PheHB [Homo cds sapiens] 4054 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4055 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4056 U95102 Xenopus laevis 3e-009 2072296 (U95098) mitotic 5.6 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4057 U95094 Xenopus laevis 0.0005 2981221 (AF053091) eyelid 2.6 XL-INCENP [Drosophila (XL-INCENP) melanogaster] mRNA, complete cds 4058 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4059 U95094 Xenopus laevis 8e-007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4060 U95094 Xenopus laevis 3e-010 2072296 (U95098) mitotic 9.6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4061 U11081 Human type 1 0.43 <NONE> <NONE> <NONE> vasoactive intestinal peptide receptor (VIRG) gene, exon3. 4062 X82272 Human 8e-081 1196429 (M14123) pol/env 6e-058 endogenous ORF (bases 3878- retrovirus env 8257) first start mRNA codon at 4172; Xxx; putative [Homo sapiens] 4063 S61789 NF1 = neurofibro 0.0005 2494294 NEUROGENIC 4.3 matosis type 1 LOCUS NOTCH {deletion 3 PROTEIN breakpoint, tetrameric STR} [human, neurofibmsarcom a tissue, Genomic Mutant, 698 nt] 4064 U95102 Xenopus laevis 0.0005 3264773 (AF072439) zinc- 3.3 mitotic finger protein-37; phosphoprotein ZFP-37 [Rattus 90 mRNA, norvegicus] complete cds 4065 U95102 Xenopus laevis 3e-010 2072296 (U95098) mitotic 4.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4066 U47322 Cloning vector 9e-054 2072296 (U95098) mitotic 0.6 DNA, complete phosphoprotein 44 sequence. [Xenopus laevis] 4067 U95102 Xenopus laevis 1e-609 2072296 (U95098) mitotic 3.4 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4068 U31557 Ovine adenovirus 0.0002 3002875 (AF042104) 2.6 IVa2 protein envelope gene, DNA glycoprotein polymerase gene, [Human terminal protein immunodeficiency gene and 52, 55 virus type 1] kDa protein gene, partial cds 4069 AL023973 Human DNA 7e-017 728831 !!!! ALU 0.061 sequence from SUBFAMILY J clone 1033E15 on WARNING chromosome ENTRY 22q13.1-13.2. Contains part of a novel gene, ESTs and a GSS, complete sequence [Homo sapiens] 4070 U95098 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4071 X07679 Xenopus laevis 0.39 2281044 (Z95636) laminin 0.9 XK70A gene for alpha 5 chain type 1 keratin [Homo sapiens] 4072 X96886 H. sapiens 5e-014 <NONE> <NONE> <NONE> spcDNA, clone 2- 65 4073 U95098 Xenopus laevis 9e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4074 U95098 Xenopus laevis 6e-005 1079278 activin receptor II 1.3 mitotic STK3 precursor - phosphoprotein African clawed 44 mRNA, partial frog cds >gi|260044|bbs|11 8656 (S49438) aclivin receptor, XAR1 [Xenopus, oocytes, Peptide, 510 aa] 4075 AF097909 Peptostreptococc 0.046 <NONE> <NONE> <NONE> us micros fibril- like structure subunit FibA (fibA) gene, complete cds; excreted protein FibB (fibB) gene, partial cds; and unknown gene 4076 U95094 Xenopus laevis 4e-010 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4077 AL009008 Plasmodium 0.45 <NONE> <NONE> <NONE> falciparum DNA *** SEQUENCING IN PROGRESS *** from contig 3-58, complete sequence 4078 L34686 Serpulina 0.015 <NONE> <NONE> <NONE> hyodysenteriae flagellar protein 4079 AJ130718 Homo sapiens 1e-022 3582136 (AB015432) 2e-008 mRNA for LAT1 (L-1 type glycoprotein- amino acid associated amino transporter 1) acid transporter [Rattus y+LATI norvegicus] 4080 X51969 Cyprinus carpio 1.2 <NONE> <NONE> <NONE> growth honnone gene 4081 U95094 Xenopus laevis 3e-010 2072296 (U95098) mitotic 1.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4082 U95094 Xenopus laevis 4e-011 2072296 (U95098) mitotic 3.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4083 L38961 Human putative 1e-071 1174470 OLIGOSACCHA 1e-008 transmembrane RYL protein precursor TRANSFERASE (B5) mRNA, STT3 SUBUNIT complete cds HOMOLOG (B5) (INTEGRAL MEMBRANE PROTEIN 1) musculus] >gil|1588285|prf∥2 208301A integral membrane protein [Mus musculus] 4084 U95102 Xenopus laevis 2e-013 267449 HYPOTHETICAL 7e-014 mitotic 12.5 KD phosphoprotein PROTEIN 90 mRNA, ZK637.2 IN complete cds CHROMOSOME III >gi|102507|pir∥S1 5787 hypothetical protein 1 (cosmid ZK637) - Caenorhabditis elegans Genefinder; cDNA EST yk217b5.3 comes from this gene; cDNA EST yk217b5.5 comes from this gene; cDNA EST yk340g12.3 4085 U95098 Xenopus laevis 8e-008 2072296 (U95098) mitotic 3.4 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 44 mRNA, partial cds 4086 X77733 T. aestivum 0.005 <NONE> <NONE> <NONE> VDAC 1 mRNA. 4087 U95094 Xenopus laevis 1e-009 3123172 ZINC FINGER 2e-010 XL-INCENP PROTEIN 151 (XL-INCENP) (MIZ-1 mRNA, complete PROTEIN) cds >gi|2230871|gn1|PI D|e286602 (Y09723) Miz-1 protein [Homo sapiens] 4088 U95102 Xenopus laevis 1e-010 180498 (M17517) 5.8 mitotic complement H phosphoprotein factor [Homo 90 mRNA, sapiens] complete cds 4089 U95102 Xenopus laevis 8e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4090 U24697 Chironomus 0.13 3880999 (AL021492) 7e-022 samoensis nanos Y45F10D.11 homolog (Cs nos) [Caenorhabditis gene, complete elegans] cds. 4091 U95094 Xenopus laevis 4e-012 2072296 (U95098) mitotic 5.7 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4092 U81504 Homo sapiens 6e-088 2199512 (U81504) beta- 0.0001 beta-3A-adaptin 3A-adaptin subunit of the subunit of the AP- AP-3 complex 3 complex [Homo mRNA, complete sapiens] cds 4093 AF053304 Homo sapiens  e-108 3378104 (AF047473) testis 3e-024 mitotic mitotic checkpoint checkpoint BUB3 [Homo component Bub3 sapiens] 4094 S70431 type-1 4e-013 126295 LINE-1 3e-005 angiotensin II REVERSE receptor (exons 1 TRANSCRIPTAS and 2, promoter} E HOMOLOG [human, peripheral lymphocytes, Genomic, 2853 nt, segment 1 of 2] 4095 U95094 Xenopus laevis 4e-013 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4096 D10355 Human mRNA 3e-082 111345 alanine 4e-042 for alanine transaminase (EC aminotransferase 2.6.1.2) - rat 4097 AF043252 Homo sapiens  e-167 3941342 (AF043250) 7e-013 mitochondrial mitochondrial outer membrane outer membrane protein (Tom40) protein [Homo gene, nuclear sapiens] gene encoding >gi|3941347 mitochondrial (AF043253) protein, exons 7, mitochondrial 8 and 9 outer membrane protein [Homo sapiens] >gi|4105703 (AF050154) D19S1177E [Homo sapiens] 4098 U41668 Human  e-125 2833282 DEOXYGUANOS 2e-009 deoxyguanosine INE KINASE kinase mRNA, PRECURSOR complete cds sapiens] 4099 AF017416 Bacillus 0.14 <NONE> <NONE> <NONE> thuringiensis d- endotoxin gene, complete cds 4100 U95102 Xenopus laevis 1e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4101 AF017416 Bacillus 0.14 <NONE> <NONE> <NONE> thuringiensis d- endotoxin gene, complete cds 4102 U95102 Xenopus laevis 1e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4103 AJ003081 Homo sapiens 5e-024 <NONE> <NONE> <NONE> repetitive DNA 4104 U95102 Xenopus laevis 8e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4105 U95102 Xenopus laevis 7e-006 1572756 (U70848) 4e-038 mitotic C43G2.1 gene phosphoprotein product 90 mRNA, [Caenorhabditis complete cds elegans] 4106 U33915 Craterostigma 0.14 <NONE> <NONE> <NONE> plantagineum myb-related transcription factor (cpm 10) gene, complete cds 4107 U46493 Cloning vector 5e-033 987050 (X65335) lacZ 0.004 pFlp recombinase gene product gene, complete [unidentified cds cloning vector] 4108 U95102 Xenopus laevis 1e-009 3417298 (AC002044) 0.33 mitotic Alpha-fetoprotein phosphoprotein enhancer binding 90 mRNA, protein (3′ partial) complete cds [Homo sapiens] 4109 M16039 Dictyostelium 0.0002 <NONE> <NONE> <NONE> discoideum pst- cath gene encoding pst- cathepsin, complete cds. 4110 D21851 Human mRNA 6e-005 <NONE> <NONE> <NONE> for KIAA0028 gene, partial cds 4111 U95094 Xenopus laevis 7e-007 1723920 HYPOTHETICAL 8e-006 XL-INCENP 37.4 KD (XL-INCENP) PROTEIN IN mRNA, complete SEC27-SSM1B cds INTERGENIC REGION >gi|2131603|pir∥S 64149 hypothetical protein YGL136c - yeast (Saccharomyces cerevisiae) >gi|1246842|gnl|PI D|e210737 (X92670) G2830 4112 X75861 H. sapiens TEGT  e-180 2072296 (U95098) mitotic 2.6 gene phosphoprotein 44 [Xenopus laevis] 4113 U95094 Xenopus laevis 8e-008 1399962 (U62317) choline 0.67 XL-INCENP kinase isolog (XL-INCENP) 384D8_3 [Homo mRNA, complete sapiens] cds 4114 Y07660 M. tuberculosis 2e-059 465847 HYPOTHETICAL 4e-056 accBC gene 66.5 KD PROTEIN F02A9.5 IN CHROMOSOME III >gi|280542|pir∥S2 8313 hypothetical protein F02A9.5 - Caenorhabditis elegans Genefinder; similar to Propionyl-CoA carboxylase beta chain; cDNA EST EMBL: M89018 comes from this gene; cDNA EST EMBL: D2806 4115 U95102 Xenopus laevis 0.014 765086 (D30786) feline 1.9 mitotic CD9 [Felis catus] phosphoprotein 90 mRNA, complete cds 4116 D29011 Human mRNA  e-125 2136006 proteasome 4e-008 for proteasome subunit MB1 - subunit X, human (fragment) complete cds MB1 = LMP7 homolog [human, JY T-cells, Peptide Partial, 215 aa] [Homo sapiens] 4117 U95094 Xenopus laevis 4e-012 2072296 (U95098) mitotic 6.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4118 Z11692 H. sapiens mRNA  e-178 119172 ELONGATION 6e-054 for elongation FACTOR 2 (EF-2) factor2 eEF-2 - human >gi|31106 (X51466) elongation factor 2 factor 2 [Homo sapiens] 4119 AF070530 Homo sapiens 0 3387886 (AF070530) 4e-013 clone 24751 unknown [Homo unknown mRNA sapiens] 4120 D12646 Mouse kif4 6e-057 1170659 KINESIN-LIKE 2e-022 mRNA for PROTEIN KIF4 microtubule- musculus] based motor protein KIF4, complete cds 4121 U95094 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4122 X75861 H. sapiens TEGT  e-180 2072296 (U95098) mitotic 2.6 gene phosphoprotein 44 [Xenopus laevis] 4123 U95094 Xenopus laevis 4e-012 630864 LRR47 protein - 0.0002 XL-INCENP fruit fly (XL-INCENP) (Drosophila mRNA, complete melanogaster) cds >gi|415947 (X75760) LRR47 [Drosophila melanogaster] 4124 U95102 Xenopus laevis 5e-014 3876775 (Z81077) 1e-015 mitotic predicted using phosphoprotein Genefinder; 90 mRNA, Similarity to Yeast complete cds protein 8248 (TR:G587531) 4125 U95102 Xenopus laevis 2e-008 480516 transposase (clone 2.8 mitotic 22.5) - African phosphoprotein malaria mosquito 90 mRNA, transposon complete cds mariner (fragment) >gi|159600 4126 U95102 Xenopus laevis 8e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4127 X65279 pWE15 cosmid 2e-066 987050 (X65335) lacZ 4e-015 vector DNA gene product [unidentified cloning vector] 4128 U95094 Xenopus laevis 4e-012 2072296 (U95098) mitotic 3.8 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4129 U95094 Xenopus laevis 3e-008 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4130 U95094 Xenopus laevis 3e-008 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4131 X74871 H. sapiens gene 1.1 1182038 (Z69368) 0.86 for RNA pol II unknown largest subunit, [Schizosaccharom exons 20-22 yces pombe] 4132 M64983 Human 0.23 <NONE> <NONE> <NONE> fibrinogen beta chain gene, complete mRNA. > gb|147706|147706 Sequence 3 from U.S. Pat. No. 5639940 4133 D12646 Mouse kif4 6e-057 1170659 KINESIN-LIKE 2e-022 mRNA for PROTEIN KIF4 microtubule- musculus] based motor protein KIF4, complete cds 4134 D86957 Human mRNA 1.1 <NONE> <NONE> <NONE> for KIAA0202 gene, partial cds 4135 U95094 Xenopus laevis 7e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4136 M20902 Human 4e-008 <NONE> <NONE> <NONE> apolipoprotein C- I (VLDL) gene, complete cds. 4137 L36849 Cloning vector 9e-040 987050 (X65335) lacZ 9e-007 pZEO (isolate gene product SV1) [unidentified phleomycin/zeoci cloning vector] n-binding protein gene, complete cds. 4138 X80910 H. sapiens 0 <NONE> <NONE> <NONE> PPP1CB mRNA 4139 M77812 Rabbit myosin 0.0002 2088793 (AF003150). 0.23 heavy chain similar to cuticular mRNA, complete collagen cds. [Caenorhabditis elegans] 4140 U41165 Human 0.13 <NONE> <NONE> <NONE> recombination ‘hot spot’ region associated with the CMT1A duplication and the HNPP deletion containing a mariner transposon-like element 4141 U95094 Xenopus laevis 0.0006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4142 AC001502 Homo sapiens 0.014 3164130 (D78600) 7.5 (subclone 2_c7 cytochrome P450 from P1 H43) monooxygenase DNA sequence 4143 U95102 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4144 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4145 L31760 Human STS 0.17 <NONE> <NONE> <NONE> UT8178. 4146 U95094 Xenopus laevis 5e-013 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4147 U95102 Xenopus laevis 0.0006 2662587 (AF036696) 2e-016 mitotic contains similarity phosphoprotein to Brassica 90 mRNA, oleracea non-green complete cds plastid phosphate/triose- phosphate translocator precursor (GB: U13632) [Caenorhabditis elegans] 4148 X56807 Human DSC2 6e-037 319943 desmocollin 3b 7e-014 mRNA for precursor - human desmocollins type 2a and 2b 4149 U95102 Xenopus laevis 1e-012 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4150 U95102 Xenopus laevis 2e-005 2854155 (AF045640) 3.4 mitotic contains similarity phosphoprotein to ion channel 90 mRNA, proteins complete cds 4151 U95102 Xenopus laevis 3e-010 2507153 VACUOLAR 0.011 mitotic PROTEIN phosphoprotein SORTING- 90 mRNA, ASSOCIATED complete cds PROTEIN VPS16 >gi|2133204|pir∥S 62031 vacuolar protein sorting- associated protein VPS16 - yeast (Saccharomyces cerevisiae) >gi|1171414 (U44030) Vsp16p: Vacuolar sorting protein [Saccharomyces cerevisiae] 4152 D12646 Mouse kif4 2e-035 3877579 (Z82271) 2e-054 mRNA for Similarity to microtubule- Mouse kinensin- based motor like protein KIF4 protein KIF4, (SW:P33174); complete cds cDNA EST EMBL: D27320 comes from this gene; cDNA EST EMBL: D27322 comes from this gene; cDNA EST EMBL: D27321 comes from this gene; cDNA EST EMBL: D35764 comes . . . Mouse kinensin-like protein 4153 D12646 Mouse kif4 2e-035 3877579 (Z82271) 2e-054 mRNA for Similarity to microtubule- Mouse kinensin- based motor like protein KIF4 protein KIF4, (SW: P33174); complete cds cDNA EST EMBL: D27320 comes from this gene; cDNA EST EMBL: D27322 comes from this gene; cDNA EST EMBL: D27321 comes from this gene; cDNA EST EMBL: D35764 comes . . . Mouse kinensin-like protein 4154 D12646 Mouse kif4 2e-035 3877579 (Z82271) 9e-058 mRNA for Similarity to microtubule- Mouse kinensin- based motor like protein KIF4 protein KIF4, (SW: P33174); complete cds cDNA EST EMBL: D27320 comes from this gene; cDNA EST EMBL: D27322 comes from this gene; cDNA EST EMBL: D27321 comes from this gene; cDNA EST EMBL: D35764 comes . . . kinensin- like protein KIF4 4155 M30539 Human SK2c- 0.13 137334 66 KD PROTEIN 10 Ha-ras-1 >gi|77357|pir∥JQ0 oncogene- 107 hypothetical encoded protein 66K protein - gene, exon 1. Ononis yellow mosaic virus 4156 L05096 Homo Sapiens 2e-086 1173044 60S 3e-007 ribosomal protein RIBOSOMAL L39 mRNA, PROTEIN L39 complete cds norvegicus] >gi|1373419 (U57846) ribosonial protein L39 ribosomal protein L39 [Homo sapiens] 4157 D13749 Plasmid pKA1 2e-025 987050 (X65335) lacZ 0.18 DNA gene product [unidentified cloning vector] 4158 AF007157 Homo sapiens 2e-057 2131036 (Z95890) 6.3 clone 23856 PE_PGRS unknown mRNA, [Mycobacterium partial cds tuberculosis] 4159 AF031400 Poecilia orri 1.2 3327168 (AB014577) 0.0008 NADH KIAA0677 protein dehydrogenase [Homo sapiens] subunit 2 gene, mitochondrial gene encoding mitochondrial protein, complete cds 4160 U58468 Human 3e-009 <NONE> <NONE> <NONE> vasoactive intestinal peptide gene, 5′ flanking sequence from - 5172 to -1924 4161 D11078 Homo sapiens 4e-032 2119507 alpha-1C- 1.2 RGH2 gene, adrenergic retrovirus-like receptor isoform 2 element - human >gi|927209|gn∥PI D|d1007476 (D32202) alpha 1C adrenergic receptor isoform 2 [Homo sapiens] 4162 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4163 M31061 Human ornithine 2e-023 728831 !!!! ALU 0.002 decarboxylase SUBFAMILY J gene, complete WARNING cds. ENTRY 4164 M19980 M. fervidus gap 0.4 1825606 (U88169) similar 3e-057 gene encoding to molybdoterin glyceraldehyde-3- biosynthesis phosphate MOEB proteins dehydrogenase, [Caenorhabditis complete cds. elegans] 4165 D17036 Human HepG2 5e-025 <NONE> <NONE> <NONE> partial cDNA, clone hmd3e08m5 4166 L14714 C. elegans 0.39 3874412 (Z70034) 1e-033 cosmid ZC97. similarity to 35.1KD hypothetical yeast protein (Swiss Prot accession number P38805); cDNA EST CEMSE65F comes from this gene; cDNA EST EMBL: T01315 comes from this gene; cDNA EST yk452e10.3 comes from this gene; cDNA . . . 35.1 KD hypothetical yeast p 4167 U95102 Xenopus laevis 8e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4168 Z49867 Caenorhabditis 0.044 3876784 (Z81530) 5.9 elegans cosmid predicted using C33D3, complete Genefinder sequence [Caenorhabditis elegans] 4169 U95102 Xenopus laevis 9e-010 3549676 (AL031394) 3.1 mitotic putative protein phosphoprotein 90 mRNA, complete cds 4170 D87001 Human (lambda) 0.36 3133246 (AB013170) 2.4 DNA for NADH immunoglobulin dehydrogenase light chain subunit 5 4171 M37191 Human ras  e-122 107561 Ras inhibitor 3e-035 inhibitor mRNA, (clone JC310) - partial cds. human sapiens] 4172 AB018374 Mus musculus 2e-046 3724364 (AB018374) 2e-008 GARP34 mRNA, GARP34 [Mus complete cds musculus] 4173 X62527 R. norvegicus 1.2 1155068 (X94976) cell 1.6 gene for CNS- wall-plasma myelin membrane linker proteolipid protein protein (exon 6) 4174 U95094 Xenopus laevis 8e-008 2781355 (AC003113) 0.52 XL-INCENP F24O1.11 (XL-INCENP) [Arabidopsis mRNA, complete thaliana] cds 4175 AF002715 Homo sapiens  e-168 2352277 (AF002715) MAP 1e-042 MAP kinase kinase kinase kinase kinase kinase [Homo (MTK1) mRNA, sapiens] complete cds 4176 U07807 Human 0.047 <NONE> <NONE> <NONE> metallothionein IV (MTIV) gene, complete cds. 4177 D11129 Pneumonia virus 0.14 <NONE> <NONE> <NONE> of mice gene 7 4178 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4179 AF070557 Homo sapiens 0 <NONE> <NONE> <NONE> clone 24422 mRNA sequence 4180 U95098 Xenopus laevis 0.005 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4181 AF045765 Homo sapiens G 9e-018 728833 !!!! ALU 0.051 protein-coupled SUBFAMILY receptor SB1 WARNING ENTRY 4182 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4183 X62162 B. burgdorferi 0.41 <NONE> <NONE> <NONE> gene for PC protein 4184 Z81315 Human DNA 1.2 <NONE> <NONE> <NONE> sequence from fosmid F62D4 on chromosome 22q12-qterv > :: emb|Z81316|HSF 62D4A Human DNA sequence from fosmid F62D4 on chromosome 22, complete sequence 4185 U95094 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4186 L08108 Human low- 0.0006 462387 IMMEDIATE- 0.25 affinity Fc- EARLY receptor IIB gene, PROTEIN IE180 exons 4-7. herpesvirus 1 (strain Kaplan) >gi|334071 (M34651) immediate-early protein [Pseudorabies virus] 4187 AJ228330 Pinus pinaster 1.3 3108187 (AC004663) 1.3 reverse Notch 3 [Homo transcriptase gene sapiens] of Line- retroelement (clone pPpLi1) 4188 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4189 AF048991 Homo sapiens 0.002 3986756 (AF109905) NG23 0.066 MutS homolog 5 [Mus musculus] (MSH5) gene, exons 13 through 25 and complete cds 4190 Z59608 H. sapiens CpG 2e-014 1055183 (U40061) Similar 2.4 DNA, clone to sodium- 165g8, reverse dependent read phosphate cpg165g8.rt1a. transporter. [Caenorhabditis elegans] 4191 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4192 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4193 U95094 Xenopus laevis 2e-006 2128837 hypothetical 7.6 XL-INCENP protein MJ1401 - (XL-INCENP) Methanococcus mRNA, complete jannaschii cds >gi|1592049 (U67580) putative ATP dependent RNA helicase [Methanococcus jannaschii] 4194 X99691 B. taurus DNA for 9e-009 <NONE> <NONE> <NONE> agouti gene 4195 U95098 Xenopus laevis 8e-008 306929 (M28696) IgG Fc 0.64 mitotic receptor beta-Fc- phosphoprotein gamma-RII 44 mRNA, partial [Homo sapiens] cds 4196 U37521 Sus scrofa E- 0.042 539800 calcium-activated 3.3 selectin gene, potassium channel complete cds mSlo - mouse >gi|347144 (L16912) mSlo [Mus musculus] 4197 U95098 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4198 U95098 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4199 V01087 Hemagglutinin 0.18 4038537 (AL021106) 1- 8.5 gene of influenza evidence=predicte virus strain d by match; 1- A/duck/Ukraine/1 match_accession= /63 > :: AA392988; 1- gb|J02109|FLAH match_description AMU Influenza =LD12167.5prime A/duck/ukraine/1/ LD Drosophila 63 (h3n8), melanogaster hemagglutinin embryo BlueScript (seg 4), cdna. Drosophila melanogaster cDNA clone LD12167 5prime.; 1- match_species=Dr osop . . . 4200 X83107 H. sapiens Bmx 0.38 1147597 (U31221) 3.3 mRNA for viscerotropic cytoplasmic leishmaniasis tyrosine kinase antigen [Leishmania tropica] 4201 U95102 Xenopus laevis 2e-014 2072296 (U95098) mitotic 1.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4202 X71642 M. musculus 3.5 2760302 (D89074) 1.5 GEG-154 mRNA hypothetical protein [Vibrio cholerae O139 fsl phage] 4203 U95094 Xenopus laevis 2e-013 2072296 (U95098) mitotic 3.7 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4204 U95102 Xenopus laevis 9e-009 1574918 (U19728) organic 5.8 mitotic anion transporter phosphoprotein [Raja erinacea] 90 mRNA, complete cds 4205 U95102 Xenopus laevis 4e-012 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4206 U95094 Xenopus laevis 4e-011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4207 U95102 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4208 U95094 Xenopus laevis 4e-011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4209 U50523 Human BRCA2 0 3121764 ARP2/3 9e-026 region, mRNA COMPLEX 34 sequence CG037 KD SUBUNIT 4210 X80909 H. sapiens alpha 8e-050 2072296 (U95098) mitotic 5.9 NAC mRNA phosphoprotein 44 [Xenopus laevis] 4211 AF039955 Homo sapiens 7e-006 <NONE> <NONE> <NONE> liver CC chemokine-1 precursor 4212 U95102 Xenopus laevis 3e-010 2072296 (U95098) mitotic 4.6 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4213 L35670 Homo sapiens 7e-017 <NONE> <NONE> <NONE> (subclone H8 1.0_g5 from P1 35 H5 C8) DNA sequence. 4214 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4215 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4216 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4217 L33354 Lobostemon 0.35 1483615 (Z77856) beta- 9 fruticosus Buek glucosidase chloroplast [Thermotoga trnL(UAA)- neapolitana] trnF(GAA) intergenic spacer DNA. 4218 Z12112 pWE15A cosmid 5e-033 987050 (X65335) lacZ 4e-008 vector DNA gene product [unidentified cloning vector] 4219 X65279 pWE15 cosmid 2e-079 987050 (X65335) lacZ 3e-015 vector DNA gene product [unidentified cloning vector] 4220 AF052165 Homo sapiens e-170 2065177 (Y12790) Supt5h 1e-059 clone 24522 protein [Homo mRNA sequence sapiens] sapiens] 4221 U95102 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4222 U95102 Xenopus laevis 2e-014 2072296 (U95098) mitotic 1.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4223 AF055024 Homo sapiens 0 <NONE> <NONE> <NONE> clone 24763 mRNA sequence 4224 S39048 knob associated 0.39 <NONE> <NONE> <NONE> histidine-rich protein KAHRP 4225 U95102 Xenopus laevis 4e-011 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4226 U34377 Human tyrosine 2e-028 1709347 SERINE/THREO 8e-008 kinase TXK (txk) NINE-PROTEIN gene, exon 13. KINASE NRK2 (SERINE/THREO NINE KINASE 2) >gi|348245 (L20321) protein serine/threonine kinase [Homo sapiens] 4227 U25748 Pan troglodytes 0 3182993 EPIDIDYMAL 7e-040 epididymal SECRETORY secretory protein PROTEIN E1 precursor (EPI-1) PRECURSOR mRNA, complete (EPI-1) (HEI) cds. (EPIDIDYMAL SECRETORY PROTEIN 14.6) (ESP14.6) >gi|106343|pir∥S2 5641 hypothetical protein - human >gi|2134519|pir∥I5 3929 epididymal secretory protein 14.6 - crab-eating macaque human >gi|37477 (X676 4228 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4229 U95102 Xenopus laevis 0.017 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4230 X74929 H. sapiens KRT8 6e-036 <NONE> <NONE> <NONE> mRNA for keratin 8 4231 U95102 Xenopus laevis 8e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4232 U95094 Xenopus laevis 5e-013 2072296 (U95098) mitotic 6 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4233 U41010 Caenorhabditis 4.2 <NONE> <NONE> <NONE> elegans cosmid T05A12 4234 U95094 Xenopus laevis 3e-007 1363925 hypothetical 4.7 XL-INCENP protein 2 - North (XL-INCENP) American mRNA, complete opossum cds (fragment) >gi|897721 (Z48955) ORF-2, putative RT [Didelphis virginiana] 4235 U95094 Xenopus laevis 0.0002 439493 (D26086) zinc- 8.5 XL-INCENP finger protein (XL-INCENP) [Petunia x mRNA, complete hybrida] cds 4236 U95094 Xenopus laevis 0.0002 2501599 HYPOTHETICAL 0.002 XL-INCENP 29.1 KD (XL-INCENP) PROTEIN mRNA, complete W06E11.4 IN cds CHROMOSOME III >gi|669022 (U20862) W06E11.4 gene product [Caenorhabditis elegans] 4237 X94118 P. falciparum PK4 1.2 <NONE> <NONE> <NONE> gene 4238 Z18944 S. cerevisiae 7.30E-01 2119161 unknown - chicken 0.61 BDF1 gene (fragment) >gi|537433 4239 AF031939 Mus musculus e-154 2677843 (AF031939) 5e-016 RalBP1- RalBP1-associated associated EH EH domain protein domain protein Reps1 Reps1 (reps1) mRNA, complete cds 4240 U95102 Xenopus laevis 1e-014 2072296 (U95098) mitotic 2.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4241 L35566 Gallus gallus 3e-044 1708809 HOMEOBOX 4e-021 homeobox PROTEIN LH-2 protein (LH-2) >gi|508712 mRNA, complete cds. 4242 Z83086 H. sapiens 3.00E-07 <NONE> <NONE> <NONE> Fanconi anaemia group A gene, exon 29 4243 U63810 Homo sapiens 0.00E+00 3219331 (AC004020) 1e-096 WD40 protein Unknown gene Ciao 1 mRNA, product [Homo complete cds sapiens] 4244 U15110 Mycoplasma 1.1 <NONE> <NONE> <NONE> capricolum ptsI- crr operon phosphocarrier protein enzyme I (ptsI) and phosphocarrier protein enzyme IIA (crr) genes, complete cds, and lipopolysaccharid e biosynthesis (kdtB) gene, complete cds. 4245 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4246 U95094 Xenopus laevis 4e-011 730888 OCTAPEPTIDE- 1.4 XL-INCENP REPEAT (XL-INCENP) PROTEIN T2 mRNA, complete cds 4247 U95102 Xenopus laevis 0.074 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4248 AJ224152 Plasmodium 0.54 <NONE> <NONE> <NONE> berghei gene encoding cdc2- related kinase 2 4249 M24971 D. discoideum 2e-008 119110 EBNA-1 2e-009 CT-rich satellite NUCLEAR rDNA, clone PROTEIN pCT11. herpesvirus 4 (strain B95-8) >gi|1334880 (V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 4250 Z72969 S. cerevisiae 1.2 <NONE> <NONE> <NONE> chromosome VII reading frame ORF YGR184c 4251 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4252 AJ224326 Homo sapiens 0 <NONE> <NONE> <NONE> mRNA for putative ribulose- 5-phosphate- epimerase, partial cds 4253 U45245 Homo sapiens 2.1 <NONE> <NONE> <NONE> paired-box protein PAX2 (PAX2) gene, promoter and exon 1 4254 AE001157 Borrelia 0.63 <NONE> <NONE> <NONE> burgdorferi (section 43 of 70) of the complete genome 4255 U95102 Xenopus laevis 3e-010 2072296 (U95098) mitotic 5.8 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4256 U95098 Xenopus laevis 0.0005 2773162 (AF039595) 9.6 mitotic sulfonylurea phosphoprotein receptor 1B 44 mRNA, partial [Rattus cds norvegicus] 4257 U95102 Xenopus laevis 5e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4258 L11130 Influenza 0.67 <NONE> <NONE> <NONE> A/gul1/MD/19/77 (H2N8) hemagglutinin 4259 AB018270 Homo sapiens 0 2072296 (U95098) mitotic 3 mRNA for phosphoprotein 44 KIAA0727 [Xenopus laevis] protein, partial cds 4260 U67494 Methanococcus 0.014 <NONE> <NONE> <NONE> jannaschii section 36 of 150 of the complete genome 4261 L09209 Homo sapiens 6e-089 <NONE> <NONE> <NONE> amyloid protein homologue mRNA, complete cds > :: gb|113782|I13782 Sequence 12 from patent U.S. Pat. No. 5441931 > :: gb|I68752|I68752 Sequence 12 from patent U.S. Pat. No. 5677146 4262 M27866 Human e-158 2072296 (U95098) mitotic 1.7 retinoblastoma phosphoprotein 44 susceptibility [Xenopus laevis] protein gene, exon 27. > :: gb|I09392| Sequence 25 from Patent WO 8906703 4263 U59629 Human 1e-052 2828799 (U55386) 0.097 transcription unknown factor LZIP-alpha [Anabaena mRNA, complete PCC7120] cds 4264 U95102 Xenopus laevis 2e-006 3176395 (AB015041) PIF1 3e-005 mitotic [Caenorhabditis phosphoprotein elegans] 90 mRNA, complete cds 4265 AF069250 Homo sapiens 2e-068 3037018 (AF041330) 0.002 okadaic acid- NADH inducible dehydrogenase phosphoprotein subunit 5 [Bodo (OA48-18) saltans] mRNA, complete cds 4266 M11560 Human aldolase 0.00E+00 113606 FRUCTOSE- 5e-055 A mRNA, BISPHOSPHATE complete cds. ALDOLASE A fructose- bisphosphate aldolase (EC 4.1.2.13) A- [human sapiens] 4267 U95102 Xenopus laevis 2e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4268 U95102 Xenopus laevis 1e-005 2688708 (AE001176) 8.5 mitotic conserved phosphoprotein hypothetical 90 mRNA, protein [Borrelia complete cds burgdorferi] 4269 L35566 Gallus gallus 6e-041 1708809 HOMEOBOX 7e-019 homeobox PROTEIN LH-2 protein (LH-2) >gi|508712 mRNA, complete cds. 4270 U95094 Xenopus laevis 1.00E-11 1709997 DNA REPAIR 6e-027 XL-INCENP PROTEIN RAD18 (XL-INCENP) >gi|1150622 mRNA, complete protein rad18 cds [Schizosaccharom yces pombe] 4271 U95094 Xenopus laevis 2e-009 586442 NUCLEOPORIN 0.44 XL-INCENP NUP170 (XL-INCENP) (NUCLEAR mRNA, complete PORE PROTEIN cds NUP170) >gi|626192|pir∥S4 5429 probable membrane protein YBL079w - yeast [(Saccharomyces cerevisiae) cerevisiae] >gi|536127 (Z35840) ORF YBL079w 4272 U95094 Xenopus laevis 3e-013 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4273 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4274 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4275 X00334 Drosophila virilis 6e-010 119110 EBNA-1 2e-016 simple DNA NUCLEAR sequence (pDv- PROTEIN 19) herpesvirus 4 (strain B95-8) >gi|1334880 (V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 4276 U95094 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4277 AF069250 Homo sapiens 2e-068 3037018 (AF041330) 0.002 okadaic acid- NADH inducible dehydrogenase phosphoprotein subunit 5 [Bodo (OA48-18) saltans] mRNA, complete cds 4278 Y10183 H. sapiens mRNA e-162 <NONE> <NONE> <NONE> for MEMD protein 4279 D86960 Human mRNA 2e-078 <NONE> <NONE> <NONE> for KIAA0205 gene, complete cds 4280 X65319 Cloning vector 3e-081 987050 (X65335) lacZ 3e-015 pCAT-Enhancer gene product [unidentified cloning vector] 4281 X86693 H. sapiens mRNA 0.18 <NONE> <NONE> <NONE> for hevin like protein 4282 U95094 Xenopus laevis 0.0001 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4283 M33156 A. aegypti D7 1.30E+00 <NONE> <NONE> <NONE> gene, exons 1-5. 4284 X02317 Human mRNA 0 218564 (D90358) HB- 7e-032 for Cu/Zn SOD superoxide [Schizosaccharom dismutase (SOD) yces pombe] 4285 U95094 Xenopus laevis 2.00E-04 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4286 U95094 Xenopus laevis 2.00E-04 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4287 X02317 Human mRNA 0 134611 SUPEROXIDE 2e-079 for Cu/Zn DISMUTASE superoxide (CU-ZN) dismutase (SOD) dismutase (aa 1- 154) [Homo sapiens] >gi|338276 (K00065) superoxide dismutase [Homo sapiens] >gi|1237407 (L44139) Cu/Zn- superoxide dismutase [Homo sapiens] 4288 X04408 Human mRNA 0 386748 (M14631) guanine 2e-073 for coupling nucleotide-binding protein G(s) alpha protein alpha subunit (adenylyl subunit cyclase) 4289 M28161 Rabbit MHC 2.4 <NONE> <NONE> <NONE> class II RLA-DR- alpha gene, complete cds. 4290 U33956 Human Down 0.37 <NONE> <NONE> <NONE> Syndrome region of chromosome 21, genomic sequence, clone A12H1-1F8. 4291 U90331 Mus musculus 0.15 135063 SUPPRESSOR 5.2 neural OF SABLE plakophilin PROTEIN fruit fly related arm- (Drosophila repeat protein melanogaster) (NPRAP) mRNA, >gi|158517 complete cds (M57889) su(s) protein [Drosophila melanogaster] 4292 AF045531 Homo sapiens 0.005 <NONE> <NONE> <NONE> germline chromosome 22, 22q11.2 region 4293 D86960 Human mRNA 2e-078 <NONE> <NONE> <NONE> for KIAA0205 gene, complete cds 4294 U95094 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4295 U95098 Xenopus laevis 5.00E-03 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4296 U17073 Neurospora 0.041 3152938 (AF065482) 0.83 crassa frequency sorting nexin 2 (frq) mRNA, [Homo sapiens] complete cds. 4297 M93051 Pisum sativum 0.2 <NONE> <NONE> <NONE> ascorbate peroxidase (ApxI) gene, complete cds. 4298 U28153 Caenorhabditis 0.37 <NONE> <NONE> <NONE> elegans UNC-76 (unc-76) gene, complete cds. 4299 U28153 Caenorhabditis 0.37 <NONE> <NONE> <NONE> elegans UNC-76 (unc-76) gene, complete cds. 4300 U20240 Human C/EBP e-141 1705750 CCAAT/ENHAN 1e-011 gamma mRNA, CER BINDING complete cds > :: PROTEIN gb|G28590|G285 GAMMA (C/EBP 90 human STS GAMMA) SHGC-35371. >gi|1363931|pir∥J C4243 transcription CCAAT enhancer binding protein- gamma - human >gi|727294 (U20240) C/EBP gamma [Homo sapiens] 4301 Y16359 Calonectris 4e-075 595780 (U13871) lacZ 0.0001 diomedea random alpha peptide amplified [Cloning vector] polymorphic DNA, clone Cd- O8f1 4302 U95094 Xenopus laevis 5e-013 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4303 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4304 U90331 Mus musculus 0.15 135063 SUPPRESSOR 5.2 neural OF SABLE plakophilin PROTEIN fruit fly related arm- (Drosophila repeat protein melanogaster) (NPRAP) mRNA, >gi|158517 complete cds (M57889) su(s) protein [Drosophila melanogaster] 4305 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4306 D86960 Human mRNA 0 1653865 (D90917) UDP-N- 4.40E+00 for KIAA0205 acetylglucosamine gene, complete -N- cds acetylmuramyl- (pentapeptide) pyrophosphoryl - undecaprenol N- acetylglucosamine transferase [Synechocystis sp.] 4307 U95094 Xenopus laevis 1e-013 4105520 (AF046933) 2.4 XL-INCENP carboxysome (XL-INCENP) structural mRNA, complete polypeptide cds 4308 Y14723 Choanomphalus 0.36 <NONE> <NONE> <NONE> incertus mitochondrial cytochrome c oxidase subunit I gene, partial 4309 AB018327 Homo sapiens 0 3882289 (AB018327) 4e-041 mRNA for KIAA0784 protein KIAA0784 [Homo sapiens] protein, partial cds 4310 AB007860 Homo sapiens 0 <NONE> <NONE> <NONE> KIAA0400 mRNA, complete cds 4311 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4312 U96440 Drosophila 0.053 119110 EBNA-1 0.0004 melanogaster cut NUCLEAR gene, partial PROTEIN sequence herpesvirus 4 (strain B95-8) >gi|1334880 <V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 4313 X64707 H. sapiens BBC1 3e-090 1350662 60S 2e-025 mRNA RIBOSOMAL PROTEIN L13 (A52) 4314 U67522 Methanococcus 0.38 <NONE> <NONE> <NONE> jannaschii section 64 of 150 of the complete genome 4315 M11560 Human aldolase 0.00E+00 113606 FRUCTOSE- 5e-055 A mRNA, BISPHOSPHATE complete cds. ALDOLASE A fructose- bisphosphate aldolase (EC 4.1.2.13) A- [human sapiens] 4316 X92098 H. sapiens mRNA e-123 3914237 COP-COATED 1e-017 for VESICLE transmembrane MEMBRANE protein mp24 PROTEIN P24 PRECURSOR (P24A) (RNP24) >gi|1212965|gnl|PI D|e205529 4317 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4318 D86960 Human mRNA 0 1653865 (D90917) UDP-N- 4.40E+00 for KIAA0205 acetylglucosamine gene, complete -N- cds acetylmuramyl- (pentapeptide) pyrophosphoryl - undecaprenol N- acetylglucosamine transferase [Synechocystis sp.] 4319 M83094 Homo sapiens 0.00E+00 <NONE> <NONE> <NONE> cytosolic selenium- dependent glutathione peroxidase gene, complete cds, and rhoh12 gene, 3′ end. 4320 U95102 Xenopus laevis 5e-015 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4321 U95102 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, comptete cds 4322 U95098 Xenopus laevis 3.3 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4323 U95102 Xenopus laevis 1.40E-02 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4324 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4325 U95102 Xenopus laevis 3e-010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4326 AF088034 Homo sapiens 0 854598 (X87611) ORF 2e-024 full length insert YJR83.18 cDNA clone [Saccharomyces ZC24F03 cerevisiae] 4327 U47322 Cloning vector 6.00E-06 <NONE> <NONE> <NONE> DNA, complete sequence. 4328 U47322 Cloning vector 6.00E-06 <NONE> <NONE> <NONE> DNA, complete sequence. 4329 D86960 Human mRNA 0.00E+00 1653865 (D90917) UDP-N- 1.4 for KIAA0205 acetylglucosamine gene, complete -N- cds acetylmuramyl- (pentapeptide) pyrophosphoryl - undecaprenol N- acetylglucosamine transferase [Synechocystis sp.] 4330 Z70316 D. melanogaster 1.5 <NONE> <NONE> <NONE> mRNA for tyramine-beta- hydroxylase 4331 L28010 Homo sapiens 3e-070 1710628 HETEROGENEO 2e-005 HnRNP F protein US NUCLEAR mRNA, complete RIBONUCLEOPR cds OTEIN F (HNRNP F) >gi|631210|pir∥S4 3484 hnRNP F protein - human >gi|452048 (L28010) HnRNP F protein [Homo sapiens] 4332 U95098 Xenopus laevis 1.40E-01 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4333 U95098 Xenopus laevis 0.13 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4334 U95102 Xenopus laevis 0.004 1723286 VERY 3.1 mitotic HYPOTHETICAL phosphoprotein 11.9 KD 90 mRNA, PROTEIN complete cds C4H3.12C IN CHROMOSOME I>gi|1184025 (Z69380) unknown 4335 <NONE> <NONE> <NONE> 2314752 (AE000654) rare 7.3 lipoprotein A (rlpA) [Helicobacter pylori] 4336 AB007963 Homo sapiens 8e-078 3413938 (AB007963) 1.00E-11 mRNA for KIAA0494 protein KIAA0494 [Homo sapiens] protein, complete cds 4337 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4338 X12597 Human mRNA 3e-048 123371 HIGH MOBILITY 0.006 for high mobility GROUP group-1 protein PROTEIN HMG1 protein HMG-1- pig >gi|164490 (M21683) non- histone protein HMG1 [Sus scrofa] 4339 U95102 Xenopus laevis 1e-013 2853095 (AL021767) very 0.043 mitotic hypothetical phosphoprotein protein 90 mRNA, complete cds 4340 U95102 Xenopus laevis 8e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4341 U95094 Xenopus laevis 7e-006 3063453 (AC003981) 4.5 XL-INCENP F22O13.15 (XL-INCENP) [Arabidopsis mRNA, complete thaliana] cds 4342 U95094 Xenopus laevis 4.00E-11 231629 BILE-SALT- 9.6 XL-INCENP ACTIVATED (XL-INCENP) LIPASE mRNA, complete PRECURSOR cds (ESTER LIPASE) (STEROL ESTERASE) (CHOLESTEROL ESTERASE) salt- activated lipase [Homo sapiens] sapiens] 4343 L31732 Human STS 1.6 <NONE> <NONE> <NONE> UT643, 5′ primer bind. 4344 AF037332 Homo sapiens 0.66 <NONE> <NONE> <NONE> Eph-like receptor tyrosine kinase hEphB1b (EphB1) mRNA, complete cds 4345 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4346 U95102 Xenopus laevis 2.00E-05 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4347 U95102 Xenopus laevis 4e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4348 Z30961 H. sapiens DNA 7.00E-17 728835 !!!! ALU 0.5 for Mhc Alu SUBFAMILY SC elements WARNING ENTRY 4349 U34887 Yeast integrating 7e-068 3152967 (Y14016) 9 vector pRS306 hypothetical containing a protein fragment of lacZ. 4350 D28124 Human mRNA 0 1825638 (U88172) similar 0.062 for unknown to protein-tyrosine product, complete phosphatase cds 4351 AF069503 Carcharhinus 4.20E+00 <NONE> <NONE> <NONE> plumbeus microsatellite repeat region 4352 AF069503 Carcharhinus 4.20E+00 <NONE> <NONE> <NONE> plumbeus microsatellite repeat region 4353 D10848 Alkalophilic 0.033 <NONE> <NONE> <NONE> Bacillus sp. genomic DNA for lipo-penicillinase 4354 D28124 Human mRNA 0 1825638 (U88172) similar 0.062 for unknown to protein-tyrosine product, complete phosphatase cds 4355 U19482 Mus musculus 3.70E+00 <NONE> <NONE> <NONE> C10-like chemokine mRNA, complete cds 4356 AF050068 Homo sapiens 1.4 1916844 (U82987) Bcl-2 0.042 growth arrest binding specific 11 component 3 [Homo sapiens] 4357 U95094 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4358 AE000026 Mycoplasma 1.3 <NONE> <NONE> <NONE> pneumoniae section 26 of 63 of the complete genome 4359 <NONE> <NONE> <NONE> 2114321 (D88733) 8.00E-01 membrane glycoprotein [Equine herpesvirus 1] 4360 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4361 Y07660 M. tuberculosis 2e-068 465847 HYPOTHETICAL 4e-079 accBC gene 66.5 KD PROTEIN F02A9.5 IN CHROMOSOME III >gi|280542|pir∥S2 8313 hypothetical protein F02A9.5 - Caenorhabditis elegans Genefinder; similar to Propionyl-CoA carboxylase beta chain; cDNA EST EMBL:M89018 comes from this gene; cDNA EST EMBL:D2806 4362 U12022 Human e-127 <NONE> <NONE> <NONE> calmodulin (CALM1) gene, exons 2, 3, 4, 5 and 6, and complete cds 4363 AC001178 Homo sapiens 3.00E-28 <NONE> <NONE> <NONE> (subclone 2_g12 from BAC H94) DNA sequence 4364 <NONE> <NONE> <NONE> 4063042 (AF068065) 0.52 GP900; mucin-like glycoprotein [Cryptosporidium parvum] 4365 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4366 U95102 Xenopus laevis 1.00E-12 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4367 X14448 Human GLA 3 <NONE> <NONE> <NONE> gene for alpha-D- galactosidase A (EC 3.2.1.22) 4368 U95102 Xenopus laevis 5.00E-04 3873753 (Z66519) similar 2e-008 mitotic to phytoene phosphoprotein synthase 90 mRNA, precursor; cDNA complete cds EST yk340f7.3 comes from this gene; cDNA EST yk340f7.5 comes from this gene [Caenorhabditis elegans] 4369 X04098 Human mRNA 0 <NONE> <NONE> <NONE> for cytoskeletal gamma-actin 4370 M13452 Human lamin A 0 125962 LAMIN A (70 KD 3e-057 mRNA, 3′ end. LAMIN) 4371 AF068863 Homo sapiens 3.4 <NONE> <NONE> <NONE> oligodendrocyte- specific protein 4372 U95098 Xenopus laevis 1.40E-01 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4373 L04636 Homo sapiens 0 730772 COMPLEMENT 2e-050 pre-mRNA COMPONENT 1, splicing factor 2 Q p32 subunit SUBCOMPONEN (SF2p32) mRNA, T BINDING complete cds. PROTEIN PRECURSOR (GLYCOPROTEI N GC1QBP) (GC1Q-R PROTEIN) (HYALURONAN -BINDING PROTEIN 1) chain precursor - human >gi|338045 (L04636) splicing factor [Homo sapiens] >gi|472956 (X75913) gCIq-R [Homo sapiens] >gi 4374 M59832 Human merosin 0.043 <NONE> <NONE> <NONE> mRNA, 3′ end. 4375 <NONE> <NONE> <NONE> 188864 (M74027) mucin 0.042 [Homo sapiens] 4376 X17206 Human mRNA 0 88570 ribosomal protein 6e-078 for LLRep3 S2 - [human (fragment) sapiens] 4377 X17206 Human mRNA 0 88570 ribosomal protein 6e-078 for LLRep3 S2 - [human (fragment) sapiens] 4378 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4379 X98420 S. shibatae topR 1.10E+00 2746890 (AF040655) No 9.3 gene definition line found [Caenorhabditis elegans] 4380 X98420 S. shibatae topR 1.10E+00 2746890 (AF040655) No 9.3 gene definition line found [Caenorhabditis elegans] 4381 X75787 P. falciparum 4 <NONE> <NONE> <NONE> (FAF-2) mRNA for aspartic hemoglobinase 4382 AF044209 Homo sapiens 0 3510603 (AF044209) 4e-029 nuclear receptor nuclear receptor co-repressor N- co-repressor N- CoR mRNA, CoR [Homo complete cds sapiens] 4383 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4384 X64707 H. sapiens BBC1 e-110 1350662 60S 0.003 mRNA RIBOSOMAL PROTEIN L13 (A52) 4385 Z70316 D. melanogaster 1.5 <NONE> <NONE> <NONE> mRNA for tyramine-beta- hydroxylase 4386 AF000371 Vitis vinifera 0.19 <NONE> <NONE> <NONE> UDP glucose:flavonoid 3-o- glucosyltransferas e mRNA, partial cds 4387 U95094 Xenopus laevis 3e-013 2072296 (U95098) mitotic 1.8 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4388 AE000688 Aquifex aeolicus 3.8 <NONE> <NONE> <NONE> section 20 of 109 of the complete genome 4389 L05612 Dictyostelium 2.8 <NONE> <NONE> <NONE> purpureum DNA sequence, repeat region. 4390 U33761 Human cyclin 2e-079 2134952 cyclin A/CDK2- 1e-025 A/CDK2- associated p45 - associated p45 [human sapiens] (Skp2) mRNA, complete cds 4391 U48288 Rattus norvegicus 0.48 <NONE> <NONE> <NONE> A-kinase anchoring protein AKAP 220 mRNA, complete cds 4392 AB007963 Homo sapiens 0.00E+00 3413938 (AB007963) 6e-071 mRNA for KIAA0494 protein KIAA0494 [Homo sapiens] protein, complete cds 4393 <NONE> <NONE> <NONE> 119110 EBNA-1 6e-027 NUCLEAR PROTEIN herpesvirus 4 (strain B95-8) >gi|1334880 (V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 4394 U52784 Ansonia muelleri 0.014 <NONE> <NONE> <NONE> CMNH H1476 16S rRNA gene, mitochondrial gene encoding mitochondrial rRNA, partial sequence 4395 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4396 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4397 U38376 Rattus norvegicus 1.1 <NONE> <NONE> <NONE> cytosolic phospholipase A2 mRNA, complete cds 4398 U78770 Mus musculus 0.028 <NONE> <NONE> <NONE> spasmolytic polypeptide (mSP) gene, complete cds 4399 U95102 Xenopus laevis 0.12 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4400 U95094 Xenopus laevis 2e-014 2072296 (U95098) mitotic 5.8 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4401 U95098 Xenopus laevis 0.0003 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4402 X70288 H. sapiens gene 3e-030 <NONE> <NONE> <NONE> for thioredoxin, exons 4 and 5 4403 X76683 Plasmid vector 7e-080 987050 (X65335) lacZ 3e-015 pHM2 gene product betalactamase [unidentified gene cloning vector] 4404 X69295 H. sapiens MSX2 0.43 <NONE> <NONE> <NONE> mRNA for transcription factor 4405 U20371 Mus musculus 0.6 <NONE> <NONE> <NONE> homeobox protein (Hoxa11) gene, complete cds. 4406 D49842 Rabbit mRNA for 1.10E+00 135554 TETRACYCLINE 1.4 CD86, complete RESISTANCE cds PROTEIN Bacillus cereus plasmid pBC16 >gi|72838|pir∥YTS OG tetracycline resistance protein - Streptococcus agalactiae plasmid pMV158 >gi|80428|pir∥JQ1 211 tetracycline resistance protein - Bacillus sp. plasmid pTB19 >gi|151696 (M63 4407 AB007194 Oryza sativa 3.5 <NONE> <NONE> <NONE> mRNA for fructose-1,6- bisphosphatase (plastidic isoform), complete cds 4408 U95098 Xenopus laevis 1e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4409 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4410 U28924 Pisum sativum 0.008 3769486 (AF074946) DNA 1.3 cytosolic polymerase glutamine [hemorrhagic synthetase enteritis virus] 4411 D30783 Homo sapiens 0 1723438 HYPOTHETICAL 0.13 mRNA for 52.3 KD epiregulin, PROTEIN complete cds C56F8.06C IN CHROMOSOME I PRECURSOR >gi|1204228 (Z69728) unknown [Schizosaccharom yces pombe] 4412 AJ012449 Homo sapiens 0 3851214 (AJ012449) NS1- 4e-088 mRNA for NS1- binding protein binding protein [Homo sapiens] 44184413 X62357 H. sapiens Alu 1e-006 <NONE> <NONE> <NONE> repeat (clones 2- 48) 4414 U95102 Xenopus laevis 6.00E-05 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4415 Z15015 D. pulex 2.2 1076802 extensin-like 8e-027 mitochondrion protein - maize genes for NADH >gi|600118 dehydrogenase subunit 2, cytochrome C oxidase subunit 1, tRNA-Val, tRNA-Ile, tRNA- Gln, tRNA-fMet, tRNA-Trp, tRNA-Cys, tRNA-Tyr, small subunit rRNA, large subunit rRNA 4416 D87942 Homo sapiens 2e-027 728838 !!!! ALU 7.5 mRNA for SUBFAMILY SX alpha(1,2)fucosyl WARNING transferase, ENTRY complete cds 4417 D86977 Human mRNA 0 3024898 PUTATIVE PRE- 2e-053 for KIAA0224 MRNA gene, complete SPLICING cds FACTOR ATP- DEPENDENT RNA HELICASE KIAA0224 (HA4657) putative ATP-dependent RNA helicase K03H1.2 of C. elegans (S41025) [Homo sapiens] >gi|3123906 (AF038391) pre- mRNA splicing factor [Homo sapiens] 4418 L28010 Homo sapiens 0 1710628 HETEROGENEO 5e-045 HnRNP F protein US NUCLEAR mRNA, complete RIBONUCLEOPR cds OTEIN F (HNRNP F) >gi|631210|pir∥S4 3484 hnRNP F protein - human >gi|452048 (L28010) HnRNP F protein [Homo sapiens] 4419 U95094 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4420 U95094 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4421 X14313 Arabidopsis CRB 0.24 <NONE> <NONE> <NONE> gene for 12S seed storage protein > gene, exons 1-4. 4422 X14313 Arabidopsis CRB 0.24 <NONE> <NONE> <NONE> gene for 12S seed storage protein > gene, exons 1-4. 4423 U95094 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4424 U95098 Xenopus laevis 3.00E-08 1125753 (U42833) coded 1e-019 mitotic for by C. elegans phosphoprotein cDNA 44 mRNA, partial CEESN37F; cds Similar to ammonium transport protein. [Caenorhabditis elegans] 4425 U95094 Xenopus laevis 2.00E-05 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4426 U95102 Xenopus laevis 3e-009 1125753 (U42833) coded 2e-008 mitotic for by C. elegans phosphoprotein cDNA 90 mRNA, CEESN37F; complete cds Similar to ammonium transport protein. [Caenorhabditis elegans] 4427 AF053649 Homo sapiens 3e-008 <NONE> <NONE> <NONE> cellular apoptosis susceptibility protein (CSE1) gene, exons 15 and 16 4428 U95098 Xenopus laevis 1e-007 2072296 (U95098) mitotic 8.8 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 44 mRNA, partial cds 4429 X94253 S. scrofa mRNA 6e-023 <NONE> <NONE> <NONE> for heterogeneous nuclear ribonucleoprotein 4430 AF005039 Homo sapiens 0 2232243 (AF005039) 8e-008 secretory carrier secretory carrier membrane membrane protein protein [Homo sapiens] 4431 AF037332 Homo sapiens 0.12 3861156 (AJ235272) 0.37 Eph-like receptor unknown tyrosine kinase [Rickettsia hEphB1b prowazekii] (EphB1) mRNA, complete cds 4432 D28124 Human mRNA 7e-067 <NONE> <NONE> <NONE> for unknown product, complete cds 4433 U95094 Xenopus laevis 3e-013 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4434 M93426 Human protein 0 400199 PROTEIN- 4e-051 tyrosine TYROSINE phosphatase zeta- PHOSPHATASE polypeptide ZETA (PTPRZ) mRNA, PRECURSOR (R- complete cds. > :: PTP-ZETA) gb|G20044|G200 >gi|476869|pir∥A4 44 sWSS1987 6151 protein- Eric D. Green tyrosine- Homo sapiens phosphatase (EC STS genomic, 3.1.3.48), receptor sequence tagged type zeta - human site [Homo >gi|190744 sapiens] (M93426) protein tyrosine phosphatase zeta- polypeptide [Homo sapiens] 4435 U54562 Human 0 2498490 VIRAL e-110 translation INTEGRATION initiation factor SITE PROTEIN eIF3 p48 subunit INT-6 (Int-6) mRNA, >gi|1854579 complete cds (L35556) Int-6 [Mus musculus] sapiens] >gi|2351382 (U54562) eIF3- p48 [Homo sapiens] sapiens] 4436 U54562 Human 0 2498490 VIRAL e-110 translation INTEGRATION initiation factor SITE PROTEIN eIF3 p48 subunit INT-6 (Int-6) mRNA, >gi|1854579 complete cds (L35556) Int-6 [Mus musculus] sapiens] >gi|2351382 (U54562) eIF3- p48 [Homo sapiens] sapiens] 4437 U95102 Xenopus laevis 0.12 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4438 U95094 Xenopus laevis 3e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4439 X03558 Human mRNA 0 1169475 ELONGATION 4e-083 for elongation FACTOR 1- factor 1 alpha ALPHA 1 subunit 4440 J03607 Human 40-kDa 0 1070608 keratin 19, type 1, 4e-058 keratin cytoskeletal - intermediate [human sapiens] filament precursor gene. 4441 <NONE> <NONE> <NONE> 4063042 (AF068065) 0.011 GP900; mucin-like glycoprotein [Cryptosporidium parvum] 4442 <NONE> <NONE> <NONE> 4063042 (AF068065) 0.011 GP900; mucin-like glycoprotein [Cryptosporidium parvum] 4443 Y13401 Homo sapiens 8e-008 <NONE> <NONE> <NONE> CD3 delta gene, enhancer sequence 4444 X04409 Human mRNA 0 71879 GTP-binding 7e-092 for coupling regulatory protein protein G(s) Gs alpha chain G- alpha-subunit s-alpha-4 [Homo (alpha-S1) sapiens] (stimulatory regulatory component Gs of adenylyl cyclase) 4445 AF038958 Homo sapiens 1e-072 3329386 (AF038958) 6e-019 synaptic synaptic glycoprotein SC2 glycoprotein SC2 spliced variant spliced variant mRNA, complete cds 4446 D17244 Human HepG2 3′ 1e-075 2500256 50S 0.043 region MboI RIBOSOMAL cDNA, clone PROTEIN L13 hmd4h04m3 protein L13 [Streptomyces coelicolor] 4447 <NONE> <NONE> <NONE> 4063042 (AF068065) 0.005 GP900; mucin-like glycoprotein [Cryptosporidium parvum] 4448 M24597 Beet curly top 4.1 <NONE> <NONE> <NONE> virus (clone pBCT028) DNA, complete genome. 4449 U59706 Gallus gallus 0.014 3283975 (AF072521) poly- 0.02 alternatively (ADPribosyl)- spliced AMPA transferase glutamate homolog PARP receptor, isoform GluR2 flop, (GluR2) mRNA, partial cds. 4450 AJ010014 Homo sapiens 0 3342452 (AF072814) PHD 2e-029 mRNA for M96A finger DNA protein binding protein isoform 1 4451 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4452 X06960 Aspergillus 0.23 <NONE> <NONE> <NONE> nidulans mitochondrial DNA for cytochrome oxidase subunit 3, tRNA-Tyr 4453 L01089 Human 1.3 <NONE> <NONE> <NONE> profilaggrin (FLG) gene exons 2-3, 5′end. 4454 X65319 Cloning vector 1e-071 987050 (X65335) lacZ 1e-014 pCAT-Enhancer gene product [unidentified cloning vector] 4455 X87212 H. sapiens mRNA 0 1582221 prepro-cathepsin C 6e-046 for cathepsin C [Homo sapiens] 4456 X53123 Cloning vector 5 <NONE> <NONE> <NONE> pAST 19a for C. elegans 4457 D15057 Human mRNA 0 2944452 (AF051310) 1e-015 for DAD-1, defender against complete cds death 1 [Mus musculus] 4458 X83860 H. sapiens mRNA 1.2 2137044 unknown protein - 7e-014 for prostaglandin [rabbit (fragment) E receptor (EP3c) cuniculus] 4459 M95058 Rattus rattus 0.42 <NONE> <NONE> <NONE> steroid 5-alpha- reductase 2 mRNA, complete cds. 4460 AF044588 Homo sapiens 2e-043 2865521 (AF044588) 4e-015 protein regulating protein regulating cytokinesis 1 cytokinesis 1; PRC1 [Homo sapiens] 4461 X54282 Human 0.014 1911867 cadherin 3 9.8 chromosome 11 [Caenorhabditis DNA, approx. 20 elegans, Peptide, kb 3′ of beta- 3337 aa] globin gene, nuclear scaffold associated region 4462 U95102 Xenopus laevis 3e-010 3875640 (Z92781) F09C3.3 9.6 mitotic [Caenorhabditis phosphoprotein elegans] 90 mRNA, complete cds 4463 M73791 Human novel 0 1172810 60S 7e-085 gene mRNA, RIBOSOMAL complete cds. PROTEIN L10 (QM PROTEIN HOMOLOG) >gi|543339|pir∥JC 2013 ribosomal protein L10, cytosolic - mouse >gi|2143959|pir∥J C4911 ribosomal protein L10 - rat >gi|407466 (X75312) QM protein [Mus musculus] >gi|410742 (M93980) 24.6 kda protein [Mus musc] 4464 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4465 Z27116 S. cerevisiae 0.058 <NONE> <NONE> <NONE> HBS1, MRP-L20 and PRP-16 genes 4466 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4467 M96575 Drosophila 3.60E+00 <NONE> <NONE> <NONE> melanogaster collagen type IV gene, complete cds. 4468 D50010 Human DNA for 1e-006 <NONE> <NONE> <NONE> alpha-platelet- derived growth factor receptor, exon 15 4469 X70649 Homo sapiens 0 539572 DEAD box protein 3e-036 DDX1 gene, RB - human complete CDS 4470 AJ223377 Puumala virus S- 1.4 <NONE> <NONE> <NONE> segment RNA 4471 Y14599 Staphylococcus 1.4 3659505 (AC005084) 0.63 xylosus lacR, similar to mouse lacP, lacH genes mCASK-A; and 2 ORF's similar to e1288039 4472 X13336 Spinach plastid 0.15 1330375 (U58758) similar 0.27 genes rps3, rps19, to rat GAP- rpl14, rpl16 and associated protein rpl22 for p190 ribosomal proteins S3, S19, L14, L16 and L22 4473 AF056022 Homo sapiens 0 3283072 (AF056022) p60 7e-029 p60 katanin katanin [Homo mRNA, complete sapiens] cds 4474 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4475 M86849 Human connexin 0 127542 ALDOSE 1- 5.2 26 (GJB2) EPIMERASE mRNA. PRECURSOR [calcoaceticus] 4476 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4477 X95455 G. gallus mRNA 9e-031 1321818 (X95455) RING 9e-038 for RING zinc zinc finger protein finger protein [Gallus gallus] 4478 U95098 Xenopus laevis 0.13 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4479 J03607 Human 40-kDa 0 1070608 keratin 19, type 1, 9e-068 keratin cytoskeletal - intermediate [human sapiens] filament precursor gene. 4480 M90104 Human splicing e-120 3929382 SPLICING 1.1 factor SC35 FACTOR, mRNA, complete ARGININE/SERI cds. NE-RICH 10 (PUTATIVE MYELIN REGULATORY FACTOR 1) (MRF-1) >gi|555924 (U14648) putative myelin regulatory factor 1; MRF-1 [Mus musculus] 4481 AF020762 Homo sapiens 6e-067 <NONE> <NONE> <NONE> clone 1400 unknown protein mRNA, partial cds 4482 AE001386 Plasmodium 0.72 <NONE> <NONE> <NONE> falciparum chromosome 2, section 23 of 73 of the complete sequence 4483 AF054868 Pseudomonas 0.005 1709793 SALIVARY 0.13 aeruginosa PROLINE-RICH autoinducer PROTEIN PO synthetase [sapiens] chloramphenicol- sensitive protein (rarD), and hypothetical protein (yafL) gene . . . 4484 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4485 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4486 AE001406 Plasmodium 0.001 <NONE> <NONE> <NONE> falciparum chromosome 2, section 43 of 73 of the complete sequence 4487 AE001417 Plasmodium 2.1 <NONE> <NONE> <NONE> falciparum chromosome 2, section 54 of 73 of the complete sequence 4488 X90446 Canine 4.4 <NONE> <NONE> <NONE> herpesvirus DNA for ORF 1 (HSV1 UL44, EHV1 ORF 15 homolog) ORF2 (EHV1 ORF 16 homolog) 4489 U95102 Xenopus laevis 0.17 4008355 (Z68297) 3e-007 mitotic Similarity to Yeast phosphoprotein TAT-binding 90 mRNA, homolog 7 complete cds (SW:TBP7_YEAS T); cDNA EST EMBL:D37124 comes from this gene; cDNA EST EMBL:D35150 comes from this gene; cDNA EST EMBL:D35400 comes from this gene; cDNA EST EMBL:D34900 comes . . . >gi|4008373|gnl∥PI D|e135984 4490 D78130 Homo sapiens 0 2443316 (D78130) squalene 5e-008 mRNA for epoxidase [Homo squalene sapiens] epoxidase, complete cds 4491 L18931 Buchnera 0.16 <NONE> <NONE> <NONE> aphidicola Arginyl tRNA synthetase promoter region. 4492 X17206 Human mRNA e-112 1350976 40S 2e-005 for LLRep3 RIBOSOMAL PROTEIN S2 >gi|939718 4493 D28473 Human T- e-157 440799 (U04953) 3e-005 lymphocyte isoleucyl-tRNA mRNA for synthetase [Homo isoleucyl-tRNA sapiens] synthetase, complete cds 4494 L13624 Cercopithecus 3.6 <NONE> <NONE> <NONE> aethiops C4 complement 4495 M13011 Rat c-ras-H-1 0.25 <NONE> <NONE> <NONE> gene, complete cds. 4496 Y10252 L. japonicus panC 0.38 627071 histidine-rich 4.4 gene protein - Plasmodium lophurae 4497 X76683 Plasmid vector 1e-093 987050 (X65335) lacZ 3e-015 pHM2 gene product betalactamase [unidentified gene cloning vector] 4498 M24486 Human prolyl 4- 0 129365 PROLYL 4- 2e-057 hydroxylase HYDROXYLASE alpha subunit ALPHA mRNA, complete SUBUNIT cds, clone PA-11. 1.14.11.2) alpha chain - chicken 4499 D80004 Human mRNA 2e-068 <NONE> <NONE> <NONE> for KIAA0182 gene, partial cds 4500 U22233 Human 0 <NONE> <NONE> <NONE> methylthioadenos ine phosphorylase (MTAP) mRNA, complete cds. 4501 D63875 Human mRNA 0 961442 (D63875) 2e-019 for KIAA0155 KIAA0155 gene gene, complete product is related cds > :: to C. elegans gb|G28541|G285 B0464.2 protein. 41 human STS [Homo sapiens] SHGC-31621. 4502 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4503 X85018 H. sapiens mRNA e-110 1709559 POLYPEPTIDE 2e-018 for UDP- N- GalNAc:polypept ACETYLGALAC ide N- TOSAMINYLTR acetylgalactosami ANSFERASE nyltransferase (PROTEIN-UDP (T1) ACETYLGALAC TOSAMINYLTR ANSFERASE) N- ACETYLGALAC TOSAMINYLTR ANSFERASE) (GALNAC-T1) polypeptide N- acetylgalactosamin yltransferase [Rattus norvegicus] 4504 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4505 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4506 AF067782 Papio hamadryas 0.48 <NONE> <NONE> <NONE> BC200 alpha scRNA gene, complete sequence 4507 AF073298 Homo sapiens e-166 3641536 (AF073297) 3e-013 4F5rel mRNA, 4F5rel [Mus. complete cds musculus] >gi|3641538 (AF073298) 4F5rel [Homo sapiens] 4508 M12922 Yeast 2e-010 188864 (M74027) mucin 6e-023 (S. cerevisiae) [Homo sapiens] chromosome III L terminal region DNA. 4509 X69524 M. squamata 1.3 <NONE> <NONE> <NONE> cabcl mRNA for chlorophyll a/b/c binding protein precursor 4510 U95098 Xenopus laevis 1.2 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4512 U12404 Human Csa-19 0 1709973 60S 4e-056 mRNA, complete RIBOSOMAL cds. PROTEIN L10A (CSA-19) 4513 U95094 Xenopus laevis 8e-014 <NONE> <NONE> <NONE> XL-INCENP (XL-NCENP) mRNA, complete cds 4514 <NONE> <NONE> <NONE> 121627 GLYCINE-RICH 2e-030 CELL WALL STRUCTURAL PROTEIN 1 PRECURSOR >gi|82244|pir∥A26 099 glycine-rich cell wall structural protein - [garden petunia >gi|20553 hybrida] >gi|225181|prf∥12 10313A Gly rich structural protein [Petunia sp.] 4515 D87255 Hepatitis G virus 0.19 930045 (X15332) alpha-1 0.002 RNA for (III) collagen polyprotein, [Homo sapiens] complete cds 4516 U31820 Gallus gallus 3.3 1718187 ENVELOPE 0.096 Mel-1a melatonin GLYCOPROTEIN receptor mRNA, GP340 complete cds. glycoprotein 350/220 - [human herpesvirus 4 >gi|59164 virus] >gi|306293 (L07923) glycoprotein 340 4517 X68107 M. sativa 3.4 <NONE> <NONE> <NONE> msCHSII mRNA for chalcone synthase 4518 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4519 U95098 Xenopus laevis 6e-006 1065484 (U40415) similar 0.001 mitotic to S. cerevisiae phosphoprotein LAG1 44 mRNA, partial (SP:P38703) cds 4520 D87671 Rat mRNA for 1e-043 1799570 (D87671) TIP120 0.01 TIP120, complete [Rattus cds norvegicus] 4521 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4522 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4523 X16869 Human mRNA 4e-022 1085204 translation 5.1 for elongation elongation factor factor 1-alpha eEF-1 alpha chain (clone CEF4) - zebra fish >gi|408805 (L23807) elongation factor 1-alpha [Danio rerio] >gi|454915 (X77689) translational elongation factor-1 alpha [Danio rerio] >gi|1009241 [rerio] >gi|1091578|prf∥2 021264A elongation fact 4524 U95102 Xenopus laevis 3e-010 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4525 U95102 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4526 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4527 AF069250 Homo sapiens 7e-080 3037018 (AF041330) 0.0001 okadaic acid- NADH inducible dehydrogenase phosphoprotein subunit 5 [Bodo (OA48-18) saltans] mRNA, complete cds 4528 AF069250 Homo sapiens 7e-080 3037018 (AF041330) 0.0001 okadaic acid- NADH inducible dehydrogenase phosphoprotein subunit 5 [Bodo (OA48-18) saltans] mRNA, complete cds 4529 U66532 Human beta4- 0.51 119110 EBNA-1 1e-023 integrin (ITGB4) NUCLEAR gene, exons PROTEIN 7, 8, 9, 10, 11 and herpesvirus 4 12 (strain B95-8) >gi|1334880 (V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 4530 X65329 Cloning vector 1e-074 987050 (X65335) lacZ 8e-011 pCAT-Enhancer gene product [unidentified cloning vector] 4531 AJ010841 Homo sapiens 8e-028 3646128 (AJ010841) 0.062 mRNA for thioredoxin-like putative protein thioredoxin-like protein 4532 D14034 Human gene for 0.005 <NONE> <NONE> <NONE> Zn-alpha2- glycoprotein, complete cds 4533 M12670 Human fibroblast 6e-098 1351250 METALLOPROT 7e-008 collagenase EINASE inhibitor mRNA, INHIBITOR 1 complete cds. PRECURSOR (TIMP-1) >gi|1363927|pir∥J C4303 matrix metalloproteinase- 1 tissue inhibitor - baboon >gi|561546 [hamadryas cynocephalus] 4534 M17196 A. californica 0.019 2135765 mucin 2 precursor, 0.003 (marine intestinal - human gastropod mollusc) neuropeptide gene (ganglion R14), exon 1, 5′ end. 4535 AJ001454 Homo sapiens 1.4 <NONE> <NONE> <NONE> mRNA for testican-3 4536 X75757 G. gallus cycB3 9e-040 729112 G2/MITOTIC- 9e-019 mRNA. SPECIFIC CYCLIN B3 4537 Z27116 S. cerevisiae 0.058 <NONE> <NONE> <NONE> HBS1, MRP-L20 and PRP-16 genes 4538 AF083322 Homo sapiens 9e-051 1079393 chromokinesin - 0.012 centriole chicken associated protein >gi|603761 CEP110 mRNA, (U18309) complete cds chromokinesin [Gallus gallus] 4539 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4540 M26325 Human 0 125083 KERATIN, TYPE 2e-093 cytokeratin 18 I mRNA, 3′ end. CYTOSKELETA L 18 keratin 18, type I, cytoskeletal - human >gi|34037 4541 U37066 Human 1.3 252486 P-selectin, CD62 1.8 endogenous [mice, Peptide, retrovirus strain [768 aa] musculus] XA38 pol polyprotein (pol) gene, partial cds 4542 Z30543 Turkey 2e-027 <NONE> <NONE> <NONE> herpesvirus (HVT-delUs- Beta1 PKI3) gene for protein kinase 4543 M90077 Wheat translation 0.14 <NONE> <NONE> <NONE> elongation factor 1 alpha-subunit (TEF1) mRNA, complete cds. 4544 AJ001235 Papio hamadryas 2e-044 <NONE> <NONE> <NONE> ERV-9 like LTR insertion 4545 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4546 AF100654 Caenorhabditis 0.41 <NONE> <NONE> <NONE> elegans cosmid C24E9 4547 L28821 Homo sapiens 0 1679607 (X97650) myosin- 4.5 alpha I [Mus musculus] mannosidase II isozyme mRNA, complete cds. 4548 U95094 Xenopus laevis 4e-013 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4549 L20140 Zea mays pollen 0.92 <NONE> <NONE> <NONE> specific pectate lyase homologue gene, complete cds. 4550 U33955 Human Down 4.4 <NONE> <NONE> <NONE> Syndrome region of chromosome 21, genomic sequence, clone A12H1-1F2. 4551 U95094 Xenopus laevis 0.0005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4552 U95094 Xenopus laevis 0.042 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4553 X12660 Human 1e-006 2117245 (Z95586) 2.1 chromosome 14 hypothetical Ig JH (switch mu) protein Rv1592c DNA showing scattered homology to bcl2 gene exon 2 3′UTR 4554 U95102 Xenopus laevis 0.002 284314 modulator 7.1 mitotic recognition factor phosphoprotein 1 - human factor I 90 mRNA, [Homo sapiens] complete cds 4555 AF070523 Homo sapiens 0 3322740 (AE001222) 5.9 JWA protein conserved mRNA, complete hypothetical cds protein [Treponema pallidum] 4556 Z11900 H. sapiens OTF3 0.13 <NONE> <NONE> <NONE> gene 4557 M24972 D. discoideum 4e-007 2605798 (AF027735) minor 5.30E-01 CT-rich satellite ampullate silk rDNA, clone protein MiSp1 pCT8. [Nephila clavipes] 4558 U95098 Xenopus laevis 8e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4559 D32056 Human gene for 0.06 <NONE> <NONE> <NONE> 2-oxoglutarate dehydrogenase, exon 1 sequence 4560 AF034085 Caenorhabditis 0.025 1652167 (D90903) 4.8 elegans UNC-45 hypothetical (unc-45) gene, protein complete cds 4561 AF091242 Homo sapiens 0.0003 <NONE> <NONE> <NONE> ATP sulfurylase/APS kinase 2 mRNA, complete cds 4562 M31520 Human ribosomal 1e-031 2072296 (U95098) mitotic 5.7 protein S24 phosphoprotein 44 mRNA. [Xenopus laevis] 4563 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4564 U95094 Xenopus laevis 0.0005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4565 AB015432 Rattus norvegicus 4e-022 1665759 (D87432) Similar 5e-024 mRNA for LAT1 to Schistosoma (L-type amino mansoni amino acid transporter acid permease 1), complete cds (L25068). [Homo sapiens] 4566 AE001397 Plasmodium 0.0005 3875266 (Z77655) 5.90E+00 falciparum predicted using chromosome 2, Genefinder; section 34 of 73 similar to 7tm of the complete receptor sequence [Caenorhabditis elegans] 4567 AE001397 Plasmodium 0.0005 3875266 (Z77655) 5.90E+00 falciparum predicted using chromosome 2, Genefinder; Section 34 of 73 similar to 7tm of the complete receptor sequence [Caenorhabditis elegans] 4568 Y15155 Homo sapiens 4e-033 2072296 (U95098) mitotic 5.7 PHKB gene, exon phosphoprotein 44 8, and repetitive [Xenopus laevis] elements 4569 U95094 Xenopus laevis 2.00E-03 2622750 (AE000921) DNA 2.6 XL-INCENP topoisomerase I (XL-INCENP) [Methanobacteriu mRNA, complete m cds thermoautotrophic um] 4570 AE000688 Aquifex aeolicus 4.5 <NONE> <NONE> <NONE> section 20 of 109 of the complete genome 4571 Z95123 Caenorhabditis 0.4 <NONE> <NONE> <NONE> elegans cosmid VZK822l, complete sequence [Caenorhabditis elegans] 4572 U95102 Xenopus laevis 3.00E-08 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4573 U95094 Xenopus laevis 4e-012 2072296 (U95098) mitotic 3.3 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4574 U95102 Xenopus laevis 7e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4575 U18671 Human Stat2 2e-023 728831 !!!! ALU 0.002 gene, complete SUBFAMILY J cds. WARNING ENTRY 4576 Z83241 Caenorhabditis 1.1 117698 IOLD PROTEIN 5.3 elegans cosmid protein [Bacillus T25C8, complete subtilis] sequence >gi|2636519|gnl|PI [Caenorhabditis D|e1184698 elegans] catabolism [Bacillus subtilis] 4577 L04690 Cricetulus griseus 3.2 212906 (L02621) 4.1 cholesterol 7- intestinal zipper alpha- protein [Gallus hydroxylase gene, gallus] complete cds. > :: gb|I26617|I26617 Sequence 35 from patent U.S. Pat. No. 5558999 > :: gb|AR008072|AR 008072 Sequence 35 from patent U.S. Pat. No. 5753431 4578 Z54191 A. pleuropneumon 0.54 2102696 (U72761) 8.6 iae tfbB gene karyopherin beta 3 encoding [Homo sapiens] transferrin receptor. 4579 X17025 Human homolog 2e-035 <NONE> <NONE> <NONE> of yeast IPP isomerase > :: gb|G27043|G270 43 human STS SHGC-31614. 4580 L32977 Homo sapiens 0.00E+00 1351361 UBIQUINOL- 1e-070 (clone f17252) CYTOCHROME ubiquinol C REDUCTASE cytochrome c IRON-SULFUR reductase Rieske SUBUNIT iron-sulphur PRECURSOR protein (RIESKE IRON- (UQCRFS1) SULFUR gene, exon 2 PROTEIN) (RISP) >gi|488299 (L32977) Rieske Fe-S protein 4581 M26708 Human 0 190369 (J04798) open 6e-018 prothymosin reading frame A; alpha mRNA putative [Homo (ProT-alpha), sapiens] complete cds. 4582 U95094 Xenopus laevis 2e-04 2314130 (AE000607) H. 3.3 XL-INCENP pylori predicted (XL-INCENP) coding region mRNA, complete HP0985 cds 4583 U95102 Xenopus laevis 4e-011 1236083 (U49507) Lisch7 4.3 mitotic [Mus musculus] phosphoprotein 90 mRNA, complete cds 4584 U95094 Xenopus laevis 2e-014 348196 (L19917) 9.7 XL-INCENP immunoglobulin (XL-INCENP) heavy-chain mRNA, complete subgroup VIII V- cds D-J region [Homo sapiens] 4585 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4586 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4587 X52601 H. sapiens hTOP1 4.6 <NONE> <NONE> <NONE> gene for topoisomerase, 5′end 4588 AF038604 Caenorhabditis 0.17 <NONE> <NONE> <NONE> elegans cosmid B0546 4589 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4590 U23441 Tetrahymena 0.0005 1469281 (U08801) 1.1 thermophila B envelope internal deletion glycoprotein sequence. [Human immunodeficiency virus type 1] 4591 AC005276 Homo sapiens 0.009 <NONE> <NONE> <NONE> clone fragment UWGC:gap3 from 7q31.3, complete sequence [Homo sapiens] 4592 D84117 Homo sapiens 0.48 <NONE> <NONE> <NONE> DNA for prostacyclin synthase, exon 3 4593 U28153 Caenorhabditis 1.30E-01 <NONE> <NONE> <NONE> elegans UNC-76 (unc-76) gene, complete cds. 4594 U67274 Human 1e-008 <NONE> <NONE> <NONE> metastasis suppressor (KAII) gene, exon 1, and complete cds 4595 AF009621 Onchocerca 4 <NONE> <NONE> <NONE> volvulus cytosolic Cu/Zn superoxide dismutase (OvSOD1) and extracellular Cu/Zn superoxide dismutase (OvSOD2) genes, complete cds 4596 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4597 <NONE> <NONE> <NONE> 2078483 (U43200) 0.78 antifreeze glycopeptide AFGP polyprotein precursor [Boreogadus saida] 4598 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4599 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4600 AL021806 Homo sapiens 4e-029 728836 !!!! ALU 0.002 DNA sequence SUBFAMILY SP from PAC WARNING 779B17 on ENTRY chromosome 22q13.1. Contains exon trap, complete sequence 4601 AL022222 Plasmodium 4.9 <NONE> <NONE> <NONE> falciparum DNA *** SEQUENCING IN PROGRESS *** from contig 3-118, complete sequence 4602 Z73149 N. tabacum DNA 1.6 <NONE> <NONE> <NONE> (recombination breakpoint between T-DNA and plant DNA) 4603 AF082835 Mus spretus E6- 4 <NONE> <NONE> <NONE> AP ubiquitin- protein ligase 4604 AF050123 Homo sapiens 3e-009 728838 !!!! ALU 6.7 hypoxia-inducible SUBFAMILY SX factor 1 alpha WARNING subunit (HIF1A) ENTRY gene, exon 10 4605 U95102 Xenopus laevis 7e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4606 AF001355 Pseudomonas 2.1 3041736 TRANSCRIPTIO 8.9 syringae pv. N FACTOR SOX- syringae DNA 11 binding protein HpkR (hpkR), histidine protein kinase HpkY (hpkY), phosphate acceptor regulatory protein CheY-2 (cheY-2), ankyrin AnkF (ankF), and catalase isozyme catalytic subuni . . . 4607 U95102 Xenopus laevis 8.00E-08 3123155 HYPOTHETICAL 2e-027 mitotic 49.0 KD TRP- phosphoprotein ASP REPEATS 90 mRNA, CONTAINING complete cds PROTEIN F55F8.5 IN CHROMOSOME I family [Caenorhabditis elegans] 4608 <NONE> <NONE> <NONE> 1170978 MYOCYTE 0.18 NUCLEAR FACTOR (MNF) [musculus] 4609 U95098 Xenopus laevis 4e-009 2072296 (U95098) mitotic 8.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 44 mRNA, partial cds 4610 U95094 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4611 X75861 H. sapiens TEGT e-177 2072296 (U95098) mitotic 2.8 gene phosphoprotein 44 [Xenopus laevis] 4612 U19867 Cloning vector 5e-055 987050 (X65335) lacZ 3e-011 pSPL3, exon gene product splicing vector, [unidentified complete cloning vector] sequence, HIV envelope protein gp160 and beta- lactamase, complete cds. 4613 U73332 Human non- 8e-008 <NONE> <NONE> <NONE> coding genomic sequence upstream from unique L0 sequence in the alpha-globin gene cluster 4614 <NONE> <NONE> <NONE> 193952 (J03770) 6 homeobox protein [Mus musculus] 4615 U95102 Xenopus laevis 6e-006 586875 HYPOTHETICAL 5e-019 mitotic 29.2 KD phosphoprotein PROTEIN IN 90 mRNA, METS-KSGA complete cds INTERGENIC REGION >gi|2127033|pir∥S 66068 hypothetical protein - [Bacillus subtilis subtilis] >gi|2632306|gnl|PI D|e1181972 (Z99104) similar to hypothetical proteins [Bacillus subtilis] 4616 K00384 Yeast 0.001 <NONE> <NONE> <NONE> (S. cerevisiae) mitochondrial var1 gene, 5′ flank. 4617 J04628 Rattus norvegicus e-154 416873 3- 1e-049 3-hydroxyiso- HYDROXYISOB butyrate mRNA, UTYRATE 3′ end. DEHYDROGENA SE PRECURSOR (HIBADH) >gi|111295|pir∥A3 2867 3- hydroxyisobutyrat e dehydrogenase (EC 1.1.1.31) precursor - rat (fragment) >gi|556389 (J04628) 3- hydroxyisobutyrat e dehydrogenase [Rattus norvegicus] 4618 U95098 Xenopus laevis 0.38 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4619 U10361 Saccharomyces 2.7 <NONE> <NONE> <NONE> cerevisiae Snf8p (SNF8) gene, complete cds. 4620 D42044 Human mRNA e-151 577301 (D42044) The 4e-052 for KIAA0090 ha3523 gene gene, partial cds product is related to S. cerevisiae gene product located in chromosome III. [Homo sapiens] 4621 U10361 Saccharomyces 2.7 <NONE> <NONE> <NONE> cerevisiae Snf8p (SNF8) gene, complete cds. 4622 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4623 U95102 Xenopus laevis 3.00E-10 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4624 U95102 Xenopus laevis 3.00E-10 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4625 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4626 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4627 X06747 Human hnRNP 7e-049 87650 heterogeneous 6e-005 core protein A1 ribonuclear particle protein A1.beta - human >gi|36102 (X06747) protein A1-alpha (AA 1- 320) [Homo sapiens] 4628 X03559 Human mRNA e-100 114549 ATP SYNTHASE 2e-024 for F1-ATPase BETA CHAIN, beta subunit (F-1 MITOCHONDRI beta) > :: AL PRECURSOR dbj|D00022|HUM >gi|106207|pir∥A3 F1B Homo 3370 H+- sapiens mRNA transporting ATP for F1 beta synthase (EC subunit, complete 3.6.1.34) beta cds chain precursor, mitochondrial - human >gi|179281 (M27132) ATP synthase beta subunit precursor [Homo sapiens] 4629 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4630 K00915 paramecium 7.00E-05 <NONE> <NONE> <NONE> species 1,168 mt dna dimer: replication init. region. 4631 K00915 paramecium 7.00E-05 <NONE> <NONE> <NONE> species 1,168 mt dna dimer: replication init. region. 4632 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4633 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4634 Z28261 S. cerevisiae 0.042 417748 PROTEIN 0.0002 chromosome XI TRANSPORT reading frame PROTEIN SEC13 ORF YKR036c 4635 U95102 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4636 AF088034 Homo sapiens 0 854598 (X87611) ORF 2e-024 full length insert YJR83.18 cDNA clone [Saccharomyces ZC24F03 cerevisiae] 4637 M83094 Homo sapiens 3.00E-08 <NONE> <NONE> <NONE> cytosolic selenium- dependent glutathione peroxidase gene, complete cds, and rhoh12 gene, 3′ end. 4638 U95102 Xenopus laevis 2e-006 1176711 HYPOTHETICAL 2e-017 mitotic 21.6 KD phosphoprotein PROTEIN 90 mRNA, F37A4.2 IN complete cds CHROMOSOME III >gi|1078851|pir∥S 44639 F37A4.2 protein - Caenorhabditis elegans >gi|458960 4639 U95102 Xenopus laevis 2e-006 1176711 HYPOTHETICAL 2e-017 mitotic 21.6 KD phosphoprotein PROTEIN 90 mRNA, F37A4.2 IN complete cds CHROMOSOME III >gi|1078851|pir∥S 44639 F37A4.2 protein - Caenorhabditis elegans >gi|458960 4640 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4641 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4642 U95094 Xenopus laevis 2e-005 4056582 (AF039530) RepA 3.4 XL-INCENP [Egyptian (XL-INCENP) sugarcane streak mRNA, complete virus] cds 4643 U96174 Onchocerca 3.2 <NONE> <NONE> <NONE> volvulus OvB8 mRNA, partial cds 4644 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4645 U95102 Xenopus laevis 6e-005 3236220 (U62541) 4.5 mitotic immunoreactive phosphoprotein 14 kDa protein 90 mRNA, BA14k [Brucella complete cds abortus] 4646 U95102 Xenopus laevis 6e-005 3236220 (U62541) 4.5 mitotic immunoreactive phosphoprotein 14 kDa protein 90 mRNA, BA14k [Brucella complete cds abortus] 4647 AL010224 Plasmodium 0.003 2492906 ANNEXIN VII 1.4 falciparum DNA (SYNEXIN) frog *** >gi|790544 SEQUENCING (U16365) annexin IN PROGRESS VII [Xenopus *** from contig laevis] 4-04, complete sequence 4648 L39413 Atractylodes 0.003 <NONE> <NONE> <NONE> japonica chloroplast NADH dehydrogenase (ndhF) gene, complete cds 4649 U95094 Xenopus laevis 4e-013 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4650 U79403 Meleagris 0.46 2498691 OUTER DENSE 1.4 gallopavo FIBER PROTEIN microsatellite bovine repeat sequence >gi|1165006 (X69514) outer dense fiber protein protein [Bos taurus] 4651 U27780 Stealth virus 1 2 <NONE> <NONE> <NONE> clone C16138 T3.1 4652 U27780 Stealth virus 1 2 <NONE> <NONE> <NONE> clone C16138 T3.1 4653 U78817 Saccharomyces 0.026 <NONE> <NONE> <NONE> cerevisiae killer virus M1, complete genome 4654 U78817 Saccharomyces 0.026 <NONE> <NONE> <NONE> cerevisiae killer virus M1, complete genome 4655 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4656 X07036 Human mRNA 3e-071 232142 GUANINE 8e-027 stimulatory GTP- NUCLEOTIDE- binding protein BINDING alpha subunit PROTEIN G(S), ALPHA SUBUNIT (ADENYLATE CYCLASE- STIMULATING G ALPHA PROTEIN) >gi|71886|pir∥RG PGA2 GTP- binding regulatory protein Gs alpha-2 chain (adenylate cyclase- stimulating) - pig >gi|1958 (X63893) alpha-stimulatory subunit 4657 L05586 Kinetoplast 0.0001 4063042 (AF068065) 0.19 Trypanosoma GP900; mucin-like brucei (IsTaR 1 glycoprotein serodeme) [Cryptosporidium putative NADH parvum] dehydrogenase subunit (nd9) mRNA, complete cds. 4658 AF044763 Cecropis ariel 3e-006 <NONE> <NONE> <NONE> microsatellite HrU6 allele 1 repeat region 4659 X82630 A. longa plastid 0.22 <NONE> <NONE> <NONE> rps12, orf126 and orf288 genes 4660 U68098 Human poly(A)- 0.023 <NONE> <NONE> <NONE> binding protein (PABP) gene, exons 6 and 7 4661 U68098 Human poly(A)- 0.023 <NONE> <NONE> <NONE> binding protein (PABP) gene, exons 6 and 7 4662 U95094 Xenopus laevis 1e-011 1022683 (U23146) SSeCKS 1.4 XL-INCENP [Rattus (XL-INCENP) norvegicus] mRNA, complete cds 4663 M15353 Homo sapiens 0 <NONE> <NONE> <NONE> cap-binding protein mRNA, completc cds 4664 Z57610 H. sapiens CpG 3e-048 417134 HEPATOCYTE 2.00E-10 DNA, clone NUCLEAR 187a10, reverse FACTOR 3-BETA read [norvegicus] cpg187a10.rtla. 4665 L11707 Hevea 2.6 <NONE> <NONE> <NONE> brasiliensis Mn- superoxide dismutase (SODMn) gene, complete cds. 4666 D42073 Human mRNA 3e-019 2072296 (U95098) mitotic 6.4 for reticulocalbin, phosphoprotein 44 complete cds [Xenopus laevis] 4667 L12350 Human 0 <NONE> <NONE> <NONE> thrombospondin 2 (THBS2) mRNA, complete cds. 4668 L11707 Hevea 2.6 <NONE> <NONE> <NONE> brasiliensis Mn- superoxide dismutase (SODMn) gene, complete cds. 4669 AC000043 Homo sapiens 2e-016 134589 TRANSCRIPTIO 1.5 Chromosome N 22q13 Cosmid REGULATORY Clone p74a8, PROTEIN SNF2 complete SWI2) sequence [Homo (REGULATORY sapiens] PROTEIN GAM1) (TRANSCRIPTIO N FACTOR TYE3) >gi|101629|pir∥S1 5047 SNF2 protein - yeast protein [Saccharomyces cerevisiae] >gi|172632 (M61703) SNF2 protein [Saccharomyces cerevisiae] cerevisiae]>gi|127 4670 U95094 Xenopus laevis 6e-006 69700 interleukin-1 beta 0.6 XL-INCENP precursor - bovine (XL-INCENP) mRNA, complete cds 4671 U44975 Homo sapiens 2e-045 1848233 (U44975) DNA- 0.009 DNA-binding binding protein protein CPBP CPBP [Homo (CPBP) mRNA, sapiens] partial cds 4672 AF038406 Homo sapiens 0 2326168 (U32107) type VII 1.5 NADH collagen [Mus dehydrogenase- musculus] ubiquinone Fe-S protein 8 23 kDa subunit (NDUFS8) gene, nuclear gene encoding mitochondrial protein, complete cds 4673 X67951 H. sapiens mRNA 0 548453 THIOREDOXIN 2e-083 for proliferation- PEROXIDASE 2 associated gene CELL ENHANCING (FACTOR A) (NKEF-A) >gi|423025|pir∥A4 6711 proliferation associated gene (pag) protein - human gene product [Homo sapiens] 4674 AC001013 Homo sapiens 2e-017 2072961 (U93568) putative 0.0001 (subclone 2_d1 p150 [Homo from P1 H43) sapiens] DNA sequence 4675 U95094 Xenopus laevis 4e-012 1589837 (U68729) cuticle 0.035 XL-INCENP preprocollagen (XL-INCENP) [Meloidogyne mRNA, complete incognita] cds 4676 M15353 Homo sapiens 0 <NONE> <NONE> <NONE> cap-binding protein mRNA, complete cds 4677 M37583 Human histone 0 121994 HISTONE H2A.Z 1e-055 (H2A.Z) mRNA, >gi|89608|pir∥S03 complete cds. 642 histone H2A.Z - bovine >gi|92380|pir∥S03 644 histone H2A.Z - rat >gi|106267|pir∥A3 5881 histone H2A.Z - [human sapiens] >gi|57808 (X52316) histone H2A.Z (AA 1- 127) [taurus] >gi|184060 (M37583) histone (H2A.Z) [Homo sapien] 4678 M15353 Homo sapiens 0 <NONE> <NONE> <NONE> cap-binding protein mRNA, complete cds 4679 Z57610 H. sapiens CpG 4e-094 404764 (L10409) fork 4e-024 DNA, clone head related 187a10, reverse protein [Mus read musculus] cpg187a10.rtla. 4680 Z57610 H. sapiens CpG 4e-094 404764 (L10409) fork 4e-024 DNA, clone head related 187a10, reverse protein [Mus read musculus] cpg187a10.rtla. 4681 Z57610 H. sapiens CpG 4e-094 404764 (L10409) fork 4e-024 DNA, clone head related 187a10, reverse protein [Mus read musculus] cpg187a10.rtla. 4682 L11707 Hevea 2.6 <NONE> <NONE> <NONE> brasiliensis Mn- superoxide dismutase (SODMn) gene, complete cds. 4683 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4684 <NONE> <NONE> <NONE> 2114323 (D88734) 0.052 membrane glycoprotein [Equine herpesvirus 1] 4685 AJ224875 Homo sapiens 0 2996578 (AJ224875) e-118 mRNA for glucosyltransferas putative e [Homo sapiens] glucosyltransferas e, partial cds 4686 AB019534 Homo sapiens 2e-045 <NONE> <NONE> <NONE> gene for cathepsin L2, complete cds 4687 J03799 Human colin e-166 34272 (X15005) pot. 5e-032 carcinoma lamimin-binding laminin-binding protein (AA 1- protein mRNA, 300) [Homo complete cds. sapiens] 4688 <NONE> <NONE> <NONE> 2114323 (D88734) 0.052 membrane glycoprotein [Equine herpesvirus 1] 4689 U95098 Xenopus laevis 9e-009 2072296 (U95098) mitotic 9.8 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 44 mRNA, partial cds 4690 D44598 Saccharomyces 1e-009 3947877 (AL034382) 6e-061 cerevisiae putative mitosis chromosome VI and maintenance phage 4121 of ploidy protein [Schizosaccharom yces pombe] 4691 AF053520 Homo sapiens 0.61 <NONE> <NONE> <NONE> allele 12 fragile site locus 4692 D16195 Mouse gene for 0.059 <NONE> <NONE> <NONE> acrogranin precursor, complete cds 4693 U90904 Human clone 0 3130153 (AB008857) 1.5 23773 mRNA calcium2+ sensing sequence receptor 4694 L22398 Homo sapiens 7e-017 987050 (X65335) lacZ 0.1 DNA sequence, gene product repeat region. [unidentified cloning vector] 4695 L22398 Homo sapiens 7e-017 987050 (X65335) lacZ 0.1 DNA sequence, gene product repeat region. [unidentified cloning vector] 4696 J03746 Human e-170 121740 GLUTATHIONE 2e-038 glutathione S- S- transferase TRANSFERASE, mRNA, complete MICROSOMAL cds. >gi|87562|pir∥B28 083 glutathione transferase glutathione S- transferase [Homo sapiens] >gi|1195483 sapiens] >gi|1621433 (U71213) microsomal glutathione s- transferase [Homo sapiens] 4697 AF082283 Homo sapiens 5e-046 4049460 (AJ006288) bcl-10 0.005 CARD- [Homo sapiens] containing signaling protein apoptotic [Homo sapiens] signaling protein (BCL10) mRNA, complete cds 4698 D64142 Human mRNA 1e-039 <NONE> <NONE> <NONE> for histone H1x, complete cds 4699 AB001899 Homo sapiens 4e-012 3860844 (AJ235271) 3.5 PACE4 gene, NADH exon 2 DEHYDROGENA SE I CHAIN L 4700 X16869 Human mRNA 0 1169475 ELONGATION 6e-061 for elongation FACTOR 1- factor 1-alpha ALPHA 1 (clone CEF4) 4701 U95102 Xenopus laevis 6.00E-05 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4702 U95094 Xenopus laevis 4e-013 2501465 PROBABLE 0.0003 XL-INCENP UBIQUITIN (XL-INCENP) CARBOXYL- mRNA, complete TERMINAL cds HYDROLASE FAM (UBIQUITIN THIOLESTERAS E FAM) 4703 D44598 Saccharomyces 1e-009 3947877 (AL034382) 6e-061 cerevisiae putative mitosis chromosome VI and maintenance phage 4121 of ploidy protein [Schizosaccharom yces pombe] 4704 U95094 Xenopus laevis 6e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4705 U95094 Xenopus laevis 1e-012 2072296 (U95098) mitotic 6.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4706 AB001899 Homo sapiens 4e-012 3860844 (AJ235271) 3.4 PACE4 gene, NADH exon 2 DEHYDROGENA SE I CHAIN L 4707 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4708 U95102 Xenopus laevis 1e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4709 U95094 Xenopus laevis 1e-009 2072296 (U95098) mitotic 6.40E+00 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4710 L39064 Homo sapiens 1e-006 4063042 (AF068065) 1e-006 interleukin 9 GP900; mucin-like receptor glycoprotein precursor (IL9R) gene, complete cds 4711 U95098 Xenopus laevis 0.0002 331908 (K02714) 8 mitotic envelope phosphoprotein polyprotein 44 mRNA, partial [Friend murine cds leukemia virus] 4712 AF065249 Entodinium 1 <NONE> <NONE> <NONE> caudatum 14-3-3 protein mRNA, partial cds 4713 U95102 Xenopus laevis 2e-013 2072296 (U95098) mitotic 7.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4714 <NONE> <NONE> <NONE> 186396 (M94131) mucin 2.5 [Homo sapiens] 4715 U95094 Xenopus laevis 8e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4716 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4717 Z56314 H. sapiens CpG 4e-012 2444024 (U77782) N- 9.8 DNA, clone methyl-D- 10h10, reverse aspartate receptor read 2C subunit cpg10h10.rtla. precursor [Homo sapiens] 4718 D55696 Human mRNA e-113 2842759 LEGUMAIN 1e-006 for cysteine PRECURSOR protease, (ASPARAGINYL complete cds ENDOPEPTIDAS E) >gi|1743266|gnl|PI D|e286211 (Y09862) legumain [Homo sapiens] 4719 U95094 Xenopus laevis 9e-008 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4720 D63480 Human mRNA 0 1469874 (D63480) The 2e-079 for KIAA0146 KIAA0146 gene gene, partial cds product is novel. [Homo sapiens] 4721 AB001579 Rice dwarf virus 1.3 <NONE> <NONE> <NONE> genomic RNA, segment 2, complete sequence 4722 <NONE> <NONE> <NONE> 3873550 (AL033534) 2.7 serine-rich protein 4723 AL010156 Plasmodium 0.77 <NONE> <NONE> <NONE> falciparum DNA *** SEQUENCING IN PROGRESS *** from contig 3-87, complete sequence 4724 AF059198 Homo sapiens 2 119110 EBNA-1 8e-007 protein NUCLEAR kinase/endoribon PROTEIN ulcease herpesvirus 4 (strain B95-8) >gi|1334880 (V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 4725 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4727 D38616 Human mRNA 3.5 3522948 (AC004411) 0.18 for phosphorylase hypothetical kinase alpha protein subunit, complete [Arabidopsis cds thaliana] 4728 D38616 Human mRNA 3.5 3522948 (AC004411) 0.18 for phosphorylase hypothetical kinase alpha protein subunit, complete [Arabidopsis cds thaliana] 4729 Z11808 T. glis 1.6 <NONE> <NONE> <NONE> interphotorecepto r retinoid binding protein gene, exon 1 4730 AF065988 Homo sapiens 1.4 <NONE> <NONE> <NONE> keratocan gene, complete cds 4731 X60026 M. domesticus 0.0003 2853301 (AF007194) 5.5 small nuclear 4.5 mucin [Homo S RNA gene sapiens] 4732 M13793 Mouse 56 kdal 0.3 136814 HYPOTHETICAL 2.3 protein mRNA PROTEIN UL11 from an RL11 FAMILY interferon [Human activated gene, cytomegalovirus] exon 1, 5′ end. 4733 D55696 Human mRNA e-113 2842759 LEGUMAIN 1e-006 for cysteine PRECURSOR protease, (ASPARAGINYL complete cds ENDOPEPTIDAS E) >gi|1743266|gnl|PI D|e286211 (Y09862) legumain [Homo sapiens] 4734 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4735 <NONE> <NONE> <NONE> 322647 glycine-rich 3e-021 protein GRP22 - rape >gi|17821 4736 <NONE> <NONE> <NONE> 188864 (M74027) mucin 0.002 [Homo sapiens] 4737 U95102 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4738 AB018270 Homo sapiens 0 2072296 (U95098) mitotic 1.8 mRNA for phosphoprotein 44 KIAA0727 [Xenopus laevis] protein, partial cds 4739 AB018270 Homo sapiens 0 2072296 (U95098) mitotic 1.8 mRNA for phosphoprotein 44 KIAA0727 (Xenopus laevis] protein, partial cds 4740 AE001382 Plasmodium 0.25 <NONE> <NONE> <NONE> falciparum chromosome 2, section 19 of 73 of the complete sequence 4741 AE001382 Plasmodium 0.25 <NONE> <NONE> <NONE> falciparum chromosome 2, section 19 of 73 of the complete sequence 4742 X55038 Mouse mCENP- 0.001 3879362 (Z81113) similar 7e-007 B gene for to DnaJ, centromere prokaryotic heat autoantigen B shock protein, Zinc finger, C2H2 type; cDNA EST yk290e12.5 comes from this gene; cDNA EST yk290e12.3 comes from this gene; cDNA EST yk447h4.5 comes from this gene; cDNA EST yk474e4 . . . 4743 AF054024 Rattus norvegicus 0.62 <NONE> <NONE> <NONE> polymorphic marker D9UIA2 sequence 4744 U95094 Xenopus laevis 0.0005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4745 Z11808 T. glis 1.6 <NONE> <NONE> <NONE> interphotorecepto r retinoid binding protein gene, exon 1 4746 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4747 AF047470 Homo sapiens 1e-019 2995307 (AL022268) 0.12 malate putative dehydrogenase aminotransferase precursor complete cds 4748 AF029890 Homo sapiens e-161 2745883 (AF029890) 2e-044 hepatitis B virus hepatitis B virus X X interacting interacting protein protein (XIP) [Homo sapiens] mRNA, complete cds 4750 U95094 Xenopus laevis 8e-008 1723019 HYPOTHETICAL 2.5 XL-INCENP 29.6 KD (XL-INCENP) PROTEIN mRNA, complete CY251.12C cds >gi|1405764|gnl|PI D|e249453 (Z74410) hypothetical protein Rv0093c [Mycobacterium tuberculosis] 4751 M37583 Human histone 0 121994 HISTONE H2A.Z 1e-055 (H2A.Z) mRNA, >gi|89608|pir∥S03 complete cds. 642 histone H2A.Z - bovine >gi|92380|pir∥S03 644 histone H2A.Z - rat >gi|106267|pir∥A3 5881 histone H2A.Z - [human sapiens] >gi|57808 (X52316) histone H2A.Z (AA 1- 127) [taurus] >gi|184060 (M37583) histone (H2A.Z) [Homo sapien] 4752 U95094 Xenopus laevis 5e-014 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4753 X65279 pWE15 cosmid 7e-079 987050 (X65335) lacZ 1e-013 vector DNA gene product [unidentified cloning vector] 4754 D38549 Human mRNA e-169 <NONE> <NONE> <NONE> for KIAA0068 gene, partial cds 4755 L27835 Pangasianodon 1.5 538251 (D00322) 5.8 gigas growth polyprotein hormone (GH) [Tomato black mRNA, complete ring virus] cds. 4756 U95094 Xenopus laevis 0.0002 1477565 (U50078) p619 8.9 XL-INCENP [Homo sapiens] (XL-INCENP) mRNA, complete cds 4757 U95094 Xenopus laevis 0.0002 1477565 (U50078) p619 8.9 XL-INCENP [Homo sapiens] (XL-INCENP) mRNA, complete cds 4758 U47414 Human cyclin G2 e-116 <NONE> <NONE> <NONE> mRNA, complete cds 4759 AB014560 Homo sapiens e-173 <NONE> <NONE> <NONE> mRNA for KIAA0660 protein, complete cds 4760 L35664 Homo sapiens 1e-030 2072966 (U93570) p40 0.001 (subclone H8 [Homo sapiens] 8_f5 from P1 35 H5 C8) DNA sequence. 4761 U95094 Xenopus laevis 4e-013 2072296 (U95098) mitotic 3.1 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4762 U95094 Xenopus laevis 4e-013 2072296 (U95098) mitotic 3.1 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4763 U95094 Xenopus laevis 1e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4764 U95094 Xenopus laevis 1e-012 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4765 M59317 Mouse low 1e-006 2135765 mucin 2 precursor, 0.0003 affinity IgE intestinal - human receptor (FceRII) gene sequence. 4766 D14034 Human gene for 3e-008 119379 RETROVIRUS- 6e-007 Zn-alpha2- RELATED ENV glycoprotein, POLYPROTEIN complete cds 4767 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4768 M61185 Bovine glutamic 0.01 2781362 (AC003113) 1.1 acid-rich protein F24O1.18 mRNA, complete [Arabidopsis cds. thaliana] 4769 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4770 Z62012 H. sapiens GpG 0.076 1582765 YFW1 gene 2.9 DNA, clone [Saccharomyces 61g4, reverse cerevisiae] read cpg61g4.rtla . 4771 M29065 Human hnRNP 0 4049652 (AF063866) ORF 5.9 A2 protein MSV017 mRNA. hypothetical protein [Melanoplus sanguinipes entomopoxvirus] 4772 D12525 Homo sapiens 6e-016 728837 !!!! ALU 9.6 cytochrome SUBFAMILY SQ P450IA1 gene, WARNING 3′flanking region ENTRY 4773 M16660 Human 90-kDa e-109 2119731 HSP90 - mouse 1e-023 heat-shock (fragment) protein protein gene, {C-terminal} cDNA, complete [mice, heart, cds. Peptide Partial, 194 aa] [Mus sp.] 4774 AF043105 Homo sapiens 9e-020 728831 !!!! ALU 0.63 glutathione S- SUBFAMILY J transferase mu 3 WARNING ENTRY 4775 U43374 Human normal 0 120179 FINQ PROTEIN 9 keratinocyte >gi|73172|pir∥BV mRNA. ECFQ finQ protein - Escherichia coli plasmid R820a 4776 U00684 Human unknown 2e-014 2224667 (AB002361) 6.6 mRNA. KIAA0363 [Homo sapiens] 4777 M22299 Human T-plastin 4e-008 <NONE> <NONE> <NONE> polypeptide mRNA, complete cds, clone p4. > :: gb|I08151| Sequence 1 from Patent EP 0345726 4778 M95623 Homo sapiens 3e-018 3002527 (AF010144) 0.52 hydroxymethylbil neuronal thread ane synthase protein AD7c- gene, complete NTP [Homo cds. sapiens] 4779 X52329 pBluescript II 0 2117615 catalase - 2e-009 KS(−) vector Campylobacter DNA, phagemid jejuni excised from lambda ZAPII 4780 X52329 pBluescript II 0 2117615 catalase - 2e-009 KS(−) vector Campylobacter DNA, phagemid jejuni excised from lambda ZAPII 4781 AF061034 Homo sapiens 0 3127084 (AF061034) FIP2 9e-089 FIP2 alternatively [Homo sapiens] translated mRNA, complete cds 4782 Z64776 H. sapiens CpG 0.0002 1777782 (U52513) ISG 1.8 DNA, clone family member 167d8, forward [Homo sapiens] read cpg167d8.ftlb. 4783 D31786 Acyrthosiphon 1.1 2134310 cell division 4e-005 kondoi control protein endosymbiont CDC37 homolog DNA, S10 and splice form 1 - spc ribosomal chicken protein gene operons, complete and partial cds 4784 L05491 Homo sapiens T- 0 2506254 T-PLASTIN 3e-018 plastin gene, last exon (16). 4785 U95102 Xenopus laevis 8e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4786 U95102 Xenopus laevis 7e-006 3877438 (Z72510) similar 2 mitotic to G-protein phosphoprotein coupled receptor 90 mRNA, [Caenorhabditis complete cds elegans] 4787 L38250 Mycoplasma 0.041 <NONE> <NONE> <NONE> penetrans p35 lipoprotein and p33 lipoprotein genes, complete cds 4788 J03537 Human ribosomal e-138 133978 40S 3e-033 protein S6 RIBOSOMAL mRNA, complete PROTEIN S6 cds. protein S6 - rat >gi|70933|pir∥R3 MS6 ribosomal protein S6 - mouse >gi|319910|pir∥R3 HU6 ribosomal protein S6 - human >gi|36148 (X67309) ribosomal protein S6 [Homo sapiens] >gi|54010 (Y00348) ribosomal protein S6 [Mus musculus] >g 4789 U95102 Xenopus laevis 1e-011 2072296 (U95098) mitotic 2.6 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4790 AF041210 Homo sapiens 0.41 <NONE> <NONE> <NONE> midline 1 fetal kidney isoform 3 4791 U95094 Xenopus laevis 3e-010 2072296 (U95098) mitotic 3.2 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4792 S60885 LYAR=cell 2e-026 2498524 CELL GROWTH 0.43 growth regulating REGULATING nucleolar protein NUCLEOLAR PROTEIN >gi|423488|pir∥A4 0683 cell growth regulating nucleolar protein LYAR - mouse >gi|300372|bbs|13 1782 4793 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4794 U28687 Human zinc 3e-027 1731444 ZINC FINGER 3e-008 finger containing PROTEIN 84 protein ZNF157 (ZINC FINGER PROTEIN HPF2) >gi|1020145 (M27878) DNA binding protein 4795 AF086438 Homo sapiens 0.0002 <NONE> <NONE> <NONE> full length insert cDNA clone ZD80G11 4796 L28997 Homo sapiens 3e-006 <NONE> <NONE> <NONE> ARL1 mRNA, complete cds 4797 U95094 Xenopus laevis 3e-008 1280126 (U55375) 2e-012 XL-INCENP K03E6.4 (XL-INCENP) [Caenorhabditis mRNA, complete elegans] cds 4798 AE001415 Plasmodium 0.015 <NONE> <NONE> <NONE> falciparum chromosome 2, section 52 of 73 of the complete sequence 4799 D21853 Human mRNA 0 729821 EUKARYOTIC 2e-010 for KIAA0111 INITIATION gene, complete FACTOR 4A- cds LIKE NUK-34 (HA0659) >gi|631472|pir∥S4 5142 translation initiation factor eIF-4A2 homolog - human >gi|496902 4800 M76425 H. sapiens intron 0.014 <NONE> <NONE> <NONE> 2 Alu repetitive element. 4801 X87212 H. sapiens mRNA 0 1582221 prepro-cathepsin C 1e-052 for cathepsin C [Homo sapiens] 4802 D80005 Human mRNA e-114 1136426 (D80005) 7e-025 for KIAA0183 KIAA0183 [Homo gene, partial cds sapiens] 4803 AF026029 Homo sapiens 2e-055 <NONE> <NONE> <NONE> poly(A) binding protein II (PABP2) gene, complete cds 4804 Z68322 Human DNA 2e-016 2072296 (U95098) mitotic 5.6 sequence from phosphoprotein 44 cosmid L79F5, [Xenopus laevis] Huntington's Disease Region, chromosome 4p16.3 4805 M63180 Human threonyl- 0 135177 THREONYL- 5e-070 tRNA synthetase TRNA mRNA, complete SYNTHETASE, cds CYTOPLASMIC (THREONINE- TRNA LIGASE) (THRRS) (6.1.1.3) - human >gi|1464742 (M63180) threonyl-tRNA synthetase [Homo sapiens] 4806 U95102 Xenopus laevis 3.7 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4807 D16431 Human mRNA 3e-010 <NONE> <NONE> <NONE> for hepatoma- derived growth factor, complete cds 4808 AF086168 Homo sapiens e-148 1465826 (U64856) weak 2e-014 full length insert similarity to TPR cDNA clone domains ZB82D09 [Caenorhabditis elegans] 4809 U95094 Xenopus laevis 4e-012 2072296 (U95098) mitotic 4.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4810 M34651 Pseudorabies 0.4 417134 HEPATOCYTE 0.047 virus with NUCLEAR upstream and FACTOR 3-BETA downsteam [norvegicus] sequences. 4811 U95094 Xenopus laevis 3e-010 1353390 (U34998) Rad9 3e-010 XL-INCENP [Coprinus (XL-INCENP) cinereus] mRNA, complete cds 4812 M94314 Homo sapiens 1e-064 <NONE> <NONE> <NONE> ribosomal protein L30 mRNA, complete cds 4813 X95276 P. falciparum 0.001 <NONE> <NONE> <NONE> complete gene map of plastid- like DNA (IR-B) 4814 X12716 Human 5e-024 <NONE> <NONE> <NONE> Retrovirus mRNA for LTR (clone cH6) 4815 J03537 Human ribosomal e-138 133978 40S 3e-033 protein S6 RIBOSOMAL mRNA, complete PROTEIN S6 cds. protein S6 - rat >gi|70933|pir∥R3 MS6 ribosomal protein S6 - mouse >gi|319910|pir∥R3 HU6 ribosomal protein S6- human >gi|36148 (X67309) ribosomal protein S6 [Homo sapiens] >gi|54010 (Y00348) ribosomal protein S6 [Mus musculus]>g 4816 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4817 U61945 Caenorhabditis 1.8 <NONE> <NONE> <NONE> elegans cosmid C49C8. 4818 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4819 M20020 Human ribosomal 7e-072 225901 ribosomal protein 2e-015 protein S6 S6 [Rattus mRNA, complete norvegicus] cds. 4820 U95102 Xenopus laevis 0.058 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4821 AL023973 Human DNA 3e-009 2352260 (AF000949) 0.037 sequence from keratin [Canis clone 1033E15 on familiaris] chromosome 22q13.1-13.2. Contains part of a novel gene, ESTs and a GSS, complete sequence [Homo sapiens] 4822 M37430 Pea Chloroplast 4.7 4093193 (AF106583) 4.8 4.5S, 5S, 16S and unknown 23S mRNA. [Caenorhabditis elegans] 4823 M63488 Human 0 1350579 REPLICATION 8e-079 replication PROTEIN A 70 protein A 70 kDa KD DNA- subunit mRNA BINDING complete cds. SUBUNIT (RP-A) (RF-A) (REPLICATION FACTOR-A PROTEIN 1) (SINGLE- STRANDED DNA-BINDING PROTEIN) subunit [Homo sapiens] 4824 X83791 C. tentans BR1 1.2 <NONE> <NONE> <NONE> gene 4825 U67576 Methanococcus 4 <NONE> <NONE> <NONE> jannaschii section 118 of 150 of the complete genome 4826 U95094 Xenopus laevis 1e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4827 X65319 Cloning vector 2e-077 987050 (X65335) lacZ 2e-011 pCAT-Enhancer gene product [unidentified cloning vector] 4828 X03558 Human mRNA 0 1169475 ELONGATION e-109 for elongation FACTOR 1- factor 1 alpha ALPHA 1 subunit 4829 X76538 H. sapiens Mpv17 6.00E-98 730059 MPV17 PROTEIN 3e-010 mRNA >gi|631208|pir∥S4 5343 glomerulosclerosis protein Mpv17 - human 4830 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4831 <NONE> <NONE> <NONE> 2078483 (U43200) 0.014 antifreeze glycopeptide AFGP polyprotein precursor [Boreogadus saida] 4832 X83617 H. sapiens mRNA 3.4 3924670 (AC004990). 3e-040 for RanBP1 supported by Genscan and several ESTs: C83049 4833 U95094 Xenopus laevis 1e-011 3024677 ISOLEUCYL- 0.005 XL-INCENP TRNA (XL-INCENP) SYNTHETASE mRNA, complete isoleucyl-tRNA cds synthetase (ileS) [Helicobacter pylori] 4834 J02763 Human calcyclin 1e-043 <NONE> <NONE> <NONE> gene, complete cds. 4835 L10910 Homo sapiens 0.00E+00 <NONE> <NONE> <NONE> splicing factor (CC1.3) mRNA, complete cds. 4836 X53586 Human mRNA 2e-099 2072296 (U95098) mitotic 5 for integrin alpha phosphoprotein 44 6 [Xenopus laevis] 4837 Z57594 H. sapiens CpG 1.4 <NONE> <NONE> <NONE> DNA, clone 186c5, reverse read cpg186c5.rtlb. 4838 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4839 U95102 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4840 Y00371 Human hsc70 e-145 987050 (X65335) lacZ 7e-011 gene for 71 kd gene product heat shock [unidentified cognate protein > cloning vector] :: gb|AR013986|AR 013986 Sequence 15 from patent U.S. Pat. No. 5773245 4841 AF074991 Homo sapiens 0.0005 <NONE> <NONE> <NONE> full length insert cDNA YH88A03 4842 AF055030 Homo sapiens 2e-049 2842711 ZINC-FINGER 2e-016 clone 24538 PROTEIN UB1- mRNA sequence D4 [sapiens] 4843 U95094 Xenopus laevis 2e-005 1353531 (U38906) ORF14 7.1 XL-INCENP [Bacteriophage (XL-INCENP) rlt] mRNA, complete cds 4844 Z57588 H. sapiens CpG 0.41 <NONE> <NONE> <NONE> DNA, clone 186b7, reverse read cpg186b7.rtlb. 4845 X65319 Cloning vector 9e-051 987050 (X65335) lacZ 0.37 pCAT-Enhancer gene product [unidentified cloning vector] 4846 X78411 B. pasteurii ureA, 3.1 <NONE> <NONE> <NONE> ureB and ureC genes. 4847 U95102 Xenopus laevis 3e-009 2224697 (AB002376) 5e-008 mitotic KIAA0378 [Homo phosphoprotein sapiens] 90 mRNA, complete cds 4848 U78729 Homo sapiens 4.7 <NONE> <NONE> <NONE> mad protein homolog Smad2 gene, exon 6 4849 D55696 Human mRNA 0 2842759 LEGUMAIN 3e-030 for cysteine PRECURSOR protease, (ASPARAGINYL complete cds ENDOPETIDAS E) >gi|1743266|gnl|PI D|e286211 (Y09862) legumain [Homo sapiens] 4850 U95097 Xenopus laevis 0.43 3005603 (AF053141) 2.2 mitotic progesterone phosphoprotein receptor [Equus 43 mRNA, partial caballus] cds 4851 U46118 Rattus norvegicus 0.38 <NONE> <NONE> <NONE> cytochrome P450 3A9 mRNA, complete cds 4852 U95102 Xenopus laevis 2e-006 2495726 HYPOTHETICAL 1e-005 mitotic PROTEIN phosphoprotein KIAA0254 90 mRNA, [sapiens] complete cds 4853 L10911 Homo sapiens e-117 <NONE> <NONE> <NONE> splicing factor (CC1.4) mRNA, complete cds. 4854 D00132 Acremonium 1.7 130998 SALIVARY 0.45 chrysogenum PROLINE-RICH ARS DNA PROTEIN fragment PRECURSOR (CLONE CP7) [CONTAINS: BASIC PEPTIDE P-F] glycoprotein precursor PRB2 - human (fragment) precursor [Homo sapiens] 4855 U95102 Xenopus laevis 4e-011 2072296 (U95098) mitotic 5.9 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 4856 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4857 AC002186 Homo sapiens 1e-041 2072966 (U93570) p40 4e-013 (subclone 1_fl2 [Homo sapiens] from P1 H115) DNA sequence 4858 AF053520 Homo sapiens 0.61 <NONE> <NONE> <NONE> allele 12 fragile site locus 4859 X65319 Cloning vector 2e-077 987050 (X65335) lacZ 2e-011 pCAT-Enhancer gene product [unidentified cloning vector] 4860 AJ005866 Homo sapiens e-179 4008517 (AJ005866) Sqv- 3e-049 mRNA for 7-like protein putative Sqv-7- [Homo sapiens] like protein, partial 4861 AF052165 Homo sapiens 4e-072 2065177 (Y12790) Supt5h 1e-021 clone 24522 protein [Homo mRNA sequence sapiens] sapiens] 4862 M90058 Human serglycin 0.005 <NONE> <NONE> <NONE> gene, exons 1, 2, and 3. 4863 U17662 Human 1.3 <NONE> <NONE> <NONE> neurofibromatosis 1 (NF1) gene, exons 4c and 5 and partial cds 4864 U64453 Human ELK1 3e-018 <NONE> <NONE> <NONE> pseudogene (ELK2) and immunoglobulin heavy chain gamma pseudogene (IGHGP) 4865 U95102 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4866 X16826 Drosophila 2.2 <NONE> <NONE> <NONE> melanogaster DNA for 60C beta tubulin gene making beta 3 tubulin isoform 4867 U95094 Xenopus laevis 4e-009 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4868 X65319 Cloning vector 8e-081 987050 (X65335) lacZ 3e-015 pCAT-Enhancer gene product [unidentified cloning vector] 4869 AL031322 S. pombe 0.38 <NONE> <NONE> <NONE> chromosome II cosmid c17D1 4870 M11560 Human aldolase 0 553861 (J05517) aldolase 2e-066 A mRNA, A [Mus musculus] complete cds. 4871 U28831 Human protein e-106 896065 (U28831) protein 1e-014 immuno-reactive that is immuno- with anti-PTH reactive with anti- polyclonal PTH polyclonal antibodies antibodies [Homo mRNA, partial sapiens] cds. > :: gb|I40055|I40055 Sequence 1 from patent U.S. Pat. No. 5618695 4872 U95102 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4873 <NONE> <NONE> <NONE> 107112 mucin, tracheal 4e-009 (AMN-22) - human (fragment) 4874 U95094 Xenopus laevis 1e-011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4875 U95094 Xenopus laevis 1e-011 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4876 D85752 Enterococcus 0.042 1123087 (U42436) 0.001 faecalis plasmid C49H3.3 gene pPD1 bacA, product bacB, bacC, [Caenorhabditis bacD, bacE, elegans] bacF, bacG, bacH and bacI genes, complete cds 4877 AC001443 Homo sapiens 1e-033 2072961 (U93568) putative 3e-007 (subclone 2_f10 p150 [Homo from BAC 2913 sapiens] 4878 U95102 Xenopus laevis 4e-012 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4879 S81433 heme oxygenase- 4.2 <NONE> <NONE> <NONE> 2 {5′ region, alternative splicing} 4880 M34312 S. cerevisiae 5e-010 188864 (M74027) mucin 2e-007 telomeric [Homo sapiens] sequence DNA, clone YLP108CA-4-ii. 4881 AF075079 Homo sapiens 1.00E-12 2072296 (U95098) mitotic 4.6 full length insert phosphoprotein 44 cDNA YQ80A08 [Xenopus laevis] 4882 U95102 Xenopus laevis 0.015 3176689 (AC003671) 4.5 mitotic Contains similarity phosphoprotein to ubiquitin 90 mRNA, carboxyl-terminal complete cds hydrolase 14 gb|Z35927 from S. cerevisiae. [Arabidopsis thaliana] 4883 U95102 Xenopus laevis 0.12 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4884 U95102 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4885 U95162 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4886 U74586 Rattus norvegicus 3.5 2828280 (AL021687) 4e-008 double-stranded putative protein RNA specific [Arabidopsis adenosine thaliana] deaminase >gi|2832633|gnl|PI (RED2) mRNA, D|e1249651 complete cds (AL021711) putative protein [Arabidopsis thaliana] 4887 U95094 Xenopus laevis 5e-014 2497599 LAMININ BETA- 5.4 XL-INCENP 2 CHAIN (XL-INCENP) PRECURSOR mRNA, complete cds 4888 D78572 House mouse; 7e-017 1545807 (D78572) 1.2 Musculus membrane domesticus glycoprotein [Mus mRNA for musculus] membrane glycoprotein, complete cds > :: dbj|E12950|E129 50 cDNA GA3- 43 encoding novel polypeptide which appear when differentiate from embryo-tumor cell P19 to nerve cell 4889 L07273 Rattus norvegicus 3.2 <NONE> <NONE> <NONE> carboxypeptidase E (CPE) gene, exon 1. 4890 Z46629 Homo sapiens e-132 <NONE> <NONE> <NONE> SOX9 mRNA. > :: gb|G28593|G285 93 human STS SHGC-35378. 4891 M30802 Human aromatase 3.3 <NONE> <NONE> <NONE> cytochrome P- 450 gene, exon 8. 4892 M28699 Homo sapiens 5e-088 2072296 (U95098) mitotic 5.2 nucleolar phosphoprotein 44 phosphoprotein [Xenopus laevis] B23 (NPM1) mRNA, complete cds. 4893 M89955 Human 5-HT1D- 0 2494923 5- 3e-008 type serotonin HYDROXYTRYP receptor gene, TAMINE 1D complete cds. RECEPTOR 1D [Cavia porcellus] 4894 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4895 AF004230 Homo sapiens 2e-012 <NONE> <NONE> <NONE> monocyte/macrop hage Ig-related receptor MIR-7 (MIR cl-7) mRNA, complete cds 4896 D50463 Mouse SDR1 0 1806276 (X99337) e-103 mRNA, complete glycoprotein 55 cds [Rattus norvegicus] 4897 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4898 AB014597 Homo sapiens 2e-067 3327208 (AB014597) 9e-051 mRNA for KIAA0697 protein KIAA0697 [Homo sapiens] protein, partial cds 4899 AF047598 Homo sapiens e-110 2736149 (AF022108) 7e-005 origin recognition putative complex subunit replication 4 (ORC4L) initiator origin mRNA, complete recognition cds complex subunit Orc4Lp [Homo sapiens] subunit 4; Orc4p [Homo sapiens] 4900 U95102 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4901 U95102 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4902 U22325 Mus musculus 1.20E+00 <NONE> <NONE> <NONE> faciogenital dysplasis (Fgd1) mRNA, complete cds. 4903 U22325 Mus musculus 1.20E+00 <NONE> <NONE> <NONE> faciogenital dysplasis (Fgd1) mRNA, complete cds. 4904 U22325 Mus musculus 1.20E+00 <NONE> <NONE> <NONE> faciogenital dysplasis (Fgd1) mRNA, complete cds. 4905 U26162 Human myosin 0 228542 myosin:SUBUNIT 3e-068 regulatory light =regulatory light chain mRNA, chain complete cds. 4906 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4907 U95094 Xenopus laevis 1e-011 3822225 (AF079183) 4e-006 XL-INCENP RING-H2 finger (XL-INCENP) protein RHG1a mRNA, complete [Arabidopsis cds thaliana] 4908 X65319 Cloning vector 1e-075 987050 (X65335) lacZ 8e-019 pCAT-Enhancer gene product [unidentified cloning vector] 4909 AJ010475 Arabidopsis 0.62 <NONE> <NONE> <NONE> thaliana mRNA for DEAD box RNA helicase, RH28 4910 U48364 Mus musculus 0.2 <NONE> <NONE> <NONE> muscle-specific transcriptional activator alpha- NAC gp220 (Naca) mRNA, complete cds 4911 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4912 J03750 Mouse single e-135 1709514 ACTIVATED 1e-020 stranded DNA RNA binding protein POLYMERASE II p9 mRNA, TRANSCRIPTIO complete cds. NAL COACTIVATOR PIS (PC4) (P14) cofactor p15 - human >gi|531395 (U12979) PC4 [Homo sapiens] >gi|619161 (X79805) PC4, p15 [Homo sapiens] 4913 U70263 Border disease 3.2 <NONE> <NONE> <NONE> virus strain BD31, complete genome 4914 AB012086 Canine 0.37 <NONE> <NONE> <NONE> herpesvirus gene for immediate- early protein, complete cds 4915 X05908 Human mRNA e-162 113944 ANNEXIN I 9e-041 for lipocortin (LIPOCORTIN I) (CALPACTIN II) (CHROMOBINDI N 9) (P35) (PHOSPHOLIPAS E A2 INHIBITORY PROTEIN) >gi|71756|pir∥LU HU annexin I - human >gi|34388 4916 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4917 U90911 Human clone 0.13 <NONE> <NONE> <NONE> 23652 mRNA sequence 4918 U95094 Xenopus laevis 8e-007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4919 X57830 H. sapiens 4e-011 <NONE> <NONE> <NONE> serotonin 5-HT2 receptor mRNA > :: gb|G28536|G285 36 human STS SHGC-31576. 4920 U67559 Methanococcus 3.5 <NONE> <NONE> <NONE> jannaschii section 101 of 150 of the complete genome 4921 M20020 Human ribosomal 0 133978 40S 2e-072 protein S6 RIBOSOMAL mRNA, complete PROTEIN S6 cds. protein S6 - rat >gi|70933|pir∥R3 MS6 ribosomal protein S6 - mouse >gi|319910|pir∥R3 HU6 ribosomal protein S6 - human >gi|36148 (X67309) ribosomal protein S6 [Homo sapiens] >gi|54010 (Y00348) ribosomal protein S6 [Mus musculus]>g 4922 U95102 Xenopus laevis 6e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4923 U95102 Xenopus laevis 6e-006 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4924 X76683 Plasmid vector e-160 987050 (X65335) lacZ 3e-015 pHM2 gene product betalactamase [unidentified gene cloning vector] 4925 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4926 U95098 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 44 mRNA, partial cds 4927 D50369 Homo sapiens e-152 3024781 UBIQUINOL- 6e-023 mRNA for low CYTOCHROME molecular mass C REDUCTASE ubiquinone- COMPLEX binding protein, UBIQUINONE- complete cds BINDING PROTEIN QP-C PROTEIN) (COMPLEX III SUBUNIT VII) >gi|2605590 (D50369) low molecular mass ubiquinone- binding protein [Homo sapiens] 4928 M63391 Human desmin 4e-013 <NONE> <NONE> <NONE> gene, complete cds. 4929 D38417 Mouse mRNA for e-110 <NONE> <NONE> <NONE> arylhydrocarbon receptor, complete cds 4930 U38253 Rattus norvegicus e-175 2494312 TRANSLATION 4e-040 initiation factor INITIATION eIF-2B gamma FACTOR EIF-2B subunit (eIF-2B GAMMA gamma) mRNA, SUBUNIT (EIF- complete cds 2B GDP-GTP EXCHANGE FACTOR) subunit [Rattus norvegicus] 4931 D38417 Mouse mRNA for e-110 <NONE> <NONE> <NONE> arylhydrocarbon receptor, complete cds 4932 U50767 Mus musculus 1.2 <NONE> <NONE> <NONE> alpha 1 type I collagen gene, partial cds and 3′ flanking region. 4933 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4934 U86137 Mus musculus 1.70E-011 3327268 (AB014597) 9e-066 telomerase KIAA0697 protein protein-1 mRNA, [Homo sapiens] complete cds 4935 S57980 Crp1=cystatin- 0.041 <NONE> <NONE> <NONE> related protein-1 [rats, Genomic, 7673 nt] 4936 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4937 AB012047 Arabidopsis 0.14 3915658 ATP- 6.1 thaliana gene for DEPENDENT sulfate RNA HELICASE transporter, A helicase II complete cds, [Homo sapiens] clone:AST56 4938 U95102 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4939 AB018374 Mus musculus 3e-037 <NONE> <NONE> <NONE> GARP34 mRNA, complete cds 4940 AF001498 Campylobacter 3e-005 <NONE> <NONE> <NONE> jejuni polysaccharide biosynthesis protein homolog gene, partial cds, galactosyl transferase homolog, UDP- galactose phosphate transferase homolog, acetyl transferase homolog and aminotransferase homolog gen . . . 4941 J04617 Human 3e-090 <NONE> <NONE> <NONE> elongation factor EF-1-alpha gene, complete cds. > :: dbj|E02629|E026 29 DNA of human polypeptide chain elongation factor- 1 alpha 4942 Z54349 H. sapiens 2e-007 <NONE> <NONE> <NONE> MN/CA9 GENE 4943 AF077374 Homo sapiens 1.3 <NONE> <NONE> <NONE> small proline-rich protein (SPRR3) gene, exons 1, 2, and 3 and complete cds 4944 X59828 Human 0.0003 <NONE> <NONE> <NONE> chromosome 22 flanking hypervariable simple repeat DNA (clone HZREP42) 4945 U95094 Xenopus laevis 1.00E-09 124180 TRANSCRIPTIO 5.8 XL-INCENP NAL (XL-INCENP) REGULATOR mRNA, complete IE63 human cds herpesvirus 1 (strain 17) [herpesvirus 1] >gi|221713 (D00374) immediate early transcriptional modulating protein IE63 (gene UL54) [herpesvirus 1] 4946 U95094 Xenopus laevis 1.00E-09 124180 TRANSCRIPTIO 5.8 XL-INCENP NAL (XL-INCENP) REGULATOR mRNA, complete IE63 human cds herpesvirus 1 (strain 17) [herpesvirus 1] >gi|221713 (D00374) immediate early transcriptional modulating protein IE63 (gene UL54) [herpesvirus 1] 4947 X76683 Plasmid vector 8e-092 987050 (X65335) lacZ 3e-015 pHM2 gene product betalactamase [unidentified gene cloning vector] 4948 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4949 U95094 Xenopus laevis 2.00E-04 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 4950 X16972 Drosophila 1.20E-01 1362688 morphogen Xhh 1.9 melanogaster precursor - African cecropin gene clawed frog cluster >gi|790938 (L39213) morphogen [Xenopus laevis] 4951 U12022 Human 0 2072296 (U95098) mitotic 5.9 calmodulin phosphoprotein 44 (CALM1) gene, [Xenopus laevis] exons 2, 3, 4, 5 and 6, and complete cds 4952 X56536 Rabbit mRNA for 2.3 119110 EBNA-1 4e-018 pH regulatory NUCLEAR protein (Na+/H+ PROTEIN exchanger), herpesvirus 4 partial (strain B95-8) >gi|1334880 (V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 4953 AF037438 Homo sapiens 2e-006 <NONE> <NONE> <NONE> short chain L-3- hydroxyacyl-CoA dehydrogenase (SCHAD) gene, complete cds 4954 U95094 Xenopus laevis 4e-012 2072296 (U95098) mitotic 3.4 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 4955 AB000467 Homo sapiens 2e-012 <NONE> <NONE> <NONE> mRNA, partial cds, clone:RES4- 25 4956 U31525 Human 0 1707996 GLYCOGENIN 5e-042 glycogenin <gi|2135280|pir∥J mRNA, complete C4695 glycogenin cds glucosyltransferas e (EC 2.4.1.186) - human 4957 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4958 AF003836 Mesocricetus 1.30E+00 <NONE> <NONE> <NONE> auratus isopentenyl diphosphate:dime thylallyl diphosphate isomerase mRNA, complete cds 4959 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4960 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4961 U95102 Xenopus laevis 4.90E-02 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4962 U95102 Xenopus laevis 4.90E-02 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4963 L32537 Homo sapiens 5.00E-03 <NONE> <NONE> <NONE> (clone XP6G6B) mRNA, partial EST. 4964 L32537 Homo sapiens 5.00E-03 <NONE> <NONE> <NONE> (clone XP6G6B) mRNA, partial EST. 4965 X63787 T. thermophila 0.41 <NONE> <NONE> <NONE> gene for snRNA U3-2 4966 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4967 U27341 Bos taurus 7e-015 <NONE> <NONE> <NONE> endothelin converting enzyme-2 Sequence 1 from patent U.S. Pat. No. 5736376 4968 U35114 Human 9e-005 <NONE> <NONE> <NONE> apolipoprotein E (APOE) gene, hepatic control region HCR-2 4969 M86374 Rat tropoelastin 0.13 <NONE> <NONE> <NONE> gene, intron 25 (partial). 4970 U95102 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4971 U95102 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4972 U95102 Xenopus laevis 2e-007 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4973 U95102 Xenopus laevis 7.00E-07 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4974 U95102 Xenopus laevis 7.00E-07 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4975 U95102 Xenopus laevis 7.00E-07 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 4976 U95102 Xenopus laevis 0.005 2995290 (AL022268) 1.50E-02 mitotic putative phosphoprotein transmembrane 90 mRNA, transport protein complete cds [Streptomyces coelicolor] 4977 U95102 Xenopus laevis 0.005 2995290 (AL022268) 1.50E-02 mitotic putative phosphoprotein transmembrane 90 mRNA, transport proteln complete cds [Streptomyces coelicolor] 4978 U95102 Xenopus laevis 0.005 2995290 (AL022268) 1.50E-02 mitotic putative phosphoprotein transmembrane 90 mRNA, transport protein complete cds [Streptomyces coelicolor] 4979 U95094 Xenopus laevis 2.00E-05 2983512 (AE000718) 2.2 XL-INCENP putative protein (XL-INCENP) [Aquifex aeolicus] mRNA, complete cds 4980 X56536 Rabbit mRNA for 2.3 119110 EBNA-1 4e-018 pH regulatory NUCLEAR protein (Na+/H+ PROTEIN exchanger), herpesvirus 4 partial (strain B95-8) >gi|1334880 V01555) BKRF1 encodes EBNA-1 protein, latent cycle gene. [Human herpesvirus 4] 4981 Z11508 A. thaliana rpl15 5.00E-03 3283910 (AF070638) 2.5 gene for plastid unknown [Homo ribosomal protein sapiens] CL15 4982 X95834 H. sapiens DNA 7e-070 1588365 signal 1e-043 sequence peptidase:SUBUN surrounding NotI IT=12 kD [Homo site, clone sapiens] NRLA143D 4983 U95102 Xenopus laevis 2e-007 4008081 (AF106835) 3e-010 mitotic putative DnaJ phosphoprotein [Methylovorus sp. 90 mRNA, strain SS1] complete cds 4984 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4985 U43626 Human 2e-018 2197085 (AF003535) 0.0002 chromosome ORF2-like protein 15q11-q13 [Homo sapiens] putative DNA replication origin in the g- aminobutyric acid receptor b3 and a5 gene cluster 4986 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4987 D21272 Rice mRNA for 1.1 1708084 EXOGLUCANAS 5.8 ADP-glucose E B PRECURSOR pyrophosphorylas 1,4-beta- e cellobiosidase (EC 3.2.1.91) precursor - Cellulomonas fimi >gi|790698 (L38827) beta-1,4- cellobiohydrolase [Cellulomonas fimi] 4988 U59706 Gallus gallus 0.015 <NONE> <NONE> <NONE> alternatively spliced AMPA glutamate receptor, isoform GluR2 flop, (GluR2) mRNA, partial cds. 4989 AF086033 Homo sapiens e-174 <NONE> <NONE> <NONE> full length insert cDNA clone YW26E09 4990 L31840 Rattus norvegicus e-179 1709212 NUCLEAR PORE 2e-083 nuclear pore COMPLEX complex protein PROTEIN NUP107 mRNA, NUP107 complete cds. 4991 AF052144 Homo sapiens e-170 1174415 SPIDROIN 2 4.8 clone 24573 and (DRAGLINE 24786 mRNA SILK FIBROIN 2) sequences >gi|345426|pir∥A4 4112 spidroin 2, dragline silk fibroin - orb spider (Nephila clavipes) (fragment) [clavipes] 4992 M22406 Human intestinal 0.085 188864 (M74027) mucin 1e-009 mucin mRNA, [Homo sapiens] partial cds, clone SMUC 42. 4993 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 4994 U24697 Chironomus 0.13 3880999 (AL021492) 7e-022 samoensis nanos Y45F10D.11 homolog (Cs nos) [Caenorhabditis gene, complete elegans] cds. 4995 M64716 Human ribosomal 4e-074 2943738 (AB011550) 4e-011 protein S25 Drosophila mRNA, complete Policomblike- cds. related gene containing PHD fingers. [Mus musculus] 4996 X54326 H. sapiens mRNA 0 135104 MULTIFUNCTIO 1e-088 for glutaminyl- NAL tRNA synthetase AMINOACYL- TRNA SYNTHETASE (CONTAINS: GLUTAMYL- TRNA SYNTHETASE glutamyl-prolyl- tRNA synthetase - human >gi|31958 4997 Z12112 pWE15A cosmid 2e-028 987050 (X65335) lacZ 2e-007 vector DNA gene product [unidentified cloning vector] 4998 Z62939 H. sapiens CpG 3e-010 <NONE> <NONE> <NONE> DNA, clone 75f1, forward read cpg75f1.ftlb. 4999 <NONE> <NONE> <NONE> 2134574 mucin - rhesus 5e-005 macaque (fragment) >gi|437055 5000 U95102 Xenopus laevis 9e-009 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5001 Z93950 H. sapiens DNA; 0.15 <NONE> <NONE> <NONE> chromosome Y repeat regions 5002 X64037 H. sapiens mRNA 5e-056 <NONE> <NONE> <NONE> for RNA polymerase II associated protein RAP74 5003 M37583 Human histone e-132 121994 HISTONE H2A.Z 2e-044 (H2A.Z) mRNA, >gi|89608|pir∥S03 complete cds. 642 histone H2A.Z - bovine >gi|92380|pir∥S03 644 histone H2A.Z - rat >gi|106267|pir∥A3 5881 histone H2A.Z - [human sapiens] >gi|57808 (X52316) histone H2A.Z (AA 1- 127) [taurus] >gi|184060 (M37583) histone (H2A.Z) [Homo sapien] 5004 U95102 Xenopus laevis 4e-011 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5005 U95102 Xenopus laevis 4e-011 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5006 M94764 Glycine max cv. 0.043 <NONE> <NONE> <NONE> Dare nodulin 26 gene fragment. 5007 Z34287 B. subtilis 1.2 <NONE> <NONE> <NONE> (SO113) genomic DNA (5425bp) 5008 X76683 Plasmid vector 6e-078 987050 (X65335) lacZ 2e-014 pHM2 gene product betalactamase [unidentified gene cloning vector] 5009 D17577 Mouse mRNA for e-109 2497524 KINESIN-LIKE 9e-041 kinesin-like PROTETN KIF1B protein (Kif1b), mouse complete cds >gi|407339|gnl|PI D|d1005029 (D17577) Kif1b [Mus musculus] 5010 X91192 H. sapiens PLC 1e-096 3294231 (AJ223970) mono- 3 beta 3 gene (exon methyl transferase 1) and SOM172 gene (exon 1) 5011 D88271 Human (lambda) 1e-021 <NONE> <NONE> <NONE> DNA for immunogloblin light chain 5012 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5013 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5014 AF052133 Homo sapiens 0 2072296 (U95098) mitotic 5.9 clone 23970 phosphoprotein 44 mRNA sequence [Xenopus laevis] 5015 M21731 Human e-169 999934 Annexin V 4e-005 lipocortin-V (Lipocortin V, mRNA, complete Endonexin Ii, cds. Placental Anticoagulant Protein) Mutant With Glu 17 Replaced By Gly, Glu 78 Replaced By Gln (E17g, E78q) Complexed With Calcium 5016 M21731 Human e-169 999934 Annexin V 4e-005 lipocortin-V (Lipocortin V, mRNA, complete Endonexin Ii, cds. Placental Anticoagulant Protein) Mutant With Glu 17 Replaced By Gly, Glu 78 Replaced By Gln (E17g, E78q) Complexed With Calcium 5017 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5018 L44118 Homo sapiens 0.0005 <NONE> <NONE> <NONE> proximal CMT1A-REP repeat 5019 Y16849 Bacillus sp. D3 2e-015 <NONE> <NONE> <NONE> xynA and abfA genes and ORF1 5020 U95094 Xenopus laevis 2e-006 465975 PUTATIVE ATP- 9e-005 XL-INCENP DEPENDENT (XL-INCENP) RNA HELICASE mRNA, complete T26G10.1 IN cds CHROMOSOME III >gi|482102|pir∥S4 0731 ATP- dependent RNA helicase homolog T26G10.1 - Caenorhabditis elegans >gi|3880293|gnl|PI D|e1349766 1397- 1495 which introduced stop codon at 3′ splice; 5′ splice looks v. 5021 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 5022 U02455 Cloning vector 0.35 2132302 hypothetical 1e-031 rpDR2, complete protein YPR144c - sequence. yeast similarity near C-terminus to RNA Polymerase beta subunit (Swiss Prot. accession number P11213) and CCAAT-binding transcription factor (PIR accession number A36368) [Saccharomyces cerevisiae] 5023 X97999 H. sapiens mRNA 0 3024690 TRANSCRIPTIO 4e-083 for transcription N INITIATION factor IID, FACTOR TFIID subunit TAFII55 55 KD SUBUNIT (TAFII-55) (TAFII55) factor IID [Homo sapiens] 5024 X71642 M. musculus 3e-092 <NONE> <NONE> <NONE> GEG-154 mRNA 5025 X71642 M. musculus 3e-092 <NONE> <NONE> <NONE> GEG-154 mRNA 5026 AB018270 Homo sapiens 4e-061 2072296 (U95098) mitotic 7.6 mRNA for phosphoprotein 44 KIAA0727 [Xenopus laevis] protein, partial cds 5027 D90086 Human pyruvate 4e-011 2143936 probable 7.7 dehydrogenase regulatory protein (EC 1.2.4.1) beta 322 - rat subunit gene, exons 1-10 5028 U95102 Xenopus laevis 0.002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5029 X65319 Cloning vectors 2e-081 987050 (X65335) lacZ 3e-015 pCAT-Enhancer gene product [unidentified cloning vector] 5030 <NONE> <NONE> <NONE> 188864 (M74027) mucin 0.001 [Homo sapiens] 5031 U95094 Xenopus laevis 0.0002 3258141 (AP000007) 138aa 9.6 XL-INCENP long hypothetical (XL-INCENP) protein mRNA, complete [Pyrococcus cds horikoshii] 5032 X98001 H. sapiens mRNA e-129 2506788 GERANYLGERA 3e-026 for NYL geranylgeranyl TRANSFERASE transferase II TYPE II BETA SUBUNIT (RAB GERANYLGERA NYLTRANSFER ASE BETA SUBUNIT) (RAB GERANYL- GERANYLTRAN SFERASE BETA SUBUNIT) transferase II [Homo sapiens] 5033 U72789 Human cosmid 5e-023 <NONE> <NONE> <NONE> U197H5, complete sequence [Homo sapiens] 5034 U72789 Human cosmid 5e-023 <NONE> <NONE> <NONE> U197H5, complete sequence [Homo sapiens] 5035 U19239 Choristoneura 3.8 <NONE> <NONE> <NONE> fumiferana entomopoxvirus spheroidin gene, complete cds, G4R gene, partial cds, and nucleoside triphosphate phosphohydrolase (NPH I) gene, partial cds 5036 U95098 Xenopus laevis 8e-009 2690166 (AE000788) B. 4 mitotic burgdorferi phosphoprotein predicted coding 44 mRNA, partial region BBK23 cds 5037 U66871 Human enhancer 0 2498336 ENHANCER OF 6e-057 of rudimentary RUDIMENTARY homolog mRNA, HOMOLOG complete cds homologous to DROER protein [Homo sapiens] >gi|1519519 sapiens] 5038 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5039 X99728 H. sapiens 3e-092 2829450 NADH- 1e-015 NDUFV3 gene, UBIQUINONE exon 3 OXIDOREDUCTASE 9 KD SUBUNIT PRECURSOR (COMPLEX I- 9 KD) (CI-9 KD) 5040 X78730 M. musculus 2 <NONE> <NONE> <NONE> DNA for the flanking sequences of the hypothalamic GRH first exons 5041 X84373 H. sapiens mRNA e-155 <NONE> <NONE> <NONE> for nuclear factor RIP140 > :: gb|G28540|G285 40 human STS SHGC-31616. 5042 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5043 X82272 Human 8e-081 1196429 (M14123) pol/env 6e-058 endogenous ORF (bases 3878- retrovirus env 8257) first start mRNA codon at 4172; Xxx; putative [Homo sapiens] 5044 AF029982 Mus musculus 0.003 3873550 (AL033534) 0.018 sarco(endo)plasmic serine-rich protein reticulum calcium ATPase (SERCA2) gene, promoter region, exons 1-3, and partial cds 5045 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5046 Y12781 Homo sapiens 1e-084 3021409 (Y12781) 2e-064 mRNA for transducin (beta) transducin (beta) like 1 protein like 1 protein [Homo sapiens] 5047 S63912 D10S102=FBRNP 4e-084 <NONE> <NONE> <NONE> [human, fetal brain, mRNA, 3043 nt] 5048 X91192 H. sapiens PLC 1e-096 3294231 (AJ223970) mono- 3 beta 3 gene (exon methyl transferase 1) and SOM172 gene (exon 1) 5049 X03558 Human mRNA 0 1169475 ELONGATION e-108 for elongation FACTOR 1- factor 1 alpha ALPHA 1 subunit 5050 L31783 Mus musculus 3e-029 1718058 URIDINE 4e-011 uridine kinase KINASE mRNA, partial (URIDINE cds MONOPHOSPHO KINASE) >gi|471981 (L31783) uridine kinase 5051 X75652 A. longa plastid 1.3 <NONE> <NONE> <NONE> genes for tRNAs, ribosomal protein, rRNA and elongation factor 5052 Z93123 M. acuminata 1.1 <NONE> <NONE> <NONE> mRNA; clone pBAN UD75 5053 D16901 Human HepG2 3′ 1.5 <NONE> <NONE> <NONE> region cDNA, clone hmd2h05 5054 U95094 Xenopus laevis 1e-011 2072296 (U95098) mitotic 5.7 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 5055 AF043252 Homo sapiens e-106 3941342 (AF043250) 6e-007 mitochondrial mitochondrial outer membrane outer membrane protein (Tom40) protein [Homo gene, nuclear sapiens] gene encoding >gi|3941347 mitochondrial (AF043253) protein, exons 7, mitochondrial 8 and 9 outer membrane protein [Homo sapiens] >gi|4105703 (AF050154) D19S1177E [Homo sapiens] 5056 X66494 R. norvegicus 1e-012 1545807 (D78572) 3e-007 CHOT1 mRNA membrane glycoprotein [Mus musculus] 5057 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5058 U95094 Xenopus laevis 2e-007 3513368 (AB017202) 3e-005 XL-INCENP entactin-2 [Mus (XL-INCENP) musculus] mRNA, complete cds 5059 U77107 Fundulus 0.37 3947877 (AL034382) 7e-026 lineolatus putative mitosis cytochrome b and maintenance (cytb) gene, of ploidy protein mitochondrial [Schizosaccharomyces gene encoding pombe] mitochondrial protein, partial cds 5060 X52317 Human mRNA 5e-014 <NONE> <NONE> <NONE> for histone H2A.Z 5061 U95102 Xenopus laevis 3e-008 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5062 U95094 Xenopus laevis 1.2 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 5063 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5064 U95102 Xenopus laevis 1e-011 2072296 (U95098) mitotic 1.5 mitotic phosphoprotein 44 phosphoprotein [Xenopus laevis] 90 mRNA, complete cds 5065 U95102 Xenopus laevis 0.0002 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5066 X15943 Human 1e-012 1575563 (U66464) 5.6 calcitonin/alpha- hematopoietic CGRP gene progenitor kinase [Homo sapiens] 5067 AF001175 Homo sapiens 0 4100563 (AF001175) 2e-032 ribonuclease P ribonuclease P protein subunit protein subunit p14 (Rpp14) p14 [Homo mRNA, complete sapiens] cds 5068 L29260 Arabidopsis 0.41 <NONE> <NONE> <NONE> thaliana 1-amino- 1- cyclopropanecarboxylate synthase (ACS5) gene, complete cds. 5069 X57268 Mouse DNA for 1.2 <NONE> <NONE> <NONE> t-haplotype- specific elements (located in H-2 complex, ETn related) 5070 U95094 Xenopus laevis 1e-010 2072296 (U95098) mitotic 5.5 XL-INCENP phosphoprotein 44 (XL-INCENP) [Xenopus laevis] mRNA, complete cds 5071 Y11896 M. musculus 3e-018 2196874 (Y11896) BRX 3e-011 mRNA for Brx protein [Mus gene, partial musculus] 5072 Y00711 Human mRNA 0 126041 L-LACTATE e-102 for lactate DEHYDROGENASE dehydrogenase B H CHAIN (LDH-B) dehydrogenase B (AA 1 - 334) [Homo sapiens] >gi|1200083 5073 AF065482 Homo sapiens 0 3152938 (AF065482) 3e-072 sorting nexin 2 sorting nexin 2 (SNX2) mRNA, [Homo sapiens] complete cds 5074 M86374 Rat tropoelastin 0.13 <NONE> <NONE> <NONE> gene, intron 25 (partial). 5075 D50418 Mouse mRNA for 6e-047 2495271 SKELETAL 2e-006 AREC3, partial MUSCLE- cds SPECIFIC ARE BINDING PROTEIN AREC3 (HOMEOBOX PROTEIN SIX4) M18) - mouse >gi|1255626|gnl|PI D|d1009550 (D50416) AREC3 5076 D17448 Microcystis 0.13 <NONE> <NONE> <NONE> aeruginosa plasmid pMA2 DNA, complete genome sequence 5077 M29548 Human e-166 1169475 ELONGATION 6e-010 elongation factor FACTOR 1- 1-alpha (EF1A) ALPHA 1 mRNA, partial cds. 5078 AF081496 Homo sapiens 6e-044 2921873 (AF047472) 3e-006 kinetochore spleen mitotic protein BUB3 checkpoint BUB3 (BUB3) mRNA, [Homo sapiens] complete cds protein BUB3 [Homo sapiens] 5079 U95094 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 5080 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5081 M14123 Human 2e-065 1196429 (M14123) pol/env 6e-037 endogenous ORF (bases 3878- retrovirus HERV- 8257) first start K10. codon at 4172; Xxx; putative [Homo sapiens] 5082 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5083 D30655 Homo sapiens 0 673433 (X56953) protein 2e-092 mRNA for synthesis initiation eukaryotic factor 4A [Mus initiation factor musculus] 4AII, complete cds 5084 X16869 Human mRNA 5e-045 3122072 ELONGATION 1e-009 for elongation FACTOR 1- factor 1-alpha ALPHA 1 chicken (clone CEF4) >gi|488468 (L00677) elongation factor 1 alpha 5085 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5086 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5087 U78310 Homo sapiens e-122 2194203 (U78310) 9e-009 pescadillo pescadillo [Homo mRNA, complete sapiens] cds 5088 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5089 U95094 Xenopus laevis 2e-005 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 5090 U09368 Human zinc 0 1731416 ZINC FINGER 2e-062 finger protein PROTEIN 140 ZNF140 human >gi|487787 (U09368) zinc finger protein ZNF140 5091 M98509 Human NFB 1e-010 <NONE> <NONE> <NONE> genomic fragment. 5092 AB002322 Human mRNA e-130 2996650 (AC004493) 9e-018 for KIAA0324 KIAA0324 [Homo gene, partial cds sapiens] 5093 AJ007670 Homo sapiens 2e-014 403460 (L24521) 3.8 mRNA for transformation- LGMD2B protein related protein [Homo sapiens] 5094 X16869 Human mRNA 0 181967 (M29548) 2e-036 for elongation elongation factor factor 1-alpha 1-alpha [Homo (clone CEF4) sapiens] 5095 U95094 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 5096 U95102 Xenopus laevis 0.0005 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5097 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 5098 U95094 Xenopus laevis 2e-006 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 5099 U45421 Borrelia 0.014 3510605 (AF044267) 3.4 burgdorferi 2.9-1 gyrase subunit B locus, ORF 5-8, [Chlamydia ORF-A-D, REP+, trachomatis]. REP−, and lipoprotein (LP) genes, complete cds 5100 L54057 Homo sapiens 0 <NONE> <NONE> <NONE> CLP mRNA, partial cds. 5101 D14660 Human mRNA 0 1350786 PUTATIVE 60S e-111 for KIAA0104 RIBOSOMAL gene, complete PROTEIN cds sapiens] >gi|3947438 (AC005034) ribosomal protein- like 5102 X78627 H. sapiens mRNA 0 1082873 translin - human 5e-068 for translin. >gi|607130 (X78627) translin [Homo sapiens] >gi|1586346|prf||2 203413A recombination hotspot-binding protein [Homo sapiens] 5103 U95102 Xenopus laevis 0.0001 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5104 M12585 Mouse alpha-1 2e-006 3873550 (AL033534) 1.7 antitrypsin gene, serine-rich protein segment 1. 5105 X52967 Human mRNA 0 423072 ribosomal protein 7e-061 for ribosomal L7 - human protein L7 5106 U95094 Xenopus laevis 7e-007 <NONE> <NONE> <NONE> XL-INCENP (XL-INCENP) mRNA, complete cds 5107 X78722 M. musculus 0.34 1685115 (U68754) putative 3.8 GLUT2 gene for transcription glucose factor transporter [Dictyostelium discoideum] 5108 AF002677 Dictyostelium 0.28 3293508 (AF069188) 0.81 discoideum NADH DEAD-box RNA dehydrogenase 1 helicase [Ephedrus laevicollis] 5109 AB018263 Homo sapiens 0.87 107240 oncogene 1 (tre-2 0.19 mRNA for locus) (clone 210) KIAA0720 - human protein, partial cds 5110 AF017115 Homo sapiens 0.77 <NONE> <NONE> <NONE> cytochrome c oxidase subunit IV precursor (COX4) gene, nuclear gene encoding mitochondrial protein, complete cds 5111 AE001383 Plasmodium 0.15 2315754 (AF016681) No 9.6 falciparum definition line chromosome 2, found section 20 of 73 [Caenorhabditis of the complete elegans] sequence 5112 D49577 Pig mRNA for 0.91 <NONE> <NONE> <NONE> rearranged T-cell receptor delta- chain/Vdelta1.14- Ddeltas-Jdelta1, partial cds 5113 U63810 Homo sapiens 0.0 3219331 (AC004020) 3e-92 WD40 protein Unknown gene Ciao 1 mRNA, product [Homo complete cds sapiens] 5114 AF085858 Homo sapiens e-172 3329465 (AF064553) 8e-54 full length insert NSD1 protein cDNA clone [Mus musculus] YN49B07 5115 X01682 Mouse gene for 0.026 1381394 (U40989) tat 4.0 cytochrome P3- interactive protein 450 [Homo sapiens] 5116 AE001432 Plasmodium 1.5 3873713 (Z74026) cDNA 9e-11 falciparum EST yk452h4.3 chromosome 2, comes from this section 69 of 73 gene; cDNA EST of the complete yk452h4.5 comes sequence from this gene 5117 U31973 Human 2.3 136976 PROTEIN UL87 8.1 phosphodiesterase >gi|76594|pir||S09 A′ subunit 851 hypothetical (PDE6C) mRNA, protein UL87 - complete cds. > :: human gb|G28549|G285 cytomegalovirus 49 human STS cytomegalovirus] SHGC-31657. 5118 X02212 Chicken alpha- 2.6 <NONE> <NONE> <NONE> cardiac actin gene 5119 AE000838 Methanobacterium 0.89 765086 (D30786) feline 1.4 thermoautotrophicum CD9 [Felis catus] from bases 494834 to 505698 (section 44 of 148) of the complete genome 5120 U89744 Rattus norvegicus 0.68 728850 GLUCOAMYLASE 9e-06 putative cell S1/S2 surface antigen PRECURSOR mRNA, complete (GLUCAN 1,4- cds ALPHA- GLUCOSIDASE) (1,4-ALPHA-D- GLUCAN GLUCOHYDROLASE) >gi|626156|pir||S4 8478 glucan 1,4- alpha-glucosidase (EC 3.2.1.3) - yeast sta1, len: 1367, CAI: 0.3, AMYH_YEAST P08640 GLUCOAMYLASE S1 (EC 3.2.1.3) [Saccharomyc 5121 J04974 Human alpha-2 1.2 114887 BREAKPOINT 9.4 type XI collagen CLUSTER mRNA REGION (COL11A2). PROTEIN protein, splice form 1 - human >gi|29421 (X02596) bcr gene product [Homo sapiens] 5122 AL021806 Homo sapiens 0.046 2827756 EPHRIN TYPE-A 1.9 DNA sequence RECEPTOR 1 from PAC PRECURSOR 779B17 on chromosome 22q13.1. Contains exon trap, complete sequence 5123 X68826 P. sativum mRNA 0.95 1314248 (U24681) 2e-05 for fructose 1,6 NADH:cytochrome biphosphatase c reductase [synthetic construct] 5124 M14431 Bacteriophage 0.035 <NONE> <NONE> <NONE> phi-29 gene-16 gene, complete cds. 5125 U17033 Human 180 kDa 0.36 722372 (U23139) similar 3e-08 transmembrane to beta transducin PLA2 receptor proteins mRNA, complete containing TRP- cds. ASP domains [Caenorhabditis elegans] 5126 Z50202 P. vulgaris arc5-1 0.007 1151256 (U43319) 0.13 gene transmembrane receptor [Mus musculus] 5127 AF013711 Homo sapiens 22 2e-10 <NONE> <NONE> <NONE> kDa actin-binding protein 5128 AF086324 Homo sapiens 5e-09 3318653 (U83192) post- 0.001 full length insert synaptic density cDNA clone protein 95 [Homo ZD53E07 sapiens] 5129 D90117 T. thermophila 0.63 <NONE> <NONE> <NONE> mRNA for citrate synthase (EC 4.1.3.7) 5130 D45105 Metschnikowia 0.78 <NONE> <NONE> <NONE> reukaufii 26S rRNA, partial sequence 5131 D85088 Ectoplana limuli 0.41 267408 PROBABLE 7.2 DNA for 18s DNA ribosomal RNA PACKAGING PROTEIN packaging protein [Human herpesvirus 4] 5132 X89886 P. patens mRNA 0.41 3875246 (Z81490) similar 2e-22 for 5- to WD domain, G- aminolevulinate beta repeats (2 dehydratase domains); cDNA EST EMBL:T00482 comes from this gene; cDNA EST EMBL:T00923 comes from this gene; cDNA EST yk449d4.3 comes from this gene; cDNA EST yk449d4.5 comes from this gen . . . 5133 AB014564 Homo sapiens 0.0 2981221 (AF053091) 0.076 mRNA for eyelid [Drosophila KIAA0664 melanogaster] protein, partial cds 5134 AE001403 Plasmodium 0.003 2495297 HYPOTHETICAL 3.7 falciparum 26.3 KD chromosome 2, HOMEOBOX section 40 of 73 PROTEIN of the complete C02F12.5 IN sequence CHROMOSOME X >gi|1109893 (U41545) strong similarity to homeobox proteins; similar to inhibitor domain of tissue factor pathway inhibitor 5135 U92574 Fugu rubripes 0.54 <NONE> <NONE> <NONE> homeobox protein HOXB-1 (FrHOXB-1) gene, complete cds 5136 U31118 Xenopus laevis 0.26 3879530 (Z49130) cDNA 8e-07 cytoplasmic EST yk486b9.3 myosin II comes from this regulatory light gene; cDNA EST chain mRNA, yk486b9.5 comes complete cds from this gene 5137 L49035 Gorilla gorilla 0.21 4007066 (AJ131571) X 1.3 ABC-transporter protein [Hepatitis (TAP2) mRNA, B virus] complete cds 5138 AF068628 Mus musculus 4e-04 <NONE> <NONE> <NONE> DNA cytosine-5 methyltransferase 3B3 (Dnmt3b) mRNA, alternatively spliced, complete cds 5139 M64982 Human 0.062 <NONE> <NONE> <NONE> fibrinogen alpha chain gene, complete mRNAs. 5140 M19262 Rat clathrin light 0.25 2088802 (AF003151) 0.012 chain (LCB3) D1007.4 gene mRNA, complete product cds. [Caenorhabditis elegans] 5141 X94947 L. esculentum 3.7 2315770 (AF016683) 0.096 mRNA for K09F6.1 gene homeobox product protein [Caenorhabditis elegans] 5142 <NONE> <NONE> <NONE> <NONE> <NONE> <NONE> 5143 M33782 Human TFEB 0.36 <NONE> <NONE> <NONE> protein mRNA, partial cds. 5144 AB011098 Homo sapiens 2e-07 2501115 TBX2 PROTEIN 0.90 mRNA for (T-BOX KIAA0526 PROTEIN 2) protein, complete cds 5145 AF039029 Homo sapiens 0.0 3834390 (AF039029) e-108 snurportin1 snurportin1 mRNA, complete [Homo sapiens] cds 5146 U22970 Human 0.21 <NONE> <NONE> <NONE> interferon- inducible peptide (6-16) gene, complete cds 5147 D63880 Human mRNA 2e-64 <NONE> <NONE> <NONE> for KIAA0159 gene, complete cds 5148 AB011174 Homo sapiens e-164 3043728 (AB011174) 2e-53 mRNA for KIAA0602 protein KIAA0602 [Homo sapiens] protein, partial cds 5149 AF053551 Homo sapiens 0.0 3283049 (AF053551) 1e-76 metaxin 2 metaxin 2 [Homo (MTX2) mRNA, sapiens] nuclear gene encoding mitochondrial protein, complete cds 5150 Y13382 Arabidopsis 0.012 <NONE> <NONE> <NONE> thaliana ferrochelatase-I gene and promoter sequence 5151 AF044854 Colias eurytheme 1.3 <NONE> <NONE> <NONE> large subunit ribosomal RNA gene, partial sequence; tRNA- Val gene, complete sequence; and small subunit ribosomal RNA gene, partial sequence, mitochondrial genes for mitochondrial RNAs 5152 AF005059 Toxoplasma 0.90 2570049 (Y08701) Pinin 1.3 gondii p97 [Mus musculus] mRNA, complete cds 5153 D84307 Human mRNA 0.013 <NONE> <NONE> <NONE> for phosphoethanolamine cytidylyltransferase, complete cds 5154 D38050 Aspen prxA3a 0.018 1723942 HYPOTHETICAL 0.39 gene for 20.8 KD peroxidase, PROTEIN IN complete cds COX4-GTS1 INTERGENIC REGION >gi|2131614|pir||S 61134 hypothetical protein YGL183c - yeast (Saccharomyces cerevisiae) >gi|1143564|gnl|PI D|e199057 (X91489) putative HMG box [Saccharomyces cerevisiae] 5155 AL010208 Plasmodium 0.13 1850115 (Z86089) fadD2 1.5 falciparum DNA [Mycobacterium *** tuberculosis] SEQUENCING IN PROGRESS *** from contig 3-103, complete sequence 5156 U07807 Human 0.004 <NONE> <NONE> <NONE> metallothionein IV (MTIV) gene, complete cds. 5157 AF048991 Homo sapiens 0.001 3986756 (AF109905) 0.007 MutS homolog 5 NG23 [Mus (MSH5) gene, musculus] exons 13 through 25 and complete cds 5158 U39079 Schizosaccharomyces 0.50 <NONE> <NONE> <NONE> pombe ARS binding protein 1 5159 X01706 Mouse 0.41 2224713 (AB002384) 8e-04 intracisternal A- KIAA0386 [Homo particle (IAP) sapiens] gene 62 long terminal repeat (LTR) 5160 AF030558 Rattus norvegicus 8e-13 <NONE> <NONE> <NONE> phosphatidylinositol 5-phosphate 4- kinase gamma mRNA, complete cds 5161 L06453 Strongylocentrotus 0.33 3914031 BETA- 0.087 purpuratus GALACTOSIDE (clone C) high SPECIFIC mobility group I LECTIN I A protein (HMG1 CHAIN (MLA) homologue) gene, (ML-I A) (RRNA complete cds. N- GLYCOSIDASE) 5162 Z68320 Caenorhabditis 0.28 2500558 PUTATIVE 2e-25 elegans cosmid RIBONUCLEASE W07A12, III (RNASE III) complete >gi|3876420|gnl|PI sequence D|e1346063 [Caenorhabditis (Z81070) similar elegans] to ribonuclease [Caenorhabditis elegans] 5163 U40397 Mus musculus 5e-04 <NONE> <NONE> <NONE> serum amyloid A- 4 protein (Saa4) gene, complete cds 5164 X00367 Chlamydomonas 0.046 <NONE> <NONE> <NONE> chloroplast DNA region with ARS element 03 (ARS = autonomously replicating sequence) 5165 U43838 Glycine max 1.2 132918 50S 2.4 choline kinase RIBOSOMAL GmCK1p mRNA, PROTEIN L35, complete cds CHLOROPLAST PRECURSOR (CL35) >gi|81486|pir||A36 107 ribosomal protein L35 precursor, chloroplast - spinach oleracea] 5166 U67590 Methanococcus 0.097 <NONE> <NONE> <NONE> jannaschii section 132 of 150 of the complete genome 5167 AB006787 Mus musculus 0.39 1263187 (U24215) 0.83 mRNA for HOMODA apoptosis signal- hydrolase regulating kinase [Pseudomonas 1, complete cds putida] putida] 5168 U43567 Trypanosoma 0.054 <NONE> <NONE> <NONE> cruzi kinetoplast maxicircle DNA, clone TRCKPMAX 5169 U04706 Bos taurus 50 0.0 2498104 ADRENAL 8e-83 kDa protein MEDULLA 50 (adp50) mRNA, KD PROTEIN complete cds. 5170 L14684 Rattus norvegicus e-137 585084 ELONGATION 3e-59 nuclear-encoded FACTOR G, mitochondrial MITOCHONDRIAL elongation factor PRECURSOR G mRNA, (MEF-G) complete cds. >gi|543383|pir||S4 0780 translation elongation factor G, mitochondrial - rat >gi|310102 5171 U01120 Human glucose- 2e-04 544361 GLUCOSE-6- 4e-12 6-phosphatase PHOSPHATASE mRNA, complete (G6PASE) cds. > 3.1.3.9) - human >gi|452444 (U01120) glucose- 6-phosphatase [Homo sapiens] 5172 D87671 Rat mRNA for e-144 1799570 (D87671) TIP120 3e-69 TIP120, complete [Rattus cds norvegicus] 5173 U22296 Rattus norvegicus e-120 3024053 CASEIN KINASE 8e-54 casein kinase 1 I, GAMMA 1 gamma 1 isoform ISOFORM kinase mRNA, complete 1 gamma 1 cds isoform [Rattus norvegicus] 5174 Y07648 A. thaliana nit2 0.007 2429486 (AF025464) No 9.5 gene, nit1 gene definition line and nit3 gene found [Caenorhabditis elegans] 5175 AB013721 Oryctolagus 3e-91 3628745 (AB013721) 0.006 cuniculus mRNA mitsugumin 23 for mitsugumin [Oryctolagus 23, complete cds cuniculus] 5176 M74069 Saccharomyces 2.5 <NONE> <NONE> <NONE> cerevisiae endochitinase (CTS1-1) gene, complete cds. 5177 Z61469 H. sapiens CpG 1e-77 1184072 (U40766) COL-1 0.002 DNA, clone [Meloidogyne 52h1, forward incognita] read cpg52h1.ft1a. 5178 AF015043 Homo sapiens 0.0 2492914 APOLIPOPROTEIN 3.0 EH-binding C-IV protein mRNA, PRECURSOR partial cds cluster E-C1-C2 linked gene [Mus musculus] 5179 X74560 H. sapiens (clone 3e-04 3687469 (AL031798) 3e-23 pS2) sequence putative diphthine synthase 5180 X94768 H. sapiens RP3 1e-05 <NONE> <NONE> <NONE> gene (XLRP gene 3) 5181 X80937 M. musculus 0.48 107750 synapsin Ib - 3e-04 mRNA for RIP1 human protein 5182 M12759 Human Ig J chain 0.036 <NONE> <NONE> <NONE> gene, exons 3 and 4. 5183 M30773 Human 0.002 3878494 (Z79602) 3e-06 calcineurin B predicted using mRNA, complete Genefinder; cds Similarity to Yeast hypothetical protein YAE2 gene; cDNA EST EMBL:M88949 comes from this gene 5184 U08831 Human 0.015 <NONE> <NONE> <NONE> immunodeficiency virus type 1, sample 019 from Thailand (E2TH019W.01di 1sCD), envelope glycoprotein c2v3 region (env) gene, partial cds. 5185 Z98303 Human DNA 0.005 <NONE> <NONE> <NONE> sequence from BAC 140H19 on chromosome Xq24-25. Contains STS 5186 AE000952 Archaeoglobus 2e-07 3257245 (AP000003) 571aa 5e-08 fulgidus section long hypothetical 155 of 172 of the oxaloacetate complete genome decarboxylase alpha chain [Pyrococcus horikoshii] 5187 L48476 Homo sapiens 2e-04 3877439 (Z72510) 0.19 (subclone 3_e10 similarity to yeast from P1 H21) UTR3 protein DNA sequence. (Swiss Prot accession number P21374); cDNA EST EMBL:D72822 comes from this gene; cDNA EST EMBL:D75763 comes from this gene; cDNA EST yk274e3.3 comes from this gene; cDNA EST yk274e3 . . . 5188 U95102 Xenopus laevis 3e-09 <NONE> <NONE> <NONE> mitotic phosphoprotein 90 mRNA, complete cds 5189 AF055022 Homo sapiens e-102 2708743 (AC003952) 4.0 clone 24684 putative Tal-1-like mRNA sequence reverse transcriptase 5190 AJ009761 Homo sapiens e-121 4050050 (AF102147) 8e-48 mRNA for putative putative dimethyladenosine dimethyladenosine transferase [Homo transferase, sapiens] partial 5191 Y08238 H. pylori clpB 0.27 1572756 (U70848) - 1e-21 gene C43G2.1 gene product [Caenorhabditis elegans] 5192 <NONE> <NONE> <NONE> 2828280 (AL021687) 9e-36 putative protein [Arabidopsis thaliana] >gi|2832633|gnl|PI D|e1249651 (AL021711) putative protein [Arabidopsis thaliana] 5193 J00747 Rat insulin-1 (ins- 6e-05 4154522 (AE001441) 3.2 1) gene. putative [Helicobacter pylori] 5194 U64454 Human 3′ of 0.83 281204 gene LF3 protein - 0.069 immunoglobulin human herpesvirus heavy chain locus 4 virus] 5195 AB002383 Human mRNA 8e-13 2498318 DXS6673E 2e-24 for KIAA0385 PROTEIN gene, complete retardation cds candidate gene [Homo sapiens] 5196 M81840 Human NRL 0.029 3875740 (Z81497) similar 6e-18 gene product to mannosyl- mRNA, complete oligosaccharide cds. alpha-1,2- mannosidase; cDNA EST EMBL:D67155 comes from this gene; cDNA EST EMBL:D64219 comes from this gene; cDNA EST yk260e12.3 comes from this gene; cDNA EST yk260e12.5 comes f . . . 5197 U12523 Rattus norvegicus 1e-10 3219914 HYPOTHETICAL 2e-11 ultraviolet B 16.8 KD radiation- PROTEIN activated UV98 C30D10.04 IN mRNA, partial CHROMOSOME sequence. II >gi|2276353|gnl|PI D|e330328 pombe] 5198 AB017026 Mus musculus 0.0 3551523 (AB017026) e-120 mRNA for oxysterol-binding oxysterol-binding protein protein, complete cds 5199 U83981 Homo sapiens e-119 3258618 (U83981) 7e-26 apoptosis apoptosis associated protein associated protein (GADD34) [Homo sapiens] mRNA, complete cds 5200 U37580 Streptomyces 0.048 2459916 (AF005859) 0.18 coelicolor anon2D7 phosphotyrosine [Drosophila protein melanogaster] phosphatase (ptpA) gene, putative cystathionine gamma-lyase (cysA) gene, and LysR-like protein gene, complete cds 5201 D00723 Human mRNA 3e-19 <NONE> <NONE> <NONE> for hydrogen carrier protein, a component of an enzyme complex, glycine synthase (EC 2.1.2.10) 5202 X89366 A. thaliana DNA 0.025 1209669 (U38810) CAGR1 0.008 for 40 kDa [Homo sapiens] protein gene >gi|3098420 (AF040945) homeotic regulator homolog MAB21 [Mus musculus] 5203 AF067158 HIV-1 isolate 2.4 <NONE> <NONE> <NONE> 301905 from India, complete genome 5204 U09954 Human ribosomal 5e-37 <NONE> <NONE> <NONE> protein L9 gene, 5′ region and complete cds. 5205 AF029984 Lycopersicon 7e-37 4090943 (AF029984) 2e-49 esculentum COP1 COP1 homolog homolog (COP1) [Lycopersicon mRNA, complete esculentum] cds 5206 U43076 Mus musculus 2e-17 2655422 (AF035530) 2e-22 cdc37 homolog CDC37 [Gallus mRNA, complete gallus] cds 5207 U07745 Lycopersicon 4e-32 533707 (U12536) 3- 4e-49 esculentum methylcrotonyl- biotin-containing CoA carboxylase subunit of precursor methylcrotonyl- CoA carboxylase mRNA, partial cds. 5208 X74465 Human 1.3 3879121 (Z70310) 2e-56 papillomavirus predicted using type 10 genomic Genefinder; DNA Similarity to Mouse ankyrin (PIR Acc. No. S37771); cDNA EST EMBL:T01923 comes from this gene; cDNA EST EMBL:D32335 comes from this gene; cDNA EST EMBL:D32723 comes from this gene; cDNA ES . . . Genefinder; Similarity to M 5209 X99261 A. evecta gene 0.14 2257939 (AF005665) 7.6 encoding blue- properdin [Homo light sapiens] photoreceptor, intron 5210 M35296 Human tyrosine 1.1 1125781 (U42841) short 0.61 kinase arg gene region of weak mRNA. similarity to chicken limb deformity protein (PIR:S24286) [Caenorhabditis elegans] 5211 Z57610 H. sapiens CpG e-102 404764 (L10409) fork 1e-16 DNA, clone head related 187a10, reverse protein [Mus read musculus] cpg187a10.rt1a. 5212 X85753 Homo sapiens 6e-59 1171821 NADH- 9.5 mRNA for CDK8 UBIQUINONE protein kinase > :: OXIDOREDUCTASE emb|A61243|A61 CHAIN 5 243 Sequence 1 >gi|559499|gnl|PI from Patent D|e1192548 WO9709432 (X54253) ND5 protein 5213 U27341 Bos taurus 7e-61 2136744 endothelin 3e-29 endothelin converting converting enzyme-2 - bovine enzyme-2 Sequence 1 from U.S. Pat. No. 5736376 5214 U63648 Mus musculus 4e-58 2645205 (U63648) p160 2e-34 p160 myb- myb-binding binding protein protein [Mus (P160) mRNA, musculus] complete cds 5215 AF035940 Homo sapiens e-140 2306969 (AF007860) xl- 3e-76 MAGOH mRNA, Mago [Xenopus complete cds laevis] 5216 X80045 O. aries mRNA 2e-54 542750 acetyl-CoA 8e-10 for acetyl-CoA carboxylase (EC carboxylase 6.4.1.2) - human sapiens] >gi|740964|prf||20 06242A Ac-CoA carboxylase 5217 Z46372 R. norvegicus e-134 3876360 (Z68315) 3e-12 RNA for DNA Similarity to topoisomerase II. Human MAP kinase phosphatase-1 (SW:PTN7_HUMAN) [Caenorhabditis elegans] 5218 AF035940 Homo sapiens e-143 2330011 (AF007862) mm- 7e-81 MAGOH mRNA, Mago [Mus complete cds musculus] >gi|2909828 (AF035939) similar to mago nashi [Mus musculus] >gi|2909830 5219 Z72521 Human DNA 6e-04 <NONE> <NONE> <NONE> sequence from cosmid N29F4 on chromosome 22q11.2-qter contains STS 5220 S74340 {clone E572, 4e-29 <NONE> <NONE> <NONE> estrogen induced gene} [rats, Sprague-Dawley, hypothalamus, mRNA Partial, 130 nt] 5221 AL008711 Human DNA 0.33 1184707 (U40868) 7.9 sequence from folylpolyglutamate PAC 390N22 on synthetase [Homo chromosome sapiens] Xp22.2 5222 AE000012 Mycoplasma 0.15 <NONE> <NONE> <NONE> pneumoniae section 12 of 63 of the complete genome 5223 D78333 Human mRNA e-113 2501141 T-COMPLEX 2e-42 for testis-specific PROTEIN 1, TCP20, complete ZETA-LIKE cds SUBUNIT (TCP- 1-ZETA-LIKE) (CCT-ZETA- LIKE) TCP20 [Homo sapiens] 5224 AF042333 Oryza sativa 24- 0.003 3883124 (AF082300) 0.006 methylene arabinogalactan- lophenol protein C24(1)methyltransferase [Arabidopsis mRNA, thaliana] complete cds 5225 U15426 Human 4e-06 1123105 (U42438) similar 0.34 anonymous to S. cerevisiae mRNA sequence longevity- with CCA repeat assurance protein region. 1 (SP:P38703) [Caenorhabditis elegans] 5226 AF052497 Homo sapiens 0.003 1144514 (U34781) Antho- 4.3 clone B18 LWamidII unknown mRNA preprohormone [Anthopleura elegantissima] >gi|1586846|prf||2 204411A prepro- hormone 5227 D86590 Zinnia elegans 0.13 <NONE> <NONE> <NONE> mRNA for cinnamyl alcohol dehydrogenase, partial cds 5228 AF081144 Rattus norvegicus 5e-14 1718004 TEGUMENT 1.4 CL1AA mRNA, PROTEIN UL49 complete cds HOMOLOG herpesvirus 1] >gi|995634 (Z54206) UL49 [Bovine herpesvirus 1] >gi|2653299|gnl|PI D|e1187295 (AJ004801) virion protein (tegument) [Bovine herpesvirus type 1.1] 5229 M63016 Human X 6e-04 <NONE> <NONE> <NONE> chromosome enhancer-like sequence. 5230 L24755 Mus musculus 1.2 <NONE> <NONE> <NONE> bone morphogenetic protein (Bmp-1) mRNA, complete cds. 5231 <NONE> <NONE> <NONE> 2828280 (AL021687) 9e-36 putative protein [Arabidopsis thaliana] >gi|2832633|gnl|PI D|e1249651 (AL021711) putative protein [Arabidopsis thaliana] 5232 U27341 Bos taurus 1e-22 2136744 endothelin 2e-09 endothelin converting converting enzyme-2 - bovine enzyme-2 Sequence 1 from U.S. Pat. No. 5736376 5233 M81840 Human NRL 0.030 3875740 (Z81497) similar 6e-18 gene product to mannosyl- mRNA, complete oligosaccharide cds. alpha-1,2- mannosidase; cDNA EST EMBL:D67155 comes from this gene; cDNA EST EMBL:D64219 comes from this gene; cDNA EST yk260e12.3 comes from this gene; cDNA EST yk260e12.5 comes f . . . 5234 AJ000097 Homo sapiens 2.7 3395586 (AL031179) 6e-38 mRNA for similarity to EYA1B gene phosphomannomutases [Schizosaccharomyces pombe] 5235 U30788 Rattus norvegicus 1e-68 3523162 (AF076292) TGF- 1.4 Tclone4 mRNA beta/activin signal transducer FAST- 1p 5236 U88964 Human HEM45 0.0 2062680 (U88964) HEM45 7e-77 mRNA, complete [Homo sapiens] cds 5237 AF061016 Homo sapiens 0.0 3127127 (AF061016) UDP- 5e-90 UDP-glucose glucose dehydrogenase dehydrogenase (UGDH) mRNA, [Homo sapiens] complete cds dehydrogenase [Homo sapiens] 5238 D43921 Mouse AZ1 3e-15 2137118 acrosomal protein 0.007 mRNA for pre- AZ1 - mouse acrosome localization localization protein [Mus protein, complete musculus] cds 5239 AF056022 Homo sapiens 0.0 3283072 (AF056022) p60 2e-60 p60 katanin katanin [Homo mRNA, complete sapiens] cds 5240 U77949 Human Cdc6- 1e-83 <NONE> <NONE> <NONE> related protein (HsCDC6) mRNA, complete cds 5241 AJ005016 Homo sapiens 0.0 3005931 (AJ005016) ABC 3e-70 mRNA for transporter [Homo putative ABC sapiens] transporter, partial 5242 X56756 Sheep mRNA for 4.5 <NONE> <NONE> <NONE> tumor necrosis factor alpha 5243 AF020833 Homo sapiens 0.0 2460200 (AF020833) e-158 eukaryotic eukaryotic translation translation initiation factor 3 initiation factor 3 subunit (p42) subunit [Homo mRNA, complete sapiens] cds 5244 X69878 H. sapiens Flt4 4e-43 <NONE> <NONE> <NONE> mRNA for transmembrane tyrosine kinase 5245 M27826 Human 1e-66 <NONE> <NONE> <NONE> endogenous retroviral protease mRNA, complete cds. 5246 U20285 Human Gps1 2e-54 644879 (U20285) Gps1 8e-20 (GSP1) mRNA, [Homo sapiens] complete cds 5247 AF049528 Homo sapiens 5e-75 3341990 (AF049528) 2e-20 huntingtin- huntingtin- interacting interacting protein protein HYPA/FBP11 HYPA/FBP11 (HYPA) mRNA, partial cds 5248 U87277 Human splicing 0.14 267449 HYPOTHETICAL 1e-08 factor SRp30c 12.5 KD gene, exon 1 PROTEIN ZK637.2 IN CHROMOSOME III >gi|102507|pir||S1 5787 hypothetical protein 1 (cosmid ZK637) - Caenorhabditis elegans Genefinder; cDNA EST yk217b5.3 comes from this gene; cDNA EST yk217b5.5 comes from this gene; cDNA EST yk340g12.3 5249 D16919 Human HepG2 3′ e-164 3152559 (AC002986) 2e-52 region cDNA, Similarity to A. clone hmd3e06 thaliana gene product F21M12.20, gb|AC000132. EST gb|Z25651 comes from this gene. [Arabidopsis thaliana] 5250 AJ006064 Rattus norvegicus e-142 3757680 (AJ006064) 5e-73 mRNA for coronin-like coronin-like protein [Rattus protein norvegicus] 5251 AB011000 Mus musculus 1e-18 2780752 (AB006607) 0.001 mRNA for choline/ethanolamine choline/ethanolamine kinase kinase, complete cds 5252 X80169 M. musculus 0.0 1717793 PROTEIN TSG24 e-150 mRNA for 200 (MEIOTIC kD protein CHECK POINT REGULATOR) >gi|1083553|pir||A 55117 tsg24 protein - mouse

TABLE 3 Polynucleotides encoding gene products of a protein family or having a known functional domain(s). Biological SEQ ID Activity NO: Validation Sequence (Profile) Start Stop Score Direction 3920 393.E10.sp6:148957 7tm_1 531 710 9520 for 2667 172.F10.sp6:133946 7tm_2 45 724 8708 rev 2758 177.C6.sp6:134733 7tm_2 41 697 9828 rev 2933 184.C7.sp6:135556 7tm_2 3 834 8987 for 3129 121.E12.sp6:131940 7tm_2 245 1324 9550 rev 3365 172.A7.sp6:133883 7tm_2 94 761 8743 rev 3418 123.F9.sp6:132333 7tm_2 203 585 8785 rev 3419 123.F9.sp6:132333 7tm_2 203 585 8785 rev 3597 394.G2.sp6:149165 7tm_2 73 793 9209 for 3648 370.C5.sp6:141726 7tm_2 76 770 9269 for 3686 370.B1.sp6:141710 7tm_2 89 662 8791 for 3695 368.A12.sp6:141322 7tm_2 121 719 9015 rev 3696 368.A12.sp6:141322 7tm_2 121 719 9015 rev 4172 219.C10.sp6:139007 7tm_2 46 774 11394 rev 4216 368.D11.sp6:141357 7tm_2 66 775 9384 rev 4228 368.A11.sp6:141321 7tm_2 7 1079 9097 for 4441 99.F7.sp6:131296 7tm_2 534 1265 10956 rev 4442 99.F7.sp6:131296 7tm_2 534 1265 10956 rev 4482 100.D2.sp6:131459 7tm_2 122 1404 9296 rev 4495 395.B12.sp6:149307 7tm_2 79 1432 10427 rev 4525 90.B4.sp6:130874 7tm_2 4 691 9435 for 4616 100.D5.sp6:131462 7tm_2 655 1349 9255 for 4653 100.D7.sp6:131464 7tm_2 357 1346 11461 rev 4654 100.D7.sp6:131464 7tm_2 357 1346 11461 rev 4658 100.H6.sp6:131511 7tm_2 119 1035 10001 rev 4659 100.G6.sp6:131499 7tm_2 363 1188 9901 rev 4660 100.F6.sp6:131487 7tm_2 50 1127 8799 for 4661 100.F6.sp6:131487 7tm_2 50 1127 8799 for 4710 367.H9.sp6:141210 7tm_2 143 1266 11883 rev 4755 370.F4.sp6:141761 7tm_2 78 704 8942 for 4856 367.H11.sp6:141212 7tm_2 176 1227 9975 rev 4885 123.E10.sp6:132322 7tm_2 210 691 9071 rev 4900 123.E10.sp6:132322 7tm_2 210 691 9071 rev 4901 123.E10.sp6:132322 7tm_2 210 691 9071 rev 2656 176.H11.sp6:134606 ANK 207 290 4450 for 2555 180.C9.sp6:135947 asp 156 670 6710 for 3632 368.H11.sp6:141405 asp 136 1226 6880 rev 4205 368.B5.sp6:141327 asp 309 806 6073 for 4251 369.D6.sp6:141546 asp 434 1332 6263 rev 4253 396.F9.sp6:149544 asp 97 1106 5999 rev 4261 216.G10.sp6:139247 asp 74 703 6188 rev 4365 122.H12.sp6:132168 asp 152 1040 6183 rev 4498 80.H6.sp6:130297 asp 61 418 5944 rev 4664 172.E5.sp6:133929 asp 219 976 6434 for 4718 185.D9.sp6:135762 asp 31 872 5944 rev 4733 185.D9.sp6:135762 asp 31 872 5944 rev 4746 176.B10.sp6:134533 asp 253 1446 6079 rev 4822 177.F3.sp6:134766 asp 0 894 6336 rev 4854 184.F11.sp6:135596 asp 61 737 6416 rev 4856 367.H11.sp6:141212 asp 81 1187 6182 rev 4929 180.E6.sp6:135968 asp 81 706 6150 for 4931 180.E6.sp6:135968 asp 81 706 6150 for 2723 180.F2.sp6:135976 ATPases 135 627 11664 for 2842 217.H11.sp6:139452 ATPases 2 701 5972 for 3019 216.B1.sp6:139178 ATPases 170 616 6150 for 3046 121.B8.sp6:131900 ATPases 13 635 5867 rev 3190 80.D2.sp6:130245 ATPases 13 386 6068 for 3290 176.C6.sp6:134541 ATPases 85 579 5883 for 3670 369.C10.sp6:141538 ATPases 329 730 6206 for 3998 394.H8.sp6:149183 ATPases 21 571 5954 rev 4119 218.F11.sp6:138852 ATPases 313 816 6057 for 4159 219.A7.sp6:138980 ATPases 88 662 6145 for 4223 368.F9.sp6:141379 ATPases 178 648 5937 for 4384 181.G11.sp6:135354 ATPases 362 769 5900 rev 4473 369.B4.sp6:141520 ATPases 4 412 14130 for 4540 218.C8.sp6:138813 ATPases 12 576 5782 rev 4560 404.G6.sp6:162933 ATPases 86 605 6001 rev 4689 367.H8.sp6:141209 ATPases 17 476 5905 rev 4785 184.E5.sp6:135578 ATPases 184 632 5943 for 4792 184.C6.sp6:135555 ATPases 333 813 5773 for 4847 184.B11.sp6:135548 ATPases 14 498 6140 for 5041 377.C1.sp6:141918 ATPases 4 655 5933 for 3404 176.F10.sp6:134581 Bcl-2 69 356 16419 for 4036 367.F5.sp6:141182 bromodomain 40 210 8810 for 4489 369.D3.sp6:141543 bromodomain 63 230 10270 for 3408 172.E1.sp6:133925 BZIP 146 298 4066 for 3951 393.G5.sp6:148976 BZIP 116 304 5931 for 4850 172.E9.sp6:133933 BZIP 91 260 4366 for 3618 370.B12.sp6:141721 cyclin 118 324 8980 for 3895 395.G6.sp6:149361 cyclin 11 281 6930 for 4536 395.G8.sp6:149363 cyclin 12 279 5950 for 4455 99.F5.sp6:131294 Cys-protease 72 348 18479 for 4684 180.D1.sp6:135951 Cys-protease 38 992 10103 rev 4688 180.D1.sp6:135951 Cys-protease 38 992 10103 rev 4801 177.E4.sp6:134755 Cys-protease 48 326 19999 for 4659 100.G6.sp6:131499 DAG_PE_bind 605 702 6290 rev 4821 377.C8.sp6:141925 Dead_box_helic 172 828 7867 rev 5083 216.A1.sp6:139166 Dead_box_helic 44 589 26532 for 2734 177.G4.sp6:134779 EFhand 79 153 3780 for 2893 185.A1.sp6:135718 EFhand 287 358 2580 rev 3775 377.A5.sp6:141898 EFhand 477 563 3010 for 4056 367.B7.sp6:141136 EFhand 225 272 2500 rev 4152 218.B10.sp6:138803 EFhand 40 114 2640 rev 4153 218.B10.sp6:130003 EFhand 40 114 2640 rev 4154 218.C10.sp6:138815 EFhand 39 113 2640 rev 4905 393.H12.sp6:148995 EFhand 145 231 4640 for 4943 219.A9.sp6:138982 EFhand 685 750 2550 rev 2849 218.B5.sp6:138798 Ets_Nterm 340 531 10400 for 2728 180.A2.sp6:135916 FNtypeII 291 423 6400 rev 3018 216.C1.sp6:139190 FNtypeII 501 634 6460 for 4496 218.G1.sp6:138854 FNtypeII 20 141 6180 rev 4914 393.H8.sp6:148991 FNtypeII 448 576 6110 for 2504 181.C3.sp6:135298 G-alpha 66 715 8084 rev 3290 176.C6.sp6:134541 G-alpha 62 690 9062 for 4288 121.B4.sp6:131896 G-alpha 46 447 21415 for 4444 217.D12.sp6:139405 G-alpha 15 702 40404 for 4562 404.B7.sp6:162874 G-alpha 120 682 8424 for 2503 180.A11.sp6:135925 helicase_C 165 479 4494 for 4469 369.C4.sp6:141532 helicase_C 559 756 3732 rev 5020 185.D12.sp6:135765 helicase_C 381 534 5000 for 4241 396.H8.sp6:149567 homeobox 80 230 5170 for 2550 180.E5.sp6:135967 mkk 342 612 5791 for 3407 172.F1.sp6:133937 mkk 94 669 5688 rev 3451 123.A2.sp6:132266 mkk 26 378 7889 for 3600 394.B3.sp6:149106 mkk 32 782 9544 for 3646 370.H4.sp6:141785 mkk 18 307 9394 for 3680 369.G11.sp6:141587 mkk 182 725 5375 for 4175 219.H10.sp6:139067 mkk 280 723 15454 for 4205 368.B5.sp6:141327 mkk 249 725 5502 for 4278 181.C9.sp6:135304 mkk 168 880 5551 rev 4322 121.F6.sp6:131946 mkk 111 730 5399 for 4777 177.E2.sp6:134753 mkk 288 636 5720 rev 4482 100.D2.sp6:131459 PDEase 849 1195 5945 for 2578 181.H11.sp6:135366 protkinase 116 710 5531 for 2712 177.G7.sp6:134782 protkinase 6 511 5445 for 2835 218.C1.sp6:138806 protkinase 127 747 5492 for 2843 218.E1.sp6:138830 protkinase 64 726 5592 rev 2971 217.F4.sp6:139421 protkinase 83 702 5818 rev 3009 217.A4.sp6:139361 protkinase 57 682 5395 rev 3084 121.E2.sp6:131930 protkinase 69 658 5593 rev 3226 100.D8.sp6:131465 protkinase 174 620 5453 for 3274 100.C3.sp6:131448 protkinase 228 736 5616 for 3356 172.B5.sp6:133893 protkinase 148 715 5381 for 3377 172.B6.sp6:133894 protkinase 119 775 5616 for 3451 123.A2.sp6:132266 protkinase 24 384 9797 for 3600 394.B3.sp6:149106 protkinase 357 780 11395 for 3635 377.G11.sp6:141976 protkinase 117 739 5992 for 3646 370.H4.sp6:141785 protkinase 24 275 8338 for 3665 370.F2.sp6:141759 protkinase 33 800 5658 for 3669 369.B10.sp6:141526 protkinase 1 482 5504 rev 3700 369.D2.sp6:141542 protkinase 28 661 5428 for 3710 369.G6.sp6:141582 protkinase 71 631 5751 for 3791 396.C11.sp6:149510 protkinase 27 709 5793 rev 3905 393.H7.sp6:148990 protkinase 88 680 5470 rev 3919 393.D10.sp6:148945 protkinase 72 594 5617 for 4044 367.G4.sp6:141193 protkinase 30 699 5439 for 4072 368.B2.sp6:141324 protkinase 44 800 5556 for 4117 218.D11.sp6:138828 protkinase 38 781 6423 for 4175 219.H10.sp6:139067 protkinase 277 717 15720 for 4373 216.E5.sp6:139218 protkinase 115 710 5537 for 4569 100.C10.sp6:131455 protkinase 56 783 5556 rev 4755 370.F4.sp6:141761 protkinase 39 803 5635 for 4760 370.F3.sp6:141760 protkinase 188 775 5771 for 4807 184.H3.sp6:135612 protkinase 23 699 5515 for 5059 180.B5.sp6:135931 protkinase 182 671 5718 rev 5102 393.F4.sp6:148963 protkinase 28 650 5345 for 3671 369.D10.sp6:141550 ras 12 332 9802 for 3936 393.A3.sp6:148902 Thioredox 0 263 5887 rev 3927 393.F11.sp6:148970 TNFR_c6 151 261 6445 for 2956 184.E10.sp6:135583 transmembrane4 19 483 8339 rev 2981 217.E6.sp6:139411 transmembrane4 83 728 8417 for 3836 396.C9.sp6:149508 transmembrane4 300 924 9444 rev 4038 367.A6.sp6:141123 transmembrane4 32 495 8407 rev 4364 123.A1.sp6:132265 transmembrane4 1289 1548 8114 rev 4406 122.C1.sp6:132097 transmembrane4 6 535 8122 for 4431 122.E4.sp6:132124 transmembrane4 10 530 8829 for 4441 99.F7.sp6:131296 transmembrane4 613 1253 9443 rev 4442 99.F7.sp6:131296 transmembrane4 613 1253 9443 rev 4653 100.D7.sp6:131464 transmembrane4 335 1207 8255 rev 4654 100.D7.sp6:131464 transmembrane4 335 1207 8255 rev 4710 367.H9.sp6:141210 transmembrane4 398 1130 8352 rev 4944 180.H7.sp6:136005 transmembrane4 356 983 8356 rev 3381 176.D9.sp6:134556 trypsin 164 764 9670 rev 4684 180.D1.sp6:135951 trypsin 371 1229 10479 rev 4688 180.D1.sp6:135951 trypsin 371 1229 10479 rev 2754 177.H6.sp6:134793 WD_domain 345 437 6510 for 3046 121.B8.sp6:131900 WD_domain 98 193 6400 fbr 3227 100.B10.sp6:131443 WD_domain 544 642 6590 for 4243 121.A8.sp6:131888 WD_domain 93 188 6400 for 5046 185.F10.sp6:135787 WD_domain 382 480 5880 for 3129 121.E12.sp6:131940 Wnt_dev_sign 101 821 12160 rev 3173 99.G6.sp6:131307 Wnt_dev_sign 49 880 12334 rev 3390 176.C9.sp6:134544 Wnt_dev_sign 249 854 11038 rev 3391 176.C9.sp6:134544 Wnt_dev_sign 249 854 11038 rev 3656 370.G6.sp6:141775 Wnt_dev_sign 211 785 11490 rev 3836 396.C9.sp6:149508 Wnt_dev_sign 282 1017 12318 rev 4253 396.F9.sp6:149544 Wnt_dev_sign 482 1298 11217 rev 4330 122.A2.sp6:132074 Wnt_dev_sign 94 933 12383 rev 4359 123.B2.sp6:132278 Wnt_dev_sign 538 1435 11785 for 4364 123.A1.sp6:132265 Wnt_dev_sign 760 1544 12660 rev 4375 122.G10.sp6:132154 Wnt_dev_sign 29 884 11603 rev 4385 122.A2.sp6:132074 Wnt_dev_sign 94 933 12383 rev 4409 121.F12.sp6:131952 Wnt_dev_sign 9 734 11167 rev 4441 99.F7.sp6:131296 Wnt_dev_sign 560 1399 13749 rev 4442 99.F7.sp6:131296 Wnt_dev_sign 560 1399 13749 rev 4535 395.F10.sp6:149353 Wnt_dev_sign 100 907 11535 rev 4586 123.A4.sp6:132268 Wnt_dev_sign 80 1122 11249 rev 4605 404.D5.sp6:162896 Wnt_dev_sign 31 816 11304 rev 4653 100.D7.sp6:131464 Wnt_dev_sign 467 1314 11882 rev 4654 100.D7.sp6:131464 Wnt_dev_sign 467 1314 11882 rev 4665 177.B11.sp6:134726 Wnt_dev_sign 137 1266 12708 rev 4668 177.B11.sp6:134726 Wnt_dev_sign 137 1266 12708 rev 4682 177.B11.sp6:134726 Wnt_dev_sign 137 1266 12708 rev 4710 367.H9.sp6:141210 Wnt_dev_sign 692 1481 12886 rev 4718 185.D9.sp6:135762 Wnt_dev_sign 129 890 11145 rev 4724 377.D2.sp6:141931 Wnt_dev_sign 400 1227 11044 rev 4733 185.D9.sp6:135762 Wnt_dev_sign 129 890 11145 rev 4856 367.H11.sp6:141212 Wnt_dev_sign 295 1669 13366 rev 4866 377.D4.sp6:141933 Wnt_dev_sign 549 1380 14522 rev 4925 219.B12.sp6:138997 Wnt_dev_sign 312 1214 13188 rev 4959 219.B12.sp6:138997 Wnt_dev_sign 312 1214 13188 rev 3409 172.D1.sp6:133913 Y_phosphatase 476 804 6932 for 3418 123.F9.sp6:132333 Y_phosphatase 28 439 6096 rev 3419 123.F9.sp6:132333 Y_phosphatase 28 439 6096 rev 3657 370.H6.sp6:141787 Y_phosphatase 148 554 6481 for 3804 404.B10.sp6:162877 Y_phosphatase 104 466 6446 rev 3806 404.D10.sp6:162901 Y_phosphatase 9 614 6516 for 3974 395.F2.sp6:149345 Y_phosphatase 164 645 6093 rev 4238 121.E9.sp6:131937 Y_phosphatase 240 777 6147 rev 4263 216.F10.sp6:139235 Y_phosphatase 21 504 6342 for 4343 122.E9.sp6:132129 Y_phosphatase 381 807 6036 rev 4363 123.B1.sp6:132277 Y_phosphatase 61 510 6229 rev 4434 219.F4.sp6:139037 Y_phosphatase 2 261 10353 for 4473 369.B4.sp6:141520 Y_phosphatase 231 768 6110 rev 4629 404.E11.sp6:162914 Y_phosphatase 580 920 6005 rev 5094 217.A3.sp6:139360 Y_phosphatase 263 622 6222 rev 2738 177.A6.sp6:134709 Zincfing_C2H2 65 127 4380 for 2760 177.A6.sp6:134709 Zincfing_C2H2 65 127 4380 for 2832 218.B2.sp6:138795 Zincfing_C2H2 94 156 4940 for 3736 377.H8.sp6:141985 Zincfing_C2H2 495 557 4850 for 3762 377.G2.sp6:141967 Zincfing_C2H2 52 114 4380 for 3763 377.G2.sp6:141967 Zincfing_C2H2 52 114 4380 for 4794 377.G4.sp6:141969 Zincfing_C2H2 247 308 3930 for 5090 185.C4.sp6:135745 Zincfing_C2H2 238 300 4540 for 3774 377.E4.sp6:141945 Zincfing_C3HC4 128 244 9335 for 4477 181.E3.sp6:135322 Zincfing_C3HC4 321 445 8221 for

TABLE 19 Polynucleotides Specifically Expressed in C I n SEQ ID lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 lib 20 NO: Sequence Name cluster clones clones clones clones clones clones clones clones 3 RTA00000197AF.e.24.1 39250 2 0 0 0 0 0 0 0 7 RTA00000197AR.e.12.1 22095 3 0 0 0 0 0 0 0 16 RTA00000196AF.e.16.1 39252 2 0 0 0 0 0 0 0 18 RTA00000196AF.c.17.1 39602 2 0 0 0 0 0 0 0 21 RTA00000131A.g.19.2 36535 2 0 0 0 0 0 0 0 22 RTA00000187AR.o.10.2 8984 4 3 0 0 0 2 0 0 23 RTA00000198R.b.08.1 22636 3 0 0 0 0 0 0 0 26 RTA00000200R.g.09.1 22785 3 0 0 0 0 0 0 0 29 RTA00000200AF.b.19.1 22847 3 0 0 0 0 0 0 0 31 RTA00000200F.m.15.1 22601 3 0 0 0 1 0 0 0 37 RTA00000181AF.n.15.2 86128 1 0 0 0 0 0 0 0 38 RTA00000196R.k.07.1 22443 2 0 0 0 0 0 0 1 40 RTA00000200AR.e.02.1 36059 2 0 0 0 1 1 1 0 48 RTA00000177AR.a.23.5 6995 4 2 0 0 0 0 0 0 49 RTA00000198R.o.05.1 26702 2 0 0 0 0 0 0 0 50 RTA00000201R.a.02.1 35362 2 0 0 0 0 0 0 0 61 RTA00000197AF.h.11.1 22264 3 0 0 0 0 0 0 0 66 RTA00000199F.c.09.2 16824 3 1 0 0 0 0 0 0 75 RTA00000180AR.h.19.2 84182 1 0 0 0 0 0 0 0 78 RTA00000199R.f.09.1 22907 3 0 0 0 0 0 0 0 79 RTA00000199AF.p.4.1 10282 3 3 0 0 0 0 0 0 85 RTA00000200R.o.03.1 22807 3 0 0 0 0 0 0 0 86 RTA00000189AF.l.22.1 33333 1 1 0 0 0 0 0 0 87 RTA00000195AF.d.20.1 37574 2 0 0 0 0 0 0 0 92 RTA00000198AF.j.18.1 22759 3 0 0 0 0 0 0 0 95 RTA00000180AF.g.3.1 9024 5 2 0 0 0 0 0 0 102 RTA00000199R.j.08.1 37844 2 0 0 0 0 0 0 0 103 RTA00000199F.e.10.1 22906 3 0 0 0 0 0 1 0 105 RTA00000179AF.g.12.3 36390 2 0 0 0 0 0 0 0 108 RTA00000183AR.h.23.2 18957 3 0 0 0 0 0 0 0 109 RTA00000197AF.d.12.1 39546 2 0 0 0 0 0 0 0 116 RTA00000181AR.k.24.3 7005 8 2 0 0 0 0 0 0 119 RTA00000181AR.k.24.2 7005 8 2 0 0 0 0 0 0 124 RTA00000199AR.m.06.1 19122 3 0 0 0 0 0 0 0 129 RTA00000134A.d.10.1 18957 3 0 0 0 0 0 0 0 137 RTA00000181AF.m.4.3 13238 4 1 0 0 0 0 0 0 141 RTA00000196AF.c.6.1 23148 3 0 0 0 0 0 0 0 142 RTA00000198AF.k.19.1 75879 1 0 0 0 0 0 0 0 143 RTA00000199R.h.09.1 76020 1 0 0 0 0 0 0 0 144 RTA00000198AF.o.18.1 13018 4 0 0 0 1 0 0 0 148 RTA00000199F.h.17.2 36254 2 0 0 0 0 0 0 0 149 RTA00000181AR.h.06.3 87226 1 0 0 0 0 0 0 0 166 RTA00000198AF.f.21.1 22676 3 0 0 0 0 0 0 0 173 RTA00000200AR.b.07.1 17125 4 0 0 0 0 0 0 0 178 RTA00000200F.o.03.1 22807 3 0 0 0 0 0 0 0 180 RTA00000199AF.j.12.1 22461 3 0 0 0 0 0 0 0 185 RTA00000195AF.d.4.1 22766 3 0 0 0 0 0 0 0 194 RTA00000200R.k.01.1 40049 2 0 0 0 0 0 0 0 195 RTA00000198AF.c.10.1 77149 1 0 0 0 0 0 0 0 198 RTA00000197AR.e.07.1 86969 1 0 0 0 0 0 0 0 199 RTA00000199R.c.09.1 16824 3 1 0 0 0 0 0 0 206 RTA00000181AF.o.04.2 22205 3 0 0 0 0 0 0 0 207 RTA00000199AF.l.19.1 22460 3 0 0 0 0 0 0 0 208 RTA00000198AF.h.22.1 22366 2 1 0 0 0 0 0 0 211 RTA00000199AF.m.15.1 10101 3 0 0 0 0 0 0 0 212 RTA00000197AF.j.9.1 13236 4 1 0 0 0 0 0 0 230 RTA00000185AR.b.18.1 12171 3 2 0 0 0 0 0 0 235 RTA00000201AF.a.02.1 35362 2 0 0 0 0 0 0 0 236 RTA00000183AR.h.23.1 18957 3 0 0 0 0 0 0 0 238 RTA00000187AR.k.12.1 78415 1 0 0 0 0 0 0 0 242 RTA00000198AF.m.17.1 77992 1 0 0 0 0 0 0 0 243 RTA00000181AF.m.15.3 12081 4 0 0 0 0 0 0 0 248 RTA00000198R.c.14.1 39814 2 0 0 0 0 0 0 0 249 RTA00000200R.o.03.2 22807 3 0 0 0 0 0 0 0 251 RTA00000192AF.n.13.1 8210 2 6 0 0 0 0 0 0 256 RTA00000184AR.e.15.1 16347 4 0 0 0 0 0 0 0 260 RTA00000198R.m.17.1 77992 1 0 0 0 0 0 0 0 270 RTA00000178R.l.08.1 39648 2 0 0 0 0 0 0 0 278 RTA00000198AF.p.16.1 71877 1 0 0 0 0 0 0 0 280 RTA00000193AF.b.18.1 7542 8 0 0 2 1 0 1 0 284 RTA00000199F.d.10.2 22049 3 0 0 0 0 0 0 0 287 RTA00000200AF.b.07.1 17125 4 0 0 0 0 0 0 0 288 RTA00000181AR.i.06.3 19119 3 0 0 0 0 0 0 0 289 RTA00000196F.k.07.1 22443 2 0 0 0 0 0 0 1 294 RTA00000198AF.k.23.1 8995 2 5 0 0 0 0 0 0 296 RTA00000196AF.f.20.1 22774 3 0 0 0 0 0 0 0 300 RTA00000195AF.c.12.1 37582 2 0 0 0 0 0 0 0 302 RTA00000186AF.d.1.2 40044 2 0 0 1 0 0 0 0 307 RTA00000200F.n.05.2 18989 3 0 0 0 0 0 0 0 308 RTA00000178AF.j.20.1 15066 4 0 0 0 0 0 0 0 310 RTA00000188AF.m.08.1 22155 3 0 0 0 0 0 0 0 315 RTA00000199R.d.23.1 37477 2 0 0 0 0 0 0 0 319 RTA00000200F.n.05.1 18989 3 0 0 0 0 0 0 0 320 RTA00000196AF.m.13.1 16290 4 0 0 0 0 0 0 0 325 RTA00000182AF.d.18.4 37435 2 0 0 0 0 0 0 0 328 RTA00000200AF.g.09.1 22785 3 0 0 0 0 0 0 0 330 RTA00000177AR.m.17.4 14391 3 1 0 0 0 0 0 0 331 RTA00000197AR.c.20.1 16282 4 0 0 0 0 0 0 0 337 RTA00000177AR.m.17.3 14391 3 1 0 0 0 0 0 0 342 RTA00000196AF.d.10.1 22256 3 0 0 0 0 0 0 0 343 RTA00000201F.a.18.1 16837 2 2 0 0 0 0 0 0 344 RTA00000198AF.o.02.1 68756 1 0 0 0 0 0 0 0 345 RTA00000187AF.h.21.1 39171 2 0 0 0 0 0 0 0 347 RTA00000199F.b.03.2 38340 2 0 0 0 0 0 0 0 358 RTA00000198AF.g.7.1 13386 3 2 0 0 0 0 0 0 362 RTA00000197AR.c.24.1 82498 1 0 0 0 0 0 0 0 371 RTA00000197F.e.7.1 86969 1 0 0 0 0 0 0 0 378 RTA00000181AF.k.24.3 7005 8 2 0 0 0 0 0 0 382 RTA00000200AF.j.6.1 22902 3 0 0 0 0 0 0 0 384 RTA00000196AF.h.17.1 39215 2 0 0 0 0 0 0 0 392 RTA00000185AF.b.11.2 9024 5 2 0 0 0 0 0 0 397 RTA00000198AF.b.22.1 38956 2 0 0 0 0 0 0 0 399 RTA00000186AF.m.15.2 40122 2 0 0 0 0 0 0 0 406 RTA00000199F.f.09.2 22907 3 0 0 0 0 0 0 0 408 RTA00000183AR.l.15.1 39383 2 0 0 0 0 0 0 0 413 RTA00000200F.a.12.1 16751 4 0 0 0 0 0 0 0 416 RTA00000199F.a.5.1 22134 3 0 0 0 0 0 0 0 418 RTA00000187AR.k.01.1 78356 1 0 0 0 0 0 0 0 424 RTA00000187AR.j.24.1 78356 1 0 0 0 0 0 0 0 426 RTA00000199AF.o.19.1 36927 2 0 0 0 0 0 0 0 429 RTA00000196F.i.19.1 39498 2 0 0 0 0 0 0 0 430 RTA00000198R.k.23.1 8995 2 5 0 0 0 0 0 0 432 RTA00000198AF.o.05.1 26702 2 0 0 0 0 0 0 0 433 RTA00000198R.j.18.1 22759 3 0 0 0 0 0 0 0 435 RTA00000182AR.c.22.1 16283 3 0 0 0 0 0 0 0 438 RTA00000180AR.g.03.4 9024 5 2 0 0 0 0 0 0 451 RTA00000200AF.b.20.1 40403 2 0 0 0 0 0 0 0 455 RTA00000198AF.d.12.1 21142 2 1 0 0 0 0 0 0 456 RTA00000200AF.b.12.1 22053 3 0 0 0 0 0 0 0 457 RTA00000191AR.l.7.2 14391 3 1 0 0 0 0 0 0 461 RTA00000190AF.e.13.1 38961 2 0 0 0 0 0 0 0 462 RTA00000196AF.n.17.1 12477 4 1 0 0 0 0 0 0 467 RTA00000195AF.b.19.1 77678 1 0 0 0 0 0 0 0 475 RTA00000187AR.m.3.3 17055 4 0 0 0 0 0 0 0 476 RTA00000200R.g.15.1 22898 3 0 0 0 0 0 0 0 482 RTA00000187AF.j.7.1 78091 1 0 0 0 0 0 0 0 485 RTA00000196AF.c.14.1 23105 3 0 0 0 0 0 0 0 486 RTA00000190AR.p.22.2 16368 4 0 0 0 0 0 0 0 492 RTA00000198AF.b.8.1 22636 3 0 0 0 0 0 0 0 493 RTA00000177AF.m.17.1 14391 3 1 0 0 0 0 0 0 494 RTA00000200AF.k.1.1 40049 2 0 0 0 0 0 0 0 498 RTA00000190AF.h.12.1 12977 5 0 0 0 0 0 0 0 499 RTA00000199F.b.22.2 17018 4 0 0 0 0 0 0 0 508 RTA00000187AF.i.14.2 19406 2 1 0 0 0 0 0 0 511 RTA00000196AF.g.10.1 12498 3 1 1 0 0 0 0 0 517 RTA00000184AF.e.14.1 16347 4 0 0 0 0 0 0 0 522 RTA00000178AR.h.17.2 23824 2 1 0 0 0 0 0 0 531 RTA00000195F.a.3.1 27179 2 0 0 0 0 0 0 0 544 RTA00000196F.j.13.1 23170 3 0 0 0 0 0 0 0 547 RTA00000196AF.g.8.1 39665 2 0 0 0 0 0 0 0 549 RTA00000198AF.c.16.1 26801 2 0 0 0 0 0 0 0 553 RTA00000201F.b.22.1 35728 2 0 0 0 0 0 0 1 559 RTA00000197AF.p.20.1 22795 3 0 0 0 0 0 0 0 563 RTA00000192AR.o.16.2 9061 5 2 0 0 0 0 0 0 565 RTA00000191AF.c.10.1 40422 2 0 0 0 0 0 0 0 568 RTA00000196AF.p.01.2 87143 1 0 0 0 0 0 0 0 578 RTA00000180AF.g.17.1 16653 3 1 0 0 0 0 0 0 583 RTA00000190AR.h.12.2 12977 5 0 0 0 0 0 0 0 585 RTA00000198AF.n.18.1 16715 3 1 0 0 0 0 0 0 586 RTA00000199R.o.11.1 23172 3 0 0 0 0 0 0 0 588 RTA00000191AF.b.4.1 14936 3 0 0 0 0 0 0 0 589 RTA00000192AF.l.1.1 16392 3 0 0 0 0 0 0 0 593 RTA00000196R.c.14.2 23105 3 0 0 0 0 0 0 0 595 RTA00000195R.a.06.1 35265 2 0 1 0 0 0 0 0 602 RTA00000195AF.b.21.1 39055 2 0 0 0 0 0 0 0 612 RTA00000197AR.e.22.1 78758 1 0 0 0 0 0 0 0 615 RTA00000197R.p.20.1 22795 3 0 0 0 0 0 0 0 618 RTA00000192AF.a.14.1 6874 6 3 0 0 1 0 0 0 623 RTA00000198R.b.24.1 19047 3 0 0 0 0 0 0 0 627 RTA00000199F.h.15.2 22269 3 0 0 0 0 0 0 0 628 RTA00000198AF.g.16.1 6602 1 1 0 0 0 0 0 0 634 RTA00000192AF.j.6.1 11494 4 0 0 0 0 0 0 0 635 RTA00000181AF.p.7.3 38773 2 0 0 0 0 0 0 0 637 RTA00000200AF.g.15.1 22898 3 0 0 0 0 0 0 0 643 RTA00000184AF.c.9.1 16245 4 0 0 0 0 0 0 0 645 RTA00000177AF.k.9.1 16245 4 0 0 0 0 0 0 0 649 RTA00000190AR.l.19.2 88204 1 0 0 0 0 0 0 0 662 RTA00000201R.a.15.1 57347 1 0 0 0 0 0 0 0 664 RTA00000195R.a.23.1 86432 1 0 0 0 0 0 0 0 670 RTA00000186AF.p.17.3 38383 2 0 0 0 0 0 0 0 674 RTA00000197AR.e.24.1 39250 2 0 0 0 0 0 0 0 683 RTA00000187AR.j.01.1 79028 1 0 0 0 0 0 0 0 686 RTA00000201F.f.07.1 51116 1 0 0 0 0 0 0 0 694 RTA00000201R.c.19.1 22357 2 1 0 0 0 0 0 0 702 RTA00000177AR.b.8.5 17062 3 0 0 0 0 0 0 0 712 RTA00000201F.b.21.1 9071 3 4 0 0 0 0 0 0 717 RTA00000200F.o.10.2 36432 2 0 0 0 0 0 0 0 718 RTA00000196F.l.14.2 23144 3 0 0 0 0 0 0 0 725 RTA00000197AF.b.1.1 12134 1 1 0 0 0 0 0 0 733 RTA00000200AF.d.20.1 26600 2 0 0 0 0 0 0 0 743 RTA00000178AF.k.9.1 16342 3 0 0 0 0 0 0 0 748 RTA00000198AF.b.24.1 19047 3 0 0 0 0 0 0 0 757 RTA00000406F.d.16.1 15040 2 2 0 0 0 0 0 0 760 RTA00000408F.o.12.2 78578 1 0 0 0 0 0 0 0 761 RTA00000119A.j.15.1 79623 1 0 0 0 0 0 0 0 762 RTA00000413F.d.12.1 66467 1 0 0 0 0 0 0 0 763 RTA00000423F.i.12.1 9118 4 3 0 0 0 0 0 0 766 RTA00000411F.k.05.1 64777 1 0 0 0 0 0 0 0 769 RTA00000419F.b.09.1 78128 1 0 0 0 0 0 0 0 772 RTA00000411F.m.15.1 78014 1 0 0 0 0 0 0 0 774 RTA00000123A.k.23.1 80313 1 0 0 0 0 0 0 0 777 RTA00000130A.m.15.1 81630 1 0 0 0 0 0 0 0 778 RTA00000411F.k20.1 64973 1 0 0 0 0 0 0 0 780 RTA00000418F.k.05.1 73021 1 0 0 0 0 0 0 0 781 RTA00000423F.h.18.1 37972 2 0 0 0 0 0 0 0 783 RTA00000422F.p.06.2 39282 2 0 0 0 0 0 0 0 784 RTA00000404F.n.16.2 39095 2 0 0 0 0 0 0 0 785 RTA00000411F.m.24.1 77568 1 0 0 0 0 0 0 0 786 RTA00000134A.j.10.1 81383 1 0 0 0 0 0 0 0 787 RTA00000409F.j.02.1 76417 1 0 0 0 0 0 0 0 788 RTA00000403F.j.15.1 23840 2 1 0 0 0 0 0 0 789 RTA00000411F.n.11.1 77276 1 0 0 0 0 0 0 0 790 RTA00000339F.i.13.1 5970 6 4 0 0 0 0 0 0 792 RTA00000406F.o.15.1 37482 2 0 0 0 0 0 0 0 793 RTA00000412F.g.04.2 64457 1 0 0 0 0 0 0 0 795 RTA00000352R.l.06.1 40343 2 0 0 0 0 0 0 0 796 RTA00000419F.b.12.1 63148 1 0 0 0 0 0 0 0 797 RTA00000423F.k.17.2 37512 2 0 0 0 0 0 0 0 799 RTA00000418F.k.14.1 76133 1 0 0 0 0 1 0 0 800 RTA00000409F.l.12.1 26755 1 0 0 0 0 0 0 0 801 RTA00000404F.c.20.1 39088 2 0 0 0 0 0 1 0 802 RTA00000423F.g.09.1 38958 2 0 0 0 0 0 0 0 804 RTA00000406F.d.12.1 38575 2 0 0 0 0 0 0 0 805 RTA00000411F.f.02.1 63386 1 0 0 0 0 0 0 0 806 RTA00000129A.n.21.1 79381 1 0 0 0 0 0 0 0 807 RTA00000409F.m.12.1 73490 1 0 0 0 0 0 0 0 808 RTA00000410F.c.04.1 74099 1 0 0 0 0 0 0 0 810 RTA00000406F.m.09.1 26891 2 0 0 0 0 0 0 0 811 RTA00000411F.b.06.1 77884 1 0 0 0 0 0 0 0 812 RTA00000409F.l.21.1 73143 1 0 0 0 0 0 0 0 818 RTA00000404F.l.20.2 38638 2 0 0 0 0 0 0 0 819 RTA00000413F.d.18.1 65305 1 0 0 0 0 0 0 0 820 RTA00000404F.p.04.2 39069 2 0 0 0 0 0 0 0 821 RTA00000405F.g.19.2 37150 2 0 0 0 0 0 0 0 822 RTA00000409F.a.22.1 75200 1 0 0 0 0 0 0 0 824 RTA00000405F.o.18.1 11016 4 2 0 0 0 0 0 0 829 RTA00000408F.e.22.2 26930 1 0 0 0 0 0 0 0 831 RTA00000413F.d.16.1 63331 1 0 0 0 0 0 0 0 834 RTA00000419F.g.08.1 66700 1 0 0 0 0 0 0 0 835 RTA00000122A.g.16.1 81366 1 0 0 0 0 0 0 0 836 RTA00000419F.c.16.1 65254 1 0 0 0 0 0 0 0 837 RTA00000411F.b.03.1 23634 1 2 0 0 0 0 0 0 842 RTA00000403F.l.20.1 18267 1 0 0 0 0 0 0 0 845 RTA00000411F.a.02.1 78537 1 0 0 0 0 0 0 0 847 RTA00000412F.l.04.1 66372 1 0 0 0 0 0 0 0 849 RTA00000406F.a.23.1 38712 2 0 0 0 0 0 0 0 851 RTA00000120A.n.19.3 80004 1 0 0 0 0 0 0 0 852 RTA00000403F.e.01.1 38965 2 0 0 0 0 0 0 0 853 RTA00000411F.l.03.1 62702 1 0 0 0 0 0 0 0 856 RTA00000121A.m.2.1 81064 1 0 0 0 0 0 0 0 858 RTA00000418F.j.12.1 73316 1 0 0 0 0 0 0 0 862 RTA00000125A.g.16.1 21497 2 1 0 0 0 0 0 0 863 RTA00000418F.o.18.1 78676 1 0 0 0 0 0 0 0 865 RTA00000408F.k.14.1 73856 1 0 0 0 0 0 0 0 871 RTA00000403F.o.15.1 39140 2 0 0 0 0 0 0 0 872 RTA00000341F.m.13.1 26502 1 0 0 0 0 0 0 0 873 RTA00000408F.h.03.1 78382 1 0 0 0 0 0 0 0 874 RTA00000423F.k.05.1 37472 2 0 0 0 0 0 0 0 876 RTA00000418F.p.19.1 78544 1 0 0 0 0 0 0 0 877 RTA00000420F.f.06.1 64812 1 0 0 0 0 0 0 0 878 RTA00000122A.j.18.1 81317 1 0 0 0 0 0 0 0 879 RTA00000420F.d.05.1 64432 1 0 0 0 0 0 0 0 880 RTA00000403F.m.18.1 39185 2 0 0 0 0 0 0 0 882 RTA00000411F.j.05.1 40709 1 1 0 0 0 0 0 0 883 RTA00000403F.a.04.1 23529 2 1 0 0 0 0 0 0 885 RTA00000406F.f.12.1 21895 2 1 0 0 0 0 0 0 886 RTA00000418F.g.22.1 74837 1 0 0 0 0 0 0 0 888 RTA00000404F.l.20.1 38638 2 0 0 0 0 0 0 0 889 RTA00000408F.i.08.2 75811 1 0 0 0 0 0 0 0 890 RTA00000122A.d.5.1 81155 1 0 0 0 0 0 0 0 894 RTA00000419F.b.19.1 65534 1 0 0 0 0 0 0 0 896 RTA00000418F.k.19.1 74932 1 0 0 0 0 0 0 0 900 RTA00000419F.g.12.1 66171 1 0 0 0 0 0 0 0 901 RTA00000404F.n.11.2 38001 2 0 0 0 0 0 0 0 904 RTA00000419F.o.24.1 65092 1 0 0 0 0 0 0 0 905 RTA00000419F.k.19.1 75447 1 0 0 0 0 0 0 0 907 RTA00000127A.i.20.1 81418 1 0 0 0 0 0 0 0 908 RTA00000422F.g.22.1 22561 3 0 0 0 0 0 0 0 910 RTA00000413F.h.13.1 65190 1 0 0 0 0 0 0 0 913 RTA00000348R.j.16.1 7005 8 2 0 0 0 0 0 0 916 RTA00000418F.n.22.1 79062 1 0 0 0 0 0 0 0 917 RTA00000406F.l.08.1 39016 2 0 0 0 0 0 0 0 920 RTA00000409F.j.07.1 75190 1 0 0 0 0 0 0 0 923 RTA00000411F.e.22.1 63638 1 0 0 0 0 0 0 0 924 RTA00000347F.a.17.1 16723 3 1 0 0 0 0 0 0 926 RTA00000404F.n.20.1 26865 2 0 0 0 0 0 0 0 929 RTA00000404F.b.02.1 38984 2 0 0 0 0 0 0 0 931 RTA00000403F.b.10.1 73268 1 0 0 0 0 0 0 0 932 RTA00000406F.i.12.1 39080 2 0 0 0 0 0 0 0 933 RTA00000406F.h.08.1 16228 2 2 0 0 0 0 0 0 934 RTA00000418F.i.19.1 79180 1 0 0 0 0 0 0 0 936 RTA00000412F.h.21.1 64348 1 0 0 0 0 0 0 0 938 RTA00000120A.g.18.1 81255 1 0 0 0 0 0 0 0 940 RTA00000423F.j.05.1 37958 2 0 0 0 0 0 0 0 941 RTA00000132A.k.6.1 81284 1 0 0 0 0 0 0 0 943 RTA00000406F.p.04.1 37458 2 0 0 0 0 0 0 0 944 RTA00000347F.a.13.1 22446 3 0 0 0 0 0 0 0 945 RTA00000419F.p.23.1 64748 1 0 0 0 0 0 0 0 946 RTA00000419F.d.17.1 64353 1 0 0 0 0 0 0 0 949 RTA00000124A.k.5.1 80252 1 0 0 0 0 0 0 0 950 RTA00000404F.h.22.1 18735 2 1 0 0 0 0 1 0 952 RTA00000410F.o.05.1 75262 1 0 0 0 0 0 0 0 953 RTA00000339R.l.14.1 19119 3 0 0 0 0 0 0 0 954 RTA00000403F.m.13.2 39077 2 0 0 0 0 0 0 0 957 RTA00000419F.g.22.1 64515 1 0 0 0 0 0 0 0 958 RTA00000404F.g.21.1 37947 2 0 0 0 0 0 0 0 960 RTA00000138A.n.4.1 21920 2 1 0 0 0 0 0 0 961 RTA00000410F.b.15.1 77100 1 0 0 0 0 0 0 0 963 RTA00000419F.j.23.1 74470 1 0 0 0 0 0 0 0 964 RTAD0000411F.j.02.1 65310 1 0 0 0 0 0 0 0 965 RTA00000419F.p.24.1 63477 1 0 0 0 0 0 0 0 966 RTA00000404F.a.19.1 38624 2 0 0 0 0 0 0 0 973 RTA00000346F.e.13.1 74653 1 0 0 0 0 0 0 0 974 RTA00000419F.c.18.1 41394 1 1 0 0 0 0 0 0 978 RTA00000404F.c.22.1 11344 3 3 0 0 0 0 0 0 981 RTA00000125A.k.10.1 81644 1 0 0 0 0 0 0 0 982 RTA00000347F.c.06.1 18846 2 1 0 0 0 0 0 0 983 RTA00000411F.k.19.1 64200 1 0 0 0 0 0 0 0 984 RTA00000345F.l.09.1 27250 2 0 0 0 0 0 0 0 985 RTA00000423F.k.01.1 40426 2 0 0 0 0 0 0 0 986 RTA00000408F.d.06.1 78997 1 0 0 0 0 0 0 0 987 RTA00000128A.b.20.1 79761 1 0 0 0 0 0 0 0 989 RTA00000195AF.d.4.1 22766 3 0 0 0 0 0 0 0 991 RTA00000403F.h.12.1 15205 2 1 0 0 0 0 0 0 992 RTA00000119A.j.22.1 80336 1 0 0 0 0 0 0 0 995 RTA00000126A.n.7.2 79557 1 0 0 1 0 0 0 0 997 RTA00000404F.j.08.1 39066 2 0 0 0 0 0 0 0 998 RTA00000410F.c.14.1 77809 1 0 0 0 0 0 0 0 999 RTA00000120A.g.23.1 81189 1 0 0 0 0 0 0 0 1000 RTA00000195AF.d.20.1 37574 2 0 0 0 0 0 0 0 1002 RTA00000412F.j.17.1 64071 1 0 0 0 0 0 0 0 1004 RTA00000119A.j.10.1 79646 1 0 0 0 0 0 0 0 1010 RTA00000419F.o.16.1 62867 1 0 0 0 0 0 0 0 1012 RTA00000411F.c.17.1 77664 1 0 0 0 0 0 0 0 1013 RTA00000406F.k.15.1 38549 2 0 0 0 0 0 0 0 1014 RTA00000406F.a.02.1 37744 2 0 0 0 0 0 0 0 1016 RTA00000341F.b.06.1 17008 4 0 0 0 0 0 0 0 1017 RTA00000409F.n.14.1 78190 1 0 0 0 0 0 0 0 1019 RTA00000345F.j.08.1 16731 3 1 0 0 0 0 0 0 1021 RTA00000419F.g.15.1 32519 1 1 0 0 0 0 0 0 1022 RTA00000423F.a.19.1 21396 1 2 0 0 0 0 0 0 1024 RTA00000422F.e.08.1 39020 2 0 0 0 0 0 0 0 1025 RTA00000411F.d.15.1 74890 1 0 0 0 0 0 0 0 1027 RTA00000411F.l.15.1 66704 1 0 0 0 0 0 0 0 1029 RTA00000405F.e.08.1 37916 2 0 0 0 1 0 0 0 1030 RTA00000353R.j.24.1 23089 3 0 0 0 0 0 0 0 1032 RTA00000418F.o.06.1 75930 1 0 0 0 0 0 0 0 1033 RTA00000404F.c.10.1 23534 2 1 0 0 0 0 0 0 1034 RTA00000418F.i.21.1 78728 1 0 0 0 0 0 0 0 1036 RTA00000411F.l.13.1 43114 1 1 0 0 0 0 0 0 1037 RTA00000407F.a.24.1 37560 2 0 0 0 0 0 0 0 1038 RTA00000346F.n.06.1 12439 4 0 0 0 0 0 0 0 1039 RTA00000412F.l.21.1 65183 1 0 0 0 0 0 0 0 1040 RTA00000413F.i.02.1 65857 1 0 0 0 0 0 0 0 1041 RTA00000404F.i.19.1 38698 2 0 0 0 0 0 0 0 1043 RTA00000403F.a.11.1 73109 1 0 0 0 0 0 0 0 1045 RTA00000411F.k.16.1 64759 1 0 0 0 0 0 1 0 1046 RTA00000405F.c.01.1 19236 2 0 0 0 0 0 0 0 1047 RTA00000423F.i.18.1 14996 4 0 0 0 0 0 0 0 1050 RTA00000406F.a.07.1 26607 2 0 0 0 0 0 0 0 1051 RTA00000347F.d.06.1 39122 2 0 0 0 0 0 0 0 1052 RTA00000419F.b.18.1 67034 1 0 0 0 0 0 0 0 1053 RTA00000406F.h.07.1 38003 2 0 0 0 0 0 0 0 1054 RTA00000405F.l.15.1 19575 2 1 0 0 0 0 0 0 1055 RTA00000406F.g.17.1 37979 2 0 0 0 0 0 0 0 1058 RTA00000130A.h.22.1 80933 1 0 0 0 0 0 0 0 1061 RTA00000404F.d.13.1 39036 2 0 0 0 0 0 0 0 1064 RTA00000340F.n.01.1 39081 2 0 0 0 0 0 0 0 1065 RTA00000419F.d.06.1 65496 1 0 0 0 0 0 0 0 1066 RTA00000419F.n.09.1 66070 1 0 0 0 0 0 0 0 1067 RTA00000399F.i.08.1 38927 2 0 0 0 0 0 0 0 1069 RTA00000423F.g.13.1 38028 2 0 0 0 0 0 0 0 1072 RTA00000195AF.b.21.1 39055 2 0 0 0 0 0 0 0 1073 RTA00000403F.h.05.1 39096 2 0 0 0 0 0 0 0 1075 RTA00000422F.p.07.2 39024 2 0 0 1 0 0 0 0 1078 RTA00000421F.n.19.1 16409 3 1 0 0 0 0 0 0 1080 RTA00000345F.k.21.1 40204 2 0 0 0 0 0 0 0 1082 RTA00000405F.a.11.1 39124 2 0 0 0 0 0 0 0 1084 RTA00000413F.e.16.1 63836 1 0 0 0 0 0 0 0 1086 RTA00000404F.o.18.2 39110 2 0 0 0 0 0 0 0 1087 RTA00000409F.i.24.1 76967 1 0 0 0 0 0 0 0 1091 RTA00000340F.n.13.1 17055 4 0 0 0 0 0 0 0 1092 RTA00000340F.p.04.1 78533 1 0 0 0 0 0 0 0 1093 RTA00000411F.c.05.1 73368 1 0 0 0 0 0 0 0 1097 RTA00000404F.i.02.1 39015 2 0 0 0 0 0 0 0 1099 RTA00000403F.m.15.2 26901 2 0 0 0 0 0 0 0 1100 RTA00000412F.h.23.2 65118 1 0 0 0 0 0 0 0 1101 RTA00000418F.j.08.1 73382 1 0 0 0 0 0 0 0 1102 RTA00000125A.n.4.1 81984 1 0 0 0 0 0 0 0 1103 RTA00000412F.l.19.1 65825 1 0 0 0 0 0 0 0 1105 RTA00000129A.p.3.1 32644 1 1 0 0 0 0 0 0 1106 RTA00000340F.p.20.1 17008 4 0 0 0 0 0 0 0 1107 RTA00000411F.a.10.1 73073 1 0 0 0 0 0 0 0 1108 RTA00000409F.n.17.1 76725 1 0 0 0 0 0 0 0 1109 RTA00000404F.c.03.2 39198 2 0 0 0 0 0 0 0 1110 RTA00000420F.a.19.1 34192 1 1 0 0 0 0 0 0 1114 RTA00000420F.d.12.1 64095 1 0 0 0 0 0 0 0 1115 RTA00000409F.j.19.1 73792 1 0 0 0 0 0 0 0 1116 RTA00000422F.d.16.1 39133 2 0 0 0 0 0 0 0 1117 RTA00000418F.m.16.1 74986 1 0 0 0 0 0 0 0 1118 RTA00000405F.c.11.1 39068 2 0 0 0 0 0 0 0 1119 RTA00000404F.k.22.1 39084 2 0 0 0 0 0 0 0 1120 RTA00000418F.k.07.1 75067 1 0 0 0 0 0 0 0 1121 RTA00000403F.c.10.1 75261 1 0 0 0 0 0 0 0 1124 RTA00000410F.m.05.1 74964 1 0 0 0 0 0 0 0 1125 RTA00000405F.i.20.1 38532 2 0 0 0 0 0 0 0 1127 RTA00000408F.p.24.1 74286 1 0 0 0 0 0 0 0 1128 RTA00000418F.k.18.1 75385 1 0 0 0 0 0 0 0 1129 RTA00000422F.m.04.1 38702 2 0 0 0 0 0 0 0 1133 RTA00000403F.a.07.1 73559 1 0 0 0 0 0 0 0 1135 RTA00000403F.b.19.3 22327 2 1 0 0 0 0 0 0 1136 RTA00000418F.m.23.1 77195 1 0 0 0 0 0 0 0 1138 RTA00000404F.i.18.1 21912 2 1 0 0 0 0 0 0 1139 RTA00000422F.i.14.1 39300 2 0 0 0 0 0 0 0 1140 RTA00000418F.m.14.1 75711 1 0 0 1 0 0 0 0 1141 RTA00000406F.o.12.1 37459 2 0 0 0 0 0 0 0 1143 RTA00000411F.a.07.1 74547 1 0 0 0 0 0 0 0 1144 RTA00000411F.c.02.1 72852 1 0 0 0 0 0 0 0 1146 RTA00000130A.h.16.1 80761 1 0 0 0 0 0 0 0 1147 RTA00000410F.p.23.1 73948 1 0 0 0 0 0 0 0 1148 RTA00000418F.m.24.1 77114 1 0 0 0 0 0 0 0 1150 RTA00000408F.j.19.2 73752 1 0 0 0 0 0 0 0 1152 RTA00000118A.d.17.1 81921 1 0 0 0 0 0 0 0 1153 RTA00000407F.b.04.1 63221 1 0 0 0 0 0 0 0 1154 RTA00000411F.e.07.1 65008 1 0 0 0 0 0 0 0 1156 RTA00000132A.c.11.1 87278 1 0 0 0 0 0 0 0 1157 RTA00000420F.e.16.1 63639 1 0 0 0 0 0 0 0 1159 RTA00000404F.b.11.1 39079 2 0 0 0 0 0 0 0 1160 RTA00000418F.k.17.1 75390 1 0 0 0 0 0 0 0 1161 RTA00000129A.k.12.1 79322 1 0 0 0 0 0 0 0 1162 RTA00000340R.m.07.1 78415 1 0 0 0 0 0 0 0 1163 RTA00000405F.d.14.1 35209 2 0 0 0 0 0 1 0 1164 RTA00000406F.f.11.1 38601 2 0 0 0 0 0 0 0 1165 RTA00000120A.h.5.1 80344 1 0 0 0 0 0 0 0 1167 RTA00000411F.g.06.1 66065 1 0 0 0 0 0 0 0 1168 RTA00000408F.d.16.1 76318 1 0 0 0 0 0 0 0 1171 RTA00000404F.c.19.1 39026 2 0 0 0 0 0 0 1 1173 RTA00000410F.a.01.1 73354 1 0 0 0 0 0 0 0 1174 RTA00000408F.h.08.1 74575 1 0 0 0 0 0 0 0 1175 RTA00000422F.b.16.1 17045 4 0 0 0 0 0 0 0 1176 RTA00000419F.f.10.1 66193 1 0 0 0 0 0 0 0 1177 RTAG0000418F.l.04.1 74140 1 0 0 0 0 0 0 0 1178 RTA00000410F.a.16.1 73548 1 0 0 0 0 0 0 0 1179 RTA00000138A.e.13.1 79608 1 0 0 0 0 0 0 0 1180 RTA00000130A.b.5.1 79579 1 0 0 0 0 0 0 0 1181 RTA00000408F.j.15.2 74759 1 0 0 0 0 0 0 0 1182 RTA00000410F.m.20.1 74285 1 0 0 0 0 0 0 0 1185 RTA00000419F.e.04.1 62963 1 0 0 0 0 0 0 0 1187 RTA00000418F.g.05.1 73075 1 0 0 0 0 0 0 0 1188 RTA00000419F.n.02.1 65963 1 0 0 0 0 0 0 0 1191 RTA00000119A.m.15.1 80989 1 0 0 0 0 0 0 0 1194 RTA00000413F.g.23.1 40700 1 1 0 0 0 0 0 0 1195 RTA00000403F.a.18.1 75726 1 0 0 0 0 0 0 0 1196 RTA00000404F.m.20.2 39144 2 0 0 0 0 0 0 0 1199 RTA00000419F.h.04.1 65034 1 0 0 0 0 0 0 0 1200 RTA00000408F.d.12.1 75782 1 0 0 0 0 0 0 0 1201 RTA00000133A.m.19.2 80167 1 0 0 0 0 0 0 0 1206 RTA00000126A.o.22.1 81752 1 0 0 0 0 0 0 0 1207 RTA00000419F.n.13.1 66026 1 0 0 0 0 0 0 0 1208 RTA00000130A.h.13.1 80790 1 0 0 0 0 0 0 0 1212 RTA00000411F.m.19.1 74924 1 0 0 0 0 0 0 0 1214 RTA00000419F.k.06.1 78493 1 0 0 0 0 0 0 0 1216 RTA00000412F.d.16.1 26829 1 0 0 0 0 0 0 0 1217 RTA00000119A.j.23.1 79835 1 0 0 0 0 0 0 0 1219 RTA00000195AF.c.12.1 37582 2 0 0 0 0 0 0 0 1223 RTA00000423F.c.19.1 40472 2 0 0 0 0 0 0 0 1224 RTA00000405F.g.24.1 39076 2 0 0 0 0 0 0 0 1226 RTA00000419F.c.11.1 65504 1 0 0 0 0 0 0 0 1227 RTA00000135A.f.14.2 79969 1 0 0 0 0 0 0 0 1228 RTA00000403F.a.05.1 18808 1 1 0 0 0 0 0 0 1229 RTA00000405F.e.17.1 38662 2 0 0 0 0 0 0 0 1230 RTA00000411F.d.05.1 75812 1 0 0 0 0 0 0 0 1232 RTA00000418F.d.03.1 76824 1 0 0 0 0 0 0 0 1233 RTA00000418F.h.08.1 76401 1 0 0 0 0 0 0 0 1234 RTA00000418F.m.10.1 79110 1 0 0 0 0 0 0 0 1235 RTA00000411F.i.15.1 31612 1 1 0 0 0 0 0 0 1236 RTA00000413F.i.23.1 63073 1 0 0 0 0 0 0 0 1237 RTA00000411F.e.24.1 64781 1 0 0 0 0 0 0 0 1238 RTA00000406F.g.22.1 38590 2 0 0 0 0 0 0 0 1239 RTA00000126A.n.13.2 79735 1 0 0 0 0 0 0 0 1240 RTA00000419F.a.02.1 77993 1 0 0 0 0 0 0 0 1241 RTA00000346F.l.13.1 7542 8 0 0 2 1 0 1 0 1245 RTA00000120A.d.15.1 80533 1 0 0 0 0 0 0 0 1246 RTA00000418F.f.21.1 75157 1 0 0 0 0 0 0 0 1248 RTA00000129A.d.1.2 80058 1 0 0 0 0 0 0 0 1251 RTA00000419F.m.20.1 76720 1 0 0 0 0 0 0 0 1253 RTA00000406F.e.15.1 39074 2 0 0 0 0 0 0 0 1255 RTA00000411F.c.10.1 73117 1 0 0 0 0 0 0 0 1259 RTA00000413F.d.05.1 64788 1 0 0 0 0 0 0 0 1260 RTA00000121A.o.3.1 81437 1 0 0 0 0 0 0 0 1262 RTA00000420F.e.02.1 40259 2 0 0 0 0 0 0 0 1268 RTA00000126A.k.7.2 79866 1 0 0 0 0 0 0 0 1270 RTA00000419F.l.03.1 79060 1 0 0 0 0 0 0 0 1272 RTA00000118A.a.2.1 38067 2 0 0 0 0 0 0 0 1273 RTA00000410F.m.18.1 76365 1 0 0 0 0 0 0 0 1275 RTA00000406F.c.20.1 38578 2 0 0 0 0 0 0 0 1276 RTA00000413F.b.14.1 66591 1 0 0 0 0 0 0 0 1277 RTA00000406F.c.18.1 14368 2 0 0 0 0 0 0 0 1278 RTA00000418F.j.09.1 76352 1 0 0 0 0 0 0 0 1279 RTA00000419F.f.23.1 65002 1 0 0 0 0 0 0 0 1281 RTA00000411F.a.05.1 76699 1 0 0 0 0 0 0 0 1282 RTA00000419F.m.21.1 77947 1 0 0 0 0 0 0 0 1283 RTA00000405F.n.16.1 21503 2 1 1 0 0 0 0 0 1284 RTA00000422F.o.19.2 13084 3 2 0 0 0 0 0 0 1285 RTA00000408F.n.02.2 76993 1 0 0 0 0 0 0 0 1290 RTA00000119A.g.7.1 83580 1 0 0 0 0 0 0 0 1291 RTA00000411F.i.02.1 66975 1 0 0 0 0 0 0 0 1292 RTA00000408F.l.09.1 75487 1 0 0 0 0 0 0 0 1293 RTA00000423F.g.04.1 23012 2 1 0 0 0 0 0 0 1295 RTA00000418F.i.18.1 78024 1 0 0 0 0 0 0 0 1296 RTA00000411F.h.15.1 65160 1 0 0 0 0 0 0 0 1297 RTA00000410F.i.19.1 78988 1 0 0 0 0 0 0 0 1298 RTA00000419F.k.24.1 75596 1 0 0 0 0 0 0 0 1301 RTA00000409F.i.09.1 75279 1 0 0 0 0 0 0 0 1302 RTA00000419F.h.02.1 63985 1 0 0 0 0 0 0 0 1303 RTA00000413F.b.12.1 64932 1 0 0 0 0 0 0 0 1304 RTA00000121A.h.18.1 16376 4 0 0 0 0 0 0 0 1305 RTA00000411F.n.20.1 75816 1 0 0 0 0 0 0 0 1307 RTA00000411F.n.12.1 73308 1 0 0 0 0 0 0 0 1308 RTA00000408F.j.12.2 18226 1 0 0 0 0 0 0 0 1309 RTA00000409F.i.03.1 75968 1 0 0 0 0 0 0 0 1312 RTA00000409F.j.05.1 74128 1 0 0 0 0 0 0 0 1313 RTA00000419F.m.04.1 74367 1 0 0 0 0 0 0 0 1314 RTA00000418F.k.03.1 78901 1 0 0 0 0 0 0 0 1315 RTA00000419F.d.16.1 64357 1 0 0 0 0 0 0 0 1316 RTA00000420F.e.10.1 65899 1 0 0 0 0 0 0 0 1319 RTA00000418F.k.08.1 18259 1 0 0 0 0 0 0 0 1322 RTA00000410F.c.02.1 75055 1 0 0 0 0 0 0 0 1324 RTA00000403F.h.18.1 39241 2 0 0 0 0 0 0 0 1325 RTA00000405F.n.13.1 23810 2 1 0 0 0 0 0 0 1326 RTA00000355R.e.14.1 16837 2 2 0 0 0 0 0 0 1327 RTA00000422F.l.03.1 39147 2 0 0 0 0 0 0 0 1329 RTA00000403F.o.14.1 38971 2 0 0 0 0 0 0 0 1333 RTA00000127A.f.11.1 81463 1 0 0 0 0 0 0 0 1335 RTA00000403F.o.07.1 39037 2 0 0 0 0 0 0 0 1336 RTA00000403F.d.19.1 39243 2 0 0 0 0 0 0 0 1338 RTA00000406F.l.17.1 37902 2 0 0 0 0 0 0 0 1339 RT060000418F.d.22.1 75324 1 0 0 0 0 0 0 0 1340 RTA00000340R.o.12.1 53732 1 0 0 0 0 0 0 0 1341 RTA00000125A.g.24.1 80397 1 0 0 0 0 0 0 0 1342 RTA00000130A.o.21.1 80218 1 0 0 0 0 0 0 0 1343 RTA00000420F.a.23.1 42158 1 1 0 0 0 0 0 0 1344 RTA00000411F.m.18.1 75629 1 0 0 0 0 0 0 0 1345 RTA00000407F.b.22.1 37487 2 0 0 0 0 0 0 0 1346 RTA00000409F.a.16.1 73990 1 0 0 0 0 0 0 0 1348 RTA00000341F.k.12.1 62985 1 0 0 0 0 0 0 0 1349 RTA00000129A.c.18.2 37216 2 0 0 0 0 0 0 0 1350 RTA00000410F.d.10.1 77561 1 0 0 0 0 0 0 0 1351 RTA00000351R.i.03.1 6874 6 3 0 0 1 0 0 0 1352 RTA00000135A.l.1.2 39426 2 0 0 0 0 0 0 0 1353 RTA00000420F.b.15.1 66136 1 0 0 0 0 0 0 0 1356 RTA00000403F.o.13.1 39049 2 0 0 0 0 0 0 0 1357 RTA00000411F.f.06.1 64186 1 0 0 0 0 0 0 0 1359 RTA00000351R.c.13.1 11476 6 0 0 0 0 0 0 0 1362 RTA00000420F.d.16.1 64485 1 0 0 0 0 0 0 0 1363 RTA00000404F.i.12.1 39001 2 0 0 0 0 0 0 0 1364 RTA00000404F.o.10.2 16785 2 2 0 0 0 0 0 0 1365 RTA00000419F.d.07.1 21421 1 2 0 0 0 0 0 0 1366 RTA00000404F.p.02.2 39097 2 0 1 0 0 0 0 0 1367 RTA00000125A.k.14.1 79457 1 0 0 0 0 0 0 0 1368 RTA00000122A.j.22.1 81151 1 0 0 0 0 0 0 0 1369 RTA00000406F.i.13.1 37904 2 0 0 0 0 0 0 0 1370 RTA00000135A.b.23.1 35241 2 0 0 0 0 0 0 0 1373 RTA00000423F.l.04.1 14320 2 0 0 0 0 0 0 0 1374 RTA00000420F.b.04.1 63820 1 0 0 0 0 0 0 0 1376 RTA00000408F.i.18.2 74410 1 0 0 0 0 0 0 0 1378 RTA00000341F.j.05.1 36177 2 0 0 0 0 0 0 0 1379 RTA00000420F.a.16.1 63345 1 0 0 0 0 0 0 0 1381 RTA00000410F.j.01.1 73399 1 0 0 0 0 0 0 0 1382 RTA00000408F.p.21.1 77930 1 0 0 0 0 0 0 0 1383 RTA00000412F.d.19.1 75743 1 0 0 0 0 0 0 0 1384 RTA00000352R.c.04.1 71976 1 0 0 0 0 0 0 0 1385 RTA00000413F.f.19.1 65189 1 0 0 0 0 0 0 0 1386 RTA00000411F.e.03.1 73648 1 0 0 0 0 0 0 0 1389 RTA00000418F.c.04.1 41587 1 1 0 0 0 0 0 0 1390 RTA00000418F.o.17.1 79069 1 0 0 0 0 0 0 0 1391 RTA00000418F.e.21.1 74773 1 0 0 0 0 0 0 0 1392 RTA00000419F.d.14.1 64945 1 0 0 0 0 0 0 0 1396 RTA00000410F.j.20.1 73601 1 0 0 0 0 0 0 0 1399 RTA00000119A.j.9.1 82060 1 0 0 0 0 0 0 0 1403 RTA00000340F.i.13.1 79299 1 0 0 0 0 0 0 0 1404 RTA00000412F.g.03.1 64740 1 0 0 0 0 0 0 0 1405 RTA00000122A.g.17.1 32655 1 1 0 0 0 0 0 0 1407 RTA00000419F.n.12.1 66086 1 0 0 0 0 0 0 0 1410 RTA00000351R.p.14.1 13166 2 3 0 0 0 0 0 0 1411 RTA00000403F.e.08.1 19126 3 0 0 0 0 0 0 0 1412 RTA00000124A.k.20.1 80913 1 0 0 0 0 0 0 0 1413 RTA00000121A.n.2.1 33585 1 1 0 0 0 0 0 0 1414 RTA00000422F.m.24.1 39159 2 0 1 0 1 1 2 2 1415 RTA00000408F.e.24.2 75002 1 0 0 0 0 0 0 0 1418 RTA00000403F.b.12.1 78775 1 0 0 0 0 0 0 0 1419 RTA00000404F.a.09.1 38985 2 0 0 0 0 0 0 0 1421 RTA00000403F.o.19.1 78615 1 0 0 0 0 0 0 0 1424 RTA00000410F.b.10.1 74504 1 0 0 0 0 0 0 0 1426 RTA00000413F.h.12.1 66929 1 0 0 0 0 0 0 0 1427 RTA00000406F.k.14.1 38651 2 0 0 0 0 0 0 0 1429 RTA00000411F.f.17.1 65661 1 0 0 0 0 0 0 0 1430 RTA00000411F.k.10.1 64506 1 0 0 0 0 0 0 0 1431 RTA00000411F.g.21.1 64500 1 0 0 0 0 0 0 0 1432 RTA00000119A.h.24.1 82266 1 0 0 0 0 0 0 0 1434 RTA00000408F.m.22.2 72949 1 0 0 0 0 0 0 0 1437 RTA00000410F.i.17.1 78147 1 0 0 0 0 0 0 0 1440 RTA00000129A.a.13.2 79780 1 0 0 0 0 0 0 0 1441 RTA00000129A.k.21.1 82067 1 0 0 0 0 0 0 0 1442 RTA00000350R.g.10.1 9026 7 0 0 1 0 0 0 0 1443 RTA00000413F.d.23.1 66030 1 0 0 0 0 0 0 0 1447 RTA00000411F.d.10.1 76445 1 0 0 0 0 0 0 0 1448 RTA00000404F.b.19.1 39281 2 0 0 0 0 0 0 0 1449 RTA00000418F.c.07.1 73245 1 0 0 0 0 0 0 0 1450 RTA00000418F.j.15.1 74855 1 0 0 0 0 1 0 0 1453 RTA00000413F.b.16.1 65126 1 0 0 0 0 0 0 0 1455 RTA00000350R.m.14.1 39171 2 0 0 0 0 0 0 0 1456 RTA00000418F.l.11.1 77158 1 0 0 0 0 0 0 0 1457 RTA00000130A.d.5.1 82051 1 0 0 0 0 0 0 0 1458 RTA00000339F.n.05.1 39648 2 0 0 0 0 0 0 0 1460 RTA00000407F.a.23.1 23489 2 1 0 0 0 0 0 0 1462 RTA00000403F.h.11.1 39219 2 0 0 0 0 0 0 0 1463 RTA00000406F.j.13.1 38688 2 0 0 0 0 0 0 0 1464 RTA00000352R.p.09.1 16915 4 0 0 0 0 0 0 0 1465 RTA00000413F.g.24.1 65481 1 0 0 0 0 0 0 0 1469 RTA00000420F.a.08.1 19473 1 2 0 0 0 0 0 0 1472 RTA00000404F.i.22.1 39082 2 0 0 0 0 0 0 0 1473 RTA00000124A.k.23.1 81350 1 0 0 0 0 0 0 0 1474 RTA00000404F.e.11.1 38991 2 0 0 0 0 0 0 0 1475 RTA00000129A.d.2.4 80119 1 0 0 0 0 0 0 0 1478 RTA00000419F.o.15.1 32487 1 1 0 0 0 0 0 0 1479 RTA00000119A.m.17.1 79536 1 0 0 0 0 0 0 0 1480 RTA00000410F.b.07.1 78916 1 0 0 0 0 0 0 0 1481 RTA00000420F.b.19.1 36873 2 0 0 0 0 0 0 0 1483 RTA00000411F.b.21.1 10051 1 0 0 0 0 0 0 0 1485 RTA00000356R.c.16.1 16915 4 0 0 0 0 0 0 0 1487 RTA00000412F.h.11.1 63175 1 0 0 0 0 0 0 0 1490 RTA00000420F.a.11.1 66460 1 0 0 0 0 0 0 0 1491 RTA00000120A.c.7.1 80985 1 0 0 1 0 0 0 0 1492 RTA00000404F.e.15.1 39101 2 0 0 0 0 0 0 0 1493 RTA00000422F.n.20.1 38676 2 0 0 0 0 0 1 0 1494 RTA00000423F.h.20.1 38639 2 0 0 0 0 0 0 0 1497 RTA00000410F.b.18.1 76701 1 0 0 0 0 0 0 0 1499 RTA00000423F.g.15.1 35173 2 0 0 0 0 0 0 0 1500 RTA00000413F.b.04.1 66427 1 0 0 0 0 0 0 0 1503 RTA00000346F.f.11.1 38528 2 0 0 0 0 0 0 0 1506 RTA00000422F.i.02.1 76436 1 0 0 0 0 0 0 0 1507 RTA00000410F.a.08.1 73324 1 0 0 0 0 0 0 0 1509 RTA00000419F.e.02.1 65010 1 0 0 0 0 0 0 0 1511 RTA00000403F.g.13.1 38718 2 0 0 0 0 0 0 0 1513 RTA00000407F.a.01.1 12501 3 1 0 0 0 0 0 0 1516 RTA00000411F.f.14.1 62984 1 0 0 0 0 0 0 0 1517 RTA00000411F.c.04.1 76858 1 0 0 0 0 0 0 0 1518 RTA00000135A.m.18.1 19255 2 0 0 0 0 0 0 0 1519 RTA00000413F.c.17.1 36831 2 0 0 0 0 0 0 0 1521 RTA00000404F.j.01.1 26859 2 0 0 0 0 0 0 0 1522 RTA00000138A.p.10.1 81625 1 0 0 0 0 0 0 0 1526 RTA00000423F.h.07.1 37933 2 0 0 0 0 0 0 0 1527 RTA00000413F.e.04.1 64176 1 0 0 0 0 0 0 0 1528 RTA00000406F.h.03.1 38585 2 0 0 0 0 0 0 0 1529 RTA00000403F.e.24.1 16432 2 2 0 0 0 0 0 0 1531 RTA00000403F.i.11.1 23535 2 1 0 0 0 0 0 0 1532 RTA00000419F.g.02.1 62839 1 0 0 0 0 0 0 0 1533 RTA00000347F.e.05.1 39814 2 0 0 0 0 0 0 0 1534 RTA00000408F.l.16.1 73468 1 0 0 0 0 0 0 0 1536 RTA00000423F.f.09.1 64823 1 0 0 0 0 0 0 0 1537 RTA00000419F.k.03.1 40822 1 1 0 0 0 0 0 0 1538 RTA00000406F.b.02.1 38744 2 0 0 0 0 0 0 0 1539 RTA00000418F.o.14.1 33524 1 1 0 0 0 0 0 0 1541 RTA00000404F.b.09.1 39166 2 0 0 0 0 0 0 0 1547 RTA00000406F.k.11.1 38715 2 0 0 0 0 0 0 0 1549 RTA00000406F.c.06.1 37924 2 0 0 0 0 0 0 0 1550 RTA00000418F.n.07.1 76316 1 0 0 0 0 0 0 0 1551 RTA00000419F.n.15.1 63484 1 0 0 0 0 0 0 0 1552 RTA00000408F.n.06.2 76642 1 0 0 0 0 0 0 0 1553 RTA00000420F.c.04.1 65007 1 0 0 0 0 0 0 0 1554 RTA00000411F.j.15.1 66871 1 0 0 0 0 0 0 0 1556 RTA00000128A.m.23.1 81441 1 0 0 0 0 0 0 0 1557 RTA00000406F.g.03.1 38690 2 0 0 0 0 0 0 0 1558 RTA00000405F.h.05.2 75706 1 0 0 0 0 0 0 0 1559 RTA00000129A.n.24.1 81409 1 0 0 0 0 0 0 0 1562 RTA00000418F.n.11.1 78977 1 0 0 0 0 0 0 0 1565 RTA00000120A.h.9.1 80736 1 0 0 0 0 0 0 0 1566 RTA00000413F.a.12.1 63403 1 0 0 0 0 0 0 0 1567 RTA00000412F.o.05.1 63575 1 0 0 0 0 0 0 0 1571 RTA00000354R.n.04.1 22049 3 0 0 0 0 0 0 0 1573 RTA00000406F.h.05.1 38542 2 0 0 0 0 0 0 0 1574 RTA00000410F.b.24.1 75104 1 0 0 0 0 0 0 0 1575 RTA00000423F.d.11.1 38950 2 0 0 0 0 0 0 0 1578 RTA00000119A.k.1.1 81282 1 0 0 0 0 0 0 0 1579 RTA00000420F.f.07.1 66312 1 0 0 0 0 0 0 0 1580 RTA00000404F.k.22.2 39084 2 0 0 0 0 0 0 0 1581 RTA00000422F.e.07.1 38964 2 0 0 0 0 0 0 0 1582 RTA00000410F.f.12.1 73883 1 0 0 0 0 0 0 0 1584 RTA00000411F.m.11.1 73196 1 0 0 0 0 0 0 0 1587 RTA00000403F.o.10.2 38964 2 0 0 0 0 0 0 0 1590 RTA00000413F.c.10.1 65600 1 0 0 0 0 0 0 0 1591 RTA00000411F.b.17.1 72893 1 0 0 0 0 0 0 0 1593 RTA00000408F.k.19.1 77593 1 0 0 0 0 0 0 0 1596 RTA00000119A.i.8.1 82593 1 0 0 0 0 0 0 0 1598 RTA00000418F.g.03.1 78737 1 0 0 0 0 0 0 0 1599 RTA00000411F.a.09.1 78629 1 0 0 0 0 0 0 0 1601 RTA00000419F.j.11.1 73183 1 0 0 0 0 0 0 0 1603 RTA00000404F.n.18.2 37169 2 0 0 0 0 0 0 0 1604 RTA00000122A.n.16.1 80553 1 0 0 0 0 0 0 0 1605 RTA00000420F.c.07.1 65555 1 0 0 0 0 0 0 0 1608 RTA00000408F.j.13.2 42275 1 1 0 0 0 0 0 0 1610 RTA00000423F.a.01.1 39103 2 0 0 0 0 0 0 0 1613 RTA00000341F.e.20.1 67422 1 0 0 0 0 0 0 0 1614 RTA00000419F.m.22.1 75600 1 0 0 0 0 0 0 0 1615 RTA00000419F.m.23.1 64263 1 0 0 0 0 0 0 0 1616 RTA00000419F.b.06.1 76728 1 0 0 0 0 0 0 0 1618 RTA00000406F.p.08.1 37573 2 0 0 0 0 0 0 2 1619 RTA00000129A.n.17.1 79811 1 0 0 0 0 0 0 0 1621 RTA00000407F.b.08.1 37513 2 0 0 0 0 0 0 0 1623 RTA00000406F.i.08.1 37946 2 0 0 0 0 0 0 0 1624 RTA00000403F.h.07.1 26856 2 0 0 0 0 0 0 0 1625 RTA00000418F.n.24.1 73153 1 0 0 0 0 0 0 0 1627 RTA00000409F.l.20.1 74394 1 0 0 0 0 0 0 0 1628 RTA00000418F.l.06.1 73317 1 0 0 0 0 0 0 0 1629 RTA00000346F.o.22.1 7381 2 6 0 0 0 0 0 0 1630 RTA00000129A.k.22.1 79639 1 0 0 0 0 0 0 0 1632 RTA00000418F.m.22.1 74567 1 0 0 0 0 0 0 0 1633 RTA00000413F.c.12.1 65334 1 0 0 0 0 0 0 0 1635 RTA00000418F.g.20.1 74626 1 0 0 0 0 0 0 0 1636 RTA00000413F.d.15.1 64943 1 0 0 0 0 0 0 0 1639 RTA00000412F.c.10.1 76372 1 0 0 0 0 0 0 0 1640 RTA00000122A.j.17.1 62736 1 0 0 0 0 0 0 0 1645 RTA00000418F.j.19.1 78399 1 0 0 0 0 0 0 0 1646 RTA00000137A.p.12.1 80614 1 0 0 0 0 0 0 0 1648 RTA00000418F.p.10.1 75323 1 0 0 0 0 0 0 0 1649 RTA00000408F.k.12.1 77246 1 0 0 0 0 0 0 0 1650 RTA00000137A.j.11.4 79752 1 0 0 0 0 0 0 0 1652 RTA00000419F.n.24.1 65995 1 0 0 0 0 0 0 0 1653 RTA00000418F.l.03.1 79058 1 0 0 0 0 0 0 0 1655 RTA00000419F.m.13.1 79052 1 0 0 0 0 0 0 0 1656 RTA00000418F.j.14.1 32623 1 1 0 0 0 0 0 0 1657 RTA00000403F.a.10.1 73952 1 0 0 0 0 0 0 0 1658 RTA00000420F.a.21.1 66241 1 0 0 0 0 0 0 0 1659 RTA00000127A.e.6.1 5885 4 2 0 0 0 0 0 0 1660 RTA00000405F.g.21.2 38966 2 0 0 0 0 0 0 0 1661 RTA00000405F.g.21.1 38966 2 0 0 0 0 0 0 0 1662 RTA00000419F.m.06.1 75749 1 0 0 0 0 0 0 0 1663 RTA00000423F.g.03.1 38007 2 0 0 0 0 0 0 0 1665 RTA00000418F.f.03.1 78911 1 0 0 0 0 0 0 0 1668 RTA00000120A.c.20.1 43235 1 1 0 0 0 1 0 0 1669 RTA00000138A.m.15.1 41603 1 1 0 0 0 0 0 0 1670 RTA00000408F.f.14.2 73024 1 0 0 0 0 0 0 0 1671 RTA00000418F.p.20.1 78023 1 0 0 0 0 0 0 0 1672 RTA00000423F.e.21.1 66961 1 0 0 0 0 0 0 0 1673 RTA00000419F.j.22.1 73525 1 0 0 0 0 0 0 0 1674 RTA00000410F.d.18.1 75458 1 0 0 0 0 0 0 0 1675 RTA00000403F.b.24.1 78838 1 0 0 0 0 0 0 0 1677 RTA00000410F.e.09.1 76093 1 0 0 0 0 0 0 0 1680 RTA00000353R.h.10.1 39498 2 0 0 0 0 0 0 0 1682 RTA00000411F.d.21.1 74794 1 0 0 0 0 0 0 0 1683 RTA00000340F.m.04.1 19406 2 1 0 0 0 0 0 0 1684 RTA00000411F.n.09.1 78962 1 0 0 0 0 0 0 0 1685 RTA00000127A.h.22.2 13155 2 3 0 0 0 0 0 0 1686 RTA00000420F.e.09.1 66325 1 0 0 0 0 0 0 0 1687 RTA00000405F.p.03.1 11346 3 3 0 0 0 0 0 0 1688 RTA00000419F.a.18.1 78484 1 0 0 0 0 0 0 0 1691 RTA00000121A.n.23.1 26981 2 0 0 0 0 0 0 0 1692 RTA00000121A.n.15.1 40849 1 1 0 0 0 0 0 0 1693 RTA00000403F.i.23.1 11364 4 2 0 0 0 0 0 0 1694 RTA00000405F.a.03.1 39065 2 0 0 0 0 0 0 0 1696 RTA00000419F.p.08.1 65560 1 0 0 0 0 0 0 0 1697 RTA00000126A.n.6.2 79917 1 0 0 0 0 0 0 0 1698 RTA00000413F.c.03.1 64527 1 0 0 1 0 0 0 0 1699 RTA00000422F.k.24.1 39118 2 0 0 0 0 0 0 0 1700 RTA00000412F.c.17.1 75620 1 0 0 0 0 0 0 0 1702 RTA00000347F.g.08.1 23121 3 0 0 0 0 0 0 0 1703 RTA00000419F.o.06.1 64643 1 0 0 0 0 0 0 0 1704 RTA00000340R.j.07.1 38954 2 0 0 0 0 0 0 0 1705 RTA00000423F.j.02.1 38617 2 0 0 0 0 0 0 0 1706 RTA00000419F.c.04.1 63749 1 0 0 0 0 0 0 0 1707 RTA00000411F.a.01.1 74524 1 0 0 0 0 0 0 0 1708 RTA00000406F.f.05.1 22961 2 1 0 0 0 0 1 0 1709 RTA00000410F.n.05.1 77830 1 0 0 0 0 0 0 0 1710 RTA00000404F.e.06.1 39315 2 0 0 0 0 0 0 0 1712 RTA00000411F.c.03.1 79280 1 0 0 0 0 0 0 0 1718 RTA00000405F.l.07.1 38636 2 0 0 0 0 0 0 0 1720 RTA00000411F.n.06.1 73886 1 0 0 0 0 0 0 0 1721 RTA00000422F.k.15.1 19253 2 0 0 0 0 0 0 0 1722 RTA00000406F.h.16.1 38618 2 0 0 0 0 0 0 0 1723 RTA00000419F.f.24.1 18717 1 1 0 0 0 0 0 0 1724 RTA00000411F.d.18.1 76063 1 0 0 0 0 0 0 0 1727 RTA00000408F.d.15.1 78467 1 0 0 0 0 0 0 0 1728 RTA00000339F.b.22.1 6867 7 3 0 0 0 0 0 0 1730 RTA00000411F.n.02.1 78049 1 0 0 0 0 0 0 0 1731 RTA00000419F.b.17.1 63261 1 0 0 0 0 0 0 0 1733 RTA00000130A.e.20.1 79502 1 0 0 0 0 0 0 0 1735 RTA00000411F.i.13.1 66138 1 0 0 0 0 0 0 0 1736 RTA00000420F.e.20.1 64762 1 0 0 0 0 0 0 0 1737 RTA00000126A.p.23.2 80915 1 0 0 0 0 0 0 0 1739 RTA00000406F.g.08.1 37963 2 0 0 0 0 0 0 0 1740 RTA00000409F.a.08.1 74978 1 0 0 0 0 0 0 0 1741 RTA00000406F.d.24.1 37997 2 0 0 0 0 0 0 0 1744 RTA00000418F.i.12.1 78971 1 0 0 0 0 0 0 0 1745 RTA00000121A.h.19.1 80334 1 0 0 0 0 0 0 0 1746 RTA00000419F.b.10.1 78566 1 0 0 0 0 0 0 0 1747 RTA00000406F.m.10.1 38004 2 0 0 0 0 0 0 0 1748 RTA00000406F.o.05.1 37894 2 0 0 0 0 0 0 0 1749 RTA00000408F.b.04.2 39933 2 0 0 0 0 0 0 0 1750 RTA00000411F.k.04.1 65407 1 0 0 0 0 0 0 0 1752 RTA00000134A.l.9.1 81814 1 0 0 0 0 0 0 0 1754 RTA00000418F.k.04.1 75864 1 0 0 0 0 0 0 0 1757 RTA00000419F.p.18.1 63002 1 0 0 0 0 0 0 0 1759 RTA00000419F.a.24.1 79290 1 0 0 0 0 0 0 0 1761 RTA00000129A.e.14.1 80053 1 0 0 0 0 0 0 0 1762 RTA00000404F.a.01.1 19251 2 0 0 0 0 0 0 0 1765 RTA00000408F.n.16.2 73720 1 0 0 0 0 0 0 0 1769 RTA00000412F.l.14.1 62792 1 0 0 0 0 0 0 0 1770 RTA00000129A.b.6.2 39111 2 0 0 0 0 0 0 0 1771 RTA00000406F.n.12.1 37517 2 0 0 0 0 0 0 0 1772 RTA00000418F.e.03.1 73442 1 0 0 0 0 0 0 0 1774 RTA00000403F.g.03.1 23537 2 1 0 0 0 0 0 0 1775 RTA00000412F.p.06.1 65485 1 0 0 0 0 0 0 0 1776 RTA00000419F.b.21.1 65366 1 0 0 0 0 0 0 0 1779 RTA00000351R.j.16.1 64773 1 0 0 0 0 0 0 0 1781 RTA00000419F.f.18.1 64047 1 0 0 0 0 0 0 0 1782 RTA00000423F.i.16.1 38604 2 0 0 0 0 0 0 0 1784 RTA00000411F.f.04.1 64526 1 0 0 0 0 0 0 0 1785 RTA00000125A.c.17.1 80619 1 0 0 0 0 0 0 0 1786 RTA00000404F.g.08.1 38980 2 0 0 0 0 0 0 0 1787 RTA00000423F.c.13.1 39059 2 0 0 0 0 0 0 0 1790 RTA00000404F.k.15.1 18225 2 0 0 0 0 0 0 0 1792 RTA00000339F.l.12.1 7711 4 1 0 0 0 0 0 0 1793 RTA00000406F.b.01.1 39006 2 0 0 0 0 0 0 0 1794 RTA00000407F.c.08.1 37549 2 0 0 0 0 0 0 0 1796 RTA00000403F.b.05.1 74300 1 0 0 0 0 0 0 0 1800 RTA00000408F.j.05.2 73878 1 0 0 0 0 0 0 0 1802 RTA00000419F.c.14.1 65727 1 0 0 0 0 0 0 0 1806 RTA00000346F.h.24.1 4379 9 2 0 0 0 0 0 0 1807 RTA00000420F.b.02.1 64013 1 0 0 0 0 0 0 0 1808 RTA00000413F.b.24.1 65117 1 0 0 0 0 0 0 0 1809 RTA00000412F.d.08.1 75328 1 0 0 0 0 0 0 0 1811 RTA00000419F.m.18.1 76014 1 0 0 0 0 0 0 0 1812 RTA00000419F.l.24.1 74628 1 0 0 0 0 0 0 0 1813 RTA00000408F.c.06.1 78619 1 0 0 0 0 0 0 0 1814 RTA00000405F.h.21.2 39072 2 0 0 0 0 0 0 0 1816 RTA00000405F.g.05.2 38987 2 0 0 0 0 0 0 0 1817 RTA00000411F.f.20.1 63501 1 0 0 0 0 0 0 0 1819 RTA00000420F.d.19.1 43146 1 1 0 0 0 0 0 0 1820 RTA00000195R.a.06.1 35265 2 0 1 0 0 0 0 0 1821 RTA00000123A.f.2.1 80379 1 0 0 0 0 0 0 0 1822 RTA00000411F.j.11.1 66154 1 0 0 0 0 0 0 0 1827 RTA00000419F.j.03.1 77578 1 0 0 0 0 0 0 0 1829 RTA00000423F.h.11.1 38977 2 0 0 0 0 0 0 0 1830 RTA00000413F.b.17.1 21704 1 2 0 0 0 0 0 0 1833 RTA00000423F.f.03.1 63852 1 0 0 0 0 0 0 0 1834 RTA00000419F.e.10.1 63225 1 0 0 0 0 0 0 0 1836 RTA00000403F.d.02.1 39224 2 0 0 0 0 0 0 0 1838 RTA00000418F.j.20.1 77101 1 0 0 0 0 0 0 0 1846 RTA00000356R.h.05.1 35052 2 0 1 0 0 0 0 0 1848 RTA00000340F.i.15.1 26815 1 0 0 0 0 0 0 0 1850 RTA00000345F.c.12.1 23824 2 1 0 0 0 0 0 0 1852 RTA00000412F.o.03.1 65039 1 0 0 0 0 0 0 0 1853 RTA00000409F.d.16.1 76090 1 0 0 0 0 0 0 0 1856 RTA00000408F.j.17.2 78935 1 0 0 0 0 0 0 0 1857 RTA00000126A.j.15.2 40425 2 0 0 0 0 0 0 0 1861 RTA00000410F.b.17.1 77458 1 0 0 0 0 0 0 0 1862 RTA00000419F.l.22.1 78444 1 0 0 0 0 0 0 0 1864 RTA00000422F.f.22.1 38703 2 0 0 0 0 0 0 0 1867 RTA00000418F.c.05.1 76475 1 0 0 0 0 0 0 0 1868 RTA00000418F.p.21.1 78068 1 0 0 0 0 0 0 0 1870 RTA00000340F.i.08.1 12005 2 1 0 0 0 0 0 0 1871 RTA00000410F.o.04.1 79018 1 0 0 0 0 0 0 0 1872 RTA00000411F.l.16.1 16122 1 3 0 0 0 0 0 0 1873 RTA00000411F.j.03.1 66263 1 0 0 0 0 0 0 0 1874 RTA00000126A.k.24.1 39428 2 0 0 0 0 0 0 0 1876 RTA00000120A.m.10.3 81376 1 0 0 0 0 0 0 0 1877 RTA00000419F.f.16.1 64679 1 0 0 0 0 0 0 0 1878 RTA00000408F.c.23.1 42261 1 1 0 0 0 0 0 0 1881 RTA00000136A.h.6.1 81620 1 0 0 0 0 0 0 0 1886 RTA00000418F.e.20.1 73741 1 0 0 0 0 0 0 0 1888 RTA00000405F.l.03.1 38580 2 0 0 0 0 0 0 0 1889 RTA00000418F.m.02.1 74550 1 0 0 0 0 0 0 0 1891 RTA00000406F.c.05.1 22077 3 0 1 0 0 0 0 0 1893 RTA00000411F.k.21.1 65349 1 0 0 0 0 0 0 0 1897 RTA00000418F.l.06.1 75151 1 0 0 0 0 0 0 0 1898 RTA00000423F.a.03.1 26796 2 0 0 0 0 0 0 0 1900 RTA00000423F.k.21.2 37499 2 0 0 0 0 0 0 0 1902 RTA00000404F.c.18.1 38982 2 0 0 0 0 0 0 0 1905 RTA00000411F.g.24.1 65233 1 0 0 0 0 0 0 0 1907 RTA00000405F.m.07.1 37733 2 0 0 0 0 0 0 0 1908 RTA00000411F.j.07.1 66963 1 0 0 0 0 0 0 0 1910 RTA00000353R.h.04.1 17123 4 0 0 0 0 0 0 0 1911 RTA00000408F.f.10.2 75309 1 0 0 0 0 0 0 0 1913 RTA00000405F.o.03.1 37575 2 0 0 0 0 0 0 0 1914 RTA00000413F.b.18.1 39873 2 0 0 0 0 0 0 0 1920 RTA00000408F.c.08.1 73473 1 0 0 0 0 0 0 0 1922 RTA00000410F.c.06.1 77784 1 0 0 0 1 0 0 0 1924 RTA00000405F.b.08.1 39182 2 0 0 0 0 0 0 0 1925 RTA00000409F.l.24.1 73174 1 0 0 0 0 0 0 0 1926 RTA00000406F.j.06.1 38952 2 0 0 0 0 0 0 0 1927 RTA00000423F.h.03.1 37903 2 0 0 0 0 0 0 0 1929 RTA00000121A.k.22.1 79523 1 0 0 0 0 0 0 0 1931 RTA00000411F.m.06.1 24195 2 1 0 0 0 0 0 0 1932 RTA00000126A.b.9.1 81279 1 0 0 0 0 0 0 0 1935 RTA00000404F.l.05.1 38671 2 0 0 0 0 0 0 0 1941 RTA00000419F.p.10.1 41448 1 1 0 0 0 0 0 0 1942 RTA00000120A.c.19.1 81016 1 0 0 0 0 0 0 0 1948 RTA00000411F.k.14.1 63987 1 0 0 0 0 0 0 0 1949 RTA00000420F.e.05.1 63908 1 0 0 0 0 0 0 0 1952 RTA00000128A.j.10.1 80085 1 0 0 0 0 0 0 0 1953 RTA00000412F.f.10.2 65405 1 0 0 0 0 0 0 0 1955 RTA00000422F.k.17.1 38955 2 0 0 0 0 0 0 0 1957 RTA00000347F.h.10.1 22779 3 0 0 0 0 0 0 0 1959 RTA00000419F.l.02.1 75736 1 0 0 0 0 0 0 0 1961 RTA00000418F.b.20.1 73560 1 0 0 0 0 0 0 0 1964 RTA00000408F.n.05.2 77883 1 0 0 0 0 0 0 0 1965 RTA00000419F.o.09.1 66396 1 0 0 0 0 0 0 0 1970 RTA00000422F.o.08.2 26832 2 0 0 0 0 0 0 0 1973 RTA00000418F.m.18.1 76479 1 0 0 0 0 0 0 0 1974 RTA00000347F.e.20.1 39911 2 0 0 0 0 0 0 0 1975 RTA00000419F.e.23.1 65772 1 0 0 0 0 0 0 0 1982 RTA00000411F.g.05.1 64664 1 0 0 0 0 0 0 0 1983 RTA00000404F.h.10.1 37148 2 0 0 0 0 0 0 0 1984 RTA00000422F.n.14.1 26787 2 0 0 0 0 0 0 0 1986 RTA00000120A.m.13.3 80608 1 0 0 0 0 0 0 0 1987 RTA00000412F.i.03.1 65617 1 0 0 0 0 0 0 0 1988 RTA00000418F.l.02.1 39316 2 0 0 0 0 0 0 0 1990 RTA00000411F.j.04.1 66219 1 0 0 0 0 0 0 0 1995 RTA00000404F.a.18.1 36267 2 0 0 0 0 0 0 0 1996 RTA00000408F.l.14.1 12001 2 3 0 0 0 0 0 0 1997 RTA00000405F.d.10.1 39000 2 0 0 0 0 0 0 0 1999 RTA00000418F.h.23.1 75153 1 0 0 0 0 0 0 0 2001 RTA00000418F.j.11.1 73853 1 0 0 0 0 0 0 0 2002 RTA00000408F.o.13.1 74895 1 0 0 0 0 0 0 0 2003 RTA00000419F.o.07.1 14059 1 0 0 0 0 0 0 0 2004 RTA00000419F.n.17.1 63186 1 0 0 0 0 0 0 0 2005 RTA00000403F.f.15.1 22768 3 0 0 0 0 0 0 0 2006 RTA00000408F.d.03.1 22768 3 0 0 0 0 0 0 0 2008 RTA00000346F.f.02.1 62757 1 0 0 0 0 0 0 0 2010 RTA00000413F.i.21.1 64066 1 0 0 0 0 0 0 0 2012 RTA00000419F.h.21.1 64828 1 0 0 0 0 0 0 0 2021 RTA00000121A.a.2.1 81843 1 0 0 0 0 0 0 0 2022 RTA00000527F.g.13.1 36035 2 0 0 0 0 0 0 0 2025 RTA00000426F.h.11.1 75479 1 0 0 0 0 0 0 0 2030 RTA00000522F.b.22.1 75181 1 0 0 0 0 0 0 0 2033 RTA00000522F.a.23.1 38613 2 0 0 0 0 0 0 0 2035 RTA00000523F.b.02.1 65163 1 0 0 0 0 0 0 0 2036 RTA00000425F.j.14.1 73397 1 0 0 0 0 0 0 0 2039 RTA00000522F.e.16.1 75283 1 0 0 0 0 0 0 0 2042 RTA00000523F.h.17.1 65586 1 0 0 0 0 0 0 0 2044 RTA00000522F.p.07.1 76888 1 0 0 0 0 0 0 0 2045 RTA00000522F.n.08.1 76343 1 0 0 0 0 0 0 0 2046 RTA00000425F.c.06.1 78041 1 0 0 0 0 0 0 0 2047 RTA00000427F.b.23.1 64297 1 0 0 0 0 0 0 0 2048 RTA00000527F.p.02.1 36844 2 0 0 0 0 0 0 0 2049 RTA00000427F.d.08.1 63967 1 0 0 0 0 0 0 0 2051 RTA00000426F.m.07.1 63504 1 0 0 0 0 0 0 0 2052 RTA00000427F.c.10.1 65478 1 0 0 0 0 0 0 0 2055 RTA00000424F.m.15.1 73759 1 0 0 0 0 0 0 0 2056 RTA00000426F.f.11.1 63102 1 0 0 0 0 0 0 0 2058 RTA00000426F.f.20.1 65134 1 0 0 0 0 0 0 0 2063 RTA00000527F.i.19.2 38089 2 0 0 0 0 0 0 0 2068 RTA00000523F.e.18.1 62898 1 0 0 0 0 0 0 0 2069 RTA00000527F.k.21.1 36051 2 0 0 0 0 0 0 0 2072 RTA00000522F.n.02.1 74959 1 0 0 0 0 0 0 0 2075 RTA00000425F.f.19.1 32635 1 1 0 0 0 0 0 0 2076 RTA00000528F.e.23.1 19242 3 0 0 0 0 0 0 0 2077 RTA00000522F.n.16.1 26769 1 0 0 0 0 0 0 0 2078 RTA00000427F.c.20.1 26527 1 0 0 0 0 0 0 0 2079 RTA00000527F.k.06.1 12469 3 1 0 0 0 0 0 0 2081 RTA00000523F.i.06.1 66341 1 0 0 0 0 0 0 0 2082 RTA00000427F.f.21.1 36853 2 0 0 0 0 0 0 0 2083 RTA00000427F.j.19.1 41395 1 1 0 0 0 0 0 0 2084 RTA00000522F.b.01.1 75691 1 0 0 0 0 0 0 0 2085 RTA00000424F.i.24.1 79101 1 0 0 0 0 0 0 0 2086 RTA00000523F.c.01.1 65710 1 0 0 0 0 0 0 0 2087 RTA00000427F.b.15.1 66891 1 0 0 0 0 0 0 0 2090 RTA00000522F.j.15.2 76535 1 0 0 0 0 0 0 0 2093 RTA00000426F.f.19.1 66701 1 0 1 0 0 0 0 0 2096 RTA00000523F.i.22.1 64688 1 0 0 0 0 0 0 0 2098 RTA00000425F.i.17.1 43213 1 1 0 0 0 0 0 0 2101 RTA00000425F.p.12.1 73219 1 0 0 0 0 0 0 0 2102 RTA00000427F.j.07.1 64819 1 0 0 0 0 0 0 0 2104 RTA00000527F.i.05.2 37481 2 0 0 0 0 0 0 0 2107 RTA00000523F.k.01.1 41437 1 1 0 0 0 0 0 0 2108 RTA00000425F.j.11.1 76667 1 0 0 0 0 0 0 0 2109 RTA00000424F.b.22.4 72971 1 0 0 0 0 0 0 0 2111 RTA00000525F.a.03.1 36786 2 0 0 0 0 0 0 0 2112 RTA00000527F.i.21.2 37490 2 0 0 0 0 0 0 0 2113 RTA00000424F.a.24.4 73951 1 0 0 0 0 0 0 0 2114 RTA00000522F.k.14.1 74280 1 0 0 0 0 0 0 0 2115 RTA00000522F.n.05.1 73260 1 0 0 0 0 0 0 0 2116 RTA00000523F.c.18.1 66179 1 0 0 0 0 0 0 0 2117 RTA00000523F.b.13.1 66330 1 0 0 0 0 0 0 0 2119 RTA00000527F.p.16.1 23798 2 1 0 0 0 0 0 0 2120 RTA00000425F.c.20.1 73581 1 0 0 0 0 0 0 0 2121 RTA00000424F.i.21.1 73482 1 0 0 0 0 0 0 0 2122 RTA00000523F.j.19.1 65910 1 0 0 0 0 0 0 0 2124 RTA00000424F.b.22.1 72971 1 0 0 0 0 0 0 0 2125 RTA00000527F.b.18.1 37469 2 0 0 0 0 0 0 0 2129 RTA00000525F.e.16.1 36837 2 0 0 0 0 0 0 0 2131 RTA00000522F.d.08.1 74284 1 0 0 0 0 0 0 0 2134 RTA00000527F.g.07.1 37488 2 0 0 0 0 0 0 0 2136 RTA00000525F.b.05.1 21116 2 1 0 0 0 0 0 0 2137 RTA00000425F.n.05.1 73965 1 0 0 0 0 0 0 0 2138 RTA00000523F.d.18.1 64072 1 0 0 0 0 0 0 0 2139 RTA00000525F.a.02.1 37454 2 0 0 0 0 0 0 0 2141 RTA00000426F.h.09.1 78797 1 0 0 0 0 0 0 0 2144 RTA00000427F.g.05.1 63138 1 0 0 0 0 0 0 0 2145 RTA00000424F.m.12.1 77675 1 0 0 0 0 0 0 0 2151 RTA00000427F.h.12.1 36894 2 0 0 0 0 0 0 0 2152 RTA00000523F.c.15.1 36935 2 0 0 0 0 0 0 0 2153 RTA00000427F.k.17.1 64965 1 0 0 0 0 0 0 0 2155 RTA00000424F.c.14.3 76614 1 0 0 0 0 0 0 0 2156 RTA00000522F.k.10.2 77619 1 0 0 0 0 0 0 0 2157 RTA00000424F.m.22.1 72943 1 0 0 0 0 0 0 0 2158 RTA00000527F.h.17.1 37799 2 0 0 0 0 0 0 0 2159 RTA00000527F.c.22.1 37496 2 0 0 0 0 0 0 0 2160 RTA00000425F.k.22.1 78123 1 0 0 0 0 0 0 0 2161 RTA00000424F.m.14.1 77491 1 0 0 0 0 0 0 0 2162 RTA00000522F.k.19.1 32625 1 1 0 0 0 0 0 0 2163 RTA00000523F.i.18.1 64463 1 0 0 0 0 0 0 0 2164 RTA00000425F.j.22.1 73882 1 0 0 0 0 0 0 0 2165 RTA00000527F.g.23.1 37538 2 0 0 0 0 0 0 0 2166 RTA00000426F.m.24.1 63943 1 0 0 0 0 0 0 0 2168 RTA00000425F.d.21.1 78920 1 0 0 0 0 0 0 0 2170 RTA00000424F.d.04.3 76505 1 0 0 0 0 0 0 0 2171 RTA00000424F.d.04.1 76505 1 0 0 0 0 0 0 0 2172 RTA00000427F.c.12.1 66995 1 0 0 0 0 0 0 0 2174 RTA00000527F.l.13.1 36904 2 0 0 0 0 0 0 0 2175 RTA00000522F.h.13.1 40823 1 1 0 0 0 0 0 0 2176 RTA00000424F.l.19.1 75454 1 0 0 0 0 0 0 0 2179 RTA00000427F.a.06.1 66550 1 0 0 0 0 0 0 0 2180 RTA00000525F.c.19.1 38159 2 0 0 0 0 0 0 0 2181 RTA00000523F.f.06.1 62871 1 0 0 0 0 0 0 0 2182 RTA00000424F.h.10.1 72925 1 0 0 0 0 0 0 0 2183 RTA00000522F.a.12.1 33515 1 1 0 0 0 0 0 0 2184 RTA00000522F.h.01.1 75010 1 0 0 0 0 0 0 0 2186 RTA00000425F.e.21.1 77203 1 0 0 0 0 0 0 0 2187 RTA00000523F.f.07.1 62799 1 0 0 0 0 0 0 0 2189 RTA00000424F.j.12.1 73827 1 0 0 0 0 0 0 0 2191 RTA00000523F.d.12.1 64888 1 0 0 0 0 0 0 0 2192 RTA00000523F.e.10.1 62878 1 0 0 0 0 0 0 0 2193 RTA00000425F.f.11.1 79275 1 0 0 0 0 0 0 0 2194 RTA00000426F.m.18.1 62974 1 0 0 0 0 0 0 0 2197 RTA00000522F.g.15.1 76536 1 0 0 0 0 0 0 0 2198 RTA00000522F.n.12.1 74117 1 0 0 0 0 0 0 0 2200 RTA00000424F.d.10.3 73110 1 0 0 0 0 0 0 0 2204 RTA00000527F.c.04.1 23090 3 0 0 0 0 0 0 0 2206 RTA00000527F.h.21.1 37630 2 0 0 0 0 0 0 0 2207 RTA00000425F.c.07.1 76042 1 0 0 0 0 0 0 0 2209 RTA00000525F.c.15.1 7692 2 0 0 0 0 0 0 0 2210 RTA00000424F.d.22.3 76189 1 0 0 0 0 0 0 0 2211 RTA00000523F.h.12.1 65745 1 0 0 0 0 0 0 0 2212 RTA00000522F.g.22.1 77504 1 0 0 0 0 0 0 0 2215 RTA00000522F.j.12.2 74341 1 0 0 0 0 0 0 0 2216 RTA00000523F.i.08.1 65099 1 0 0 0 0 0 0 0 2218 RTA00000425F.j.20.1 26760 1 0 0 0 0 0 0 0 2220 RTA00000427F.f.24.1 64572 1 0 0 0 0 0 0 0 2221 RTA00000527F.a.13.1 37740 2 0 0 0 0 0 0 0 2225 RTA00000424F.a.09.4 77833 1 0 0 0 0 0 0 0 2227 RTA00000525F.f.07.1 37500 2 0 0 0 0 0 0 0 2228 RTA00000424F.j.07.1 79211 1 0 0 0 0 0 0 0 2229 RTA00000424F.m.10.1 34251 1 1 0 0 0 0 0 0 2231 RTA00000522F.g.06.1 78221 1 0 0 0 0 0 0 0 2232 RTA00000424F.h.03.1 74447 1 0 0 0 0 0 0 0 2233 RTA00000424F.n.06.1 74737 1 0 0 0 0 0 0 0 2234 RTA00000427F.c.22.1 63990 1 0 0 0 0 0 0 0 2235 RTA00000424F.k.12.1 77666 1 0 0 0 0 0 0 0 2236 RTA00000425F.f.02.1 76982 1 0 0 0 0 0 0 0 2237 RTA00000427F.h.11.1 26494 1 0 0 0 0 0 0 0 2238 RTA00000425F.j.16.1 75631 1 0 0 0 0 0 0 0 2240 RTA00000427F.f.17.1 63803 1 0 0 0 0 0 0 0 2241 RTA00000522F.o.18.1 76366 1 0 0 0 0 0 0 0 2242 RTA00000427F.j.22.1 66367 1 0 0 0 0 0 0 0 2243 RTA00000426F.p.10.1 65845 1 0 0 0 0 0 0 0 2244 RTA00000522F.m.02.1 76834 1 0 0 0 0 0 0 0 2247 RTA00000425F.e.15.1 75921 1 0 0 0 0 0 0 0 2250 RTA00000424F.n.13.1 74942 1 0 0 0 0 0 0 0 2251 RTA00000424F.g.14.1 74879 1 0 0 0 0 0 0 0 2252 RTA00000426F.e.17.1 64089 1 0 0 0 0 0 0 0 2256 RTA00000427F.g.19.1 64611 1 0 0 0 0 0 0 0 2258 RTA00000522F.c.01.1 74938 1 0 0 0 0 0 0 0 2259 RTA00000522F.g.17.1 76486 1 0 0 0 0 0 0 0 2260 RTA00000523F.j.17.1 63610 1 0 0 0 0 0 0 0 2261 RTA00000522F.n.14.1 73410 1 0 0 0 0 0 1 0 2263 RTA00000523F.e.20.1 65164 1 0 0 0 0 0 0 0 2264 RTA00000424F.c.15.3 73533 1 0 0 0 0 0 0 0 2265 RTA00000426F.p.09.1 66665 1 0 0 0 0 0 0 0 2266 RTA00000522F.p.09.1 75204 1 0 0 0 0 0 0 0 2267 RTA00000426F.m.21.1 64915 1 0 0 0 0 0 0 0 2268 RTA00000425F.j.21.1 77373 1 0 0 0 0 0 0 0 2270 RTA00000523F.h.21.1 41440 1 1 0 0 0 0 0 0 2271 RTA00000427F.h.24.1 65193 1 0 0 0 0 0 0 0 2272 RTA00000425F.f.24.1 40841 1 1 0 0 0 0 0 0 2273 RTA00000425F.m.03.1 76045 1 0 0 0 0 0 0 0 2274 RTA00000426F.m.08.1 63781 1 0 0 0 0 0 0 0 2275 RTA00000523F.d.24.1 64799 1 0 0 0 0 0 0 0 2276 RTA00000523F.c.14.1 66015 1 0 0 0 0 0 0 0 2277 RTA00000523F.b.20.1 66492 1 0 0 0 0 0 0 0 2278 RTA00000522F.h.07.1 75149 1 0 0 0 0 0 0 0 2279 RTA00000527F.g.10.1 37820 2 0 0 0 0 0 0 0 2282 RTA00000427F.i.22.1 63199 1 0 0 0 0 0 0 0 2284 RTA00000527F.n.07.1 15939 2 2 0 0 0 0 0 0 2285 RTA00000425F.e.09.1 75550 1 0 0 0 0 0 0 0 2286 RTA00000427F.h.02.1 63652 1 0 0 0 0 0 0 0 2287 RTA00000426F.f.16.1 65613 1 0 0 0 0 0 0 0 2288 RTA00000425F.i.21.1 75305 1 0 0 0 0 0 0 0 2289 RTA00000427F.k.19.1 62851 1 0 0 0 0 0 0 0 2291 RTA00000426F.g.16.1 41446 1 1 0 0 0 0 0 0 2292 RTA00000527F.l.05.1 13016 4 0 0 1 1 0 0 0 2293 RTA00000426F.m.02.1 66237 1 0 0 0 0 0 0 0 2296 RTA00000522F.l.22.1 75801 1 0 0 0 0 0 0 0 2297 RTA00000427F.h.19.1 63047 1 0 0 0 0 0 0 0 2299 RTA00000522F.g.21.1 77310 1 0 0 0 0 0 0 0 2301 RTA00000522F.g.20.1 77688 1 0 0 0 0 0 0 0 2304 RTA00000425F.k.20.1 74048 1 0 0 0 0 0 0 0 2306 RTA00000522F.b.07.1 78634 1 0 0 0 0 0 0 0 2307 RTA00000426F.g.19.1 63672 1 0 0 0 0 0 0 0 2308 RTA00000525F.d.19.1 36860 2 0 0 0 0 0 0 0 2310 RTA00000427F.d.10.1 40685 1 1 0 0 0 0 0 0 2313 RTA00000424F.a.05.4 77976 1 0 0 0 0 0 0 0 2315 RTA00000424F.a.05.1 77976 1 0 0 0 0 0 0 0 2316 RTA00000522F.l.15.1 74691 1 0 0 0 0 0 0 0 2317 RTA00000425F.e.02.1 76143 1 0 0 0 0 0 0 0 2318 RTA00000525F.c.11.1 37895 2 0 0 0 0 0 0 0 2320 RTA00000522F.c.14.1 75449 1 0 0 0 0 0 0 0 2321 RTA00000424F.m.08.1 19402 1 2 0 0 0 0 0 0 2322 RTA00000527F.f.18.1 37577 2 0 0 0 0 0 0 0 2324 RTA00000522F.a.06.1 73662 1 0 0 0 0 0 0 0 2327 RTA00000522F.d.23.1 73868 1 0 0 0 0 0 0 0 2330 RTA00000523F.j.10.1 63384 1 0 0 0 0 0 0 0 2331 RTA00000527F.p.08.1 36013 2 0 0 0 0 0 0 0 2333 RTA00000426F.f.17.1 66334 1 0 0 0 0 0 0 0 2334 RTA00000523F.j.21.1 36925 2 0 0 0 0 0 0 0 2339 RTA00000523F.a.01.1 74923 1 0 0 0 0 0 0 0 2341 RTA00000427F.j.06.1 63676 1 0 0 0 0 0 0 0 2342 RTA00000424F.m.04.1 79017 1 0 0 0 0 0 0 0 2343 RTA00000523F.i.17.1 65779 1 0 0 0 0 0 0 0 2346 RTA00000525F.c.18.1 24208 2 1 0 0 0 0 0 0 2347 RTA00000527F.e.09.1 37521 2 0 0 0 0 0 0 0 2348 RTA00000424F.j.08.1 73972 1 0 0 0 0 0 0 0 2350 RTA00000527F.c.09.1 64859 1 0 0 0 0 0 0 0 2353 RTA00000523F.c.03.1 36913 2 0 0 0 0 0 0 0 2354 RTA00000427F.k.21.1 62880 1 0 0 0 0 0 0 0 2356 RTA00000427F.d.09.1 66486 1 0 0 0 0 0 0 0 2357 RTA00000426F.n.17.1 66572 1 0 0 0 0 0 0 0 2360 RTA00000426F.m.03.1 66480 1 0 0 0 0 0 0 0 2361 RTA00000424F.h.06.1 77552 1 0 0 0 0 0 0 0 2362 RTA00000425F.d.06.1 77660 1 0 0 0 0 0 0 0 2363 RTA00000427F.e.12.1 62813 1 0 0 0 0 0 0 0 2366 RTA00000426F.n.23.1 18176 1 0 0 0 0 0 0 0 2367 RTA00000522F.m.19.1 41544 1 1 0 0 0 0 0 0 2368 RTA00000522F.a.05.1 32611 1 1 0 0 0 0 0 0 2369 RTA00000427F.i.09.1 65916 1 0 0 0 0 0 0 0 2370 RTA00000424F.j.09.1 74387 1 0 0 0 0 0 0 0 2371 RTA00000424F.n.11.1 73874 1 0 0 0 0 0 0 0 2373 RTA00000527F.e.13.1 37588 2 0 0 0 0 0 0 0 2375 RTA00000425F.j.19.1 77925 1 0 0 0 0 0 0 0 2376 RTA00000522F.g.12.1 78783 1 0 0 0 0 0 0 0 2377 RTA00000523F.a.07.1 75804 1 0 0 0 0 0 0 0 2378 RTA00000425F.e.19.1 73409 1 0 0 0 0 0 0 0 2379 RTA00000425F.n.19.1 78324 1 0 0 0 0 0 0 0 2384 RTA00000427F.k.07.1 63742 1 0 0 0 0 0 0 0 2387 RTA00000522F.a.17.1 79032 1 0 0 0 0 0 0 0 2388 RTA00000527F.l.19.1 36856 2 0 0 0 0 0 0 0 2389 RTA00000424F.i.11.1 41569 1 1 0 0 0 0 0 0 2391 RTA00000424F.d.19.3 73180 1 0 0 0 0 0 0 0 2392 RTA00000522F.j.09.2 78522 1 0 0 0 0 0 0 0 2393 RTA00000424F.m.24.1 77045 1 0 0 0 0 0 0 0 2394 RTA00000522F.j.19.2 76224 1 0 0 0 0 0 0 0 2398 RTA00000527F.j.12.2 37503 2 0 0 0 0 0 0 0 2399 RTA00000522F.g.11.1 75432 1 0 0 0 0 0 0 0 2400 RTA00000522F.k.02.2 77622 1 0 0 0 0 0 0 0 2401 RTA00000427F.e.13.1 66080 1 0 0 0 0 0 0 0 2402 RTA00000426F.f.18.1 63271 1 0 0 0 0 0 0 0 2403 RTA00000427F.a.12.1 63377 1 0 0 0 0 0 0 0 2404 RTA00000424F.b.23.4 77322 1 0 0 0 0 0 0 0 2408 RTA00000427F.f.02.1 36822 2 0 0 0 0 0 0 0 2410 RTA00000424F.i.15.1 78043 1 0 0 0 0 0 0 0 2412 RTA00000522F.m.03.1 79194 1 0 0 0 0 0 0 0 2413 RTA00000522F.a.20.1 74070 1 0 0 0 0 0 0 0 2414 RTA00000424F.b.15.4 74958 1 0 0 0 0 0 0 0 2415 RTA00000527F.g.14.1 37532 2 0 0 0 0 0 0 0 2416 RTA00000522F.d.06.1 74809 1 0 0 0 0 0 0 0 2418 RTA00000427F.e.10.1 64599 1 0 0 0 0 0 0 0 2419 RTA00000527F.c.16.1 22908 3 0 0 0 0 0 0 0 2421 RTA00000523F.f.17.1 63984 1 0 0 0 0 0 0 0 2423 RTA00000527F.p.24.1 36832 2 0 0 0 0 0 0 0 2424 RTA00000425F.n.17.1 78304 1 0 0 0 0 0 0 0 2426 RTA00000425F.e.07.1 75992 1 0 0 0 0 0 0 0 2428 RTA00000523F.h.08.1 62893 1 0 0 0 0 0 0 0 2429 RTA00000522F.o.10.1 78798 1 0 0 0 0 0 0 0 2430 RTA00000425F.l.10.1 26893 1 0 0 0 0 0 0 0 2431 RTA00000427F.f.16.1 64122 1 0 0 0 0 0 0 0 2434 RTA00000425F.i.10.1 78736 1 0 0 0 0 0 0 0 2435 RTA00000426F.m.12.1 63740 1 0 0 0 0 0 0 0 2436 RTA00000527F.g.12.1 37746 2 0 0 0 0 0 0 0 2439 RTA00000425F.i.18.1 42255 1 1 0 0 0 0 0 0 2441 RTA00000424F.j.13.1 74485 1 0 0 0 0 0 0 0 2445 RTA00000424F.k.10.1 73232 1 0 0 0 0 0 0 0 2446 RTA00000522F.i.07.2 78377 1 0 0 0 0 0 0 0 2448 RTA00000522F.b.08.1 26915 1 0 0 0 0 0 0 0 2449 RTA00000522F.l.08.1 78781 1 0 0 0 0 0 0 0 2450 RTA00000525F.a.14.1 37566 2 0 0 0 0 0 0 0 2451 RTA00000424F.g.08.1 74928 1 0 0 0 0 0 0 0 2452 RTA00000425F.l.09.1 75251 1 0 0 0 0 0 0 0 2453 RTA00000522F.o.20.1 74853 1 0 0 0 0 0 0 0 2454 RTA00000527F.j.04.2 11809 3 1 0 0 0 0 0 0 2456 RTA00000523F.c.13.1 40668 1 1 0 0 0 0 0 0 2457 RTA00000427F.i.21.1 65540 1 0 0 0 0 0 0 0 2459 RTA00000522F.h.02.1 74947 1 0 0 0 0 0 0 0 2460 RTA00000522F.g.10.1 74294 1 0 0 0 0 0 0 0 2464 RTA00000425F.k.16.1 75282 1 0 0 0 0 0 0 0 2465 RTA00000525F.b.09.1 23472 2 1 0 0 0 0 0 0 2466 RTA00000522F.j.08.2 76613 1 0 0 0 0 0 0 0 2468 RTA00000523F.f.19.1 34169 1 1 0 0 0 0 0 0 2469 RTA00000425F.j.18.1 75561 1 0 0 0 0 1 0 0 2470 RTA00000426F.m.04.1 36865 2 0 0 0 0 0 0 0 2471 RTA00000527F.g.21.1 36028 2 0 0 0 0 0 0 0 2473 RTA00000525F.a.22.1 36848 2 0 0 0 0 0 0 0 2474 RTA00000522F.p.22.1 73322 1 0 0 0 0 0 0 0 2475 RTA00000424F.d.12.2 74342 1 0 0 0 0 0 0 0 2476 RTA00000424F.g.24.1 79156 1 0 0 0 0 0 0 0 2477 RTA00000427F.a.10.1 65370 1 0 0 0 0 0 0 0 2478 RTA00000426F.h.20.1 23187 3 0 0 0 0 0 0 0 2479 RTA00000424F.d.12.3 74342 1 0 0 0 0 0 0 0 2480 RTA00000425F.c.03.1 74643 1 0 0 0 0 0 0 0 2481 RTA00000523F.f.16.1 26522 1 0 0 0 0 0 0 0 2482 RTA00000427F.f.15.1 66734 1 0 0 0 0 0 0 0 2485 RTA00000522F.p.18.1 76376 1 0 0 0 0 0 0 0 2493 RTA00000522F.g.18.1 73226 1 0 0 0 0 0 0 0 2495 RTA00000522F.h.05.1 73358 1 0 0 0 0 0 0 0 2497 RTA00000425F.n.16.1 18265 1 0 0 0 0 0 0 0 2498 RTA00000527F.l.21.1 36439 2 0 0 0 0 0 0 0 2501 RTA00000424F.d.17.3 73958 1 0 0 0 0 0 0 0 2502 RTA00000523F.j.02.1 62853 1 0 0 0 0 0 0 0

TABLE 21 Clones Dep sited on Jan. 22, 1999 cDNA Library Ref. ATCC Library ES17 Library ES18 Library ES19 No 207064 207065 207066 Clone M00001601A:E09 M00001594A:D06 M00003906A:F04 Names M00001368A:D07 M00001613D:H10 M00003908A:F12 M00003917A:D02 M00001596D:E10 M00003914A:G09 M00001673A:A04 M00001592C:G04 M00003915C:H04 M00003868B:G11 M00001599D:A09 M00003905D:B08 M00003917C:D03 M00001619B:A09 M00003908C:G09 M00003791C:E09 M00001593B:E11 M00003914B:A11 M00003870A:C05 M00001605A:E06 M00003916C:C05 M00003922A:D02 M00001608A:D03 M00003959A:A03 M00003861C:H02 M00001616C:A02 M00003905D:C08 M00003931B:A11 M00001617A:D06 M00003908D:D12 M00001679D:B05 M00001595C:E01 M00003901B:H04 M00001679C:D05 M00001616C:A11 M00004031A:E01 M00001687A:G01 M00001608C:E11 M00004029C:C12 M00003945A:E09 M00001610C:E06 M00003911A:F10 M00003908A:H09 M00001612B:D11 M00003914C:F09 M00001649B:G12 M00001618B:E05 M00003963D:B05 M00003813D:H12 M00001621C:C10 M00003986C:E09 M00004087C:D03 M00001647A:H08 M00004031A:F07 M00004269B:C08 M00001631D:B10 M00003907C:C02 M00004348A:A02 M00001608D:E09 M00003911B:F08 M00001679C:D01 M00001641B:C10 M00003914C:H05 M00001490A:E11 M00001641D:E02 M00003918C:C12 M00001387A:E10 M00001630D:H10 M00003914C:C02 M00001397B:G03 M00001585C:D10 M00003914A:E04 M00001441D:E04 M00001560A:H10 M00003903B:D03 M00001352C:G09 M00001573B:C06 M00003905A:F09 M00001370D:A12 M00001660C:D11 M00003867C:E11 M00001387B:A06 M00001641C:C05 M00003870B:B08 M00001397C:A10 M00001578B:B05 M00003879D:A08 M00001536D:G02 M00001587C:C10 M00003891D:B10 M00003895C:A10 M00001590B:C07 M00003901C:A08 M00001464B:B03 M00001554A:E04 M00003903C:C04 M00004370A:G05 M00001570C:G06 M00003905A:F10 M00001490B:H11 M00001576A:B09 M00003906C:D06 M00001530B:D10 M00001582A:H01 M00003907D:A12 M00001579C:E09 M00001582B:E12 M00003905C:G11 M00001587A:H03 M00001615B:F07 M00003914D:D10 M00001457C:H12 M00001571C:A04 M00003972A:G09 M00001535C:E01 M00001573D:D10 M00003975D:C06 M00001561D:C05 M00001576A:F11 M00003905C:B02 M00001589A:C01 M00001579C:G05 M00003907D:F11 M00001664D:G07 M00001582D:A02 M00003914A:G06 M00001565A:H09 M00001589B:E07 M00003914D:E03 M00001381C:B08 M00001575B:B02 M00003972C:F08 M00001395C:F11 M00001578C:G06 M00003976C:D06 M00001429D:F11 M00001591A:B08 M00003907C:C04 M00001449A:F01 M00001607A:F11 M00003905B:C06 M00001391C:H02 M00001579C:E06 M00004088C:A12 M00001429D:H12 M00001661C:F11 M00004103C:D04 M00001450A:G11 M00001650B:C10 M00004107A:D01 M00001344B:F12 M00001654C:E04 M00004110A:E04 M00001391D:C06 M00001656B:A08 M00004062A:H06 M00003971A:A06 M00001662C:B02 M00004075D:C10 M00001346A:E04 M00001656B:D05 M00004081D:H09 M00001455C:G07 M00001661C:F10 M00004089A:B08 M00001402D:F02 M00001663A:C11 M00004103D:F10 M00001438D:C06 M00001669A:C10 M00004107B:B04 M00001349B:G05 M00001651B:B12 M00004032C:B02 M00001389C:A08 M00001653B:E06 M00004078C:F04 M00001439B:A10 M00001659C:F02 M00004038B:H10 M00001455B:A09 M00001661B:F03 M00004089A:E02 M00001441B:D11 M00001663C:F10 M00004096B:F05 M00001453A:B01 M00001669A:G12 M00004104C:H12 M00001456D:E08 M00001674D:C10 M00004110D:A10 M00001399A:C03 M00001651B:E06 M00004036D:F02 M00004496C:H03 M00001651C:C05 M00004088C:E04 M00004135D:G02 M00001657C:C07 M00004104D:A04 M00004692A:E07 M00001662A:C12 M00004107D:E12 M00004374D:E10 M00001663D:C06 M00004115D:D08 M00004405D:C04 M00001590B:C05 M00003846A:D03 M00004312B:H07 M00001483C:G06 M00004072C:F08 M00003976A:A10 M00001653A:G07 M00004039B:G08 M00004043A:D02 M00001625B:C10 M00003986D:D02 M00004081C:H06 M00001626C:D12 M00003914A:B07 M00004050D:A06 M00001634D:D02 M00003914D:B02 M00001361B:C07 M00001641C:C06 M00003971B:B07 M00004341B:G03 M00001642D:F02 M00003978C:A03 M00001342B:E01 M00001647B:E04 M00003983B:C08 M00004064D:A11 M00001632B:E05 M00004033D:D07 M00004087A:G08 M00001639A:C11 M00004072D:H12 M00004344B:H04 M00001642D:G10 M00004077B:H11 M00004497A:H03 M00001624A:G11 M00004080A:F01 M00001338C:E10 M00001626C:G08 M00004092C:B03 M00001366D:E12 M00001672D:D04 M60004037B:C04 M00001390D:E03 M00001639A:H06 M00004073C:D04 M00001413B:H09 M00001662C:A04 M00004081A:A08 M00004271B:B06 M00001641B:B01 M00004085B:B05 M00004151D:E03 M00001673C:A02 M00004090C:C07 M00001660B:C04 M00001650A:A12 M00004086D:B09 M00003802D:B11 M00001659D:D03 M00004088D:B03 M00001579C:E08 M00001661B:B05 M00004090C:C10 M00001557D:C08 M00001671D:E10 M00004102C:D09 M00003779B:E12 M00001652D:A06 M00004105C:E09 M00001638A:D10 M00001654C:D05 M00004035A:G10 M00003794A:B03 M00001656A:B07 M00003906A:H07 M00001616C:F07 M00001647B:C09 M00004083B:G03 M00001679A:F01 M00001635A:C06 M00001675B:E02 M00001604C:E09 M00001482D:A04 M00003793C:D09 M00001653B:E09 M00001485C:B10 M00003762B:H09 M00001585A:F07 M00001457D:A07 M00001694C:F12 M00003811D:A12 M00001461A:E05 M00001678D:C11 M00001653C:F12 M00001477A:G07 M00001677D:B07 M00001679D:F06 M00001479D:H03 M00001677B:A02 M00003751D:B02 M00001482C:D02 M00001675B:H03 M00003801A:B10 M00001484D:G05 M00003808D:D04 M00003844C:A08 M00001459B:D03 M00003752B:C02 M00001636C:C01 M00001464B:C11 M00003819D:B11 M00001669C:B01 M00001511A:A05 M00001677D:B02 M00003755A:A09 M00001477B:C02 M00001694C:G04 M00003798D:H08 M00001471A:D04 M00003789C:F06 M00001444C:D05 M00001485C:H10 M00001678C:C06 M00004040B:F10 M00001485D:E05 M00001675B:D02 M00001355A:C12 M00001487C:G03 M00003750C:H05 M00001401A:H07 M00001514A:B04 M00001694A:B12 M00001393B:B09 M00001530C:G10 M00001677B:H06 M00001409D:F11 M00001534A:G06 M00001675C:G01 M00001387B:H07 M00001539A:C12 M00001675B:C01 M00001394C:C11 M00001547A:F11 M00003857B:F07 M00001344A:H07 M00001550D:A04 M00003812B:D07 M00001490C:D07 M00001460A:F07 M00001694B:B08 M00001352C:F06 M00001472C:A01 M00001677B:E06 M00001476D:003 M00001481B:A07 M00004037A:E04 M00001399C:D09 M00001456D:F05 M00003870A:H01 M00001347C:G08 M00001456D:G11 M00003842C:D11 M00001453D:G12 M00001477D:F10 M00003828B:F09 M00001382A:F04 M00001481A:G06 M00003856C:H09 M00001392D:H04 M00001464A:B03 M00003851A:C10 M00001429C:G12 M00001469A:G11 M00003841C:E04 M00001454A:C11 M00001478B:D07 M00003837C:G08 M00001517B:G08 M00001473A:C11 M00003828B:E07 M00001535A:D02 M00001457A:G03 M00003772C:B12 M00001352A:E12 M00001669B:G02 M00001677D:F03 M00001381B:F06 M00001479D:G06 M00001678B:B12 M00004117A:D11 M00001473D:B11 M00001678D:G03 M00004217C:D03 M00001475A:A12 M00001675C:F01 M00004270A:F11 M00001460A:G07 M00003809A:H04 M00003996A:A06 M00001464A:D03 M00003771D:G05 M00004056B:D09 M00001473D:G01 M00001678A:F05 M00004142A:B12 M00001476D:C05 M00001677B:B06 M00001396D:B03 M00001484A:A10 M00003794A:E12 M00001370D:E12 M00001457C:F02 M00003771B:E05 M00001390C:C11 M00001459B:A12 M00001678A:A11 M00003989A:H11 M00001464A:E07 M00003805B:C04 M00001426A:A09 M00001467A:B03 M00001680B:E10 M00004498D:D05 M00001514A:B08 M00001679B:H07 M00001391B:G12 M00001464A:B07 M00003904D:B12 M00001391D:D10 M00001579A:C03 M00003856C:B08 M00001376B:A02 M00001517A:G08 M00003858D:G06 M00001405B:D07 M00001530B:G09 M00003870B:F04 M00001368A:A03 M00001538A:F12 M00003871C:B05 M00001392D:B11 M00001540C:B03 M00003875A:C04 M00003900D:B10 M00001547A:F06 M00003901B:A09 M00001494B:C01 M00001550A:F07 M00003901C:D03 M00001352C:A05 M00001567B:G11 M00003904C:B06 M00001408B:G06 M00001572A:A10 M00003901C:F09 M00004252C:E03 M00001575B:G01 M00003904D:B10 M00003901C:A03 M00001487D:C11 M00003850D:H11 M00004071D:A10 M00001577B:A03 M00003902B:D06 M00001377B:H01 M00001539D:E10 M00003879A:C01 M00003939A:A02 M00001587A:F05 M00003877D:G05 M00004250D:D10 M00001560A:F03 M00003881D:C12 M00004290A:B03 M00001569B:G11 M00003903A:H09 M00003911D:B04 M00001573A:A06 M00003905A:A06 M00004128B:G01 M00001575D:A10 M00003875D:D09 M00004142A:D08 M00001583A:D01 M00003879B:A06 M00003977A:E04 M00001587A:F08 M00003823D:G05 M00004236C:D10 M00001590B:B02 M00003763A:C01 M00004388B:A08 M00001553A:E07 M00003903B:C02 M00004409B:A11 M00001560A:H06 M00003905A:E07 M00003965A:B11 M00001589C:A11 M00003867A:D12 M00003988A:E10 M00001538A:C08 M00003857C:C09 M00004138A:H09 M00001531A:H03 M00003829C:D10 M00003933C:D06 M00001548A:G01 M00003839D:E02 M00004193C:G11 M00001531A:H07 M00003841C:F03 M00004039C:C01 M00001542A:E04 M00003903D:C06 M00003924B:D04 M00001487A:F10 M00003852D:E08 M00004375C:D01 M00001503C:G05 M00003845D:A09 M00001511A:G08 M00003824A:G10 M00001539A:H12 M00003841C:F06 M00001542A:F06 M00003848A:C09 M00001549A:F01 M00003857C:F11 M00001514A:A12 M00003816C:C01 M00001516A:D05 M00003843A:E08 M00001546C:C07 M00003850A:F06 M00001549A:H11 M00003813B:A11 M00001538A:D03 M00003855C:F10 M00001544A:C09 M00003850D:B05 M00001546B:F12 M00003841D:F06 M00001550A:D09 M00003858B:G05 M00001487B:F02 M00003854D:A12 M00001513A:G07 M00003857C:G01 M00001530A:F12 M00003816C:E09 M00001538A:D12 M00003813A:G04 M00001587A:G06 M00003850D:A05 M00001551A:D04 M00001485B:C03

TABLE 22 Clones Deposited on Jan. 23, 1999 cDNA Ref No.; ATCC cDNA Library cDNA Ref cDNA Library Acces- Ref ES20 No. ES27 Ref ES28 sion ATCC No. 207067 ATCC No. 207074 ATCC No. 207075 Clone M00004891D:A07 M00001623B:G07 M00001550D:H02 Names M00004118B:C11 M00001619D:G05 M00001549C:D02 in M00004105A:B10 M00001616C:C09 M00001549A:A09 Library M00004099A:F11 M00001615C:F03 M00001548A:B11 M00004037C:D07 M00001614D:D09 M00001546C:G10 M00004033D:C05 M00001608B:A03 M00001544C:C06 M00003983D:A09 M00001607D:F07 M00003820B:C05 M00004029B:H08 M00001623D:C10 M00001543A:H12 M00004927A:A02 M00001599B:E09 M00001540C:B10 M00003983C:F10 M00001632C:C09 M00001552B:G05 M00003980B:C06 M00001605C:D12 M00001543C:F01 M00004033D:B07 M00001625D:C07 M00001552D:G08 M00004034C:E08 M00001629B:E06 M00001554B:B07 M00005100B:H07 M00001594A:B12 M00001555A:B01 M00005136A:D10 M00001632C:A02 M00001557A:F01 M00005173D:H02 M00001567C:H12 M00001558A:E11 M00004891D:C11 M00001635C:A03 M00001561C:E11 M00004101A:F07 M00001636C:H09 M00001571D:B11 M00003982B:B06 M00001638A:E07 M00001563B:D11 M00004108C:E01 M00001639A:F10 M00001569C:B06 M00005136D:B07 M00001656C:G08 M00001539B:H06 M00004118D:A11 M00001632A:F12 M00001571B:E03 M00005102C:C01 M00001557A:D02 M00001561D:C11 M00005177C:A01 M00001529B:C04 M00001487C:D06 M00004927C:H11 M00001534B:C12 M00001454B:D08 M00005174D:B02 M00001535D:C01 M00003772D:E10 M00004027A:D06 M00001536D:A12 M00001573C:D03 M00005217A:G10 M00001540B:C09 M00001454D:E05 M00003984A:B06 M00001540D:D02 M00001455D:F09 M00003851C:D07 M00001541C:B07 M00001457C:C11 M00003959C:G06 M00001546B:B02 M00001459B:C09 M00005100B:G11 M00001575B:C09 M00001460A:E01 M00005213C:G01 M00001554B:C07 M00001460C:H02 M00003982B:H07 M00001578D:C04 M00001456A:H02 M00004029C:B03 M00001557C:H07 M00001477B:F04 M00004033D:G06 M00001558B:D08 M00003845D:B04 M00004091B:H09 M00001560D:A03 M00001488A:E01 M00003959D:A04 M00001561C:F06 M00001492D:A11 M00004030D:B06 M00001564D:C09 M00001496C:G10 M00004034C:C06 M00003748B:F02 M00001499A:A05 M00004030C:D12 M00001570D:A03 M00001500A:B02 M00003982C:H10 M00001660C:B12 M00001500D:E10 M00003971C:F09 M00001577B:H02 M00001513D:A03 M00004031B:A06 M00001548A:A08 M00001528A:C11 M00003966B:D02 M00003868B:D12 M00001528C:H04 M00004028B:G08 M00001718D:F07 M00001531B:E09 M00004031C:H10 M00003829C:A11 M00001463A:F06 M00004076D:B09 M00003832B:E01 M00003755A:B03 M00004092D:B11 M00003842B:D09 M00001653B:G07 M00003981C:F05 M00003845A:H12 M00001654D:G11 M00004031D:F05 M00003847B:003 M00001656B:A07 M00004097B:D03 M00003847C:E09 M00001664B:D06 M00003986D:G07 M00003853D:G08 M00001664C:H10 M00004033B:C02 M00003828A:E04 M00001680B:C01 M00004037B:A04 M00003867C:H09 M00001681A:F03 M00004092C:B12 M00003822A:F02 M00001684B:G03 M00005140D:G09 M00003868C:H10 M00001771A:A07 M00004897D:G05 M00003871A:A05 M00003774C:D02 M00004960B:D12 M00003879C:G10 M00003754D:D02 M00005134C:G04 M00003880C:F10 M00001640B:F03 M00005139A:F01 M00003881D:D06 M00003763B:H01 M00005176A:C12 M00003884D:007 M00003812C:A05 M00005178A:A07 M00003887A:A06 M00003803C:D09 M00005212A:A02 M00003889A:D10 M00003801B:B10 M00005229D:H07 M00003889D:B09 M00003798D:E03 M00004115C:H04 M00003858D:F12 M00003773B:G01 M00004687A:C03 M00003774B:B08 M00003771A:G10 M00004900C:E11 M00001680D:D02 M00001452A:E07 M00004695B:E04 M00001528A:F09 M00004029B:F11 M00005134D:A06 M00003748A:B07 M00003751B:A05 M00004103B:B07 M00001655A:F06 M00001609B:A11 M00005177A:B06 M00003750A:D01 M00001573D:F10 M00005178A:A08 M00003761D:E02 M00001579C:B11 M00004104D:B05 M00003763D:E10 M00001579C:H10 M00004117B:G01 M00003768A:E02 M00001579D:G07 M00004900D:B10 M00003829B:G03 M00001583B:E10 M00005134D:H03 M00003772A:D07 M00001586D:E02 M00005173C:A02 M00001661B:C08 M00001587D:A10 M00005177A:H09 M00003778A:D08 M00001589A:D12 M00005178B:H01 M00003799A:D09 M00001590C:H08 M00005216C:B09 M00003800A:C09 M00001651B:A11 M00003826B:E11 M00003804A:H04 M00001597A:E12 M00001596A:G06 M00003806D:G05 M00001649C:B10 M00005100B:D02 M00003808C:B05 M00001614A:E06 M00005137A:E01 M00003511A:E03 M00001615C:D02 M00004119A:A06 M00003815D:H09 M00001621D:D03 M00004891D:E07 M00003818B:G12 M00001623D:G03 M00004958B:D01 M00003769B:D03 M00001624A:F09 M00005102C:F09 M00001390A:A09 M00001624C:A06 M00005136D:C01 M00001432A:E06 M00001630B:A11 M00005174D:H02 M00001381A:D02 M00001634B:C10 M00005177C:B04 M00001383A:G04 M00001639D:B07 M00005218B:D09 M00001384C:E03 M00001573D:F04 M00004102C:F03 M00001384C:F12 M00001595B:A09 M00004114B:D09 M00001384D:H07 M00004156B:A12 M00004119D:A07 M00001385B:F10 M00004319D:G09 M00004895C:G05 M00001385C:H11 M00004096A:G02 M00004235A:A12 M00001386A:C02 M00004101C:G08 M00005134B:E01 M00001372C:F07 M00004102A:H02 M00004115C:G03 M00001389D:G11 M00004108A:A09 M00005175B:H04 M00001371D:G01 M00004111D:D11 M00005214B:D11 M00001392C:D10 M00004115D:C08 M00004102D:B05 M00001392D:H06 M00004118D:E08 M00004115A:B12 M00001397B:B09 M00004121C:F06 M00004119D:H06 M00001398A:003 M00004131B:H09 M00004897D:F03 M00001400A:F06 M00004141D:A09 M00004960B:A09 M00001410B:G05 M00004090A:F09 M00005134C:E11 M00001413A:F02 M00004146A:C08 M00005138B:D12 M00001415B:E09 M00004078B:A11 M00005176A:A05 M00001425A:C11 M00004176B:E08 M00005214c:A09 M00001386A:D11 M00004188C:A09 M00004102C:D01 M00001354C:B06 M00004233C:H09 M00004960B:A08 M00001339D:G02 M00004241D:F11 M00001476D:A09 M00001660A:C12 M00004246c:A09 M00001572A:B06 M00001528A:A01 M00004247C:C12 M00005217D:F12 M00001343D:C04 M00004248B:E08 M00005233A:G08 M00001347B:E01 M00004257C:H06 M00005236B:F10 M00001345A:D04 M00004260D:C12 M00005259B:C01 M00001349C:C05 M00004295B:D02 M00005254D:B08 M00001350A:D06 M00004040D:F01 M00005259C:B05 M00001352D:C05 M00004142D:E10 M00001575A:D06 M00001380C:E05 M00003853D:D03 M00005259D:H08 M00001354B:B10 M00003860D:H07 M00003813C:D08 M00001380C:F02 M00003878C:E04 M00001530D:E06 M00001354C:C10 M00003879A:G05 M00004891B:B12 M00001355B:G11 M00003880B:C08 M00001596B:C11 M00001356D:F06 M00003881A:D09 M00004300C:H09 M00001360D:E11 M00003881C:G09 M00001486D:D12 M00001361C:H11 M00003901B:A05 M00001585D:F03 M00001362C:A10 M00003904D:D10 M00001596B:D09 M00001363C:H02 M00003905C:G10 M00001570D:E06 M00001366D:G02 M00003906B:F12 M00001582C:E01 M00001369A:H12 M00003909A:H04 M00001586C:E06 M00001352D:D02 M00004091B:D11 M00001593B:D10 M00001485D:B10 M00003963A:E03 M00001595C:H11 M00001457B:E03 M00004353C:H07 M00001596B:H05 M00001457C:C12 M00003919A:A10 M00001576A:C11 M00001458C:E01 M00003938A:B04 M00001596C:F09 M00001462B:A10 M00003939C:F04 M00001567A:H05 M00001464D:F06 M00003946D:C11 M00001585D:D11 M00001467D:H05 M00003979A:F03 M00004688A:A02 M00001468B:H06 M00003985C:F01 M00004927A:E06 M00001505C:H01 M00003997B:G07 M00005229D:H09 M00001470A:H01 M00003860D:A01 M00004117B:A12 M00001457A:B07 M00004035A:A04 M00004187D:G09 M00001479B:A01 M00004042D:H02 M00005173B:F01 M00001469D:D02 M00004073B:B01 M00005218A:G05 M00001487A:A05 M00003946A:H10 M00004118A:H08 M00001352C:H02 M00001423D:A09 M00005134A:D11 M00001488D:C10 M00004314B:G07 M00005176C:C09 M00001490C:C12 M00001405D:D11 M00005230D:F06 M00001493B:D09 M00001408A:H04 M00005234D:B04 M00001504D:D11 M00001408D:D04 M00005101C:E09 M00001376B:C06 M00001411D:F05 M00004206A:E02 M00001506B:D09 M00001412A:E04 M00001570C:A05 M00001511B:C06 M00001413A:F03 M00005231A:H04 M00001476B:F10 M00001417B:C04 M00005235A:A03 M00001450D:D04 M00001417D:A04 M00004118B:B04 M00001433A:G07 M00001418B:F07 M00005136D:D06 M00001470C:B10 M00001419D:C10 M00005231C:B01 M00001437D:C04 M00001402B:F12 M00004153B:B03 M00001447C:C01 M00001423A:G05 M00004897C:D06 M00001448B:F06 M00001401C:H03 M00005136D:G06 M00001449D:A06 M00001423D:D12 M00005212B:A02 M00001433B:H11 M00001424B:H04 M00005232A:C10 M00001451D:C10 M00001428B:A09 M00004692A:H10 M00001452A:C07 M00001430A:A02 M00005101C:B09 M00001453C:A11 M00001432D:F05 M00004144A:F04 M00001456B:C09 M00001438B:B09 M00003852B:D11 M00001454B:G03 M00001445B:E04 M00001660D:E05 M00001454B:G07 M00001445C:A08 M00003808A:F09 M00001454C:C08 M00001446C:D09 M00001656A:D10 M00001454C:F02 M00001448A:G09 M00001671A:H06 M00001454D:D06 M00001449C:H12 M00003809C:H07 M00001456B:F10 M00001422C:F12 M00003853C:C06 M00001455D:A09 M00001352C:H10 M00003860A:A08 M00001455D:A11 M00004375A:H01 M00003822B:D08 M00001448D:F09 M00004380B:A05 M00003845A:E12 M00004444B:D11 M00003854C:C02 M00001338B:E02 M00003860B:G09 M00001341A:F12 M00003822B:G01 M00001344A:G07 M00001670A:C11 M00001345A:G11 M00003852A:B03 M00001345B:E10 M00003829D:A11 M00001345C:B01 M00003854C:F01 M00001346B:B07 M00003856B:C04 M00001405B:E09 M00003905A:H11 M00001352B:F04 M00001530A:F11 M00001451C:E01 M00003840B:E07 M00001361A:H07 M00003905B:G03 M00001362B:H06 M00003840B:E08 M00001372C:G12 M00003855A:C12 M00001375B:G12 M00003905B:H05 M00001376A:C05 M00003826B:B04 M00001376B:A08 M00003851C:B06 M00001377C:E12 M00003853B:C08 M00001382B:F12 M00003829A:F03 M00001385A:F12 M00001638C:G01 M00001394A:E04 M00003845D:B02 M00001395A:C09 M00001653D:G07 M00001396A:H03 M00001578B:A02 M00001350B:G11 M00001590B:H10 M00001595C:A09 M00001596A:E07 M00001607A:B06 M00001607A:D10 M00001652C:B09 M00001671B:F02 M00001632C:D08 M00001638C:H07 M00001652D:B09 M00001614C:E11 M00001633B:B11 M00001651C:A04 M00001639D:G12 M00001671C:F11 M00001638A:B04 M00001637C:H12 M00001669B:H06 M00001639D:F02 M00001590A:C08 M00001636A:C02 M00001614A:A04 M00001639D:G06

TABLE 23 Library Deposited on Jan. 22, 1999 cDNA Ref No.; ATCC cDNA Library Ref ES29 cDNA Library Ref ES30 Accession No. ATCC No. 207076 ATCC No. 207077 Clone Names in M00001449D:B01 M00001594D:B08 Library M00001476D:F03 M00001593A:B07 M00001456C:B12 M00001594A:C01 M00001469B:B01 M00001594A:D08 M00001471A:B04 M00001594A:G09 M00001472A:D08 M00001595C:B05 M00001473A:A07 M00001594B:F12 M00001473C:D09 M00001596D:E03 M00001475B:C04 M00001594D:C03 M00001475C:G11 M00001592C:F11 M00001476A:D11 M00001590D:G07 M00001476B:D10 M00001595D:A04 M00001468A:C05 M00001595D:G03 M00001476C:C11 M00001601A:A06 M00001467A:H07 M00001590C:F10 M00001477B:E02 M00001589B:B08 M00001478B:H08 M00001589C:E06 M00001479C:E01 M00001611B:A05 M00001480A:D03 M00001601A:E02 M00001480C:A05 M00001587A:D01 M00001481A:H08 M00001591B:B12 M00001481B:D09 M00001590B:G08 M00001482A:H05 M00001592C:E05 M00001482D:H11 M00001591B:B06 M00001483C:G09 M00001591D:C07 M00001485A:C05 M00001591D:F06 M00001476B:F08 M00001592A:E02 M00001460A:E11 M00001592A:H05 M00001456C:C11 M00001592B:A04 M00001457A:C05 M00001587A:B10 M00001457A:G12 M00001609D:G10 M00001458A:A11 M00005231D:B09 M00001458C:D10 M00001614B:E08 M00001458D:A01 M00005217C:C01 M00001458D:A02 M00001587A:B01 M00001458D:C11 M00001613D:B03 M00001458D:D01 M00001613A:F03 M00001459B:C11 M00001611C:H11 M00001468A:H10 M00001611C:C12 M00001460A:C10 M00001611B:E06 M00001485B:F05 M00001611B:A09 M00001460A:H11 M00001610D:D05 M00001461A:F05 M00001610B:C07 M00001462A:D03 M00001610C:E07 M00001464A:B02 M00001610A:E09 M00001464A:E10 M00001601A:E12 M00001465A:B12 M00001609B:C09 M00001465A:C12 M00001608D:D11 M00001465A:E10 M00001608B:A09 M00001465A:G06 M00001607D:F06 M00001466A:F08 M00001607B:C05 M00001467A:C10 M00001606A:H09 M00001460A:B12 M00001605A:H03 M00001545A:B12 M00001605A:E09 M00001535A:D10 M00001605A:A06 M00001536A:F11 M00001604A:C11 M00001537A:H05 M00001604A:C07 M00001539A:E01 M00001604A:B08 M00001539A:H02 M00001604A:A09 M00001539B:G07 M00001610A:H05 M00001539D:B10 M00005214B:A06 M00001540D:E02 M00005228A:A09 M00001541B:E05 M00001567A:B09 M00001542A:G12 M00001561A:D01 M00001485B:D09 M00001559A:C08 M00001545A:B10 M00001559A:A11 M00001533A:G05 M00001558A:G09 M00001545A:F02 M00001555A:B12 M00001545A:G05 M00001554A:A08 M00001546A:D08 M00001552A:H10 M00001548A:H04 M00001552A:F06 M00001550A:E07 M00005231C:B07 M00001551A:A11 M00005218D:G10 M00001551A:D06 M00001570A:H01 M00001551A:H06 M00005214D:D10 M00001551D:H07 M00001570C:G03 M00001552A:E10 M00005213C:A01 M00001450A:B08 M00005212D:F08 M00001544A:F05 M00005212A:D10 M00001512A:G05 M00005211C:E09 M00001483B:D04 M00005211A:E09 M00001485B:H03 M00005210D:C09 M00001485C:C08 M00005179D:B03 M00001486B:D07 M00005179B:H02 M00001486B:E12 M00005177D:F09 M00001487B:A11 M00005177C:G04 M00001487B:E10 M00005177B:H02 M00001507A:A11 M00001614D:B08 M00001507A:B02 M00001615A:D06 M00001507A:C05 M00005216B:D02 M00001507A:E04 M00001579C:A01 M00001534A:D03 M00001585B:C03 M00001511A:G01 M00001585B:A06 M00001533D:A08 M00001584D:H02 M00001513A:F05 M00001584A:G03 M00001514A:G03 M00001583D:B08 M00001516A:D02 M00001583B:F02 M00001516A:F06 M00001583A:F07 M00001517A:B11 M00001583A:A05 M00001529D:C05 M00001582D:F02 M00001530A:A09 M00001582D:B01 M00001530A:E10 M00001582A:A03 M00001532A:C01 M00001579D:H09 M00001532D:A06 M00001567D:B03 M00001485B:D10 M00001579C:H06 M00001511A:A02 M00001585B:F01 M00004249D:B08 M00001579B:F04 M00004185D:E04 M00001579A:E03 M00004188D:G08 M00001578C:F05 M00004197C:F03 M00001577D:H06 M00004198B:D02 M00001577B:F10 M00004204D:C03 M00001576C:G05 M00004208B:F05 M00001575D:D12 M00004208D:B10 M00001575D:B10 M00004210B:B05 M00001575D:A02 M00001362D:H01 M00001573B:G08 M00004216D:D03 M00001573A:E01 M00004167A:H03 M00001572A:B05 M00004275A:B03 M00001571D:F05 M00004285C:A08 M00001579D:F04 M00004316A:G09 M00001636A:F08 M00004465B:D04 M00001643B:E05 M00004493B:D09 M00001642C:G02 M00001347B:H04 M00001642A:F03 M00001351C:B06 M00001641D:C04 M00001360A:G10 M00001641C:H07 M00004216D:C03 M00001641C:F01 M00004076D:D04 M00001641C:D02 M00001484C:A04 M00001641B:F12 M00001456B:G01 M00001634A:B04 M00003972D:C09 M00001636B:G11 M00003974C:E04 M00001649C:D05 M00003979A:E11 M00001636A:C03 M00003983C:F03 M00001635D:D05 M00003989B:F11 M00001635D:C12 M00004031D:B05 M00001635B:H02 M00004177C:A01 M00001635B:H01 M00004076B:G03 M00001634D:G11 M00004167D:A07 M00001634D:D04 M00004078A:A06 M00001634A:H05 M00004085A:B02 M00001641A:A11 M00004107B:A06 M00001638B:E12 M00004111C:E11 M00001640A:H02 M00004130D:H01 M00001614C:E06 M00004157D:B03 M00001636D:F09 M00004159C:F09 M00001637A:A03 M00004162C:A07 M00001637A:A06 M00004135B:G01 M00001637A:E10 M00004040A:G12 M00001637A:F10 M00001453B:H12 M00001637C:C06 M00001448A:E11 M00001644A:H01 M00001448B:F09 M00001638B:E03 M00001448B:H05 M00001649A:E11 M00001448C:E11 M00001638B:F10 M00001448C:F10 M00001639A:C03 M00001448D:F12 M00001639A:G07 M00001449B:B03 M00001639B:H01 M00001449C:C05 M00001639B:H05 M00001449D:G10 M00001639C:A09 M00001448A:B12 M00001639C:C02 M00001453A:D08 M00001649C:E11 M00001451B:A04 M00001649C:H10 M00001454A:F11 M00001637C:E03 M00001454A:G03 M00001617A:A08 M00001455A:F04 M00001622A:H12 M00001455B:E07 M00001621C:H12 M00001455D:A06 M00001621B:G05 M00001364B:B06 M00001620D:H02 M00004117A:G01 M00001620D:G11 M00001455D:D11 M00001619D:D10 M00001456B:A06 M00001619C:C07 M00001451A:C10 M00001619A:E05 M00001395A:E03 M00001623A:F04 M00001366D:C06 M00001618A:A03 M00001365A:H10 M00001615B:D09 M00001366D:C12 M00001617A:A01 M00001373D:B03 M00001616D:C11 M00001453B:F08 M00001615C:G05 M00001444D:C01 M00001615C:A11 M00001375B:C06 M00001615B:G07 M00001392C:D05 M00001633D:H06 M00001395A:A12 M00001639C:A10 M00001395A:H02 M00001615B:A09 M00001397D:G08 M00001615B:G01 M00001434A:B10 M00001618A:F10 M00001416A:D09 M00001632C:H07 M00001433C:F10 M00001633D:D12 M00001416A:H02 M00001633D:D09 M00001428D:B10 M00001618A:F08 M00001428B:D01 M00001633D:G09 M00001426D:D12 M00001624A:A03 M00001400C:D02 M00001633C:F09 M00001427C:D01 M00001633C:H05 M00001633C:B09 M00001633A:E06 M00001633C:H11 M00001632C:B10 M00001625D:G10 M00001631D:G05 M00001629C:E07 M00001629B:B08 M00001626C:E04 M00001626C:C11 M00001632A:B10 M00001624B:B10 M00001633C:A05 M00001625C:G05

TABLE 24 Clones Deposited on Jan. 22, 1999 cDNA Ref No.; ATCC Acces- cDNA cDNA cDNA sion Library Ref ES31 Ref No. ES32 Library Ref ES33 No. ATCC No. 207078 ATCC No. 207079 ATCC No. 207080 Clone M00003843A:E04 M00003906A:F12 M00005254D:A10 Names M00003842C:G03 M00003906B:H06 M00005260B:E11 in Lib- M00003842A:A03 M00003906C:C05 M00005260A:F04 rary M00003841D:A04 M00003997A:F01 M00005260A:A12 M00003841B:E06 M00003907B:C03 M00005259B:D12 M00003841C:H11 M00003907B:D05 M00005257D:H11 M00003844A:A11 M00003918A:D08 M00005257D:G07 M00003841C:F01 M00003918A:F09 M00005257D:A06 M00003841C:H08 M00003918C:H10 M00005257C:G01 M00003841C:D07 M00003924A:D08 M00005257A:H11 M00003844D:A07 M00003958B:E11 M00005236B:H10 M00003845D:G08 M00003958B:H08 M00005236B:G03 M00003852C:B06 MOOO03960A:G07 M00005257C:E05 M00003854B:A07 M00003971B:A10 M00001608C:D02 M00003854B:D04 M00003972D:H02 M00001608C:G04 M00003859D:C05 M00003973C:C03 M00001608D:F11 M00003860B:F11 M00003974B:B11 M00001609C:A12 M00003867B:G07 M00003974D:F02 M00001609C:G05 M00003867B:G08 M00003974D:H04 M00001610C:B07 M00003841B:E03 M00003975C:F07 M00001612D:D12 M00003822D:B10 M00003977C:A06 M00001612D:F06 M00003867D:A06 M00003977C:B03 M00001613A:D02 M00003868B:G06 M00003977D:A03 M00001614A:B10 M00003867B:D10 M00003977D:A06 M00001614C:G07 M00003831C:G05 M00003977D:D04 M00001615C:E07 M00003901C:B01 M00003978D:G04 M00001625C:F10 M00003868C:C07 M00003980A:F04 M00001626D:A02 M00003820A:A08 M00003980B:C11 M00001629A:H09 M00003820B:D07 M00003981C:B04 M00001629D:B10 M00003820B:D10 M00003982A:B12 M00001629D:D10 M00003822D:C06 M00003982C:G04 M0000163OC:F09 M00003823B:F07 M00003984D:B08 M00001631A:D03 M0000382AC:D07 M00003985B:G04 M00001631A:F06 M00003825B:B10 M00003985D:E10 M00001631A:F12 M00003825B:B11 M00003986B:A08 M00001631B:H04 M00003828A:D05 M00003986C:D09 M00001633A:F11 M00003822D:D04 M00003986D:C08 M00001633A:G10 M00003830C:A03 M00003987B:E12 M00001633B:A12 M00003840D:H10 M00003987B:F08 M00001633B:E03 M00003832A:A09 M00003987C:G03 M00001633C:A08 M00003833B:B03 M00003988D:A08 M00001633C:E12 M00003833B:C12 M00003989C:D03 M00001635B:B02 M00003834B:G04 M00003989C:G05 M00001636A:H12 M00003835A:A09 M00003989D:F12 M00001638A:C08 M00003835B:H11 M00004029B:F01 M00001638B:C08 M00003835D:G06 M00004029C:C05 M00001639D:C12 M00003837C:E05 M00004029C:G10 M00001640A:F05 M00003837C:F10 M00004030D:F11 M00001642D:G08 M00003839A:D07 M00004034A:A01 M00001647D:G07 M00003839D:E11 M00004034C:G02 M00001649A:E10 M00003829C:H05 M00004034D:E09 M00001650D:D10 M0000390IB:C03 M00004035B:H09 M00001650D:F11 M00003878C:F06 M00004036D:B04 M00001651C:D11 M00003878C:G08 M00004036D:B09 M00001651C:G12 M00003879A:A02 M00004038A:F02 M00001652B:D06 M00003879A:B08 M00004038D:G06 M00001652D:G02 M00003879A:C11 M00004039A:C03 M00001652D:G06 M00003879A:D02 M00004039A:H11 M00001653A:A05 M00003879B:G02 M00004039B:A05 M00001653D:H07 M00003880B:D11 M00004039B:E12 M00001654A:E08 M00003880C:E11 M00004040C:A01 M00001654B:A01 M00003880C:H03 M00004051D:E01 M00001654C:D10 M00003901B:F10 M00004072D:F09 M00001655C:G07 M00003890B:C08 M00004073A:D10 M00001654C:G09 M00003877C:A11 M00004075B:G09 M00001655C:C07 M00003819D:B01 M00004076A:D12 M00001655D:E08 M00003901B:G11 M00004076D:H07 M00001655D:H11 M00001692A:G06 M00004078A:C11 M00001656A:H12 M00003903C:C05 M00004078A:E05 M00001656D:C04 M00003903C:E12 M00004078A:F07 M00001656D:C04 M00003903D:C12 M00004078B:C11 M00001657C:C11 M00003903D:D10 M00004078B:F12 M00001657D:A10 M00003903D:H11 M00004079D:G08 M00001659D:A09 M00003904A:C04 M00004081A:E02 M00001661D:D05 M00003904B:C03 M00004081A:G01 M00001664B:E08 M00003904C:A08 M00004081C:A10 M00001664B:F06 M00003881B:F10 M00004083A:E08 M00001669B:C12 M00003871D:G06 M00004083B:C01 M00001669C:B09 M00003868D:D09 M00004086D:G08 M00001670A:F09 M00003868D:D11 M00004087B:A12 M00001678C:F09 M00003870C:A01 M00004087C:A01 M00001693A:H06 M00003870C:A10 M00004088C:F01 M00003805D:E06 M00003870C:E10 M00004088D:A11 M00003806C:A06 M00003871A:A02 M00004088D:B05 M00003809B:A03 M00003871A:B09 M00004088D:B10 M00003810A:A02 M00003871A:C11 M00004090B:B04 M00003810B:B11 M00003871A:G09 M00004090B:H06 M00003810C:B06 M00003871C:E04 M00004092B:E05 M00003810D:H09 M00003871C:F12 M00004093C:C02 M00003811C:C02 M00003878C:D08 M00004096D:H03 M00003813B:F02 M00003871D:E11 M00004099D:F01 M00003813C:H08 M00003877C:G12 M00004100B:C07 M00003813D:B12 M00003875A:A07 M00004103B:E09 M00003813D:C02 M00003875A:B01 M00004105C:B05 M00003813D:G06 M00003875B:F12 M00004105C:C08 M00003814B:C01 M00003875C:A01 M00004107A:A12 M00003817C:A10 M00003875C:A09 M00004107B:D07 M00003817C:G06 M00003875C:G02 M00004108B:B02 M00003817D:D12 M00003876B:C05 M00004108D:E07 M00003821A:H09 M00003876C:D02 M00004108D:G04 M00003822B:G12 M00003876C:F02 M00004110A:A10 M00003822C:A07 M00003877B:H10 M00004110B:A07 M00003823C:B01 M00003868D:B09 M00004118B:A03 M00003823C:C04 M00003871D:A10 M00004118B:F01 M00003824A:G11 M00001669D:D06 M00004118D:B05 M00003824B:C09 M00001661A:B11 M00004119A:C09 M00003824C:A10 M00001661B:F06 M00004136D:B02 M00003824D:D08 M00001662A:C07 M00004137A:D06 M00003825B:F10 M00001662A:G01 M00004139C:A12 M00003825D:F01 M00001662B:F06 M00004149C:B02 M00003826C:F05 M00001663C:F12 M00004159C:G12 M00003829A:B08 M00001664A:F08 M00004169D:B11 M00003829C:E08 M00001664D:F04 M00004187D:H06 M00003829D:D12 M00001661A:E06 M00004228C:H03 M00003829D:F03 M00001669A:B02 M00004244C:G07 M00003830D:B11 M00001669B:B12 M00004358D:C02 M00003830D:H11 M00001669C:C08 M00004690A:G08 M00003833D:H08 M00001675A:G10 M00004891B:D01 M00003833D:H10 M00001669D:C03 M00004891C:D04 M00003840A:C10 M00001660B:E03 M00004895B:E12 M00003840B:F05 M00001669D:F05 M00004895B:G04 M00003840C:C02 M00001670B:G12 M00004895D:G07 M00003845C:D04 M00001671A:A10 M00004898C:F03 M00003845D:A04 M00001671B:G05 M00004899D:G06 M00003846B:C05 M00001671C:C11 M00004959D:H12 M00003846C:F08 M00001672D:E08 M00004960A:B08 M00003848B:E07 M00001673A:G08 M00004960C:E10 M00003848D:G02 M00001673B:B07 M00005100A:B02 M00003850C:G09 M00001673B:F07 M00005100A:C01 M00003851A:A06 M00001673D:D06 M00005101C:E12 M00003851B:D03 M00001673D:F10 M00005102C:D03 M00003851B:E01 M00001674A:G07 M00005134B:E08 M00003851C:F09 M00001692D:B01 M00005139A:H03 M00003851D:H11 M00001669C:D09 M00005140C:B10 M00003852B:G04 M00001655C:E01 M00005140D:C06 M00003852C:F07 M00001649D:A08 M00005178D:H04 M00003853B:C10 M00001650A:C11 M00005210A:E06 M00003854C:C09 M00001651A:H11 M00005212B:E01 M00003855A:A01 M00001652A:A01 M00005212C:C03 M00003855A:F01 M00001652B:G10 M00005212C:D02 M00003855B:B09 M00001652D:E05 M00005212C:H02 M00003856A:G04 M00001652D:E09 M00005212D:D09 M00003856B:A12 M00001653B:C06 M00005212D:H01 M00003857A:E12 M00001653B:G10 M00005216A:D09 M00003857A:H10 M00001653C:D10 M00005216A:H01 M00003857C:E05 M00001654D:A03 M00005217B:A06 M00003858B:G02 M00001654D:E12 M00005218A:F09 M00003860D:E06 M00001654D:F11 M00005228A:B03 M00003905C:F12 M00001660C:B06 M00005228C:C05 M00003911A:D12 M00001658D:G12 M00005229B:G12 M00003966B:A04 M00001675C:A04 M00005229B:H04 M00003966C:A12 M00001660B:D03 M00005229B:H06 M00003966C:F03 M00001660B:A09 M00005229D:H03 M00003973D:F08 M00001659D:C09 M00005230B:H09 M00003974D:E01 M00001659D:B05 M00005232A:H12 M00003974D:H07 M00001654D:F12 M00005233B:D04 M00003976B:E06 M00001659A:D12 M00005233D:H07 M00003976B:H07 M00001655A:B11 M00005235B:F10 M00003978A:E01 M00001658B:A07 M00005236A:E04 M00003978A:E09 M00001658A:G09 M00005236A:G10 M00003978C:A12 M00001657D:A04 M00005236B:A12 M00003980C:E12 M00001657D:B04 M00001448B:A07 M00003980C:F12 M00001656B:E01 M00001448B:G07 M00003981A:A07 M00001660B:E04 M00001448D:E11 M00003981B:B12 M00001659C:F10 M00001455A:D10 M00003982A:G03 M00003808C:A05 M00001455A:E11 M00003982B:C10 M00001694D:C12 M00001476D:F12 M00003982B:H10 M00003746C:E02 M00001478A:F12 M00003983A:D02 M00003779D:E08 M00001482C:F09 M00003983A:F06 M00003792A:B10 M00001485C:D07 M00003983A:G02 M00003793D:A11 M00001485C:G06 M00003983D:E08 M00003794D:G03 M00001485D:A05 M00003983D:H02 M00003797A:C11 M00001487C:A11 M00003985A:C01 M00003797A:D06 M00001487C:G09 M00003986C:G11 M00003797A:G03 M00001530A:B02 M00003986D:H12 M00003800B:F03 M00001530A:H05 M00004027A:A08 M00003805A:F02 M00001530D:A11 M00004028A:B10 M00003806B:C09 M00001539B:B10 M00004028A:G03 M00001674A:G11 M00001567A:C04 M00004029B:A01 M00003806D:D11 M00001567A:C11 M00004029B:A06 M00001693D:E08 M00001567C:B08 M00004029B:G10 M00003808D:D08 M00001567C:E07 M00004029C:F02 M00003809A:C01 M00001570C:B02 M00004029C:F05 M00003809A:F01 M00001570D:E05 M00004030B:A12 M00003809B:B02 M00001570D:E07 M00004030B:D08 M00003809B:E10 M00001573B:A06 M00004030C:A08 M00003813A:B02 M00001573B:H12 M00004030C:C02 M00003813A:D08 M00001575A:D05 M00004034C:F05 M00003813B:E09 M00001575B:C01 M00004035B:F05 M00003814B:C12 M00001576C:H02 M00004036A:A11 M00003814B:F12 M00001577A:A03 M00004037C:D04 M00003815C:C06 M00001578B:A06 M00004038A:E05 M00003815C:D12 M00001579D:F02 M00004038B:D01 M00003817B:C04 M00001582C:C04 M00004039C:E02 M00003806B:G05 M00001582C:G02 M00004039D:B10 M00001679A:D10 M00001584A:A07 M00004040A:A07 M00001675C:C03 M00001584D:B06 M00004040A:B04 M00001675C:D12 M00001584D:C11 M00004040A:C08 M00001675D:E10 M00001585D:B12 M00004040B:C05 M00001676B:B09 M00001586C:H07 M00004040B:F07 M00001676B:E01 M00001589D:A01 M00004069A:E12 M00001676C:A04 M00001590D:B04 M00004069C:C08 M00001676C:E07 M00001592B:B02 M00004077A:G12 M00001676D:A02 M00001592D:H02 M00004085B:G01 M00001676D:B02 M0000159AC:E05 M00004087A:B05 M00001677A:G11 M0000159AC:H03 M00004090D:F12 M00001677B:A12 M00001594D:G11 M00004092C:D08 M00001677B:B04 M00001595A:C07 M00004097C:E03 M00001677D:B01 M00001595A:D12 M00004097C:H08 M00001678D:B11 M00001595A:E07 M00004097D:B05 M00001681C:A08 M00001595B:G07 M00003819B:G01 M00001595B:G10 M00001693C:E09 M00001595B:H11 M00001693C:C12 M00001595C:A01 M00001692B:E01 M00001595C:A05 M00001692A:B06 M00001595C:B12 M00001678B:H01 M00001595C:E05 M00001681D:C12 M00001595C:E09 M00001694A:E03 M00001595D:C11 M00001680B:D02 M00001596A:A02 M00001680A:B02 M00001596A:D01 M00001679D:F02 M00001596C:G05 M00001679D:B02 M00001607A:A01 M00001679A:G06 

1. An isolated polynucleotide comprising at least 50 contiguous nucleotides of a sequence selected from SEQ ID NO:253 and the complement thereof.
 2. A vector comprising a polynucleotide of claim
 1. 3. A host cell comprising the vector of claim
 2. 4. An isolated polynucleotide comprising at least 50 contiguous nucleotides of SEQ ID NO:253 and which hybridizes under stringent conditions to a polynucleotide of a sequence selected from SEQ ID NO:253 and the complement thereof.
 5. The polynucleotide of claim 4, wherein hybridization is conducted at least 50° C. and using 0.1X SSC (9 mM saline/0.9 mM sodium citrate).
 6. A polynucleotide comprising at least 50 contiguous nucleotides of either strand of a nucleotide sequence of an insert contained in a vector deposited as clone number M00001448D:C09 of A.T.C.C. Deposit Number 207032, wherein the insert is a human cDNA and the clone is obtained from a human cDNA library.
 7. An isolated polynucleotide comprising at least 50 contiguous nucleotides of SEQ ID NO:253, said polynucleotide obtained by amplifying a fragment of cDNA using at least one polynucleotide primer comprising at least 15 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO: 253 and the complement thereof.
 8. A vector comprising a polynucleotide of claim
 7. 9. A host cell comprising the vector of claim
 8. 